FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Lima, MNN
   Cassiano, GC
   Tomaz, KCP
   Silva, AC
   Sousa, BKP
   Ferreira, LT
   Tavella, TA
   Calit, J
   Bargieri, DY
   Neves, BJ
   Costa, FTM
   Andrade, CH
AF Lima, Marilia N. N.
   Cassiano, Gustavo C.
   Tomaz, Kaira C. P.
   Silva, Arthur C.
   Sousa, Bruna K. P.
   Ferreira, Leticia T.
   Tavella, Tatyana A.
   Calit, Juliana
   Bargieri, Daniel Y.
   Neves, Bruno J.
   Costa, Fabio T. M.
   Andrade, Carolina Horta
TI Integrative Multi-Kinase Approach for the Identification of Potent
   Antiplasmodial Hits
SO FRONTIERS IN CHEMISTRY
LA English
DT Article
DE malaria; shape-based; machine learning; virtual screening; Plasmodium
   falciparum; multi-target
ID DEPENDENT PROTEIN-KINASE; PLASMODIUM-FALCIPARUM; DRUG DISCOVERY; MALARIA
   PARASITES; QSAR; GENERATION; CALCIUM; MODEL; VALIDATION; RESISTANCE
AB Malaria is a tropical infectious disease that affects over 219 million people worldwide. Due to the constant emergence of parasitic resistance to the current antimalarial drugs, the discovery of new antimalarial drugs is a global health priority. Multi-target drug discovery is a promising and innovative strategy for drug discovery and it is currently regarded as one of the best strategies to face drug resistance. Aiming to identify new multi-target antimalarial drug candidates, we developed an integrative computational approach to select multi-kinase inhibitors for Plasmodium falciparum calcium-dependent protein kinases 1 and 4 (CDPK1 and CDPK4) and protein kinase 6 (PK6). For this purpose, we developed and validated shape-based and machine learning models to prioritize compounds for experimental evaluation. Then, we applied the best models for virtual screening of a large commercial database of drug-like molecules. Ten computational hits were experimentally evaluated against asexual blood stages of both sensitive and multi-drug resistant P. falciparum strains. Among them, LabMol-171, LabMol-172, and LabMol-181 showed potent antiplasmodial activity at nanomolar concentrations (EC50 <= 700 nM) and selectivity indices >15 folds. In addition, LabMol-171 and LabMol-181 showed good in vitro inhibition of P. berghei ookinete formation and therefore represent promising transmission-blocking scaffolds. Finally, docking studies with protein kinases CDPK1, CDPK4, and PK6 showed structural insights for further hit-to-lead optimization studies.
C1 [Lima, Marilia N. N.; Silva, Arthur C.; Sousa, Bruna K. P.; Andrade, Carolina Horta] Univ Fed Goias, Fac Pharm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.
   [Cassiano, Gustavo C.; Tomaz, Kaira C. P.; Ferreira, Leticia T.; Tavella, Tatyana A.; Costa, Fabio T. M.; Andrade, Carolina Horta] Univ Campinas UNICAMP, Inst Biol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Dept Genet Evolut Microbiol & Immunol, Campinas, SP, Brazil.
   [Calit, Juliana; Bargieri, Daniel Y.] Univ Sao Paulo, Dept Parasitol, Inst Biomed Sci, Sao Paulo, SP, Brazil.
   [Neves, Bruno J.] Univ Ctr Anapolis UniEVANGELICA, Lab Cheminformat, Anapolis, Go, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Pharm, LabMol Lab Mol Modeling & Drug Design, Goiania, Go, Brazil.; Andrade, CH (corresponding author), Univ Campinas UNICAMP, Inst Biol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Dept Genet Evolut Microbiol & Immunol, Campinas, SP, Brazil.
EM carolina@ufg.br
RI Neves, Bruno Junior/E-6295-2016; Costa, Fabio/E-1181-2012; de Carvalho e
   Silva, Arthur/S-7803-2018; Capatti Cassiano, Gustavo/G-5728-2013
OI Costa, Fabio/0000-0001-9969-7300; de Carvalho e Silva,
   Arthur/0000-0001-9866-3344; De Paula Sousa, Bruna
   Katiele/0000-0002-3204-5591; Capatti Cassiano,
   Gustavo/0000-0002-6971-5974; Calit, Juliana/0000-0002-4835-249X; Neves,
   Bruno/0000-0002-1309-8743
FU CNPqNational Council for Scientific and Technological Development (CNPq)
   [405996/2016-0, 400760/2014-2]; FAPESPFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2018/05926-2, 2017/02353-9, 2012/16525-2,
   2017/18611-7, 2018/07007-4, 2013/13119-6, 2018/24878-9, 2015/20774-6];
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES)CAPES [001]; Instituto Serrapilheira [G-1709-16618]
FX CA was supported by CNPq (grant 400760/2014-2) and FAPESP #2017/02353-9.
   FC was supported by FAPESP (Grants #2012/16525-2, #2017/18611-7, and
   2018/07007-4). DB was supported by FAPESP (Grant #2013/13119-6),
   Instituto Serrapilheira (Grant #G-1709-16618), and CNPq (Grant
   405996/2016-0). JC was supported by FAPESP (Fellowship #2018/24878-9).
   GC was supported by FAPESP (Fellowship 2015/20774-6). KT was supported
   by FAPESP (Fellowship 2018/05926-2). This study was financed in part by
   the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil
   (CAPES) - Finance Code 001.
CR Aher RB, 2017, SAR QSAR ENVIRON RES, V28, P390, DOI 10.1080/1062936X.2017.1326401
   ANDERSON S, 1984, J MOL GRAPHICS, V2, P83, DOI 10.1016/0263-7855(84)80060-0
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131
   Ashley EA, 2014, NEW ENGL J MED, V371, P411, DOI 10.1056/NEJMoa1314981
   Ashley EA, 2018, LANCET, V391, P1608, DOI 10.1016/S0140-6736(18)30324-6
   Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535
   Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797
   Bansal A, 2018, P NATL ACAD SCI USA, V115, P774, DOI 10.1073/pnas.1715443115
   Berthold MR, 2008, STUD CLASS DATA ANAL, P319, DOI 10.1145/1656274.1656280
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Billker O, 2004, CELL, V117, P503, DOI 10.1016/S0092-8674(04)00449-0
   Blagborough Andrew M, 2013, Methods Mol Biol, V923, P577
   Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197
   Bracchi-Ricard V, 2000, BIOCHEM J, V347, P255, DOI 10.1042/0264-6021:3470255
   Braga RC, 2013, CURR TOP MED CHEM, V13, P1127, DOI 10.2174/1568026611313090010
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Bullard Kristen M, 2013, Methods Mol Biol, V993, P205, DOI 10.1007/978-1-62703-342-8_14
   Burrows JN, 2017, MALARIA J, V16, DOI 10.1186/s12936-016-1675-x
   Calit J, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.01053-18, 10.1128/aac.01053-18]
   CARHART RE, 1985, J CHEM INF COMP SCI, V25, P64, DOI 10.1021/ci00046a002
   CHAKRABARTI D, 1993, P NATL ACAD SCI USA, V90, P12020, DOI 10.1073/pnas.90.24.12020
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Crowther GJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149996
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095
   Dill J. D., 1981, 182 NAT M AM CHEM SO, P23
   Durant JL, 2002, J CHEM INF COMP SCI, V42, P1273, DOI 10.1021/ci010132r
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   GADALETA D, 2016, INT J QUANT STRUCT P, V1, P45, DOI DOI 10.4018/IJQSPR.2016010102
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   Garuti L, 2015, CURR MED CHEM, V22, P695, DOI 10.2174/0929867321666141216125528
   Gedeck P, 2006, J CHEM INF MODEL, V46, P1924, DOI 10.1021/ci050413p
   Govindasamy K, 2016, MOL MICROBIOL, V102, P349, DOI 10.1111/mmi.13466
   Hartwig CL, 2013, METHODS MALARIA RES, P122
   Hawkins PCD, 2007, J MED CHEM, V50, P74, DOI 10.1021/jm0603365
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Huang ZN, 2016, J CHEM INF MODEL, V56, P21, DOI 10.1021/acs.jcim.5b00299
   Jain V, 2017, STRUCTURE, V25, P1495, DOI 10.1016/j.str.2017.07.015
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jebiwott S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079171
   Katsuno K, 2015, NAT REV DRUG DISCOV, V14, P751, DOI 10.1038/nrd4683
   Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1
   Lucet IS, 2012, FUTURE MED CHEM, V4, P2295, DOI [10.4155/fmc.12.183, 10.4155/FMC.12.183]
   MORGAN HL, 1965, J CHEM DOC, V5, P107, DOI 10.1021/c160017a018
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nagamune Kisaburo, 2008, V47, P70
   National Center for Biotechnology Information, 2009, PUBCHEM BIOASSAY DAT
   Netzeva TI, 2005, ATLA-ALTERN LAB ANIM, V33, P155, DOI 10.1177/026119290503300209
   Neves BJ, 2016, EXPERT OPIN DRUG DIS, V11, P557, DOI 10.1080/17460441.2016.1178230
   Patel TS, 2019, ARCH PHARM, V352, DOI 10.1002/ardp.201900099
   Patel TS, 2019, BIOORGAN MED CHEM, V27, P3574, DOI 10.1016/j.bmc.2019.06.038
   Rogers D, 2010, J CHEM INF MODEL, V50, P742, DOI 10.1021/ci100050t
   Rogers WO, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-10
   Sebastian S, 2012, CELL HOST MICROBE, V12, P9, DOI 10.1016/j.chom.2012.05.014
   Sondergaard CR, 2011, J CHEM THEORY COMPUT, V7, P2284, DOI 10.1021/ct200133y
   Srivastava IK, 1999, MOL MICROBIOL, V33, P704, DOI 10.1046/j.1365-2958.1999.01515.x
   Svetnik V, 2003, J CHEM INF COMP SCI, V43, P1947, DOI 10.1021/ci034160g
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Triglia T, 1998, EMBO J, V17, P3807, DOI 10.1093/emboj/17.14.3807
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Wang YL, 2012, NUCLEIC ACIDS RES, V40, pD400, DOI 10.1093/nar/gkr1132
   Ward P, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-79
   Waters NC, 2003, EXPERT OPIN THER TAR, V7, P7, DOI 10.1517/eott.7.1.7.21162
   Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858
   Who, 2017, WORLD MAL REP 2017, V196
   WHO, 2018, WORLD MAL REP 2018
   Witkowski B, 2013, ANTIMICROB AGENTS CH, V57, P914, DOI 10.1128/AAC.01868-12
   Wu YM, 1996, P NATL ACAD SCI USA, V93, P1130, DOI 10.1073/pnas.93.3.1130
   Zhang SX, 2006, J CHEM INF MODEL, V46, P1984, DOI 10.1021/ci060132x
NR 75
TC 3
Z9 3
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2646
J9 FRONT CHEM
JI Front. Chem.
PD NOV 21
PY 2019
VL 7
AR 773
DI 10.3389/fchem.2019.00773
PG 14
WC Chemistry, Multidisciplinary
SC Chemistry
GA JT9FC
UT WOS:000501286100001
PM 31824917
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Lima, MNN
   Neves, BJ
   Cassiano, GC
   Gomes, MN
   Tomaz, KCP
   Ferreira, LT
   Tavella, TA
   Calit, J
   Bargieri, DY
   Muratov, EN
   Costa, FTM
   Andrade, CH
AF Lima, Marilia N. N.
   Neves, Bruno J.
   Cassiano, Gustavo C.
   Gomes, Marcelo N.
   Tomaz, Kaira C. P.
   Ferreira, Leticia T.
   Tavella, Tatyana A.
   Calit, Juliana
   Bargieri, Daniel Y.
   Muratov, Eugene N.
   Costa, Fabio T. M.
   Andrade, Carolina Horta
TI Chalcones as a basis for computer-aided drug design: innovative
   approaches to tackle
SO FUTURE MEDICINAL CHEMISTRY
LA English
DT Article
DE drug design; experimental validation; molecular docking; pharmacophore;
   Plasmodium falciparum; virtual screening
ID PROTEIN; DISCOVERY; PREDICTION; CURATION; VERIFY; SERVER; TRUST; CDK
AB Aim: Computer-aided drug design approaches were applied to identify chalcones with antiplasmodial activity. Methodology: The virtual screening was performed as follows: structural standardization of in-house database of chalcones; identification of potential Plasmodium falciparum protein targets for the chalcones; homology modeling of the predicted P. falciparum targets; molecular docking studies; and in vitro experimental validation. Results: Using these models, we prioritized 16 chalcones with potential antiplasmodial activity, for further experimental evaluation. Among them, LabMol-86 and LabMol-87 showed potent in vitro antiplasmodial activity against P. falciparum, while LabMol-63 and LabMol-73 were potent inhibitors of Plasodium berghei progression into mosquito stages. Conclusion: Our results encourage the exploration of chalcones in hit-to-lead optimization studies for tackling malaria.
   [GRAPHICS]
   .
C1 [Lima, Marilia N. N.; Neves, Bruno J.; Gomes, Marcelo N.; Andrade, Carolina Horta] Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design, LabMol, Rua 240,Qd 87, BR-74605170 Goiania, Go, Brazil.
   [Neves, Bruno J.] Univ Ctr Anapolis UniEVANGEL, Lab Cheminformat, BR-75083515 Anapolis, Go, Brazil.
   [Cassiano, Gustavo C.; Tomaz, Kaira C. P.; Ferreira, Leticia T.; Tavella, Tatyana A.; Costa, Fabio T. M.; Andrade, Carolina Horta] Univ Estadual Campinas, Prof Dr Luiz da Jacintho Silva Dept Genet Evolut, Lab Trop Dis, Inst Biol, BR-13083970 Campinas, SP, Brazil.
   [Gomes, Marcelo N.] FAMA, Metropolitan Coll Anapolis, BR-75064780 Anapolis, Go, Brazil.
   [Gomes, Marcelo N.] InSiChem Drug Discovery, BR-75132903 Anapolis, Go, Brazil.
   [Calit, Juliana; Bargieri, Daniel Y.] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, SP, Brazil.
   [Muratov, Eugene N.] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC 27955 USA.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, UA-65000 Odessa, Ukraine.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design, LabMol, Rua 240,Qd 87, BR-74605170 Goiania, Go, Brazil.; Andrade, CH (corresponding author), Univ Estadual Campinas, Prof Dr Luiz da Jacintho Silva Dept Genet Evolut, Lab Trop Dis, Inst Biol, BR-13083970 Campinas, SP, Brazil.
EM carolina@ufg.br
RI Costa, Fabio/E-1181-2012; Neves, Bruno Junior/E-6295-2016; Capatti
   Cassiano, Gustavo/G-5728-2013
OI Costa, Fabio/0000-0001-9969-7300; Calit, Juliana/0000-0002-4835-249X;
   Neves, Bruno/0000-0002-1309-8743; Capatti Cassiano,
   Gustavo/0000-0002-6971-5974
FU Brazilian funding agency, CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian funding agency, CAPESCAPES;
   Brazilian funding agency, FAPESPFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP); Brazilian funding agency, FAPEG; NIHUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [1U01CA207160, R01-GM114015]; CNPqNational Council for Scientific
   and Technological Development (CNPq) [400760/2014-2, 405996/2016-0];
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2017/02353-9, 2012/16525-2, 2017/18611-7, 2018/0700-4, 2013/13119-6,
   2018/24878-9, 2017/20774-6, 2017/02031-1]; Instituto Serrapilheira
   [G-1709-16618]
FX The authors thank Brazilian funding agencies, CNPq, CAPES, FAPESP and
   FAPEG for financial support and fellowships. CH Andrade and FTM Costa
   are productivity fellows of CNPq. EN Muratov gratefully thank the NIH
   (grants 1U01CA207160 and R01-GM114015). CH Andrade is supported by CNPq
   (grant 400760/2014-2) and FAPESP #2017/02353-9. FTM Costa is supported
   by FAPESP (grants #2012/16525-2, #2017/18611-7 and 2018/0700-4). DY
   Bargieri is supported by FAPESP (grant #2013/13119-6), Instituto
   Serrapilheira (grant #G-1709-16618) and CNPq (grant 405996/2016-0). J
   Calit, GG Cassiano and LT Ferreira were supported by FAPESP (Fellowships
   #2018/24878-9, #2017/20774-6, and #2017/02031-1, respectively). We are
   grateful to ChemAxon (https://chemaxon.com/) for providing academic
   license of their program. The authors have no other relevant
   affiliations or financial involvement with any organization or entity
   with a financial interest in or financial conflict with the subject
   matter or materials discussed in the manuscript apart from those
   disclosed.
CR Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI 10.1093/nar/gkh131
   Ashley EA, 2014, NEW ENGL J MED, V371, P411, DOI 10.1056/NEJMoa1314981
   Aurrecoechea C, 2009, NUCLEIC ACIDS RES, V37, pD539, DOI 10.1093/nar/gkn814
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Blackman MJ, 2008, CELL MICROBIOL, V10, P1925, DOI 10.1111/j.1462-5822.2008.01176.x
   Blagborough Andrew M, 2013, Methods Mol Biol, V923, P577
   Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197
   BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201
   Burrows JN, 2017, MALARIA J, V16, DOI 10.1186/s12936-016-1675-x
   Calit J, 2018, ANTIMICROB AGENTS CH, V62, DOI [10.1128/AAC.01053-18, 10.1128/aac.01053-18]
   COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916
   Deshmukh AS, 2015, MOL MICROBIOL, V98, P17, DOI 10.1111/mmi.13099
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Gaulton A, 2012, NUCLEIC ACIDS RES, V40, pD1100, DOI 10.1093/nar/gkr777
   Geyer JA, 2009, BIOORG MED CHEM LETT, V19, P1982, DOI 10.1016/j.bmcl.2009.02.042
   Gomes MN, 2017, MOLECULES, V22, DOI 10.3390/molecules22081210
   Gomes MN, 2017, EUR J MED CHEM, V137, P126, DOI 10.1016/j.ejmech.2017.05.026
   Gomes MN, 2017, BIOORG MED CHEM LETT, V27, P2459, DOI 10.1016/j.bmcl.2017.04.010
   Graeser R, 1996, MOL BIOCHEM PARASIT, V79, P125, DOI 10.1016/0166-6851(96)02643-6
   Graeser R, 1996, MOL BIOCHEM PARASIT, V82, P37, DOI 10.1016/0166-6851(96)02716-8
   Hartwig CL, 2013, METHODS MALARIA RES, P122
   Klabunde T, 2007, BRIT J PHARMACOL, V152, P5, DOI 10.1038/sj.bjp.0707308
   Ko J, 2012, NUCLEIC ACIDS RES, V40, pW294, DOI 10.1093/nar/gks493
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944
   Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148
   Liu XF, 2010, NUCLEIC ACIDS RES, V38, pW609, DOI 10.1093/nar/gkq300
   LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0
   Moura PA, 2009, ANTIMICROB AGENTS CH, V53, P4968, DOI 10.1128/AAC.00882-09
   Plouffe DM, 2016, CELL HOST MICROBE, V19, P114, DOI 10.1016/j.chom.2015.12.001
   Pollastri MP, 2011, FUTURE MED CHEM, V3, P1307, DOI [10.4155/FMC.11.92, 10.4155/fmc.11.92]
   Rogers WO, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-10
   Rognan D, 2007, BRIT J PHARMACOL, V152, P38, DOI 10.1038/sj.bjp.0707307
   Sharma N, 2012, J MED CHEM, V55, P297, DOI 10.1021/jm201216y
   Singh A, 2017, CHEM BIOL DRUG DES, V90, P590, DOI 10.1111/cbdd.12982
   Smit FJ, 2014, BIOORGAN MED CHEM, V22, P1128, DOI 10.1016/j.bmc.2013.12.032
   Sondergaard CR, 2011, J CHEM THEORY COMPUT, V7, P2284, DOI 10.1021/ct200133y
   Sriwilaijaroen Nongluk, 2006, Southeast Asian Journal of Tropical Medicine and Public Health, V37, P607
   Tiwari H. K., 2011, Journal of Pharmacy Research, V4, P1253
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Wang X, 2016, J CHEM INF MODEL, V56, P1175, DOI 10.1021/acs.jcim.5b00690
   Witkowski B, 2013, ANTIMICROB AGENTS CH, V57, P914, DOI 10.1128/AAC.01868-12
   Wright MH, 2014, NAT CHEM, V6, P112, DOI [10.1038/NCHEM.1830, 10.1038/nchem.1830]
NR 47
TC 0
Z9 0
U1 2
U2 8
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1756-8919
EI 1756-8927
J9 FUTURE MED CHEM
JI Future Med. Chem.
PD OCT
PY 2019
VL 11
IS 20
BP 2635
EP 2646
DI 10.4155/fmc-2018-0255
PG 12
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA JQ3GW
UT WOS:000498838500003
PM 31556721
OA Green Published
DA 2020-12-08
ER

PT J
AU Ferreira, LT
   Venancio, VP
   Kawano, T
   Abrao, LCC
   Tavella, TA
   Almeida, LD
   Pires, GS
   Bilsland, E
   Sunnerhagen, P
   Azevedo, L
   Talcott, ST
   Mertens-Talcott, SU
   Costa, FTM
AF Ferreira, Leticia T.
   Venancio, Vinicius P.
   Kawano, Taila
   Abrao, Lailah C. C.
   Tavella, Tatyana A.
   Almeida, Ludimila D.
   Pires, Gabriel S.
   Bilsland, Elizabeth
   Sunnerhagen, Per
   Azevedo, Luciana
   Talcott, Stephen T.
   Mertens-Talcott, Susanne U.
   Costa, Fabio T. M.
TI Chemical Genomic Profiling Unveils the in Vitro and in Vivo
   Antiplasmodial Mechanism of Acai (Euterpe oleracea Mart.) Polyphenols
SO ACS OMEGA
LA English
DT Article
ID HUMAN MALARIA PARASITES; EXTRACTS; REVEALS; STABILITY; PATHWAYS
AB Malaria remains a major detrimental parasitic disease in the developing world, with more than 200 million cases annually. Widespread drug-resistant parasite strains push for the development of novel antimalarial drugs. Plant-derived natural products are key sources of antimalarial molecules. Euterpe oleracea Martius ("acai") originates from Brazil and has anti-inflammatory and antineoplasic properties. Here, we evaluated the antimalarial efficacy of three phenolic fractions of acai; total phenolics (1), nonanthocyanin phenolics (2), and total anthocyanins (3). In vitro, fraction 2 moderately inhibited parasite growth in chloroquine-sensitive (HB3) and multiresistant (Dd2) Plasmodium falciparum strains, while none of the fractions was toxic to noncancer cells. Despite the limited activity in vitro, the oral treatment with 20 mg/kg of fraction 1 reduced parasitemia by 89.4% in Plasmodium chabaudi-infected mice and prolonged survival. Contrasting in vitro and in vivo activities of 1 suggest key antiplasmodial roles for polyphenol metabolites rather than the fraction itself. Finally, we performed haploinsufficiency chemical genomic profiling (HIP) utilizing heterozygous Saccharomyces cerevisiae deletion mutants to identify molecular mechanisms of acai fractions. HIP results indicate proteostasis as the main cellular pathway affected by fraction 2. These results open avenues to develop acai polyphenols as potential new antimalarial candidates.
C1 [Ferreira, Leticia T.; Tavella, Tatyana A.; Costa, Fabio T. M.] Univ Campinas UNICAMP, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Dept Genet Evolut Microbiol & Immunol, BR-13083970 Campinas, SP, Brazil.
   [Almeida, Ludimila D.; Pires, Gabriel S.; Bilsland, Elizabeth] Univ Campinas UNICAMP, Synthet Biol Lab, Dept Struct & Funct Biol, Inst Biol, BR-13083970 Campinas, SP, Brazil.
   [Venancio, Vinicius P.; Kawano, Taila; Abrao, Lailah C. C.; Talcott, Stephen T.; Mertens-Talcott, Susanne U.] Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX 77843 USA.
   [Kawano, Taila; Abrao, Lailah C. C.] Univ Fed Alfenas, Fac Pharmaceut Sci, BR-37130001 Alfenas, MG, Brazil.
   [Sunnerhagen, Per] Univ Gothenburg, Dept Chem & Mol Biol, SE-40530 Gothenburg, Sweden.
   [Azevedo, Luciana] Univ Fed Alfenas, Lab Nutr & Toxicol Anal Vivo LANTIN, Fac Nutr, Alfenas, MG, Brazil.
RP Costa, FTM (corresponding author), Univ Campinas UNICAMP, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Dept Genet Evolut Microbiol & Immunol, BR-13083970 Campinas, SP, Brazil.; Mertens-Talcott, SU (corresponding author), Texas A&M Univ, Dept Nutr & Food Sci, College Stn, TX 77843 USA.
EM smtalcott@tamu.edu; fabiotmc72@gmail.com
RI Costa, Fabio/E-1181-2012; Sunnerhagen, Per/G-1696-2012
OI Costa, Fabio/0000-0001-9969-7300; Sunnerhagen, Per/0000-0002-0967-8729
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2017/18611-7,
   2015/03553-6]; FCT- FAPESP [2018/07007-4]; Texas A&M University TAMU
   FAPESP Grant [2017/50400-6]; Texas A&M AgriLife Vector Disease Program
   Funding, College Station, TX; Conselho Nacional de Desenvolvimento
   Cientifco e Tecnologico ( CNPq)National Council for Scientific and
   Technological Development (CNPq); Coordenacao de Aperfeicoamento de
   Pessoal de Nivel SuperiorCAPES [CAPES-TAMU 002/2014]; Swedish Research
   CouncilSwedish Research Council [2016-05627]; CAPES fellowshipCAPES;
   FAPESP fellowshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2017/01986-8, 2018/05328- 8]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP-Grants 2017/18611-7 and 2015/03553-6), FCT- FAPESP
   (Grant 2018/07007-4), Texas A&M University TAMU FAPESP Grant
   (2017/50400-6), Texas A&M AgriLife Vector Disease Program Funding,
   College Station, TX, Conselho Nacional de Desenvolvimento Cientifco e
   Tecnologico ( CNPq) and Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES-TAMU 002/2014), and the Swedish Research Council
   (Grant 2016-05627). L.T.F. and T.A.T. were supported by a CAPES
   fellowship. L.D.A. was sponsored by a FAPESP fellowship (2017/01986-8).
   G.S.P. was sponsored by a FAPESP fellowship (2018/05328- 8). F.T.M.C. is
   a CNPq researcher fellow level 1C.
CR Achan J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-144
   Ainsworth EA, 2007, NAT PROTOC, V2, P875, DOI 10.1038/nprot.2007.102
   Ariey F, 2014, NATURE, V505, P50, DOI 10.1038/nature12876
   Atay I., 2016, PHARM BIOL, P1
   Bankole AE, 2016, PARASITOL RES, V115, P299, DOI 10.1007/s00436-015-4747-x
   Batinovic S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16044
   Bilsland E, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004401
   Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456
   BRANDAO MGL, 1992, J ETHNOPHARMACOL, V36, P175, DOI 10.1016/0378-8741(92)90018-M
   Dekker C, 2011, EMBO J, V30, P3078, DOI 10.1038/emboj.2011.208
   Del Pozo-Insfran D, 2004, J AGR FOOD CHEM, V52, P1539, DOI 10.1021/jf035189n
   Dong JS, 2005, MOL CELL BIOL, V25, P9859, DOI 10.1128/MCB.25.22.9859-9873.2005
   Eckers E, 2009, BIOCHEMISTRY-US, V48, P1410, DOI 10.1021/bi801859b
   El Babili F, 2010, PHYTOMEDICINE, V17, P157, DOI 10.1016/j.phymed.2009.05.014
   FABREGAT A, 2017, BMC BIOINFORMATICS, V18, P1
   Salazar LFG, 2015, DEV NEUROREHABIL, V18, P1, DOI 10.3109/17518423.2014.948640
   Garcia-Alvarez MC, 2013, J ETHNOPHARMACOL, V149, P676, DOI 10.1016/j.jep.2013.07.024
   Giaever G, 1999, NAT GENET, V21, P278, DOI 10.1038/6791
   Haldar K, 2018, NAT REV MICROBIOL, V16, P156, DOI 10.1038/nrmicro.2017.161
   Hartl FU, 2011, NATURE, V475, P324, DOI 10.1038/nature10317
   Heessen S, 2005, MOL CELL, V18, P225, DOI 10.1016/j.molcel.2005.03.015
   Hoepfner D, 2014, MICROBIOL RES, V169, P107, DOI 10.1016/j.micres.2013.11.004
   Hostetler GL, 2017, ADV NUTR, V8, P423, DOI 10.3945/an.116.012948
   Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118
   Lima RBS, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0999-2
   Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081
   Mbengue A, 2015, TRAFFIC, V16, P461, DOI 10.1111/tra.12266
   Mertens-Talcott SU, 2008, J AGR FOOD CHEM, V56, P7796, DOI 10.1021/jf8007037
   Mok S, 2015, SCIENCE, V347, P431, DOI 10.1126/science.1260403
   Moneriz C, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-279
   Moyo R, 2016, J ETHNOPHARMACOL, V185, P235, DOI 10.1016/j.jep.2016.03.036
   Muganza DM, 2016, J ETHNOPHARMACOL, V193, P510, DOI 10.1016/j.jep.2016.09.051
   Neef DW, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000291
   Noratto GD, 2011, J AGR FOOD CHEM, V59, P7999, DOI 10.1021/jf201056x
   Oliveira DR, 2015, J ETHNOPHARMACOL, V173, P424, DOI 10.1016/j.jep.2015.07.035
   Pacheco-Palencia LA, 2008, J AGR FOOD CHEM, V56, P4631, DOI 10.1021/jf800161u
   Parsons AB, 2006, CELL, V126, P611, DOI 10.1016/j.cell.2006.06.040
   Pierce SE, 2007, NAT PROTOC, V2, P2958, DOI 10.1038/nprot.2007.427
   Pujol-Carrion N, 2010, APPL ENVIRON MICROB, V76, P7826, DOI 10.1128/AEM.01755-10
   Quashie NB, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-95
   Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3
   Spillman N. J., 2018, CELL MICROBIOL, V19, P1
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Tu YY, 2011, NAT MED, V17, P1217, DOI 10.1038/nm.2471
   WHO, 2018, WORLD MAL REP 2018
   Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492
NR 46
TC 3
Z9 3
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2470-1343
J9 ACS OMEGA
JI ACS Omega
PD SEP 24
PY 2019
VL 4
IS 13
BP 15628
EP 15635
DI 10.1021/acsomega.9b02127
PG 8
WC Chemistry, Multidisciplinary
SC Chemistry
GA JB8UJ
UT WOS:000488852700034
PM 31572864
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Costa, FT
   Jardim, KV
   Palomec-Garfias, AF
   Caceres-Velez, PR
   Chaker, JA
   Medeiros, AMMS
   Moya, SE
   Sousa, MH
AF Costa, Fabio T.
   Jardim, Katiuscia, V
   Palomec-Garfias, Abraham F.
   Caceres-Velez, Paolin R.
   Chaker, Juliano A.
   Medeiros, Anderson M. M. S.
   Moya, Sergio E.
   Sousa, Marcelo H.
TI Highly Magnetizable Crosslinked Chloromethylated Polystyrene-Based
   Nanocomposite Beads for Selective Molecular Separation of 4-Aminobenzoic
   Acid
SO ACS OMEGA
LA English
DT Article
ID FERRITE NANOPARTICLES; SURFACE; REMOVAL; SPECTROSCOPY; FERROFLUIDS;
   RAMAN
AB In this work, we describe the preparation and characterization of highly magnetizable chloromethylated polystyrene-based nanocomposite beads. For synthesis optimization, acid-resistant core-shelled maghemite (gamma-Fe2O3) nanoparticles are coated with sodium oleate and directly incorporated into the organic medium during a suspension polymerization process. A crosslinking agent, ethylene glycol dimethacrylate, is used for copolymerization with 4-vinylbenzyl chloride to increase the resistance of the microbeads against leaching. X-ray diffraction, inductively coupled plasma atomic emission spectroscopy, thermogravimetric analysis, scanning electron microscopy, transmission electron microscopy, and optical microscopy are used for bead characterization. The beads form a magnetic composite consisting of similar to 500 nm-sized crosslinked polymeric microspheres, embedding similar to 8 nm gamma-Fe2O3 nanoparticles. This nanocomposite shows large room temperature magnetization (similar to 24 emu/g) due to the high content of maghemite (similar to 45 wt %) and resistance against leaching even in acidic media. Moreover, the presence of superficial chloromethyl groups is probed by Fourier transform infrared and X-ray photoelectron spectroscopy. The nanocomposite beads displaying chloromethyl groups can be used to selectively remove aminated compounds that are adsorbed on the beads, as is shown here for the molecular separation of 4-aminobenzoic acid from a mixture with benzoic acid. The high magnetization of the composite beads makes them suitable for in situ molecular separations in environmental and biological applications.
C1 [Costa, Fabio T.; Jardim, Katiuscia, V; Palomec-Garfias, Abraham F.; Chaker, Juliano A.; Sousa, Marcelo H.] Univ Brasilia, Green Nanotechnol Grp, BR-72220900 Brasilia, DF, Brazil.
   [Caceres-Velez, Paolin R.; Moya, Sergio E.] CIC biomaGUNE, Soft Matter Nanotechnol Lab, San Sebastian 20009, Guip, Spain.
   [Medeiros, Anderson M. M. S.] Univ Bordeaux, Lab Chim Polymeres Organ, Bordeaux INP, ENSCBP,CNRS,UMR5629, 16 Ave Pey Berland, F-33607 Pessac, France.
RP Sousa, MH (corresponding author), Univ Brasilia, Green Nanotechnol Grp, BR-72220900 Brasilia, DF, Brazil.
EM mhsqui@gmail.com
RI Sousa, Marcelo Henrique/D-5420-2012; Moya, Sergio E/I-1446-2015; Sousa,
   Marcelo Henrique/AAM-3003-2020; Costa, Fabio/E-1181-2012
OI Sousa, Marcelo Henrique/0000-0003-1210-8329; Costa,
   Fabio/0000-0001-9969-7300; Caceres Velez, Paolin
   Rocio/0000-0002-8345-1581; Moya, Sergio/0000-0002-7174-1960; Palomec
   Garfias, Abraham Francisco/0000-0002-6985-005X
FU Brazilian Agency: Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Brazilian Agency: Coordenaca de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES); Brazilian Agency: Fundacao de Apoio a
   Pesquisa do Distrito Federal (FAPDF); Brazilian Agency: Decanato de
   Pesquisa e Inovacao (DPI-UnB); Brazilian Agency: Fundacao de
   Empreendimentos Cientificos e Tecnologicos (FINATEC); Ministerio de
   Economia, Industria y Competitividad, gobierno de Espana
   [MAT2017-88752-R]
FX The authors gratefully acknowledge financial support from Brazilian
   Agencies: Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq), Coordenaca de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES), Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF),
   Decanato de Pesquisa e Inovacao (DPI-UnB), and Fundacao de
   Empreendimentos Cientificos e Tecnologicos (FINATEC). The authors also
   thank LabMic-UFG for TEM measurements. S.E.M. thanks the MAT2017-88752-R
   Retos project from the Ministerio de Economia, Industria y
   Competitividad, gobierno de Espana.
CR Andrianov K. A., 1959, B ACAD SCI USSR CH, V8, P255
   Borlido L, 2013, BIOTECHNOL ADV, V31, P1374, DOI 10.1016/j.biotechadv.2013.05.009
   Bronstein LM, 2007, CHEM MATER, V19, P3624, DOI 10.1021/cm062948j
   Chen ZM, 2017, RSC ADV, V7, P35169, DOI 10.1039/c7ra05723g
   Cheng ZP, 2005, IND ENG CHEM RES, V44, P7098, DOI 10.1021/ie050225o
   Coelho BCP, 2017, RSC ADV, V7, P11223, DOI 10.1039/c6ra27539g
   Cuenca JA, 2016, J PHYS-CONDENS MAT, V28, DOI 10.1088/0953-8984/28/10/106002
   Darwish MSA, 2011, J MATER SCI, V46, P2123, DOI 10.1007/s10853-010-5048-5
   Darwish MSA, 2011, J POLYM RES, V18, P79, DOI 10.1007/s10965-010-9393-5
   Foo KY, 2010, CHEM ENG J, V156, P2, DOI 10.1016/j.cej.2009.09.013
   Palomec-Garfias AF, 2018, COLLOID SURFACE A, V549, P13, DOI 10.1016/j.colsurfa.2018.03.070
   Gervald AY, 2010, RUSS CHEM REV+, V79, P219, DOI 10.1070/RC2010v079n03ABEH004068
   Gomes JA, 2006, J MAGN MAGN MATER, V300, pE213, DOI 10.1016/j.jmmm.2005.10.083
   Gomes JD, 2008, J PHYS CHEM C, V112, P6220, DOI 10.1021/jp7097608
   Jardim KV, 2018, MAT SCI ENG C-MATER, V92, P184, DOI 10.1016/j.msec.2018.06.039
   Kafrouni L, 2016, PROG BIOMATER, V5, P147, DOI 10.1007/s40204-016-0054-6
   Kumar KV, 2006, J HAZARD MATER, V137, P1538, DOI 10.1016/j.jhazmat.2006.04.036
   Lam T, 2016, NANOMATERIALS-BASEL, V6, DOI 10.3390/nano6060100
   Lapwanit S, 2016, CHEM ENG J, V289, P286, DOI 10.1016/j.cej.2015.12.073
   Li CC, 2016, CHEM MATER, V28, P6089, DOI 10.1021/acs.chemmater.6b01434
   Lu WT, 2014, J POWER SOURCES, V248, P905, DOI 10.1016/j.jpowsour.2013.08.141
   Medrano JJA, 2018, J MAGN MAGN MATER, V466, P359, DOI 10.1016/j.jmmm.2018.07.036
   MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025
   Mote VD, 2012, J THEOR APPL PHYS, V6, DOI 10.1186/2251-7235-6-6
   Ngomsik AF, 2005, CR CHIM, V8, P963, DOI 10.1016/j.crci.2005.01.001
   Nunes ADC, 2014, INT J NANOMED, V9, P3299, DOI 10.2147/IJN.S64254
   Philippova O, 2011, EUR POLYM J, V47, P542, DOI 10.1016/j.eurpolymj.2010.11.006
   Rana S, 1999, TETRAHEDRON LETT, V40, P8137, DOI 10.1016/S0040-4039(99)01572-5
   Rodovalho FL, 2016, CHEM ENG J, V302, P725, DOI 10.1016/j.cej.2016.05.110
   Siiman O, 2001, J COLLOID INTERF SCI, V234, P44, DOI 10.1006/jcis.2000.7279
   Sousa EC, 2004, J MAGN MAGN MATER, V272, pE1215, DOI 10.1016/j.jmmm.2003.12.295
   Sousa EC, 2005, J MAGN MAGN MATER, V289, P118, DOI 10.1016/j.jmmm.2004.11.035
   Sousa MH, 2011, MICROCHEM J, V97, P182, DOI 10.1016/j.microc.2010.09.002
   Sousa MH, 2000, J RAMAN SPECTROSC, V31, P185, DOI 10.1002/(SICI)1097-4555(200003)31:3<185::AID-JRS511>3.0.CO;2-B
   Thunhorst KL, 1997, POLYMER MODIFICATION, P97
   Wang XM, 2010, CHEM ENG J, V162, P158, DOI 10.1016/j.cej.2010.05.017
   YAJIMA H, 1988, TETRAHEDRON, V44, P805, DOI 10.1016/S0040-4020(01)86118-4
   Zhang L, 2006, APPL SURF SCI, V253, P2611, DOI 10.1016/j.apsusc.2006.05.023
   Zhang W, 2014, SPECTROCHIM ACTA A, V121, P715, DOI 10.1016/j.saa.2013.11.101
NR 39
TC 1
Z9 1
U1 0
U2 2
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2470-1343
J9 ACS OMEGA
JI ACS Omega
PD MAR
PY 2019
VL 4
IS 3
BP 5640
EP 5649
DI 10.1021/acsomega.9b00142
PG 10
WC Chemistry, Multidisciplinary
SC Chemistry
GA HR1UT
UT WOS:000462921900121
PM 31459718
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Bastos, MF
   Albrecht, L
   Gomes, AM
   Lopes, SCP
   Vicente, CP
   de Almeida, RPM
   Cassiano, GC
   Fonseca, RJC
   Werneck, CC
   Pavao, MSG
   Costa, FTM
AF Bastos, Marcele F.
   Albrecht, Letusa
   Gomes, Angelica M.
   Lopes, Stefanie C. P.
   Vicente, Cristina P.
   de Almeida, Rodrigo P. M.
   Cassiano, Gustavo C.
   Fonseca, Roberto J. C.
   Werneck, Claudio C.
   Pavao, Mauro S. G.
   Costa, Fabio T. M.
TI A new heparan sulfate from the mollusk Nodipecten nodosus inhibits
   merozoite invasion and disrupts rosetting and cytoadherence of
   Plasmodium falciparum
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE glycosaminoglycan; severe malaria; adhesion; antimalarial; adjuvant
   therapy
ID MALARIA
AB BACKGROUND Despite treatment with effective antimalarial drugs, the mortality rate is still high in severe cases of the disease, highlighting the need to find adjunct therapies that can inhibit the adhesion of Plasmodium falciparum-infected erythrocytes (Pf-iEs).
   OBJECTIVES In this context, we evaluated a new heparan sulfate (HS) from Nodipecten nodosus for antimalarial activity and inhibition of P. falciparum cytoadhesion and rosetting.
   METHODS Parasite inhibition was measured by SYBR green using a cytometer. HS was assessed in rosetting and cytoadhesion assays under static and flow conditions using Chinese hamster ovary (CHO) and human lymphatic endothelial cell (HLEC) cells expressing intercellular adhesion molecule-1 (ICAM1) and chondroitin sulfate A (CSA), respectively.
   FINDINGS This HS inhibited merozoite invasion similar to heparin. Moreover, mollusk HS decreased cytoadherence of P. falciparum to CSA and ICAM-1 on the surface of endothelial cells under static and flow conditions. In addition, this glycan efficiently disrupted rosettes.
   CONCLUSIONS These findings support a potential use for mollusk HS as adjunct therapy for severe malaria.
C1 [Bastos, Marcele F.; Cassiano, Gustavo C.; Costa, Fabio T. M.] Univ Estadual Campinas, Dept Genet Evolucao Microbiol & Imunol, Lab Doencas Trop, Campinas, SP, Brazil.
   [Albrecht, Letusa; de Almeida, Rodrigo P. M.] Fundacao Oswaldo Cruz Fiocruz, Inst Carlos Chagas, Curitiba, Parana, Brazil.
   [Gomes, Angelica M.] Cleveland Clin, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44106 USA.
   [Lopes, Stefanie C. P.] Fundacao Oswaldo Cruz Fiocruz, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil.
   [Vicente, Cristina P.] Univ Estadual Campinas, Dept Biol Estrutural & Func, Campinas, SP, Brazil.
   [Fonseca, Roberto J. C.] Univ Fed Rio de Janeiro, Hosp Univ Clementino Fraga Filho, Ctr Ciencias Saude, Inst Ciencias Biomed,Lab Tecido Conjunt, Rio De Janeiro, RJ, Brazil.
   [Werneck, Claudio C.] Univ Estadual Campinas, Dept Bioquim & Biol Tecidual, Campinas, SP, Brazil.
   [Pavao, Mauro S. G.] Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo de Meis, Programa Glicobiol, Rio De Janeiro, RJ, Brazil.
RP Costa, FTM (corresponding author), Univ Estadual Campinas, Dept Genet Evolucao Microbiol & Imunol, Lab Doencas Trop, Campinas, SP, Brazil.
EM fabiotmc72@gmail.com
RI Costa, Fabio/E-1181-2012; Albrecht, Letusa/I-1837-2012; Cassiano,
   Gustavo C/G-5728-2013; /D-8928-2012; Werneck, Claudio
   Chrysostomo/C-7568-2012
OI Costa, Fabio/0000-0001-9969-7300; Albrecht, Letusa/0000-0001-6406-2057;
   Cassiano, Gustavo C/0000-0002-6971-5974; Lopes,
   Stefanie/0000-0002-6981-2192; /0000-0001-9896-4630; CASTRO FONSECA,
   ROBERTO JOSE/0000-0001-7500-1348; Werneck, Claudio
   Chrysostomo/0000-0002-9413-0572
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2012/16525-2, 2017/18611-7, 2010/18571-6, 2015/20774-6]; CNPqNational
   Council for Scientific and Technological Development (CNPq)
FX FAPESP (grants 2012/16525-2; 2017/18611-7), CNPq. MFB and GCC were
   sponsored by a FAPESP fellowship (2010/18571-6; 2015/20774-6,
   respectively). FTMC, CCW and MSGP are CNPq research fellows. MSGP is a
   researcher fellow from FAPERJ.
CR Angeletti D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118898
   Avril M, 2004, MICROBES INFECT, V6, P249, DOI 10.1016/j.micinf.2003.12.007
   Bastos MF, 2014, ANTIMICROB AGENTS CH, V58, P1862, DOI 10.1128/AAC.00686-13
   Chakravorty SJ, 2005, EUR J CELL BIOL, V84, P15, DOI 10.1016/j.ejcb.2004.09.002
   Cunnington AJ, 2013, TRENDS PARASITOL, V29, P585, DOI 10.1016/j.pt.2013.10.004
   Faiz MA, 2005, LANCET, V366, P717
   Gomes AM, 2010, J BIOL CHEM, V285, P7312, DOI 10.1074/jbc.M109.091546
   Gomes AM, 2015, GLYCOBIOLOGY, V25, P386, DOI 10.1093/glycob/cwu119
   Hughes KR, 2010, MOL BIOCHEM PARASIT, V169, P71, DOI 10.1016/j.molbiopara.2009.09.007
   Kyriacou HM, 2007, ANTIMICROB AGENTS CH, V51, P1321, DOI 10.1128/AAC.01216-06
   Rampengan T H, 1991, Paediatr Indones, V31, P59
   Recuenco FC, 2014, SCI REP-UK, V4, DOI 10.1038/srep04723
   Russell B, 2013, ANTIMICROB AGENTS CH, V57, P5170, DOI 10.1128/AAC.00682-13
   Senczuk AM, 2001, BLOOD, V98, P3132, DOI 10.1182/blood.V98.10.3132
   Sharma L, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00117
   Skidmore MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186276
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   WHO, 2017, WORLD MALARIA REPORT
   Yam XY, 2017, TRENDS PARASITOL, V33, P309, DOI 10.1016/j.pt.2016.12.012
   Zhang Y, 2013, J PROTEOME RES, V12, P2185, DOI 10.1021/pr400038j
NR 20
TC 0
Z9 0
U1 2
U2 4
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PY 2019
VL 114
AR e190088
DI 10.1590/0074-02760190088
PG 4
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA IC9IU
UT WOS:000471296900001
PM 31188952
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Proenca-Modena, JL
   Milanez, GP
   Costa, ML
   Judice, CC
   Costa, FTM
AF Proenca-Modena, Jose Luiz
   Milanez, Guilherme Paier
   Costa, Maria Laura
   Judice, Carla C.
   Maranhao Costa, Fabio Trindade
TI Zika virus: lessons learned in Brazil
SO MICROBES AND INFECTION
LA English
DT Article
DE Zika virus; Epidemics setting; Transmission; Pathogenesis; Arboviruses;
   Brazil
ID NEURAL PROGENITORS; INFECTION; CELLS; AMERICA; BRAIN; TRANSMISSION;
   PATHOGENESIS; ENHANCEMENT; MONOCYTES; GUILLAIN
AB Zika virus (ZIKV) greatly impacted the international scientific and public health communities in the last two years due to its association with microcephaly and other neonatal alterations. This review will discuss lessons learned from viral pathogenesis, epidemiology and clinical findings observed during the ZIKV outbreak occurred between 2014 and 2016 in Brazil. (C) 2018 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.
C1 [Proenca-Modena, Jose Luiz; Milanez, Guilherme Paier] Univ Estadual Campinas, Lab Emerging Viruses, Dept Genet Evolut Microbiol & Immunol, Inst Biol,Unicamp, Campinas, SP, Brazil.
   [Costa, Maria Laura] Univ Estadual Campinas, Obstet & Gynecol Dept, Sch Med Sci, UNICAMP, Campinas, SP, Brazil.
   [Judice, Carla C.; Maranhao Costa, Fabio Trindade] Univ Estadual Campinas, Lab Trop Dis, Dept Genet Evolut Microbiol & Immunol, Inst Biol,Unicamp, Campinas, SP, Brazil.
RP Proenca-Modena, JL (corresponding author), Univ Estadual Campinas, Lab Emerging Viruses, Dept Genet Evolut Microbiol & Immunol, Inst Biol, Rua Monteiro Lobato 255, BR-13083862 Campinas, SP, Brazil.; Costa, FTM (corresponding author), Univ Estadual Campinas, Lab Trop Dis, Dept Genet Evolut Microbiol & Immunol, Inst Biol, Rua Carl Von Linaeus 2-238, BR-13083864 Campinas, SP, Brazil.
EM jlmodena@unicamp.br; costaftm@unicamp.br
RI Costa, Fabio/E-1181-2012; Milanez, Guilherme/G-6457-2016; Modena, Jose
   Luiz Proenca/C-8231-2014; Proenca-Modena, Jose Luiz/AAU-7622-2020;
   Judice, Carla/P-4738-2014
OI Costa, Fabio/0000-0001-9969-7300; Milanez,
   Guilherme/0000-0002-8599-1098; Modena, Jose Luiz
   Proenca/0000-0002-4996-3153; Proenca-Modena, Jose
   Luiz/0000-0002-4996-3153; Judice, Carla/0000-0003-1839-053X
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2016/00194-8]; Conselho
   Nacional de Desenvolvimento Cientifico e TecnologicoNational Council for
   Scientific and Technological Development (CNPq) [440761/2016-6]
FX We thank Ana Carolina Andrade Vitor Kayano for all figures included in
   this review. All studies with arbovirus in Unicamp (University of
   Campinas) were supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (grant 2016/00194-8 and fellowship to J. A. L.); and the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (grant
   440761/2016-6, including research fellowships to C. C. J., G. P. M, and
   F. T. M. C.).
CR Adibi JJ, 2016, LANCET, V387, P1587, DOI 10.1016/S0140-6736(16)00650-4
   Aliota MT, 2017, ANTIVIR RES, V144, P223, DOI 10.1016/j.antiviral.2017.06.001
   Assis AMO, 2007, CAD SAUDE PUBLICA, V23, P2337, DOI 10.1590/S0102-311X2007001000009
   Bagasra O, 2017, APPL IMMUNOHISTO M M, V25, P679, DOI 10.1097/PAI.0000000000000580
   Bardina SV, 2017, SCIENCE, V356, P175, DOI 10.1126/science.aal4365
   Baud D, 2017, LANCET, V390, P2099, DOI [10.1016/S0140-6736(17)31450-2, 10.1016/s0140-6736(17)31450-2]
   Bayless NL, 2016, CELL HOST MICROBE, V20, P423, DOI 10.1016/j.chom.2016.09.006
   Terzian ACB, 2017, CLIN INFECT DIS, V65, P1260, DOI 10.1093/cid/cix558
   Blom K, 2017, J INTERN MED, V282, P206, DOI 10.1111/joim.12638
   Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
   Cao B, 2017, J EXP MED, V214, P2303, DOI 10.1084/jem.20170957
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   CDC, 2017, ZIK VIR COLL SUBM SP
   Chimelli L, 2017, ACTA NEUROPATHOL, V133, P983, DOI 10.1007/s00401-017-1699-5
   Corry J, 2017, P NATL ACAD SCI USA, V114, P9433, DOI 10.1073/pnas.1707513114
   da Silva Voorham JM, 2012, PLOS ONE, V7, DOI DOI 10.1371/J0URNAL.P0NE.0029957
   Dang J, 2016, CELL STEM CELL, V19, P258, DOI 10.1016/j.stem.2016.04.014
   de Araujo TVB, 2016, LANCET INFECT DIS, V16, P1356, DOI 10.1016/S1473-3099(16)30318-8
   Cavalcanti LPD, 2016, J INFECT DEV COUNTR, V10, P563, DOI 10.3855/jidc.8575
   de Noronha L, 2016, MEM I OSWALDO CRUZ, V111, P287, DOI 10.1590/0074-02760160085
   Dejnirattisai W, 2016, NAT IMMUNOL, V17, P1102, DOI 10.1038/ni.3515
   Faria NR, 2017, NATURE, V546, P406, DOI 10.1038/nature22401
   Faria NR, 2016, SCIENCE, V352, P345, DOI 10.1126/science.aaf5036
   Foo SS, 2017, NAT MICROBIOL, V2, P1558, DOI 10.1038/s41564-017-0016-3
   Franca GVA, 2016, LANCET, V388, P891, DOI 10.1016/S0140-6736(16)30902-3
   Garcez PP, 2016, SCIENCE, V352, P816, DOI 10.1126/science.aaf6116
   Gavegnano Christina, 2017, Pathog Immun, V2, P199, DOI 10.20411/pai.v2i2.190
   Guedes DRD, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.59
   Guimarães Reinaldo, 2006, Cad. Saúde Pública, V22, P1775, DOI 10.1590/S0102-311X2006000900002
   Guo XX, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.102
   Honein MA, 2017, JAMA-J AM MED ASSOC, V317, P59, DOI 10.1001/jama.2016.19006
   Hunter FF, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01248
   Kam YW, 2017, J INFECT DIS, V216, P172, DOI 10.1093/infdis/jix261
   Kumar A, 2016, EMBO REP, V17, P1766, DOI 10.15252/embr.201642627
   Passos SRL, 2017, EMERG INFECT DIS, V23, P2120, DOI 10.3201/eid2312.171375
   Lazear HM, 2016, CELL HOST MICROBE, V19, P720, DOI 10.1016/j.chom.2016.03.010
   Li C, 2016, CELL STEM CELL, V19, P120, DOI 10.1016/j.stem.2016.04.017
   Li HD, 2016, CELL STEM CELL, V19, P593, DOI 10.1016/j.stem.2016.08.005
   Liu SF, 2016, CIRC RES, V119, P1183, DOI [10.1161/CIRCRESAHA.116.309866, 10.1161/circresaha.116.309866]
   Marcondes CB, 2017, J MED ENTOMOL, V54, P509, DOI 10.1093/jme/tjw209
   Martines RB, 2016, MMWR-MORBID MORTAL W, V65
   Michlmayr D, 2017, NAT MICROBIOL, V2, P1462, DOI 10.1038/s41564-017-0035-0
   Miner JJ, 2017, CELL HOST MICROBE, V21, P134, DOI 10.1016/j.chom.2017.01.004
   Miner JJ, 2016, CELL, V165, P1080, DOI 10.1016/j.cell.2016.05.008
   Miner JJ, 2016, CURR OPIN IMMUNOL, V38, P18, DOI 10.1016/j.coi.2015.10.008
   Mladinich MC, 2017, MBIO, V8, DOI [10.1128/mBio.00952-17, 10.1128/mbio.00952-17]
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Figueiredo LTM, 2015, REV SOC BRAS MED TRO, V48, P233, DOI 10.1590/0037-8682-0179-2015
   Moreira J, 2017, CLIN MICROBIOL INFEC, V23, P296, DOI 10.1016/j.cmi.2016.12.027
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Nascimento OJM, 2017, CURR OPIN NEUROL, V30, P500, DOI 10.1097/WCO.0000000000000471
   Neu N, 2015, CLIN PERINATOL, V42, P77, DOI 10.1016/j.clp.2014.11.001
   Ngono AE, 2017, CELL HOST MICROBE, V21, P35, DOI 10.1016/j.chom.2016.12.010
   Pan American Health Organization, 2017, ZIK EP REP BRAZ
   Piersen TC, 2013, FIELDS VIROLOGY, P747
   Quicke KM, 2016, CELL HOST MICROBE, V20, P83, DOI 10.1016/j.chom.2016.05.015
   Ritter JM, 2017, ARCH PATHOL LAB MED, V141, P49, DOI 10.5858/arpa.2016-0397-SA
   Roe K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102598
   Rossi SL, 2016, AM J TROP MED HYG, V94, P1362, DOI 10.4269/ajtmh.16-0111
   Screaton G, 2015, NAT REV IMMUNOL, V15, P745, DOI 10.1038/nri3916
   Slavov SN, 2017, TRANSFUSION, V57, P2897, DOI 10.1111/trf.14322
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Tabata T, 2016, CELL HOST MICROBE, V20, P155, DOI 10.1016/j.chom.2016.07.002
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   van den Hurk AF, 2017, LANCET INFECT DIS, V17, P1014, DOI 10.1016/S1473-3099(17)30518-2
   Victora CG, 2011, LANCET, V377, P2042, DOI 10.1016/S0140-6736(11)60055-X
   Wang L, 2016, CELL HOST MICROBE, V19, P561, DOI 10.1016/j.chom.2016.04.006
   Wen JS, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.36
   Yuan L, 2017, SCIENCE, V358, P933, DOI 10.1126/science.aam7120
   Yuki N, 2012, NEW ENGL J MED, V366, P2294, DOI 10.1056/NEJMra1114525
NR 70
TC 8
Z9 8
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD DEC
PY 2018
VL 20
IS 11-12
BP 661
EP 669
DI 10.1016/j.micinf.2018.02.008
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA HC7TC
UT WOS:000452003500003
PM 29501560
DA 2020-12-08
ER

PT J
AU Mottin, M
   Borba, JVVB
   Braga, RC
   Torres, PHM
   Martini, MC
   Proenca-Modena, JL
   Judice, CC
   Costa, FTM
   Ekins, S
   Perryman, AL
   Andrade, CH
AF Mottin, Melina
   Borba, Joyce V. V. B.
   Braga, Rodolpho C.
   Torres, Pedro H. M.
   Martini, Matheus C.
   Proenca-Modena, Jose Luiz
   Judice, Carla C.
   Costa, Fabio T. M.
   Ekins, Sean
   Perryman, Alexander L.
   Andrade, Carolina Horta
TI The A-Z of Zika drug discovery
SO DRUG DISCOVERY TODAY
LA English
DT Review
ID VIRUS NS2B-NS3 PROTEASE; NORDIHYDROGUAIARETIC ACID NDGA; INTERFERENCE
   COMPOUNDS PAINS; SMALL-MOLECULE INHIBITORS; DEPENDENT RNA-POLYMERASE;
   INFECTION IN-VITRO; DENGUE VIRUS; BROAD-SPECTRUM; CRYSTAL-STRUCTURE;
   ANTIVIRAL ACTIVITY
AB Despite the recent outbreak of Zika virus (ZIKV), there are still no approved treatments, and early-stage compounds are probably many years away from approval. A comprehensive A-Z review of the recent advances in ZIKV drug discovery efforts is presented, highlighting drug repositioning and computationally guided compounds, including discovered viral and host cell inhibitors. Promising ZIKV molecular targets are also described and discussed, as well as targets belonging to the host cell, as new opportunities for ZIKV drug discovery. All this knowledge is not only crucial to advancing the fight against the Zika virus and other flaviviruses but also helps us prepare for the next emerging virus outbreak to which we will have to respond.
C1 [Mottin, Melina; Borba, Joyce V. V. B.; Braga, Rodolpho C.; Andrade, Carolina Horta] Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.
   [Torres, Pedro H. M.] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, BR-21040900 Rio De Janeiro, RJ, Brazil.
   [Torres, Pedro H. M.] Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.
   [Martini, Matheus C.; Proenca-Modena, Jose Luiz] Univ Estadual Campinas, Lab Emerging Viruses LEVE, Dept Genet Evolut Microbiol & Immunol, Inst Biol, BR-13083864 Campinas, SP, Brazil.
   [Judice, Carla C.; Costa, Fabio T. M.; Andrade, Carolina Horta] Univ Estadual Campinas, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Dept Genet Evolut Microbiol & Immunol, Inst Biol, BR-13083864 Campinas, SP, Brazil.
   [Ekins, Sean] Collaborat Pharmaceut Inc, 840 Main Campus Dr,Lab 3510, Raleigh, NC 27606 USA.
   [Perryman, Alexander L.] Rutgers State Univ, New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, Newark, NJ 07103 USA.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Farm, LabMol Lab Mol Modeling & Drug Design, BR-74605170 Goiania, Go, Brazil.; Andrade, CH (corresponding author), Univ Estadual Campinas, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Dept Genet Evolut Microbiol & Immunol, Inst Biol, BR-13083864 Campinas, SP, Brazil.
EM carolina@ufg.br
RI Borba, Joyce V. B./S-7813-2018; Braga, Rodolpho C/A-9655-2011; Mottin,
   Melina/D-8700-2016; Modena, Jose Luiz Proenca/C-8231-2014; Torres, Pedro
   Henrique Monteiro/C-7657-2015; Martini, Matheus C/E-9416-2015;
   Proenca-Modena, Jose Luiz/AAU-7622-2020; Costa, Fabio/E-1181-2012;
   Judice, Carla/P-4738-2014
OI Borba, Joyce V. B./0000-0002-2663-5173; Braga, Rodolpho
   C/0000-0003-3814-3464; Mottin, Melina/0000-0003-0878-9029; Modena, Jose
   Luiz Proenca/0000-0002-4996-3153; Torres, Pedro Henrique
   Monteiro/0000-0002-0945-1495; Martini, Matheus C/0000-0003-0135-4364;
   Proenca-Modena, Jose Luiz/0000-0002-4996-3153; Costa,
   Fabio/0000-0001-9969-7300; Judice, Carla/0000-0003-1839-053X
FU Brazilian CNPq/FAPEG DCR [300508/2017-4]; Sao Paulo Research Foundation
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [16/00194-8, 2017/02353-9, 2016/13805-5, 2012/16525-2]; FAPESP Visiting
   Researcher Program [2017/02353-9]; CNPqNational Council for Scientific
   and Technological Development (CNPq); L'Oreal-UNESCO-ABC Para Mulheres
   na Ciencia; L'Oreal-UNESCO International Rising Talents Program
FX This work was partially supported by the Brazilian CNPq/FAPEG DCR Grant
   300508/2017-4 and by the Sao Paulo Research Foundation (FAPESP) Grants
   16/00194-8, 2017/02353-9, 2016/13805-5, 2012/16525-2. C.H.A. thanks the
   FAPESP Visiting Researcher Program (grant 2017/02353-9). F.T.M.C. and
   C.H.A. have CNPq productivity fellowships. C.H.A. also thanks the
   L'Oreal-UNESCO-ABC Para Mulheres na Ciencia and L'Oreal-UNESCO
   International Rising Talents Program for the awards and fellowships
   received. We sincerely thank the OpenZika project
   (http://openzika.ufg.br), the wonderful ongoing support and
   encouragement of the IBM's World Community Grid team and the community
   of volunteers who donate their computer time.
CR Adcock RS, 2017, ANTIVIR RES, V138, P47, DOI 10.1016/j.antiviral.2016.11.018
   Al-Bari MAA, 2017, PHARMACOL RES PERSPE, V5, DOI 10.1002/prp2.293
   Albulescu IC, 2017, ANTIVIR RES, V143, P230, DOI 10.1016/j.antiviral.2017.04.016
   Aleshin AE, 2007, PROTEIN SCI, V16, P795, DOI 10.1110/ps.072753207
   Andrae-Marobela K, 2013, CURR DRUG METAB, V14, P392, DOI 10.2174/13892002113149990095
   Ashour J, 2010, CELL HOST MICROBE, V8, P410, DOI 10.1016/j.chom.2010.10.007
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Bahramsoltani R, 2016, EXPERT REV ANTI-INFE, V14, P57, DOI 10.1586/14787210.2016.1120670
   Balasubramanian A, 2017, ANTIVIR RES, V137, P141, DOI 10.1016/j.antiviral.2016.11.015
   Barrow-Grint K, 2016, PLOS NEGLECT TROP D, V10, P1
   Barrows NJ, 2016, CELL HOST MICROBE, V20, P259, DOI 10.1016/j.chom.2016.07.004
   Basavannacharya C, 2014, BIOCHEM BIOPH RES CO, V453, P539, DOI 10.1016/j.bbrc.2014.09.113
   Bekerman E, 2017, J CLIN INVEST, V127, P1338, DOI 10.1172/JCI89857
   Bekerman E, 2015, SCIENCE, V348, P282, DOI 10.1126/science.aaa3778
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Best SM, 2005, J VIROL, V79, P12828, DOI 10.1128/JVI.79.20.12828-12839.2005
   Bhattacharyya S, 2013, CELL HOST MICROBE, V14, P136, DOI 10.1016/j.chom.2013.07.005
   Blazquez AB, 2014, FRONT MICROBIOL, V5, DOI [10.3389/fmicb.2014.00266, 10.3389/fmicb.2014.00797]
   Blecha JE, 2007, BIOORG MED CHEM LETT, V17, P4026, DOI 10.1016/j.bmcl.2007.04.092
   Boldescu V, 2017, NAT REV DRUG DISCOV, V16, P565, DOI 10.1038/nrd.2017.33
   Brecher M, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006411
   Browning DJ, 2014, HYDROXYCHLOROQUINE C
   Byrd CM, 2013, ANTIMICROB AGENTS CH, V57, P1902, DOI 10.1128/AAC.02251-12
   Byrd CM, 2013, ANTIMICROB AGENTS CH, V57, P15, DOI 10.1128/AAC.01429-12
   Cao B, 2017, J EXP MED, V214, P2303, DOI 10.1084/jem.20170957
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Carneiro BM, 2016, VIROLOGY, V496, P215, DOI 10.1016/j.virol.2016.06.012
   Carteaux G, 2016, NEW ENGL J MED, V374, P1595, DOI 10.1056/NEJMc1602964
   Chan JFW, 2017, ANTIVIR RES, V141, P29, DOI 10.1016/j.antiviral.2017.02.002
   Chang JH, 2013, ANTIVIR RES, V99, P251, DOI 10.1016/j.antiviral.2013.06.011
   Ciesek S, 2009, HEPATOLOGY, V50, P1638, DOI 10.1002/hep.23281
   Cihlar T, 2010, ANTIVIR RES, V85, P39, DOI 10.1016/j.antiviral.2009.09.014
   Costello A, 2016, B WORLD HEALTH ORGAN, V94, P406, DOI 10.2471/BLT.16.176990
   Coutard B, 2017, J VIROL, V91, DOI 10.1128/JVI.02202-16
   Crance JM, 2003, ANTIVIR RES, V58, P73, DOI 10.1016/S0166-3542(02)00185-7
   Dai LP, 2016, CELL HOST MICROBE, V19, P696, DOI 10.1016/j.chom.2016.04.013
   Dar HA, 2017, INFECT GENET EVOL, V51, P143, DOI 10.1016/j.meegid.2017.03.027
   De Clercq E, 2011, ANNU REV PHARMACOL, V51, P1, DOI 10.1146/annurev-pharmtox-010510-100228
   Delvecchio R, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8120322
   Denisova OV, 2012, J BIOL CHEM, V287, P35324, DOI 10.1074/jbc.M112.392142
   Duan D, 2015, ACS CHEM BIOL, V10, P978, DOI 10.1021/cb5009487
   Egger D, 2002, J VIROL, V76, P5974, DOI 10.1128/JVI.76.12.5974-5984.2002
   Ekins S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005023
   Ekins Sean, 2016, F1000Res, V5, P275
   Ekins Sean, 2016, F1000Res, V5, P150, DOI 10.12688/f1000research.8013.1
   Eyer L, 2017, ANTIVIR RES, V142, P63, DOI 10.1016/j.antiviral.2017.03.012
   Eyer L, 2016, J INFECT DIS, V214, P707, DOI 10.1093/infdis/jiw226
   Faye O, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002636
   Fernando S, 2016, MOL BIOTECHNOL, V58, P801, DOI 10.1007/s12033-016-9979-1
   Fonseca BD, 2012, J BIOL CHEM, V287, P17530, DOI 10.1074/jbc.M112.359638
   Food and Drug Administration HHS, 2014, Fed Regist, V79, P72063
   Furtado JM, 2016, NEW ENGL J MED, V375, P394, DOI 10.1056/NEJMc1603618
   Goder V, 2012, CURR PROTEIN PEPT SC, V13, P425, DOI 10.2174/138920312802430572
   Grant A, 2016, CELL HOST MICROBE, V19, P882, DOI 10.1016/j.chom.2016.05.009
   Hazin AN, 2016, NEW ENGL J MED, V374, P2193, DOI 10.1056/NEJMc1603617
   Heaton NS, 2010, P NATL ACAD SCI USA, V107, P17345, DOI 10.1073/pnas.1010811107
   Hedstrom L, 2009, CHEM REV, V109, P2903, DOI 10.1021/cr900021w
   Hercik K, 2017, ARCH VIROL, V162, P2091, DOI 10.1007/s00705-017-3345-x
   Hercik K, 2017, ANTIVIR RES, V137, P131, DOI 10.1016/j.antiviral.2016.11.020
   Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5
   Hussein HA, 2015, NUCLEIC ACIDS RES, V43, pW436, DOI 10.1093/nar/gkv462
   Ikeda M, 2006, HEPATOLOGY, V44, P117, DOI 10.1002/hep.21232
   Jain R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01756-7
   Jain R, 2016, NAT STRUCT MOL BIOL, V23, P752, DOI 10.1038/nsmb.3258
   Julander JG, 2017, ANTIVIR RES, V137, P14, DOI 10.1016/j.antiviral.2016.11.003
   Jurgeit A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002976
   Kanno Tomoko, 2002, Physiological Chemistry and Physics and Medical NMR, V34, P1
   Kota S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032207
   Kuivanen S, 2017, ANTIVIR RES, V139, P117, DOI 10.1016/j.antiviral.2016.12.022
   Laurent-Rolle M, 2014, CELL HOST MICROBE, V16, P314, DOI 10.1016/j.chom.2014.07.015
   Lee H, 2017, ANTIVIR RES, V139, P49, DOI 10.1016/j.antiviral.2016.12.016
   Lei J, 2016, SCIENCE, V353, P503, DOI 10.1126/science.aag2419
   Leon D, 2016, FEBS OPEN BIO, V6, P1000, DOI 10.1002/2211-5463.12106
   Li CF, 2017, IMMUNITY, V46, P446, DOI 10.1016/j.immuni.2017.02.012
   Li T, 2018, CELL RES, V28, P497, DOI 10.1038/s41422-018-0007-9
   Li Y, 2017, STRUCTURE, V25, P1242, DOI 10.1016/j.str.2017.06.006
   Li Z, 2017, CELL RES, V27, P1046, DOI 10.1038/cr.2017.88
   Liang QM, 2016, CELL STEM CELL, V19, P663, DOI 10.1016/j.stem.2016.07.019
   Lim HJ, 2017, BIOTECHNOL LETT, V39, P415, DOI 10.1007/s10529-016-2261-6
   Lim SP, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005737
   Lim SP, 2015, ANTIVIR RES, V119, P57, DOI 10.1016/j.antiviral.2015.04.010
   Lim SP, 2013, ANTIVIR RES, V100, P500, DOI 10.1016/j.antiviral.2013.09.013
   Lin RJ, 2006, J VIROL, V80, P5908, DOI 10.1128/JVI.02714-05
   Lindenbach BD, 2007, FIELDS VIROLOGY, P1101
   Lu G, 2017, ANTIMICROB AGENTS CH, V61, P1
   Lu J.-M, 2010, MED SCI MONITOR, DOI [10.1111/j.1600-6143.2008.02497.x.Plasma, DOI 10.1111/J.1600-6143.2008.02497.X.PLASMA]
   Lucas-Hourani M, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003678
   Luo D, 2008, J VIROL, V82, P173, DOI 10.1128/JVI.01788-07
   Mastrangelo E, 2007, J MOL BIOL, V372, P444, DOI 10.1016/j.jmb.2007.06.055
   Mastrangelo E, 2012, J ANTIMICROB CHEMOTH, V67, P1884, DOI 10.1093/jac/dks147
   McGovern SL, 2002, J MED CHEM, V45, P1712, DOI 10.1021/jm010533y
   McGrath J, 2015, PHARMACOL THERAPEUT, V150, P1, DOI 10.1016/j.pharmthera.2015.01.002
   Mecharles S, 2016, LANCET, V8, P6736, DOI DOI 10.1136/BCR-2012-007094.4
   Meertens L, 2017, CELL REP, V18, P324, DOI 10.1016/j.celrep.2016.12.045
   Meertens L, 2012, CELL HOST MICROBE, V12, P544, DOI 10.1016/j.chom.2012.08.009
   Merino-Ramos T, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00376-17, 10.1128/aac.00376-17]
   Metz JT, 2007, J COMPUT AID MOL DES, V21, P139, DOI 10.1007/s10822-007-9109-z
   Miller S, 2006, J BIOL CHEM, V281, P8854, DOI 10.1074/jbc.M512697200
   Miller S, 2007, J BIOL CHEM, V282, P8873, DOI 10.1074/jbc.M609919200
   Mohr EL, 2015, ANTIVIR RES, V120, P40, DOI 10.1016/j.antiviral.2015.05.003
   Monel B, 2017, EMBO J, V36, P1653, DOI 10.15252/embj.201695597
   Mottin M., 2017, BIOCHEM BIOPH RES CO, V2017, P1
   Mumtaz N, 2017, ANTIVIR RES, V146, P161, DOI 10.1016/j.antiviral.2017.09.004
   Noble CG, 2012, J VIROL, V86, P438, DOI 10.1128/JVI.06225-11
   Park GS, 2007, J VIROL, V81, P6936, DOI 10.1128/JVI.02830-06
   Pascoalino Bruno S, 2016, F1000Res, V5, P2523
   Patkar CG, 2009, ANTIMICROB AGENTS CH, V53, P4103, DOI 10.1128/AAC.00074-09
   Perera R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002584
   Pernia Sonia, 2016, P T, V41, P713
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pouliot M, 2016, J MED CHEM, V59, P497, DOI 10.1021/acs.jmedchem.5b00361
   Qing M, 2009, ANTIMICROB AGENTS CH, V53, P3226, DOI 10.1128/AAC.00189-09
   Qu XW, 2011, ANTIMICROB AGENTS CH, V55, P1036, DOI 10.1128/AAC.01319-10
   Ram B. M., 1843, BIOCHIM BIOPHYS ACTA, P2497
   Ramharack P, 2018, J BIOMOL STRUCT DYN, V36, P1118, DOI 10.1080/07391102.2017.1313175
   Rausch K, 2017, CELL REP, V18, P804, DOI 10.1016/j.celrep.2016.12.068
   Rishton GM, 2003, DRUG DISCOV TODAY, V8, P86, DOI 10.1016/S1359644602025722
   Rothwell C, 2009, VIROLOGY, V389, P8, DOI 10.1016/j.virol.2009.03.025
   Roy A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170541
   Sahoo Maheswata, 2016, Genomics & Informatics, V14, P104, DOI 10.5808/GI.2016.14.3.104
   Saladino R, 2008, CURR MED CHEM, V15, P1500, DOI 10.2174/092986708784638889
   SALARI H, 1984, PROSTA LEUKOTR MED, V13, P53, DOI 10.1016/0262-1746(84)90102-1
   Samsa MM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000632
   Sarkey JP, 2007, J NEUROCHEM, V100, P1265, DOI 10.1111/j.1471-4159.2006.04309.x
   Savidis G, 2016, CELL REP, V16, P232, DOI 10.1016/j.celrep.2016.06.028
   Saw WG, 2017, ANTIVIR RES, V141, P73, DOI 10.1016/j.antiviral.2017.02.005
   Scaturro P, 2014, J VIROL, V88, P11540, DOI 10.1128/JVI.01745-14
   Shang B.-D., 2015, J GEN VIROL, V96, P1264
   Shang ZF, 2018, J MOL BIOL, V430, P948, DOI 10.1016/j.jmb.2018.02.006
   Sharma N, 2017, INT J BIOL MACROMOL, V104, P1046, DOI 10.1016/j.ijbiomac.2017.06.105
   Shiryaev SA, 2017, ANTIVIR RES, V143, P218, DOI 10.1016/j.antiviral.2017.04.015
   Sirohi D., 2016, SCIENCE, DOI [10.1126/science.aafS316, DOI 10.1126/SCIENCE.AAFS316]
   Smit JM, 2011, VIRUSES-BASEL, V3, P160, DOI 10.3390/v3020160
   Sperandio S, 2004, CELL DEATH DIFFER, V11, P1066, DOI 10.1038/sj.cdd.4401465
   Stephen P, 2016, J AM CHEM SOC, V138, P16212, DOI 10.1021/jacs.6b10399
   Stevens AJ, 2009, J MED CHEM, V52, P7911, DOI 10.1021/jm900652e
   Stevenson B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001188
   Syed GH, 2011, HEPATOLOGY, V54, P1936, DOI 10.1002/hep.24619
   Tang HL, 2016, CELL STEM CELL, V18, P587, DOI 10.1016/j.stem.2016.02.016
   Tang WC, 2014, J VIROL, V88, P6793, DOI 10.1128/JVI.00045-14
   Tay MYF, 2013, ANTIVIR RES, V99, P301, DOI 10.1016/j.antiviral.2013.06.002
   Tiwari SK, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.9
   Tritsch D, 2015, BIOORG CHEM, V59, P140, DOI 10.1016/j.bioorg.2015.02.008
   Umareddy I, 2006, J GEN VIROL, V87, P2605, DOI 10.1099/vir.0.81844-0
   van Cleef KWR, 2013, ANTIVIR RES, V99, P165, DOI 10.1016/j.antiviral.2013.05.011
   Varghese FS, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.02227-16, 10.1128/aac.02227-16]
   Versteeg GA, 2010, CURR OPIN MICROBIOL, V13, P508, DOI 10.1016/j.mib.2010.05.009
   Wagstaff K. M., 2012, BIOCHEM J, P443
   Wang BX, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14763
   Wang QY, 2015, J VIROL, V89, P8233, DOI 10.1128/JVI.00855-15
   Wang ZY, 2017, J GEN VIROL, V98, P2061, DOI 10.1099/jgv.0.000886
   Warren TK, 2014, NATURE, V508, P402, DOI 10.1038/nature13027
   Watterson D, 2016, ANTIVIR RES, V130, P7, DOI 10.1016/j.antiviral.2016.02.014
   Whitehorn J, 2016, CLIN INFECT DIS, V62, P468, DOI 10.1093/cid/civ949
   Wu YH, 2016, WORLD J GASTROENTERO, V22, P188, DOI 10.3748/wjg.v22.i1.188
   Xie XP, 2017, J INFECT DIS, V216, pS945, DOI 10.1093/infdis/jix406
   Xie XP, 2015, ANTIVIR RES, V118, P39, DOI 10.1016/j.antiviral.2015.03.007
   Xie XP, 2011, J VIROL, V85, P11183, DOI 10.1128/JVI.05468-11
   Xin QL, 2017, J VIROL, V91, DOI [10.1128/jvi.00554-17, 10.1128/JVI.00554-17]
   Xu HT, 2017, J ANTIMICROB CHEMOTH, V72, P727, DOI 10.1093/jac/dkw514
   Xu M, 2016, NAT MED, V22, P1101, DOI 10.1038/nm.4184
   Yang W, 2013, BIOORGAN MED CHEM, V21, P1050, DOI 10.1016/j.bmc.2013.01.013
   Yokoyama T, 2014, J MED CHEM, V57, P8928, DOI 10.1021/jm500997m
   Youn S, 2012, J VIROL, V86, P7360, DOI 10.1128/JVI.00157-12
   Yu GY, 2006, J VIROL, V80, P6013, DOI 10.1128/JVI.00053-06
   Yuan L, 2017, SCIENCE, V358, P933, DOI 10.1126/science.aam7120
   Yuan SF, 2017, ANTIVIR RES, V145, P33, DOI 10.1016/j.antiviral.2017.07.007
   Zavodovskaya M, 2008, J CELL BIOCHEM, V103, P624, DOI 10.1002/jcb.21435
   Zhang ZZ, 2016, SCIENCE, V354, P1597, DOI 10.1126/science.aai9309
   Zhao BY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14762
   Zmurko J, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004695
   Zou J, 2015, J VIROL, V89, P3455, DOI 10.1128/JVI.03453-14
NR 172
TC 15
Z9 16
U1 2
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-6446
EI 1878-5832
J9 DRUG DISCOV TODAY
JI Drug Discov. Today
PD NOV
PY 2018
VL 23
IS 11
BP 1833
EP 1847
DI 10.1016/j.drudis.2018.06.014
PG 15
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA HD5NT
UT WOS:000452577900006
PM 29935345
OA Green Published
DA 2020-12-08
ER

PT J
AU Bittencourt, NC
   Leite, JA
   Silva, ABIE
   Pimenta, TS
   Silva, JL
   Cassiano, GC
   Lopes, SCP
   dos-Santos, JCK
   Bourgard, C
   Nakaya, HI
   Ventura, AMRD
   Lacerda, MVG
   Ferreira, MU
   Machado, RLD
   Albrecht, L
   Costa, FTM
AF Bittencourt, Najara C.
   Leite, Juliana A.
   Silva, Ana Beatriz I. E.
   Pimenta, Tamirys S.
   Silva-Filho, Joao Luiz
   Cassiano, Gustavo C.
   Lopes, Stefanie C. P.
   dos-Santos, Joao C. K.
   Bourgard, Catarina
   Nakaya, Helder I.
   Revoredo da Silva Ventura, Ana Maria
   Lacerda, Marcus V. G.
   Ferreira, Marcelo U.
   Machado, Ricardo L. D.
   Albrecht, Letusa
   Costa, Fabio T. M.
TI Genetic sequence characterization and naturally acquired immune response
   to Plasmodium vivax Rhoptry Neck Protein 2 (PvRON2)
SO MALARIA JOURNAL
LA English
DT Article
DE Genetic diversity; RON2; Plasmodium vivax; Immunogenicity; Malaria
ID APICAL MEMBRANE ANTIGEN-1; MEROZOITE SURFACE PROTEIN-1; HOST-CELL
   INVASION; VACCINE CANDIDATE; ANTIBODY-RESPONSE; FALCIPARUM; DIVERSITY;
   SELECTION; MALARIA; POLYMORPHISM
AB BackgroundThe genetic diversity of malaria antigens often results in allele variant-specific immunity, imposing a great challenge to vaccine development. Rhoptry Neck Protein 2 (PvRON2) is a blood-stage antigen that plays a key role during the erythrocyte invasion of Plasmodium vivax. This study investigatesthe genetic diversity of PvRON2 and the naturally acquired immune response to P. vivax isolates.ResultsHere, the genetic diversity of PvRON2(1828-2080) and the naturally acquired humoral immune response against PvRON2(1828-2080) in infected and non-infected individuals from a vivax malaria endemic area in Brazil was reported. The diversity analysis of PvRON2(1828-2080) revealed that the protein is conserved in isolates in Brazil and worldwide. A total of 18 (19%) patients had IgG antibodies to PvRON2(1828-2080). Additionally, the analysis of the antibody response in individuals who were not acutely infected with malaria, but had been infected with malaria in the past indicated that 32 patients (33%) exhibited an IgG immune response against PvRON2.ConclusionsPvRON2 was conserved among the studied isolates. The presence of naturally acquired antibodies to this protein in the absence of the disease suggests that PvRON2 induces a long-term antibody response. These results indicate that PvRON2 is a potential malaria vaccine candidate.
C1 [Bittencourt, Najara C.; Leite, Juliana A.; Silva-Filho, Joao Luiz; Cassiano, Gustavo C.; dos-Santos, Joao C. K.; Bourgard, Catarina; Costa, Fabio T. M.] Univ Campinas UNICAMP, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Campinas, SP, Brazil.
   [Silva, Ana Beatriz I. E.; Albrecht, Letusa] Fiocruz MS, Fundacao Oswaldo Cruz, Inst Carlos Chagas, Curitiba, PR, Brazil.
   [Pimenta, Tamirys S.; Revoredo da Silva Ventura, Ana Maria; Machado, Ricardo L. D.] Inst Evandro Chagas SVS MS, Lab Ensaios Clin & Imunogenet Malaria, Ananindeua, PA, Brazil.
   [Lopes, Stefanie C. P.; Lacerda, Marcus V. G.] Fiocruz MS, Fundacao Oswaldo Cruz, Inst Leonidas & Maria Deane, Manaus, AM, Brazil.
   [Lopes, Stefanie C. P.; Lacerda, Marcus V. G.] Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, AM, Brazil.
   [Nakaya, Helder I.] Univ Sao Paulo, Sch Pharmaceut Sci, Sao Paulo, Brazil.
   [Ferreira, Marcelo U.] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, Brazil.
RP Costa, FTM (corresponding author), Univ Campinas UNICAMP, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Campinas, SP, Brazil.; Albrecht, L (corresponding author), Fiocruz MS, Fundacao Oswaldo Cruz, Inst Carlos Chagas, Curitiba, PR, Brazil.
EM letusa.albrecht@fiocruz.br; costaftm@unicamp.br
RI Nakaya, Helder I/A-1397-2010; Cassiano, Gustavo C/G-5728-2013; Ferreira,
   Marcelo U/G-8289-2011; ventura, ana maria r s/E-4027-2017; Machado,
   Ricardo Luiz Dantas Dantas/P-1288-2014; Bourgard, Catarina/N-3630-2019;
   Bourgard, Catarina/AAF-8186-2020; Albrecht, Letusa/I-1837-2012; Pimenta,
   Tamirys Simao/AAT-1853-2020; Nakaya, Helder/AAF-1738-2020; Silva-Filho,
   Joao Luiz/I-5704-2016; Costa, Fabio/E-1181-2012
OI Nakaya, Helder I/0000-0001-5297-9108; Cassiano, Gustavo
   C/0000-0002-6971-5974; Ferreira, Marcelo U/0000-0002-5293-9090; ventura,
   ana maria r s/0000-0002-4737-1533; Machado, Ricardo Luiz Dantas
   Dantas/0000-0002-8955-3204; Bourgard, Catarina/0000-0003-3469-703X;
   Albrecht, Letusa/0000-0001-6406-2057; Pimenta, Tamirys
   Simao/0000-0001-7588-6203; Nakaya, Helder/0000-0001-5297-9108;
   Silva-Filho, Joao Luiz/0000-0003-4762-2205; Costa,
   Fabio/0000-0001-9969-7300; Lopes, Stefanie/0000-0002-6981-2192
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/16525-2];
   Evandro Chagas core grant;  [2015/02808-0];  [2013/25807-4]; 
   [2016/12855-9];  [2015/20774-6];  [2013/20509-5]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) Grant 2012/16525-2, and fellowships grants
   2015/02808-0 (to NB), 2013/25807-4 (to JAL), 2016/12855-9 (to JLS-F),
   2015/20774-6 (to GCC), 2013/20509-5 (to CB). Evandro Chagas core grant
   (to RLDM). MUF, MVGL and FTMC are Conselho Nacional do Desenvolvimento
   Cientifico e Tecnologico (CNPq) research fellows.2
CR Alexander DL, 2005, PLOS PATHOG, V1, P137, DOI 10.1371/journal.ppat.0010017
   Amoah LE, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2338-7
   Arevalo-Pinzon G, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-60
   Arnott A, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-233
   Arnott A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002506
   Aurrecoechea C, 2009, NUCLEIC ACIDS RES, V37, pD539, DOI 10.1093/nar/gkn814
   Baird JK, 1998, ANN TROP MED PARASIT, V92, P367, DOI 10.1080/00034989859366
   Bargieri DY, 2010, VACCINE, V28, P2818, DOI 10.1016/j.vaccine.2010.02.004
   Barry AE, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00359
   Benson DA, 2005, NUCLEIC ACIDS RES, V33, pD34, DOI 10.1093/nar/gki063
   Bermudez M, 2018, CELL MICROBIOL, V20, DOI 10.1111/cmi.12835
   Buitrago SP, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1563-4
   Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358
   Cao J, 2009, PARASITOL INT, V58, P29, DOI 10.1016/j.parint.2008.09.005
   Chenet SM, 2013, INFECT GENET EVOL, V20, P239, DOI 10.1016/j.meegid.2013.09.011
   Cole-Tobian J, 2003, MOL BIOCHEM PARASIT, V127, P121, DOI 10.1016/S0166-6851(02)00327-4
   Collins CR, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000273
   Cortes A, 2003, INFECT IMMUN, V71, P1416, DOI 10.1128/IAI.71.3.1416-1426.2003
   de Cassan SC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00348
   de Sousa TN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022944
   Dias S, 2013, GENE, V518, P381, DOI 10.1016/j.gene.2013.01.003
   Escalante AA, 2001, MOL BIOCHEM PARASIT, V113, P279, DOI 10.1016/S0166-6851(01)00229-8
   Ferreira MU, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1335-1
   Ferreira MU, 1998, MEM I OSWALDO CRUZ, V93, P631, DOI 10.1590/S0074-02761998000500013
   Garg S, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-154
   Garzon-Ospina D, 2015, INFECT GENET EVOL, V33, P182, DOI 10.1016/j.meegid.2015.05.001
   Garzon-Ospina D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045962
   Garzon-Ospina D, 2010, INFECT GENET EVOL, V10, P261, DOI 10.1016/j.meegid.2009.12.004
   Gentil F, 2010, VACCINE, V28, P6183, DOI 10.1016/j.vaccine.2010.07.017
   Giovannini D, 2011, CELL HOST MICROBE, V10, P591, DOI 10.1016/j.chom.2011.10.012
   Gomez A, 2006, PARASITOLOGY, V133, P661, DOI 10.1017/S0031182006001168
   Goncalves R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048469
   Gonzalez-Ceron L, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1266-7
   Gunasekera AM, 2007, MOL BIOL EVOL, V24, P939, DOI 10.1093/molbev/msm013
   Gutierrez A, 2000, EXP PARASITOL, V95, P215, DOI 10.1006/expr.2000.4534
   Khosravi A, 2011, PARASITE IMMUNOL, V33, P145, DOI 10.1111/j.1365-3024.2010.01260.x
   KOLASKAR AS, 1990, FEBS LETT, V276, P172, DOI 10.1016/0014-5793(90)80535-Q
   Lopez C, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00156
   MARQUES AC, 1987, PARASITOL TODAY, V3, P166, DOI 10.1016/0169-4758(87)90170-0
   Marsh K, 2006, PARASITE IMMUNOL, V28, P51, DOI 10.1111/j.1365-3024.2006.00808.x
   MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315
   Mehrizi AA, 2016, INFECT GENET EVOL, V43, P50, DOI 10.1016/j.meegid.2016.05.015
   Moll K., 2008, METHODS MALARIA RES
   Moon SU, 2010, ACTA TROP, V114, P71, DOI 10.1016/j.actatropica.2010.01.006
   Mueller I, 2015, VACCINE, V33, P7489, DOI 10.1016/j.vaccine.2015.09.060
   Mueller I, 2013, ADV PARASIT, V81, P77, DOI 10.1016/B978-0-12-407826-0.00003-5
   Ord RL, 2016, INFECT IMMUN, V84, P1574, DOI 10.1128/IAI.00107-16
   Patel P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182674
   Pizarro JC, 2005, SCIENCE, V308, P408, DOI 10.1126/science.1107449
   Prajapati SK, 2010, J VECTOR DIS, V47, P85
   Putaporntip C, 2001, GENE, V268, P97, DOI 10.1016/S0378-1119(01)00425-5
   Putaporntip C, 2009, INFECT GENET EVOL, V9, P821, DOI 10.1016/j.meegid.2009.04.017
   Recht J, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-1925-6
   Richards JS, 2013, J IMMUNOL, V191, P795, DOI 10.4049/jimmunol.1300778
   Richards JS, 2009, IMMUNOL CELL BIOL, V87, P377, DOI 10.1038/icb.2009.27
   Rodrigues-da-Silva RN, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00077
   Rouhani M, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0547-0
   Sambrook J., 2006, CSH PROTOC, V2006, P1, DOI DOI 10.1101/PDB.PR0T3944
   Snounou Georges, 2002, Methods Mol Med, V72, P189, DOI 10.1385/1-59259-271-6:189
   Spring MD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005254
   Srinivasan P, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0015-7
   Srinivasan P, 2014, P NATL ACAD SCI USA, V111, P10311, DOI 10.1073/pnas.1409928111
   Srinivasan P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3261
   Srinivasan P, 2011, P NATL ACAD SCI USA, V108, P13275, DOI 10.1073/pnas.1110303108
   Stowers AW, 2002, INFECT IMMUN, V70, P6961, DOI 10.1128/IAI.70.12.6961-6967.2002
   Takala SL, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000257
   Tang JX, 2012, PARASITOLOGY, V139, P709, DOI 10.1017/S0031182011002447
   Taylor RR, 1998, AM J TROP MED HYG, V58, P406, DOI 10.4269/ajtmh.1998.58.406
   Thakur A, 2008, GENE, V419, P35, DOI 10.1016/j.gene.2008.04.012
   Thera MA, 2011, NEW ENGL J MED, V365, P1004, DOI 10.1056/NEJMoa1008115
   Tonkin ML, 2011, SCIENCE, V333, P463, DOI 10.1126/science.1204988
   Vallejo AF, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1104-1
   Vicentin EC, 2014, INFECT IMMUN, V82, P1296, DOI 10.1128/IAI.01169-13
   Vulliez-Le Normand B, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002755
   Vulliez-LeNormand B, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.018319828817634, DOI 10.1371/JOURNAL.PONE.0183198]
   Weaver R, 2016, SCI REP-UK, V6, DOI 10.1038/srep33094
   Yeom JS, 2008, J PARASITOL, V94, P1410, DOI 10.1645/GE-1484.1
   Zakeri S, 2006, TROP MED INT HEALTH, V11, P729, DOI 10.1111/j.1365-3156.2006.01613.x
   Zeyrek FY, 2006, PARASITE IMMUNOL, V28, P201, DOI 10.1111/j.1365-3024.2006.00822.x
NR 79
TC 3
Z9 3
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD OCT 31
PY 2018
VL 17
AR 401
DI 10.1186/s12936-018-2543-7
PG 13
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA GZ1FO
UT WOS:000449112600001
PM 30382855
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Bastos, MF
   Kayano, ACAV
   Silva, JL
   Dos-Santos, JCK
   Judice, C
   Blanco, YC
   Shryock, N
   Sercundes, MK
   Ortolan, LS
   Francelin, C
   Leite, JA
   Oliveira, R
   Elias, RM
   Camara, NOS
   Lopes, SCP
   Albrecht, L
   Farias, AS
   Vicente, CP
   Werneck, CC
   Giorgio, S
   Verinaud, L
   Epiphanio, S
   Marinho, CRF
   Lalwani, P
   Amino, R
   Aliberti, J
   Costa, FTM
AF Bastos, Marcele F.
   Kayano, Ana Carolina A. V.
   Silva-Filho, Joao Luiz
   Dos-Santos, Joao Conrado K.
   Judice, Carla
   Blanco, Yara C.
   Shryock, Nathaniel
   Sercundes, Michelle K.
   Ortolan, Luana S.
   Francelin, Carolina
   Leite, Juliana A.
   Oliveira, Rafaella
   Elias, Rosa M.
   Camara, Niels O. S.
   Lopes, Stefanie C. P.
   Albrecht, Letusa
   Farias, Alessandro S.
   Vicente, Cristina P.
   Werneck, Claudio C.
   Giorgio, Selma
   Verinaud, Liana
   Epiphanio, Sabrina
   Marinho, Claudio R. F.
   Lalwani, Pritesh
   Amino, Rogerio
   Aliberti, Julio
   Costa, Fabio T. M.
TI Inhibition of hypoxia-associated response and kynurenine production in
   response to hyperbaric oxygen as mechanisms involved in protection
   against experimental cerebral malaria
SO FASEB JOURNAL
LA English
DT Article
DE brain; aryl-hydrocarbon receptor; tryptophan metabolism; endothelial
   cell activation
ID ARYL-HYDROCARBON RECEPTOR; INDUCIBLE FACTOR-I; BLOOD-BRAIN-BARRIER;
   CD8(+) T-CELLS; HEME OXYGENASE-1; COGNITIVE IMPAIRMENT; PATHWAY
   METABOLISM; AFRICAN CHILDREN; INFLAMMATION; SEQUESTRATION
AB Cerebral malaria (CM) is a multifactorial syndrome involving an exacerbated proinflammatory status, endothelial cell activation, coagulopathy, hypoxia, and accumulation of leukocytes and parasites in the brain microvasculature. Despite significant improvements in malaria control, 15% of mortality is still observed in CM cases, and 25% of survivors develop neurologic sequelae for lifeeven after appropriate antimalarial therapy. A treatment that ameliorates CM clinical signs, resulting in complete healing, is urgently needed. Previously, we showed a hyperbaric oxygen (HBO)-protective effect against experimental CM. Here, we provide molecular evidence that HBO targets brain endothelial cells by decreasing their activation and inhibits parasite and leukocyte accumulation, thus improving cerebral microcirculatory blood flow. HBO treatment increased the expression of aryl hydrocarbon receptor over hypoxia-inducible factor 1- (HIF-1), an oxygen-sensitive cytosolic receptor, along with decreased indoleamine 2,3-dioxygenase 1 expression and kynurenine levels. Moreover, ablation of HIF-1 expression in endothelial cells in mice conferred protection against CM and improved survival. We propose that HBO should be pursued as an adjunctive therapy in CM patients to prolong survival and diminish deleterious proinflammatory reaction. Furthermore, our data support the use of HBO in therapeutic strategies to improve outcomes of non-CM disorders affecting the brain.Bastos, M. F., Kayano, A. C. A. V., Silva-Filho, J. L., Dos-Santos, J. C. K., Judice, C., Blanco, Y. C., Shryock, N., Sercundes, M. K., Ortolan, L. S., Francelin, C., Leite, J. A., Oliveira, R., Elias, R. M., Camara, N. O. S., Lopes, S. C. P., Albrecht, L., Farias, A. S., Vicente, C. P., Werneck, C. C., Giorgio, S., Verinaud, L., Epiphanio, S., Marinho, C. R. F., Lalwani, P., Amino, R., Aliberti, J., Costa, F. T. M. Inhibition of hypoxia-associated response and kynurenine production in response to hyperbaric oxygen as mechanisms involved in protection against experimental cerebral malaria.
C1 [Bastos, Marcele F.; Kayano, Ana Carolina A. V.; Silva-Filho, Joao Luiz; Dos-Santos, Joao Conrado K.; Judice, Carla; Blanco, Yara C.; Leite, Juliana A.; Lopes, Stefanie C. P.; Albrecht, Letusa; Farias, Alessandro S.; Costa, Fabio T. M.] Univ Estadual Campinas, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Campinas, SP, Brazil.
   [Francelin, Carolina; Verinaud, Liana] Univ Estadual Campinas, Dept Funct & Struct Biol, Campinas, SP, Brazil.
   [Werneck, Claudio C.] Univ Estadual Campinas, Dept Biochem & Tissue Biol, Campinas, SP, Brazil.
   [Giorgio, Selma] Univ Estadual Campinas, Dept Anim Biol, Campinas, SP, Brazil.
   [Shryock, Nathaniel; Aliberti, Julio] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
   [Sercundes, Michelle K.; Ortolan, Luana S.; Vicente, Cristina P.; Epiphanio, Sabrina] Univ Sao Paulo, Dept Clin & Toxicol Anal, Sao Paulo, Brazil.
   [Elias, Rosa M.; Camara, Niels O. S.] Univ Sao Paulo, Dept Immunol, Sao Paulo, Brazil.
   [Marinho, Claudio R. F.] Univ Sao Paulo, Dept Parasitol, Sao Paulo, Brazil.
   [Oliveira, Rafaella; Lopes, Stefanie C. P.; Lalwani, Pritesh] Fundacao Oswaldo Cruz, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil.
   [Albrecht, Letusa] Fundacao Oswaldo Cruz, Inst Carlos Chagas, Curitiba, Parana, Brazil.
   [Amino, Rogerio] Inst Pasteur, Unit Malaria Infect & Immun, Paris, France.
   [Aliberti, Julio] NIAID, Div Extramural Act, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Aliberti, J (corresponding author), NIAID, Div Extramural Act, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.; Aliberti, J (corresponding author), NIAID, Sci Review Program, Div Extramural Act, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.; Costa, FTM (corresponding author), Univ Estadual Campinas, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, UNICAMP, Rua Monteiro Lobato 255, BR-13083862 Campinas, SP, Brazil.
EM julio.aliberti@nih.gov; costaftm@unicamp.br
RI Farias, Alessandro/C-6879-2012; Albrecht, Letusa/I-1837-2012;
   Silva-Filho, Joao Luiz/I-5704-2016; Farias, Alessandro/AAH-2228-2020;
   Costa, Fabio/E-1181-2012; Camara, Niels OS/G-8336-2011; Epiphanio,
   Sabrina/C-7572-2012; Francelin, Carolina/AAZ-9572-2020; Epiphanio,
   Sabrina/S-2564-2019; Vicente, Cristina/D-8928-2012; Werneck, Claudio
   C/C-7568-2012; Marinho, Claudio Romero Farias/F-7507-2012; camara,
   niels/AAX-3269-2020
OI Farias, Alessandro/0000-0001-6759-1819; Albrecht,
   Letusa/0000-0001-6406-2057; Silva-Filho, Joao Luiz/0000-0003-4762-2205;
   Farias, Alessandro/0000-0001-6759-1819; Costa,
   Fabio/0000-0001-9969-7300; Camara, Niels OS/0000-0001-5436-1248;
   Epiphanio, Sabrina/0000-0001-6094-9750; Francelin,
   Carolina/0000-0001-7439-3124; Epiphanio, Sabrina/0000-0001-6094-9750;
   Vicente, Cristina/0000-0001-9896-4630; Werneck, Claudio
   C/0000-0002-9413-0572; Marinho, Claudio Romero
   Farias/0000-0002-1227-3845; camara, niels/0000-0001-5436-1248; Lopes,
   Stefanie/0000-0002-6981-2192; dos Santos Ortolan,
   Luana/0000-0003-1153-9987; Amino, Rogerio/0000-0002-8086-2932
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/16525-2,
   2014/20451-0, 2016/07030-0, 2016/12855-9]; FAPESPFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP); U.S. National Institutes of
   Health, National Institute of Allergy and Infectious DiseasesUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [AI118302-02]; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R21AI118302, R21AI118302]
   Funding Source: NIH RePORTER
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) Grants 2012/16525-2 (to F.T.M.C.), 2014/20451-0 (to
   S.E.), 2016/07030-0 (to C.R.F.M.), and 2016/12855-9 (to J.L.S-F.);
   FAPESP (http://www.fapesp.br/en/); and U.S. National Institutes of
   Health, National Institute of Allergy and Infectious Diseases Grant
   AI118302-02. A.S.F., C.C.W., S.G., L.V., S.E., C.R.F.M., and F.T.M.C.
   are Conselho Nacional do Desenvolvimento Cientifico e Tecnologico (CNPq)
   research fellows. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. The authors declare no conflicts of interest.
CR Al-Waili NS, 2005, ADV THER, V22, P659, DOI 10.1007/BF02849960
   Alam J, 2007, AM J RESP CELL MOL, V36, P166, DOI 10.1165/rcmb.2006-0340TR
   Baptista FG, 2010, INFECT IMMUN, V78, P4033, DOI 10.1128/IAI.00079-10
   Belnoue E, 2002, J IMMUNOL, V169, P6369, DOI 10.4049/jimmunol.169.11.6369
   Blanco YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003126
   Brant F, 2014, INFECT IMMUN, V82, P3127, DOI 10.1128/IAI.01733-14
   Cabrales P, 2013, VIRULENCE, V4, P686, DOI 10.4161/viru.26348
   Chakravorty SJ, 2005, EUR J CELL BIOL, V84, P15, DOI 10.1016/j.ejcb.2004.09.002
   Dondorp AM, 2003, REDOX REP, V8, P292, DOI 10.1179/135100003225002934
   Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1
   Dorovini-Zis K, 2011, AM J PATHOL, V178, P2146, DOI 10.1016/j.ajpath.2011.01.016
   Engelhardt S, 2014, J CELL PHYSIOL, V229, P1096, DOI 10.1002/jcp.24544
   Engwerda C, 2005, CURR TOP MICROBIOL, V297, P103
   Fecher RA, 2016, J IMMUNOL, V197, P565, DOI 10.4049/jimmunol.1600342
   FELDMEIER JJ, 2003, HYPERBARIC OXYGEN 20
   Francischetti IMB, 2008, MICROCIRCULATION, V15, P81, DOI 10.1080/10739680701451516
   Gazzinelli RT, 2014, NAT REV IMMUNOL, V14, P744, DOI 10.1038/nri3742
   Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567
   Hempel C, 2011, AM J PATHOL, V179, P1939, DOI 10.1016/j.ajpath.2011.06.027
   Howland SW, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004963
   Howland SW, 2013, EMBO MOL MED, V5, P984, DOI 10.1002/emmm.201202273
   Howland SW, 2015, SEMIN IMMUNOPATHOL, V37, P221, DOI 10.1007/s00281-015-0476-6
   Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1
   Hunt NH, 2007, NAT MED, V13, P667, DOI 10.1038/nm0607-667
   Hunt NH, 2017, NEUROPHARMACOLOGY, V112, P389, DOI 10.1016/j.neuropharm.2016.02.029
   Idro R, 2005, LANCET NEUROL, V4, P827, DOI 10.1016/S1474-4422(05)70247-7
   Jacob A, 2015, J NEUROCHEM, V132, P373, DOI 10.1111/jnc.12972
   Jambou R, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001021
   Jewell UR, 2001, FASEB J, V15, P1312
   John CC, 2008, PEDIATRICS, V122, pE92, DOI 10.1542/peds.2007-3709
   John CC, 2008, AM J TROP MED HYG, V78, P198, DOI 10.4269/ajtmh.2008.78.198
   Kaur C, 2008, CURR NEUROVASC RES, V5, P71, DOI 10.2174/156720208783565645
   Lacerda-Queiroz N, 2010, EXP PARASITOL, V125, P271, DOI 10.1016/j.exppara.2010.02.002
   Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375
   MACPHERSON GG, 1985, AM J PATHOL, V119, P385
   Mascanfroni ID, 2015, NAT MED, V21, P638, DOI 10.1038/nm.3868
   McBerry C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038384
   Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670
   Moxon CA, 2013, BLOOD, V122, P842, DOI 10.1182/blood-2013-03-490219
   Neubauer JA, 2012, RESP PHYSIOL NEUROBI, V184, P178, DOI 10.1016/j.resp.2012.06.027
   Nizet V, 2009, NAT REV IMMUNOL, V9, P609, DOI 10.1038/nri2607
   Ochola LB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014741
   Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9
   Owe-Young R, 2008, J NEUROCHEM, V105, P1346, DOI 10.1111/j.1471-4159.2008.05241.x
   Schwarcz R, 2012, NAT REV NEUROSCI, V13, P465, DOI 10.1038/nrn3257
   Seixas E, 2009, P NATL ACAD SCI USA, V106, P15837, DOI 10.1073/pnas.0903419106
   Sharp FR, 2004, NAT REV NEUROSCI, V5, P437, DOI 10.1038/nrn1408
   Strasser B, 2017, NEUROPHARMACOLOGY, V112, P286, DOI 10.1016/j.neuropharm.2016.02.030
   van der Heyde HC, 2006, TRENDS PARASITOL, V22, P503, DOI 10.1016/j.pt.2006.09.002
   Vignau J, 2004, BIOMED CHROMATOGR, V18, P872, DOI 10.1002/bmc.445
   Vorrink SU, 2014, CHEM-BIOL INTERACT, V218, P82, DOI 10.1016/j.cbi.2014.05.001
   Wang YT, 2010, NAT MED, V16, P279, DOI 10.1038/nm.2092
   World Health Organization, 2015, WORLD MAL REP 2015
   Zhang XQ, 2009, J CHROMATOGR B, V877, P1678, DOI 10.1016/j.jchromb.2009.04.013
NR 54
TC 2
Z9 3
U1 0
U2 9
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD AUG
PY 2018
VL 32
IS 8
BP 4470
EP 4481
DI 10.1096/fj.201700844R
PG 12
WC Biochemistry & Molecular Biology; Biology; Cell Biology
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA GN7MJ
UT WOS:000439325400034
PM 29558201
OA Green Published
DA 2020-12-08
ER

PT J
AU Silveira, AAA
   Dominical, VM
   Vital, DM
   Ferreira, WA
   Costa, FTM
   Werneck, CC
   Costa, FF
   Conran, N
AF Antoniellis Silveira, Angelica Aparecida
   Dominical, Venina Marcela
   Vital, Daiana Morelli
   Ferreira, Wilson Alves, Jr.
   Maranhao Costa, Fabio Trindade
   Werneck, Claudio C.
   Costa, Fernando Ferreira
   Conran, Nicola
TI Attenuation of TNF-induced neutrophil adhesion by simvastatin is
   associated with the inhibition of Rho-GTPase activity, p50 activity and
   morphological changes
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Adhesion; Inflammation; Integrin; Leukocyte; Rho GTPase; Simvastatin
ID NF-KAPPA-B; LEUKOCYTE; EXPRESSION; INFLAMMATION; RECRUITMENT;
   ACTIVATION; MIGRATION; INTEGRIN; INJURY; MICE
AB Neutrophil adhesion to the vasculature in response to potent inflammatory stimuli, such as TNF-alpha (TNF), can contribute to atheroprogression amongst other pathophysiological mechanisms. Previous studies have shown that simvastatin, a statin with known pleiotropic anti-inflammatory properties, can partially abrogate the effects of TNF-induced neutrophil adhesion, in association with the modulation of beta(2)-integrin expression. We aimed to further characterize the effects of this statin on neutrophil and leukocyte adhesive mechanisms in vitro and in vivo. A microfluidic assay confirmed the ability of simvastatin to inhibit TNF-induced human neutrophil adhesion to fibronectin ligand under conditions of shear stress, while intravital imaging microscopy demonstrated an abrogation of leukocyte recruitment by simvastatin in the microvasculature of mice that had received a TNF stimulus. This inhibition of neutrophil adhesion was accompanied by the inhibition of TNF-induced RhoA activity in human neutrophils, and alterations in cell morphology and (beta(2)-integrin activity. Additionally, TNF augmented the activity of the p50 NF kappa B subunit in human neutrophils and TNF-induced neutrophil adhesion and beta(2)-integrin activity could be abolished using pharmacological inhibitors of NF kappa B translocation, BAY11-7082 and SC514. Accordingly, the TNF-induced elevation of neutrophil p50 activity was abolished by simvastatin. In conclusion, our data provide further evidence of the ability of simvastatin to inhibit neutrophil adhesive interactions in response to inflammatory stimuli, both in vivo and in vitro. Simvastatin appears to inhibit neutrophil adhesion by interfering in TNF-induced cytoskeletal rearrangements, in association with the inhibition of Rho A activity, NF kappa B translocation and, consequently, beta(2)-integrin activity.
C1 [Antoniellis Silveira, Angelica Aparecida; Dominical, Venina Marcela; Vital, Daiana Morelli; Ferreira, Wilson Alves, Jr.; Costa, Fernando Ferreira; Conran, Nicola] Univ Estadual Campinas, UNICAMP, Sch Med, Hematol & Hemotherapy Ctr, Campinas, SP, Brazil.
   [Maranhao Costa, Fabio Trindade] Univ Estadual Campinas, UNICAMP, Inst Biol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva,Dept, Campinas, SP, Brazil.
   [Werneck, Claudio C.] Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Biochem & Tissue Biol, Campinas, SP, Brazil.
   [Dominical, Venina Marcela] NHLBI, Flow Cytometry Core Facil, NIH, Bldg 10, Bethesda, MD 20892 USA.
RP Conran, N (corresponding author), Hemoctr, Rua Carlos Chagas 480,Cidade Univ, BR-13083970 Campinas, SP, Brazil.
EM conran@unicamp.br
RI Conran, Nicola/B-8961-2012; Costa, Fernando/D-1566-2012; Werneck,
   Claudio C/C-7568-2012; Costa, Fabio/E-1181-2012
OI Conran, Nicola/0000-0001-5726-7919; Costa, Fernando/0000-0002-4632-572X;
   Werneck, Claudio C/0000-0002-9413-0572; Costa, Fabio/0000-0001-9969-7300
FU FAPESP (Sao Paulo State Research Foundation)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2010/17082-1, 2014/19173-5];
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2012/22048-2, 2010/19916-7]; CNPqNational Council for Scientific and
   Technological Development (CNPq) [308368/2016-9]
FX This study was funded by FAPESP (Sao Paulo State Research Foundation),
   grant numbers 2010/17082-1 and 2014/19173-5. AAS is the recipient of a
   grant from FAPESP (2012/22048-2). CCW is a recipient of grants from
   FAPESP (2010/19916-7) and CNPq (308368/2016-9). Confocal microscopy was
   carried out at the LACTAD facility, UNICAMP. The authors would also like
   to thank Flavia Costa Leonardo for laboratory assistance and Guilherme
   Barbosa for assistance with Image J analysis.
CR Almeida CB, 2015, BLOOD, V126, P711, DOI 10.1182/blood-2014-12-616250
   Silveira AAA, 2018, J LEUKOCYTE BIOL, V103, P87, DOI 10.1189/jlb.3A0916-388RR
   Silveira AAA, 2013, INFLAMM RES, V62, P127, DOI 10.1007/s00011-012-0579-7
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chu LW, 2015, ACS CHEM NEUROSCI, V6, P889, DOI 10.1021/acschemneuro.5b00032
   de Oliveira S, 2016, NAT REV IMMUNOL, V16, P378, DOI 10.1038/nri.2016.49
   Dyson HJ, 2012, IUBMB LIFE, V64, P499, DOI 10.1002/iub.1044
   Eccles KA, 2008, ATHEROSCLEROSIS, V200, P69, DOI 10.1016/j.atherosclerosis.2007.12.018
   Ferrari GL, 2011, CYTOKINE, V54, P144, DOI 10.1016/j.cyto.2011.02.005
   Fortenberry JD, 2001, INFLAMM RES, V50, P89
   Gottschalk O, 2014, SCAND J RHEUMATOL, V43, P356, DOI 10.3109/03009742.2013.879606
   Grommes J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038917
   Hoppe C, 2017, BRIT J HAEMATOL, V177, P620, DOI 10.1111/bjh.14580
   Kang S, 2016, THROMB HAEMOSTASIS, V116, P496, DOI 10.1160/TH15-11-0858
   Kolodziejczyk AM, 2017, PHARMACOL REP, V69, P1165, DOI 10.1016/j.pharep.2017.06.007
   Lauterbach M, 2008, J LEUKOCYTE BIOL, V83, P1423, DOI 10.1189/jlb.0607421
   Li JX, 2013, ADV IMMUNOL, V119, P135, DOI 10.1016/B978-0-12-407707-2.00005-9
   Liao BR, 2008, BIOMARK INSIGHTS, V3, P147
   Liu L, 2002, J IMMUNOL, V169, P2330, DOI 10.4049/jimmunol.169.5.2330
   Lokuta MA, 2005, J LEUKOCYTE BIOL, V78, P210, DOI 10.1189/jlb.0205067
   Mandosi E, 2010, J ATHEROSCLER THROMB, V17, P539, DOI 10.5551/jat.2956
   Matoba K, 2014, AM J PHYSIOL-RENAL, V307, pF571, DOI 10.1152/ajprenal.00113.2014
   Montecucco F, 2008, CELL SIGNAL, V20, P557, DOI 10.1016/j.cellsig.2007.11.008
   Nakagami H, 2003, ANN MED, V35, P398, DOI 10.1080/07853890310001294
   Osaka M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/962369
   Pende A, 2016, EUR J CLIN INVEST, V46, P252, DOI 10.1111/eci.12566
   Peres RS, 2016, PHARMACOL RES, V112, P37, DOI 10.1016/j.phrs.2016.01.015
   Petri B, 2018, CELL TISSUE RES, V371, P425, DOI 10.1007/s00441-017-2776-8
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Soulaidopoulos S, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00024
   Suda K, 2011, J APPL PHYSIOL, V111, P1118, DOI 10.1152/japplphysiol.00158.2011
   Tong L., 2014, BIOSCI REP, V34
   Turhan A, 2002, P NATL ACAD SCI USA, V99, P3047, DOI 10.1073/pnas.052522799
   Volk APD, 2011, J INNATE IMMUN, V3, P298, DOI 10.1159/000321439
   Yi XY, 2017, J STROKE CEREBROVASC, V26, P352, DOI 10.1016/j.jstrokecerebrovasdis.2016.09.030
   Zahir N, 2003, J CELL BIOL, V163, P1397, DOI 10.1083/jcb.200302023
   Zelova H, 2013, INFLAMM RES, V62, P641, DOI 10.1007/s00011-013-0633-0
   Zhao YL, 2014, INFLAMMATION, V37, P1865, DOI 10.1007/s10753-014-9918-x
NR 38
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD MAY
PY 2018
VL 58
BP 160
EP 165
DI 10.1016/j.intimp.2018.03.025
PG 6
WC Immunology; Pharmacology & Pharmacy
SC Immunology; Pharmacology & Pharmacy
GA GG3UI
UT WOS:000432618300021
PM 29604489
DA 2020-12-08
ER

PT J
AU Bilsland, E
   Tavella, TA
   Krogh, R
   Stokes, JE
   Roberts, A
   Ajioka, J
   Spring, DR
   Andricopulo, AD
   Costa, FTM
   Oliver, SG
AF Bilsland, Elizabeth
   Tavella, Tatyana A.
   Krogh, Renata
   Stokes, Jamie E.
   Roberts, Annabelle
   Ajioka, James
   Spring, David R.
   Andricopulo, Adriano D.
   Costa, Fabio T. M.
   Oliver, Stephen G.
TI Antiplasmodial and trypanocidal activity of violacein and deoxyviolacein
   produced from synthetic operons
SO BMC BIOTECHNOLOGY
LA English
DT Article
DE Violacein; Deoxyviolacein; Plasmodium falciparum; Trypanosoma cruzi;
   Synthetic operon; Antiparasitic; Escherichia coli
ID CHROMOBACTERIUM-VIOLACEUM; BIOSYNTHETIC-PATHWAY; ESCHERICHIA-COLI;
   IN-VITRO; JANTHINOBACTERIUM-LIVIDUM; GROWTH-CONDITIONS; DRUGS VIOLACEIN;
   STRAIN; SEQUENCE; CELLS
AB Background: Violacein is a deep violet compound that is produced by a number of bacterial species. It is synthesized from tryptophan by a pathway that involves the sequential action of 5 different enzymes (encoded by genes vioA to vioE). Violacein has antibacterial, antiparasitic, and antiviral activities, and also has the potential of inducing apoptosis in certain cancer cells.
   Results: Here, we describe the construction of a series of plasmids harboring the complete or partial violacein biosynthesis operon and their use to enable production of violacein and deoxyviolacein in E. coli. We performed in vitro assays to determine the biological activity of these compounds against Plasmodium, Trypanosoma, and mammalian cells. We found that, while deoxyviolacein has a lower activity against parasites than violacein, its toxicity to mammalian cells is insignificant compared to that of violacein.
   Conclusions: We constructed E. coli strains capable of producing biologically active violacein and related compounds, and propose that deoxyviolacein might be a useful starting compound for the development of antiparasite drugs.
C1 [Bilsland, Elizabeth; Roberts, Annabelle; Oliver, Stephen G.] Univ Cambridge, Cambridge Syst Biol Ctr, Cambridge, England.
   [Bilsland, Elizabeth; Roberts, Annabelle; Oliver, Stephen G.] Univ Cambridge, Dept Biochem, Cambridge, England.
   [Bilsland, Elizabeth] Univ Estadual Campinas, Inst Biol, Dept Struct & Funct Biol, Campinas, SP, Brazil.
   [Bilsland, Elizabeth; Tavella, Tatyana A.; Costa, Fabio T. M.] Univ Estadual Campinas, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Campinas, SP, Brazil.
   [Krogh, Renata; Andricopulo, Adriano D.] Univ Sao Paulo, Lab Med & Computat Chem, Sao Carlos, SP, Brazil.
   [Stokes, Jamie E.; Spring, David R.] Univ Cambridge, Dept Chem, Cambridge, England.
   [Ajioka, James] Univ Cambridge, Dept Pathol, Cambridge, England.
RP Bilsland, E (corresponding author), Univ Cambridge, Cambridge Syst Biol Ctr, Cambridge, England.; Bilsland, E (corresponding author), Univ Cambridge, Dept Biochem, Cambridge, England.; Bilsland, E (corresponding author), Univ Estadual Campinas, Inst Biol, Dept Struct & Funct Biol, Campinas, SP, Brazil.
EM bilsland@unicamp.br
RI Costa, Fabio/E-1181-2012; Andricopulo, Adriano D/B-7672-2012
OI Costa, Fabio/0000-0001-9969-7300; Andricopulo, Adriano
   D/0000-0002-0457-818X; Bilsland, Elizabeth/0000-0002-8697-3553
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2012/16525-2, 2015/03553-6]; European
   Commission under the Collaborative Program, UNICELLSYS; UK Biotechnology
   and Biological Sciences Research CouncilBiotechnology and Biological
   Sciences Research Council (BBSRC) [BB/F008228/1]; Bill and Melinda Gates
   foundationBill & Melinda Gates Foundation [OPP1087646]; CNPqNational
   Council for Scientific and Technological Development (CNPq)
FX This study has supported by Sao Paulo Research Foundation (FAPESP) Grant
   2012/16525-2 to FTMC and Grant 2015/03553-6 to EB, contract from the
   European Commission under the FP7 Collaborative Program, UNICELLSYS to
   SGO, UK Biotechnology and Biological Sciences Research Council
   (BB/F008228/1) to SGO and The Bill and Melinda Gates foundation
   (OPP1087646 to EB and SGO). TAT was supported by a CNPq fellowship and
   FTMC is a CNPq research fellow level 1C.
CR Andrighetti-Frohner CR, 2003, MEM I OSWALDO CRUZ, V98, P843, DOI 10.1590/S0074-02762003000600023
   Antonio Regina Vasconcellos, 2004, Genet Mol Res, V3, P85
   Antonisamy P, 2009, FUND CLIN PHARMACOL, V23, P483, DOI 10.1111/j.1472-8206.2009.00701.x
   Aruldass CA, 2018, ENVIRON SCI POLLUT R, V25, P5164, DOI 10.1007/s11356-017-8855-2
   August PR, 2000, J MOL MICROB BIOTECH, V2, P513
   Avgustin JA, 2013, ANTON LEEUW INT J G, V103, P763, DOI 10.1007/s10482-012-9858-0
   Ballestriero F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109201
   Becker MH, 2009, APPL ENVIRON MICROB, V75, P6635, DOI 10.1128/AEM.01294-09
   Blosser RS, 2000, J MICROBIOL METH, V40, P47, DOI 10.1016/S0167-7012(99)00136-0
   Brady SF, 2001, ORG LETT, V3, P1981, DOI 10.1021/ol015949k
   Buckner FS, 1996, ANTIMICROB AGENTS CH, V40, P2592, DOI 10.1128/AAC.40.11.2592
   Choi SY, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/465056
   Chuang James, 2018, Methods Mol Biol, V1671, P211, DOI 10.1007/978-1-4939-7295-1_14
   de Carvalho DD, 2006, TOXICOL IN VITRO, V20, P1514, DOI 10.1016/j.tiv.2006.06.007
   Dodou HV, 2017, J APPL MICROBIOL, V123, P853, DOI 10.1111/jam.13547
   DURAN N, 1994, WORLD J MICROB BIOT, V10, P686, DOI 10.1007/BF00327960
   DURAN N, 1989, Anais da Academia Brasileira de Ciencias, V61, P31
   Duran N, 2007, BIOTECHNOL APPL BIOC, V48, P127, DOI 10.1042/BA20070115
   Fang MY, 2015, MICROB CELL FACT, V14, DOI 10.1186/s12934-015-0192-x
   FARRELL K, 1979, PAPUA NEW GUINEA MED, V22, P94
   Ferreira RS, 2014, J MED CHEM, V57, P2380, DOI 10.1021/jm401709b
   Fuller JJ, 2016, J BIOL CHEM, V291, P20068, DOI 10.1074/jbc.M116.741561
   He L, 2017, METAB ENG, V39, P247, DOI 10.1016/j.ymben.2016.12.008
   Jiang PX, 2010, APPL MICROBIOL BIOT, V86, P1077, DOI 10.1007/s00253-009-2375-z
   Jones JA, 2015, SCI REP-UK, V5, DOI 10.1038/srep11301
   Leon LL, 2001, J ANTIMICROB CHEMOTH, V48, P449, DOI 10.1093/jac/48.3.449
   LICHSTEIN HC, 1946, J BACTERIOL, V52, P145, DOI 10.1128/JB.52.1.145-146.1946
   Lopes SCP, 2009, ANTIMICROB AGENTS CH, V53, P2149, DOI 10.1128/AAC.00693-08
   Lu Y, 2009, BIOCHEM ENG J, V43, P135, DOI 10.1016/j.bej.2008.09.009
   Masuelli L, 2016, TUMOR BIOL, V37, P3705, DOI 10.1007/s13277-015-4207-3
   Millet J, 2004, ANTIMICROB AGENTS CH, V48, P4869, DOI 10.1128/AAC.48.12.4869-4872.2004
   Myeong NR, 2016, J BIOTECHNOL, V223, P36, DOI 10.1016/j.jbiotec.2016.02.027
   Pantanella F, 2007, J APPL MICROBIOL, V102, P992, DOI 10.1111/j.1365-2672.2006.03155.x
   Patijanasoontorn B, 1992, J Med Assoc Thai, V75 Suppl 2, P6
   PONTE R, 1992, PEDIATR INFECT DIS J, V11, P583, DOI 10.1097/00006454-199207000-00013
   RIVEROS R, 1989, BRAZ J MED BIOL RES, V22, P569
   Rodrigues AL, 2013, METAB ENG, V20, P29, DOI 10.1016/j.ymben.2013.08.004
   Rodrigues AL, 2012, BIOTECHNOL LETT, V34, P717, DOI 10.1007/s10529-011-0827-x
   Rodrigues AL, 2014, BIOTECHNOL BIOENG, V111, P2280, DOI 10.1002/bit.25297
   Sanchez C, 2006, CHEMBIOCHEM, V7, P1231, DOI 10.1002/cbic.200600029
   Sasidharan A, 2015, J MICROBIOL, V53, P694, DOI 10.1007/s12275-015-5173-6
   Shinoda K, 2007, CHEM COMMUN, P4140, DOI 10.1039/b705358d
   Smith HJ, 2016, GENOME ANNOUNC, V4
   Sun HN, 2016, MICROB CELL FACT, V15, DOI 10.1186/s12934-016-0545-0
   TI TY, 1993, CLIN INFECT DIS, V17, P505, DOI 10.1093/clinids/17.3.505
   Wang HS, 2012, BIOCHEM ENG J, V67, P148, DOI 10.1016/j.bej.2012.06.005
   Wilkinson B, 2007, NAT CHEM BIOL, V3, P379, DOI 10.1038/nchembio.2007.7
   Wille G, 2001, SYNTHESIS-STUTTGART, P759
   Xu P, 2017, ACS SYNTH BIOL, V6, P148, DOI 10.1021/acssynbio.6b00187
NR 49
TC 4
Z9 4
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6750
J9 BMC BIOTECHNOL
JI BMC Biotechnol.
PD APR 11
PY 2018
VL 18
AR 22
DI 10.1186/s12896-018-0428-z
PG 8
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA GC5RN
UT WOS:000429845900001
PM 29642881
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Padua, TA
   Torres, ND
   Candea, ALP
   Costa, MFS
   Silva, JD
   Silva, JL
   Costa, FTM
   Rocco, PRM
   Souza, MC
   Henriques, MG
AF Padua, Tatiana A.
   Torres, Natalia D.
   Candea, Andre L. P.
   Souza Costa, Maria Fernanda
   Silva, Johnatas D.
   Silva-Filho, Joao Luiz
   Costa, Fabio T. M.
   Rocco, Patricia R. M.
   Souza, Mariana C.
   Henriques, Maria G.
TI Therapeutic effect of Lipoxin A(4)in malaria-induced acute lung injury
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE cytoskeleton remodeling; lung; LXA(4) receptor; Plasmodium berghei;
   specialized proresolving mediators
ID LIPID MEDIATORS; ACTIN REORGANIZATION; CEREBRAL MALARIA; PIVOTAL ROLE;
   NEUTROPHILS; RESOLUTION; INFLAMMATION; PATHOGENESIS; RECEPTOR;
   ASSOCIATION
AB Acute lung injury (ALI) models are characterized by neutrophil accumulation, tissue damage, alteration of the alveolar capillary membrane, and physiological dysfunction. Lipoxin A(4)(LXA(4)) is an anti-inflammatory eicosanoid that was demonstrated to attenuate lipopolysaccharide-induced ALI. Experimental models of severe malaria can be associated with lung injury. However, to date, a putative effect of LXA(4)on malaria (M)-induced ALI has not been addressed. In this study, we evaluated whether LXA(4) exerts an effect on M-ALI. Male C57BL/6 mice were randomly assigned to the following five groups: noninfected; saline-treatedPlasmodium berghei-infected; LXA(4)-pretreated P. berghei-infected (LXA(4)administered 1 h before infection and daily, from days 0 to 5 postinfection),LXA(4)- and LXA(4) receptor antagonist BOC-2-pretreated P. berghei-infected; and LXA(4)-posttreatedP. berghei-infected (LXA(4)administered from days 3 to 5 postinfection).By day 6, pretreatment or posttreatment with LXA(4)ameliorate lung mechanic dysfunction reduced alveolar collapse, thickening and interstitial edema;impaired neutrophil accumulation in the pulmonary tissue and blood;and reduced the systemic production of CXCL1.Additionally,in vitro treatment with LXA(4) prevented neutrophils from migrating toward plasma collected fromP. berghei-infected mice. LXA(4)also impaired neutrophil cytoskeleton remodeling by inhibiting F-actin polarization. Ex vivoanalysis showed that neutrophils from pretreated and posttreated mice were unable to migrate. In conclusion, we demonstrated that LXA(4)exerted therapeutic effects in malaria-induced ALI by inhibiting lung dysfunction, tissue injury, and neutrophil accumulation in lung as well as in peripheral blood. Furthermore, LXA(4) impaired the migratory ability of P. berghei-infected mice neutrophils.
C1 [Padua, Tatiana A.; Torres, Natalia D.; Candea, Andre L. P.; Souza Costa, Maria Fernanda; Souza, Mariana C.; Henriques, Maria G.] Fundacao Oswaldo Cruz, Lab Appl Pharmacol, Farmanguinhos, Rio De Janeiro, Brazil.
   [Padua, Tatiana A.; Torres, Natalia D.; Candea, Andre L. P.; Souza Costa, Maria Fernanda; Souza, Mariana C.; Henriques, Maria G.] Fiocruz MS, Natl Inst Sci & Technol Innovat Dis Neglected Pop, Rio De Janeiro, Brazil.
   [Silva, Johnatas D.; Rocco, Patricia R. M.] Univ Fed Rio de Janeiro, Carlos Chagas Filho Inst Biophys, Lab Pulm Invest, Rio De Janeiro, Brazil.
   [Silva-Filho, Joao Luiz; Costa, Fabio T. M.] Univ Campinas UNICAMP, Dept Genet Evolut & Bioagents, Inst Biol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Campinas, SP, Brazil.
RP Henriques, MG (corresponding author), Farmanguinhos, Lab Farmacol Aplicada, Rua Sizenando Nabuco 100, BR-21041250 Rio De Janeiro, RJ, Brazil.
EM gracahenriques@fiocruz.br
RI Costa, Fabio/E-1181-2012; Silva-Filho, Joao Luiz/I-5704-2016; Silva,
   Johnatas/I-6478-2017
OI Costa, Fabio/0000-0001-9969-7300; Silva-Filho, Joao
   Luiz/0000-0003-4762-2205; Silva, Johnatas/0000-0003-4379-4237
FU Brazilian Council for Scientific and Technological Development
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Rio de Janeiro State Research Supporting Foundation
   (FAPERJ)Carlos Chagas Filho Foundation for Research Support of the State
   of Rio de Janeiro (FAPERJ); Coordination for the Improvement of Higher
   Education Personnel (CAPES)CAPES; Oswaldo Cruz Foundation (FIOCRUZ);
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Sao Paulo Research
   Foundation, FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2016/12855-9]; FAPESPFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP)
FX This work was supported by grants from the Brazilian Council for
   Scientific and Technological Development (CNPq), Carlos Chagas Filho,
   the Rio de Janeiro State Research Supporting Foundation (FAPERJ), the
   Coordination for the Improvement of Higher Education Personnel (CAPES),
   Oswaldo Cruz Foundation (FIOCRUZ) and Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (Sao Paulo Research Foundation, FAPESP, Grant
   #2016/12855-9). The authors express their gratitude to Dr. Carmen Penido
   at the Laboratory of Applied Pharmacology (Farmanguinhos, FIOCRUZ) for
   her critical reading of this manuscript. Tatiana A. Padua and Natalia D.
   Torres are students of the postgraduate program in Cell and Molecular
   Biology at Oswaldo Cruz Institute, FIOCRUZ; Maria Fernanda Souza Costa
   is a postdoctoral fellow from CAPES/CDTS/FIOCRUZ Program, FIOCRUZ. Joao
   Luiz SilvaFilho receives a postdoctoral fellowship from FAPESP.
CR Aitken EH, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-230
   Baer K, 2007, PLOS PATHOG, V3, P1651, DOI 10.1371/journal.ppat.0030171
   Bannenberg G, 2004, BRIT J PHARMACOL, V143, P43, DOI 10.1038/sj.bjp.0705912
   BATES JHT, 1988, J APPL PHYSIOL, V65, P408
   Burburan SM, 2007, ANESTH ANALG, V104, P631, DOI 10.1213/01.ane.0000255073.96001.cb
   Chan MMY, 2010, J IMMUNOL, V184, P6418, DOI 10.4049/jimmunol.0903816
   Chen KX, 2010, BIOSENS BIOELECTRON, V25, P1675, DOI 10.1016/j.bios.2009.12.006
   Chen MJ, 2008, J EXP MED, V205, P2791, DOI 10.1084/jem.20080767
   Chen N, 2013, INT IMMUNOPHARMACOL, V16, P139, DOI 10.1016/j.intimp.2013.04.014
   Cheng X, 2016, FREE RADICAL BIO MED, V93, P52, DOI 10.1016/j.freeradbiomed.2016.01.026
   Chou RC, 2010, IMMUNITY, V33, P266, DOI 10.1016/j.immuni.2010.07.018
   Conte FP, 2010, BRIT J PHARMACOL, V161, P911, DOI 10.1111/j.1476-5381.2010.00950.x
   de Souza JB, 2010, PARASITOLOGY, V137, P755, DOI 10.1017/S0031182009991715
   Deroost K, 2013, AM J RESP CELL MOL, V48, P589, DOI 10.1165/rcmb.2012-0450OC
   Dorward DA, 2015, AM J PATHOL, V185, P1172, DOI 10.1016/j.ajpath.2015.01.020
   El Kebir D, 2009, AM J RESP CRIT CARE, V180, P311, DOI 10.1164/rccm.200810-1601OC
   Epiphanio S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000916
   Erlich JM, 2011, CHEST, V139, P289, DOI 10.1378/chest.10-0891
   Feintuch CM, 2016, MBIO, V7, DOI 10.1128/mBio.01300-15
   Fukunaga K, 2005, J IMMUNOL, V174, P5033, DOI 10.4049/jimmunol.174.8.5033
   Guilherme RF, 2013, AM J RESP CELL MOL, V49, P1029, DOI 10.1165/rcmb.2012-0462OC
   HASTON WS, 1987, J CELL SCI, V88, P495
   Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627
   Jones CN, 2012, P NATL ACAD SCI USA, V109, P20560, DOI 10.1073/pnas.1210269109
   Kamp ME, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010090
   Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399
   Kor DJ, 2011, CRIT CARE MED, V39, P2393, DOI 10.1097/CCM.0b013e318225757f
   Kutsuna H, 2004, AM J PHYSIOL-CELL PH, V286, pC55, DOI 10.1152/ajpcell.00131.2003
   Lefebvre JS, 2010, FASEB J, V24, P637, DOI 10.1096/fj.09-135624
   Mackintosh CL, 2004, TRENDS PARASITOL, V20, P597, DOI 10.1016/j.pt.2004.09.006
   Maderna P, 2002, AM J PATHOL, V160, P2275, DOI 10.1016/S0002-9440(10)61175-3
   Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST
   Milner D, 2013, HUM PATHOL, V44, P2719, DOI 10.1016/j.humpath.2013.07.018
   Miyake M, 2013, LAB INVEST, V93, P768, DOI 10.1038/labinvest.2013.71
   Monteiro APT, 2014, AM J RESP CELL MOL, V50, P87, DOI 10.1165/rcmb.2012-0525OC
   Murray CJL, 2012, LANCET, V379, P413, DOI 10.1016/S0140-6736(12)60034-8
   Norling LV, 2011, J IMMUNOL, V186, P5543, DOI 10.4049/jimmunol.1003865
   Ortiz-Munoz G, 2014, BLOOD, V124, P2625, DOI 10.1182/blood-2014-03-562876
   Planaguma A, 2015, PULM PHARMACOL THER, V34, P37, DOI 10.1016/j.pupt.2015.08.002
   Predescu D, 2004, AM J PHYSIOL-LUNG C, V287, pL895, DOI 10.1152/ajplung.00075.2004
   Prikhodko AS, 2015, BIOCHEMISTRY-MOSCOW+, V80, P629, DOI 10.1134/S0006297915050168
   Quispe AM, 2014, AM J TROP MED HYG, V91, P11, DOI 10.4269/ajtmh.12-0610
   Russell CD, 2014, IMMUNOLOGY, V141, P166, DOI 10.1111/imm.12206
   Ryan AD, 2010, CURR OPIN PHARMACOL, V10, P166, DOI 10.1016/j.coph.2010.02.005
   Sadik CD, 2011, TRENDS IMMUNOL, V32, P452, DOI 10.1016/j.it.2011.06.008
   SENALDI G, 1994, INFECT IMMUN, V62, P1144, DOI 10.1128/IAI.62.4.1144-1149.1994
   Sercundes MK, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006054
   Serhan CN, 2015, SEMIN IMMUNOL, V27, P200, DOI 10.1016/j.smim.2015.03.004
   Shryock N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061882
   Sogawa Y, 2011, J PHARMACOL SCI, V115, P63, DOI 10.1254/jphs.10194FP
   Souza MC, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0093-2
   Souza MC, 2015, INT IMMUNOPHARMACOL, V24, P400, DOI 10.1016/j.intimp.2014.12.033
   Souza MC, 2013, RESP PHYSIOL NEUROBI, V186, P65, DOI 10.1016/j.resp.2012.12.008
   Spieth PM, 2015, ANESTHESIOLOGY, V122, P106, DOI 10.1097/ALN.0000000000000415
   Taylor TE, 2015, ANN NY ACAD SCI, V1342, P44, DOI 10.1111/nyas.12690
   Taylor WRJ, 2012, CHEST, V142, P492, DOI 10.1378/chest.11-2655
   Van den Steen PE, 2013, TRENDS PARASITOL, V29, P346, DOI 10.1016/j.pt.2013.04.006
   Van den Steen PE, 2010, AM J RESP CRIT CARE, V181, P957, DOI 10.1164/rccm.200905-0786OC
   Wang Q, 2013, AM J RESP CELL MOL, V48, P610, DOI 10.1165/rcmb.2012-0274OC
   WHO, 2015, GUID TREATM MAL
   Wu B, 2015, PROSTAG LEUKOTR ESS, V94, P55, DOI 10.1016/j.plefa.2014.11.005
   Yang Y, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/862628
   Yap B, 2005, J APPL PHYSIOL, V99, P2323, DOI 10.1152/japplphysiol.00503.2005
NR 63
TC 4
Z9 5
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-5400
EI 1938-3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD APR
PY 2018
VL 103
IS 4
BP 657
EP 670
DI 10.1002/JLB.3A1016-435RRR
PG 14
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA GB1ZE
UT WOS:000428849400005
PM 29345368
DA 2020-12-08
ER

PT J
AU Barboza, R
   Lima, FA
   Reis, AS
   Murillo, OJ
   Peixoto, EPM
   Bandeira, CL
   Fotoran, WL
   Sardinha, LR
   Wunderlich, G
   Bevilacqua, E
   Lima, MRD
   Alvarez, JM
   Costa, FTM
   Goncalves, LA
   Epiphanio, S
   Marinho, CRF
AF Barboza, Renato
   Lima, Flavia Afonso
   Reis, Aramys Silva
   Murillo, Oscar Javier
   Machado Peixoto, Erika Paula
   Bandeira, Carla Leticia
   Fotoran, Wesley Luzetti
   Sardinha, Luis Roberto
   Wunderlich, Gerhard
   Bevilacqua, Estela
   D'Imperio Lima, Maria Regina
   Alvarez, Jose Maria
   Maranhao Costa, Fabio Trindade
   Goncalves, Ligia Antunes
   Epiphanio, Sabrina
   Farias Marinho, Claudio Romero
TI TLR4-Mediated Placental Pathology and Pregnancy Outcome in Experimental
   Malaria (vol 7, 2017)
SO SCIENTIFIC REPORTS
LA English
DT Correction
C1 [Barboza, Renato] Univ Fed Sao Paulo, Dept Ciencias Biol, Diadema, Brazil.
   [Lima, Flavia Afonso; Reis, Aramys Silva; Murillo, Oscar Javier; Machado Peixoto, Erika Paula; Bandeira, Carla Leticia; Fotoran, Wesley Luzetti; Wunderlich, Gerhard; Goncalves, Ligia Antunes; Farias Marinho, Claudio Romero] Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Sao Paulo, Brazil.
   [Sardinha, Luis Roberto] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Bevilacqua, Estela] Univ Sao Paulo, Dept Biol Celular & Desenvolvimento, Sao Paulo, Brazil.
   [D'Imperio Lima, Maria Regina; Alvarez, Jose Maria] Univ Estadual Campinas, Inst Biol, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
   [Maranhao Costa, Fabio Trindade] Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, Sao Paulo, Brazil.
   [Epiphanio, Sabrina] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo, Brazil.
RP Marinho, CRF (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Sao Paulo, Brazil.
EM marinho@usp.br
RI Costa, Fabio/E-1181-2012; Epiphanio, Sabrina/C-7572-2012; Peixoto, Erika
   Paula Machado/AAB-5441-2020; Barboza, Renato/G-5833-2012; D'Imperio
   Lima, Maria Regina/I-4747-2012; Murillo, Oscar/F-4999-2014
OI Costa, Fabio/0000-0001-9969-7300; Epiphanio,
   Sabrina/0000-0001-6094-9750; Barboza, Renato/0000-0002-6441-7513;
   D'Imperio Lima, Maria Regina/0000-0002-4683-7709; Murillo,
   Oscar/0000-0003-1204-7984; Reis, AlessanRSS/0000-0001-8486-7469
CR Barboza R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08299-x
NR 1
TC 0
Z9 0
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 6
PY 2018
VL 8
AR 4275
DI 10.1038/s41598-018-21982-x
PG 1
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FY2NK
UT WOS:000426652400004
PM 29511268
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Baia-da-Silva, DC
   Alvarez, LCS
   Lizcano, OV
   Costa, FTM
   Lopes, SCP
   Orfano, AS
   Pascoal, DO
   Nacif-Pimenta, R
   Rodriguez, IC
   Guerra, MDVB
   Lacerda, MVG
   Secundino, NFC
   Monteiro, WM
   Pimenta, PFP
AF Baia-da-Silva, Djane Clarys
   Salazar Alvarez, Luis Carlos
   Vera Lizcano, Omaira
   Maranhao Costa, Fabio Trindade
   Pinto Lopes, Stefanie Costa
   Orfano, Alessandra Silva
   Pascoal, Denner Oliveira
   Nacif-Pimenta, Rafael
   Rodriguez, Iria Cabral
   Vale Barbosa Guerra, Maria das Gracas
   Guimaraes Lacerda, Marcus Vinicius
   Costa Secundino, Nagila Francinete
   Monteiro, Wuelton Marcelo
   Paolucci Pimenta, Paulo Filemon
TI The role of the peritrophic matrix and red blood cell concentration in
   Plasmodium vivax infection of Anopheles aquasalis
SO PARASITES & VECTORS
LA English
DT Article
DE Malaria; Plasmodium vivax; Peritrophic matrix; Trypsin; Chitinase;
   Hematocrit
ID AEDES-AEGYPTI; MALARIA TRANSMISSION; PARASITE CHITINASE; MOSQUITOS
   DIPTERA; MIDGUT; DIGESTION; LARVAE; CULICIDAE; MEMBRANE; GALLINACEUM
AB Background: Plasmodium vivax is predominant in the Amazon region, and enhanced knowledge of its development inside a natural vector, Anopheles aquasalis, is critical for future strategies aimed at blocking parasite development. The peritrophic matrix (PM), a chitinous layer produced by the mosquito midgut in response to blood ingestion, is a protective barrier against pathogens. Plasmodium can only complete its life-cycle, and consequently be transmitted to a new host, after successfully passing this barrier. Interestingly, fully engorged mosquitoes that had a complete blood meal form a thicker, well-developed PM than ones that feed in small amounts. The amount of red blood cells (RBC) in the blood meal directly influences the production of digestive enzymes and can protect parasites from being killed during the meal digestion. A specific study interrupting the development of the PM associated with the proteolytic activity inhibition, and distinct RBC concentrations, during the P. vivax infection of the New World malaria vector An. aquasalis is expected to clarify whether these factors affect the parasite development.
   Results: Absence of PM in the vector caused a significant reduction in P. vivax infection. However, the association of chitinase with trypsin inhibitor restored infection rates to those of mosquitoes with a structured PM. Also, only the ingestion of trypsin inhibitor by non-chitinase treated mosquitoes increased the infection intensity. Moreover, the RBC concentration in the infected P. vivax blood meal directly influenced the infection rate and its intensity. A straight correlation was observed between RBC concentrations and infection intensity.
   Conclusions: This study established that there is a balance between the PM role, RBC concentration and digestive enzyme activity influencing the establishment and development of P. vivax infection inside An. aquasalis. Our results indicate that the absence of PM in the midgut facilitates digestive enzyme dispersion throughout the blood meal, causing direct damage to P. vivax. On the other hand, high RBC concentrations support a better and thick, well-developed PM and protect P. vivax from being killed. Further studies of this complex system may provide insights into other details of the malaria vector response to P. vivax infection.
C1 [Baia-da-Silva, Djane Clarys; Salazar Alvarez, Luis Carlos; Pascoal, Denner Oliveira; Rodriguez, Iria Cabral; Vale Barbosa Guerra, Maria das Gracas; Monteiro, Wuelton Marcelo; Paolucci Pimenta, Paulo Filemon] Fundacao Med Trop Dr Heitor Vieira Dourado, Diretoria Ensino & Pesquisa, Manaus, Amazonas, Brazil.
   [Baia-da-Silva, Djane Clarys; Salazar Alvarez, Luis Carlos; Pinto Lopes, Stefanie Costa; Vale Barbosa Guerra, Maria das Gracas; Guimaraes Lacerda, Marcus Vinicius; Monteiro, Wuelton Marcelo; Paolucci Pimenta, Paulo Filemon] Univ Estado Amazonas, Programa Posgrad Med Trop, Manaus, Amazonas, Brazil.
   [Vera Lizcano, Omaira] Univ Santiago Cali, Dept Biol, Grp Invest QUIBIO, Valle Del Cauca, Colombia.
   [Maranhao Costa, Fabio Trindade] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut & Bioagents, Campinas, SP, Brazil.
   [Pinto Lopes, Stefanie Costa; Guimaraes Lacerda, Marcus Vinicius] Fiocruz MS, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil.
   [Orfano, Alessandra Silva; Nacif-Pimenta, Rafael; Costa Secundino, Nagila Francinete; Paolucci Pimenta, Paulo Filemon] Fundacao Oswaldo Cruz Minas Gerais, Inst Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
RP Pimenta, PFP (corresponding author), Fundacao Med Trop Dr Heitor Vieira Dourado, Diretoria Ensino & Pesquisa, Manaus, Amazonas, Brazil.; Pimenta, PFP (corresponding author), Univ Estado Amazonas, Programa Posgrad Med Trop, Manaus, Amazonas, Brazil.; Pimenta, PFP (corresponding author), Fundacao Oswaldo Cruz Minas Gerais, Inst Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
EM pimenta@cpqrr.fiocruz.br
RI Pimenta, Paulo/AAH-1502-2020; Alvarez, Luis Carlos
   Salazar/AAD-2147-2019; Secundino, Nagila/AAM-4553-2020; Costa,
   Fabio/E-1181-2012
OI Alvarez, Luis Carlos Salazar/0000-0001-5340-1412; Costa,
   Fabio/0000-0001-9969-7300; Lopes, Stefanie/0000-0002-6981-2192
FU Bill and Melinda Gates Foundation (TransEpi Study); National Institutes
   of HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01AI031478]; Foundation of the
   Institute Oswaldo Cruz (FIOCRUZ); Strategic Programme for Supporting
   Health Research (PAPES V); Brazilian Council for Scientific and
   Technological Development (CNPq)National Council for Scientific and
   Technological Development (CNPq); Minas Gerais State Research Support
   Foundation (FAPEMIG)Minas Gerais State Research Foundation (FAPEMIG);
   Sao Psulo Research Foundation (FAPESP) [2012/16525-2]; Amazonas State
   Research Support Foundation (PAPAC) [015/2014]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R01AI031478,
   R01AI031478, R01AI031478, R01AI031478, R01AI031478, R01AI031478,
   R01AI031478, R01AI031478, R01AI031478, R01AI031478, R01AI031478,
   R01AI031478, R01AI031478, R01AI031478, R01AI031478, R01AI031478,
   R01AI031478, R01AI031478, R01AI031478, R01AI031478, R01AI031478,
   R01AI031478, R01AI031478, R01AI031478, R01AI031478, R01AI031478,
   R01AI031478, R01AI031478] Funding Source: NIH RePORTER
FX This study was partially funded by Bill and Melinda Gates Foundation
   (TransEpi Study), a grant from the National Institutes of Health
   (R01AI031478), and by the following Brazilian agencies: Foundation of
   the Institute Oswaldo Cruz (FIOCRUZ), Strategic Programme for Supporting
   Health Research (PAPES V), Brazilian Council for Scientific and
   Technological Development (CNPq), Minas Gerais State Research Support
   Foundation (FAPEMIG), Sao Psulo Research Foundation (FAPESP #
   2012/16525-2) and Amazonas State Research Support Foundation (PAPAC,
   Call 015/2014). The funders had no role in study design, data collection
   and analysis, decision to publish or preparation of the manuscript.
CR Abraham EG, 2004, INSECT BIOCHEM MOLEC, V34, P667, DOI 10.1016/j.ibmb.2004.03.019
   Bahia AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057014
   Bahia AC, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001317
   Bahia AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009795
   Baton LA, 2012, INT J PARASITOL, V42, P249, DOI 10.1016/j.ijpara.2011.12.005
   BERTI J, 1993, MEM I OSWALDO CRUZ, V88, P353, DOI 10.1590/S0074-02761993000300003
   Bhattacharya D, 2007, CRIT REV BIOTECHNOL, V27, P21, DOI 10.1080/07388550601168223
   BILLINGSLEY PF, 1992, J PARASITOL, V78, P430, DOI 10.2307/3283640
   BRIEGEL H, 1985, J MED ENTOMOL, V22, P612, DOI 10.1093/jmedent/22.6.612
   Chadee DD, 1999, AM J TROP MED HYG, V61, P513, DOI 10.4269/ajtmh.1999.61.513
   CHADEE DD, 1995, ANN TROP MED PARASIT, V89, P55, DOI 10.1080/00034983.1995.11812929
   Clements AN, 1992, BIOL MOSQUITOES, V1
   Da Silva ANM, 2006, J MED ENTOMOL, V43, P107, DOI 10.1603/0022-2585(2006)043[0107:LCOAAD]2.0.CO;2
   DEANE L M, 1986, Memorias do Instituto Oswaldo Cruz, V81, P5, DOI 10.1590/S0074-02761986000600002
   Dinglasan RR, 2009, INSECT BIOCHEM MOLEC, V39, P125, DOI 10.1016/j.ibmb.2008.10.010
   Edwards MJ, 2000, J INSECT PHYSIOL, V46, P1313, DOI 10.1016/S0022-1910(00)00053-6
   Filho BPD, 2002, INSECT BIOCHEM MOLEC, V32, P1723, DOI 10.1016/S0965-1748(02)00112-1
   FREYVOGEL THIERRY A., 1965, ACTA TROP, V22, P118
   GRAF R, 1982, REV SUISSE ZOOL, V89, P845, DOI 10.5962/bhl.part.82479
   Haldar Kasturi, 2009, Hematology Am Soc Hematol Educ Program, P87, DOI 10.1182/asheducation-2009.1.87
   Hegedus D, 2009, ANNU REV ENTOMOL, V54, P285, DOI 10.1146/annurev.ento.54.110807.090559
   HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807
   Kato N, 2008, VECTOR-BORNE ZOONOT, V8, P701, DOI 10.1089/vbz.2007.0270
   Koepfli C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126747
   Laubach HE, 2001, W INDIAN MED J, V50, P319
   Ministerio da Saude, 2010, GUIA PRAT TRAT MAL B
   Noriega FG, 1999, J INSECT PHYSIOL, V45, P613, DOI 10.1016/S0022-1910(99)00052-9
   Noriega FG, 2001, J INSECT PHYSIOL, V47, P515, DOI 10.1016/S0022-1910(00)00145-1
   Okuda K, 2002, TISSUE CELL, V34, P210, DOI 10.1016/S0040-8166(02)00032-0
   Orfano AS, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1451-y
   Pascoa V, 2002, INSECT BIOCHEM MOLEC, V32, P517, DOI 10.1016/S0965-1748(01)00130-8
   Pimenta PFP, 2015, MEM I OSWALDO CRUZ, V110, P23, DOI 10.1590/0074-02760140266
   Pimenta PFP, 1997, PARASITOLOGY, V115, P359, DOI 10.1017/S0031182097001510
   PIMENTA PFP, 1983, EXP PARASITOL, V56, P194, DOI 10.1016/0014-4894(83)90063-2
   Rios-Velasquez CM, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-460
   ROSENBERG R, 1984, EXP PARASITOL, V57, P158, DOI 10.1016/0014-4894(84)90075-4
   Secundino NFC, 2005, J MED ENTOMOL, V42, P928, DOI 10.1603/0022-2585(2005)042[0928:LLPMFS]2.0.CO;2
   Shahabuddin M, 1995, EXP PARASITOL, V81, P386, DOI 10.1006/expr.1995.1129
   SHAHABUDDIN M, 1993, P NATL ACAD SCI USA, V90, P4266, DOI 10.1073/pnas.90.9.4266
   Sinka ME, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-72
   Taylor PJ, 2001, PARASITOLOGY, V122, P491, DOI 10.1017/S0031182001007776
   Tellam RL, 2000, INSECT BIOCHEM MOLEC, V30, P1189, DOI 10.1016/S0965-1748(00)00097-7
   Terra W. R., 1996, P206
   TERRA WR, 1994, COMP BIOCHEM PHYS B, V109, P1, DOI 10.1016/0305-0491(94)90141-4
   Toprak U, 2010, INSECT MOL BIOL, V19, P163, DOI 10.1111/j.1365-2583.2009.00966.x
   VAUGHAN JA, 1991, J MED ENTOMOL, V28, P780, DOI 10.1093/jmedent/28.6.780
   Vera O, 2015, ANTIMICROB AGENTS CH, V59, P6638, DOI 10.1128/AAC.01136-15
   Villalon JM, 2003, J INSECT PHYSIOL, V49, P891, DOI 10.1016/S0022-1910(03)00135-5
   Weiss BL, 2014, J IMMUNOL, V193, P773, DOI 10.4049/jimmunol.1400163
   WHO, 2016, WORLD MALARIA REPORT, V2015
NR 50
TC 9
Z9 9
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-3305
J9 PARASITE VECTOR
JI Parasites Vectors
PD MAR 6
PY 2018
VL 11
AR 148
DI 10.1186/s13071-018-2752-5
PG 10
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA FY8RF
UT WOS:000427131800004
PM 29510729
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Lima, MNN
   Melo, CC
   Cassiano, GC
   Neves, BJ
   Alves, VM
   Braga, RC
   Cravo, PVL
   Muratov, EN
   Calit, J
   Bargieri, DY
   Costa, FTM
   Andrade, CH
AF Lima, Marilia N. N.
   Melo-Filho, Cleber C.
   Cassiano, Gustavo C.
   Neves, Bruno J.
   Alves, Vinicius M.
   Braga, Rodolpho C.
   Cravo, Pedro V. L.
   Muratov, Eugene N.
   Calit, Juliana
   Bargieri, Daniel Y.
   Costa, Fabio T. M.
   Andrade, Carolina H.
TI QSAR-Driven Design and Discovery of Novel Compounds With Antiplasmodial
   and Transmission Blocking Activities
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE malaria; virtual screening; QSAR; Plasmodium falciparum; dUTPase;
   transmission blocker
ID EFFICIENT GENERATION; NUCLEOSIDE ANALOGS; AM1-BCC MODEL; DRUG DESIGN;
   DERIVATIVES; INHIBITORS; VALIDATION; PREDICTION; TOXICITY; CURATION
AB Malaria is a life-threatening infectious disease caused by parasites of the genus Plasmodium, affecting more than 200 million people worldwide every year and leading to about a half million deaths. Malaria parasites of humans have evolved resistance to all current antimalarial drugs, urging for the discovery of new effective compounds. Given that the inhibition of deoxyuridine triphosphatase of Plasmodium falciparum (PfdUTPase) induces wrong insertions in plasmodial DNA and consequently leading the parasite to death, this enzyme is considered an attractive antimalarial drug target. Using a combi-QSAR (quantitative structure-activity relationship) approach followed by virtual screening and in vitro experimental evaluation, we report herein the discovery of novel chemical scaffolds with in vitro potency against asexual blood stages of both P. falciparum multidrug-resistant and sensitive strains and against sporogonic development of P. berghei. We developed 2D- and 3D-QSAR models using a series of nucleosides reported in the literature as PfdUTPase inhibitors. The best models were combined in a consensus approach and used for virtual screening of the ChemBridge database, leading to the identification of five new virtual PfdUTPase inhibitors. Further in vitro testing on P. falciparum multidrug-resistant (W2) and sensitive (3D7) parasites showed that compounds LabMol-144 and LabMol-146 demonstrated fair activity against both strains and presented good selectivity versus mammalian cells. In addition, LabMol-144 showed good in vitro inhibition of P. berghei ookinete formation, demonstrating that hit-to-lead optimization based on this compound may also lead to new antimalarials with transmission blocking activity.
C1 [Lima, Marilia N. N.; Melo-Filho, Cleber C.; Neves, Bruno J.; Alves, Vinicius M.; Braga, Rodolpho C.; Andrade, Carolina H.] Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design, LabMol, Goiania, Go, Brazil.
   [Cassiano, Gustavo C.; Costa, Fabio T. M.; Andrade, Carolina H.] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Campinas, SP, Brazil.
   [Neves, Bruno J.] Univ Ctr Anapolis UniEVANGELICA, SOMA, PPG, Lab Cheminformat, Anapolis, Brazil.
   [Cravo, Pedro V. L.] Univ Nova Lisboa, Inst Higiene & Med Trop, Unidade Parasitol Med, Global Hlth & Trop Med Ctr, Lisbon, Portugal.
   [Muratov, Eugene N.] Univ N Carolina, Eshelman Sch Pharm, Div Chem Biol & Med Chem, Lab Mol Modeling, Chapel Hill, NC USA.
   [Muratov, Eugene N.] Odessa Natl Polytech Univ, Dept Chem Technol, Odessa, Ukraine.
   [Calit, Juliana; Bargieri, Daniel Y.] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, Brazil.
RP Andrade, CH (corresponding author), Univ Fed Goias, Fac Pharm, Lab Mol Modeling & Drug Design, LabMol, Goiania, Go, Brazil.; Andrade, CH (corresponding author), Univ Estadual Campinas, Inst Biol, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Campinas, SP, Brazil.
EM carolina@ufg.br
RI Lima, Marilia/S-7810-2018; Neves, Bruno/R-7068-2019; Cravo, Pedro
   VL/G-3532-2012; Bargieri, Daniel Youssef/A-4461-2013; Cassiano, Gustavo
   C/G-5728-2013; Melo-Filho, Cleber C./V-1119-2018; Costa,
   Fabio/E-1181-2012; Neves, Bruno Junior/E-6295-2016; Braga, Rodolpho
   C/A-9655-2011; Alves, Vinicius M./G-7955-2015; Andrade,
   Carolina/C-3960-2014
OI Lima, Marilia/0000-0002-7394-0031; Neves, Bruno/0000-0002-1309-8743;
   Cravo, Pedro VL/0000-0003-1675-4504; Bargieri, Daniel
   Youssef/0000-0003-2564-3742; Cassiano, Gustavo C/0000-0002-6971-5974;
   Melo-Filho, Cleber C./0000-0003-0056-6971; Costa,
   Fabio/0000-0001-9969-7300; Braga, Rodolpho C/0000-0003-3814-3464; Alves,
   Vinicius M./0000-0002-6182-1748; Calit, Juliana/0000-0002-4835-249X;
   Andrade, Carolina/0000-0003-0101-1492
FU Brazilian funding agency, CNPqNational Council for Scientific and
   Technological Development (CNPq); Brazilian funding agency, FAPEG;
   Brazilian funding agency, FAPESPFundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP); Brazilian funding agency, CAPESCAPES;
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2012/16525-2, 2015/20774-6, 2017/02353-9, 2013/13119-6, 2016/16649-4];
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [405996/2016-0, 400760/2014-2]; NIHUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [1U01CA207160,
   GM5105946]; Fundacao Nacional de Desenvolvimento do Ensino Superior
   Particular - Funadesp, via UniEvangelica - Centro Universitario de
   Anapolis; NATIONAL CANCER INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [U01CA207160, U01CA207160, U01CA207160] Funding
   Source: NIH RePORTER
FX The authors would like to thank Brazilian funding agencies, CNPq, FAPEG,
   FAPESP, and CAPES for financial support and fellowships. FC, GC, and CA
   were supported by FAPESP (Grants #2012/16525-2, #2015/20774-6, and
   #2017/02353-9, respectively). DB was supported by FAPESP (Grant
   #2013/13119-6) and CNPq (Grant #405996/2016-0). JC was supported by
   FAPESP fellowship (#2016/16649-4). EM appreciates support from NIH
   (Grant 1U01CA207160 and GM5105946) and CNPq (Grant # 400760/2014-2). CA,
   PC, and FC are CNPq research fellows. PC was partially supported by the
   Fundacao Nacional de Desenvolvimento do Ensino Superior Particular -
   Funadesp, via UniEvangelica - Centro Universitario de Anapolis.
CR Alves V. M., 2014, PROCEEDINGS OF THE 2
   [Anonymous], 2016, GLOB TUB REP
   Thu AM, 2017, FEBS J, V284, P2569, DOI 10.1111/febs.14127
   Banks JL, 2005, J COMPUT CHEM, V26, P1752, DOI 10.1002/jcc.20292
   Baragana B, 2011, BIOORGAN MED CHEM, V19, P2378, DOI 10.1016/j.bmc.2011.02.012
   Blagborough M. A., 2012, MALARIA METHODS PROT, V923, P577
   Braga RC, 2015, MOL INFORM, V34, P698, DOI 10.1002/minf.201500040
   Braga RC, 2014, CURR TOP MED CHEM, V14, P1399, DOI 10.2174/1568026614666140506124442
   ChemBridge Online Chemical Store, 2017, ONLINE
   Cheng FX, 2012, J CHEM INF MODEL, V52, P3099, DOI 10.1021/ci300367a
   Cherkasov A, 2014, J MED CHEM, V57, P4977, DOI 10.1021/jm4004285
   Doweyko AM, 2004, J COMPUT AID MOL DES, V18, P587, DOI 10.1007/s10822-004-4068-0
   ELHAJJ HH, 1988, J BACTERIOL, V170, P1069, DOI 10.1128/jb.170.3.1069-1075.1988
   Filimonov D.A., 2004, PHARM CHEM J, V38, P21, DOI DOI 10.1023/B:PHAC.0000027639.17115.5D
   Fourches D, 2016, J CHEM INF MODEL, V56, P1243, DOI 10.1021/acs.jcim.6b00129
   Fourches D, 2015, NAT CHEM BIOL, V11, P535, DOI 10.1038/nchembio.1881
   Fourches D, 2010, J CHEM INF MODEL, V50, P1189, DOI 10.1021/ci100176x
   FRIESNER RA, 2004, MURPHY
   GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x
   Gomes MN, 2017, EUR J MED CHEM, V137, P126, DOI 10.1016/j.ejmech.2017.05.026
   Hampton SE, 2011, CHEMMEDCHEM, V6, P1816, DOI 10.1002/cmdc.201100255
   HARTWIG CL, 2013, RESEARCH, P122
   Hawkins PCD, 2007, J MED CHEM, V50, P74, DOI 10.1021/jm0603365
   Hawkins PCD, 2010, J CHEM INF MODEL, V50, P572, DOI 10.1021/ci100031x
   Hoffman SL, 2015, AM J PREV MED, V49, pS319, DOI 10.1016/j.amepre.2015.09.011
   Jakalian A, 2002, J COMPUT CHEM, V23, P1623, DOI 10.1002/jcc.10128
   Jakalian A, 2000, J COMPUT CHEM, V21, P132, DOI 10.1002/(SICI)1096-987X(20000130)21:2<132::AID-JCC5>3.3.CO;2-G
   Kuz'min VE, 2008, J COMPUT AID MOL DES, V22, P403, DOI 10.1007/s10822-008-9179-6
   Lagunin A, 2011, MOL INFORM, V30, P241, DOI 10.1002/minf.201000151
   Lagunin A, 2009, TOXICOL LETT, V189, pS264, DOI 10.1016/j.toxlet.2009.06.393
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   Leelananda SP, 2016, BEILSTEIN J ORG CHEM, V12, P2694, DOI 10.3762/bjoc.12.267
   LINDBERG W, 1983, ANAL CHEM, V55, P643, DOI 10.1021/ac00255a014
   Lopez-Barragan MJ, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-587
   McCarthy O, 2009, EUR J MED CHEM, V44, P678, DOI 10.1016/j.ejmech.2008.05.018
   McGann M, 2011, J CHEM INF MODEL, V51, P578, DOI 10.1021/ci100436p
   MELOFILHO CC, 2014, CURR COMPUT AIDED DR, V2174
   MELOFILHO CC, 2016, J CHEM INF MODEL, V55
   METHOD, 1921, J MED CHEM
   Miyakoshi H, 2012, J MED CHEM, V55, P2960, DOI 10.1021/jm201627n
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Neves BJ, 2016, J MED CHEM, V59, P7075, DOI 10.1021/acs.jmedchem.5b02038
   Nguyen C, 2005, J MED CHEM, V48, P5942, DOI [10.1021/jm050111e, 10.1021/jm050091g]
   Nguyen C, 2006, J MED CHEM, V49, P4183, DOI 10.1021/jm060126s
   Nyman PO, 2001, CURR PROTEIN PEPT SC, V2, P277, DOI 10.2174/1389203013381071
   Ojha PK, 2013, COMB CHEM HIGH T SCR, V16, P739
   Otto TD, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0086-0
   Pecsi I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037461
   Recio E, 2011, EUR J MED CHEM, V46, P3309, DOI 10.1016/j.ejmech.2011.04.052
   Ruda GF, 2011, CHEMMEDCHEM, V6, P309, DOI 10.1002/cmdc.201000445
   Sanders JM, 2017, J MED CHEM, V60, P6771, DOI 10.1021/acs.jmedchem.6b01577
   SAVIN NE, 1977, ECONOMETRICA, V45, P1989, DOI 10.2307/1914122
   Shelley JC, 2007, J COMPUT AID MOL DES, V21, P681, DOI 10.1007/s10822-007-9133-z
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   TRIPOS, 2010, HQSAR TM MANUAL SYBY
   *TRIPOS, 2010, QSAR AND COMFASUPSUP, V1, P2010
   Tropsha A, 2003, QSAR COMB SCI, V22, P69, DOI 10.1002/qsar.200390007
   Tropsha A, 2010, MOL INFORM, V29, P476, DOI 10.1002/minf.201000061
   van de Waterbeemd H, 2003, NAT REV DRUG DISCOV, V2, P192, DOI 10.1038/nrd1032
   Varnek A, 2008, CURR COMPUT-AID DRUG, V4, P191, DOI 10.2174/157340908785747465
   Verma J, 2010, CURR TOP MED CHEM, V10, P95, DOI 10.2174/156802610790232260
   Vogel G, 2014, SCIENCE, V346, P1276, DOI 10.1126/science.346.6215.1276
   Whittingham JL, 2005, STRUCTURE, V13, P329, DOI 10.1016/j.str.2004.11.015
NR 63
TC 8
Z9 8
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 6
PY 2018
VL 9
AR 146
DI 10.3389/fphar.2018.00146
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA FY3CH
UT WOS:000426694400001
PM 29559909
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Judice, CC
   Tan, JJL
   Parise, PL
   Kam, YW
   Milanez, GP
   Leite, JA
   Caserta, LC
   Arns, CW
   Resende, MR
   Angerami, R
   Amaral, E
   Passini, R
   Freitas, ARR
   Costa, FTM
   Proenca-Modena, JL
   Ng, LFP
AF Judice, Carla Cristina
   Tan, Jeslin J. L.
   Parise, Pierina Lorencini
   Kam, Yiu-Wing
   Milanez, Guilherme Paier
   Leite, Juliana Almeida
   Caserta, Leonardo Cardia
   Arns, Clarice Weis
   Resende, Mariangela Ribeiro
   Angerami, Rodrigo
   Amaral, Eliana
   Passini Junior, Renato
   Ribas Freitas, Andre Ricardo
   Maranhao Costa, Fabio Trindade
   Proenca-Modena, Jose Luiz
   Ng, Lisa F. P.
CA Zika-Unicamp Network
TI Efficient detection of Zika virus RNA in patients' blood from the 2016
   outbreak in Campinas, Brazil
SO SCIENTIFIC REPORTS
LA English
DT Article
ID EPIDEMIC; DISEASE
AB Infection with Zika virus (ZIKV), a mosquito-borne flavivirus has been casually linked with increased congenital microcephaly in Brazil from 2015 through 2016. Sensitive and specific diagnosis of patients with Zika fever (ZIKF) remains critical for patient management. We developed a ZIKV NS5 qRT-PCR assay by combining primers described by Balm et al. and a new Taqman probe. The assay was evaluated and compared with another assay described by Lanciotti et al. (ZIKV 1107) using 51 blood and 42 urine samples from 54 suspected ZIKV patients. ZIKV NS5 performed better in terms of sensitivity with more samples detected as ZIKV-positive (n = 37) than ZIKV 1107 (n = 34) for urine, and ZIKV-positive (n = 29) than ZIKV 1107 (n = 26) for blood. Both assays displayed good overall agreement for urine (kappa appa = 0.770) and blood (kappa appa = 0.825) samples. Improved availability of validated diagnostic tests, such ZIKV NS5 qRT-PCR, will be critical to ensure adequate and accurate ZIKV diagnosis.
C1 [Judice, Carla Cristina; Leite, Juliana Almeida; Maranhao Costa, Fabio Trindade; Proenca-Modena, Jose Luiz] Univ Estadual Campinas, UNICAMP, Dept Genet Evolut & Bioagents, Inst Biol,Lab Trop Dis, Campinas, SP, Brazil.
   [Tan, Jeslin J. L.; Kam, Yiu-Wing; Ng, Lisa F. P.] ASTAR, Singapore Immunol Network, Singapore, Singapore.
   [Parise, Pierina Lorencini; Milanez, Guilherme Paier; Proenca-Modena, Jose Luiz] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut & Bioagents, Lab Emerging Viruses, Campinas, SP, Brazil.
   [Caserta, Leonardo Cardia; Arns, Clarice Weis] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut & Bioagents, Lab Anim Viruses, Campinas, SP, Brazil.
   [Resende, Mariangela Ribeiro; Angerami, Rodrigo] Univ Estadual Campinas, Sch Med Sci, Clin Pathol Dept, Campinas, SP, Brazil.
   [Amaral, Eliana; Passini Junior, Renato] Univ Estadual Campinas, Sch Med Sci, Obstet & Gynecol Dept, Campinas, SP, Brazil.
   [Ribas Freitas, Andre Ricardo] Campinas Dept Publ Hlth Surveillance, Campinas, SP, Brazil.
   [Ng, Lisa F. P.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
RP Proenca-Modena, JL (corresponding author), Univ Estadual Campinas, UNICAMP, Dept Genet Evolut & Bioagents, Inst Biol,Lab Trop Dis, Campinas, SP, Brazil.; Ng, LFP (corresponding author), ASTAR, Singapore Immunol Network, Singapore, Singapore.; Proenca-Modena, JL (corresponding author), Univ Estadual Campinas, Inst Biol, Dept Genet Evolut & Bioagents, Lab Emerging Viruses, Campinas, SP, Brazil.; Ng, LFP (corresponding author), Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
EM jlmodena@unicamp.br; lisa_ng@immunol.a-star.edu.sg
RI Toledo-Teixeira, Daniel A./C-6940-2017; Milanez, Guilherme/G-6457-2016;
   Colella-Santos, Maria Francisca/A-6008-2013; Resende,
   Mariangela/U-9938-2019; Freitas, Andre Ricardo Ribas/L-1969-2016; Costa,
   Fabio/E-1181-2012; Angerami, Rodrigo Nogueira/A-8926-2013; Garcia,
   Marcia Teixeira/AAS-8548-2020; Modena, Jose Luiz Proenca/C-8231-2014;
   Proenca-Modena, Jose Luiz/AAU-7622-2020; Fertrin, Kleber/M-4175-2013;
   Arns, Clarice/F-2762-2015; Judice, Carla/P-4738-2014
OI Milanez, Guilherme/0000-0002-8599-1098; Colella-Santos, Maria
   Francisca/0000-0002-7456-9502; Freitas, Andre Ricardo
   Ribas/0000-0003-0291-7771; Costa, Fabio/0000-0001-9969-7300; Angerami,
   Rodrigo Nogueira/0000-0002-4976-9238; Garcia, Marcia
   Teixeira/0000-0003-3319-115X; Modena, Jose Luiz
   Proenca/0000-0002-4996-3153; Proenca-Modena, Jose
   Luiz/0000-0002-4996-3153; Fertrin, Kleber/0000-0003-2637-3297; Arns,
   Clarice/0000-0002-7308-460X; Judice, Carla/0000-0003-1839-053X; Calil,
   Roseli/0000-0001-5120-6955; Ribeiro-do-Valle,
   Carolina/0000-0002-2630-9909; Ng, Lisa/0000-0003-4071-5222;
   Toledo-Teixeira, Daniel A./0000-0002-4055-058X; Vinolo, Marco
   Aurelio/0000-0003-1335-760X
FU Biomedical Research Council (BMRC)Agency for Science Technology &
   Research (ASTAR); BMRC A*STAR-led Zika Virus Consortium Fund
   [15/1/82/27/001]; Agency for Science, Technology and Research (A* STAR),
   SingaporeAgency for Science Technology & Research (ASTAR); Sao Paulo
   Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2016/00194-8]
FX We thank the study subjects for their participation and clinical teams
   within the network in patient recruitment, sample collection and data
   entry. This work is supported by core research grants provided to the
   Singapore Immunology Network by the Biomedical Research Council (BMRC),
   and also partially supported by the BMRC A*STAR-led Zika Virus
   Consortium Fund (project number: 15/1/82/27/001), Agency for Science,
   Technology and Research (A* STAR), Singapore. In addition, this work is
   supported by Sao Paulo Research Foundation (FAPESP - 2016/00194-8). FTMC
   is a research fellow from CNPq (Brazilian National Council for
   Scientific and Technological Development).
CR Balm MND, 2012, J MED VIROL, V84, P1501, DOI 10.1002/jmv.23241
   Bingham AM, 2016, MMWR-MORBID MORTAL W, V65, P475, DOI 10.15585/mmwr.mm6518e2
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Charrel RN, 2016, B WORLD HEALTH ORGAN, V94, P574, DOI 10.2471/BLT.16.171207
   Derraik JG, 2015, AUST NZ J PUBL HEAL, V39, P5, DOI 10.1111/1753-6405.12302
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Driggers RW, 2016, NEW ENGL J MED, V374, P2142, DOI 10.1056/NEJMoa1601824
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Duong V, 2017, INT J INFECT DIS, V54, P121, DOI 10.1016/j.ijid.2016.11.420
   DYER O, 2017, BMJ-BRIT MED J, V356, DOI DOI 10.1136/BMJ.J707
   Fares RCG, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/321873
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Gibson G, 2013, CAD SAUDE PUBLICA, V29, P82, DOI 10.1590/S0102-311X2013000100010
   Gourinat AC, 2015, EMERG INFECT DIS, V21, P84, DOI 10.3201/eid2101.140894
   Honorio NA, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000545
   Ioos S, 2014, MED MALADIES INFECT, V44, P302, DOI 10.1016/j.medmal.2014.04.008
   Jeong YE, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0740-6
   Kuno G, 2007, ARCH VIROL, V152, P687, DOI 10.1007/s00705-006-0903-z
   Kutsuna S, 2014, EUROSURVEILLANCE, V19, P8, DOI 10.2807/1560-7917.ES2014.19.4.20683
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Matheron S, 2016, CLIN INFECT DIS, V63, DOI 10.1093/cid/ciw509
   Maurer-Stroh S., 2016, EURO SURVEILL, V21
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Figueiredo LTM, 2015, REV SOC BRAS MED TRO, V48, P233, DOI 10.1590/0037-8682-0179-2015
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   Musso D, 2016, CLIN MICROBIOL REV, V29, P487, DOI 10.1128/CMR.00072-15
   Musso D, 2015, J CLIN VIROL, V68, P53, DOI 10.1016/j.jcv.2015.04.021
   Nicastri E, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.32.30314
   Oehler E, 2014, EURO SURVEILL, V19
   Ong SP, 2006, ANTIVIR RES, V72, P216, DOI 10.1016/j.antiviral.2006.06.005
   Petersen LR, 2016, NEW ENGL J MED, V374, P1552, DOI 10.1056/NEJMra1602113
   Rabe IB, 2016, MMWR-MORBID MORTAL W, V65, P543, DOI 10.15585/mmwr.mm6521e1
   St George K, 2017, J CLIN MICROBIOL, V55, P535, DOI 10.1128/JCM.01232-16
   Tan JJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08806-0
   Tetro JA, 2016, MICROBES INFECT, V18, P167, DOI 10.1016/j.micinf.2015.12.010
   Verma R, 2013, HUM VACC IMMUNOTHER, V9, P1268, DOI 10.4161/hv.23950
   Waggoner JJ, 2016, CLIN INFECT DIS, V63, P1584, DOI 10.1093/cid/ciw589
   Waggoner JJ, 2016, J CLIN MICROBIOL, V54, P860, DOI 10.1128/JCM.00279-16
NR 39
TC 7
Z9 9
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 5
PY 2018
VL 8
AR 4012
DI 10.1038/s41598-018-22159-2
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FY0ZI
UT WOS:000426540800045
PM 29507368
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Bourgard, C
   Albrecht, L
   Kayano, ACAV
   Sunnerhagen, P
   Costa, FTM
AF Bourgard, Catarina
   Albrecht, Letusa
   Kayano, Ana C. A. V.
   Sunnerhagen, Per
   Costa, Fabio T. M.
TI Plasmodium vivax Biology: Insights Provided by Genomics, Transcriptomics
   and Proteomics
SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
LA English
DT Review
DE malaria; Plasmodium vivax; genome; transcriptome; proteome
ID NATURAL ANTISENSE TRANSCRIPTS; RED-BLOOD-CELLS; GENETIC DIVERSITY;
   MALARIA PARASITES; DRUG-RESISTANCE; POPULATION-STRUCTURE; MICROSATELLITE
   DIVERSITY; EVOLUTIONARY HISTORY; FALCIPARUM-MALARIA; LUNG INJURY
AB During the last decade, the vast omics field has revolutionized biological research, especially the genomics, transcriptomics and proteomics branches, as technological tools become available to the field researcher and allow difficult question-driven studies to be addressed. Parasitology has greatly benefited from next generation sequencing (NGS) projects, which have resulted in a broadened comprehension of basic parasite molecular biology, ecology and epidemiology. Malariology is one example where application of this technology has greatly contributed to a better understanding of Plasmodium spp. biology and host-parasite interactions. Among the several parasite species that cause human malaria, the neglected Plasmodium vivax presents great research challenges, as in vitro culturing is not yet feasible and functional assays are heavily limited. Therefore, there are gaps in our P. vivax biology knowledge that affect decisions for control policies aiming to eradicate vivax malaria in the near future. In this review, we provide a snapshot of key discoveries already achieved in P. vivax sequencing projects, focusing on developments, hurdles, and limitations currently faced by the research community, as well as perspectives on future vivax malaria research.
C1 [Bourgard, Catarina; Albrecht, Letusa; Kayano, Ana C. A. V.; Costa, Fabio T. M.] Univ Campinas UNICAMP, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis, Campinas, SP, Brazil.
   [Albrecht, Letusa] Inst Carlos Chagas, Lab Regulat Gene Express, Curitiba, Parana, Brazil.
   [Sunnerhagen, Per] Univ Gothenburg, Dept Chem & Mol Biol, Gothenburg, Sweden.
RP Costa, FTM (corresponding author), Univ Campinas UNICAMP, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis, Campinas, SP, Brazil.
EM fabiotmc72@gmail.com
RI Albrecht, Letusa/I-1837-2012; Bourgard, Catarina/N-3630-2019; Bourgard,
   Catarina/AAF-8186-2020; Costa, Fabio/E-1181-2012; Sunnerhagen,
   Per/G-1696-2012
OI Albrecht, Letusa/0000-0001-6406-2057; Bourgard,
   Catarina/0000-0003-3469-703X; Costa, Fabio/0000-0001-9969-7300;
   Sunnerhagen, Per/0000-0002-0967-8729
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [(FAPESP 2012/16525-2];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Swedish Research CouncilSwedish Research Council [2014-4234];
   FAPESP fellowshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [FAPESP 2013/20509-5]; CNPq fellowshipNational Council for
   Scientific and Technological Development (CNPq) [150030/2017-7]
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP 2012/16525-2), the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), and the Swedish
   Research Council (2014-4234). CB was supported by a FAPESP fellowship
   (FAPESP 2013/20509-5). FC is a CNPq research fellow and AK was supported
   by a CNPq fellowship (150030/2017-7).
CR Acharya P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026623
   Acharya P, 2009, PROTEOM CLIN APPL, V3, P1314, DOI 10.1002/prca.200900090
   Adjalley SH, 2016, CELL REP, V14, P2463, DOI 10.1016/j.celrep.2016.02.025
   Alexandre MA, 2010, EMERG INFECT DIS, V16, P1611, DOI 10.3201/eid1610.100685
   Anderson DC, 2015, J PROTEOMICS, V115, P157, DOI 10.1016/j.jprot.2014.12.010
   Andrade BB, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-13
   Anstey NM, 2007, J INFECT DIS, V195, P589, DOI 10.1086/510756
   Anstey NM, 2009, TRENDS PARASITOL, V25, P220, DOI 10.1016/j.pt.2009.02.003
   Anstey NM, 2002, J INFECT DIS, V185, P1326, DOI 10.1086/339885
   Auburn S, 2017, INT J PARASITOL, V47, P77, DOI 10.1016/j.ijpara.2016.08.006
   Auburn Sarah, 2016, Wellcome Open Res, V1, P4, DOI 10.12688/wellcomeopenres.9876.1
   Auburn S, 2016, J INFECT DIS, V214, P1235, DOI 10.1093/infdis/jiw323
   Auburn S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053160
   Bahl A, 2003, NUCLEIC ACIDS RES, V31, P212, DOI 10.1093/nar/gkg081
   Baird JK, 2007, TRENDS PARASITOL, V23, P533, DOI 10.1016/j.pt.2007.08.011
   Baird J Kevin, 2007, Curr Infect Dis Rep, V9, P39, DOI 10.1007/s11908-007-0021-4
   Baird JK, 2010, LANCET, V376, P1883, DOI 10.1016/S0140-6736(10)61494-8
   Baird JK, 2004, ANTIMICROB AGENTS CH, V48, P4075, DOI 10.1128/AAC.48.11.4075-4083.2004
   Baniecki ML, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003539
   Barcus MJ, 2007, AM J TROP MED HYG, V77, P984, DOI 10.4269/ajtmh.2007.77.984
   Barnweil JW, 2014, NAT MED, V20, P237, DOI 10.1038/nm.3498
   BARNWELL JW, 1990, EXP PARASITOL, V70, P85, DOI 10.1016/0014-4894(90)90088-T
   Barry AE, 2015, PATHOG GLOB HEALTH, V109, P142, DOI 10.1179/2047773215Y.0000000012
   Battle KE, 2012, ADV PARASIT, V80, P1, DOI 10.1016/B978-0-12-397900-1.00001-3
   Bautista JM, 2014, J PROTEOMICS, V97, P107, DOI 10.1016/j.jprot.2013.10.011
   Beeson JG, 2007, PLOS MED, V4, P1862, DOI 10.1371/journal.pmed.0040350
   Beutler E, 2007, AM J TROP MED HYG, V77, P779, DOI 10.4269/ajtmh.2007.77.779
   Bitoh Tomoyuki, 2011, Environmental Health and Preventive Medicine, V16, P171, DOI 10.1007/s12199-010-0184-8
   Boopathi PA, 2014, GENOM DATA, V2, P199, DOI 10.1016/j.gdata.2014.06.024
   Boopathi PA, 2013, INFECT GENET EVOL, V20, P428, DOI 10.1016/j.meegid.2013.09.026
   Boopathi PA, 2016, ACTA TROP, V164, P438, DOI 10.1016/j.actatropica.2016.10.002
   Bousema T, 2011, CLIN MICROBIOL REV, V24, P377, DOI 10.1128/CMR.00051-10
   Boyd M. F., 1937, American Journal of Tropical Medicine, V17, P253
   Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005
   Bozdech Z, 2008, P NATL ACAD SCI USA, V105, P16290, DOI 10.1073/pnas.0807404105
   Brazeau NF, 2016, AM J TROP MED HYG, V95, P1409, DOI 10.4269/ajtmh.16-0566
   Bright AT, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-262
   Bright AT, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002882
   Lanca EFC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035406
   Carlton J, 2003, TRENDS PARASITOL, V19, P227, DOI 10.1016/S1471-4922(03)00066-7
   Carlton JM, 2008, NATURE, V455, P757, DOI 10.1038/nature07327
   Carlton JM, 2013, ADV PARASIT, V81, P203, DOI 10.1016/B978-0-12-407826-0.00005-9
   Carlton JM, 2008, TRENDS PARASITOL, V24, P545, DOI 10.1016/j.pt.2008.09.003
   Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099
   Chan ER, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003566
   Chan ER, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001811
   Chang HH, 2012, MOL BIOL EVOL, V29, P3427, DOI 10.1093/molbev/mss161
   Cheeseman IH, 2016, MOL BIOL EVOL, V33, P603, DOI 10.1093/molbev/msv282
   Chen JH, 2010, J PROTEOME RES, V9, P6479, DOI 10.1021/pr100705g
   Chung BH, 2008, NEPHRON CLIN PRACT, V110, pC172, DOI 10.1159/000167023
   Cole-Tobian J, 2003, MOL BIOCHEM PARASIT, V127, P121, DOI 10.1016/S0166-6851(02)00327-4
   COLLINS WE, 1972, J PARASITOL, V58, P332, DOI 10.2307/3278097
   Cornejo OE, 2006, TRENDS PARASITOL, V22, P558, DOI 10.1016/j.pt.2006.09.007
   Cornejo OE, 2015, GENOME BIOL EVOL, V7, P106, DOI 10.1093/gbe/evu267
   Coura JR, 2006, MEM I OSWALDO CRUZ, V101, P229, DOI 10.1590/S0074-02762006000300001
   Cui Liwang, 2009, V470, P263, DOI 10.1007/978-1-59745-204-5_18
   Cui LW, 2003, AM J TROP MED HYG, V68, P613, DOI 10.4269/ajtmh.2003.68.613
   Culleton R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029137
   de Araujo FCF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049871
   de Lacerda MVG, 2007, REV SOC BRAS MED TRO, V40, P489, DOI 10.1590/S0037-86822007000400026
   del Portillo HA, 2004, INT J PARASITOL, V34, P1547, DOI 10.1016/j.ijpara.2004.10.012
   DELPORTILLO HA, 1988, EXP PARASITOL, V67, P346, DOI 10.1016/0014-4894(88)90081-1
   Dembele L, 2014, NAT MED, V20, P307, DOI 10.1038/nm.3461
   Desai SA, 2014, TRENDS PARASITOL, V30, P151, DOI 10.1016/j.pt.2014.01.003
   Dharia NV, 2010, P NATL ACAD SCI USA, V107, P20045, DOI 10.1073/pnas.1003776107
   Duval L, 2010, P NATL ACAD SCI USA, V107, P10561, DOI 10.1073/pnas.1005435107
   Erhart LM, 2004, AM J TROP MED HYG, V70, P8, DOI 10.4269/ajtmh.2004.70.8
   Escalante AA, 2015, AM J TROP MED HYG, V93, P79, DOI 10.4269/ajtmh.15-0005
   Eyre-Walker A, 2001, NAT REV GENET, V2, P549, DOI 10.1038/35080577
   Feng XR, 2003, P NATL ACAD SCI USA, V100, P8502, DOI 10.1073/pnas.1232502100
   Fernandez-Becerra C, 2005, MOL MICROBIOL, V58, P648, DOI 10.1111/j.1365-2958.2005.04850.x
   Fernandez-Becerra C, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-55
   Field J., 1956, MICROSCOPUIC DIAGNOS, P251
   de Santana FS, 2007, EMERG INFECT DIS, V13, P1125, DOI 10.3201/eid1307.061386
   Flannery EL, 2015, ACS INFECT DIS, V1, P367, DOI 10.1021/acsinfecdis.5b00049
   Foth BJ, 2003, SCIENCE, V299, P705, DOI 10.1126/science.1078599
   Frazer KA, 2003, GENOME RES, V13, P1, DOI 10.1101/gr.222003
   Frech C, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002320
   Friedrich LR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004526
   Galinski MR, 2012, AM COLL LAB, P299, DOI 10.1016/B978-0-12-381366-4.00005-5
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   Genton B, 2008, PLOS MED, V5, P881, DOI 10.1371/journal.pmed.0050127
   Gething PW, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001814
   Glazko GV, 2003, MOL BIOL EVOL, V20, P424, DOI 10.1093/molbev/msg050
   Guerra CA, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000774
   Gunawardena S, 2010, AM J TROP MED HYG, V82, P235, DOI 10.4269/ajtmh.2010.09-0588
   Gupta BK, 2010, T ROY SOC TROP MED H, V104, P690, DOI 10.1016/j.trstmh.2010.07.001
   Haldar Kasturi, 2009, Hematology Am Soc Hematol Educ Program, P87, DOI 10.1182/asheducation-2009.1.87
   Handayani S, 2009, J INFECT DIS, V199, P445, DOI 10.1086/596048
   Hemingway J, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002380
   Hemmer CJ, 2006, TROP MED INT HEALTH, V11, P817, DOI 10.1111/j.1365-3156.2006.01635.x
   Hester J, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002569
   HOLLINGDALE MR, 1985, AM J TROP MED HYG, V34, P216, DOI 10.4269/ajtmh.1985.34.216
   Hoo R, 2016, EBIOMEDICINE, V7, P255, DOI 10.1016/j.ebiom.2016.04.011
   Howes RE, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1265
   Hupalo DN, 2016, NAT GENET, V48, P953, DOI 10.1038/ng.3588
   Hussain MM, 2013, SAUDI J BIOL SCI, V20, P195, DOI 10.1016/j.sjbs.2013.01.003
   Hutchinson RA, 2006, LANCET, V367, P1947, DOI 10.1016/S0140-6736(06)68850-8
   Imwong M, 2003, ANTIMICROB AGENTS CH, V47, P1514, DOI 10.1128/AAC.47.5.1514-1521.2003
   Imwong M, 2007, INT J PARASITOL, V37, P1013, DOI 10.1016/j.ijpara.2007.02.010
   Imwong M, 2007, J INFECT DIS, V195, P927, DOI 10.1086/512241
   Iriko H, 2009, PARASITOL INT, V58, P196, DOI 10.1016/j.parint.2009.02.002
   Jongwutiwes S, 2005, MOL BIOL EVOL, V22, P1733, DOI 10.1093/molbev/msi168
   Joy DA, 2008, MOL BIOL EVOL, V25, P1245, DOI 10.1093/molbev/msn073
   Judice CC, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00005
   Karunaweera ND, 2008, GENE, V410, P105, DOI 10.1016/j.gene.2007.11.022
   KARUNAWEERA ND, 1992, P NATL ACAD SCI USA, V89, P3200, DOI 10.1073/pnas.89.8.3200
   Kim A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07275-9
   Kim HC, 2009, MIL MED, V174, P762, DOI 10.7205/MILMED-D-01-6208
   Kim JR, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-71
   Kiszewski A, 2004, AM J TROP MED HYG, V70, P486, DOI 10.4269/ajtmh.2004.70.486
   KITCHEN S. F., 1938, AMER JOUR TROP MED, V18, P347
   Kochar DK, 2009, AM J TROP MED HYG, V80, P194, DOI 10.4269/ajtmh.2009.80.194
   Kochar DK, 2005, EMERG INFECT DIS, V11, P132, DOI 10.3201/eid1101.040519
   Kochar SK, 2009, J VECTOR DIS, V46, P307
   Koepfli C, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003872
   Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485
   Korsinczky M, 2004, ANTIMICROB AGENTS CH, V48, P2214, DOI 10.1128/AAC.48.6.2214-2222.2004
   KROTOSKI WA, 1982, AM J TROP MED HYG, V31, P1291, DOI 10.4269/ajtmh.1982.31.1291
   KROTOSKI WA, 1985, T ROY SOC TROP MED H, V79, P1, DOI 10.1016/0035-9203(85)90221-4
   Lacerda MVG, 2012, CLIN INFECT DIS, V55, pE67, DOI 10.1093/cid/cis615
   Lacerda MVG, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-12
   Lacerda MVG, 2004, ACTA TROP, V90, P187, DOI 10.1016/j.actatropica.2003.12.001
   Lampah DA, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001032
   Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025
   Lenhard B, 2012, NAT REV GENET, V13, P233, DOI 10.1038/nrg3163
   Lin JT, 2015, J INFECT DIS, V212, P999, DOI 10.1093/infdis/jiv142
   Lin JT, 2013, AM J TROP MED HYG, V88, P1116, DOI 10.4269/ajtmh.12-0701
   Liu WM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4346
   Lu F, 2014, J PROTEOMICS, V102, P66, DOI 10.1016/j.jprot.2014.02.029
   Luo ZP, 2015, ANN NY ACAD SCI, V1342, P53, DOI 10.1111/nyas.12708
   Manamperi A, 2008, TROP BIOMED, V25, P100
   Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959
   MARSH K, 1995, NEW ENGL J MED, V332, P1399, DOI 10.1056/NEJM199505253322102
   MAZIER D, 1984, NATURE, V307, P367, DOI 10.1038/307367a0
   MCCUTCHAN TF, 1984, SCIENCE, V225, P808, DOI 10.1126/science.6382604
   McGready R, 2004, AM J TROP MED HYG, V70, P398, DOI 10.4269/ajtmh.2004.70.398
   Mehlotra RK, 2017, MALARIA J, V16, DOI 10.1186/s12936-017-2090-7
   Melnikov A, 2011, GENOME BIOL, V12, DOI [10.1186/gb-2011-12-8-R73, 10.1186/gb-2011-12-8-r73]
   Melo GC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105922
   Menard D, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002489
   Menard D, 2010, P NATL ACAD SCI USA, V107, P5967, DOI 10.1073/pnas.0912496107
   Mendis K, 2001, AM J TROP MED HYG, V64, P97, DOI 10.4269/ajtmh.2001.64.97
   Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626
   Mideo N, 2013, TRENDS PARASITOL, V29, P321, DOI 10.1016/j.pt.2013.05.004
   Mikolajczak SA, 2015, CELL HOST MICROBE, V17, P526, DOI 10.1016/j.chom.2015.02.011
   MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602
   Moon SU, 2009, ACTA TROP, V109, P30, DOI 10.1016/j.actatropica.2008.09.006
   Moreno-Perez DA, 2015, J PROTEOMICS, V113, P268, DOI 10.1016/j.jprot.2014.10.003
   Mu JB, 2005, MOL BIOL EVOL, V22, P1686, DOI 10.1093/molbev/msi160
   Mueller I, 2002, AM J TROP MED HYG, V67, P459, DOI 10.4269/ajtmh.2002.67.459
   Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X
   Naing C, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003071
   Nair S, 2014, GENOME RES, V24, P1028, DOI 10.1101/gr.168286.113
   Neafsey DE, 2012, NAT GENET, V44, P1046, DOI 10.1038/ng.2373
   Noulin F, 2013, TRENDS PARASITOL, V29, P286, DOI 10.1016/j.pt.2013.03.012
   Orjuela-Sanchez P, 2013, EXP PARASITOL, V134, P318, DOI 10.1016/j.exppara.2013.03.029
   Otto TD, 2010, MOL MICROBIOL, V76, P12, DOI 10.1111/j.1365-2958.2009.07026.x
   Quintero JP, 2011, MEM I OSWALDO CRUZ, V106, P91, DOI 10.1590/S0074-02762011000900012
   Pain A, 2008, NATURE, V455, P799, DOI 10.1038/nature07306
   Parobek CM, 2016, P NATL ACAD SCI USA, V113, pE8096, DOI 10.1073/pnas.1608828113
   Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104
   Pava Z, 2016, ANTIMICROB AGENTS CH, V60, P361, DOI 10.1128/AAC.02207-15
   Pearson RD, 2016, NAT GENET, V48, P959, DOI 10.1038/ng.3599
   Pelle KG, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0133-7
   Poespoprodjo JR, 2008, CLIN INFECT DIS, V46, P1374, DOI 10.1086/586743
   Price RN, 2007, AM J TROP MED HYG, V77, P79, DOI 10.4269/ajtmh.2007.77.79
   Price RN, 2014, LANCET INFECT DIS, V14, P982, DOI 10.1016/S1473-3099(14)70855-2
   Price RN, 2009, CURR OPIN INFECT DIS, V22, P430, DOI 10.1097/QCO.0b013e32832f14c1
   Quispe AM, 2014, AM J TROP MED HYG, V91, P11, DOI 10.4269/ajtmh.12-0610
   Rahimi BA, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-481
   Ralph SA, 2004, NAT REV MICROBIOL, V2, P203, DOI 10.1038/nrmicro843
   Ray S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04447-5
   Ray S, 2016, SCI REP-UK, V6, DOI 10.1038/srep24557
   Ray S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041751
   Ray S, 2012, J PROTEOMICS, V75, P3063, DOI 10.1016/j.jprot.2011.10.018
   Restrepo E, 2011, ACTA TROP, V119, P23, DOI 10.1016/j.actatropica.2011.03.012
   Rodriguez-Morales AJ, 2015, NEGLECT TROP DIS, P89, DOI 10.1007/978-3-7091-1422-3_5
   Roobsoong W, 2011, J PROTEOMICS, V74, P1701, DOI 10.1016/j.jprot.2011.03.035
   Russell B, 2008, ANTIMICROB AGENTS CH, V52, P1040, DOI 10.1128/AAC.01334-07
   Saharan S, 2009, PEDIATR NEPHROL, V24, P623, DOI 10.1007/s00467-008-0945-4
   Sattabongkot J, 2006, AM J TROP MED HYG, V74, P708, DOI 10.4269/ajtmh.2006.74.708
   Severini C, 2004, T ROY SOC TROP MED H, V98, P585, DOI 10.1016/j.trstmh.2004.01.003
   Sharma J, 1993, Indian Pediatr, V30, P369
   Siegel TN, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-150
   Siqueira AM, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0302-y
   Siqueira AM, 2010, AM J TROP MED HYG, V83, P271, DOI 10.4269/ajtmh.2010.10-0027
   Sorber K, 2011, NUCLEIC ACIDS RES, V39, P3820, DOI 10.1093/nar/gkq1223
   Suratt BT, 2006, CLIN CHEST MED, V27, P579, DOI 10.1016/j.ccm.2006.06.005
   Suwanarusk R, 2004, J INFECT DIS, V189, P190, DOI 10.1086/380468
   Suwanarusk R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001089
   Tachibana M, 2012, VACCINE, V30, P1807, DOI 10.1016/j.vaccine.2012.01.003
   Tan LKK, 2008, LANCET INFECT DIS, V8, P449, DOI 10.1016/S1473-3099(08)70153-1
   Tanwar GS, 2011, ANN TROP PAEDIATR, V31, P351, DOI 10.1179/1465328111Y.0000000040
   Tasanee P, 2007, INT J PARASITOL, V37, P1551, DOI 10.1016/j.ijpara.2007.05.009
   Taylor JE, 2013, MOL BIOL EVOL, V30, P2050, DOI 10.1093/molbev/mst104
   Tjitra E, 2008, PLOS MED, V5, P890, DOI 10.1371/journal.pmed.0050128
   Udomsangpetch R, 2008, TRENDS PARASITOL, V24, P85, DOI 10.1016/j.pt.2007.09.010
   Ureta-Vidal A, 2003, NAT REV GENET, V4, P251, DOI 10.1038/nrg1043
   Watanabe J, 2002, GENE, V291, P105, DOI 10.1016/S0378-1119(02)00552-8
   Westenberger SJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000653
   White MT, 2016, P ROY SOC B-BIOL SCI, V283, DOI 10.1098/rspb.2016.0048
   White NJ, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-297
   WHO, 2010, GUID TREATM MAL
   Williams TN, 1997, QJM-INT J MED, V90, P751
   Winter DJ, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004252
   World Health Organization, 2015, WORLD MAL REP 2015
   Yadav MK, 2012, BIOINFORMATION, V8, P1230, DOI 10.6026/97320630081230
   Yuda M, 2015, P NATL ACAD SCI USA, V112, P12824, DOI 10.1073/pnas.1504389112
   Zakeri S, 2010, PARASITOL INT, V59, P15, DOI 10.1016/j.parint.2009.06.006
   Zhu L, 2016, SCI REP-UK, V6, DOI 10.1038/srep20498
NR 211
TC 16
Z9 18
U1 1
U2 21
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2235-2988
J9 FRONT CELL INFECT MI
JI Front. Cell. Infect. Microbiol.
PD FEB 8
PY 2018
VL 8
AR 34
DI 10.3389/fcimb.2018.00034
PG 22
WC Immunology; Microbiology
SC Immunology; Microbiology
GA FV3NG
UT WOS:000424474400001
PM 29473024
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Cravo, P
   Machado, RB
   Leite, JA
   Leda, T
   Suwanarusk, R
   Bittencourt, N
   Albrecht, L
   Judice, C
   Lopes, SCP
   Lacerda, MVG
   Ferreira, MU
   Soares, IS
   Goh, YS
   Bargieri, DY
   Nosten, F
   Russell, B
   Renia, L
   Costa, FTM
AF Cravo, Pedro
   Machado, Renato B.
   Leite, Juliana A.
   Leda, Taizy
   Suwanarusk, Rossarin
   Bittencourt, Najara
   Albrecht, Letusa
   Judice, Carla
   Lopes, Stefanie C. P.
   Lacerda, Marcus V. G.
   Ferreira, Marcelo U.
   Soares, Irene S.
   Goh, Yun Shan
   Bargieri, Daniel Y.
   Nosten, Francois
   Russell, Bruce
   Renia, Laurent
   Costa, Fabio T. M.
TI In silico epitope mapping and experimental evaluation of the Merozoite
   Adhesive Erythrocytic Binding Protein (MAEBL) as a malaria vaccine
   candidate
SO MALARIA JOURNAL
LA English
DT Article
ID PLASMODIUM-YOELII INFECTION; SPOROZOITE; PREDICTION; FALCIPARUM;
   PARASITES; STAGE; ANTIBODIES; EXPRESSION; MOLECULES; ALIGNMENT
AB Background: Technical limitations for culturing the human malaria parasite Plasmodium vivax have impaired the discovery of vaccine candidates, challenging the malaria eradication agenda. The immunogenicity of the M2 domain of the Merozoite Adhesive Erythrocytic Binding Protein (MAEBL) antigen cloned from the Plasmodium yoelii murine parasite, has been previously demonstrated.
   Results: Detailed epitope mapping of MAEBL through immunoinformatics identified several MHCI, MHCII and B cell epitopes throughout the peptide, with several of these lying in the M2 domain and being conserved between P. vivax, P. yoelii and Plasmodium falciparum, hinting that the M2-MAEBL is pan-reactive. This hypothesis was tested through functional assays, showing that P. yoelii M2-MAEBL antisera are able to recognize and inhibit erythrocyte invasion from both P. falciparum and P. vivax parasites isolated from Thai patients, in ex vivo assays. Moreover, the sequence of the M2-MAEBL is shown to be highly conserved between P. vivax isolates from the Amazon and Thailand, indicating that the MAEBL antigen may constitute a vaccine candidate outwitting strain-specific immunity.
   Conclusions: The MAEBL antigen is promising candidate towards the development of a malaria vaccine.
C1 [Cravo, Pedro] Univ Nova Lisboa, Global Hlth & Trop Med Ctr GHTM, IHMT, Rua Junqueira 100, P-1349008 Lisbon, Portugal.
   [Cravo, Pedro; Machado, Renato B.; Leda, Taizy] Univ Fed Goias, Inst Patol Trop & Saude Publ, GenoBio, Goiania, Go, Brazil.
   [Cravo, Pedro] Ctr Univ Anapolis, PPG SOMA, Anapolis, Go, Brazil.
   [Leite, Juliana A.; Bittencourt, Najara; Albrecht, Letusa; Judice, Carla; Lopes, Stefanie C. P.; Costa, Fabio T. M.] Univ Campinas UNICAMP, Dept Genet Evolut Microbiol & Immunol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Campinas, SP, Brazil.
   [Suwanarusk, Rossarin; Renia, Laurent] ASTAR, Singapore Immunol Network, Singapore, Singapore.
   [Albrecht, Letusa] Fundacao Oswaldo Cruz FIOCRUZ, Inst Carlos Chagas, Curitiba, PR, Brazil.
   [Lopes, Stefanie C. P.; Lacerda, Marcus V. G.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Leonidas & Maria Deane, Manaus, AM, Brazil.
   [Lacerda, Marcus V. G.] Fundacao Med Trop Dr Heitor Vieira Dourado, Gerencia Malaria, Manaus, AM, Brazil.
   [Ferreira, Marcelo U.; Bargieri, Daniel Y.] Univ Sao Paulo, Dept Parasitol, Sao Paulo, SP, Brazil.
   [Soares, Irene S.] Univ Sao Paulo, Dept Clin & Toxicol Anal, Pharmaceut Sci, Sao Paulo, SP, Brazil.
   [Nosten, Francois] NUS, Dept Microbiol, Singapore, Singapore.
   [Nosten, Francois] Mahidol Univ, Fac Trop Med, Shoklo Malaria Res Unit, Mahidol Oxford Trop Med Res Unit, Mae Sot, Thailand.
   [Russell, Bruce] Univ Oxford, Ctr Trop Med, Nuffield Dept Med, Oxford, England.
RP Cravo, P (corresponding author), Univ Nova Lisboa, Global Hlth & Trop Med Ctr GHTM, IHMT, Rua Junqueira 100, P-1349008 Lisbon, Portugal.; Cravo, P (corresponding author), Univ Fed Goias, Inst Patol Trop & Saude Publ, GenoBio, Goiania, Go, Brazil.; Cravo, P (corresponding author), Ctr Univ Anapolis, PPG SOMA, Anapolis, Go, Brazil.
EM pedrovcravo@gmail.com
RI Albrecht, Letusa/I-1837-2012; Russell, Bruce/A-9240-2011; Costa,
   Fabio/E-1181-2012; Cravo, Pedro VL/G-3532-2012; Soares, Irene
   Silva/C-5974-2012; Ferreira, Marcelo U/G-8289-2011; Bargieri, Daniel
   Youssef/A-4461-2013; Nosten, Francois/AAC-5509-2019; Judice,
   Carla/P-4738-2014
OI Albrecht, Letusa/0000-0001-6406-2057; Russell,
   Bruce/0000-0003-2333-4348; Costa, Fabio/0000-0001-9969-7300; Cravo,
   Pedro VL/0000-0003-1675-4504; Soares, Irene Silva/0000-0002-3336-6856;
   Ferreira, Marcelo U/0000-0002-5293-9090; Bargieri, Daniel
   Youssef/0000-0003-2564-3742; Nosten, Francois/0000-0002-7951-0745;
   Judice, Carla/0000-0003-1839-053X; Lopes, Stefanie/0000-0002-6981-2192
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/16525-2];
   Instituto Nacional de Ciencia e Tecnologia de Vacinas (INCTV); Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National
   Council for Scientific and Technological Development (CNPq); CAPES
   fellowshipCAPES; FAPESP fellowshipsFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP); CNPq fellowshipNational Council for
   Scientific and Technological Development (CNPq); SIgN under the Agency
   for Science, Technology and Research (A*STAR, Singapore)
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP- Grant # 2012/16525-2), Instituto Nacional de Ciencia
   e Tecnologia de Vacinas (INCTV) and the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq). RBM was supported by a
   CAPES fellowship. JAL and NB were sponsored by FAPESP fellowships. CC
   was supported by a CNPq fellowship. PC, MVGL, MUF and FTMC are CNPq
   research fellows in productivity. This study and RS and BR received
   funding from SIgN under the Agency for Science, Technology and Research
   (A*STAR, Singapore).
CR Bitencourt AR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056061
   Blair PL, 2002, MOL BIOCHEM PARASIT, V122, P35, DOI 10.1016/S0166-6851(02)00067-1
   Carlton J, 2005, CURR ISSUES MOL BIOL, V7, P23
   Carlton JMR, 1998, MOL BIOCHEM PARASIT, V93, P285, DOI 10.1016/S0166-6851(98)00043-7
   CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881
   Doolan DL, 2009, CLIN MICROBIOL REV, V22, P13, DOI 10.1128/CMR.00025-08
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Doytchinova IA, 2007, VACCINE, V25, P856, DOI 10.1016/j.vaccine.2006.09.032
   El-Manzalawy Y, 2008, J MOL RECOGNIT, V21, P243, DOI 10.1002/jmr.893
   Fraser T, 1997, INFECT IMMUN, V65, P2772, DOI 10.1128/IAI.65.7.2772-2777.1997
   Ghai M, 2002, MOL BIOCHEM PARASIT, V123, P35, DOI 10.1016/S0166-6851(02)00123-8
   Hakenberg Jorg, 2003, Appl Bioinformatics, V2, P155
   Heinson AI, 2015, INT HEALTH, V7, P85, DOI 10.1093/inthealth/ihv002
   HOLDER AA, 1983, MOL BIOCHEM PARASIT, V9, P191, DOI 10.1016/0166-6851(83)90096-8
   Hoof I, 2009, IMMUNOGENETICS, V61, P1, DOI 10.1007/s00251-008-0341-z
   Kappe SHI, 1997, MOL BIOCHEM PARASIT, V89, P137, DOI 10.1016/S0166-6851(97)00113-8
   Kappe SHI, 1998, P NATL ACAD SCI USA, V95, P1230, DOI 10.1073/pnas.95.3.1230
   Kappe SHI, 2001, P NATL ACAD SCI USA, V98, P9895, DOI 10.1073/pnas.171185198
   Kariu T, 2002, J EXP MED, V195, P1317, DOI 10.1084/jem.20011876
   Leite JA, 2015, INFECT IMMUN, V83, P3781, DOI 10.1128/IAI.00262-15
   Malaria Vaccine Funders Group, 2013, MAL VACC TECHN ROADM
   Michon P, 2002, MOL BIOL EVOL, V19, P1128, DOI 10.1093/oxfordjournals.molbev.a004171
   Nielsen M, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-238
   Nielsen M, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-296
   Noe AR, 1998, MOL BIOCHEM PARASIT, V96, P27, DOI 10.1016/S0166-6851(98)00084-X
   PARKER KC, 1994, J IMMUNOL, V152, P163
   Peng K, 2016, CELL MICROBIOL, V18, P1739, DOI 10.1111/cmi.12608
   Preiser P, 2004, INFECT IMMUN, V72, P3604, DOI 10.1128/IAI.72.6.3604-3608.2004
   RAY P, 1994, INFECT IMMUN, V62, P2354, DOI 10.1128/IAI.62.6.2354-2361.1994
   Reche PA, 2004, IMMUNOGENETICS, V56, P405, DOI 10.1007/s00251-004-0709-7
   Reche PA, 2002, HUM IMMUNOL, V63, P701, DOI 10.1016/S0198-8859(02)00432-9
   Reche Pedro A., 2007, V409, P185, DOI 10.1007/978-1-60327-118-9_13
   Reyes C, 2007, BIOCHEM BIOPH RES CO, V354, P363, DOI 10.1016/j.bbrc.2006.12.220
   Russell B, 2011, BLOOD, V118, pE74, DOI 10.1182/blood-2011-04-348748
   Singh H, 2003, BIOINFORMATICS, V19, P1009, DOI 10.1093/bioinformatics/btg108
   Snounou Georges, 2002, Methods Mol Med, V72, P189, DOI 10.1385/1-59259-271-6:189
   TAYLOR DW, 1981, INFECT IMMUN, V32, P563, DOI 10.1128/IAI.32.2.563-570.1981
   Vita R, 2015, NUCLEIC ACIDS RES, V43, pD405, DOI 10.1093/nar/gku938
   Xu LL, 2007, EXP PARASITOL, V116, P214, DOI 10.1016/j.exppara.2007.01.012
   2013, WORLD MAL REP 2013, P1
NR 40
TC 3
Z9 3
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JAN 10
PY 2018
VL 17
AR 20
DI 10.1186/s12936-017-2144-x
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA FS8XQ
UT WOS:000422698400002
PM 29316918
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Silveira, AAA
   Dominical, VM
   Almeida, CB
   Chweih, H
   Ferreira, WA
   Vicente, CP
   Costa, FTM
   Werneck, CC
   Costa, FF
   Conran, N
AF Antoniellis Silveira, Angelica Aparecida
   Dominical, Venina Marcela
   Almeida, Camila Bononi
   Chweih, Hanan
   Ferreira, Wilson Alves, Jr.
   Vicente, Cristina Pontes
   Maranhao Costa, Fabio Trindade
   Werneck, Claudio C.
   Costa, Fernando Ferreira
   Conran, Nicola
TI TNF induces neutrophil adhesion via formin-dependent cytoskeletal
   reorganization and activation of beta-integrin function
SO JOURNAL OF LEUKOCYTE BIOLOGY
LA English
DT Article
DE cytokine; inflammation; leukocytes; mDia; Rho GTPases
ID SICKLE-CELL-DISEASE; LEUKOCYTE RECRUITMENT; ACTIN CYTOSKELETON;
   SIGNALING PATHWAYS; ENDOTHELIAL-CELLS; SHEAR-STRESS; RHO-FAMILY; ALPHA;
   MIGRATION; ATHEROSCLEROSIS
AB Although essential for inflammatory responses, leukocyte recruitment to blood vessel walls in response to inflammatory stimuli, such as TNF-alpha, can contribute to vascular occlusion in inflammatorydiseases, including atherosclerosis. We aimed to further characterize the mechanisms by which TNF stimulates adhesive and morphologic alterations in neutrophils. Microfluidic and intravital assays confirmed the potent effect that TNF has on human and murine neutrophil adhesion and recruitment in vitro and in vivo, respectively. Inhibition of actin polymerization by cytochalasin D significantly diminished TNF-induced human neutrophil adhesion in vitro and abolished TNF-induced membrane alterations and cell spreading. In contrast, TNF-induced increases in.. beta 2-integrin (Mac-1 and LFA-1) expression was not significantly altered by actin polymerization inhibition. Consistent with a role for cytoskeletal rearrangements in TNF-induced adhesion, TNF augmented the activity of the Rho GTPase, RhoA, in human neutrophils. However, inhibition of the major RhoA effector protein, Rho kinase (ROCK), by Y-27632 failed to inhibit TNF-induced neutrophil adhesion. In contrast, the formin FH2 domain inhibitor, SMIFH2, abolished TNF-induced human neutrophil adhesion and diminished leukocyte recruitment in vivo. SMIFH2 also inhibited TNF-induced cytoskeletal reorganization in human neutrophils and abolished the alterations in.. beta 2-integrin expression elicited by TNF stimulation. As such, Rho GTPase/mDia formin-mediated cytoskeletal reorganization appears to participate in the orchestration of TNF-induced neutrophil-adhesive interactions, possiblymediated by formin-mediated actin nucleation and subsequent modulation of.. beta 2-integrin activity on the neutrophil surface. This pathway may represent a pharmacologic target for reducing leukocyte recruitment in inflammatory diseases.
C1 [Antoniellis Silveira, Angelica Aparecida; Dominical, Venina Marcela; Almeida, Camila Bononi; Chweih, Hanan; Ferreira, Wilson Alves, Jr.; Costa, Fernando Ferreira; Conran, Nicola] Univ Estadual Campinas, Sch Med, Hematol & Hemotherapy Ctr, Campinas, SP, Brazil.
   [Vicente, Cristina Pontes] Univ Estadual Campinas, Biol Inst, Dept Struct & Funct Biol, Campinas, SP, Brazil.
   [Maranhao Costa, Fabio Trindade] Univ Estadual Campinas, Inst Biol, Genet Evolut & Bioagents, Campinas, SP, Brazil.
   [Werneck, Claudio C.] Univ Estadual Campinas, Inst Biol, Dept Biochem & Tissue Biol, Campinas, SP, Brazil.
RP Conran, N (corresponding author), Univ Estadual Campinas, Hemoctr, Rua Carlos Chagas,480,Cidade Univ, BR-13083970 Campinas, SP, Brazil.
EM conran@unicamp.br
RI Conran, Nicola/B-8961-2012; Costa, Fabio/E-1181-2012; Costa,
   Fernando/D-1566-2012; Werneck, Claudio C/C-7568-2012; Vicente,
   Cristina/D-8928-2012
OI Conran, Nicola/0000-0001-5726-7919; Costa, Fabio/0000-0001-9969-7300;
   Costa, Fernando/0000-0002-4632-572X; Werneck, Claudio
   C/0000-0002-9413-0572; Vicente, Cristina/0000-0001-9896-4630
FU FAPESP (Sao Paulo State Research Foundation)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2010/17082-1, 2014/19173-5,
   2010/19916-7]; FAPESP, BrazilFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [2012/22048-2]; CNPqNational Council for Scientific
   and Technological Development (CNPq) [308368/2016-9]
FX This study was funded by FAPESP (Sao Paulo State Research Foundation),
   Grants 2010/17082-1 and 2014/19173-5. A.A.A.S. was the recipient of a
   grant from FAPESP, Brazil (Grant 2012/22048-2). C.C.W. was a recipient
   of grants from FAPESP (2010/19916-7) and CNPq (308368/2016-9). Confocal
   microscopy was performed at the LACTAD facility, UNICAMP. The authors
   would also like to thank Joao Batista Fabrin Neto, Flavia Costa
   Leonardo, Mariana Lazarini, Daiana Vital, and Guilherme Barbosa for
   assistance with data collection and analysis.
CR Alblas J, 2001, MOL BIOL CELL, V12, P2137, DOI 10.1091/mbc.12.7.2137
   Almeida CB, 2015, BLOOD, V126, P711, DOI 10.1182/blood-2014-12-616250
   Almeida CB, 2016, SICKLE CELL ANEMIA B, P177
   Silveira AAA, 2013, INFLAMM RES, V62, P127, DOI 10.1007/s00011-012-0579-7
   Arakawa Y, 2003, J CELL BIOL, V161, P381, DOI 10.1083/jcb.200210149
   Arden JD, 2015, MOL BIOL CELL, V26, P3704, DOI 10.1091/mbc.E14-11-1502
   Arita R, 2013, INVEST OPHTH VIS SCI, V54, P2373, DOI 10.1167/iovs.12-10757
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462
   Canalli AA, 2008, HAEMATOLOGICA, V93, P605, DOI 10.3324/haematol.12119
   Christophis C, 2011, BIOPHYS J, V101, P585, DOI 10.1016/j.bpj.2011.05.045
   DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D
   Decleva E, 2002, J LEUKOCYTE BIOL, V72, P718
   DeWard AD, 2010, BBA-MOL CELL RES, V1803, P226, DOI 10.1016/j.bbamcr.2009.11.006
   Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8
   Filippi MD, 2007, BLOOD, V109, P1257, DOI 10.1182/blood-2006-04-017731
   Frenette PS, 2002, CURR OPIN HEMATOL, V9, P101, DOI 10.1097/00062752-200203000-00003
   Fukata M, 2003, CURR OPIN CELL BIOL, V15, P590, DOI 10.1016/S0955-0674(03)00097-8
   Gerdes N, 2016, ARTERIOSCL THROM VAS, V36, P482, DOI 10.1161/ATVBAHA.115.307074
   Gupton SL, 2007, J CELL SCI, V120, P3475, DOI 10.1242/jcs.006049
   Hickey MJ, 1997, J IMMUNOL, V158, P3391
   Hordijk PL, 2016, CELL MOL LIFE SCI, V73, P1591, DOI 10.1007/s00018-016-2136-y
   Infante E, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2013.0013
   Irimia D, 2016, J LEUKOCYTE BIOL, V100, P291, DOI 10.1189/jlb.5RU0216-056R
   Jinesh S, 2015, INFLAMMOPHARMACOLOGY, V23, P71, DOI 10.1007/s10787-015-0229-0
   Kelly M, 2007, J ALLERGY CLIN IMMUN, V120, P3, DOI 10.1016/j.jaci.2007.05.017
   Kleinbongard P, 2010, PHARMACOL THERAPEUT, V127, P295, DOI 10.1016/j.pharmthera.2010.05.002
   Kuhn Sonja, 2014, Small GTPases, V5, pe29513, DOI 10.4161/sgtp.29513
   Lauterbach M, 2008, J LEUKOCYTE BIOL, V83, P1423, DOI 10.1189/jlb.0607421
   Li F, 2003, CURR BIOL, V13, P1335, DOI 10.1016/S0960-9822(03)00540-2
   Li JX, 2013, ADV IMMUNOL, V119, P135, DOI 10.1016/B978-0-12-407707-2.00005-9
   Li QH, 2016, BIOPHYS J, V111, P686, DOI 10.1016/j.bpj.2016.07.014
   Liu L, 2002, J IMMUNOL, V169, P2330, DOI 10.4049/jimmunol.169.5.2330
   Lokuta MA, 2005, J LEUKOCYTE BIOL, V78, P210, DOI 10.1189/jlb.0205067
   McKellar GE, 2009, NAT REV CARDIOL, V6, P410, DOI 10.1038/nrcardio.2009.57
   Miguel LI, 2011, INFLAMM RES, V60, P633, DOI 10.1007/s00011-011-0315-8
   Mitroulis I, 2015, PHARMACOL THERAPEUT, V147, P123, DOI 10.1016/j.pharmthera.2014.11.008
   Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779
   Montecucco F, 2008, CELL SIGNAL, V20, P557, DOI 10.1016/j.cellsig.2007.11.008
   Montes RAO, 2002, AM J HEMATOL, V70, P216, DOI 10.1002/ajh.10145
   Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481
   Nourshargh S, 2014, IMMUNITY, V41, P694, DOI 10.1016/j.immuni.2014.10.008
   PAVALKO FM, 1993, J IMMUNOL, V151, P3795
   Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463
   PICHYANGKUL S, 1988, EXP HEMATOL, V16, P588
   Podolnikova NP, 2015, BIOCHEMISTRY-US, V54, P1408, DOI 10.1021/bi5013782
   Polanowska-Grabowska R, 1999, THROMB HAEMOSTASIS, V81, P118
   Reinhardt PH, 1997, BLOOD, V89, P3837, DOI 10.1182/blood.V89.10.3837.3837_3837_3846
   Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053
   Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128
   Rizvi SA, 2009, CHEM BIOL, V16, P1158, DOI 10.1016/j.chembiol.2009.10.006
   Rodrigues SF, 2014, CURR MED CHEM, V21, P2130, DOI 10.2174/0929867321666131228192119
   SHANLEY TP, 1995, MOL MED TODAY, V1, P40, DOI 10.1016/1357-4310(95)80019-0
   Shi YQ, 2009, J IMMUNOL, V182, P3837, DOI 10.4049/jimmunol.0803838
   Sonego F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00155
   Sonego F, 2014, EXPERT REV CLIN IMMU, V10, P1019, DOI 10.1586/1744666X.2014.922876
   Thumkeo D, 2013, EUR J CELL BIOL, V92, P303, DOI 10.1016/j.ejcb.2013.09.002
   Turhan A, 2002, P NATL ACAD SCI USA, V99, P3047, DOI 10.1073/pnas.052522799
   Volk APD, 2011, J INNATE IMMUN, V3, P298, DOI 10.1159/000321439
   Watanabe N, 1999, NAT CELL BIOL, V1, P136
   Weber C, 2008, NAT REV IMMUNOL, V8, P802, DOI 10.1038/nri2415
   Wiemer AJ, 2010, MOL IMMUNOL, V47, P894, DOI 10.1016/j.molimm.2009.10.002
   Wojciak-Stothard B, 2002, VASC PHARMACOL, V39, P187, DOI 10.1016/S1537-1891(03)00008-9
   Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B
   Yagi Y, 2006, EUR J PHARMACOL, V536, P19, DOI 10.1016/j.ejphar.2006.02.024
   Yakubenko VP, 2002, J BIOL CHEM, V277, P48635, DOI 10.1074/jbc.M208877200
   Yamanaka H, 2015, ENDOCR METAB IMMUNE, V15, P129, DOI 10.2174/1871530315666150316121808
   Zelova H, 2013, INFLAMM RES, V62, P641, DOI 10.1007/s00011-013-0633-0
   Zhang DC, 2016, BLOOD, V127, P801, DOI 10.1182/blood-2015-09-618538
   Zhou XM, 2001, J BIOL CHEM, V276, P44762, DOI 10.1074/jbc.M104029200
NR 70
TC 5
Z9 5
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-5400
EI 1938-3673
J9 J LEUKOCYTE BIOL
JI J. Leukoc. Biol.
PD JAN
PY 2018
VL 103
IS 1
BP 87
EP 98
DI 10.1189/jlb.3A0916-388RR
PG 12
WC Cell Biology; Hematology; Immunology
SC Cell Biology; Hematology; Immunology
GA FS7QK
UT WOS:000419992500009
PM 28798145
OA Bronze
DA 2020-12-08
ER

PT J
AU Barboza, R
   Lima, FA
   Reis, AS
   Murillo, OJ
   Peixoto, EPM
   Bandeira, CL
   Fotoran, WL
   Sardinha, LR
   Wunderlich, G
   Bevilacqua, E
   Lima, MRD
   Alvarez, JM
   Costa, FTM
   Goncalves, LA
   Epiphanio, S
   Marinho, CRF
AF Barboza, Renato
   Lima, Flavia Afonso
   Reis, Aramys Silva
   Murillo, Oscar Javier
   Machado Peixoto, Erika Paula
   Bandeira, Carla Leticia
   Fotoran, Wesley Luzetti
   Sardinha, Luis Roberto
   Wunderlich, Gerhard
   Bevilacqua, Estela
   D'Imperio Lima, Maria Regina
   Alvarez, Jose Maria
   Maranhao Costa, Fabio Trindade
   Goncalves, Ligia Antunes
   Epiphanio, Sabrina
   Farias Marinho, Cludio Romerso
TI TLR4-Mediated Placental Pathology and Pregnancy Outcome in Experimental
   Malaria
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TOLL-LIKE RECEPTORS; NECROSIS-FACTOR-ALPHA; PLASMODIUM-FALCIPARUM;
   PATTERN-RECOGNITION; INNATE IMMUNITY; MICE;
   GLYCOSYLPHOSPHATIDYLINOSITOLS; INFLAMMATION; PARASITEMIA; EXPRESSION
AB Malaria-associate pregnancy has a significant impact on infant morbidity and mortality. The detrimental effects of malaria infection during pregnancy have been shown to correlate with immune activation in the placental tissue. Herein we sought to evaluate the effect of Toll-like receptors (TLRs) activation on placental malaria (PM) development by using the Plasmodium berghei NK65(GFP) infection model. We observed that activation of the innate immune system by parasites leads to PM due to local inflammation. We identified TLR4 activation as the main pathway involved in the inflammatory process in the placental tissue since the absence of functional TLR4 in mice leads to a decrease in the pro-inflammatory responses, which resulted in an improved pregnancy outcome. Additionally, a similar result was obtained when infected pregnant mice were treated with IAXO-101, a TLR4/CD14 blocker. Together, this study illustrates the importance of TLR4 signalling for the generation of the severe inflammatory response involved in PM pathogenesis. Therefore, our results implicate that TLR4 blockage could be a potential candidate for therapeutic interventions to reduce malaria-induced pathology both in the mother and the fetus.
C1 [Barboza, Renato] Univ Fed Sao Paulo, Dept Ciencias Biol, Diadema, Brazil.
   [Lima, Flavia Afonso; Reis, Aramys Silva; Murillo, Oscar Javier; Machado Peixoto, Erika Paula; Bandeira, Carla Leticia; Fotoran, Wesley Luzetti; Wunderlich, Gerhard; Goncalves, Ligia Antunes; Farias Marinho, Cludio Romerso] Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Sao Paulo, Brazil.
   [Sardinha, Luis Roberto] Hosp Israelita Albert Einstein, Sao Paulo, Brazil.
   [Bevilacqua, Estela] Univ Sao Paulo, Inst Ciencias Biomed, Dept Biol Celular & Desenvolvimento, Sao Paulo, Brazil.
   [D'Imperio Lima, Maria Regina; Alvarez, Jose Maria] Univ Estadual Campinas, Dept Genet Evolucao & Bioagentes, Inst Biol, Campinas, SP, Brazil.
   [Maranhao Costa, Fabio Trindade] Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, Sao Paulo, Brazil.
   [Epiphanio, Sabrina] Univ Sao Paulo, Dept Analises Clin & Toxicol, Fac Ciencias Farmaceut, Sao Paulo, Brazil.
RP Marinho, CRF (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Sao Paulo, Brazil.
EM marinho@usp.br
RI Costa, Fabio/E-1181-2012; Bandeira, Carla Leticia/U-8685-2017; Reis,
   Aramys S/N-9170-2019; Murillo, Oscar/H-5039-2017; Peixoto, Erika Paula
   Machado/AAB-5441-2020; Lima, Maria Regina D'Imperio/I-4747-2012; REIS,
   ARAMYS SILVA/G-4806-2012; Lima, Flavia Afonso/G-9713-2013; Marinho,
   Claudio Romero Farias/F-7507-2012; Wunderlich, Gerhard/G-8245-2012;
   Goncalves, Ligia Antunes/F-6242-2014; Barboza, Renato/G-5833-2012;
   Alvarez, Jose M/I-6181-2012; Epiphanio, Sabrina/C-7572-2012; Bevilacqua,
   Estela/H-3354-2011; Fotoran, Wesley/N-2545-2016
OI Costa, Fabio/0000-0001-9969-7300; Bandeira, Carla
   Leticia/0000-0002-0796-3462; Reis, Aramys S/0000-0003-4999-6382;
   Murillo, Oscar/0000-0003-1204-7984; Lima, Maria Regina
   D'Imperio/0000-0002-4683-7709; REIS, ARAMYS SILVA/0000-0003-4999-6382;
   Lima, Flavia Afonso/0000-0003-0742-2209; Marinho, Claudio Romero
   Farias/0000-0002-1227-3845; Wunderlich, Gerhard/0000-0003-1724-0337;
   Goncalves, Ligia Antunes/0000-0001-9804-6899; Barboza,
   Renato/0000-0002-6441-7513; Alvarez, Jose M/0000-0002-9711-4914;
   Epiphanio, Sabrina/0000-0001-6094-9750; Bevilacqua,
   Estela/0000-0003-4178-4625; Fotoran, Wesley/0000-0001-8203-8384; Reis,
   AlessanRSS/0000-0001-8486-7469
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo - FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/53889-0,
   2014/09964-5, 2014/20451-0, 2012/16525-2]; Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior - CAPESCAPES [AUX-PE-PNPD
   2751/2010]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico - CNPqNational Council for Scientific and Technological
   Development (CNPq) [475771/2009-5]; FAPESPFundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP) [2011/17880-8, 2013/16417-8,
   2011/19048-8, 2013/00981-1, 2015/06106-0]
FX We thank Penn Vector Core (University of Pennsylvania School of
   Medicine, USA) for kindly providing the TLR9 plasmid, Prof. Igor C.
   Almeida (University of Texas, USA) for kindly providing all other
   plasmids used in this study and Bernardo Paulo Albe for his technical
   support. This work was supported by the Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo - FAPESP (Grant # 2009/53889-0; 2014/09964-5;
   2014/20451-0; 2012/16525-2); Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior - CAPES (Grant # AUX-PE-PNPD 2751/2010) and Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq (Grant #
   475771/2009-5). RB, FAL, ASR, OJM and LAG were supported by the FAPESP
   fellowships # 2011/17880-8; 2013/16417-8; 2011/19048-8; 2013/00981-1 and
   2015/06106-0, respectively. GH, EB, JMA, MRIL, FTMC, SE and CRFM are
   CNPq research fellows.
CR Abrahams VM, 2008, IMMUNOL INVEST, V37, P427, DOI 10.1080/08820130802191599
   Abrahams VM, 2005, PLACENTA, V26, P540, DOI 10.1016/j.placenta.2004.08.010
   Arce RM, 2012, MOL ORAL MICROBIOL, V27, P373, DOI 10.1111/j.2041-1014.2012.00651.x
   Barboza R, 2014, INFECT IMMUN, V82, P830, DOI 10.1128/IAI.01288-13
   Bettoni I, 2008, GLIA, V56, P1312, DOI 10.1002/glia.20699
   Carpentier PA, 2011, AM J PATHOL, V178, P2802, DOI 10.1016/j.ajpath.2011.02.042
   Coban C, 2010, CELL HOST MICROBE, V7, P50, DOI 10.1016/j.chom.2009.12.003
   Duffy MF, 2006, INFECT IMMUN, V74, P4875, DOI 10.1128/IAI.01978-05
   FAAS MM, 1994, AM J OBSTET GYNECOL, V171, P158, DOI 10.1016/0002-9378(94)90463-4
   Franklin BS, 2009, P NATL ACAD SCI USA, V106, P5789, DOI 10.1073/pnas.0809742106
   Gais P, 2010, J IMMUNOL, V184, P5842, DOI 10.4049/jimmunol.0902456
   Gayle DA, 2004, AM J PHYSIOL-REG I, V286, pR1024, DOI 10.1152/ajpregu.00664.2003
   GENDRON RL, 1990, J REPROD FERTIL, V90, P395, DOI 10.1530/jrf.0.0900395
   Hamann L, 2010, INFECT GENET EVOL, V10, P785, DOI 10.1016/j.meegid.2010.05.005
   Janse CJ, 2006, MOL BIOCHEM PARASIT, V145, P60, DOI 10.1016/j.molbiopara.2005.09.007
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   KERN P, 1992, J INFECT DIS, V166, P930, DOI 10.1093/infdis/166.4.930
   KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331
   Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200
   Leoratti FMS, 2008, J INFECT DIS, V198, P772, DOI 10.1086/590440
   Li LP, 2010, MOL HUM REPROD, V16, P267, DOI 10.1093/molehr/gap106
   Lim JH, 2005, INFECT IMMUN, V73, P2778, DOI 10.1128/IAI.73.5.2778-2789.2005
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marinho CRF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005630
   Marzi M, 1996, CLIN EXP IMMUNOL, V106, P127, DOI 10.1046/j.1365-2249.1996.d01-809.x
   MEURIS S, 1993, AM J TROP MED HYG, V48, P603, DOI 10.4269/ajtmh.1993.48.603
   Mockenhaupt FP, 2006, P NATL ACAD SCI USA, V103, P177, DOI 10.1073/pnas.0506803102
   Neres R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001608
   Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104
   Pasare C, 2005, ADV EXP MED BIOL, V560, P11
   Peri F, 2012, BIOTECHNOL ADV, V30, P251, DOI 10.1016/j.biotechadv.2011.05.014
   Piazza M, 2009, J MED CHEM, V52, P1209, DOI 10.1021/jm801333m
   Pichyangkul S, 2004, J IMMUNOL, V172, P4926, DOI 10.4049/jimmunol.172.8.4926
   Poovassery J, 2006, INFECT IMMUN, V74, P2839, DOI 10.1128/IAI.74.5.2839-2848.2006
   Poovassery J, 2009, INFECT IMMUN, V77, P4998, DOI 10.1128/IAI.00617-09
   Renaud SJ, 2011, J IMMUNOL, V186, P1799, DOI 10.4049/jimmunol.1002679
   Rogerson SJ, 2007, LANCET INFECT DIS, V7, P105, DOI 10.1016/S1473-3099(07)70022-1
   Rounioja S, 2005, AM J PATHOL, V166, P1585, DOI 10.1016/S0002-9440(10)62469-8
   SILEN ML, 1989, AM J PATHOL, V135, P239
   Sobota RS, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1189-6
   Sylvester B, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1417-0
   Thevenon AD, 2010, J IMMUNOL, V185, P7115, DOI 10.4049/jimmunol.1002293
NR 42
TC 17
Z9 18
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 17
PY 2017
VL 7
AR 8623
DI 10.1038/s41598-017-08299-x
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FD9TG
UT WOS:000407864400004
PM 28819109
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Kam, YW
   Leite, JA
   Lum, FM
   Tan, JJL
   Lee, B
   Judice, CC
   Teixeira, DAD
   Andreata-Santos, R
   Vinolo, MA
   Angerami, R
   Resende, MR
   Freitas, ARR
   Amaral, E
   Passini, R
   Costa, ML
   Guida, JP
   Arns, CW
   Ferreira, LCS
   Nia, LR
   Proenca-Modena, JL
   Lisa, FPN
   Costa, FTM
AF Kam, Yiu-Wing
   Leite, Juliana Almeida
   Lum, Fok-Moon
   Tan, Jeslin J. L.
   Lee, Bernett
   Judice, Carla C.
   de Toledo Teixeira, Daniel Augusto
   Andreata-Santos, Robert
   Vinolo, Marco A.
   Angerami, Rodrigo
   Resende, Mariangela Ribeiro
   Ribas Freitas, Andre Ricardo
   Amaral, Eliana
   Passini Junior, Renato
   Costa, Maria Laura
   Guida, Jose Paulo
   Arns, Clarice Weis
   Ferreira, Luis Carlos S.
   Nia, Laurent R.
   Proenca-Modena, Jose Luiz
   Ng, Lisa F. P.
   Costa, Fabio T. M.
CA Zika-Unicamp Network
TI Specific Biomarkers Associated With Neurological Complications and
   Congenital Central Nervous System Abnormalities From Zika Virus-Infected
   Patients in Brazil
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE Zika virus; congenital CNS deformities; cytokines and biomarkers
ID HEPATOCYTE GROWTH-FACTOR; NK CELLS; KINETICS; AMERICA; DENGUE; BRAIN;
   MICRONESIA; EPIDEMIC; OUTBREAK; DISEASE
AB Background. Zika virus (ZIKV) infections have been linked to different levels of clinical outcomes, ranging from mild rash and fever to severe neurological complications and congenital malformations.
   Methods. We investigated the clinical and immunological response, focusing on the immune mediators profile in 95 acute ZIKV-infected adult patients from Campinas, Brazil. These patients included 6 pregnant women who later delivered during the course of this study. Clinical observations were recorded during hospitalization. Levels of 45 immune mediators were quantified using multiplex microbead-based immunoassays.
   Results. Whereas 11.6% of patients had neurological complications, 88.4% displayed mild disease of rash and fever. Several immune mediators were specifically higher in ZIKV-infected patients, and levels of interleukin 10, interferon gamma-induced protein 10 (IP-10), and hepatocyte growth factor differentiated between patients with or without neurological complications. Interestingly, higher levels of interleukin 22, monocyte chemoattractant protein 1, TNF-alpha, and IP-10 were observed in ZIKV-infected pregnant women carrying fetuses with fetal growth-associated malformations. Notably, infants with congenital central nervous system deformities had significantly higher levels of interleukin 18 and IP-10 but lower levels of hepatocyte growth factor than those without such abnormalities born to ZIKV-infected mothers.
   Conclusions. This study identified several key markers for the control of ZIKV pathogenesis. This will allow a better understanding of the molecular mechanisms of ZIKV infection in patients.
C1 [Kam, Yiu-Wing; Lum, Fok-Moon; Tan, Jeslin J. L.; Lee, Bernett; Nia, Laurent R.; Ng, Lisa F. P.] ASTAR, Singapore Immunol Network, Singapore, Singapore.
   [Leite, Juliana Almeida; Judice, Carla C.; de Toledo Teixeira, Daniel Augusto; Vinolo, Marco A.; Arns, Clarice Weis; Proenca-Modena, Jose Luiz; Costa, Fabio T. M.] Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Genet Evolut & Bioagents, Sao Paulo, Brazil.
   [Andreata-Santos, Robert; Ferreira, Luis Carlos S.] Univ Sao Paulo, Dept Microbiol, Biomed Sci Inst, Sao Paulo, Brazil.
   [Angerami, Rodrigo] Univ Estadual Campinas, Epidemiol Surveillance Sect, Hosp Clin, Campinas, SP, Brazil.
   [Resende, Mariangela Ribeiro] Univ Estadual Campinas, Fac Med Sci, Dept Internal Med, Campinas, SP, Brazil.
   [Ribas Freitas, Andre Ricardo] Univ Estadual Campinas, UNICAMP, Sch Med Sci, Obstet & Gynecol Dept, Sao Paulo, Brazil.
   [Amaral, Eliana; Passini Junior, Renato; Costa, Maria Laura; Guida, Jose Paulo] Campinas Dept Publ Hlth Surveillance, Campinas, SP, Brazil.
   [Ng, Lisa F. P.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool, Merseyside, England.
RP Ng, LFP (corresponding author), ASTAR, Singapore Immunol Network, Lab Microbial Immun, Biopolis, 8A Biomed Grove,04-06 Immunos, Singapore 138648, Singapore.
EM lisa_ng@immunol.a-star.edu.sg
RI Freitas, Andre Ricardo Ribas/L-1969-2016; Costa, Maria
   Laura/I-4980-2019; Costa, Fabio/E-1181-2012; Arns, Clarice
   W/G-7525-2012; Amorim, Mariene/C-4102-2019; Proenca-Modena, Jose
   Luiz/AAU-7622-2020; Vinolo, Marco Aurelio R/K-3753-2012; amsalu,
   ribka/G-8780-2019; Modena, Jose Luiz Proenca/C-8231-2014; Angerami,
   Rodrigo Nogueira/A-8926-2013; Toledo-Teixeira, Daniel A./C-6940-2017;
   Judice, Carla/P-4738-2014; Cavalheiro Martini, Matheus/E-9416-2015
OI Freitas, Andre Ricardo Ribas/0000-0003-0291-7771; Costa, Maria
   Laura/0000-0001-8280-3234; Costa, Fabio/0000-0001-9969-7300; Arns,
   Clarice W/0000-0002-7308-460X; Proenca-Modena, Jose
   Luiz/0000-0002-4996-3153; Modena, Jose Luiz Proenca/0000-0002-4996-3153;
   Angerami, Rodrigo Nogueira/0000-0002-4976-9238; Judice,
   Carla/0000-0003-1839-053X; Ng, Lisa/0000-0003-4071-5222;
   Toledo-Teixeira, Daniel A./0000-0002-4055-058X; Cavalheiro Martini,
   Matheus/0000-0003-0135-4364; Vinolo, Marco Aurelio/0000-0003-1335-760X
FU Biomedical Research Council (BMRC)Agency for Science Technology &
   Research (ASTAR); BMRC A*STAR-led Zika Virus Consortium Fund
   [15/1/82/27/001]; Agency for Science, Technology and Research (A*STAR),
   SingaporeAgency for Science Technology & Research (ASTAR); Fundacao de
   Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2016/00194-8]; Conselho Nacional de
   Desenvolvimento Cientifico e TecnologicoNational Council for Scientific
   and Technological Development (CNPq)
FX This work was supported by the Biomedical Research Council (BMRC; core
   research grants provided to the Singapore Immunology Network); the BMRC
   A*STAR-led Zika Virus Consortium Fund (project 15/1/82/27/001); the
   Agency for Science, Technology and Research (A*STAR), Singapore,
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (grant 2016/00194-8
   and fellowship to J.A.L.); and the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (including research fellowships to M.A.V.,
   E.A., L.C.F., and F.T.M.C.).
CR Baron R, 2008, FASEB J, V22, P2843, DOI 10.1096/fj.08-105866
   Bingham AM, 2016, MMWR-MORBID MORTAL W, V65, P475, DOI 10.15585/mmwr.mm6518e2
   Campos GS, 2015, EMERG INFECT DIS, V21, P1885, DOI 10.3201/eid2110.150847
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Cao-Lormeau VM, 2014, EMERG INFECT DIS, V20, P1085, DOI 10.3201/eid2006.140138
   Chaix J, 2008, J IMMUNOL, V181, P1627, DOI 10.4049/jimmunol.181.3.1627
   Cheng YL, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/274025
   Cloetta D, 2013, J NEUROSCI, V33, P7799, DOI 10.1523/JNEUROSCI.3294-12.2013
   Cugola FR, 2016, NATURE, V534, P267, DOI 10.1038/nature18296
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
   Enfissi A, 2016, LANCET, V387, P227, DOI 10.1016/S0140-6736(16)00003-9
   Estes ML, 2015, NAT REV NEUROSCI, V16, P469, DOI 10.1038/nrn3978
   Ferguson NM, 2016, SCIENCE, V353, P353, DOI 10.1126/science.aag0219
   Funakoshi H, 2011, CURR SIGNAL TRANSD T, V6, P156, DOI 10.2174/157436211795659982
   Gaddi PJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042850
   Hennessey M, 2016, MMWR-MORBID MORTAL W, V65, P55, DOI 10.15585/mmwr.mm6503e1
   Her Z, 2017, J INFECT DIS, V215, P42, DOI 10.1093/infdis/jiw494
   Jeong YE, 2017, VIROL J, V14, DOI 10.1186/s12985-017-0740-6
   Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
   Li F, 2015, J VIROL, V89, P5602, DOI 10.1128/JVI.00143-15
   Liu Q, 2016, CELL MOL IMMUNOL, V13, P3, DOI 10.1038/cmi.2015.74
   Lum FM, 2017, CLIN INFECT DIS, V64, P914, DOI 10.1093/cid/ciw878
   Lustig Y, 2017, J CLIN MICROBIOL, V55, P1894, DOI 10.1128/JCM.00346-17
   Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09
   Mlakar J, 2016, NEW ENGL J MED, V374, P951, DOI 10.1056/NEJMoa1600651
   Molnarfi N, 2015, AUTOIMMUN REV, V14, P293, DOI 10.1016/j.autrev.2014.11.013
   Musso D, 2014, CLIN MICROBIOL INFEC, V20, pO595, DOI 10.1111/1469-0691.12707
   OEHLER E, 2013, EUROSURVEILLANCE, V2014, P19, DOI DOI 10.2807/1560-7917.ES2014.19.9.20720
   Oliveira DBL, 2016, NEW ENGL J MED, V375, P1202, DOI 10.1056/NEJMc1607583
   Pan American Health Organization/World Health Organization, 2017, ZIK EP REP BRAZ
   Poli A, 2013, J IMMUNOL, V190, P5355, DOI 10.4049/jimmunol.1203401
   Schuler-Faccini L, 2016, MMWR-MORBID MORTAL W, V65, P59, DOI 10.15585/mmwr.mm6503e2
   Steinhagen K., 2015, EUROSURVEILLANCE, V2016, P21, DOI DOI 10.2807/1560-7917.ES.2016.21.50.30426
   Suwanmanee S, 2017, J MICROBIOL, V55, P81, DOI 10.1007/s12275-017-6494-4
   Tappe D, 2016, MED MICROBIOL IMMUN, V205, P269, DOI 10.1007/s00430-015-0445-7
   World Health Organization, 2016, WORLD MALARIA REPORT, P1, DOI [10.1017/CBO9781107415324.004, DOI 10.1017/CBO9781107415324.004]
   Wu KY, 2016, CELL RES, V26, P645, DOI 10.1038/cr.2016.58
NR 38
TC 33
Z9 34
U1 0
U2 11
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 15
PY 2017
VL 216
IS 2
BP 172
EP 181
DI 10.1093/infdis/jix261
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA FC4SX
UT WOS:000406832000005
PM 28838147
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU Rocha, MV
   Francoso, KS
   Lima, LC
   Camargo, TM
   Machado, RLD
   Costa, FTM
   Renia, L
   Nosten, F
   Russell, B
   Rodrigues, MM
   Soares, IS
AF Rocha, Mariana Vilela
   Francoso, Katia Sanches
   Lima, Luciana Chagas
   Camargo, Tarsila Mendes
   Machado, Ricardo L. D.
   Costa, Fabio T. M.
   Renia, Laurent
   Nosten, Francois
   Russell, Bruce
   Rodrigues, Mauricio M.
   Soares, Irene S.
TI Generation, characterization and immunogenicity of a novel chimeric
   recombinant protein based on Plasmodium vivax AMA-1 and MSP1(19)
SO VACCINE
LA English
DT Article
DE Malaria; Plasmodium vivax; Recombinant vaccine
ID MEROZOITE SURFACE PROTEIN-1; VACCINE CANDIDATE MSP1(19); MALARIA
   VACCINE; PICHIA-PASTORIS; DOMAIN-II; EX-VIVO; ANTIBODIES; INVASION;
   IMMUNIZATION; METAANALYSIS
AB Plasmodium vivax is the most widely distributed malaria species and the most prevalent species of malaria in America and Asia. Vaccine development against P. vivax is considered a priority in the global program for the eradication of malaria. Earlier studies have characterized the Apical Membrane Antigen 1 (AMA-1) ectodomain and the C-terminal region (19 kDa) of the Merozoite Surface Protein 1 (MSP-1) of P. vivax as immunodominant antigens. Based on this characterization, we designed a chimeric recombinant protein containing both merozoite immunodominant domains (PvAMA1(66)-MSP1(19)). The recombinant PvAMA166-MSP119 was successfully expressed in Pichia pastoris and used to immunize two different mouse strains (BALB/c and C57BL/6) in the presence of the Poly (I:C) as an adjuvant. Immunization with the chimeric protein induced high antibody titers against both proteins in both strains of mice as detected by ELISA. Antisera also recognized the native proteins expressed on the merozoites of mature P. vivax schizonts. Moreover, this antigen was able to induce IFN-gamma-secreting cells in C57BL/6 mice. These findings indicate that this novel yeast recombinant protein containing PvAMA1(66) and PvMSP1(19) is advantageous, because of improved antibody titers and cellular immune response. Therefore, this formulation should be further developed for pre-clinical trials in non-human primates as a potential candidate for a P. vivax vaccine. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Rocha, Mariana Vilela; Francoso, Katia Sanches; Lima, Luciana Chagas; Camargo, Tarsila Mendes; Soares, Irene S.] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Analises Clin & Toxicol, Sao Paulo, SP, Brazil.
   [Machado, Ricardo L. D.] Inst Evandro Chagas, Div Parasitol, Belem, Para, Brazil.
   [Costa, Fabio T. M.] Univ Estadual Campinas, Inst Biol, Dept Genet Evolucao & Bioagentes, La Doencas Tropicais, Campinas, SP, Brazil.
   [Renia, Laurent; Russell, Bruce] Agcy Sci Technol & Res, Singapore Immunol Network, Biopolis, Singapore, Singapore.
   [Nosten, Francois] Mahidol Univ, Shoklo Malaria Res Unit, Mahidol Oxford Trop Med Res Unit, Fac Trop Med, Mae Sot, Thailand.
   [Nosten, Francois] Univ Oxford, Nuffield Dept Med Res Bldg, Ctr Trop Med & Global Hlth, Old Rd Campus, Oxford, England.
   [Russell, Bruce] Univ Otago, Dept Microbiol & Immunol, Dunedin, New Zealand.
   [Rodrigues, Mauricio M.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, CTCMOL, Sao Paulo, SP, Brazil.
RP Soares, IS (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Analises Clin & Toxicol, Sao Paulo, SP, Brazil.
EM isoares@usp.br
RI Soares, Irene Silva/C-5974-2012; Francoso, Katia Sanches/M-4088-2019;
   Machado, Ricardo Luiz Dantas Dantas/P-1288-2014; Russell,
   Bruce/A-9240-2011; Costa, Fabio/E-1181-2012; Nosten,
   Francois/AAC-5509-2019; Camargo, Tarsila Mendes TMC/J-4489-2014
OI Soares, Irene Silva/0000-0002-3336-6856; Francoso, Katia
   Sanches/0000-0003-1494-2405; Machado, Ricardo Luiz Dantas
   Dantas/0000-0002-8955-3204; Russell, Bruce/0000-0003-2333-4348; Costa,
   Fabio/0000-0001-9969-7300; Nosten, Francois/0000-0002-7951-0745;
   Camargo, Tarsila Mendes TMC/0000-0001-7485-0751
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [475500/2012-1]; Instituto Nacional de Ciencia e Tecnologia de
   Vacinas (INCTV); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2012/13032-5]; FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2011/23278-9, 2013/01487-0]; CNPqNational Council for
   Scientific and Technological Development (CNPq); CAPES (Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior)CAPES
FX This work was supported by grants from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq 475500/2012-1), Instituto
   Nacional de Ciencia e Tecnologia de Vacinas (INCTV), Fundacao de Amparo
   a Pesquisa do Estado de Sao Paulo (FAPESP 2012/13032-5). MVR was
   sponsored by FAPESP fellowships (2011/23278-9 and 2013/01487-0). RLDM,
   FTMC and ISS are recipients of fellowships from CNPq. TMC is a CAPES
   (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior) fellowship
   recipient.
CR Arnott A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002506
   Bargieri DY, 2008, VACCINE, V26, P6132, DOI 10.1016/j.vaccine.2008.08.070
   Beeson JG, 2016, FEMS MICROBIOL REV, V40, P343, DOI 10.1093/femsre/fuw001
   Caskey M, 2011, J EXP MED, V208, P2357, DOI 10.1084/jem.20111171
   Cunha MG, 2001, VACCINE, V20, P385, DOI 10.1016/S0264-410X(01)00359-0
   Faber BW, 2007, INFECT IMMUN, V75, P5947, DOI 10.1128/IAI.01804-06
   Gentil F, 2010, VACCINE, V28, P6183, DOI 10.1016/j.vaccine.2010.07.017
   Holder AA, 2009, PARASITOLOGY, V136, P1445, DOI 10.1017/S0031182009990515
   Hu JH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001952
   Jimenez MCS, 2008, BBA-GEN SUBJECTS, V1780, P983, DOI 10.1016/j.bbagen.2008.03.016
   Lacerda MVG, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-12
   Langermans JAM, 2006, HUM VACCINES, V2, P222, DOI 10.4161/hv.2.5.3276
   Bouillet LEM, 2011, INFECT IMMUN, V79, P3642, DOI 10.1128/IAI.05048-11
   Olotu A, 2016, NEW ENGL J MED, V374, P2519, DOI 10.1056/NEJMoa1515257
   Pan WQ, 2004, J IMMUNOL, V172, P6167, DOI 10.4049/jimmunol.172.10.6167
   Price RN, 2014, LANCET INFECT DIS, V14, P982, DOI 10.1016/S1473-3099(14)70855-2
   Pusic KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024782
   Rahimi BA, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-481
   Remarque EJ, 2007, APICAL MEMBRANE ANTI, V1
   Reyes-Sandoval A, 2013, HUM VACC IMMUNOTHER, V9, P2558, DOI 10.4161/hv.26157
   Rosa DS, 2006, MICROBES INFECT, V8, P2130, DOI 10.1016/j.micinf.2006.03.012
   Russell B, 2012, INT J PARASITOL, V42, P1063, DOI 10.1016/j.ijpara.2012.08.010
   Russell B, 2011, BLOOD, V118, pE74, DOI 10.1182/blood-2011-04-348748
   Soares IS, 1999, MOL MED, V5, P459
   Soares IS, 2002, PARASITOLOGY, V124, P237, DOI 10.1017/S003118200100110X
   Vicentin EC, 2014, INFECT IMMUN, V82, P1296, DOI 10.1128/IAI.01169-13
NR 26
TC 6
Z9 6
U1 0
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 25
PY 2017
VL 35
IS 18
BP 2463
EP 2472
DI 10.1016/j.vaccine.2017.03.023
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA EU0QE
UT WOS:000400715600028
PM 28341111
DA 2020-12-08
ER

PT J
AU Martinez-Correa, HA
   Bitencourt, RG
   Kayano, ACAV
   Magalhaes, PM
   Costa, FTM
   Cabral, FA
AF Martinez-Correa, Hugo A.
   Bitencourt, Raphaela G.
   Kayano, Ana Carolina A. V.
   Magalhaes, Pedro M.
   Costa, Fabio T. M.
   Cabral, Fernando A.
TI Integrated extraction process to obtain bioactive extracts of Artemisia
   annua L. leaves using supercritical CO2, ethanol and water
SO INDUSTRIAL CROPS AND PRODUCTS
LA English
DT Article
DE Artemisia annua L.; Supercritical extraction; Artemisinin; Antimalarial
   activity; Phenolic compounds; Flavonoids
ID FLUID EXTRACTION; IN-VITRO; ANTIOXIDANT PROPERTIES; ANTIMALARIAL
   ACTIVITY; CHEMICAL-COMPOSITION; PHENOLIC-COMPOUNDS; SCALE-UP; PLANTS;
   YIELD; ULTRASOUND
AB Artemisia annua L. is an herb used in traditional Chinese medicine due to presence of biocompounds with biomedical and pharmaceutical applications. In this work, an integrated process for extraction of bioactive compounds present in A. annua leaves was performed. The process comprised two-step extractions: in the first step supercritical carbon dioxide (scCO(2)) was used as a solvent, and from the solid residue of the supercritical extraction other extracts were obtained (second stage) using ethanol or water as solvents. Single-step extractions using ethanol or water as solvents were also performed for comparison. In all extracts the variables analyzed were overall extraction yield, the content and yield of total phenolic, total flavonoids and artemisinin, as well as antimalarial activity. The supercritical (SC) and ethanolic (E) extracts obtained in a single step showed the highest yields of artemisinin and were very active against Plasmodium falciparum, with IC50 values less than 0.1 mu g mL(.)(-1) On the other hand, the aqueous (SCA) and ethanolic (SCE) extracts from the second extraction step were free of artemisinin, but these extracts contained roughly 90 mg of phenolic compounds per gram of extract, including a high overall yield in the aqueous extract. The volatile fraction (SC-V) obtained from the supercritical extraction consisted mainly of camphor. Therefore, the two-step extraction in two steps proved to be advantageous because the residue of supercritical extraction could be used for obtaining aqueous or ethanolic extracts containing phenolic compounds. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Martinez-Correa, Hugo A.] Univ Nacl Colombia, Dept Engn, Cr 32 12-00, Palmira, Colombia.
   [Bitencourt, Raphaela G.; Cabral, Fernando A.] Univ Campinas UNICAMP, Dept Food Engn, BR-13083862 Campinas, SP, Brazil.
   [Kayano, Ana Carolina A. V.; Costa, Fabio T. M.] Univ Estadual Campinas, Dept Genet Evolut & Bioagents, Inst Biol, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, BR-13083970 Campinas, SP, Brazil.
   [Magalhaes, Pedro M.] Univ Campinas UNICAMP, Chem Biol & Agr Pluridisciplinary Res Ctr, BR-13083970 Campinas, SP, Brazil.
RP Martinez-Correa, HA (corresponding author), Univ Nacl Colombia, Dept Engn, Cr 32 12-00, Palmira, Colombia.
EM hamartinezco@unal.edu.co
RI Costa, Fabio/E-1181-2012
OI Costa, Fabio/0000-0001-9969-7300; Cabral, Fernando/0000-0002-6485-1715
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2007/59367-0]; CAPESCAPES
FX The authors wish to thank the FAPESP (Process no. 2007/59367-0) and
   CAPES for financial support. Fabio T M Costa is a CNPq researcher fellow
   level 1C.
CR A.S.A.E, 1997, S3193 ASAE, VS319.3, P547
   Adams RP, 1995, IDENTIFICATION ESSEN
   Balint GA, 2001, PHARMACOL THERAPEUT, V90, P261, DOI 10.1016/S0163-7258(01)00140-1
   Benner BA, 1998, ANAL CHEM, V70, P4594, DOI 10.1021/ac980618f
   Briars R, 2013, IND CROP PROD, V42, P595, DOI 10.1016/j.indcrop.2012.06.043
   Cai YZ, 2004, LIFE SCI, V74, P2157, DOI 10.1016/j.lfs.2003.09.047
   Carvalho IS, 2011, IND CROP PROD, V33, P382, DOI 10.1016/j.indcrop.2010.11.005
   Chafer A, 2004, J SUPERCRIT FLUID, V32, P89, DOI 10.1016/j.supflu.2004.02.005
   Chander MP, 2016, BANGL J PHARMACOL, V11, P126, DOI 10.3329/bjp.v11i1.24055
   Covello PS, 2008, PHYTOCHEMISTRY, V69, P2881, DOI 10.1016/j.phytochem.2008.10.001
   Cseke Leland J., 2006, P1
   CURRAY JR, 1955, GEOL SOC AM BULL, V66, P1075, DOI 10.1130/0016-7606(1955)66[1075:SAROQG]2.0.CO;2
   Della Porta G, 2004, 9 M SUP FLUIDS, P1
   ELSOHLY HN, 1987, PHARMACEUT RES, V4, P258, DOI 10.1023/A:1016472531527
   Farias-Campomanes AM, 2013, J SUPERCRIT FLUID, V77, P70, DOI 10.1016/j.supflu.2013.02.006
   Ferreira JFS, 2010, MOLECULES, V15, P3135, DOI 10.3390/molecules15053135
   Garmus TT, 2014, J SUPERCRIT FLUID, V86, P4, DOI 10.1016/j.supflu.2013.11.014
   Goel D, 2008, J ESSENT OIL RES, V20, P147, DOI 10.1080/10412905.2008.9699976
   Gupta SK, 2002, IND CROP PROD, V16, P217, DOI 10.1016/S0926-6690(02)00049-3
   Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2
   Kim WS, 2015, KOREAN J PHYSIOL PHA, V19, P21, DOI 10.4196/kjpp.2015.19.1.21
   Kohler M, 1997, J CHROMATOGR A, V785, P353, DOI 10.1016/S0021-9673(97)00403-2
   Kuhn T., 2007, PROG DRUG RES, V65, P384
   Lapkin AA, 2006, J NAT PROD, V69, P1653, DOI 10.1021/np060375j
   LAUGHLIN JC, 1994, T ROY SOC TROP MED H, V88, P21, DOI 10.1016/0035-9203(94)90465-0
   Leal PF, 2008, FOOD BIOPROCESS TECH, V1, P326, DOI 10.1007/s11947-007-0030-1
   Lima RBS, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0999-2
   Lin YL, 2006, J SUPERCRIT FLUID, V39, P48, DOI 10.1016/j.supflu.2006.02.012
   Lopes SCP, 2009, ANTIMICROB AGENTS CH, V53, P2149, DOI 10.1128/AAC.00693-08
   Martinez-Correa HA, 2011, J SUPERCRIT FLUID, V55, P998, DOI 10.1016/j.supflu.2010.09.001
   Misra H., 2013, ORG CHEM INT, V2013, P1
   Mojarrab M, 2015, IRAN J PHARM RES, V14, P603
   Osorio-Tobon JF, 2014, J SUPERCRIT FLUID, V95, P167, DOI 10.1016/j.supflu.2014.08.012
   Paula JT, 2016, J SUPERCRIT FLUID, V107, P219, DOI 10.1016/j.supflu.2015.09.013
   Pereira CG, 2010, FOOD BIOPROCESS TECH, V3, P340, DOI 10.1007/s11947-009-0263-2
   Prado JM, 2012, J FOOD ENG, V109, P249, DOI 10.1016/j.jfoodeng.2011.10.007
   Quispe-Condori S, 2005, J SUPERCRIT FLUID, V36, P40, DOI 10.1016/j.supflu.2005.03.003
   Rahman MS, 1996, J FOOD ENG, V30, P135, DOI 10.1016/S0260-8774(96)00013-1
   Schwikkard S, 2002, NAT PROD REP, V19, P675, DOI 10.1039/b008980j
   Singleton VL, 1999, METHOD ENZYMOL, V299, P152
   Skowyra M, 2014, ANTIOXIDANTS, V3, P116, DOI 10.3390/antiox3010116
   Tajehmiri A, 2014, ADV STUD BIOL, V3, P93, DOI 10.12988/asb.2014.4525
   Tzeng TC, 2007, SEP PURIF TECHNOL, V56, P18, DOI 10.1016/j.seppur.2007.01.010
   Uquiche E, 2004, J FOOD ENG, V65, P55, DOI 10.1016/j.jfoodeng.2003.12.003
   van Agtmael MA, 1999, TRENDS PHARMACOL SCI, V20, P199, DOI 10.1016/S0165-6147(99)01302-4
   WHO, 2006, WHO MON GOOD AGR COL
   WOERDENBAG HJ, 1991, PHYTOCHEM ANALYSIS, V2, P215, DOI 10.1002/pca.2800020507
   Zabot GL, 2015, IND CROP PROD, V77, P758, DOI 10.1016/j.indcrop.2015.09.053
   Zhang HH, 2014, SEP SCI TECHNOL, V49, P673, DOI 10.1080/01496395.2013.862545
NR 49
TC 21
Z9 21
U1 2
U2 57
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0926-6690
EI 1872-633X
J9 IND CROP PROD
JI Ind. Crop. Prod.
PD JAN
PY 2017
VL 95
BP 535
EP 542
DI 10.1016/j.indcrop.2016.11.007
PG 8
WC Agricultural Engineering; Agronomy
SC Agriculture
GA EF8ZX
UT WOS:000390621600061
DA 2020-12-08
ER

PT J
AU Martinez-Correa, HA
   Paula, JT
   Kayano, ACAV
   Queiroga, CL
   Magalhaes, PM
   Costa, FTM
   Cabral, FA
AF Martinez-Correa, Hugo A.
   Paula, Julia T.
   Kayano, Ana Carolina A. V.
   Queiroga, Carmen L.
   Magalhaes, Pedro M.
   Costa, Fabio T. M.
   Cabral, Fernando A.
TI Composition and antimalarial activity of extracts of Curcuma longa L.
   obtained by a combination of extraction processes using supercritical
   CO2, ethanol and water as solvents
SO JOURNAL OF SUPERCRITICAL FLUIDS
LA English
DT Article
DE Curcuma longa L; Sequential extraction; Curcumin; Antimalarial activity;
   Antioxidants
ID CARBON-DIOXIDE EXTRACTION; SEQUENTIAL EXTRACTION; ESSENTIAL OIL;
   ANTIOXIDANT ACTIVITY; PHENOLIC-COMPOUNDS; ARRABIDAEA CHICA;
   MEDICINAL-PLANTS; AR-TURMERONE; IN-VITRO; LEAVES
AB Rhizome of Curcuma longa L. is rich in curcumin which is also an important natural pigment and has important biological activity. In order to obtain curcumin concentrated extracts, one-step and two-step processes were employed. The one step process involves supercritical carbon dioxide (scCO(2)) at 60 degrees C and 400 bar, ethanol at 25 degrees C and water at 60 degrees C, both at atmospheric pressure. Ethanol and/or water were used as solvents. In the two-step process, sequential extraction, using scCO(2), was performed followed by ethanol or water extraction. All the extracts obtained were analyzed and results were reported for global extraction yield, the total phenolic content, total flavonoids, curcumin, antimalarial activity and antioxidant activity. The two-step process showed the highest global yield (23.4%) when water is used as solvent in the second step. However, high concentrations of curcumin and high antioxidant activity were obtained when ethanol is used as solvent The supercritical extract presents low concentration of curcumin and high antimalarial activity; which shows that extracts of different compositions and functionality can be obtained from a sequential extraction. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Martinez-Correa, Hugo A.] Univ Nacl Colombia, Dept Engn, Cr 32 12-00, Palmira, Colombia.
   [Paula, Julia T.; Cabral, Fernando A.] Univ Estadual Campinas, Dept Food Engn, BR-13083862 Campinas, SP, Brazil.
   [Kayano, Ana Carolina A. V.; Costa, Fabio T. M.] Univ Estadual Campinas, Lab Trop Dis Prof Dr Luiz Jacintho da Silva, Dept Genet Evolut & Bioagents, Inst Biol, BR-13083970 Campinas, SP, Brazil.
   [Queiroga, Carmen L.; Magalhaes, Pedro M.] Univ Estadual Campinas, Chem Biol & Agr Pluridisciplinary Res Ctr CPQBA, BR-13083970 Campinas, SP, Brazil.
RP Martinez-Correa, HA (corresponding author), Univ Nacl Colombia, Dept Engn, Cr 32 12-00, Palmira, Colombia.
EM hamartinezco@unal.edu.co
RI Paula, Julia/C-3266-2017; QUEIROGA, CARMEN LUCIA/E-9314-2012; Costa,
   Fabio/E-1181-2012
OI QUEIROGA, CARMEN LUCIA/0000-0001-9168-277X; Costa,
   Fabio/0000-0001-9969-7300; Cabral, Fernando/0000-0002-6485-1715
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2007/59367-0]; CAPESCAPES
FX The authors wish to thank FAPESP (Process no 2007/59367-0) and CAPES for
   their financial support. Fabio T M Costa is a CNPq researcher fellow
   level 1C.
CR Adams RP, 1995, IDENTIFICATION ESSEN
   ASAE S, 1997, METH DET EXPR FIN FE, P547
   Balbi-Pena Maria I., 2006, Fitopatologia Brasileira, V31, P310, DOI 10.1590/S0100-41582006000300012
   Began G, 2000, FOOD RES INT, V33, P341, DOI 10.1016/S0963-9969(00)00053-3
   Bitencourt RG, 2014, J SUPERCRIT FLUID, V95, P355, DOI 10.1016/j.supflu.2014.09.027
   Bitencourt RG, 2014, J SUPERCRIT FLUID, V92, P272, DOI 10.1016/j.supflu.2014.06.009
   Braga MEM, 2007, J FOOD PROCESS ENG, V30, P501, DOI 10.1111/j.1745-4530.2007.00133.x
   Braga MEM, 2003, J AGR FOOD CHEM, V51, P6604, DOI 10.1021/jf0345550
   Carvalho PIN, 2015, J SUPERCRIT FLUID, V105, P44, DOI 10.1016/j.supflu.2015.03.020
   Chang LH, 2006, SEP PURIF TECHNOL, V47, P119, DOI 10.1016/j.seppur.2005.06.018
   Chassagnez-Mendez AL, 2000, IND ENG CHEM RES, V39, P4729, DOI 10.1021/ie000171c
   Cseke L. J., 2006, TRADITIONAL ANAL PRE
   Dao TT, 2012, FOOD CHEM, V134, P21, DOI 10.1016/j.foodchem.2012.02.015
   de Azevedo ABA, 2008, BRAZ J CHEM ENG, V25, P543, DOI 10.1590/S0104-66322008000300012
   del Valle JM, 2005, J FOOD ENG, V67, P35, DOI 10.1016/j.jfoodeng.2004.05.051
   Euterpio MA, 2011, ANAL BIOANAL CHEM, V401, P2977, DOI 10.1007/s00216-011-5383-7
   FERREIRA LAF, 1992, TOXICON, V30, P1211, DOI 10.1016/0041-0101(92)90437-A
   Garmus TT, 2015, J SUPERCRIT FLUID, V99, P68, DOI 10.1016/j.supflu.2015.01.016
   Garmus TT, 2014, J SUPERCRIT FLUID, V86, P4, DOI 10.1016/j.supflu.2013.11.014
   Gopalan B, 2000, J AGR FOOD CHEM, V48, P2189, DOI 10.1021/jf9908594
   Gupta Ankur, 2015, Biotechnol Rep (Amst), V6, P51, DOI 10.1016/j.btre.2015.02.001
   Jia Z, 1999, FOOD CHEM, V64, P555, DOI 10.1016/S0308-8146(98)00102-2
   Kao L, 2007, J SUPERCRIT FLUID, V43, P276, DOI 10.1016/j.supflu.2007.06.007
   Khattak S, 2005, FITOTERAPIA, V76, P254, DOI 10.1016/j.fitote.2004.12.012
   Koleva II, 2000, ANAL CHEM, V72, P2323, DOI 10.1021/ac9912451
   Lopes SCP, 2009, ANTIMICROB AGENTS CH, V53, P2149, DOI 10.1128/AAC.00693-08
   Mandal V, 2008, J PHARMACEUT BIOMED, V46, P322, DOI 10.1016/j.jpba.2007.10.020
   Manzan ACCM, 2003, J AGR FOOD CHEM, V51, P6802, DOI 10.1021/jf030161x
   MARCO GJ, 1968, J AM OIL CHEM SOC, V45, P594, DOI 10.1007/BF02668958
   Martinez-Correa HA, 2012, J SUPERCRIT FLUID, V63, P31, DOI 10.1016/j.supflu.2011.12.016
   Martinez-Correa HA, 2011, J SUPERCRIT FLUID, V55, P998, DOI 10.1016/j.supflu.2010.09.001
   Melo MM, 2005, ARQ BRAS MED VET ZOO, V57, P7, DOI 10.1590/S0102-09352005000100002
   Mensor LL, 2001, PHYTOTHER RES, V15, P127, DOI 10.1002/ptr.687
   MILLER HE, 1971, J AM OIL CHEM SOC, V48, P91, DOI 10.1007/BF02635693
   NAIK SN, 1989, FLUID PHASE EQUILIBR, V49, P115, DOI 10.1016/0378-3812(89)80009-3
   Osorio-Tobon JF, 2014, J SUPERCRIT FLUID, V95, P167, DOI 10.1016/j.supflu.2014.08.012
   Park SY, 2002, J NAT PROD, V65, P1227, DOI 10.1021/np010039x
   Paula JT, 2014, J SUPERCRIT FLUID, V86, P100, DOI 10.1016/j.supflu.2013.12.008
   Paula JT, 2013, J SUPERCRIT FLUID, V81, P33, DOI 10.1016/j.supflu.2013.04.009
   Pothitirat W., 2006, STANDARDIZATION ANTI
   Priya R., 2012, Asian Pacific Journal of Tropical Biomedicine, V2, pS695
   Ramos A, 2003, J ETHNOPHARMACOL, V87, P241, DOI 10.1016/S0378-8741(03)00156-9
   Reynertson K. A., 2005, Ethnobotany Research and Applications, V3, P25
   Roth GN, 1998, J NAT PROD, V61, P542, DOI 10.1021/np970459f
   SANAGI MM, 1993, J CHROMATOGR SCI, V31, P20, DOI 10.1093/chromsci/31.1.20
   Schleffer G.W., 2002, J CHROMATOGR RELAT T, V25, P3033
   Singleton VL, 1999, METHOD ENZYMOL, V299, P152
   Sovova H., 2006, Chemical Industry & Chemical Engineering Quarterly, V12, P168
   Sovova H, 2004, J SUPERCRIT FLUID, V30, P213, DOI 10.1016/j.supflu.2003.09.014
   Tripathi AK, 2002, J ECON ENTOMOL, V95, P183, DOI 10.1603/0022-0493-95.1.183
   Uquiche E, 2004, J FOOD ENG, V65, P55, DOI 10.1016/j.jfoodeng.2003.12.003
   Xia X, 2007, J ETHNOPHARMACOL, V110, P356, DOI 10.1016/j.jep.2006.09.042
NR 52
TC 19
Z9 19
U1 1
U2 50
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0896-8446
EI 1872-8162
J9 J SUPERCRIT FLUID
JI J. Supercrit. Fluids
PD JAN
PY 2017
VL 119
BP 122
EP 129
DI 10.1016/j.supflu.2016.08.017
PG 8
WC Chemistry, Physical; Engineering, Chemical
SC Chemistry; Engineering
GA EC3UW
UT WOS:000388053300015
DA 2020-12-08
ER

PT J
AU Carlos, BC
   Fotoran, WL
   Menezes, MJ
   Cabral, FJ
   Bastos, MF
   Costa, FTM
   Sousa-Neto, JA
   Ribolla, PEM
   Wunderlich, G
   Ferreira, MU
AF Carlos, Bianca C.
   Fotoran, Wesley L.
   Menezes, Maria J.
   Cabral, Fernanda J.
   Bastos, Marcele F.
   Costa, Fabio T. M.
   Sousa-Neto, Jayme A.
   Ribolla, Paulo E. M.
   Wunderlich, Gerhard
   Ferreira, Marcelo U.
TI Expressed var gene repertoire and variant surface antigen diversity in a
   shrinking Plasmodium falciparum population
SO EXPERIMENTAL PARASITOLOGY
LA English
DT Article
DE Plasmodium falciparum; Variant surface antigen; PfEMP-1; Antibodies;
   Amazon
ID ERYTHROCYTE-MEMBRANE PROTEIN-1; NATURALLY ACQUIRED-IMMUNITY; INFECTED
   ERYTHROCYTES; PROTECTIVE IMMUNITY; SEVERE MALARIA; ANTIBODIES; PARASITE;
   BINDING; AGGLUTINATION; ACQUISITION
AB The var gene-encoded erythrocyte membrane protein-1 of Plasmodium falciparum (PfEMP-1) is the main variant surface antigen (VSA) expressed on infected erythrocytes. The rate at which antibody responses to VSA expressed by circulating parasites are acquired depends on the size of the local VSA repertoire and the frequency of exposure to new VSA. Because parasites from areas with declining malaria endemicity, such as the Amazon, typically express a restricted PfEMP-1 repertoire, we hypothesized that Amazonians would rapidly acquire antibodies to most locally circulating VSA. Consistent with our expectations, the analysis of 5878 sequence tags expressed by 10 local P. falciparum samples revealed little PfEMP-1 DBL1 alpha domain diversity. Among the most commonly expressed DBL1 alpha types, 45% were shared by two or more independent parasite lines. Nevertheless, Amazonians displayed major gaps in their repertoire of anti-VSA antibodies, although the breadth of anti-VSA antibody responses correlated positively with their cumulative exposure to malaria. We found little antibody cross-reactivity even when testing VSA from related parasites expressing the same dominant DBL1 alpha types. We conclude that variant-specific immunity to P. falciparum VSAs develops slowly despite the relatively restricted PfEMP-1 repertoire found in low-endemicity settings. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Carlos, Bianca C.; Fotoran, Wesley L.; Menezes, Maria J.; Cabral, Fernanda J.; Wunderlich, Gerhard; Ferreira, Marcelo U.] Univ Sao Paulo, Inst Biomed Sci, Av Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, Brazil.
   [Carlos, Bianca C.; Sousa-Neto, Jayme A.; Ribolla, Paulo E. M.] State Univ Sao Paulo, Inst Biotechnol, Al Tecomarias S-N, BR-18607440 Botucatu, SP, Brazil.
   [Cabral, Fernanda J.; Bastos, Marcele F.; Costa, Fabio T. M.] Univ Estadual Campinas, Inst Biol, R Monteiro Lobato 255,Cidade Univ, BR-13083862 Campinas, SP, Brazil.
   [Bastos, Marcele F.] Univ Fed Bahia, Hosp Prof Edgard Santos, Med Genet Serv, R Dr Augusto Viana S-N, BR-40110060 Salvador, BA, Brazil.
RP Ferreira, MU (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Av Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, Brazil.; Ferreira, MU (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Av Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, SP, Brazil.
EM muferrei@usp.br
RI Ferreira, Marcelo U/G-8289-2011; Ribolla, Paulo EM/B-9122-2012; Ribolla,
   Paulo/AAH-3354-2020; Janku Cabral, Fernanda/K-1317-2014; Wunderlich,
   Gerhard/G-8245-2012; Costa, Fabio/E-1181-2012; Cabral, Fernanda
   Janku/W-5797-2019; Souza-Neto, Jayme A/E-7841-2010
OI Ferreira, Marcelo U/0000-0002-5293-9090; Ribolla, Paulo
   EM/0000-0001-8735-6090; Wunderlich, Gerhard/0000-0003-1724-0337; Costa,
   Fabio/0000-0001-9969-7300; Cabral, Fernanda Janku/0000-0001-9263-5553;
   Souza-Neto, Jayme A/0000-0001-9281-894X
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP),
   BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/17114-3, 2010/50333-8]; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), BrazilNational Council for Scientific
   and Technological Development (CNPq) [576128/2008-2]; FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/53702-7];
   CNPqNational Council for Scientific and Technological Development (CNPq)
FX We thank all inhabitants in Granada and malaria patients from Remansinho
   and Acrelandia for their enthusiastic participation in this study;
   Monica da Silva-Nunes, Natal S. da Silva, Carlos E. Cavasini, Rosely S.
   Malafronte, Camila Juncansen, and Adamilson L. de Souza for carrying out
   fieldwork; Francisco Naildo C. Leitao for overall logistic support;
   Valnice J. Peres, Melissa da Silva Bastos, and Rodrigo M. de Souza for
   laboratory support, and Susana Barbosa for help in data analysis. This
   research was supported by research grants from the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP), Brazil (grants 2009/17114-3 to
   GW and 2010/50333-8 to MUF) and the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq), Brazil (grant 576128/2008-2 to GW). BCC
   (2009/53702-7), WLW, MFB, and JAS-N are supported by FAPESP
   scholarships; FTMC, PEMR, GW and MUF receive senior researcher
   scholarships from CNPq.
CR AGUIAR JC, 1992, AM J TROP MED HYG, V47, P621
   Albrecht L, 2006, MOL BIOCHEM PARASIT, V150, P157, DOI 10.1016/j.molbiopara.2006.07.007
   Albrecht L, 2010, GENE, V453, P37, DOI 10.1016/j.gene.2010.01.001
   Alves FP, 2002, AM J TROP MED HYG, V66, P641, DOI 10.4269/ajtmh.2002.66.641
   Anderson TJC, 2000, MOL BIOL EVOL, V17, P1467, DOI 10.1093/oxfordjournals.molbev.a026247
   Avril M, 2012, P NATL ACAD SCI USA, V109, pE1782, DOI 10.1073/pnas.1120534109
   Barbosa S, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003109
   Bei AK, 2015, INFECT IMMUN, V83, P276, DOI 10.1128/IAI.01979-14
   Bull PC, 2000, J INFECT DIS, V182, P252, DOI 10.1086/315652
   Bull PC, 2002, TRENDS MICROBIOL, V10, P55, DOI 10.1016/S0966-842X(01)02278-8
   Bull PC, 2007, MOL BIOCHEM PARASIT, V154, P98, DOI 10.1016/j.molbiopara.2007.03.011
   Bull PC, 2005, PLOS PATHOG, V1, P202, DOI 10.1371/journal.ppat.0010026
   Chan JA, 2012, J CLIN INVEST, V122, P3227, DOI 10.1172/JCI62182
   Chattopadhyay R, 2003, INFECT IMMUN, V71, P597, DOI 10.1128/IAI.71.2.597-604.2003
   Chen DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016629
   Claessens A, 2012, P NATL ACAD SCI USA, V109, pE1772, DOI 10.1073/pnas.1120461109
   Coura JR, 2006, MEM I OSWALDO CRUZ, V101, P229, DOI 10.1590/S0074-02762006000300001
   da Silva NS, 2010, T ROY SOC TROP MED H, V104, P343, DOI 10.1016/j.trstmh.2009.12.010
   da Silva-Nunes M, 2008, AM J TROP MED HYG, V79, P624, DOI 10.4269/ajtmh.2008.79.624
   Doolan DL, 2009, CLIN MICROBIOL REV, V22, P13, DOI 10.1128/CMR.00025-08
   Ferreira MU, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1335-1
   Giha HA, 1999, INFECT IMMUN, V67, P4092, DOI 10.1128/IAI.67.8.4092-4098.1999
   Giha HA, 1999, PARASITOLOGY, V119, P7, DOI 10.1017/S0031182099004485
   Golnitz U, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-14
   Gysin J, 1996, RES IMMUNOL, V147, P397, DOI 10.1016/0923-2494(96)82048-7
   HASLER T, 1993, AM J TROP MED HYG, V48, P332, DOI 10.4269/ajtmh.1993.48.332
   Hviid L, 2005, ACTA TROP, V95, P270, DOI 10.1016/j.actatropica.2005.06.012
   Hviid L, 2010, HUM VACCINES, V6, P84, DOI 10.4161/hv.6.1.9602
   Kirchgatter K, 2002, MOL MED, V8, P16, DOI 10.1007/BF03401999
   Kirkman LA, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.MDNA3-0022-2014
   Ladeia-Andrade S, 2009, AM J TROP MED HYG, V80, P452, DOI 10.4269/ajtmh.2009.80.452
   Lavstsen T, 2012, P NATL ACAD SCI USA, V109, pE1791, DOI 10.1073/pnas.1120455109
   Machado RLD, 2004, J INFECT DIS, V190, P1547, DOI 10.1086/424601
   Neafsey DE, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r171
   Nielsen MA, 2002, J IMMUNOL, V168, P3444, DOI 10.4049/jimmunol.168.7.3444
   Ofori MF, 2002, INFECT IMMUN, V70, P2982, DOI 10.1128/IAI.70.6.2982-2988.2002
   Orjuela-Sanchez P, 2009, PARASITOLOGY, V136, P1097, DOI 10.1017/S0031182009990539
   Staalsoe T, 1999, CYTOMETRY, V35, P329, DOI 10.1002/(SICI)1097-0320(19990401)35:4&lt;329::AID-CYTO5&gt;3.0.CO;2-Y
   Tami A, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-7
   Tanabe K, 2010, CURR BIOL, V20, P1283, DOI 10.1016/j.cub.2010.05.053
   Tessema SK, 2015, MOL ECOL, V24, P484, DOI 10.1111/mec.13033
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Turner L, 2015, INFECT IMMUN, V83, P3096, DOI 10.1128/IAI.00271-15
   Turner L, 2013, NATURE, V498, P502, DOI 10.1038/nature12216
   van Noort SP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009778
   Vestergaard LS, 2008, INFECT IMMUN, V76, P2706, DOI 10.1128/IAI.01401-06
   Warimwe GM, 2009, P NATL ACAD SCI USA, V106, P21801, DOI 10.1073/pnas.0907590106
NR 47
TC 2
Z9 2
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4894
EI 1090-2449
J9 EXP PARASITOL
JI Exp. Parasitol.
PD NOV
PY 2016
VL 170
BP 90
EP 99
DI 10.1016/j.exppara.2016.09.006
PG 10
WC Parasitology
SC Parasitology
GA EC3XC
UT WOS:000388059400012
PM 27663467
OA Green Published
DA 2020-12-08
ER

PT J
AU Zhang, R
   Lee, WC
   Lau, YL
   Albrecht, L
   Lopes, SCP
   Costa, FTM
   Suwanarusk, R
   Nosten, F
   Cooke, BM
   Renia, L
   Russell, B
AF Zhang, Rou
   Lee, Wenn-Chyau
   Lau, Yee-Ling
   Albrecht, Letusa
   Lopes, Stefanie C. P.
   Costa, Fabio T. M.
   Suwanarusk, Rossarin
   Nosten, Francois
   Cooke, Brian M.
   Renia, Laurent
   Russell, Bruce
TI Rheopathologic Consequence of Plasmodium vivax Rosette Formation
SO PLOS NEGLECTED TROPICAL DISEASES
LA English
DT Article
ID RED-BLOOD-CELLS; INFECTED HUMAN ERYTHROCYTES; FALCIPARUM; MALARIA;
   DEFORMABILITY; CYTOADHERENCE; CYTOADHESION; ADHESION; STEVOR
AB Malaria parasites dramatically alter the rheological properties of infected red blood cells. In the case of Plasmodium vivax, the parasite rapidly decreases the shear elastic modulus of the invaded RBC, enabling it to avoid splenic clearance. This study highlights correlation between rosette formation and altered membrane deformability of P. vivax-infected erythrocytes, where the rosette-forming infected erythrocytes are significantly more rigid than their non-rosetting counterparts. The adhesion of normocytes to the PvIRBC is strong (mean binding force of 440pN) resulting in stable rosette formation even under high physiological shear flow stress. Rosetting may contribute to the sequestration of PvIRBC schizonts in the host microvasculature or spleen.
C1 [Zhang, Rou; Russell, Bruce] Natl Univ Hlth Syst, Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore.
   [Lee, Wenn-Chyau; Suwanarusk, Rossarin; Renia, Laurent] ASTAR, Singapore Immunol Network SIgN, Singapore, Singapore.
   [Lau, Yee-Ling] Univ Malaya, Fac Med, Dept Parasitol, Kuala Lumpur, Malaysia.
   [Albrecht, Letusa; Lopes, Stefanie C. P.; Costa, Fabio T. M.] Univ Estadual Campinas UNICAMP, Inst Biol, Lab Trop Dis, Campinas, SP, Brazil.
   [Nosten, Francois] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Shoklo Malaria Res Unit, Maesot, Thailand.
   [Nosten, Francois] Univ Oxford, Nuffield Dept Med, Ctr Trop Med, Oxford, England.
   [Cooke, Brian M.] Monash Univ, Monash Biomed Discovery Inst, Program Infect & Immun, Clayton, Vic 3800, Australia.
   [Cooke, Brian M.] Monash Univ, Monash Biomed Discovery Inst, Program Cardiovasc Dis, Clayton, Vic 3800, Australia.
   [Cooke, Brian M.] Monash Univ, Dept Microbiol, Clayton, Vic 3800, Australia.
   [Russell, Bruce] Univ Otago, Dept Microbiol & Immunol, Dunedin, New Zealand.
   [Albrecht, Letusa] Fundacao Oswaldo Cruz FIOCRUZ, Inst Carlos Chagas, Curitiba, Parana, Brazil.
   [Lopes, Stefanie C. P.] Fiocruz MS, Inst Leonidas & Marie Deane, Manaus, Amazonas, Brazil.
RP Russell, B (corresponding author), Natl Univ Hlth Syst, Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol & Immunol, Singapore, Singapore.; Russell, B (corresponding author), Univ Otago, Dept Microbiol & Immunol, Dunedin, New Zealand.
EM b.russell@otago.ac.nz
RI Lau, Yee Ling/C-6996-2009; Nosten, Francois/AAC-5509-2019; Russell,
   Bruce/A-9240-2011; Albrecht, Letusa/I-1837-2012; Costa,
   Fabio/E-1181-2012; LEE, Wenn-Chyau/AAR-4072-2020
OI Lau, Yee Ling/0000-0002-2037-2165; Nosten, Francois/0000-0002-7951-0745;
   Russell, Bruce/0000-0003-2333-4348; Albrecht,
   Letusa/0000-0001-6406-2057; Costa, Fabio/0000-0001-9969-7300; LEE,
   Wenn-Chyau/0000-0002-7324-5792; Lopes, Stefanie/0000-0002-6981-2192
FU SIgN, A*STAR; National University of SingaporeNational University of
   Singapore [AcRF Tier 1 FRC T1]; Singapore Ministry of Education Tier 2
   GrantMinistry of Education, Singapore [MOE2013-T2-1-145]; University of
   Malaya High Impact Research (HIR) Grant from Ministry of Higher
   Education, Malaysia [UM.C/HIR/MOHE/MED/16]; Wellcome Trust of the Great
   BritainWellcome Trust
FX This study received financial supports from the following funds: WCL, RS
   and LR were supported by funding from SIgN, A*STAR. RZ and BR were
   funded by the National University of Singapore (AcRF Tier 1 FRC T1-2013
   Apr 13) and a Singapore Ministry of Education Tier 2 Grant
   (MOE2013-T2-1-145). YLL was supported by University of Malaya High
   Impact Research (HIR) Grant (UM.C/HIR/MOHE/MED/16) from Ministry of
   Higher Education, Malaysia. SMRU is part of the Mahidol-Oxford
   University Research Unit, supported by the Wellcome Trust of the Great
   Britain. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Angus BJ, 1996, AM J TROP MED HYG, V55, P560, DOI 10.4269/ajtmh.1996.55.560
   Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815
   Ch'ng JH, 2016, SCI REP-UK, V6, DOI 10.1038/srep29317
   Chen Q, 1998, J EXP MED, V187, P15, DOI 10.1084/jem.187.1.15
   Chotivanich KT, 1998, AM J TROP MED HYG, V59, P73, DOI 10.4269/ajtmh.1998.59.73
   Cooke BM, 1996, BLOOD, V88, P4040, DOI 10.1182/blood.V88.10.4040.bloodjournal88104040
   Cooke BM, 2014, BIORHEOLOGY, V51, P99, DOI 10.3233/BIR-140654
   Crabb BS, 1997, CELL, V89, P287, DOI 10.1016/S0092-8674(00)80207-X
   DAVID PH, 1988, AM J TROP MED HYG, V38, P289, DOI 10.4269/ajtmh.1988.38.289
   Goel S, 2015, NAT MED, V21, P314, DOI 10.1038/nm.3812
   Handayani S, 2009, J INFECT DIS, V199, P445, DOI 10.1086/596048
   Hochmuth RM, 2000, J BIOMECH, V33, P15, DOI 10.1016/S0021-9290(99)00175-X
   Lee WC, 2014, BLOOD, V123, pE100, DOI 10.1182/blood-2013-12-541698
   Lopes SCP, 2014, J INFECT DIS, V209, P1403, DOI 10.1093/infdis/jiu018
   Lowe BS, 1998, T ROY SOC TROP MED H, V92, P526, DOI 10.1016/S0035-9203(98)90901-4
   Maier AG, 2008, CELL, V134, P48, DOI 10.1016/j.cell.2008.04.051
   Malleret B, 2015, BLOOD, V125, P1314, DOI 10.1182/blood-2014-08-596015
   Malleret B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076062
   Marin-Menendez A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002155
   Moxon CA, 2011, BRIT J HAEMATOL, V154, P670, DOI 10.1111/j.1365-2141.2011.08755.x
   NASH GB, 1992, BRIT J HAEMATOL, V82, P757, DOI 10.1111/j.1365-2141.1992.tb06955.x
   Niang M, 2014, CELL HOST MICROBE, V16, P81, DOI 10.1016/j.chom.2014.06.004
   Rowe JA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001082
   Rug M, 2006, BLOOD, V108, P370, DOI 10.1182/blood-2005-11-4624
   Sanyal S, 2012, BLOOD, V119, pE1, DOI 10.1182/blood-2011-08-370734
   Suwanarusk R, 2004, J INFECT DIS, V189, P190, DOI 10.1086/380468
   Udomsangpetch R, 1995, T ROY SOC TROP MED H, V89, P635, DOI 10.1016/0035-9203(95)90422-0
   Zhang R, 2016, J INFECT DIS, V213, P100, DOI 10.1093/infdis/jiv358
NR 28
TC 10
Z9 10
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1935-2735
J9 PLOS NEGLECT TROP D
JI Plos Neglect. Trop. Dis.
PD AUG
PY 2016
VL 10
IS 8
AR e0004912
DI 10.1371/journal.pntd.0004912
PG 10
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA DU7JR
UT WOS:000382390800053
PM 27509168
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Kayano, ACAV
   Dos-Santos, JCK
   Bastos, MF
   Carvalho, LJ
   Aliberti, J
   Costa, FTM
AF Kayano, Ana Carolina A. V.
   Dos-Santos, Joao Conrado K.
   Bastos, Marcele F.
   Carvalho, Leonardo J.
   Aliberti, Julio
   Costa, Fabio T. M.
TI Pathophysiological Mechanisms in Gaseous Therapies for Severe Malaria
SO INFECTION AND IMMUNITY
LA English
DT Review
ID EXPERIMENTAL CEREBRAL MALARIA; HYPERBARIC-OXYGEN THERAPY; SEVERE
   FALCIPARUM-MALARIA; INHALED NITRIC-OXIDE; BLOOD-BRAIN-BARRIER;
   RESPIRATORY-DISTRESS-SYNDROME; CARBON-MONOXIDE; HYDROGEN-SULFIDE; HEME
   OXYGENASE-1; L-ARGININE
AB Over 200 million people worldwide suffer from malaria every year, a disease that causes 584,000 deaths annually. In recent years, significant improvements have been achieved on the treatment of severe malaria, with intravenous artesunate proving superior to quinine. However, mortality remains high, at 8% in children and 15% in adults in clinical trials, and even worse in the case of cerebral malaria (18% and 30%, respectively). Moreover, some individuals who do not succumb to severe malaria present long-term cognitive deficits. These observations indicate that strategies focused only on parasite killing fail to prevent neurological complications and deaths associated with severe malaria, possibly because clinical complications are associated in part with a cerebrovascular dysfunction. Consequently, different adjunctive therapies aimed at modulating malaria pathophysiological processes are currently being tested. However, none of these therapies has shown unequivocal evidence in improving patient clinical status. Recently, key studies have shown that gaseous therapies based mainly on nitric oxide (NO), carbon monoxide (CO), and hyperbaric (pressurized) oxygen (HBO) alter vascular endothelium dysfunction and modulate the host immune response to infection. Considering gaseous administration as a promising adjunctive treatment against severe malaria cases, we review here the pathophysiological mechanisms and the immunological aspects of such therapies.
C1 [Kayano, Ana Carolina A. V.; Dos-Santos, Joao Conrado K.; Bastos, Marcele F.; Costa, Fabio T. M.] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut & Bioagents, Lab Trop Dis Prof Dr Luiz Jacintho Da Silva, Campinas, SP, Brazil.
   [Carvalho, Leonardo J.] Fiocruz MS, Inst Oswaldo Cruz, Malaria Res Lab, Rio De Janeiro, RJ, Brazil.
   [Aliberti, Julio] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
RP Costa, FTM (corresponding author), Univ Estadual Campinas, Inst Biol, Dept Genet Evolut & Bioagents, Lab Trop Dis Prof Dr Luiz Jacintho Da Silva, Campinas, SP, Brazil.
EM fabiotmc72@gmail.com
RI Carvalho, Leonardo J. M./K-7174-2013; Costa, Fabio/E-1181-2012
OI Costa, Fabio/0000-0001-9969-7300; Dos-Santos, Joao/0000-0001-5916-9845
FU HHS \ National Institutes of Health (NIH)United States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USA
   [AI118302-02]; MCTI \ Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Fabio Trindade Maranhao Costa [2012/16525-2]; Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos Chagas Filho
   Foundation for Research Support of the State of Rio de Janeiro (FAPERJ);
   Carvalho through a Cientista do Nosso Estado fellowship; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R21AI118302, R21AI118302] Funding Source: NIH RePORTER
FX HHS vertical bar National Institutes of Health (NIH) provided funding to
   Julio Aliberti under grant number AI118302-02. MCTI vertical bar
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   provided funding to Ana Carolina Andrade Vitor Kayano, Joao Conrado
   Khouri Dos-Santos, Marcele F. Bastos, Leonardo J. M. Carvalho, and Fabio
   Trindade Maranhao Costa. Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) provided funding to Ana Carolina Andrade Vitor Kayano,
   Joao Conrado Khouri Dos-Santos, Marcele F. Bastos, and Fabio Trindade
   Maranhao Costa under grant number 2012/16525-2.; Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ) provided funding to
   Leonardo J. M. Carvalho through a Cientista do Nosso Estado fellowship.
CR Adhikari NKJ, 2014, CRIT CARE MED, V42, P404, DOI 10.1097/CCM.0b013e3182a27909
   Al-Waili NS, 2006, THESCIENTIFICWORLDJO, V6, P425, DOI 10.1100/tsw.2006.78
   Anstey NM, 1996, J EXP MED, V184, P557, DOI 10.1084/jem.184.2.557
   Arrais-Silva WW, 2006, ACTA TROP, V98, P130, DOI 10.1016/j.actatropica.2006.03.001
   Arrais-Silva WW, 2005, PARASITOL INT, V54, P1, DOI 10.1016/j.parint.2004.07.002
   Bauer M, 2008, INTENS CARE MED, V34, P640, DOI 10.1007/s00134-008-1010-2
   Beare NAV, 2009, J INFECT DIS, V199, P263, DOI 10.1086/595735
   Bennett MH, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004609.pub3
   Bennett MH, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004954.pub3
   Bertinaria M, 2015, J MED CHEM, V58, P7895, DOI 10.1021/acs.jmedchem.5b01036
   Blanco YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003126
   Bloch KD, 2007, CARDIOVASC RES, V75, P339, DOI 10.1016/j.cardiores.2007.04.014
   Boivin MJ, 2007, PEDIATRICS, V119, pE360, DOI 10.1542/peds.2006-2027
   Boivin MJ, 2002, J DEV BEHAV PEDIATR, V23, P353, DOI 10.1097/00004703-200210000-00010
   BREWSTER DR, 1990, LANCET, V336, P1039, DOI 10.1016/0140-6736(90)92498-7
   Bronicki RA, 2015, J PEDIATR-US, V166, P365, DOI 10.1016/j.jpeds.2014.10.011
   Bronstein Alvin, 2011, Morbidity and Mortality Weekly Report, V60, P1014
   Brown H, 1999, NEUROPATH APPL NEURO, V25, P331
   Buras JA, 2000, AM J PHYSIOL-CELL PH, V278, pC292
   Cabrales P, 2013, VIRULENCE, V4, P686, DOI 10.4161/viru.26348
   Cabrales P, 2011, J INFECT DIS, V203, P1454, DOI 10.1093/infdis/jir058
   Cabrales P, 2010, AM J PATHOL, V176, P1306, DOI 10.2353/ajpath.2010.090691
   Camporesi EM, 2014, UNDERSEA HYPERBAR M, V41, P253
   Carter JA, 2005, J NEUROL NEUROSUR PS, V76, P476, DOI 10.1136/jnnp.2004.043893
   Carvalho LJM, 2010, TRENDS PARASITOL, V26, P271, DOI 10.1016/j.pt.2010.03.001
   Chertow JH, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005119
   Cooper JS, 2014, UNDERSEA HYPERBAR M, V41, P51
   Cunnington AJ, 2004, AM J TROP MED HYG, V71, P43, DOI 10.4269/ajtmh.2004.71.43
   Dauwe PB, 2014, PLAST RECONSTR SURG, V133, p208E, DOI 10.1097/01.prs.0000436849.79161.a4
   DellaValle B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059271
   Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1
   Epiphanio S, 2008, CELL HOST MICROBE, V3, P331, DOI 10.1016/j.chom.2008.04.003
   Faiz MA, 2005, LANCET, V366, P717
   Farrugia G, 2014, GASTROENTEROLOGY, V147, P303, DOI 10.1053/j.gastro.2014.04.041
   FELDMEIER JJ, 2003, HYPERBARIC OXYGEN 20
   Ferreira A, 2008, J MOL MED, V86, P1097, DOI 10.1007/s00109-008-0368-5
   Finney CAM, 2011, MOL MED, V17, P717, DOI 10.2119/molmed.2010.00214
   Frevert U, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00155
   Gill AL, 2004, QJM-INT J MED, V97, P385, DOI 10.1093/qjmed/hch074
   Giuliani D, 2013, NEUROBIOL LEARN MEM, V104, P82, DOI 10.1016/j.nlm.2013.05.006
   Gramaglia I, 2006, NAT MED, V12, P1417, DOI 10.1038/nm1499
   Hawkes M, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-176
   Hawkes MT, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0946-2
   Ho JJD, 2012, J MOL MED, V90, P217, DOI 10.1007/s00109-012-0880-5
   Ho M, 1999, AM J PHYSIOL-CELL PH, V276, pC1231
   Hunt NH, 2010, TRENDS PARASITOL, V26, P272, DOI 10.1016/j.pt.2010.03.006
   Jeney V, 2014, CELL REP, V8, P126, DOI 10.1016/j.celrep.2014.05.054
   John CC, 2008, PEDIATRICS, V122, pE92, DOI 10.1542/peds.2007-3709
   John CC, 2010, EXPERT REV ANTI-INFE, V8, P997, DOI [10.1586/eri.10.90, 10.1586/ERI.10.90]
   Kabil O, 2014, BBA-PROTEINS PROTEOM, V1844, P1355, DOI 10.1016/j.bbapap.2014.01.002
   Kaide CG, 2008, EMERG MED CLIN N AM, V26, P571, DOI 10.1016/j.emc.2008.01.005
   Kumar P, 2014, PEDIATRICS, V133, P164, DOI 10.1542/peds.2013-3444
   Li HG, 2000, J PATHOL, V190, P244, DOI 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8
   Li L, 2009, FREE RADICAL BIO MED, V47, P103, DOI 10.1016/j.freeradbiomed.2009.04.014
   Liu R, 2013, MAYO CLIN PROC, V88, P166, DOI 10.1016/j.mayocp.2012.10.021
   Lopansri BK, 2003, LANCET, V361, P676, DOI 10.1016/S0140-6736(03)12564-0
   Lovegrove FE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004912
   Medana IM, 2006, INT J PARASITOL, V36, P555, DOI 10.1016/j.ijpara.2006.02.004
   Meng G, 2014, BRIT J PHARMACOL, V172, P5501, DOI DOI 10.1111/BPH.12900
   Minamishima S, 2009, CIRCULATION, V120, P888, DOI 10.1161/CIRCULATIONAHA.108.833491
   Mishra SK, 2009, NAT REV NEUROL, V5, P189, DOI 10.1038/nrneurol.2009.23
   Molnar T, 2014, J STROKE CEREBROVASC, V23, P2206, DOI 10.1016/j.jstrokecerebrovasdis.2014.05.002
   Mwanga-Amumpaire J, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv111
   O'Reilly D, 2013, INT J TECHNOL ASSESS, V29, P269, DOI 10.1017/S0266462313000263
   Ong PK, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003444
   Orjuela-Sanchez P, 2013, ANTIMICROB AGENTS CH, V57, P5462, DOI 10.1128/AAC.00488-13
   Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586
   Pena AC, 2012, ANTIMICROB AGENTS CH, V56, P1281, DOI 10.1128/AAC.05571-11
   Plafki C, 2000, AVIAT SPACE ENVIR MD, V71, P119
   PONGPONRATN E, 1991, AM J TROP MED HYG, V44, P168, DOI 10.4269/ajtmh.1991.44.168
   RENCRICCA NJ, 1981, AVIAT SPACE ENVIR MD, V52, P85
   Renia L, 2010, TRENDS PARASITOL, V26, P275, DOI 10.1016/j.pt.2010.03.005
   REST JR, 1982, T ROY SOC TROP MED H, V76, P410, DOI 10.1016/0035-9203(82)90203-6
   Rochette L, 2013, PHARMACOL THERAPEUT, V137, P133, DOI 10.1016/j.pharmthera.2012.09.007
   Sambo MR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011141
   Schluesener HJ, 2001, ACTA NEUROPATHOL, V101, P65
   Serghides L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027714
   Serghides L, 2012, PPAR RES, V2012, P1, DOI 10.1155/2012/513865
   Serirom S, 2003, AM J PATHOL, V162, P1651, DOI 10.1016/S0002-9440(10)64299-X
   Suttner DM, 1999, FASEB J, V13, P1800
   Takeda M, 2005, JPN J INFECT DIS, V58, P268
   Villalpando S, 2006, AM J CLIN NUTR, V84, P197
   Walther M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002579
   Wang M, 2015, J NEUROSCI RES, V93, P487, DOI 10.1002/jnr.23504
   Wang YL, 2014, J NEUROCHEM, V129, P827, DOI 10.1111/jnc.12695
   WARRELL DA, 1988, LANCET, V2, P534
   Weerateerangkul P, 2011, MED SCI MONITOR, V17, pRA44, DOI 10.12659/MSM.881385
   Wegiel B, 2013, TRENDS MOL MED, V19, P3, DOI 10.1016/j.molmed.2012.10.001
   Weinberg JB, 2008, CURR OPIN INFECT DIS, V21, P468, DOI 10.1097/QCO.0b013e32830ef5cf
   Weinberg JB, 2014, J INFECT DIS, V210, P913, DOI 10.1093/infdis/jiu156
   White NJ, 2010, TRENDS PARASITOL, V26, P11, DOI 10.1016/j.pt.2009.10.007
   WHO, 2013, WORLD MALARIA REPORT 2013, P1
   Wraight WM, 2001, BRIT J ANAESTH, V86, P267, DOI 10.1093/bja/86.2.267
   Xu SW, 2014, INT J CARDIOL, V172, P313, DOI 10.1016/j.ijcard.2014.01.068
   Yang ZJ, 2001, EUR J APPL PHYSIOL, V85, P96, DOI 10.1007/s004210100391
   Yeo TW, 2008, J INFECT DIS, V198, P602, DOI 10.1086/590209
   Yeo TW, 2007, J EXP MED, V204, P2693, DOI 10.1084/jem.20070819
   Yeo TW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069587
   Yeo TW, 2013, J INFECT DIS, V208, P813, DOI 10.1093/infdis/jit253
   Yeo TW, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000868
   Yeo TW, 2009, J INFECT DIS, V200, P1522, DOI 10.1086/644641
   Zanini GM, 2012, J NEUROIMMUNE PHARM, V7, P477, DOI 10.1007/s11481-012-9343-6
   Zanini GM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-66
NR 103
TC 1
Z9 2
U1 0
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD APR
PY 2016
VL 84
IS 4
BP 874
EP 882
DI 10.1128/IAI.01404-15
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA DN5JV
UT WOS:000377103600002
PM 26831465
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Judice, CC
   Bourgard, C
   Kayano, ACAV
   Albrecht, L
   Costa, FTM
AF Judice, Carla C.
   Bourgard, Catarina
   Kayano, Ana C. A. V.
   Albrecht, Letusa
   Costa, Fabio T. M.
TI MicroRNAs in the Host-Apicomplexan Parasites Interactions: A Review of
   Immunopathological Aspects
SO FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
LA English
DT Review
DE microRNA; immune response; cell host; Apicomplexa; parasites
ID FALCIPARUM-INFECTED ERYTHROCYTES; EXPERIMENTAL CEREBRAL MALARIA;
   PLASMODIUM-FALCIPARUM; CRYPTOSPORIDIUM-PARVUM; TOXOPLASMA-GONDII;
   ANOPHELES-GAMBIAE; IMMUNE-RESPONSES; IN-VIVO; EXPRESSION; MIR-155
AB MicroRNAs (miRNAs), a class of small non-coding regulatory RNAs, have been detected in a variety of organisms ranging from ancient unicellular eukaryotes to mammals. They have been associated with numerous molecular mechanisms involving developmental, physiological and pathological changes of cells and tissues. Despite the fact that miRNA-silencing mechanisms appear to be absent in some Apicomplexan species, an increasing number of studies have reported a role for miRNAs in host-parasite interactions. Host miRNA expression can change following parasite infection and the consequences can lead, for instance, to parasite clearance. In this context, the immune system signaling appears to have a crucial role.
C1 [Judice, Carla C.; Bourgard, Catarina; Kayano, Ana C. A. V.; Costa, Fabio T. M.] Univ Estadual Campinas, Dept Genet Evolut & Bioagents, UNICAMP, Lab Trop Dis, Campinas, SP, Brazil.
   [Albrecht, Letusa] Fiocruz Parana, Inst Carlos Chagas, Curitiba, Parana, Brazil.
RP Judice, CC; Costa, FTM (corresponding author), Univ Estadual Campinas, Dept Genet Evolut & Bioagents, UNICAMP, Lab Trop Dis, Campinas, SP, Brazil.
EM carla.judice@gmail.com; fabiotmc72@gmail.com
RI Albrecht, Letusa/I-1837-2012; Costa, Fabio/E-1181-2012; Bourgard,
   Catarina/N-3630-2019; Bourgard, Catarina/AAF-8186-2020; Judice,
   Carla/P-4738-2014
OI Albrecht, Letusa/0000-0001-6406-2057; Costa, Fabio/0000-0001-9969-7300;
   Bourgard, Catarina/0000-0003-3469-703X; Judice,
   Carla/0000-0003-1839-053X
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/16525-2];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP; 2012/16525-2), the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq). CB and AK were
   sponsored by FAPESP fellowships. FC is a CNPq research fellow.
CR Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Amino R, 2008, CELL HOST MICROBE, V3, P88, DOI 10.1016/j.chom.2007.12.007
   Avril M, 2012, P NATL ACAD SCI USA, V109, pE1782, DOI 10.1073/pnas.1120534109
   Baltimore D, 2008, NAT IMMUNOL, V9, P839, DOI 10.1038/ni.f.209
   Banerjee A, 2010, EUR J IMMUNOL, V40, P225, DOI 10.1002/eji.200939381
   Baptista FG, 2010, INFECT IMMUN, V78, P4033, DOI 10.1128/IAI.00079-10
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Biron DG, 2013, J EXP BIOL, V216, P148, DOI 10.1242/jeb.073825
   Biryukova I, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-557
   Blandin SA, 2008, CELL HOST MICROBE, V3, P364, DOI 10.1016/j.chom.2008.05.007
   Cai YH, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-356
   Cannella D, 2014, CELL REP, V6, P928, DOI 10.1016/j.celrep.2014.02.002
   CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993
   Ceppi M, 2009, P NATL ACAD SCI USA, V106, P2735, DOI 10.1073/pnas.0811073106
   Chamnanchanunt S, 2015, EXP PARASITOL, V155, P19, DOI 10.1016/j.exppara.2015.04.013
   Chatterjee R, 2006, ACTA BIOCHIM POL, V53, P303
   Chen Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.92
   Chen XM, 2007, J BIOL CHEM, V282, P28929, DOI 10.1074/jbc.M702633200
   Chen XM, 2005, J IMMUNOL, V175, P7447, DOI 10.4049/jimmunol.175.11.7447
   Chhabra R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005848
   Cholera R, 2008, P NATL ACAD SCI USA, V105, P991, DOI 10.1073/pnas.0711401105
   Cirimotich CM, 2010, DEV COMP IMMUNOL, V34, P387, DOI 10.1016/j.dci.2009.12.005
   Claessens A, 2012, P NATL ACAD SCI USA, V109, pE1772, DOI 10.1073/pnas.1120461109
   Costa FTM, 2011, MEM I OSWALDO CRUZ, V106, P79, DOI 10.1590/S0074-02762011000900010
   Coulson RMR, 2004, GENOME RES, V14, P1548, DOI 10.1101/gr.2218604
   Cyrklaff M, 2011, SCIENCE, V334, P1283, DOI 10.1126/science.1213775
   Delic D, 2011, PARASITOL RES, V108, P1111, DOI 10.1007/s00436-010-2152-z
   Deng MQ, 2004, INT J PARASITOL, V34, P73, DOI 10.1016/j.ijpara.2003.10.001
   El-Assaad F, 2011, INFECT IMMUN, V79, P2379, DOI 10.1128/IAI.01136-10
   Elton TS, 2013, GENE, V532, P1, DOI 10.1016/j.gene.2012.12.009
   Faraoni I, 2009, BBA-MOL BASIS DIS, V1792, P497, DOI 10.1016/j.bbadis.2009.02.013
   Ferreira A, 2011, CELL, V145, P398, DOI 10.1016/j.cell.2011.03.049
   Frank B, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0974-3
   Gazzinelli RT, 2014, NAT REV IMMUNOL, V14, P744, DOI 10.1038/nri3742
   Geraci NS, 2015, PARASITE IMMUNOL, V37, P43, DOI 10.1111/pim.12156
   Ghosh J, 2013, CELL HOST MICROBE, V13, P277, DOI 10.1016/j.chom.2013.02.005
   Gong AY, 2011, INT J PARASITOL, V41, P397, DOI 10.1016/j.ijpara.2010.11.011
   Guerrant RL, 1997, EMERG INFECT DIS, V3, P51, DOI 10.3201/eid0301.970106
   Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717
   Hentzschel F, 2014, MOL THER, V22, P2130, DOI 10.1038/mt.2014.172
   Hou J, 2009, J IMMUNOL, V183, P2150, DOI 10.4049/jimmunol.0900707
   Hu GK, 2010, J INFECT DIS, V202, P125, DOI 10.1086/653212
   Hu GK, 2009, J IMMUNOL, V183, P1617, DOI 10.4049/jimmunol.0804362
   Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1
   Idro R, 2005, LANCET NEUROL, V4, P827, DOI 10.1016/S1474-4422(05)70247-7
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Jain S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098402
   Jennewein C, 2010, J BIOL CHEM, V285, P11846, DOI 10.1074/jbc.M109.066399
   Jia BY, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-433
   Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644
   Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512
   Kohlhaas S, 2009, J IMMUNOL, V182, P2578, DOI 10.4049/jimmunol.0803162
   Kuehbacher A, 2007, CIRC RES, V101, P59, DOI 10.1161/CIRCRESAHA.107.153916
   Lackner P, 2007, NEUROPATH APPL NEURO, V33, P560, DOI 10.1111/j.1365-2990.2007.00833.x
   Lai EC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-r42
   LaMonte G, 2012, CELL HOST MICROBE, V12, P187, DOI 10.1016/j.chom.2012.06.007
   Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329
   Leng J, 2009, PARASITE IMMUNOL, V31, P717, DOI 10.1111/j.1365-3024.2009.01122.x
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Lind EF, 2014, EUR J IMMUNOL, V44, P11, DOI 10.1002/eji.201343962
   Linhares-Lacerda L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00428
   Luder CGK, 2005, CURR TOP MICROBIOL, V289, P219
   Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618
   McDonald V, 2013, PARASITE IMMUNOL, V35, P55, DOI 10.1111/pim.12020
   MICHEL R, 1980, INT J PARASITOL, V10, P309, DOI 10.1016/0020-7519(80)90012-0
   Navarro IC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003828
   O'Connell RM, 2010, IMMUNITY, V33, P607, DOI 10.1016/j.immuni.2010.09.009
   O'Hara SP, 2010, J BIOL CHEM, V285, P216, DOI 10.1074/jbc.M109.041640
   Penet MF, 2005, J NEUROSCI, V25, P7352, DOI 10.1523/JNEUROSCI.1002-05.2005
   Ferreira LRP, 2014, INT J CARDIOL, V175, P409, DOI 10.1016/j.ijcard.2014.05.019
   Plattner F, 2008, ANNU REV MICROBIOL, V62, P471, DOI 10.1146/annurev.micro.62.081307.162802
   Prudencio M, 2006, NAT REV MICROBIOL, V4, P849, DOI 10.1038/nrmicro1529
   Rathjen T, 2006, FEBS LETT, V580, P5185, DOI 10.1016/j.febslet.2006.08.063
   Renia L, 2012, VIRULENCE, V3, P193, DOI 10.4161/viru.19013
   Saba R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00578
   Saeij JPJ, 2007, NATURE, V445, P324, DOI 10.1038/nature05395
   Schofield L, 2005, NAT REV IMMUNOL, V5, P722, DOI 10.1038/nri1686
   Shapira S, 2002, J INFECT DIS, V185, pS66, DOI 10.1086/338000
   Sharma A, 2009, P NATL ACAD SCI USA, V106, P5761, DOI 10.1073/pnas.0808743106
   Sheedy FJ, 2010, NAT IMMUNOL, V11, P141, DOI 10.1038/ni.1828
   Sturm A, 2006, SCIENCE, V313, P1287, DOI 10.1126/science.1129720
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Tang B, 2010, FEBS LETT, V584, P1481, DOI 10.1016/j.febslet.2010.02.063
   Thakral S, 2015, CURR GENE THER, V15, P142, DOI 10.2174/1566523214666141224095610
   Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082
   Tourneur L, 2010, TRENDS IMMUNOL, V31, P260, DOI 10.1016/j.it.2010.05.005
   Turner L, 2013, NATURE, V498, P502, DOI 10.1038/nature12216
   van der Heyde HC, 2006, TRENDS PARASITOL, V22, P503, DOI 10.1016/j.pt.2006.09.002
   Vigorito E, 2013, IMMUNOL REV, V253, P146, DOI 10.1111/imr.12057
   Vlachou D, 2005, CURR BIOL, V15, P1185, DOI 10.1016/j.cub.2005.06.044
   Wang QZ, 2012, J PHYSIOL BIOCHEM, V68, P107, DOI 10.1007/s13105-011-0124-0
   Wang XW, 2005, BIOINFORMATICS, V21, P3610, DOI 10.1093/bioinformatics/bti562
   WHO, 2015, WORLD MAL REP
   Winter F, 2007, NUCLEIC ACIDS RES, V35, P6953, DOI 10.1093/nar/gkm686
   Wurtz N, 2011, PARASITOLOGY, V138, P1, DOI 10.1017/S003118201000096X
   Xiao CC, 2009, CELL, V136, P26, DOI 10.1016/j.cell.2008.12.027
   Xue XY, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-47
   Yin QY, 2008, J BIOL CHEM, V283, P2654, DOI 10.1074/jbc.M708218200
   Zeiner GM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008742
   Zhang QF, 2014, NATURE, V513, P431, DOI 10.1038/nature13468
   Zhou R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065153
   Zhou R, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002702
   Zhou R, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000681
   Zhu LH, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00165
NR 106
TC 18
Z9 21
U1 0
U2 25
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2235-2988
J9 FRONT CELL INFECT MI
JI Front. Cell. Infect. Microbiol.
PD FEB 2
PY 2016
VL 6
AR 5
DI 10.3389/fcimb.2016.00005
PG 9
WC Immunology; Microbiology
SC Immunology; Microbiology
GA DC3BF
UT WOS:000369093500002
PM 26870701
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Vassequi-Silva, T
   Pereira, DS
   Diez, ACCN
   Braga, GG
   Godoy, JA
   Mendes, CB
   dos Santos, L
   Krieger, JE
   Antunes, E
   Costa, FTM
   Vicente, CP
   Werneck, CC
AF Vassequi-Silva, Tallita
   Pereira, Danielle Sousa
   Nery Diez, Ana Claudia C.
   Braga, Guilherme G.
   Godoy, Juliana A.
   Mendes, Camila B.
   dos Santos, Leonardo
   Krieger, Jose E.
   Antunes, Edson
   Costa, Fabio T. M.
   Vicente, Cristina P.
   Werneck, Claudio C.
TI Losartan and captopril treatment rescue normal thrombus formation in
   microfibril associated glycoprotein-1 (MAGP1) deficient mice
SO THROMBOSIS RESEARCH
LA English
DT Article
DE Microfibril-associated glycoprotein; Arterial thrombosis; Transforming
   growth factor-beta; Antihypertensive drugs; Extracellular matrix; Matrix
   metalloproteinases
ID MARFAN-SYNDROME; TGF-BETA; ARTERIAL THROMBOSIS; AORTIC-ANEURYSM; MATRIX;
   FIBRILLIN-1; BINDING; INJURY; MODEL; IDENTIFICATION
AB Introduction: MAGP1 is a glycoprotein present in the elastic fibers and is a part of the microfibrils components. MAGP1 interacts with von Willebrand factor and the active form of TGF-beta and BMP. In mice lacking MAGP1, thrombus formation is delayed, increasing the occlusion time of carotid artery despite presenting normal blood coagulation in vitro. MAGP1-containing microfibrils may play a role in hemostasis and thrombosis. In this work, we evaluated the function of MAGP1 and its relation to TGF-beta in the arterial thrombosis process.
   Methods and results: We analyzed thrombus formation time in wild type and MAGP1-deficient mice comparing Rose Bengal and Ferric Chloride induced arterial lesion. The potential participation of TGF-beta in this process was accessed when we treated both wild type and MAGP1-deficient mice with losartan (an antihypertensive drug that decreases TGF-beta activity) or captopril (an angiotensin converting enzyme inhibitor that was used as a control antihypertensive drug). Besides, we evaluated thrombus embolization and the gelatinolytic activity in the arterial walls in vitro and ex vivo. Losartan and captopril were able to recover the thrombus formation time without changing blood pressure, activated partial thromboplastin time (aPTT), PT (prothrombin time), platelet aggregation and adhesion, but decreased gelatinase activity.
   Conclusions: Our results suggest that both treatments are effective in the prevention of the sub-endothelial ECM degradation, allowing the recovery of normal thrombus formation. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Vassequi-Silva, Tallita; Pereira, Danielle Sousa; Nery Diez, Ana Claudia C.; Braga, Guilherme G.; Werneck, Claudio C.] Univ Estadual Campinas, Dept Biochem & Tissue Biol, Campinas, SP, Brazil.
   [Mendes, Camila B.; Antunes, Edson] Univ Estadual Campinas, Dept Pharmacol, Campinas, SP, Brazil.
   [dos Santos, Leonardo] Univ Fed Espirito Santo, Dept Physiol Sci, Vitoria, ES, Brazil.
   [Krieger, Jose E.] InCor HC FMUSP, Lab Genet & Mol Cardiol, Campinas, SP, Brazil.
   [Costa, Fabio T. M.] Univ Estadual Campinas, Dept Genet & Evolut & Bioagents, Campinas, SP, Brazil.
   [Godoy, Juliana A.; Vicente, Cristina P.] Univ Estadual Campinas, Dept Struct & Funct Biol, Campinas, SP, Brazil.
RP Werneck, CC (corresponding author), Univ Estadual Campinas, Dept Biochem & Tissue Biol, Campinas, SP, Brazil.
EM cwerneck@unicamp.br
RI Santos, Leonardo dos/B-6509-2013; Costa, Fabio/E-1181-2012; Vicente,
   Cristina/D-8928-2012; Godoy, Juliana/L-6386-2014; Werneck, Claudio
   C/C-7568-2012; ANTUNES, EDSON/F-6731-2012
OI Santos, Leonardo dos/0000-0002-4340-6364; Costa,
   Fabio/0000-0001-9969-7300; Vicente, Cristina/0000-0001-9896-4630;
   Werneck, Claudio C/0000-0002-9413-0572; ANTUNES,
   EDSON/0000-0003-2201-8247
FU CAPESCAPES; FapespFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) [2012/23640-2, 2010/19916-7, 2009/0950-3]; CNPqNational Council
   for Scientific and Technological Development (CNPq) [307784/2013-4]
FX This work was supported by the following Brazilian grants: CAPES to TVS,
   Fapesp 2012/23640-2 to CPV and CNPq 307784/2013-4, Fapesp 2010/19916-7
   and Fapesp 2009/0950-3 to CCW.
CR Ahimastos AA, 2005, HYPERTENSION, V45, P1194, DOI 10.1161/01.HYP.0000168945.44069.aa
   BELLAVITE P, 1994, ANAL BIOCHEM, V216, P444, DOI 10.1006/abio.1994.1066
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brooke BS, 2008, NEW ENGL J MED, V358, P2787, DOI 10.1056/NEJMoa0706585
   Chabielska E, 1998, J PHYSIOL PHARMACOL, V49, P251
   Cohn RD, 2007, NAT MED, V13, P204, DOI 10.1038/nm1536
   Craft CS, 2014, DIABETES, V63, P1920, DOI 10.2337/db13-1604
   DAVIS EC, 1994, J CELL SCI, V107, P727
   de Aro AA, 2014, ANAT REC, V297, P281, DOI 10.1002/ar.22842
   Detaint D, 2010, ARCH CARDIOVASC DIS, V103, P317, DOI 10.1016/j.acvd.2010.04.008
   FAUVELLAFEVE F, 1990, THROMB HAEMOSTASIS, V64, P145
   Frankowski H, 2012, METHODS MOL BIOL, V814, P221, DOI 10.1007/978-1-61779-452-0_15
   Habashi JP, 2006, SCIENCE, V312, P117, DOI 10.1126/science.1124287
   He L, 2002, J CLIN INVEST, V109, P213, DOI 10.1172/JCI200213432
   Jensen SA, 2001, J BIOL CHEM, V276, P39661, DOI 10.1074/jbc.M104533200
   Kuijpers MJE, 2009, J THROMB HAEMOST, V7, P152, DOI 10.1111/j.1538-7836.2008.03186.x
   Landmesser U, 2007, ARTERIOSCL THROM VAS, V27, P943, DOI 10.1161/01.ATV.0000258415.32883.bf
   Li W, 2013, REDOX BIOL, V1, P50, DOI 10.1016/j.redox.2012.11.001
   Loeys BL, 2015, DRUG DISCOV TODAY, V20, P262, DOI 10.1016/j.drudis.2014.09.022
   Mariko B, 2010, AM J PHYSIOL-CELL PH, V299, pC977, DOI 10.1152/ajpcell.00377.2009
   Massam-Wu T, 2010, J CELL SCI, V123, P3006, DOI 10.1242/jcs.073437
   Matt P, 2009, CIRCULATION, V120, P526, DOI 10.1161/CIRCULATIONAHA.108.841981
   McLoughlin D, 2011, CIRCULATION, V124, pS168, DOI 10.1161/CIRCULATIONAHA.110.012187
   Mecham RP, 1995, CIBA F SYMP, V192, P172
   Resende DM, 2008, VACCINE, V26, P4585, DOI 10.1016/j.vaccine.2008.05.091
   Ruggeri ZM, 2007, CIRC RES, V100, P1673, DOI 10.1161/01.RES.0000267878.97021.ab
   Segade F, 2002, J BIOL CHEM, V277, P11050, DOI 10.1074/jbc.M110347200
   Trask BC, 2000, MOL BIOL CELL, V11, P1499, DOI 10.1091/mbc.11.5.1499
   Trask TM, 2000, J BIOL CHEM, V275, P24400, DOI 10.1074/jbc.M003665200
   Wagenseil Jessica E., 2007, Birth Defects Research, V81, P229, DOI 10.1002/bdrc.20111
   Weinbaum JS, 2008, J BIOL CHEM, V283, P25533, DOI 10.1074/jbc.M709962200
   Werneck CC, 2004, J BIOL CHEM, V279, P23045, DOI 10.1074/jbc.M402656200
   Werneck CC, 2008, BLOOD, V111, P4137, DOI 10.1182/blood-2007-07-101733
   Yang HHC, 2010, J THORAC CARDIOV SUR, V140, P305, DOI 10.1016/j.jtcvs.2009.10.039
   Zurbano MJ, 1999, ARTERIOSCL THROM VAS, V19, P1791, DOI 10.1161/01.ATV.19.7.1791
NR 35
TC 3
Z9 3
U1 0
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0049-3848
J9 THROMB RES
JI Thromb. Res.
PD FEB
PY 2016
VL 138
BP 7
EP 15
DI 10.1016/j.thromres.2015.12.004
PG 9
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA DB9BO
UT WOS:000368811200002
PM 26826502
DA 2020-12-08
ER

PT J
AU Siqueira, AM
   Mesones-Lapouble, O
   Marchesini, P
   Sampaio, VD
   Brasil, P
   Tauil, PL
   Fontes, CJ
   Costa, FTM
   Daniel-Ribeiro, CT
   Lacerda, MVG
   Damasceno, CP
   Santelli, ACS
AF Siqueira, Andre M.
   Mesones-Lapouble, Oscar
   Marchesini, Paola
   Sampaio, Vanderson de Souza
   Brasil, Patricia
   Tauil, Pedro L.
   Fontes, Cor Jesus
   Costa, Fabio T. M.
   Daniel-Ribeiro, Claudio Tadeu
   Lacerda, Marcus V. G.
   Damasceno, Camila P.
   Santelli, Ana Carolina S.
TI fPlasmodium vivax Landscape in Brazil: Scenario and Challenges
SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
LA English
DT Article
ID PLASMODIUM-VIVAX; AMAZON REGION; PORTO VELHO; MALARIA TRANSMISSION;
   DIPTERA-CULICIDAE; NONENDEMIC AREA; WESTERN AMAZON; RONDONIA STATE;
   ELIMINATION; CHLOROQUINE
AB Brazil is the largest country of Latin America, with a considerable portion of its territoritory within the malaria-endemic Amazon region in the North. Furthermore, a considerable portion of its territory is located within the Amazon region in the north. As a result, Brazil has reported half of the total malaria cases in the Americas in the last four decades. Recent progress in malaria control has been accompanied by an increasing proportion of Plasmodium vivax, underscoring a need for a better understanding of management and control of this species and associated challenges. Among these challenges, the contribution of vivax malaria relapses, earlier production of gametocytes (compared with Plasmodium falciparum), inexistent methods to diagnose hypnozoite carriers, and decreasing efficacy of available antimalarials need to be addressed. Innovative tools, strategies, and technologies are needed to achieve further progress toward sustainable malaria elimination. Further difficulties also arise from dealing with the inherent socioeconomic and environmental particularities of the Amazon region and its dynamic changes.
C1 [Siqueira, Andre M.; Brasil, Patricia] Fiocruz MS, Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
   [Siqueira, Andre M.; Sampaio, Vanderson de Souza; Lacerda, Marcus V. G.] Univ Estado Amazonas, Programa Posgrad Med Trop, Manaus, Amazonas, Brazil.
   [Mesones-Lapouble, Oscar] Pan Amer Hlth Org, Brasilia, DF, Brazil.
   [Marchesini, Paola; Damasceno, Camila P.; Santelli, Ana Carolina S.] Minist Saude, Coordenacao Geral Programa Nacl Controle Malaria, Brasilia, DF, Brazil.
   [Sampaio, Vanderson de Souza] Fundacao Vigilancia Saude, Manaus, Amazonas, Brazil.
   [Tauil, Pedro L.] Univ Brasilia, Nucleo Med Trop, Brasilia, DF, Brazil.
   [Fontes, Cor Jesus] Univ Fed Mato Grosso, Cuiaba, Brazil.
   [Costa, Fabio T. M.] Univ Estadual Campinas, Campinas, SP, Brazil.
   [Daniel-Ribeiro, Claudio Tadeu] Fiocruz MS, Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.
   [Lacerda, Marcus V. G.] Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [Lacerda, Marcus V. G.] Fiocruz MS, Fundacao Oswaldo Cruz, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil.
RP Siqueira, AM (corresponding author), Fiocruz MS, Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Ave Brasil 4365, BR-21040360 Rio De Janeiro, Brazil.
EM andre.siqueira@ini.fiocruz.br; oscar.lapouble@gmail.com;
   paola.b.marchesini@gmail.com; vandersons@gmail.com;
   patricia.brasil@ini.fiocruz.br; pltauil@unb.br; corfontes@gmail.com;
   fabiotmc72@gmail.com; ctdr@uol.com.br; marcuslacerda.br@gmail.com;
   camilapdamasceno@gmail.com; anacarolina.santelli@gmail.com
RI Sampaio, Vanderson/AAQ-1418-2020; Sampaio, Vanderson/M-4337-2015; Costa,
   Fabio/E-1181-2012; Siqueira, Andre M/G-1340-2010; Daniel-Ribeiro,
   Claudio Tadeu/G-2216-2015; Fontes, Cor JF/G-7331-2018
OI Sampaio, Vanderson/0000-0001-7307-8851; Sampaio,
   Vanderson/0000-0001-7307-8851; Costa, Fabio/0000-0001-9969-7300;
   Siqueira, Andre M/0000-0003-2208-0294; Fontes, Cor
   JF/0000-0003-2756-0588; Mesones Lapouble, Oscar/0000-0002-6153-3594
CR Alecrim M das G, 1999, Rev Soc Bras Med Trop, V32, P67
   Alecrim MG, 2006, AM J TROP MED HYG, V74, P20, DOI 10.4269/ajtmh.2006.74.20
   [Anonymous], 2013, B EPIDEMIOL, V44, P1
   Ballut PC, 2013, ACTA TROP, V128, P504, DOI 10.1016/j.actatropica.2013.07.008
   Barreto ML, 2011, LANCET, V377, P1877, DOI 10.1016/S0140-6736(11)60202-X
   Battle KE, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-144
   BOULOS M, 1991, REV I MED TROP, V33, P143, DOI 10.1590/S0036-46651991000200009
   Bousema T, 2011, CLIN MICROBIOL REV, V24, P377, DOI 10.1128/CMR.00051-10
   Brasil P, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-122
   Braz RM, 2013, CAD SAUDE PUBLICA, V29, P935, DOI 10.1590/S0102-311X2013000500011
   Cohen JM, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-122
   Coimbra CEA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-52
   Cunha MG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113357
   de Araujo FCF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049871
   Costa KMD, 2010, REV PANAM SALUD PUBL, V28, P353
   de Oliveira FP, 2015, INTERFACE-BOTUCATU, V19, P623, DOI 10.1590/1807-57622014.1142
   de Pina-Costa A, 2014, MEM I OSWALDO CRUZ, V109, P618, DOI 10.1590/0074-0276140228
   dos Reis IC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137521
   de Santana FS, 2007, EMERG INFECT DIS, V13, P1125, DOI 10.3201/eid1307.061386
   Foley DH, 2014, J VECTOR ECOL, V39, P168, DOI 10.1111/j.1948-7134.2014.12084.x
   Mourao MPG, 2015, REV SOC BRAS MED TRO, V48, P20, DOI 10.1590/0037-8682-0133-2013
   Griffing SM, 2015, MEM I OSWALDO CRUZ, V110, P701, DOI 10.1590/0074-02760150041
   Imwong M, 2007, J INFECT DIS, V195, P927, DOI 10.1086/512241
   Imwong M, 2012, J INFECT DIS, V205, P680, DOI 10.1093/infdis/jir806
   Katsuragawa TH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009245
   Katsuragawa TH, 2009, CAD SAUDE PUBLICA, V25, P1486, DOI 10.1590/S0102-311X2009000700006
   KLEIN TA, 1991, AM J TROP MED HYG, V45, P463, DOI 10.4269/ajtmh.1991.45.463
   Lacerda MVG, 2012, CLIN INFECT DIS, V55, pE67, DOI 10.1093/cid/cis615
   Lacerda MVG, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-12
   Ladeia-Andrade S, 2016, AM J TROP MED HYG, V95, P148, DOI 10.4269/ajtmh.16-0017
   Ladeia-Andrade S, 2009, AM J TROP MED HYG, V80, P452, DOI 10.4269/ajtmh.2009.80.452
   Llanos-Cuentas A, 2014, LANCET, V383, P1049, DOI 10.1016/S0140-6736(13)62568-4
   Magalhaes BML, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003239
   Martins-Campos KM, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-351
   Ministerio da Saude, 2010, GUIA PRAT TRAT MAL B
   Monteiro WM, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-70
   Morais SA, 2012, REV INST MED TROP SP, V54, P331, DOI 10.1590/S0036-46652012000600008
   Oliveira-Ferreira J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-115
   Pedro RS, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-245
   Pereira EA, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-355
   Ramos WM, 2010, BRAZ J INFECT DIS, V14, P410, DOI 10.1590/S1413-86702010000400017
   Sampaio VS, 2015, REV SOC BRAS MED TRO, V48, P4, DOI 10.1590/0037-8682-0275-2014
   Santana MS, 2013, T ROY SOC TROP MED H, V107, P301, DOI 10.1093/trstmh/trt015
   Santana MS, 2007, REV SOC BRAS MED TRO, V40, P533, DOI 10.1590/S0037-86822007000500008
   Santelli AC, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-286
   Santos-Ciminera PD, 2007, EMERG INFECT DIS, V13, P1597, DOI 10.3201/eid1310.070052
   Scarpassa VM, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1217-6
   Shanks GD, 2012, ADV PARASIT, V80, P301, DOI 10.1016/B978-0-12-397900-1.00006-2
   Simoes LR, 2014, CAD SAUDE PUBLICA, V30, P1403, DOI 10.1590/0102-311X00169312
   Siqueira AM, 2014, SLEEPLESS LIVER
   Siqueira AM, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0302-y
   Siqueira AM, 2014, MEM I OSWALDO CRUZ, V109, P540, DOI 10.1590/0074-0276130068
   Siqueira AM, 2014, MEM I OSWALDO CRUZ, V109, P569, DOI 10.1590/0074-0276140132
   Gil LHS, 2015, REV INST MED TROP SP, V57, P263, DOI 10.1590/S0036-46652015000300014
   Tadei WP, 1998, AM J TROP MED HYG, V59, P325, DOI 10.4269/ajtmh.1998.59.325
   Val FF, 2014, MEM I OSWALDO CRUZ, V109, P522, DOI 10.1590/0074-0276140240
   Vasconcelos Cíntia Honório, 2006, Cad. Saúde Pública, V22, P517, DOI 10.1590/S0102-311X2006000300006
   Vitor-Silva S, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1326-2
   World Health Organization, 2015, WORLD MAL REP 2015
NR 59
TC 27
Z9 27
U1 0
U2 1
PU AMER SOC TROP MED & HYGIENE
PI MCLEAN
PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA
SN 0002-9637
EI 1476-1645
J9 AM J TROP MED HYG
JI Am. J. Trop. Med. Hyg.
PY 2016
VL 95
IS 6
SU S
BP 87
EP 96
DI 10.4269/ajtmh.16-0204
PG 10
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA EW6HU
UT WOS:000402611300009
PM 27708190
OA Other Gold, Green Published
DA 2020-12-08
ER

PT J
AU Vera, O
   de Brito, PB
   Albrecht, L
   Martins-Campos, KM
   Pimenta, PFP
   Monteiro, WM
   Lacerda, MVG
   Lopes, SCP
   Costa, FTM
AF Vera, Omaira
   de Brito, Paula Brelas
   Albrecht, Letusa
   Monick Martins-Campos, Keillen
   Pimenta, Paulo F. P.
   Monteiro, Wuelton M.
   Lacerda, Marcus V. G.
   Lopes, Stefanie C. P.
   Costa, Fabio T. M.
TI Purification Methodology for Viable and Infective Plasmodium vivax
   Gametocytes That Is Compatible with Transmission-Blocking Assays
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID MALARIA; BLOOD
AB Significant progress toward the control of malaria has been achieved, especially regarding Plasmodium falciparum infections. However, the unique biology of Plasmodium vivax hampers current control strategies. The early appearance of P. vivax gametocytes in the peripheral blood and the impossibility of culturing this parasite are major drawbacks. Using blood samples from 40 P. vivax-infected patients, we describe here a methodology to purify viable gametocytes and further infect anophelines. This method opens new avenues to validate transmission-blocking strategies.
C1 [Vera, Omaira; Albrecht, Letusa; Lopes, Stefanie C. P.; Costa, Fabio T. M.] Univ Estadual Campinas, UNICAMP, Dept Genet Evolucao & Bioagentes, Sao Paulo, Brazil.
   [Vera, Omaira; de Brito, Paula Brelas; Monick Martins-Campos, Keillen; Monteiro, Wuelton M.; Lacerda, Marcus V. G.; Lopes, Stefanie C. P.] Fundacao Med Trop Dr Heitor Vieira Dourado, Gerencia Malaria, Manaus, Amazonas, Brazil.
   [Albrecht, Letusa] Fiocruz MS, Fundacao Oswaldo Cruz, Inst Carlos Chagas, Curitiba, Parana, Brazil.
   [Monick Martins-Campos, Keillen; Monteiro, Wuelton M.] Univ Estado Amazonas, Escola Super Ciencias Saude, Manaus, Amazonas, Brazil.
   [Pimenta, Paulo F. P.] Fiocruz MS, Fundacao Oswaldo Cruz, Ctr Pesquisas Rene Rachou, Belo Horizonte, MG, Brazil.
   [Lacerda, Marcus V. G.; Lopes, Stefanie C. P.] Fiocruz MS, Fundacao Oswaldo Cruz, Inst Leonidas Maria Deane, Manaus, Amazonas, Brazil.
RP Lopes, SCP (corresponding author), Univ Estadual Campinas, UNICAMP, Dept Genet Evolucao & Bioagentes, Sao Paulo, Brazil.
EM stefaniecplopes@gmail.com; fabiotmc72@gmail.com
RI Albrecht, Letusa/I-1837-2012; Pimenta, Paulo/AAH-1502-2020; Lopes,
   Stefanie/A-8314-2012; Costa, Fabio/E-1181-2012
OI Albrecht, Letusa/0000-0001-6406-2057; Costa, Fabio/0000-0001-9969-7300;
   Lopes, Stefanie/0000-0002-6981-2192
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/16525-2];
   Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)Minas
   Gerais State Research Foundation (FAPEMIG); Fundacao de Amparo a
   Pesquisa do Estado do Amazonas (FAPEAM) [PPSUS 62.00652/2014]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National
   Council for Scientific and Technological Development (CNPq); FAPESP
   fellowshipsFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP) (grant 2012/16525-2), the Fundacao de Amparo a
   Pesquisa do Estado de Minas Gerais (FAPEMIG), the Fundacao de Amparo a
   Pesquisa do Estado do Amazonas (FAPEAM) (grant PPSUS 62.00652/2014), and
   the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq). O.V., L.A., and S.C.P.L. were sponsored by FAPESP fellowships.
   F.T.M.C., P.F.P.P., and M.V.G.L. are level 1 CNPq research fellows.
CR Bousema T, 2011, CLIN MICROBIOL REV, V24, P377, DOI 10.1128/CMR.00051-10
   Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815
   Goncalves LA, 2014, MEM I OSWALDO CRUZ, V109, P534, DOI 10.1590/0074-0276130579
   Lopes SCP, 2014, J INFECT DIS, V209, P1403, DOI 10.1093/infdis/jiu018
   Moreno M, 2014, AM J TROP MED HYG, V90, P612, DOI 10.4269/ajtmh.13-0708
   Noulin F, 2013, TRENDS PARASITOL, V29, P286, DOI 10.1016/j.pt.2013.03.012
   Oliveira-Ferreira J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-115
   Price RN, 2014, LANCET INFECT DIS, V14, P982, DOI 10.1016/S1473-3099(14)70855-2
   Ribaut C, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-45
   Rios-Velasquez CM, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-460
   Sinka ME, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-72
   Sriprawat K, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-115
NR 12
TC 3
Z9 3
U1 0
U2 1
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD OCT
PY 2015
VL 59
IS 10
BP 6638
EP 6641
DI 10.1128/AAC.01136-15
PG 4
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA DA1YJ
UT WOS:000367591800099
PM 26239989
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Leite, JA
   Bargieri, DY
   Carvalho, BO
   Albrecht, L
   Lopes, SCP
   Kayano, ACAV
   Farias, AS
   Chia, WN
   Claser, C
   Malleret, B
   Russell, B
   Castineiras, C
   Santos, LMB
   Brocchi, M
   Wunderlich, G
   Soares, IS
   Rodrigues, MM
   Renia, L
   Costa, FTM
AF Leite, Juliana A.
   Bargieri, Daniel Y.
   Carvalho, Bruna O.
   Albrecht, Letusa
   Lopes, Stefanie C. P.
   Kayano, Ana Carolina A. V.
   Farias, Alessandro S.
   Chia, Wan Ni
   Claser, Carla
   Malleret, Benoit
   Russell, Bruce
   Castineiras, Catarina
   Santos, Leonilda M. B.
   Brocchi, Marcelo
   Wunderlich, Gerhard
   Soares, Irene S.
   Rodrigues, Mauricio M.
   Renia, Laurent
   Costa, Fabio T. M.
TI Immunization with the MAEBL M2 Domain Protects against Lethal Plasmodium
   yoelii Infection
SO INFECTION AND IMMUNITY
LA English
DT Article
ID MEROZOITE SURFACE PROTEIN-1; TERMINAL FRAGMENT; ACQUIRED-IMMUNITY;
   FALCIPARUM MAEBL; MALARIA VACCINE; INNATE IMMUNITY; SPOROZOITE;
   ANTIBODIES; INVASION; CHALLENGES
AB Malaria remains a world-threatening disease largely because of the lack of a long-lasting and fully effective vaccine. MAEBL is a type 1 transmembrane molecule with a chimeric cysteine-rich ectodomain homologous to regions of the Duffy binding-like erythrocyte binding protein and apical membrane antigen 1 (AMA1) antigens. Although MAEBL does not appear to be essential for the survival of blood-stage forms, ectodomains M1 and M2, homologous to AMA1, seem to be involved in parasite attachment to erythrocytes, especially M2. MAEBL is necessary for sporozoite infection of mosquito salivary glands and is expressed in liver stages. Here, the Plasmodium yoelii MAEBL-M2 domain was expressed in a prokaryotic vector. C57BL/6J mice were immunized with doses of P. yoelii recombinant protein rPyM2-MAEBL. High levels of antibodies, with balanced IgG1 and IgG2c subclasses, were achieved. rPyM2-MAEBL antisera were capable of recognizing the native antigen. Anti-MAEBL antibodies recognized different MAEBL fragments expressed in CHO cells, showing stronger IgM and IgG responses to the M2 domain and repeat region, respectively. After a challenge with P. yoelii YM (lethal strain)-infected erythrocytes (IE), up to 90% of the immunized animals survived and a reduction of parasitemia was observed. Moreover, splenocytes harvested from immunized animals proliferated in a dose-dependent manner in the presence of rPyM2-MAEBL. Protection was highly dependent on CD4(+), but not CD8(+), T cells toward Th1. rPyM2-MAEBL antisera were also able to significantly inhibit parasite development, as observed in ex vivo P. yoelii erythrocyte invasion assays. Collectively, these findings support the use of MAEBL as a vaccine candidate and open perspectives to understand the mechanisms involved in protection.
C1 [Leite, Juliana A.; Carvalho, Bruna O.; Albrecht, Letusa; Lopes, Stefanie C. P.; Kayano, Ana Carolina A. V.; Farias, Alessandro S.; Castineiras, Catarina; Santos, Leonilda M. B.; Brocchi, Marcelo; Costa, Fabio T. M.] Univ Campinas UNICAMP, Dept Genet Evolut & Bioagents, Campinas, SP, Brazil.
   [Bargieri, Daniel Y.; Wunderlich, Gerhard] Univ Sao Paulo, Dept Parasitol, Sao Paulo, SP, Brazil.
   [Carvalho, Bruna O.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Oswaldo Cruz, Rio De Janeiro, RJ, Brazil.
   [Albrecht, Letusa] Fundacao Oswaldo Cruz FIOCRUZ, Inst Carlos Chagas, Curitiba, Parana, Brazil.
   [Lopes, Stefanie C. P.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil.
   [Chia, Wan Ni; Claser, Carla; Malleret, Benoit; Russell, Bruce; Renia, Laurent] ASTAR, Singapore Immunol Network, Singapore, Singapore.
   [Soares, Irene S.] Univ Sao Paulo, Dept Clin & Toxicol Anal, Pharmaceut Sci, Sao Paulo, SP, Brazil.
   [Rodrigues, Mauricio M.] Univ Fed Sao Paulo, Ctr Cellular & Mol Therapy CTCMol, Sao Paulo, SP, Brazil.
RP Costa, FTM (corresponding author), Univ Campinas UNICAMP, Dept Genet Evolut & Bioagents, Campinas, SP, Brazil.
EM fabiotmc72@gmail.com
RI Soares, Irene Silva/C-5974-2012; Malleret, Benoit/AAK-4048-2020;
   Bargieri, Daniel Youssef/A-4461-2013; Albrecht, Letusa/I-1837-2012;
   Costa, Fabio/E-1181-2012; Wunderlich, Gerhard/G-8245-2012; Farias,
   Alessandro/C-6879-2012; Claser, Carla/P-2736-2018; Brocchi,
   Marcelo/E-3723-2012; Malleret, Benoit/E-9159-2011; Russell,
   Bruce/A-9240-2011; Farias, Alessandro/AAH-2228-2020
OI Soares, Irene Silva/0000-0002-3336-6856; Malleret,
   Benoit/0000-0001-9658-7528; Bargieri, Daniel
   Youssef/0000-0003-2564-3742; Albrecht, Letusa/0000-0001-6406-2057;
   Costa, Fabio/0000-0001-9969-7300; Wunderlich,
   Gerhard/0000-0003-1724-0337; Farias, Alessandro/0000-0001-6759-1819;
   Claser, Carla/0000-0002-5395-9632; Malleret, Benoit/0000-0001-9658-7528;
   Russell, Bruce/0000-0003-2333-4348; Farias,
   Alessandro/0000-0001-6759-1819; Lopes, Stefanie/0000-0002-6981-2192
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Instituto Nacional de
   Ciencia e Tecnologia de Vacinas (INCTV); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); FAPESP
   fellowshipsFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP); CNPq fellowshipNational Council for Scientific and
   Technological Development (CNPq); SIgN under the Agency for Science,
   Technology and Research (A*STAR, Singapore)Agency for Science Technology
   & Research (ASTAR); Yong Loo Lin School of Medicine, National University
   of SingaporeNational University of Singapore
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP), the Instituto Nacional de Ciencia e Tecnologia de
   Vacinas (INCTV), and the Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPq). J.A.L., B.O.C., L.A., S.C.P.L., A.C.A.V.K.,
   D.Y.B., and A.S.F. were sponsored by FAPESP fellowships. C.C. was
   supported by a CNPq fellowship. F.T.M.C., I.S.S., M.M.R., L.M.B.S.,
   M.B., and G.W. are CNPq research fellows. We thank Ana Leda F. Longhini
   for the help with the CBA kit analysis. This study, B.M., C.C., and B.R.
   received funding from SIgN under the Agency for Science, Technology and
   Research (A*STAR, Singapore). W.N.C. is supported by a postgraduate
   scholarship from the Yong Loo Lin School of Medicine, National
   University of Singapore. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Arama C, 2014, J INTERN MED, V275, P456, DOI 10.1111/joim.12223
   Barbedo MB, 2007, MEM I OSWALDO CRUZ, V102, P335, DOI 10.1590/S0074-02762007005000040
   Bargieri DY, 2010, VACCINE, V28, P2818, DOI 10.1016/j.vaccine.2010.02.004
   Blair PL, 2002, MOL BIOCHEM PARASIT, V122, P35, DOI 10.1016/S0166-6851(02)00067-1
   Chia WN, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00586
   COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0
   Crompton PD, 2014, ANNU REV IMMUNOL, V32, P157, DOI 10.1146/annurev-immunol-032713-120220
   Doolan DL, 2009, CLIN MICROBIOL REV, V22, P13, DOI 10.1128/CMR.00025-08
   Douglas AD, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1615
   Ellis RD, 2010, HUM VACCINES, V6, P627, DOI 10.4161/hv.6.8.11446
   FAHEY JR, 1984, INFECT IMMUN, V44, P151, DOI 10.1128/IAI.44.1.151-156.1984
   Fu J, 2005, MOL BIOCHEM PARASIT, V141, P113, DOI 10.1016/j.molbiopara.2004.12.017
   Ghai M, 2002, MOL BIOCHEM PARASIT, V123, P35, DOI 10.1016/S0166-6851(02)00123-8
   Heppner DG, 2013, TRAVEL MED INFECT DI, V11, P2, DOI 10.1016/j.tmaid.2013.01.006
   Hirunpetcharat C, 1997, J IMMUNOL, V159, P3400
   Jeamwattanalert P, 2007, CLIN VACCINE IMMUNOL, V14, P342, DOI 10.1128/CVI.00397-06
   Kappe SHI, 1998, P NATL ACAD SCI USA, V95, P1230, DOI 10.1073/pnas.95.3.1230
   Kappe SHI, 2001, P NATL ACAD SCI USA, V98, P9895, DOI 10.1073/pnas.171185198
   Kappe SHI, 2010, SCIENCE, V328, P862, DOI 10.1126/science.1184785
   Kariu T, 2002, J EXP MED, V195, P1317, DOI 10.1084/jem.20011876
   Kocken CHM, 2000, MOL BIOCHEM PARASIT, V109, P147, DOI 10.1016/S0166-6851(00)00250-4
   Marsh K, 2006, PARASITE IMMUNOL, V28, P51, DOI 10.1111/j.1365-3024.2006.00808.x
   MCGREGOR IA, 1964, AM J TROP MED HYG, V13, P237, DOI 10.4269/ajtmh.1964.13.237
   Michon P, 2002, MOL BIOL EVOL, V19, P1128, DOI 10.1093/oxfordjournals.molbev.a004171
   Noe AR, 1998, MOL BIOCHEM PARASIT, V96, P27, DOI 10.1016/S0166-6851(98)00084-X
   Preiser P, 2004, INFECT IMMUN, V72, P3604, DOI 10.1128/IAI.72.6.3604-3608.2004
   Russell B, 2011, BLOOD, V118, pE74, DOI 10.1182/blood-2011-04-348748
   SABCHAREON A, 1991, AM J TROP MED HYG, V45, P297, DOI 10.4269/ajtmh.1991.45.297
   Saenz FE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002287
   Sagara I, 2009, VACCINE, V27, P7292, DOI 10.1016/j.vaccine.2009.10.087
   Sheehy SH, 2013, HUM VACC IMMUNOTHER, V9, P1831, DOI 10.4161/hv.25383
   Sheehy SH, 2012, MOL THER, V20, P2355, DOI 10.1038/mt.2012.223
   Singh N, 2004, J MOL BIOL, V343, P589, DOI 10.1016/j.jmb.2004.08.047
   Sirima SB, 2011, NEW ENGL J MED, V365, P1062, DOI 10.1056/NEJMc1100670
   Sriprawat K, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-115
   Stevenson MM, 2004, NAT REV IMMUNOL, V4, P169, DOI 10.1038/nri1311
   Swardson-Olver CJ, 2002, BLOOD, V99, P2677, DOI 10.1182/blood.V99.8.2677
   Thera MA, 2011, NEW ENGL J MED, V365, P1004, DOI 10.1056/NEJMoa1008115
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Trang DTX, 2004, MALARIA J, V3, DOI 10.1186/1475-2875-3-7
   WHO, 2013, WORLD MALARIA REPORT 2013, P1
   Woehlbier U, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-77
NR 42
TC 7
Z9 7
U1 0
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD OCT
PY 2015
VL 83
IS 10
BP 3781
EP 3792
DI 10.1128/IAI.00262-15
PG 12
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA CT0NJ
UT WOS:000362492600003
PM 26169268
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Almeida, CB
   Souza, LEB
   Leonardo, FC
   Costa, FTM
   Werneck, CC
   Covas, DT
   Costa, FF
   Conran, N
AF Almeida, Camila Bononi
   Botelho Souza, Lucas Eduardo
   Leonardo, Flavia Costa
   Maranhao Costa, Fabio Trindade
   Werneck, Claudio C.
   Covas, Dimas Tadeu
   Costa, Fernando Ferreira
   Conran, Nicola
TI Acute hemolytic vascular inflammatory processes are prevented by nitric
   oxide replacement or a single dose of hydroxyurea
SO BLOOD
LA English
DT Article
ID SICKLE-CELL-DISEASE; INTRAVASCULAR HEMOLYSIS; PLASMA HEMOGLOBIN;
   PULMONARY-ARTERY; HEME; ACTIVATION; ANEMIA; DYSFUNCTION; EXPRESSION;
   ADHESION
AB Hemolysis and consequent release of cell-free hemoglobin (CFHb) impair vascular nitric oxide (NO) bioavailability and cause oxidative and inflammatory processes. Hydroxyurea (HU), a common therapy for sickle cell disease (SCD), induces fetal Hb production and can act as an NO donor. We evaluated the acute inflammatory effects of intravenous water-induced hemolysis in C57BL/6 mice and determined the abilities of an NO donor, diethylamine NONOate (DEANO), and a single dose of HU to modulate this inflammation. Intravenous water induced acute hemolysis in C57BL/6 mice, attaining plasma Hb levels comparable to those observed in chimeric SCD mice. This hemolysis resulted in significant and rapid systemic inflammation and vascular leukocyte recruitment within 15 minutes, accompanied by NO metabolite generation. Administration of another potent NO scavenger (2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide) to C57BL/6 mice induced similar alterations in leukocyte recruitment, whereas hemin-induced inflammation occurred over a longer timeframe. Importantly, the acute inflammatory effects of water-induced hemolysis were abolished by the simultaneous administration of DEANO or HU, without altering CFHb, in an NO pathway mediated manner. In vitro, HU partially reversed the Hb-mediated induction of endothelial proinflammatory cytokine secretion and adhesion molecule expression. In summary, pathophysiological levels of hemolysis trigger an immediate inflammatory response, possibly mediated by vascular NO consumption. HU presents beneficial anti-inflammatory effects by inhibiting rapid-onset hemolytic inflammation via an NO-dependent mechanism, independently of fetal Hb elevation. Data provide novel insights into mechanisms of hemolytic inflammation and further support perspectives for the use of HU as an acute treatment for SCD and other hemolytic disorders.
C1 [Almeida, Camila Bononi; Leonardo, Flavia Costa; Costa, Fernando Ferreira; Conran, Nicola] Univ Estadual Campinas, UNICAMP, Hematol Ctr, Campinas, SP, Brazil.
   [Almeida, Camila Bononi] Hosp Israelita Albert Einstein, Inst Israelita Ensino & Pesquisa Albert Einstein, Sao Paulo, Brazil.
   [Botelho Souza, Lucas Eduardo; Covas, Dimas Tadeu] Univ Sao Paulo, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil.
   [Maranhao Costa, Fabio Trindade] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut & Bioagents, Campinas, SP, Brazil.
   [Werneck, Claudio C.] Univ Estadual Campinas, Inst Biol, Dept Biochem & Tissue Biol, Campinas, SP, Brazil.
RP Conran, N (corresponding author), Hemocentro, Rua Carlos Chagas 480,Cidade Univ, BR-13083878 Campinas, SP, Brazil.
EM conran@unicamp.br
RI Werneck, Claudio C/C-7568-2012; Conran, Nicola/B-8961-2012; Covas, Dimas
   T/C-5431-2013; Costa, Fabio/E-1181-2012; de Souza, Lucas E.
   B./F-8743-2015; Souza, Lucas E. B./W-7139-2019; Costa,
   Fernando/D-1566-2012; CTC USP, CEPID 13 18/J-8951-2014
OI Werneck, Claudio C/0000-0002-9413-0572; Conran,
   Nicola/0000-0001-5726-7919; Covas, Dimas T/0000-0002-7364-2595; Costa,
   Fabio/0000-0001-9969-7300; de Souza, Lucas E. B./0000-0003-4254-7509;
   Souza, Lucas E. B./0000-0003-4254-7509; Costa,
   Fernando/0000-0002-4632-572X; Almeida, Camila/0000-0002-1253-2165; CTC
   USP, CEPID 13 18/0000-0002-7123-9524
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Sao Paulo,
   BrazilFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2008/50582-3, 11/50959-7]; Conselho Nacional de Desenvolvimento
   Cientifico e TecnologicoNational Council for Scientific and
   Technological Development (CNPq) [565036/2010, 307784/2013-4]
FX This work was supported by grants No. 2008/50582-3 and 11/50959-7
   (C.B.A.) from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo, Sao
   Paulo, Brazil, and grants No. 565036/2010 and 307784/2013-4 (C.C.W.)
   from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico.
CR Almeida CB, 2012, BLOOD, V120, P2879, DOI 10.1182/blood-2012-02-409524
   Barbui T, 2012, BLOOD REV, V26, P205, DOI 10.1016/j.blre.2012.06.002
   Belcher JD, 2014, BLOOD, V123, P377, DOI 10.1182/blood-2013-04-495887
   Belcher JD, 2010, ANTIOXID REDOX SIGN, V12, P233, DOI 10.1089/ars.2009.2822
   Berra L, 2014, AM J RESP CRIT CARE, V190, P800, DOI 10.1164/rccm.201405-0850OC
   Canalli AA, 2008, HAEMATOLOGICA, V93, P605, DOI 10.3324/haematol.12119
   Cervantes F, 2014, BLOOD, V124, P2635, DOI 10.1182/blood-2014-07-575373
   Chang JS, 2008, BLOOD, V111, P915, DOI 10.1182/blood-2007-04-084061
   CHARACHE S, 1995, NEW ENGL J MED, V332, P1317, DOI 10.1056/NEJM199505183322001
   Charache S, 1996, MEDICINE, V75, P300, DOI 10.1097/00005792-199611000-00002
   Chen G, 2014, BLOOD, V123, P3818, DOI 10.1182/blood-2013-10-529982
   Cokic VP, 2008, BLOOD, V111, P1117, DOI 10.1182/blood-2007-05-088732
   Cokic VP, 2006, BLOOD, V108, P184, DOI 10.1182/blood-2005-11-4454
   Conran N, 2003, BIOCHEM PHARMACOL, V66, P43, DOI 10.1016/S0006-2952(03)00243-0
   Conran N, 2001, BRIT J PHARMACOL, V134, P632, DOI 10.1038/sj.bjp.0704295
   Conran N, 2014, ACTA HAEMATOL-BASEL, V132, P97, DOI 10.1159/000356836
   De Forni D, 2010, BRIT J PHARMACOL, V161, P830, DOI 10.1111/j.1476-5381.2010.00940.x
   Dutra FF, 2014, P NATL ACAD SCI USA, V111, pE4110, DOI 10.1073/pnas.1405023111
   El Nemer W, 2012, BLOOD, V120, P2777, DOI 10.1182/blood-2012-08-447102
   FAIRBANKS VF, 1992, CLIN CHEM, V38, P132
   Gladwin MT, 2002, BRIT J HAEMATOL, V116, P436, DOI 10.1046/j.1365-2141.2002.03274.x
   Glover RE, 1999, MOL PHARMACOL, V55, P1006
   GOLDBERG MA, 1990, NEW ENGL J MED, V323, P366, DOI 10.1056/NEJM199008093230602
   Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160
   IGNARRO LJ, 1987, CIRC RES, V61, P866, DOI 10.1161/01.RES.61.6.866
   Kato GJ, 2009, BRIT J HAEMATOL, V145, P506, DOI 10.1111/j.1365-2141.2009.07658.x
   Kaul DK, 2004, AM J PHYSIOL-HEART C, V287, pH293, DOI 10.1152/ajpheart.01150.2003
   King SB, 2004, FREE RADICAL BIO MED, V37, P737, DOI 10.1016/j.freeradbiomed.2004.02.073
   Manci EA, 2006, BLOOD, V107, P1651, DOI 10.1182/blood-2005-07-2839
   McGann PT, 2011, CURR OPIN HEMATOL, V18, P158, DOI 10.1097/MOH.0b013e32834521dd
   Minneci PC, 2005, J CLIN INVEST, V115, P3409, DOI 10.1172/JCI25040
   Nahavandi Masoud, 2000, Hematology, V5, P335
   Neumann B, 1997, J IMMUNOL, V158, P1862
   Olsson MG, 2012, ANTIOXID REDOX SIGN, V17, P813, DOI 10.1089/ars.2011.4282
   Porto BN, 2007, J BIOL CHEM, V282, P24430, DOI 10.1074/jbc.M703570200
   Qian J, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00003
   Qutub Y, 2010, J PHYS CHEM B, V114, P4529, DOI 10.1021/jp100611n
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Reiter CD, 2002, NAT MED, V8, P1383, DOI 10.1038/nm799
   Rother RP, 2005, JAMA-J AM MED ASSOC, V293, P1653, DOI 10.1001/jama.293.13.1653
   Schaer DJ, 2013, BLOOD, V121, P1276, DOI 10.1182/blood-2012-11-451229
   Senchenkov E, 2011, MICROCIRCULATION, V18, P452, DOI 10.1111/j.1549-8719.2011.00106.x
   Steinberg MH, 2010, AM J HEMATOL, V85, P403, DOI 10.1002/ajh.21699
   Turhan A, 2002, P NATL ACAD SCI USA, V99, P3047, DOI 10.1073/pnas.052522799
   Vinchi F, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/396527
   Vinchi F, 2013, CIRCULATION, V127, P1317, DOI 10.1161/CIRCULATIONAHA.112.130179
   Ware RE, 2010, BLOOD, V115, P5300, DOI 10.1182/blood-2009-04-146852
   Windsant ICV, 2012, CRIT CARE, V16, DOI 10.1186/cc11359
   Wood KC, 2008, FREE RADICAL BIO MED, V44, P1506, DOI 10.1016/j.freeradbiomed.2008.01.008
   Wun T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101301
   Xu C, 2011, NEUROGENETICS, V12, P19, DOI 10.1007/s10048-010-0268-z
   Yeo TW, 2009, J INFECT DIS, V200, P1522, DOI 10.1086/644641
   Yoong WC, 2003, J STEROID BIOCHEM, V84, P71, DOI 10.1016/S0960-0760(02)00266-2
NR 53
TC 45
Z9 48
U1 0
U2 11
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD AUG 6
PY 2015
VL 126
IS 6
BP 711
EP 720
DI 10.1182/blood-2014-12-616250
PG 10
WC Hematology
SC Hematology
GA CQ3RG
UT WOS:000360519600006
PM 26019278
OA Bronze
DA 2020-12-08
ER

PT J
AU Verinaud, L
   Lopes, SCP
   Prado, ICN
   Zanucoli, F
   da Costa, TA
   Di Gangi, R
   Issayama, LK
   Carvalho, AC
   Bonfanti, AP
   Niederauer, GF
   Duran, N
   Costa, FTM
   Oliveira, ALR
   Hofling, MAD
   Machado, DRS
   Thome, R
AF Verinaud, Liana
   Pinto Lopes, Stefanie Costa
   Naranjo Prado, Isabel Cristina
   Zanucoli, Fabio
   da Costa, Thiago Alves
   Di Gangi, Rosaria
   Issayama, Luidy Kazuo
   Carvalho, Ana Carolina
   Bonfanti, Amanda Pires
   Niederauer, Guilherme Francio
   Duran, Nelson
   Maranhao Costa, Fabio Trindade
   Rodrigues Oliveira, Alexandre Leite
   da Cruz Hoefling, Maria Alice
   Stach Machado, Dagmar Ruth
   Thome, Rodolfo
TI Violacein Treatment Modulates Acute and Chronic Inflammation through the
   Suppression of Cytokine Production and Induction of Regulatory T Cells
SO PLOS ONE
LA English
DT Article
ID COLLAGEN-INDUCED ARTHRITIS; DENDRITIC CELLS; CHROMOBACTERIUM-VIOLACEUM;
   IN-VITRO; CHLOROQUINE; TOLERANCE; SECRETION; DISEASE; IL-17; TREG
AB Inflammation is a necessary process to control infection. However, exacerbated inflammation, acute or chronic, promotes deleterious effects in the organism. Violacein (viola), a quorum sensing metabolite from the Gram-negative bacterium Chromobacterium violaceum, has been shown to protect mice from malaria and to have beneficial effects on tumors. However, it is not known whether this drug possesses anti-inflammatory activity. In this study, we investigated whether viola administration is able to reduce acute and chronic autoimmune inflammation. For that purpose, C57BL/6 mice were intraperitoneally injected with 1 mu g of LPS and were treated with viola (3.5mg/kg) via i.p. at the same time-point. Three hours later, the levels of inflammatory cytokines in the sera and phenotypical characterization of leukocytes were determined. Mice treated with viola presented a significant reduction in the production of inflammatory cytokines compared with untreated mice. Interestingly, although viola is a compound derived from bacteria, it did not induce inflammation upon administration to naive mice. To test whether viola would protect mice from an autoimmune inflammation, Experimental Autoimmune Encephalomyelitis (EAE)-inflicted mice were given viola i.p. at disease onset, at the 10th day from immunization. Viola-treated mice developed mild EAE disease in contrast with placebo-treated mice. The frequencies of dendritic cells and macrophages were unaltered in EAE mice treated with viola. However, the sole administration of viola augmented the levels of splenic regulatory T cells (CD4+ Foxp3+). We also found that adoptive transfer of viola-elicited regulatory T cells significantly reduced EAE. Our study shows, for the first time, that violacein is able to modulate acute and chronic inflammation. Amelioration relied in suppression of cytokine production (in acute inflammation) and stimulation of regulatory T cells (in chronic inflammation). New studies must be conducted in order to assess the possible use of viola in therapeutic approaches in human autoimmune diseases.
C1 [Verinaud, Liana; Zanucoli, Fabio; da Costa, Thiago Alves; Di Gangi, Rosaria; Issayama, Luidy Kazuo; Carvalho, Ana Carolina; Bonfanti, Amanda Pires; Niederauer, Guilherme Francio; Rodrigues Oliveira, Alexandre Leite; Stach Machado, Dagmar Ruth; Thome, Rodolfo] Univ Estadual Campinas, Inst Biol, Dept Struct & Funct Biol, Campinas, SP, Brazil.
   [Pinto Lopes, Stefanie Costa; Naranjo Prado, Isabel Cristina; Maranhao Costa, Fabio Trindade] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut & Bioagents, Campinas, SP, Brazil.
   [Duran, Nelson] Univ Estadual Campinas, Inst Chem, Biol Chem Lab, Campinas, SP, Brazil.
   [Duran, Nelson] Univ Estadual Campinas, Inst Chem, Lab Nanostruct Synth & Biosyst Interact NanoBioss, Campinas, SP, Brazil.
   [da Cruz Hoefling, Maria Alice] Univ Estadual Campinas, Inst Biol, Dept Histol & Embryol, Campinas, SP, Brazil.
RP Thome, R (corresponding author), Univ Estadual Campinas, Inst Biol, Dept Struct & Funct Biol, Campinas, SP, Brazil.
EM rodolfo.thome@gmail.com
RI Costa, Fabio/E-1181-2012; Lopes, Stefanie/A-8314-2012; Thome,
   Rodolfo/C-1564-2012; Oliveira, Alexandre/AAI-6815-2020; da Costa, Thiago
   Alves/F-8187-2016; Oliveira, Alexandre L. R./C-4436-2012
OI Costa, Fabio/0000-0001-9969-7300; Thome, Rodolfo/0000-0001-7627-4137;
   Oliveira, Alexandre/0000-0003-4224-4575; Oliveira, Alexandre L.
   R./0000-0003-4224-4575; Alves da Costa, Thiago/0000-0001-9591-331X;
   Bonfanti, Amanda/0000-0003-0896-0105; Lopes,
   Stefanie/0000-0002-6981-2192; Duran, Nelson/0000-0001-8372-5143
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2011/17965-3]; Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq) [471066/2012-5]; FAPESP
   scholarshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2014/02631-0, 2011/23664-6, 2012/01892-0]
FX This work was supported by Sao Paulo Research Foundation (FAPESP, grant
   #2011/17965-3) and Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq grant 471066/2012-5). FTMC and LV are CNPq researcher
   fellows. RT, SCPL and ICNP received FAPESP scholarships (#2014/02631-0,
   #2011/23664-6 and #2012/01892-0, respectively). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ahmed MH, 2003, J PHARMACOL EXP THER, V304, P156, DOI 10.1124/jpet.102.042523
   Alarcon GS, 2007, ANN RHEUM DIS, V66, P1168, DOI 10.1136/ard.2006.068676
   Apostolidis SA, 2011, LUPUS, V20, P120, DOI 10.1177/0961203310389100
   Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387
   Bromberg N, 2010, CHEM-BIOL INTERACT, V186, P43, DOI 10.1016/j.cbi.2010.04.016
   Chauhan SK, 2009, J IMMUNOL, V182, P1247, DOI 10.4049/jimmunol.182.3.1247
   Chu CQ, 2007, ARTHRITIS RHEUM, V56, P1145, DOI 10.1002/art.22453
   de Carvalho DD, 2006, TOXICOL IN VITRO, V20, P1514, DOI 10.1016/j.tiv.2006.06.007
   Domingues HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015531
   Doodes PD, 2010, J IMMUNOL, V184, P1552, DOI 10.4049/jimmunol.0902907
   Duran M, 2010, FOLIA MICROBIOL, V55, P535, DOI 10.1007/s12223-010-0088-4
   Duran M, 2012, MED CHEM RES, V21, P1524, DOI 10.1007/s00044-011-9654-9
   Duran N, 2007, BIOTECHNOL APPL BIOC, V48, P127, DOI 10.1042/BA20070115
   El-Behi M, 2011, NAT IMMUNOL, V12, P568, DOI 10.1038/ni.2031
   Zorzella-Pezavento SFG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/519627
   Grifka-Walk HM, 2013, EUR J IMMUNOL, V43, P2824, DOI 10.1002/eji.201343723
   Hoshino T, 2011, APPL MICROBIOL BIOT, V91, P1463, DOI 10.1007/s00253-011-3468-z
   Kang ZH, 2013, NAT NEUROSCI, V16, P1401, DOI 10.1038/nn.3505
   Lee JH, 2006, IMMUNOLOGY, V117, P280, DOI 10.1111/j.1365-2567.2005.02306.x
   Longhi MP, 2009, J EXP MED, V206, P1589, DOI 10.1084/jem.20090247
   Lopes SCP, 2009, ANTIMICROB AGENTS CH, V53, P2149, DOI 10.1128/AAC.00693-08
   Mangalam AK, 2014, J IMMUNOL, V193, P4859, DOI 10.4049/jimmunol.1302008
   McKenzie BS, 2006, TRENDS IMMUNOL, V27, P17, DOI 10.1016/j.it.2005.10.003
   Palafox D, 2010, TRANSPLANT REV-ORLAN, V24, P160, DOI 10.1016/j.trre.2010.04.003
   Park MJ, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2361
   Pena C, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/296031
   Platt D, 2014, BIOCHEM BIOPH RES CO, V455, P107, DOI 10.1016/j.bbrc.2014.10.124
   Queiroz KCS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045362
   Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122
   Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009
   Subramaniam S, 2014, PHARM BIOL, V52, P86, DOI 10.3109/13880209.2013.815634
   Sun YP, 2009, J IMMUNOL, V182, P5899, DOI 10.4049/jimmunol.0804388
   Thome R, 2014, PLOS ONE IN PRESS
   Thome R, 2013, IMMUNOLOGY LETTERS
   Thome R, 2014, IMMUNOLOGY, V143, P164, DOI 10.1111/imm.12298
   Thome R, 2014, IMMUNOL CELL BIOL, V92, P124, DOI 10.1038/icb.2013.73
   Thome R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065913
   Thome R, 2012, CELL IMMUNOL, V280, P113, DOI 10.1016/j.cellimm.2012.11.017
   Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287
   Unger WWJ, 2009, EUR J IMMUNOL, V39, P3147, DOI 10.1002/eji.200839103
   Verinaud L, 2014, CELLULAR AND MOLECUL
   Wakasa-Morimoto C, 2008, INT IMMUNOL, V20, P1331, DOI 10.1093/intimm/dxn091
   Zanucoli F, 2014, CNS NEUROSCI THER, V20, P1061, DOI 10.1111/cns.12357
   Zhao YG, 2012, J IMMUNOL, V189, P4417, DOI 10.4049/jimmunol.1200919
   Zozulya AL, 2009, J NEUROSCI, V29, P140, DOI 10.1523/JNEUROSCI.2199-08.2009
NR 45
TC 7
Z9 7
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 4
PY 2015
VL 10
IS 5
AR e0125409
DI 10.1371/journal.pone.0125409
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CH3PP
UT WOS:000353943000065
PM 25938431
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Thome, R
   Bombeiro, AL
   Issayama, LK
   Raposo, C
   Lopes, SCP
   da Costa, TA
   Di Gangi, R
   Ferreira, IT
   Longhini, ALF
   Oliveira, ALR
   Hofling, MAD
   Costa, FTM
   Verinaud, L
AF Thome, Rodolfo
   Bombeiro, Andre Luis
   Issayama, Luidy Kazuo
   Raposo, Catarina
   Pinto Lopes, Stefanie Costa
   da Costa, Thiago Alves
   Di Gangi, Rosaria
   Ferreira, Isadora Tassinari
   Figueiredo Longhini, Ana Leda
   Rodrigues Oliveira, Alexandre Leite
   da Cruz Hoefling, Maria Alice
   Maranhao Costa, Fabio Trindade
   Verinaud, Liana
TI Exacerbation of Autoimmune Neuro-Inflammation in Mice Cured from
   Blood-Stage Plasmodium berghei Infection
SO PLOS ONE
LA English
DT Article
ID MYELIN BASIC-PROTEIN; DENDRITIC CELLS; T-CELLS; MULTIPLE-SCLEROSIS;
   STREPTOCOCCAL INFECTIONS; RHEUMATIC-FEVER; IFN-GAMMA; MALARIA;
   ENCEPHALOMYELITIS; IMMUNE
AB The thymus plays an important role shaping the T cell repertoire in the periphery, partly, through the elimination of inflammatory auto-reactive cells. It has been shown that, during Plasmodium berghei infection, the thymus is rendered atrophic by the premature egress of CD4(+)CD8(+) double-positive (DP) T cells to the periphery. To investigate whether autoimmune diseases are affected after Plasmodium berghei NK65 infection, we immunized C57BL/6 mice, which was previously infected with P. berghei NK65 and treated with chloroquine (CQ), with MOG(35-55) peptide and the clinical course of Experimental Autoimmune Encephalomyelitis (EAE) was evaluated. Our results showed that NK65+CQ+EAE mice developed a more severe disease than control EAE mice. The same pattern of disease severity was observed in MOG(35-55)-immunized mice after adoptive transfer of P. berghei-elicited splenic DP-T cells. The higher frequency of IL-17(+)- and IFN-gamma+-producing DP lymphocytes in the Central Nervous System of these mice suggests that immature lymphocytes contribute to disease worsening. To our knowledge, this is the first study to integrate the possible relationship between malaria and multiple sclerosis through the contribution of the thymus. Notwithstanding, further studies must be conducted to assert the relevance of malaria-induced thymic atrophy in the susceptibility and clinical course of other inflammatory autoimmune diseases.
C1 [Thome, Rodolfo; Bombeiro, Andre Luis; Issayama, Luidy Kazuo; da Costa, Thiago Alves; Di Gangi, Rosaria; Ferreira, Isadora Tassinari; Rodrigues Oliveira, Alexandre Leite; Verinaud, Liana] Univ Estadual Campinas, Dept Struct & Funct Biol, Inst Biol, Campinas, SP, Brazil.
   [Raposo, Catarina; da Cruz Hoefling, Maria Alice] Univ Estadual Campinas, Dept Histol & Embryol, Inst Biol, Campinas, SP, Brazil.
   [Pinto Lopes, Stefanie Costa; Maranhao Costa, Fabio Trindade] Univ Estadual Campinas, Dept Genet Evolut & Bioagents, Inst Biol, Campinas, SP, Brazil.
   [Figueiredo Longhini, Ana Leda] Univ Estadual Campinas, Dept Hematol, Fac Ciencias Med, Campinas, SP, Brazil.
RP Verinaud, L (corresponding author), Univ Estadual Campinas, Dept Struct & Funct Biol, Inst Biol, Campinas, SP, Brazil.
EM verinaud@unicamp.br
RI Oliveira, Alexandre L. R./C-4436-2012; Oliveira,
   Alexandre/AAI-6815-2020; da Costa, Thiago Alves/F-8187-2016; Lopes,
   Stefanie/A-8314-2012; Thome, Rodolfo/C-1564-2012; Costa,
   Fabio/E-1181-2012
OI Oliveira, Alexandre L. R./0000-0003-4224-4575; Oliveira,
   Alexandre/0000-0003-4224-4575; Thome, Rodolfo/0000-0001-7627-4137;
   Costa, Fabio/0000-0001-9969-7300; Lopes, Stefanie/0000-0002-6981-2192;
   Alves da Costa, Thiago/0000-0001-9591-331X
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2011/17965-3]; FAPESPFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2011/13191-3]
FX This work was supported by Sao Paulo Research Foundation (FAPESP, grant
   number #2011/17965-3). RT received a FAPESP scholarship (#
   2011/13191-3). MACH, FTMC and LV are fellows of the National Council of
   Technological and Scientific Development (CNPq). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR ADU D, 1982, CLIN EXP IMMUNOL, V49, P310
   Anderson G, 2001, NAT REV IMMUNOL, V1, P31, DOI 10.1038/35095500
   Andrade CF, 2008, CELL IMMUNOL, V253, P1, DOI 10.1016/j.cellimm.2008.06.001
   Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387
   Ataide MA, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003885
   Bang K, 2001, BRIT J DERMATOL, V144, P1140, DOI 10.1046/j.1365-2133.2001.04223.x
   Bettiol E, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-64
   Bhaumik S, 2013, NATL MED J INDIA, V26, P62
   Butcher GA, 1996, MED HYPOTHESES, V47, P97, DOI 10.1016/S0306-9877(96)90446-6
   Butcher G, 2008, TRENDS PARASITOL, V24, P291, DOI 10.1016/j.pt.2008.03.010
   Capalbo D, 2012, INT REV IMMUNOL, V31, P344, DOI 10.3109/08830185.2012.697230
   Chu CQ, 2000, J EXP MED, V192, P123, DOI 10.1084/jem.192.1.123
   Clemente AM, 2013, INFECT IMMUN, V81, P1842, DOI 10.1128/IAI.01226-12
   Cockburn IA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000877
   COX HW, 1964, AM J TROP MED HYG, V13, P225, DOI 10.4269/ajtmh.1964.13.225
   Daniel-Ribeiro CT, 2000, MEM I OSWALDO CRUZ, V95, P199, DOI 10.1590/S0074-02762000000200011
   Daniel-Ribeiro CT, 2000, ACTA TROP, V76, P205, DOI 10.1016/S0001-706X(00)00099-1
   Das G, 2003, P NATL ACAD SCI USA, V100, P5324, DOI 10.1073/pnas.0831037100
   Dittel BN, 1999, J IMMUNOL, V163, P32
   Domingues HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015531
   FALANGA PB, 1987, EUR J IMMUNOL, V17, P599, DOI 10.1002/eji.1830170504
   Farias AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017849
   FAWCETT PT, 1989, CELL IMMUNOL, V118, P192, DOI 10.1016/0008-8749(89)90368-7
   Fletcher JM, 2010, CLIN EXP IMMUNOL, V162, P1, DOI 10.1111/j.1365-2249.2010.04143.x
   Francelin C, 2011, IMMUNOBIOLOGY, V216, P1148, DOI 10.1016/j.imbio.2011.03.009
   Franklin BS, 2009, P NATL ACAD SCI USA, V106, P5789, DOI 10.1073/pnas.0809742106
   Gameiro J, 2010, CELL ADHES MIGR, V4, P382, DOI 10.4161/cam.4.3.11789
   Gameiro J, 2010, IMMUNOLOGY, V129, P248, DOI 10.1111/j.1365-2567.2009.03177.x
   Gilden DH, 2005, LANCET NEUROL, V4, P195, DOI 10.1016/S1474-4422(05)01017-3
   Giusti P, 2011, INFECT IMMUN, V79, P2727, DOI 10.1128/IAI.00649-10
   Goncalves RM, 2010, INFECT IMMUN, V78, P4763, DOI 10.1128/IAI.00578-10
   Hartgers FC, 2008, INFECT IMMUN, V76, P5149, DOI 10.1128/IAI.01579-07
   Hermann I, 2006, INFECT IMMUN, V74, P4841, DOI 10.1128/IAI.00026-06
   HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4
   Itoh M, 1999, J IMMUNOL, V162, P5317
   JARRA W, 1983, CIBA F SYMP, V94, P137
   KAWAKITA S, 1976, JPN HEART J, V17, P592
   Lind EF, 2001, J EXP MED, V194, P127, DOI 10.1084/jem.194.2.127
   LLOYD CM, 1994, INFECT IMMUN, V62, P1982, DOI 10.1128/IAI.62.5.1982-1988.1994
   LOOSE LD, 1973, MICROBIOS, V8, P111
   Mauduit M, 2012, IMMUNOLOGIC RES
   McCall MBB, 2007, J IMMUNOL, V179, P162, DOI 10.4049/jimmunol.179.1.162
   Mendes-da-Cruz DA, 2003, MICROBES INFECT, V5, P825, DOI 10.1016/S1286-4579(03)00156-4
   Mix E, 2010, PROG NEUROBIOL, V92, P386, DOI 10.1016/j.pneurobio.2010.06.005
   Muxel SM, 2010, J INTERF CYTOK RES, V30, P417, DOI 10.1089/jir.2009.0095
   O'Connor RA, 2008, J IMMUNOL, V181, P3750, DOI 10.4049/jimmunol.181.6.3750
   Peron JPS, 2010, J NEUROIMMUNOL, V227, P10, DOI 10.1016/j.jneuroim.2010.06.002
   PHANUPHAK P, 1983, CLIN EXP IMMUNOL, V53, P627
   POELS LG, 1980, EXP PARASITOL, V49, P97, DOI 10.1016/0014-4894(80)90061-2
   READ SE, 1974, J CLIN INVEST, V54, P439, DOI 10.1172/JCI107780
   Sardinha LR, 2002, SCAND J IMMUNOL, V56, P408, DOI 10.1046/j.1365-3083.2002.01146.x
   Savino W, 2002, TRENDS IMMUNOL, V23, P305, DOI 10.1016/S1471-4906(02)02224-X
   Savino W, 2007, BRIT J NUTR, V98, pS11, DOI 10.1017/S0007114507832880
   Skorokhod OA, 2004, J IMMUNOL, V173, P4066, DOI 10.4049/jimmunol.173.6.4066
   Sotgiu S, 2008, MED HYPOTHESES, V70, P819, DOI 10.1016/j.mehy.2006.10.069
   Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107
   Thome R, 2014, IMMUNOLOGY IN PRESS
   Thome R, 2014, IMMUNOL CELL BIOL, V92, P124, DOI 10.1038/icb.2013.73
   Thome R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065913
   Tutaj M, 2007, J AUTOIMMUN, V28, P208, DOI 10.1016/j.jaut.2007.02.017
   Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900
   Urban Britta C, 2006, J Biol, V5, P4, DOI 10.1186/jbiol37
   Willenborg DO, 1999, J IMMUNOL, V163, P5278
   Wykes MN, 2011, P NATL ACAD SCI USA, V108, P11205, DOI 10.1073/pnas.1108579108
NR 64
TC 6
Z9 8
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 17
PY 2014
VL 9
IS 10
AR e110739
DI 10.1371/journal.pone.0110739
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AT8TF
UT WOS:000345204100105
PM 25329161
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Thome, R
   Issayama, LK
   da Costa, TA
   Gangi, RD
   Ferreira, IT
   Raposo, C
   Lopes, SCP
   Hofling, MAD
   Costa, FTM
   Verinaud, L
AF Thome, Rodolfo
   Issayama, Luidy K.
   da Costa, Thiago Alves
   Gangi, Rosaria D.
   Ferreira, Isadora T.
   Raposo, Catarina
   Lopes, Stefanie C. P.
   da Cruz Hoefling, Maria Alice
   Costa, Fabio T. M.
   Verinaud, Liana
TI Dendritic cells treated with crude Plasmodium berghei extracts acquire
   immune-modulatory properties and suppress the development of autoimmune
   neuroinflammation
SO IMMUNOLOGY
LA English
DT Article
DE dendritic cells; experimental autoimmune encephalomyelitis;
   neuroinflammation; Plasmodium extracts
ID REGULATORY T-CELLS; FALCIPARUM-INFECTED ERYTHROCYTES; INDUCED ARTHRITIS;
   IN-VITRO; ENCEPHALOMYELITIS; MATURATION; SALMONELLA; ACTIVATION;
   OMEGA-1; GAMMA
AB Dendritic cells (DCs) are professional antigen-presenting cells specifically targeted during Plasmodium infection. Upon infection, DCs show impaired antigen presentation and T-cell activation abilities. In this study, we aimed to evaluate whether cellular extracts obtained from Plasmodium berghei-infected erythrocytes (PbX) modulate DCs phenotypically and functionally and the potential therapeutic usage of PbX-modulated DCs in the control of experimental autoimmune encephalomyelitis (EAE, the mouse model for human multiple sclerosis). We found that PbX-treated DCs have impaired maturation and stimulated the generation of regulatory T cells when cultured with naive T lymphocytes in vitro. When adoptively transferred to C57BL/6 mice the EAE severity was reduced. Disease amelioration correlated with a diminished infiltration of cytokine-producing T cells in the central nervous system as well as the suppression of encephalitogenic T cells. Our study shows that extracts obtained from P. berghei-infected erythrocytes modulate DCs towards an immunosuppressive phenotype. In addition, the adoptive transfer of PbX-modulated DCs was able to ameliorate EAE development through the suppression of specific cellular immune responses towards neuro-antigens. To our knowledge, this is the first study to present evidence that DCs treated with P. berghei extracts are able to control autoimmune neuroinflammation.
C1 [Thome, Rodolfo; Issayama, Luidy K.; da Costa, Thiago Alves; Gangi, Rosaria D.; Ferreira, Isadora T.; Verinaud, Liana] Univ Estadual Campinas, Inst Biol, Dept Struct & Funct Biol, Sao Paulo, Brazil.
   [Raposo, Catarina; da Cruz Hoefling, Maria Alice] Univ Estadual Campinas, Inst Biol, Dept Histol & Embryol, Sao Paulo, Brazil.
   [Lopes, Stefanie C. P.; Costa, Fabio T. M.] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut & Bioagents, Sao Paulo, Brazil.
RP Verinaud, L (corresponding author), Univ Estadual Campinas, Inst Biol, Rua Monteiro Lobato 255,Cidade Univ, BR-13083862 Campinas, SP, Brazil.
EM verinaud@unicamp.br
RI Lopes, Stefanie/A-8314-2012; Costa, Fabio/E-1181-2012; Thome,
   Rodolfo/C-1564-2012; da Costa, Thiago Alves/F-8187-2016
OI Costa, Fabio/0000-0001-9969-7300; Thome, Rodolfo/0000-0001-7627-4137;
   Alves da Costa, Thiago/0000-0001-9591-331X; Lopes,
   Stefanie/0000-0002-6981-2192
FU Sao Paulo Funding Agency (FAPESP) [2011/17965-3]; FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/13191-3,
   2012/08303-0, 2013/01401-9, 2012/22131-7]; CAPES (Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior)CAPES
FX This work was supported by the Sao Paulo Funding Agency (FAPESP, grant
   #2011/17965-3). RT, LKI, RdG and TAC received a FAPESP scholarship
   (grants: #2011/13191-3, #2012/08303-0, #2013/01401-9 and #2012/22131-7,
   respectively). ITF received a CAPES (Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior) scholarship. MACH, FTMC and LV are fellows of
   the National Council of Technological and Scientific Development (CNPq).
   We are in debted to Marcos Cesar Meneghetti for his help with animal
   care.
CR Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767
   Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588
   Baxter AG, 2013, CELL MOL IMMUNOL, V10, P375, DOI 10.1038/cmi.2013.29
   Bettiol E, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-64
   Bueno SM, 2008, IMMUNOLOGY, V124, P522, DOI 10.1111/j.1365-2567.2008.02805.x
   Chu CQ, 2000, J EXP MED, V192, P123, DOI 10.1084/jem.192.1.123
   Clemente AM, 2013, INFECT IMMUN, V81, P1842, DOI 10.1128/IAI.01226-12
   Clemente A, 2011, CELL MICROBIOL, V13, P1328, DOI 10.1111/j.1462-5822.2011.01622.x
   Cockburn IA, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001318
   Dittel BN, 1999, J IMMUNOL, V163, P32
   Domingues HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015531
   Emmer PM, 2006, TRANSPLANTATION, V81, P1451, DOI 10.1097/01.tp.0000208801.51222.bd
   Everts B, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000667
   Everts B, 2009, J EXP MED, V206, P1673, DOI 10.1084/jem.20082460
   Farias AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017849
   Finney OC, 2012, EUR J IMMUNOL, V42, P1767, DOI 10.1002/eji.201142164
   Giusti P, 2011, INFECT IMMUN, V79, P2727, DOI 10.1128/IAI.00649-10
   Herzenberg LA, 2006, NAT IMMUNOL, V7, P681, DOI 10.1038/ni0706-681
   Ko HJ, 2010, J AUTOIMMUN, V34, P111, DOI 10.1016/j.jaut.2009.07.006
   Kuijk LM, 2012, MOL IMMUNOL, V51, P210, DOI 10.1016/j.molimm.2012.03.020
   Leung S, 2010, CELL MOL IMMUNOL, V7, P182, DOI 10.1038/cmi.2010.22
   Lutz MB, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00123
   Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X
   Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0
   Mauduit M, 2012, IMMUNOL RES, V53, P115, DOI 10.1007/s12026-012-8269-7
   Millington Owain R, 2006, J Biol, V5, P5, DOI 10.1186/jbiol34
   MOSER M, 1995, EUR J IMMUNOL, V25, P2818, DOI 10.1002/eji.1830251016
   Niedergang F, 2000, P NATL ACAD SCI USA, V97, P14650, DOI 10.1073/pnas.97.26.14650
   Osada Y, 2009, INT J PARASITOL, V39, P457, DOI 10.1016/j.ijpara.2008.08.007
   Peron JPS, 2010, J NEUROIMMUNOL, V227, P10, DOI 10.1016/j.jneuroim.2010.06.002
   Rea D, 2000, BLOOD, V95, P3162, DOI 10.1182/blood.V95.10.3162.010k18_3162_3167
   Roelen DL, 2003, TRANSPLANTATION, V76, P1608, DOI 10.1097/01.TP.0000086340.30817.BA
   Skorokhod OA, 2004, J IMMUNOL, V173, P4066, DOI 10.4049/jimmunol.173.6.4066
   Sofronic-Milosavljevic L, 2013, MED MICROBIOL IMMUN, V202, P239, DOI 10.1007/s00430-012-0286-6
   Steinfelder S, 2009, J EXP MED, V206, P1681, DOI 10.1084/jem.20082462
   Sun XJ, 2012, PARASITE IMMUNOL, V34, P430, DOI 10.1111/j.1365-3024.2012.01377.x
   Tarbell KV, 2004, J EXP MED, V199, P1467, DOI 10.1084/jem.20040180
   Terness P, 2008, P NATL ACAD SCI USA, V105, P18442, DOI 10.1073/pnas.0807185105
   Thome R, 2014, IMMUNOL CELL BIOL, V92, P124, DOI 10.1038/icb.2013.73
   Thome R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065913
   Thome R, 2012, CELL IMMUNOL, V280, P113, DOI 10.1016/j.cellimm.2012.11.017
   Unger WWJ, 2009, EUR J IMMUNOL, V39, P3147, DOI 10.1002/eji.200839103
   Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900
   Urban Britta C, 2006, J Biol, V5, P4, DOI 10.1186/jbiol37
   van der Velden AWM, 2003, J IMMUNOL, V171, P6742, DOI 10.4049/jimmunol.171.12.6742
   van Halteren AGS, 2004, J AUTOIMMUN, V23, P233, DOI 10.1016/j.jaut.2004.06.004
   Wykes MN, 2011, P NATL ACAD SCI USA, V108, P11205, DOI 10.1073/pnas.1108579108
   Zaccone P, 2011, EUR J IMMUNOL, V41, P2709, DOI 10.1002/eji.201141429
NR 48
TC 8
Z9 9
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0019-2805
EI 1365-2567
J9 IMMUNOLOGY
JI Immunology
PD OCT
PY 2014
VL 143
IS 2
BP 164
EP 173
DI 10.1111/imm.12298
PG 10
WC Immunology
SC Immunology
GA AQ6BV
UT WOS:000342893500005
PM 24689455
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Lacerda, MVG
   Costa, FTM
   Lourenco-de-Oliveira, R
AF Lacerda, Marcus V. G.
   Costa, Fabio T. M.
   Lourenco-de-Oliveira, Ricardo
TI Malaria research in Brazil: we are doing well
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Editorial Material
RI Costa, Fabio/E-1181-2012
OI Costa, Fabio/0000-0001-9969-7300
CR Costa FTM, 2012, INT J PARASITOL, V42, P1099, DOI 10.1016/j.ijpara.2012.08.007
   DEANE LM, 1988, AM J TROP MED HYG, V38, P223, DOI 10.4269/ajtmh.1988.38.223
   Editorial, 1960, BMJ-BRIT MED J, V1, P1033
   HEISCH RB, 1960, BRIT MED J, V1, P1736, DOI 10.1136/bmj.1.5187.1736
   Llanos-Cuentas A, 2014, LANCET, V383, P1049, DOI 10.1016/S0140-6736(13)62568-4
   Maciel-de-Freitas R, 2012, MEM I OSWALDO CRUZ, V107, P828, DOI 10.1590/S0074-02762012000600021
   MARSDEN PD, 1989, BRIT MED J, V299, P1328, DOI 10.1136/bmj.299.6711.1328
   Najera JA, 2011, PLOS MED, V8, DOI DOI 10.1371/J0URNAL.PMED.1000412)
   Neiva A, 1910, MEM I O CRUZ, V2, P131
   Oliveira-Ferreira J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-115
NR 10
TC 0
Z9 0
U1 0
U2 2
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD AUG
PY 2014
VL 109
IS 5
BP 515
EP 516
DI 10.1590/0074-0276143001
PG 2
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AR5CW
UT WOS:000343603800001
PM 25184995
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Fratus, ASB
   Cabral, FJ
   Fotoran, WL
   Medeiros, MM
   Carlos, BC
   dalla Martha, R
   da Silva, LHP
   Lopes, SCP
   Costa, FTM
   Wunderlich, G
AF Bassi Fratus, Alessandra Sampaio
   Cabral, Fernanda Janku
   Fotoran, Wesley Luzetti
   Medeiros, Marcia Melo
   Carlos, Bianca Cechetto
   dalla Martha, Rosimeire
   Pereira da Silva, Luiz Hildebrando
   Pinto Lopes, Stefanie Costa
   Maranhao Costa, Fabio Trindade
   Wunderlich, Gerhard
TI Antibody recognition of Plasmodium falciparum infected red blood cells
   by symptomatic and asymptomatic individuals in the Brazilian Amazon
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Plasmodium falciparum; PfEMP1; variant proteins; cytoadherence
ID INTERCELLULAR-ADHESION MOLECULE-1; ERYTHROCYTE-MEMBRANE PROTEIN-1;
   NATURALLY ACQUIRED-IMMUNITY; VAR GENE; ANTIGENIC VARIATION; SEVERE
   MALARIA; BINDING; SURFACE; PFEMP1; CYTOADHERENCE
AB In the Amazon Region, there is a virtual absence of severe malaria and few fatal cases of naturally occurring Plasmodium falciparum infections; this presents an intriguing and underexplored area of research. In addition to the rapid access of infected persons to effective treatment, one cause of this phenomenon might be the recognition of cytoadherent variant proteins on the infected red blood cell (IRBC) surface, including the var gene encoded P. falciparum erythrocyte membrane protein 1. In order to establish a link between cytoadherence, IRBC surface antibody recognition and the presence or absence of malaria symptoms, we phenotype-selected four Amazonian P. falciparum isolates and the laboratory strain 3D7 for their cytoadherence to CD36 and ICAM1 expressed on CHO cells. We then mapped the dominantly expressed var transcripts and tested whether antibodies from symptomatic or asymptomatic infections showed a differential recognition of the IRBC surface. As controls, the 3D7 lineages expressing severe disease-associated phenotypes were used. We showed that there was no profound difference between the frequency and intensity of antibody recognition of the IRBC-exposed P. falciparum proteins in symptomatic vs. asymptomatic infections. The 3D7 lineages, which expressed severe malaria-associated phenotypes, were strongly recognised by most, but not all plasmas, meaning that the recognition of these phenotypes is frequent in asymptomatic carriers, but is not necessarily a prerequisite to staying free of symptoms.
C1 [Bassi Fratus, Alessandra Sampaio; Cabral, Fernanda Janku; Fotoran, Wesley Luzetti; Medeiros, Marcia Melo; Carlos, Bianca Cechetto; Wunderlich, Gerhard] Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Sao Paulo, Brazil.
   [dalla Martha, Rosimeire; Pereira da Silva, Luiz Hildebrando] Inst Pesquisas Patol Trop, Porto Velho, RO, Brazil.
   [Pinto Lopes, Stefanie Costa; Maranhao Costa, Fabio Trindade] Univ Estadual Campinas, Inst Biol, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
RP Wunderlich, G (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Sao Paulo, Brazil.
EM gwunder@usp.br
RI Cabral, Fernanda Janku/W-5797-2019; Lopes, Stefanie/A-8314-2012; Costa,
   Fabio/E-1181-2012; Janku Cabral, Fernanda/K-1317-2014; Fotoran,
   Wesley/N-2545-2016; Wunderlich, Gerhard/G-8245-2012
OI Cabral, Fernanda Janku/0000-0001-9263-5553; Costa,
   Fabio/0000-0001-9969-7300; Fotoran, Wesley/0000-0001-8203-8384;
   Wunderlich, Gerhard/0000-0003-1724-0337; Lopes,
   Stefanie/0000-0002-6981-2192; Melo Medeiros, Marcia/0000-0002-5364-9087
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/17114-3]; CNPqNational Council for Scientific and Technological
   Development (CNPq) [576128/2008-2]
FX FAPESP (2009/17114-3), CNPq (576128/2008-2) FTMC and GW are CNPq
   fellows.
CR Albrecht L, 2006, MOL BIOCHEM PARASIT, V150, P157, DOI 10.1016/j.molbiopara.2006.07.007
   Albrecht L, 2010, GENE, V453, P37, DOI 10.1016/j.gene.2010.01.001
   Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
   Alves FP, 2002, AM J TROP MED HYG, V66, P641, DOI 10.4269/ajtmh.2002.66.641
   Anderson TJC, 1999, PARASITOLOGY, V119, P113, DOI 10.1017/S0031182099004552
   Andrews KT, 2005, INT J PARASITOL, V35, P1127, DOI 10.1016/j.ijpara.2005.05.007
   Avril M, 2012, P NATL ACAD SCI USA, V109, pE1782, DOI 10.1073/pnas.1120534109
   BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3
   Bengtsson A, 2013, J IMMUNOL, V190, P240, DOI 10.4049/jimmunol.1202578
   Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358
   Bull PC, 2007, MOL BIOCHEM PARASIT, V154, P98, DOI 10.1016/j.molbiopara.2007.03.011
   Bull PC, 2005, PLOS PATHOG, V1, P202, DOI 10.1371/journal.ppat.0010026
   Chan JA, 2012, J CLIN INVEST, V122, P3227, DOI 10.1172/JCI62182
   Claessens A, 2012, P NATL ACAD SCI USA, V109, pE1772, DOI 10.1073/pnas.1120461109
   Crompton PD, 2010, P NATL ACAD SCI USA, V107, P6958, DOI 10.1073/pnas.1001323107
   Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531
   Golnitz U, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-14
   Guizetti J, 2013, CELL MICROBIOL, V15, P718, DOI 10.1111/cmi.12115
   HASLER T, 1993, AM J TROP MED HYG, V48, P332, DOI 10.4269/ajtmh.1993.48.332
   Hviid L, 2005, ACTA TROP, V95, P270, DOI 10.1016/j.actatropica.2005.06.012
   Joergensen L, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001083
   Kyes SA, 2003, MOL MICROBIOL, V48, P1339, DOI 10.1046/j.1365-2958.2003.03505.x
   Lavstsen T, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-21
   Lavstsen T, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-27
   Lavstsen T, 2012, P NATL ACAD SCI USA, V109, pE1791, DOI 10.1073/pnas.1120455109
   LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567
   Lelievre J, 2005, EXP PARASITOL, V109, P195, DOI 10.1016/j.exppara.2004.11.012
   Maier AG, 2007, BLOOD, V109, P1289, DOI 10.1182/blood-2006-08-043364
   Marsh K, 2006, PARASITE IMMUNOL, V28, P51, DOI 10.1111/j.1365-3024.2006.00808.x
   Medeiros MM, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-608
   Moll K., 2008, METHODS MALARIA RES
   Ochola LB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014741
   Oleinikov AV, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000386
   Oliveira-Ferreira J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-115
   Pasternak ND, 2009, INT J BIOCHEM CELL B, V41, P1463, DOI 10.1016/j.biocel.2008.12.012
   Portugal S, 2013, J IMMUNOL, V190, P3039, DOI 10.4049/jimmunol.1203067
   Rask TS, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000933
   Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x
   Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418
   Segurado Aluisio Agusto Cotrim, 1997, Revista do Instituto de Medicina Tropical de Sao Paulo, V39, P85, DOI 10.1590/S0036-46651997000200004
   SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   TURNER GDH, 1994, AM J PATHOL, V145, P1057
   Turner L, 2013, NATURE, V498, P502, DOI 10.1038/nature12216
   Tutterrow YL, 2012, INFECT IMMUN, V80, P1479, DOI 10.1128/IAI.00071-12
   Vaughan AM, 2012, CURR OPIN IMMUNOL, V24, P324, DOI 10.1016/j.coi.2012.03.009
   Voss TS, 2006, NATURE, V439, P1004, DOI 10.1038/nature04407
   WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700
   Warimwe GM, 2009, P NATL ACAD SCI USA, V106, P21801, DOI 10.1073/pnas.0907590106
   Weiss GE, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000912
   WHO, 2013, WORLD MALARIA REPORT 2013, P1
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
NR 52
TC 3
Z9 3
U1 0
U2 5
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD AUG
PY 2014
VL 109
IS 5
BP 598
EP 607
DI 10.1590/0074-0276140027
PG 10
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AR5CW
UT WOS:000343603800012
PM 25099336
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Marchesini, P
   Costa, FTM
   Marinho, CRF
AF Marchesini, Paola
   Maranhao Costa, Fabio Trindade
   Farias Marinho, Claudio Romero
TI A decade of malaria during pregnancy in Brazil: what has been done
   concerning prevention and management
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE malaria; pregnancy; epidemiology; control; Brazil
ID PLASMODIUM-VIVAX MALARIA; WOMEN; FALCIPARUM
AB In Brazil, malaria remains a disease of major epidemiological importance because of the high number of cases in the Amazonian Region. Plasmodium spp infections during pregnancy are a significant public health problem with substantial risks for the pregnant woman, the foetus and the newborn child. In Brazil, the control of malaria during pregnancy is primarily achieved by prompt and effective treatment of the acute episodes. Thus, to assure rapid diagnosis and treatment for pregnant women with malaria, one of the recommended strategy for low transmission areas by World Health Organization and as part of a strategy by the Ministry of Health, the National Malaria Control Program has focused on integrative measures with woman and reproductive health. Here, we discuss the approach for the prevention and management of malaria during pregnancy in Brazil over the last 10 years (2003-2012) using morbidity data from Malaria Health Information System. Improving the efficiency and quality of healthcare and education and the consolidation of prevention programmes will be challenges in the control of malaria during pregnancy in the next decade.
C1 [Marchesini, Paola; Farias Marinho, Claudio Romero] Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, BR-05508 Sao Paulo, Brazil.
   [Maranhao Costa, Fabio Trindade] Univ Estadual Campinas, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
RP Marinho, CRF (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, BR-05508 Sao Paulo, Brazil.
EM marinho@usp.br
RI Marinho, Claudio Romero Farias/F-7507-2012; Costa, Fabio/E-1181-2012
OI Marinho, Claudio Romero Farias/0000-0002-1227-3845; Costa,
   Fabio/0000-0001-9969-7300
CR Brabin BJ, 2004, PLACENTA, V25, P359, DOI 10.1016/j.placenta.2003.10.019
   Costa FTM, 2012, INT J PARASITOL, V42, P1099, DOI 10.1016/j.ijpara.2012.08.007
   de Almeida LB, 2010, REV SOC BRAS MED TRO, V43, P304, DOI 10.1590/S0037-86822010000300018
   Dellicour S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000221
   Gutman J, 2010, LANCET INFECT DIS, V10, P739, DOI 10.1016/S1473-3099(10)70216-4
   Martinez-Espinosa FE, 2004, MEM I OSWALDO CRUZ, V99, P19, DOI 10.1590/S0074-02762004000100003
   Ndyomugyenyi R, 2011, T ROY SOC TROP MED H, V105, P607, DOI 10.1016/j.trstmh.2011.07.012
   Parekh FK, 2007, AM J TROP MED HYG, V77, P451, DOI 10.4269/ajtmh.2007.77.451
   Steketee RW, 2001, AM J TROP MED HYG, V64, P28, DOI 10.4269/ajtmh.2001.64.28
NR 9
TC 4
Z9 4
U1 0
U2 3
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD AUG
PY 2014
VL 109
IS 5
BP 706
EP 708
DI 10.1590/0074-0276140047
PG 3
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA AR5CW
UT WOS:000343603800022
PM 25185009
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Dos-Santos, JCK
   Angerami, RN
   Castineiras, CMS
   Lopes, SCP
   Albrecht, L
   Garcia, MT
   Levy, CE
   Moretti, ML
   Lacerda, MVG
   Costa, FTM
AF Dos-Santos, Joao C. K.
   Angerami, Rodrigo N.
   Castineiras, Catarina M. S.
   Lopes, Stefanie C. P.
   Albrecht, Letusa
   Garcia, Marcia T.
   Levy, Carlos E.
   Moretti, Maria L.
   Lacerda, Marcus V. G.
   Costa, Fabio T. M.
TI Imported malaria in a non-endemic area: the experience of the university
   of Campinas hospital in the Brazilian Southeast
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Non-endemic area; Brazil; Plasmodium vivax; Plasmodium
   falciparum; Severity; Epidemiology
ID PLASMODIUM-VIVAX MALARIA; DIAGNOSIS; AUSTRALIA; RISK
AB Background: Although malaria in Brazil almost exclusively occurs within the boundaries of the Amazon Region, some concerns are raised regarding imported malaria to non-endemic areas of the country, notably increased incidence of complications due to delayed diagnoses. However, although imported malaria in Brazil represents a major health problem, only a few studies have addressed this subject.
   Methods: A retrospective case series is presented in which 263 medical charts were analysed to investigate the clinical and epidemiological characterization of malaria cases that were diagnosed and treated at Hospital & Clinics, State University of Campinas between 1998 and 2011.
   Results: Amongst all medical charts analysed, 224 patients had a parasitological confirmed diagnosis of malaria. Plasmodium vivax and Plasmodium falciparum were responsible for 67% and 30% of the infections, respectively. The majority of patients were male (83%) of a productive age (median, 37 years old). Importantly, severe complications did not differ significantly between P. vivax (14 cases, 9%) and P. falciparum (7 cases, 10%) infections.
   Conclusions: Severe malaria cases were frequent among imported cases in Brazil outside of the Amazon area. The findings reinforce the idea that P. vivax infections in Brazil are not benign, regardless the endemicity of the area studied. Moreover, as the hospital is located in a privileged site, it could be used for future studies of malaria relapses and primaquine resistance mechanisms. Finally, based on the volume of cases treated and the secondary complications, referral malaria services are needed in the non-endemic areas of Brazil for a rapid and efficient and treatment.
C1 [Dos-Santos, Joao C. K.; Castineiras, Catarina M. S.; Lopes, Stefanie C. P.; Albrecht, Letusa; Costa, Fabio T. M.] Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
   [Dos-Santos, Joao C. K.] Univ Estadual Campinas, Fac Ciencias Med, Campinas, SP, Brazil.
   [Angerami, Rodrigo N.; Garcia, Marcia T.; Moretti, Maria L.] Univ Estadual Campinas, Hosp Clin, Secao Epidemiol Hosp, Campinas, SP, Brazil.
   [Moretti, Maria L.] Univ Estadual Campinas, Fac Ciencias Med, Dept Clin Med, Campinas, SP, Brazil.
   [Levy, Carlos E.] Univ Estadual Campinas, Dept Patol Clin, Campinas, SP, Brazil.
   [Lacerda, Marcus V. G.] Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [Lacerda, Marcus V. G.] Univ Estado Amazonas, Manaus, Amazonas, Brazil.
RP Costa, FTM (corresponding author), Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
EM fabiotmc72@gmail.com
RI Angerami, Rodrigo Nogueira/A-8926-2013; Costa, Fabio/E-1181-2012; Lopes,
   Stefanie/A-8314-2012; Albrecht, Letusa/I-1837-2012; Garcia, Marcia
   Teixeira/AAS-8548-2020; Levy, Carlos/AAN-7226-2020; Levy,
   Carlos/L-2116-2013
OI Angerami, Rodrigo Nogueira/0000-0002-4976-9238; Costa,
   Fabio/0000-0001-9969-7300; Albrecht, Letusa/0000-0001-6406-2057; Garcia,
   Marcia Teixeira/0000-0003-3319-115X; Levy, Carlos/0000-0002-4862-8900;
   Dos-Santos, Joao/0000-0001-5916-9845; Lopes,
   Stefanie/0000-0002-6981-2192
FU National Council of Scientific and Technological Development (CNPq,
   Brazil)National Council for Scientific and Technological Development
   (CNPq); Sao Research Foundation (FAPESP, Brazil); Maria da Conceicao
   Chagas de Almeida; LEMB-CPQGM/FIOCRUZ
FX Authors would like to acknowledge Maria da Conceicao Chagas de Almeida,
   PhD, LEMB-CPQGM/FIOCRUZ, for the support with the handling and analysis
   of the data. Also the authors would like to acknowledge the Servico de
   Arquivo M dico da UNICAMP and the NVE for the support with the access to
   the medical charts. The research was supported by the National Council
   of Scientific and Technological Development (CNPq, Brazil) and by the
   Sao Research Foundation (FAPESP, Brazil) grants.
CR Ajetunmobi WA, 2012, NIGERIA MALAR J, V11, P336, DOI DOI 10.1186/1475-2875-11-336
   Alves Maria José Chinelatto Pinheiro, 2004, Rev. Soc. Bras. Med. Trop., V37, P41, DOI 10.1590/S0037-86822004000100011
   [Anonymous], INF SYST NOT DIS
   [Anonymous], GUID
   [Anonymous], MORT SYST INF
   Askling HH, 2005, EMERG INFECT DIS, V11, P436, DOI 10.3201/eid1103.040677
   Barata R C, 1995, Cad Saude Publica, V11, P128
   BOULOS M, 1991, REV I MED TROP, V33, P143, DOI 10.1590/S0036-46651991000200009
   Brasil P, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-402
   Brasilia, 2010, PRACT GUID MAL TREAT
   Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815
   Centers for Disease Control and Preventio, 2012, MAL SURV US, V2010, P2012
   Charles DM, 2005, MED J AUSTRALIA, V182, P164, DOI 10.5694/j.1326-5377.2005.tb06646.x
   Costa AD, 2010, REV SOC BRAS MED TRO, V43, P571, DOI 10.1590/S0037-86822010000500020
   Costa FTM, 2012, INT J PARASITOL, V42, P1099, DOI 10.1016/j.ijpara.2012.08.007
   Douglas NM, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-135
   Espinosa-Vega E, 2011, J TRAVEL MED, V18, P165, DOI 10.1111/j.1708-8305.2011.00503.x
   Genton B, 2012, INFECT DIS CLIN N AM, V26, P637, DOI 10.1016/j.idc.2012.05.003
   Gjorup IE, 2007, SCAND J INFECT DIS, V39, P707, DOI 10.1080/00365540701225710
   Lacerda MVG, 2012, CLIN INFECT DIS, V55, pE67, DOI 10.1093/cid/cis615
   Lacerda MVG, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-12
   Limongi JE, 2008, REV SOC BRAS MED TRO, V41, P232, DOI 10.1590/S0037-86822008000300002
   Liu YB, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-29
   Nilles EJ, 2012, AM J EMERG MED, V30, P972, DOI 10.1016/j.ajem.2011.06.016
   O'Brien MM, 2002, KIDNEY INT, V62, P585, DOI 10.1046/j.1523-1755.2002.00486.x
   Oliveira-Ferreira J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-115
   Millet JP, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-111
   Pedro RS, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-245
   Price RN, 2007, AM J TROP MED HYG, V77, P79, DOI 10.4269/ajtmh.2007.77.79
   Rey S, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-290
   Robinson P, 2001, J TRAVEL MED, V8, P76, DOI 10.2310/7060.2001.24309
   Rodríguez-Morales Alfonso J., 2008, Rev. perú. med. exp. salud publica, V25, P208
   Roussos C, 2003, EUR RESPIR J, V22, p3S, DOI 10.1183/09031936.03.00038503
   Santos LC, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-96
   Siikamaki H, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-93
   Smith AD, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a120
   Stasi R, 2012, HEMATOL-AM SOC HEMAT, P191, DOI 10.1182/asheducation-2012.1.191
   Tan LKK, 2008, LANCET INFECT DIS, V8, P449, DOI 10.1016/S1473-3099(08)70153-1
   Tavares MB, 2012, RENAL FAILURE, V34, P1252, DOI 10.3109/0886022X.2012.723582
   WHO, 2010, GUID TREATM MAL
   World Health Organization, 2011, HAEM CONC DIAGN AN A
   World Health Organization, 2002, CLIN BEH SOC FACT RE
NR 42
TC 5
Z9 5
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUL 22
PY 2014
VL 13
AR 280
DI 10.1186/1475-2875-13-280
PG 9
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA AM1AJ
UT WOS:000339578500001
PM 25047177
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Lee, WC
   Malleret, B
   Lau, YL
   Mauduit, M
   Fong, MY
   Cho, JS
   Suwanarusk, R
   Zhang, R
   Albrecht, L
   Costa, FTM
   Preiser, P
   McGready, R
   Renia, L
   Nosten, F
   Russell, B
AF Lee, Wenn-Chyau
   Malleret, Benoit
   Lau, Yee-Ling
   Mauduit, Marjorie
   Fong, Mun-Yik
   Cho, Jee Sun
   Suwanarusk, Rossarin
   Zhang, Rou
   Albrecht, Letusa
   Costa, Fabio T. M.
   Preiser, Peter
   McGready, Rose
   Renia, Laurent
   Nosten, Francois
   Russell, Bruce
TI Glycophorin C (CD236R) mediates vivax malaria parasite rosetting to
   normocytes
SO BLOOD
LA English
DT Article
ID FALCIPARUM-INFECTED ERYTHROCYTES; RED-BLOOD-CELLS; BENIGN TERTIAN
   MALARIA; PLASMODIUM-FALCIPARUM; DISEASE SEVERITY; FORM ROSETTES;
   EX-VIVO; INVASION; PROTEIN; RETICULOCYTES
AB Rosetting phenomenon has been linked to malaria pathogenesis. Although rosetting occurs in all causes of human malaria, most data on this subject has been derived from Plasmodium falciparum. Here, we investigate the function and factors affecting rosette formation in Plasmodium vivax. To achieve this, we used a range of novel ex vivo protocols to study fresh and cryopreserved P vivax (n = 135) and P falciparum(n = 77) isolates from Thailand. Rosetting is more common in vivax than falciparum malaria, both in terms of incidence in patient samples and percentage of infected erythrocytes forming rosettes. Rosetting to P vivax asexual and sexual stages was evident 20 hours postreticulocyte invasion, reaching a plateau after 30 hours. Host ABO blood group, reticulocyte count, and parasitemia were not correlated with P vivax rosetting. Importantly, mature erythrocytes (normocytes), rather than reticulocytes, preferentially form rosetting complexes, indicating that this process is unlikely to directly facilitate merozoite invasion. Although antibodies against host erythrocyte receptors CD235a and CD35 had no effect, Ag-binding fragment against the BRIC 4 region of CD236R significantly inhibited rosette formation. Rosetting assays using CD236R knockdown normocytes derived from hematopoietic stem cells further supports the role of glycophorin C as a receptor in P vivax rosette formation.
C1 [Lee, Wenn-Chyau; Lau, Yee-Ling; Fong, Mun-Yik] Univ Malaya, Fac Med, Dept Parasitol, Kuala Lumpur, Malaysia.
   [Malleret, Benoit; Cho, Jee Sun; Zhang, Rou; Russell, Bruce] Natl Univ Singapore, Yong Loo Lin Sch Med, Natl Univ Hlth Syst, Dept Microbiol, Singapore 117597, Singapore.
   [Malleret, Benoit; Mauduit, Marjorie; Suwanarusk, Rossarin; Renia, Laurent] ASTAR, Singapore Immunol Network SlgN, Singapore, Singapore.
   [Albrecht, Letusa; Costa, Fabio T. M.] Univ Estadual Campinas, Inst Biol, Sao Paulo, Brazil.
   [Preiser, Peter] Nanyang Technol Univ, Sch Biol Sci, Singapore 639798, Singapore.
   [McGready, Rose; Nosten, Francois] Mahidol Univ, Fac Trop Med, Shoklo Malaria Res Unit, Mahidol Oxford Trop Med Res Unit, Mae Sot, Thailand.
   [McGready, Rose; Nosten, Francois] Univ Oxford, Ctr Trop Med, Nuffield Dept Med, Oxford, England.
RP Russell, B (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Vivax Malaria Lab, Dept Microbiol, 5 Sci Dr 2,Blk MD4,Level 3, Singapore 117597, Singapore.
EM micbmr@nus.edu.sg
RI Malleret, Benoit/E-9159-2011; Albrecht, Letusa/I-1837-2012; FONG, MUN
   YIK/B-5443-2010; McGready, Rose/A-3290-2014; Russell, Bruce/A-9240-2011;
   Costa, Fabio/E-1181-2012; LEE, Wenn-Chyau/AAR-4072-2020; Lau, Yee
   Ling/C-6996-2009; Nosten, Francois/AAC-5509-2019; Preiser, Peter
   R/A-2201-2011; Suwanarusk, Rossarin/E-2115-2013
OI Malleret, Benoit/0000-0001-9658-7528; Albrecht,
   Letusa/0000-0001-6406-2057; McGready, Rose/0000-0003-1621-3257; Russell,
   Bruce/0000-0003-2333-4348; Costa, Fabio/0000-0001-9969-7300; LEE,
   Wenn-Chyau/0000-0002-7324-5792; Lau, Yee Ling/0000-0002-2037-2165;
   Nosten, Francois/0000-0002-7951-0745; Suwanarusk,
   Rossarin/0000-0002-7310-245X; , Peter/0000-0003-4331-7000
FU University of Malaya Research Grant [PV044-2012-A]; University of
   Malaya, High Impact Research Fund UM-MOHE
   [UM.C/625/1/HIR/MOHE/CHAN/14/3]; Ministry of Higher Education
   MalaysiaMinistry of Education, Malaysia; SIgN; Horizontal Programme on
   Infectious Diseases; Young Investigator Grant (BMRC YIG) under the
   Agency for Science, Technology, and Research (Singapore)Agency for
   Science Technology & Research (ASTAR) [13/1/16/YA/009]; Wellcome Trust
   of Great BritainWellcome Trust; National University of Singapore Faculty
   Start-Up GrantNational University of Singapore; Singapore National
   Medical Research CouncilNational Medical Research Council, Singapore
   [NMRC/CBRG/0047/2013]
FX This work was supported by the University of Malaya Research Grant
   (PV044-2012-A) (W. C. L.), University of Malaya, High Impact Research
   Fund UM-MOHE (UM.C/625/1/HIR/MOHE/CHAN/14/3), the Ministry of Higher
   Education Malaysia (Y.L.L. and M.Y.F.), the SIgN and the Horizontal
   Programme on Infectious Diseases (L. R.), and a Young Investigator Grant
   (BMRC YIG Grant No: 13/1/16/YA/009) under the Agency for Science,
   Technology, and Research (Singapore) (B. M.). SMRU is part of the
   Mahidol Oxford University Research Unit, supported by The Wellcome Trust
   of Great Britain. And additional funding was provided by the National
   University of Singapore Faculty Start-Up Grant and the Singapore
   National Medical Research Council (NMRC/CBRG/0047/2013) (B.R. and B.M.).
CR ALYAMAN F, 1995, T ROY SOC TROP MED H, V89, P55, DOI 10.1016/0035-9203(95)90658-4
   Angus BJ, 1996, AM J TROP MED HYG, V55, P560, DOI 10.4269/ajtmh.1996.55.560
   Anstey NM, 2007, J INFECT DIS, V195, P589, DOI 10.1086/510756
   Anstey NM, 2009, TRENDS PARASITOL, V25, P220, DOI 10.1016/j.pt.2009.02.003
   Baird JK, 2009, ANN TROP PAEDIATR, V29, P251, DOI 10.1179/027249309X12547917868808
   Bammigatti C, 2011, TROP DOCT, V41, P168, DOI 10.1258/td.2011.110025
   Barragan A, 2000, INFECT IMMUN, V68, P2971, DOI 10.1128/IAI.68.5.2971-2975.2000
   Bei AK, 2012, INT J PARASITOL, V42, P575, DOI 10.1016/j.ijpara.2012.03.006
   Bei AK, 2010, J INFECT DIS, V202, P1722, DOI 10.1086/657157
   Blomqvist K., 2008, METHODS MALARIA RES, P15
   Borlon C, 2012, INT J PARASITOL, V42, P155, DOI 10.1016/j.ijpara.2011.10.011
   CARLSON J, 1990, P NATL ACAD SCI USA, V87, P2511, DOI 10.1073/pnas.87.7.2511
   Chotivanich K, 2004, J INFECT DIS, V189, P1052, DOI 10.1086/381900
   Chotivanich KT, 1998, AM J TROP MED HYG, V59, P73, DOI 10.4269/ajtmh.1998.59.73
   CHRISTOFINIS GJ, 1983, ANN TROP MED PARASIT, V77, P123, DOI 10.1080/00034983.1983.11811685
   Clough B, 1998, BRIT J HAEMATOL, V100, P99, DOI 10.1046/j.1365-2141.1998.00534.x
   Corish P, 1999, PROTEIN ENG, V12, P1035, DOI 10.1093/protein/12.12.1035
   DAVID PH, 1988, AM J TROP MED HYG, V38, P289, DOI 10.4269/ajtmh.1988.38.289
   Giarratana MC, 2011, BLOOD, V118, P5071, DOI 10.1182/blood-2011-06-362038
   HANDUNNETTI SM, 1989, AM J TROP MED HYG, V40, P115, DOI 10.4269/ajtmh.1989.40.115
   HO M, 1991, INFECT IMMUN, V59, P2135, DOI 10.1128/IAI.59.6.2135-2139.1991
   Janes JH, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002032
   KITCHEN S. F., 1938, AMER JOUR TROP MED, V18, P347
   Lee WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060303
   Leitgeb AM, 2011, AM J TROP MED HYG, V84, P390, DOI 10.4269/ajtmh.2011.10-0256
   Lowe BS, 1998, T ROY SOC TROP MED H, V92, P526, DOI 10.1016/S0035-9203(98)90901-4
   Malleret B, 2011, SCI REP-UK, V1, DOI 10.1038/srep00118
   Malleret B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076062
   Marin-Menendez A, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002155
   Rowe JA, 2007, P NATL ACAD SCI USA, V104, P17471, DOI 10.1073/pnas.0705390104
   Rowe JA, 2005, MOLECULAR APPROACHES TO MALARIA, P416
   Rowe JA, 2002, AM J TROP MED HYG, V66, P458, DOI 10.4269/ajtmh.2002.66.458
   Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888
   Russell B, 2012, INT J PARASITOL, V42, P1063, DOI 10.1016/j.ijpara.2012.08.010
   Russell B, 2011, BLOOD, V118, pE74, DOI 10.1182/blood-2011-04-348748
   TREUTIGER CJ, 1992, AM J TROP MED HYG, V46, P503, DOI 10.4269/ajtmh.1992.46.503
   UDOMSANGPETCH R, 1992, INFECT IMMUN, V60, P4483, DOI 10.1128/IAI.60.11.4483-4490.1992
   Udomsangpetch R, 1995, T ROY SOC TROP MED H, V89, P635, DOI 10.1016/0035-9203(95)90422-0
   UDOMSANGPETCH R, 1989, J EXP MED, V169, P1835, DOI 10.1084/jem.169.5.1835
   UDOMSANGPETCH R, 1993, AM J TROP MED HYG, V48, P149, DOI 10.4269/ajtmh.1993.48.149
   Vigan-Womas I, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002781
   WAHLGREN M, 1992, MEM I OSWALDO CRUZ, V87, P323, DOI 10.1590/S0074-02761992000700054
   WAHLGREN M, 1989, PARASITOL TODAY, V5, P183, DOI 10.1016/0169-4758(89)90141-5
NR 43
TC 27
Z9 27
U1 0
U2 14
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAY 1
PY 2014
VL 123
IS 18
BP E100
EP E109
DI 10.1182/blood-2013-12-541698
PG 10
WC Hematology
SC Hematology
GA AH1QP
UT WOS:000335896300001
PM 24652986
OA Green Published
DA 2020-12-08
ER

PT J
AU Lopes, SCP
   Albrecht, L
   Carvalho, BO
   Siqueira, AM
   Thomson-Luque, R
   Nogueira, PA
   Fernandez-Becerra, C
   del Portillo, HA
   Russell, BM
   Renia, L
   Lacerda, MVG
   Costa, FTM
AF Lopes, Stefanie C. P.
   Albrecht, Letusa
   Carvalho, Bruna O.
   Siqueira, Andre M.
   Thomson-Luque, Richard
   Nogueira, Paulo A.
   Fernandez-Becerra, Carmen
   del Portillo, Hernando A.
   Russell, Bruce M.
   Renia, Laurent
   Lacerda, Marcus V. G.
   Costa, Fabio T. M.
TI Paucity of Plasmodium vivax Mature Schizonts in Peripheral Blood Is
   Associated With Their Increased Cytoadhesive Potential
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE malaria; Plasmodium vivax; schizonts; disproportionality; cytoadhesion;
   sequestration
ID MALARIA
AB There is now a growing body of evidence that challenges the current view that Plasmodium vivax-infected erythrocyte (Pv-iE) are unable to sequester. Here we used ex vivo adhesion assays with Pv-iE before and after maturation to demonstrate a higher binding potential of schizonts compared to other asexual stages. These experimental results are correlated with our observations in a panel of 50 vivax malaria patients where schizonts were completely absent in 27 isolates, and few schizonts were observed in the remaining patients. These observations prompt a paradigm shift in P. vivax biology and open avenues to investigate the role of Pv-iE sequestration.
C1 [Lopes, Stefanie C. P.; Albrecht, Letusa; Carvalho, Bruna O.; Costa, Fabio T. M.] Univ Estadual Campinas, Dept Genet Evolucao & Bioagentes, Inst Biol, Campinas, SP, Brazil.
   [Lopes, Stefanie C. P.; Siqueira, Andre M.; Thomson-Luque, Richard; Lacerda, Marcus V. G.] Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [Siqueira, Andre M.; Lacerda, Marcus V. G.] Univ Estado Amazonas, Manaus, Amazonas, Brazil.
   [Thomson-Luque, Richard; Fernandez-Becerra, Carmen; del Portillo, Hernando A.] CRESIB, Barcelona Ctr Int Hlth Res, Barcelona, Spain.
   [Nogueira, Paulo A.] Fiocruz MS, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil.
   [del Portillo, Hernando A.] ICREA, Barcelona, Spain.
   [Russell, Bruce M.; Renia, Laurent] Agcy Sci Technol & Res, Singapore Immunol Network, Singapore, Singapore.
   [Russell, Bruce M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Singapore 117595, Singapore.
RP Lopes, SCP (corresponding author), Univ Campinas UNICAMP, Inst Biol, Dep Genet Evolut & Bioagents, Rua Monteiro Lobato,255,POB 6109, BR-13083862 Campinas, SP, Brazil.
EM stefaniecplopes@gmail.com
RI Lopes, Stefanie/A-8314-2012; Nogueira, Paulo/AAK-8822-2020; Albrecht,
   Letusa/I-1837-2012; Siqueira, Andre M/G-1340-2010; Fernandez Becerra,
   Carmen/L-2069-2014; del Portillo, Hernando A/L-2131-2014; Russell,
   Bruce/A-9240-2011; Costa, Fabio/E-1181-2012
OI Albrecht, Letusa/0000-0001-6406-2057; Siqueira, Andre
   M/0000-0003-2208-0294; Fernandez Becerra, Carmen/0000-0001-5154-0013;
   del Portillo, Hernando A/0000-0002-5278-3452; Russell,
   Bruce/0000-0003-2333-4348; Costa, Fabio/0000-0001-9969-7300; Lopes,
   Stefanie/0000-0002-6981-2192
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2012/16525-2];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   grants-Instituto Nacional de Tecnologia em Vacinas (CNPq-FAPEMIG);
   Universal [470688/2012-2, 471066/2012-5]; Doencas Negligenciadas
   [404154/2012-3]; ICREAICREA Funding Source: Custom
FX Financial support. This work was supported by the Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP; grant 2012/16525-2) and
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   grants-Instituto Nacional de Tecnologia em Vacinas (CNPq-FAPEMIG),
   Universal (grants 470688/2012-2 and 471066/2012-5) and Doencas
   Negligenciadas (grant 404154/2012-3).
CR Baas C. C., 1921, American Journal of Tropical Medicine, V1, P29
   Bernabeu M, 2012, CELL MICROBIOL, V14, P386, DOI 10.1111/j.1462-5822.2011.01726.x
   Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815
   Chotivanich K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034509
   Field JW, 1963, STUDIES I MED RES FE, P108
   Gething PW, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001814
   Hingst HE, 1938, AM J TROP MED HYG  S, Vs1-18, P361
   Lopez FJ, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-8
   Lacerda MVG, 2012, CLIN INFECT DIS, V55, pE67, DOI 10.1093/cid/cis615
   Siqueira AM, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001934
   MAEGRAITH BG, 1948, PATHOLOGICAL PROCESS
   Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a
   Russell B, 2011, BLOOD, V118, pE74, DOI 10.1182/blood-2011-04-348748
   Snounou Georges, 2002, Methods Mol Med, V72, P189, DOI 10.1385/1-59259-271-6:189
NR 14
TC 33
Z9 33
U1 0
U2 7
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD MAY 1
PY 2014
VL 209
IS 9
BP 1403
EP 1407
DI 10.1093/infdis/jiu018
PG 5
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AF4NK
UT WOS:000334689700012
PM 24415786
OA Bronze
DA 2020-12-08
ER

PT J
AU Bastos, MF
   Albrecht, L
   Kozlowski, EO
   Lopes, SCP
   Blanco, YC
   Carlos, BC
   Castineiras, C
   Vicente, CP
   Werneck, CC
   Wunderlich, G
   Ferreira, MU
   Marinho, CRF
   Mourao, PAS
   Pavao, MSG
   Costa, FTM
AF Bastos, Marcele F.
   Albrecht, Letusa
   Kozlowski, Eliene O.
   Lopes, Stefanie C. P.
   Blanco, Yara C.
   Carlos, Bianca C.
   Castineiras, Catarina
   Vicente, Cristina P.
   Werneck, Claudio C.
   Wunderlich, Gerhard
   Ferreira, Marcelo U.
   Marinho, Claudio R. F.
   Mourao, Paulo A. S.
   Pavao, Mauro S. G.
   Costa, Fabio T. M.
TI Fucosylated Chondroitin Sulfate Inhibits Plasmodium falciparum
   Cytoadhesion and Merozoite Invasion
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID HUMAN CEREBRAL MALARIA; RED-BLOOD-CELLS; IN-VITRO MODEL; INFECTED
   ERYTHROCYTES; ENDOTHELIAL-CELLS; PARASITIZED ERYTHROCYTES;
   POLYSACCHARIDE ACCOUNT; ANTICOAGULANT ACTIVITY; ROSETTE FORMATION;
   FUCOSE BRANCHES
AB Sequestration of Plasmodium falciparum-infected erythrocytes (Pf-iEs) in the microvasculature of vital organs plays a key role in the pathogenesis of life-threatening malaria complications, such as cerebral malaria and malaria in pregnancy. This phenomenon is marked by the cytoadhesion of Pf-iEs to host receptors on the surfaces of endothelial cells, on noninfected erythrocytes, and in the placental trophoblast; therefore, these sites are potential targets for antiadhesion therapies. In this context, glycosaminoglycans (GAGs), including heparin, have shown the ability to inhibit Pf-iE cytoadherence and growth. Nevertheless, the use of heparin was discontinued due to serious side effects, such as bleeding. Other GAG-based therapies were hampered due to the potential risk of contamination with prions and viruses, as some GAGs are isolated from mammals. In this context, we investigated the effects and mechanism of action of fucosylated chondroitin sulfate (FucCS), a unique and highly sulfated GAG isolated from the sea cucumber, with respect to P. falciparum cytoadhesion and development. FucCS was effective in inhibiting the cytoadherence of Pf-iEs to human lung endothelial cells and placenta cryosections under static and flow conditions. Removal of the sulfated fucose branches of the FucCS structure virtually abolished the inhibitory effects of FucCS. Importantly, FucCS rapidly disrupted rosettes at high levels, and it was also able to block parasite development by interfering with merozoite invasion. Collectively, these findings highlight the potential of FucCS as a candidate for adjunct therapy against severe malaria.
C1 [Bastos, Marcele F.; Albrecht, Letusa; Lopes, Stefanie C. P.; Blanco, Yara C.; Castineiras, Catarina; Costa, Fabio T. M.] Univ Estadual Campinas, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
   [Kozlowski, Eliene O.; Mourao, Paulo A. S.; Pavao, Mauro S. G.] Univ Fed Rio de Janeiro, Inst Bioquim Med, Rio De Janeiro, Brazil.
   [Carlos, Bianca C.; Wunderlich, Gerhard; Ferreira, Marcelo U.; Marinho, Claudio R. F.] Univ Sao Paulo, Dept Parasitol, Sao Paulo, Brazil.
   [Vicente, Cristina P.] Univ Estadual Campinas, Dept Biol Estrut & Func, Campinas, SP, Brazil.
   [Werneck, Claudio C.] Univ Estadual Campinas, Dept Bioquim, Campinas, SP, Brazil.
RP Costa, FTM (corresponding author), Univ Estadual Campinas, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
EM costaftm@unicamp.br
RI Ferreira, Marcelo U/G-8289-2011; Bastos, Marcele/O-8981-2014; Mourao,
   Paulo/AAA-5386-2020; Wunderlich, Gerhard/G-8245-2012; Albrecht,
   Letusa/I-1837-2012; Lopes, Stefanie/A-8314-2012; Werneck, Claudio
   C/C-7568-2012; Costa, Fabio/E-1181-2012; Vicente, Cristina/D-8928-2012;
   Marinho, Claudio Romero Farias/F-7507-2012; Pavao, Mauro Sergio
   Goncalves/B-1979-2010
OI Ferreira, Marcelo U/0000-0002-5293-9090; Wunderlich,
   Gerhard/0000-0003-1724-0337; Albrecht, Letusa/0000-0001-6406-2057;
   Werneck, Claudio C/0000-0002-9413-0572; Costa,
   Fabio/0000-0001-9969-7300; Vicente, Cristina/0000-0001-9896-4630;
   Marinho, Claudio Romero Farias/0000-0002-1227-3845; Pavao, Mauro Sergio
   Goncalves/0000-0002-1336-4271; Lopes, Stefanie/0000-0002-6981-2192
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); CNPqNational Council
   for Scientific and Technological Development (CNPq)
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) and the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq). M.F.B., L.A., S.C.P.L., and B.C.C. were
   sponsored by FAPESP fellowships. Y.C.B. was supported by a CNPq
   fellowship. F.T.M.C., C.C.W., M.U.F., P.A.S.M., G.W., and M.S.G.P. are
   CNPq research fellows. C.R.F.M. was supported by FAPESP and CNPq.
CR ALYAMAN F, 1995, T ROY SOC TROP MED H, V89, P55, DOI 10.1016/0035-9203(95)90658-4
   Andrews KT, 2005, INFECT IMMUN, V73, P4288, DOI 10.1128/IAI.73.7.4288-4294.2005
   Avril M, 2004, MICROBES INFECT, V6, P249, DOI 10.1016/j.micinf.2003.12.007
   Barragan A, 1999, EXP PARASITOL, V91, P133, DOI 10.1006/expr.1998.4349
   Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1
   Beeson JG, 2002, INFECT IMMUN, V70, P5412, DOI 10.1128/IAI.70.10.5412-5415.2002
   Beeson JG, 2001, TRENDS PARASITOL, V17, P331, DOI 10.1016/S1471-4922(01)01917-1
   BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0
   Borsig L, 2007, J BIOL CHEM, V282, P14984, DOI 10.1074/jbc.M610560200
   Boyle MJ, 2010, BLOOD, V115, P4559, DOI 10.1182/blood-2009-09-243725
   BRAY RS, 1979, T ROY SOC TROP MED H, V73, P716, DOI 10.1016/0035-9203(79)90028-2
   BUTCHER GA, 1988, T ROY SOC TROP MED H, V82, P558, DOI 10.1016/0035-9203(88)90504-4
   CARLSON J, 1992, J EXP MED, V176, P1311, DOI 10.1084/jem.176.5.1311
   CARLSON J, 1994, BLOOD, V84, P3909, DOI 10.1182/blood.V84.11.3909.bloodjournal84113909
   CARLSON J, 1990, LANCET, V336, P1457, DOI 10.1016/0140-6736(90)93174-N
   Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815
   Chen Q, 1998, J EXP MED, V187, P15, DOI 10.1084/jem.187.1.15
   Clark DL, 1997, GLYCOCONJUGATE J, V14, P473, DOI 10.1023/A:1018551518610
   CLARK IA, 1994, PARASITOL TODAY, V10, P410, DOI 10.1016/0169-4758(94)90237-2
   CLARK IA, 1991, LANCET, V337, P302, DOI 10.1016/0140-6736(91)90915-C
   Costa FTM, 2003, J INFECT DIS, V188, P153, DOI 10.1086/375800
   Dellicour S, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000221
   Douki JBL, 2002, BLOOD, V100, P1478, DOI 10.1182/blood-2002-01-0315
   Doumbo OK, 2009, AM J TROP MED HYG, V81, P987, DOI 10.4269/ajtmh.2009.09-0406
   Duffy PE, 2005, CURR TOP MICROBIOL, V295, P169
   Evans SG, 1998, T ROY SOC TROP MED H, V92, P87, DOI 10.1016/S0035-9203(98)90969-5
   Faiz MA, 2005, LANCET, V366, P717
   Fernandez V, 1998, INFECT IMMUN, V66, P2969, DOI 10.1128/IAI.66.6.2969-2975.1998
   Fievet N, 2001, J INFECT DIS, V183, P1530, DOI 10.1086/320201
   Fonseca RJC, 2006, THROMB HAEMOSTASIS, V96, P822, DOI 10.1160/TH06-06-0304
   Fried M, 1998, J IMMUNOL, V160, P2523
   Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502
   Fried M, 2006, EXP PARASITOL, V113, P36, DOI 10.1016/j.exppara.2005.12.003
   GAY F, 1995, J IMMUNOL METHODS, V184, P15, DOI 10.1016/0022-1759(95)00070-Q
   Glauser BF, 2008, THROMB HAEMOSTASIS, V100, P420, DOI 10.1160/TH08-04-0210
   HANDUNNETTI SM, 1989, AM J TROP MED HYG, V40, P115, DOI 10.4269/ajtmh.1989.40.115
   Hanson J, 2012, J INFECT DIS, V206, P571, DOI 10.1093/infdis/jis400
   HASLER T, 1993, AM J TROP MED HYG, V48, P332, DOI 10.4269/ajtmh.1993.48.332
   HAVLIK I, 1994, T ROY SOC TROP MED H, V88, P686, DOI 10.1016/0035-9203(94)90230-5
   JAROONVESAMA N, 1972, LANCET, V1, P221
   John CC, 2010, EXPERT REV ANTI-INFE, V8, P997, DOI [10.1586/eri.10.90, 10.1586/ERI.10.90]
   Valle-Delgado JJ, 2013, NANOSCALE, V5, P3673, DOI 10.1039/c2nr32821f
   Juillerat A, 2011, P NATL ACAD SCI USA, V108, P5243, DOI 10.1073/pnas.1018692108
   KULANE A, 1992, AM J TROP MED HYG, V46, P589, DOI 10.4269/ajtmh.1992.46.589
   Kyriacou HM, 2007, ANTIMICROB AGENTS CH, V51, P1321, DOI 10.1128/AAC.01216-06
   LUSE SA, 1971, AM J TROP MED HYG, V20, P655, DOI 10.4269/ajtmh.1971.20.655
   MACPHERSON GG, 1985, AM J PATHOL, V119, P385
   Menendez C, 2006, CURR MOL MED, V6, P269, DOI 10.2174/156652406776055186
   MILLER LH, 1969, AM J TROP MED HYG, V18, P860, DOI 10.4269/ajtmh.1969.18.860
   Moll K., 2008, METHODS MALARIA RES
   Mourao PAS, 1996, J BIOL CHEM, V271, P23973, DOI 10.1074/jbc.271.39.23973
   Mourao PAS, 2001, THROMB RES, V102, P167, DOI 10.1016/S0049-3848(01)00230-4
   Mourao PAS, 1998, BRIT J HAEMATOL, V101, P647, DOI 10.1046/j.1365-2141.1998.00769.x
   Muanza K, 1996, RES IMMUNOL, V147, P149, DOI 10.1016/0923-2494(96)83167-1
   MUNIR M, 1980, Paediatrica Indonesiana, V20, P47
   Newbold C, 1997, AM J TROP MED HYG, V57, P389, DOI 10.4269/ajtmh.1997.57.389
   Noviyanti R, 2001, MOL BIOCHEM PARASIT, V114, P227, DOI 10.1016/S0166-6851(01)00266-3
   OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377
   Pacheco RG, 2000, BLOOD COAGUL FIBRIN, V11, P563, DOI 10.1097/00001721-200009000-00009
   Pouvelle B, 2000, NAT MED, V6, P1264
   Pouvelle B, 1998, Med Trop (Mars), V58, P187
   Pouvelle B, 1997, MOL MED, V3, P508, DOI 10.1007/BF03401697
   Pouvelle B, 2003, J INFECT DIS, V187, P292, DOI 10.1086/346050
   Rampengan T H, 1991, Paediatr Indones, V31, P59
   Ranjan A, 1999, P NATL ACAD SCI USA, V96, P14067, DOI 10.1073/pnas.96.24.14067
   RIECKMANN KH, 1978, LANCET, V1, P22
   Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X
   Rogerson SJ, 1999, AM J TROP MED HYG, V61, P467, DOI 10.4269/ajtmh.1999.61.467
   ROGERSON SJ, 1994, AM J TROP MED HYG, V51, P198, DOI 10.4269/ajtmh.1994.51.198
   ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15
   ROWE A, 1994, EXP PARASITOL, V79, P506, DOI 10.1006/expr.1994.1111
   ROWE A, 1995, INFECT IMMUN, V63, P2323, DOI 10.1128/IAI.63.6.2323-2326.1995
   Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x
   SHEEHY TW, 1967, ANN INTERN MED, V66, P807, DOI 10.7326/0003-4819-66-4-807
   SIVARAMAN CA, 1983, INDIAN J EXP BIOL, V21, P247
   SMITSKAM.H, 1971, BRIT MED J, V1, P714, DOI 10.1136/bmj.1.5751.714
   Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342
   Steketee RW, 2001, AM J TROP MED HYG, V64, P28, DOI 10.4269/ajtmh.2001.64.28
   Suguitan AL, 2003, J INFECT DIS, V188, P1074
   Taylor R. L., 1976, METHODS CARBOHYDR CH, V7, P149
   Taylor TE, 2004, NAT MED, V10, P143, DOI 10.1038/nm986
   TREUTIGER CJ, 1992, AM J TROP MED HYG, V46, P503, DOI 10.4269/ajtmh.1992.46.503
   Turner L, 2013, NATURE, V498, P502, DOI 10.1038/nature12216
   UDOMSANGPETCH R, 1989, J EXP MED, V169, P1835, DOI 10.1084/jem.169.5.1835
   VIEIRA RP, 1988, J BIOL CHEM, V263, P18176
   VIEIRA RP, 1991, J BIOL CHEM, V266, P13530
   Vogt AM, 2006, PLOS PATHOG, V2, P853, DOI 10.1371/journal.ppat.0020100
   World Health Organization, 1986, T R SOC TROP MED H S, V80, P3
   Xiao LH, 1996, INFECT IMMUN, V64, P1373, DOI 10.1128/IAI.64.4.1373-1378.1996
   Zancan P, 2004, BLOOD COAGUL FIBRIN, V15, P45, DOI 10.1097/00001721-200401000-00008
NR 90
TC 24
Z9 24
U1 1
U2 15
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD APR
PY 2014
VL 58
IS 4
BP 1862
EP 1871
DI 10.1128/AAC.00686-13
PG 10
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA AD9SU
UT WOS:000333605600004
PM 24395239
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Barboza, R
   Reis, AS
   da Silva, LG
   Hasenkamp, L
   Pereira, KRB
   Camara, NOS
   Costa, FTM
   Lima, MRD
   Alvarez, JM
   Boscardin, SB
   Epiphanio, S
   Marinho, CRF
AF Barboza, Renato
   Reis, Aramys Silva
   da Silva, Leandro Gustavo
   Hasenkamp, Lutero
   Benevides Pereira, Keitty Raquel
   Saraiva Camara, Niels Olsen
   Maranhao Costa, Fabio Trindade
   D'Imperio Lima, Maria Regina
   Alvarez, Jose Maria
   Boscardin, Silvia Beatriz
   Epiphanio, Sabrina
   Farias Marinho, Claudio Romero
TI MyD88 Signaling Is Directly Involved in the Development of Murine
   Placental Malaria
SO INFECTION AND IMMUNITY
LA English
DT Article
ID FALCIPARUM-INFECTED ERYTHROCYTES; TOLL-LIKE RECEPTORS;
   PLASMODIUM-FALCIPARUM; CHONDROITIN SULFATE; PREGNANT-WOMEN; PRETERM
   DELIVERY; DENDRITIC CELLS; RODENT MALARIA; FETAL ANEMIA; BERGHEI
AB Malaria is a widespread infectious disease caused by the parasite Plasmodium. During pregnancy, malaria infection leads to a range of complications that can affect both the mother and fetus, including stillbirth, infant mortality, and low birth weight. In this study, we utilized a mouse model of placental malaria (PM) infection to determine the importance of the protein MyD88 in the host immune response to Plasmodium during pregnancy. Initially, we demonstrated that Plasmodium berghei NK65GFP adhered to placental tissue via chondroitin sulfate A and induced PM in mice with a C57BL/6 genetic background. To evaluate the involvement of MyD88 in the pathology of PM, we performed a histopathological analysis of placentas obtained from MyD88(-/-) and wild-type (WT) mice following infection on the 19th gestational day. Our data demonstrated that the detrimental placental alterations observed in the infected mice were correlated with the expression of MyD88. Moreover, in the absence of this protein, production of interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-alpha) was significantly reduced in the infected mice. More importantly, in contrast to fetuses from infected WT mice, which exhibited a reduction in body weight, the fetuses from infected MyD88(-/-) mice did not display significant weight loss compared to their noninfected littermates. In addition, we observed a decrement of maternal care associated with malaria infection, which was attenuated in the MyD88-deficient mice. Collectively, the results of this study illustrate the pivotal importance of the MyD88 signaling pathway in the pathogenesis of placental malaria, thus presenting new possibilities for targeting MyD88 in therapeutic interventions.
C1 [Barboza, Renato; Reis, Aramys Silva; da Silva, Leandro Gustavo; Hasenkamp, Lutero; Benevides Pereira, Keitty Raquel; Boscardin, Silvia Beatriz; Farias Marinho, Claudio Romero] Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, BR-05508 Sao Paulo, Brazil.
   [Saraiva Camara, Niels Olsen; D'Imperio Lima, Maria Regina; Alvarez, Jose Maria] Univ Sao Paulo, Inst Ciencias Biomed, Dept Imunol, BR-05508 Sao Paulo, Brazil.
   [Barboza, Renato] Univ Fed Sao Paulo, Inst Ciencias Ambientais Quim & Farmaceut, Dept Ciencias Exatas & Terra, Diadema, Brazil.
   [Epiphanio, Sabrina] Univ Fed Sao Paulo, Inst Ciencias Ambientais Quim & Farmaceut, Dept Ciencias Biol, Diadema, Brazil.
   [Maranhao Costa, Fabio Trindade] Univ Estadual Campinas, Inst Biol, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
RP Marinho, CRF (corresponding author), Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, BR-05508 Sao Paulo, Brazil.
EM marinho@usp.br
RI Costa, Fabio/E-1181-2012; Camara, Niels OS/G-8336-2011; Reis, Aramys
   S/N-9170-2019; Lima, Maria Regina D'Imperio/I-4747-2012; camara,
   niels/AAX-3269-2020; REIS, ARAMYS SILVA/G-4806-2012; Marinho, Claudio
   Romero Farias/F-7507-2012; Epiphanio, Sabrina/C-7572-2012; Barboza,
   Renato/G-5833-2012; Epiphanio, Sabrina/S-2564-2019; Boscardin, Silvia
   Beatriz/C-3397-2012; Alvarez, Jose M/I-6181-2012
OI Costa, Fabio/0000-0001-9969-7300; Camara, Niels OS/0000-0001-5436-1248;
   Reis, Aramys S/0000-0003-4999-6382; Lima, Maria Regina
   D'Imperio/0000-0002-4683-7709; camara, niels/0000-0001-5436-1248; REIS,
   ARAMYS SILVA/0000-0003-4999-6382; Marinho, Claudio Romero
   Farias/0000-0002-1227-3845; Epiphanio, Sabrina/0000-0001-6094-9750;
   Barboza, Renato/0000-0002-6441-7513; Epiphanio,
   Sabrina/0000-0001-6094-9750; Boscardin, Silvia
   Beatriz/0000-0002-7845-7110; Alvarez, Jose M/0000-0002-9711-4914
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2009/53889-0, 2009/53256-7, 2011/17880-8,
   2012/02270-2]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior-CAPESCAPES [AUX-PE-PNPD 2751/2010, 258/2010]; Conselho Nacional
   de Desenvolvimento Cientifico e Tecnologico-CNPqNational Council for
   Scientific and Technological Development (CNPq) [475771/2009-5,
   404213/2012]
FX This work was supported by Sao Paulo Research Foundation (FAPESP)
   (grants 2009/53889-0, 2009/53256-7, 2011/17880-8, and 2012/02270-2),
   Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-CAPES
   (grants AUX-PE-PNPD 2751/2010 and 258/2010), and Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico-CNPq (grants 475771/2009-5 and
   404213/2012).
CR Abrahams VM, 2008, IMMUNOL INVEST, V37, P427, DOI 10.1080/08820130802191599
   Abrahams VM, 2005, PLACENTA, V26, P540, DOI 10.1016/j.placenta.2004.08.010
   Beeson JG, 2000, NAT MED, V6, P86, DOI 10.1038/71582
   Brabin BJ, 2004, ANN TROP PAEDIATR, V24, P311, DOI 10.1179/027249304225019136
   Brabin BJ, 2004, PLACENTA, V25, P359, DOI 10.1016/j.placenta.2003.10.019
   Coban C, 2010, CELL HOST MICROBE, V7, P50, DOI 10.1016/j.chom.2009.12.003
   COX J, 1987, PARASITE IMMUNOL, V9, P543, DOI 10.1111/j.1365-3024.1987.tb00529.x
   DESOWITZ RS, 1989, AM J TROP MED HYG, V41, P630, DOI 10.4269/ajtmh.1989.41.630
   Duffy MF, 2006, INFECT IMMUN, V74, P4875, DOI 10.1128/IAI.01978-05
   Ebensperger LA, 1998, BIOL REV, V73, P321, DOI 10.1017/S0006323198005209
   ELWOOD RW, 1980, ANIM BEHAV, V28, P1188, DOI 10.1016/S0003-3472(80)80107-2
   FAAS MM, 1994, AM J OBSTET GYNECOL, V171, P158, DOI 10.1016/0002-9378(94)90463-4
   Filipovich Y, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.08.038
   Franklin BS, 2007, MICROBES INFECT, V9, P881, DOI 10.1016/j.micinf.2007.03.007
   Franklin BS, 2009, P NATL ACAD SCI USA, V106, P5789, DOI 10.1073/pnas.0809742106
   Freyre A, 2006, EXP PARASITOL, V113, P154, DOI 10.1016/j.exppara.2005.12.019
   Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502
   Gayle DA, 2004, AM J PHYSIOL-REG I, V286, pR1024, DOI 10.1152/ajpregu.00664.2003
   Hamann L, 2010, INFECT GENET EVOL, V10, P785, DOI 10.1016/j.meegid.2010.05.005
   HART BL, 1988, NEUROSCI BIOBEHAV R, V12, P123, DOI 10.1016/S0149-7634(88)80004-6
   HIOKI A, 1990, J PROTOZOOL, V37, P163, DOI 10.1111/j.1550-7408.1990.tb01121.x
   Hirsch E, 2005, J SOC GYNECOL INVEST, V12, P145, DOI 10.1016/j.jsgi.2005.01.007
   Hviid L, 2010, TRENDS PARASITOL, V26, P412, DOI 10.1016/j.pt.2010.04.010
   Ilievski V, 2007, REPROD SCI, V14, P315, DOI 10.1177/1933719107302959
   Janse CJ, 2006, MOL BIOCHEM PARASIT, V145, P60, DOI 10.1016/j.molbiopara.2005.09.007
   Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006
   Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200
   le Cessie S, 2002, ARCH DIS CHILD-FETAL, V86, P182, DOI 10.1136/fn.86.3.F182
   Leoratti FMS, 2008, J INFECT DIS, V198, P772, DOI 10.1086/590440
   Li LP, 2010, MOL HUM REPROD, V16, P267, DOI 10.1093/molehr/gap106
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marinho CRF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005630
   Marzi M, 1996, CLIN EXP IMMUNOL, V106, P127, DOI 10.1046/j.1365-2249.1996.d01-809.x
   MEURIS S, 1993, AM J TROP MED HYG, V48, P603, DOI 10.4269/ajtmh.1993.48.603
   Mockenhaupt FP, 2006, P NATL ACAD SCI USA, V103, P177, DOI 10.1073/pnas.0506803102
   Muthusamy A, 2004, AM J PATHOL, V164, P2013, DOI 10.1016/S0002-9440(10)63761-3
   Ndam NGT, 2005, J INFECT DIS, V192, P331, DOI 10.1086/430933
   Neres R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001608
   ODUOLA AMJ, 1982, J PROTOZOOL, V29, P77, DOI 10.1111/j.1550-7408.1982.tb02883.x
   Parroche P, 2007, P NATL ACAD SCI USA, V104, P1919, DOI 10.1073/pnas.0608745104
   Pasare C, 2005, ADV EXP MED BIOL, V560, P11
   PAVIA CS, 1991, AM J TROP MED HYG, V44, P176, DOI 10.4269/ajtmh.1991.44.176
   Pichyangkul S, 2004, J IMMUNOL, V172, P4926, DOI 10.4049/jimmunol.172.8.4926
   Poovassery J, 2006, INFECT IMMUN, V74, P2839, DOI 10.1128/IAI.74.5.2839-2848.2006
   Poovassery J, 2009, INFECT IMMUN, V77, P4998, DOI 10.1128/IAI.00617-09
   Poovassery JS, 2009, J IMMUNOL, V183, P5342, DOI 10.4049/jimmunol.0901669
   Ricke CH, 2000, J IMMUNOL, V165, P3309, DOI 10.4049/jimmunol.165.6.3309
   Rodrigues-Duarte L, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-231
   ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15
   Rogerson SJ, 2007, LANCET INFECT DIS, V7, P105, DOI 10.1016/S1473-3099(07)70022-1
   Salanti A, 2004, J EXP MED, V200, P1197, DOI 10.1084/jem.20041579
   Sultan AA, 1999, INFECT IMMUN, V67, P2602, DOI 10.1128/IAI.67.5.2602-2606.1999
   Thevenon AD, 2010, J IMMUNOL, V185, P7115, DOI 10.4049/jimmunol.1002293
   van der Heyde HC, 2006, TRENDS PARASITOL, V22, P503, DOI 10.1016/j.pt.2006.09.002
   Weil ZM, 2006, PHYSIOL BEHAV, V87, P694, DOI 10.1016/j.physbeh.2006.01.005
NR 55
TC 11
Z9 11
U1 0
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD FEB
PY 2014
VL 82
IS 2
BP 830
EP 838
DI 10.1128/IAI.01288-13
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 298XF
UT WOS:000330357100034
PM 24478096
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Almeida, CB
   Souza, LEB
   Costa, FTM
   Werneck, C
   Covas, DT
   Costa, FF
   Conran, N
AF Almeida, Camila Bononi
   Souza, Lucas Eduardo Botelho
   Costa, Fabio Trindade Maranhao
   Werneck, Claudio
   Covas, Dimas T.
   Costa, Fernando Ferreira
   Conran, Nicola
TI Acute Inflammatory Processes Are Induced By Hemolysis and Reversed By
   Hydroxyurea
SO BLOOD
LA English
DT Meeting Abstract
CT 55th Annual Meeting of the American-Society-of-Hematology
CY DEC 07-10, 2013
CL New Orleans, LA
SP Amer Soc Hematol
RI Werneck, Claudio C/C-7568-2012; de Souza, Lucas E. B./F-8743-2015;
   Souza, Lucas E. B./W-7139-2019; Covas, Dimas T/C-5431-2013; Conran,
   Nicola/B-8961-2012; Costa, Fabio/E-1181-2012; CTC USP, CEPID 13
   18/J-8951-2014
OI Werneck, Claudio C/0000-0002-9413-0572; de Souza, Lucas E.
   B./0000-0003-4254-7509; Souza, Lucas E. B./0000-0003-4254-7509; Covas,
   Dimas T/0000-0002-7364-2595; Conran, Nicola/0000-0001-5726-7919; Costa,
   Fabio/0000-0001-9969-7300; CTC USP, CEPID 13 18/0000-0002-7123-9524
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD NOV 15
PY 2013
VL 122
IS 21
MA 951
DI 10.1182/blood.V122.21.951.951
PG 2
WC Hematology
SC Hematology
GA AA9AB
UT WOS:000331385002122
DA 2020-12-08
ER

PT J
AU Malleret, B
   Xu, FG
   Mohandas, N
   Suwanarusk, R
   Chu, C
   Leite, JA
   Low, K
   Turner, C
   Sriprawat, K
   Zhang, R
   Bertrand, O
   Colin, Y
   Costa, FTM
   Ong, CN
   Ng, ML
   Lim, CT
   Nosten, F
   Renia, L
   Russell, B
AF Malleret, Benoit
   Xu, Fenggao
   Mohandas, Narla
   Suwanarusk, Rossarin
   Chu, Cindy
   Leite, Juliana A.
   Low, Kayen
   Turner, Claudia
   Sriprawat, Kanlaya
   Zhang, Rou
   Bertrand, Olivier
   Colin, Yves
   Costa, Fabio T. M.
   Ong, Choon Nam
   Ng, Mah Lee
   Lim, Chwee Teck
   Nosten, Francois
   Renia, Laurent
   Russell, Bruce
TI Significant Biochemical, Biophysical and Metabolic Diversity in
   Circulating Human Cord Blood Reticulocytes
SO PLOS ONE
LA English
DT Article
ID FLOW CYTOMETRIC ANALYSIS; MEMBRANE DEFORMABILITY; TRANSFERRIN RECEPTOR;
   SHEEP RETICULOCYTES; PLASMODIUM-VIVAX; THIAZOLE ORANGE; MATURITY INDEX;
   CELL MEMBRANE; ERYTHROCYTES; MATURATION
AB Background: The transition from enucleated reticulocytes to mature normocytes is marked by substantial remodeling of the erythrocytic cytoplasm and membrane. Despite conspicuous changes, most studies describe the maturing reticulocyte as a homogenous erythropoietic cell type. While reticulocyte staging based on fluorescent RNA stains such as thiazole orange have been useful in a clinical setting; these 'sub-vital' stains may confound delicate studies on reticulocyte biology and may preclude their use in heamoparasite invasion studies.
   Design and Methods: Here we use highly purified populations of reticulocytes isolated from cord blood, sorted by flow cytometry into four sequential subpopulations based on transferrin receptor (CD71) expression: CD71high, CD71medium, CD71low and CD71negative. Each of these subgroups was phenotyped in terms of their, morphology, membrane antigens, biomechanical properties and metabolomic profile.
   Results: Superficially CD71high and CD71medium reticulocytes share a similar gross morphology (large and multilobular) when compared to the smaller, smooth and increasingly concave reticulocytes as seen in the in the CD71low and CD71negativesamples. However, between each of the four sample sets we observe significant decreases in shear modulus, cytoadhesive capacity, erythroid receptor expression (CD44, CD55, CD147, CD235R, and CD242) and metabolite concentrations. Interestingly increasing amounts of boric acid was found in the mature reticulocytes.
   Conclusions: Reticulocyte maturation is a dynamic and continuous process, confounding efforts to rigidly classify them. Certainly this study does not offer an alternative classification strategy; instead we used a nondestructive sampling method to examine key phenotypic changes of in reticulocytes. Our study emphasizes a need to focus greater attention on reticulocyte biology.
C1 [Malleret, Benoit; Suwanarusk, Rossarin; Leite, Juliana A.; Renia, Laurent] ASTAR, Biopolis, Lab Malaria Immunobiol, Singapore Immunol Network SIgN, Singapore, Singapore.
   [Xu, Fenggao; Ong, Choon Nam] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
   [Mohandas, Narla] New York Blood Ctr, Red Cell Physiol Lab, New York, NY 10021 USA.
   [Chu, Cindy; Turner, Claudia; Sriprawat, Kanlaya] Shoklo Malaria Res Unit, Mae Sot, Thailand.
   [Leite, Juliana A.; Costa, Fabio T. M.] Univ Estadual Campinas UNICAMP, Inst Biol, Dept Genet Evolucao & Bioagentes, Sao Paulo, Brazil.
   [Low, Kayen] JEOL Asia Pte Ltd, Singapore, Singapore.
   [Zhang, Rou; Lim, Chwee Teck] Natl Univ Singapore, Singapore MIT Alliance, Singapore 117548, Singapore.
   [Bertrand, Olivier; Colin, Yves] INSERM, UMR S Unite Mixte Rech 665, Paris, France.
   [Bertrand, Olivier; Colin, Yves] Inst Natl Transfus Sanguine, F-75015 Paris, France.
   [Bertrand, Olivier; Colin, Yves] Univ Paris 07, Paris, France.
   [Ng, Mah Lee; Russell, Bruce] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Natl Univ Hlth Syst, Singapore 117595, Singapore.
   [Lim, Chwee Teck] Natl Univ Singapore, Dept Bioengn, Singapore 117548, Singapore.
   [Lim, Chwee Teck] Natl Univ Singapore, Dept Mech Engn, Singapore 117548, Singapore.
   [Nosten, Francois] Mahidol Oxford Univ, Res Unit, Bangkok, Thailand.
   [Nosten, Francois] Univ Oxford, Churchill Hosp, Ctr Trop Med, Oxford, England.
RP Renia, L (corresponding author), ASTAR, Biopolis, Lab Malaria Immunobiol, Singapore Immunol Network SIgN, Singapore, Singapore.
EM renia_laurent@immunol.a-star.edu.sg; micbmr@nus.edu.sg
RI Chu, Cindy S/E-3135-2014; Suwanarusk, Rossarin/E-2115-2013; Leite,
   Juliana/G-2563-2013; colin, yves/O-1910-2017; Malleret,
   Benoit/E-9159-2011; Costa, Fabio/E-1181-2012; Malleret,
   Benoit/AAK-4048-2020; Russell, Bruce/A-9240-2011; Nosten,
   Francois/AAC-5509-2019; Lim, chwee Teck/B-3307-2011
OI Chu, Cindy S/0000-0001-9465-8214; Suwanarusk,
   Rossarin/0000-0002-7310-245X; colin, yves/0000-0001-5196-4254; Malleret,
   Benoit/0000-0001-9658-7528; Costa, Fabio/0000-0001-9969-7300; Malleret,
   Benoit/0000-0001-9658-7528; Russell, Bruce/0000-0003-2333-4348; Nosten,
   Francois/0000-0002-7951-0745; Lim, chwee Teck/0000-0003-4019-9782; Ong,
   Choon Nam/0000-0002-4002-1725
FU Singapore Ministry of Health NMRCMinistry of Health-SingaporeNational
   Medical Research Council, Singapore [CBRG12nov036]; SIgN; Horizontal
   Programme on Infectious Diseases under the Agency for Science,
   Technology and Research (A*STAR, Singapore)Agency for Science Technology
   & Research (ASTAR); Wellcome Trust of Great BritainWellcome Trust;
   Oxford Tropical Medicine Research Programme of Wellcome Trust-Mahidol
   University; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2009/52013-3]; Fundacao de Amparo a Pesquisa do Estado do Amazonas
   (FAPEAM); National University of SingaporeNational University of
   Singapore; National University Health System, Singapore 'Start Up'
   Grant; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R37DK026263, R37DK026263,
   R37DK026263, R37DK026263, R37DK026263, R37DK026263, R37DK026263,
   R37DK026263, R37DK026263, R37DK026263, R37DK026263, R37DK026263,
   R37DK026263, R37DK026263, R37DK026263, R37DK026263, R37DK026263,
   R37DK026263, R37DK026263] Funding Source: NIH RePORTER
FX This study received funding from Singapore Ministry of Health NMRC
   (CBRG12nov036) grant, SIgN and from the Horizontal Programme on
   Infectious Diseases under the Agency for Science, Technology and
   Research (A*STAR, Singapore). SMRU is sponsored by The Wellcome Trust of
   Great Britain, as part of the Oxford Tropical Medicine Research
   Programme of Wellcome Trust-Mahidol University. JAL was supported by a
   fellowship from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP - Process no. 2009/52013-3), and FTMC is enrolled at the
   Programa Estrategico de Ciencia, Tecnologia & Inovacao nas Fundacoes
   Estaduais de Saude (PECTI/AM Saude) from Fundacao de Amparo a Pesquisa
   do Estado do Amazonas (FAPEAM). BR also received financial support from
   the National University of Singapore and National University Health
   System, Singapore 'Start Up' Grant. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR BERTLES JF, 1962, J BIOL CHEM, V237, P3770
   Bessis M., 1973, LIVING BLOOD CELLS T
   BRECHER G, 1950, AM J CLIN PATHOL, V20, P1079
   BRUN A, 1990, BLOOD, V76, P2397
   CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P227, DOI 10.1007/BF01870089
   Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815
   CHAMBERLAIN JK, 1978, BLOOD, V52, P959
   CHASIS JA, 1989, BLOOD, V74, P2562
   Chen K, 2009, P NATL ACAD SCI USA, V106, P17413, DOI 10.1073/pnas.0909296106
   Colella GM, 1991, BLOOD, V78
   Coste I, 2001, BLOOD, V97, P3984, DOI 10.1182/blood.V97.12.3984
   DAVIS BH, 1995, CYTOMETRY, V22, P35, DOI 10.1002/cyto.990220107
   DAVIS BH, 1989, ARCH PATHOL LAB MED, V113, P684
   Dertinger SD, 2002, MUTAT RES-GEN TOX EN, V515, P3, DOI 10.1016/S1383-5718(02)00009-8
   Ehrlich P, 1881, BERL KLIN WSCHR, V18, P43
   Eshghi S, 2007, J CELL BIOL, V177, P871, DOI 10.1083/jcb.200702080
   Goel MS, 2002, BLOOD, V100, P3797, DOI 10.1182/blood-2002-03-0712
   Goh SH, 2007, PHYSIOL GENOMICS, V30, P172, DOI 10.1152/physiolgenomics.00247.2006
   Griffiths RE, 2012, BLOOD, V119, P6296, DOI 10.1182/blood-2011-09-376475
   Heilmeyer L, 1932, Z KLIN MED, V121, P361
   Ihanus E, 2007, BLOOD, V109, P802, DOI 10.1182/blood-2006-04-014878
   Jeremy KP, 2009, HAEMATOL-HEMATOL J, V94, P1354, DOI 10.3324/haematol.2009.006585
   Key JA, 1921, ARCH INTERN MED, V28, P511, DOI 10.1001/archinte.1921.00100170012002
   Khandelwal S, 2006, EXP GERONTOL, V41, P855, DOI 10.1016/j.exger.2006.06.045
   Kono M, 2009, CLIN CHIM ACTA, V404, P105, DOI 10.1016/j.cca.2009.03.017
   KOSENOW W, 1952, Z Kinderheilkd, V70, P552
   LACELLE PL, 1970, SEMIN HEMATOL, V7, P355
   LEBLOND PF, 1971, BLOOD-J HEMATOL, V37, P40, DOI 10.1182/blood.V37.1.40.40
   Lee G, 2006, BLOOD, V108, P2064, DOI 10.1182/blood-2006-03-006759
   LEE LG, 1986, CYTOMETRY, V7, P508, DOI 10.1002/cyto.990070603
   LEWIS M, 1977, AM J HUM GENET, V29, P101
   LOWENSTEIN LM, 1959, INT REV CYTOL, V8, P135, DOI 10.1016/S0074-7696(08)62730-8
   Malleret B, 2011, SCI REP-UK, V1, DOI 10.1038/srep00118
   MEL HC, 1977, BLOOD, V49, P1001
   Mohandas N, 2008, BLOOD, V112, P3939, DOI 10.1182/blood-2008-07-161166
   NOBES PR, 1990, J CLIN PATHOL, V43, P675, DOI 10.1136/jcp.43.8.675
   PAN BT, 1985, J CELL BIOL, V101, P942, DOI 10.1083/jcb.101.3.942
   PAN BT, 1983, CELL, V33, P967, DOI 10.1016/0092-8674(83)90040-5
   PAPAYANNOPOULOU T, 1975, BLOOD CELLS, V1, P535
   Park M, 2004, MOL CELL, V16, P331, DOI 10.1016/j.molcel.2004.09.030
   PATERAKIS GS, 1993, ACTA HAEMATOL-BASEL, V90, P182
   Pushkin A, 2006, AM J PHYSIOL-RENAL, V290, pF580, DOI 10.1152/ajprenal.00252.2005
   Riley RS, 2001, J CLIN LAB ANAL, V15, P267, DOI 10.1002/jcla.1039
   Russell B, 2011, BLOOD, V118, pE74, DOI 10.1182/blood-2011-04-348748
   SAGE BH, 1983, CYTOMETRY, V4, P222, DOI 10.1002/cyto.990040306
   Salomao M, 2008, P NATL ACAD SCI USA, V105, P8026, DOI 10.1073/pnas.0803225105
   Sathyanarayana P, 2007, BLOOD, V110, P509, DOI 10.1182/blood-2006-11-056465
   Seip M, 1953, ACTA MED SCANDINAVIC, V146
   Southcott MJG, 1999, BLOOD, V93, P4425, DOI 10.1182/blood.V93.12.4425.412k22_4425_4435
   Turkez H, 2012, CYTOTECHNOLOGY
   Xu FG, 2009, RAPID COMMUN MASS SP, V23, P3243, DOI 10.1002/rcm.4246
NR 51
TC 54
Z9 54
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 8
PY 2013
VL 8
IS 10
AR e76062
DI 10.1371/journal.pone.0076062
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 233FK
UT WOS:000325552200047
PM 24116088
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU De las Salas, B
   Segura, C
   Pabon, A
   Lopes, SCP
   Costa, FTM
   Blair, S
AF De las Salas, Briegel
   Segura, Cesar
   Pabon, Adriana
   Lopes, Stefanie C. P.
   Costa, Fabio T. M.
   Blair, Silvia
TI Adherence to human lung microvascular endothelial cells (HMVEC-L) of
   Plasmodium vivax isolates from Colombia
SO MALARIA JOURNAL
LA English
DT Article
DE Cytoadherence; Plasmodium vivax; Malaria; ICAM-1; Microvascular line of
   human lung endothelium; Colombia
ID HUMAN MALARIA PARASITE; IMMUNE-RESPONSES; FALCIPARUM; COMPLICATIONS;
   ERYTHROCYTES; INFECTIONS; PROTEINS; PROFILE; INJURY
AB Background: For years Plasmodium vivax has been considered the cause of benign malaria. Nevertheless, it has been observed that this parasite can produce a severe disease comparable to Plasmodium falciparum. It has been suggested that some physiopathogenic processes might be shared by these two species, such as cytoadherence. Recently, it has been demonstrated that P. vivax-infected erythrocytes (Pv-iEs) have the capacity to adhere to endothelial cells, in which intercellular adhesion molecule-1 (ICAM-1) seems to be involved in this process.
   Methods: Adherence capacity of 21 Colombian isolates, from patients with P. vivax mono-infection to a microvascular line of human lung endothelium (HMVEC-L) was assessed in static conditions and binding was evaluated at basal levels or in tumor necrosis factor (TNF) stimulated cells. The adherence specificity for the ICAM-1 receptor was determined through inhibition with an anti-CD54 monoclonal antibody.
   Results: The majority of P. vivax isolates, 13 out of 21 (61.9%), adhered to the HMVEC-L cells, but P. vivax adherence was at least seven times lower when compared to the four P. falciparum isolates. Moreover, HMVEC-L stimulation with TNF led to an increase of 1.6-fold in P. vivax cytoadhesion, similar to P. falciparum isolates (1.8-fold) at comparable conditions. Also, blockage of ICAM-1 receptor with specific antibodies showed a significant 50% adherence reduction.
   Conclusions: Plasmodium vivax isolates found in Colombia are also capable of adhering specifically in vitro to lung endothelial cells, via ICAM-1 cell receptor, both at basal state and after cell stimulation with TNF. Collectively, these findings reinforce the concept of cytoadherence for P. vivax, but here, to a different endothelial cell line and using geographical distinct isolates, thus contributing to understanding P. vivax biology.
C1 [De las Salas, Briegel; Segura, Cesar; Pabon, Adriana; Blair, Silvia] Univ Antioquia UdeA, Fac Med, Grp Malaria, Medellin, Colombia.
   [Pabon, Adriana] Univ Atlantico, Fac Ciencias Basicas, Programa Biol, Barranquilla 080001, Colombia.
   [Lopes, Stefanie C. P.; Costa, Fabio T. M.] Univ Estadual Campinas, UNICAMP, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
RP Blair, S (corresponding author), Univ Antioquia UdeA, Fac Med, Grp Malaria, Calle 70 52-21, Medellin, Colombia.
EM silviablairt@gmail.com
RI Pabon, Adriana/H-3253-2016; Costa, Fabio/E-1181-2012; Latorre, Cesar
   Hernando Segura/AAH-5857-2020; Lopes, Stefanie/A-8314-2012
OI Pabon, Adriana/0000-0002-5535-0708; Costa, Fabio/0000-0001-9969-7300;
   Latorre, Cesar Hernando Segura/0000-0002-9979-8416; Lopes,
   Stefanie/0000-0002-6981-2192
FU ColcienciasDepartamento Administrativo de Ciencia, Tecnologia e
   Innovacion Colciencias [111549326146, RC-489-2009]; Universidad de
   Antioquia, Colombia (CODI-Estrategia de Sostenibilidad); Fundacao de
   Amparo a Pesquisa do Estado do Amazonas (FAPEAM, Amazonas - Brazil);
   FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   CNPqNational Council for Scientific and Technological Development (CNPq)
FX The authors would like to thank the patients for their willingness
   during the samples collection, and the Nuestra Senora del Carmen
   Hospital staff in El Bagre - Department of Antioquia for lending us the
   malaria sample collecting equipment, and the clinical laboratory for
   letting us use their equipment. Ana Mar a Vasquez Cardona, PhD Biology
   student, for her unconditional support in the experimental development
   of the investigation, and the Grupo Malaria. This work was supported by
   Colciencias (Grant 111549326146, RC-489-2009) and the Universidad de
   Antioquia, Colombia (CODI-Estrategia de Sostenibilidad 2013-2014). BD,
   AP, CS and SB were sponsored by Colciencias (Grant 111549326146,
   RC-489-2009) and the Universidad de Antioquia, Colombia (CODI-Estrategia
   de Sostenibilidad 2013-2014). FTMC is enrolled at the Programa
   Estrategico de Ciencia, Tecnologia & Inovacao nas Fundacoes Estaduais de
   Sa de (PECTI/AM Sa de) from Fundacao de Amparo a Pesquisa do Estado do
   Amazonas (FAPEAM, Amazonas - Brazil). SCPL was supported by a FAPESP
   fellowship and CNPq-Universal grant.
CR Alexandre MA, 2010, EMERG INFECT DIS, V16, P1611, DOI 10.3201/eid1610.100685
   Anstey NM, 2007, J INFECT DIS, V195, P589, DOI 10.1086/510756
   Arboleda M, 2012, BIOMEDICA, V32, P58, DOI 10.1590/S0120-41572012000500008
   Bernabeu M, 2012, CELL MICROBIOL, V14, P386, DOI 10.1111/j.1462-5822.2011.01726.x
   Carlton JM, 2008, NATURE, V455, P757, DOI 10.1038/nature07327
   Carmona-Fonseca Jaime, 2009, Rev Colomb Obstet Ginecol, V60, P19
   Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815
   Chotivanich K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034509
   Coban C, 2007, TRENDS MICROBIOL, V15, P271, DOI 10.1016/j.tim.2007.04.003
   Duraisingh MT, 2000, MOL MICROBIOL, V36, P955, DOI 10.1046/j.1365-2958.2000.01914.x
   Engwerda C, 2005, CURR TOP MICROBIOL, V297, P103
   Fernandez V, 1998, INFECT IMMUN, V66, P2969, DOI 10.1128/IAI.66.6.2969-2975.1998
   Fernandez-Becerra C, 2005, MOL MICROBIOL, V58, P648, DOI 10.1111/j.1365-2958.2005.04850.x
   Pineros-Jimenez JG, 2008, BIOMEDICA, V28, P471, DOI 10.7705/biomedica.v28i4.53
   George P, 2010, ASIAN PAC J TROP MED, V3, P560, DOI 10.1016/S1995-7645(10)60135-6
   GOODYER ID, 1994, ANN TROP MED PARASIT, V88, P209, DOI 10.1080/00034983.1994.11812859
   Gupta P, 2012, ACTA TROP, V124, P133, DOI 10.1016/j.actatropica.2012.07.002
   Harish R, 2009, INDIAN J PEDIATR, V76, P551, DOI 10.1007/s12098-009-0087-0
   Kumar S, 2007, SCAND J INFECT DIS, V39, P255, DOI 10.1080/00365540600904787
   Kute VB, 2012, PARASITOL RES, V110, P2573, DOI 10.1007/s00436-011-2776-7
   Lomar André V., 2005, Braz J Infect Dis, V9, P425, DOI 10.1590/S1413-86702005000500011
   Martinez O., 1996, ACTA MED COLOMB, V21, P146
   Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X
   Oliveira TR, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-83
   Pabon A, 2007, BIOMEDICA, V27, P225, DOI 10.7705/biomedica.v27i2.218
   Tan LKK, 2008, LANCET INFECT DIS, V8, P449, DOI 10.1016/S1473-3099(08)70153-1
   Tanios MA, 2001, CRIT CARE MED, V29, P665, DOI 10.1097/00003246-200103000-00037
   Tjitra E, 2008, PLOS MED, V5, P890, DOI 10.1371/journal.pmed.0050128
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Valecha N, 2009, AM J TROP MED HYG, V81, P758, DOI 10.4269/ajtmh.2009.09-0348
   Zubairi A, 2012, CHEST, V142, p194A
NR 31
TC 16
Z9 16
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD SEP 30
PY 2013
VL 12
AR 347
DI 10.1186/1475-2875-12-347
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 281IW
UT WOS:000329095400001
PM 24080027
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Versiani, FG
   Almeida, MEM
   Melo, GC
   Versiani, FOL
   Orlandi, PP
   Mariuba, LAM
   Soares, LA
   Souza, LP
   Balieiro, AAD
   Monteiro, WM
   Costa, FTM
   del Portillo, HA
   Lacerda, MVG
   Nogueira, PA
AF Versiani, Fernanda G.
   Almeida, Maria E. M.
   Melo, Gisely C.
   Versiani, Francivaldo O. L.
   Orlandi, Patricia P.
   Mariuba, Luis Andre M.
   Soares, Leidiane A.
   Souza, Luciana P.
   da Silva Balieiro, Antonio A.
   Monteiro, Wuelton M.
   Costa, Fabio T. M.
   del Portillo, Hernando A.
   Lacerda, Marcus V. G.
   Nogueira, Paulo A.
TI High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals
   who did not develop symptoms
SO MALARIA JOURNAL
LA English
DT Article
DE Malaria; Plasmodium vivax; Merozoite surface protein-1; Clinical
   protection; IgG3
ID MEROZOITE SURFACE PROTEIN-1; HUMORAL IMMUNE-RESPONSES; ASEXUAL BLOOD
   STAGES; C-TERMINAL REGIONS; MALARIA PARASITE; BRAZILIAN AMAZON; RURAL
   AMAZONIANS; IN-VITRO; BLOCK 2; FALCIPARUM
AB Background: Plasmodium vivax has the potential to infect 2.85 billion individuals worldwide. Nevertheless, the limited number of studies investigating the immune status of individuals living in malaria-endemic areas, as well as the lack of reports investigating serological markers associated with clinical protection, has hampered development of vaccines for P. vivax. It was previously demonstrated that naturally total IgG against the N-terminus of P. vivax merozoite surface protein 1 (Pv-MSP1) was associated with reduced risk of malarial infection.
   Methods: Immune response against Pv-MSP1 (N-terminus) of 313 residents of the Rio Pardo rural settlement (Amazonas State, Brazil) was evaluated in a cross-sectional and longitudinal follow up over two months (on site) wherein gold standard diagnosis by thick blood smear and rRNA gene-based nested real-time PCR were used to discriminate symptomless Plasmodium vivax-infected individuals who did not develop clinical symptoms during a 2-months from those uninfected ones or who have had acute malaria. The acquisition of antibodies against Pv-MSP1 was also evaluated as survival analysis by prospective study over a year collecting information of new malaria infections in surveillance database.
   Results: The majority of P. vivax-infected individuals (52-67%) showed immune recognition of the N-terminus of Pv-MSP1. Interesting data on infected individuals who have not developed symptoms, total IgG levels against the N-terminus Pv-MSP1 were age-dependent and the IgG3 levels were significantly higher than levels of subjects had acute malaria or those uninfected ones. The total IgG anti ICB2-5 was detected to be an important factor of protection against new malaria vivax attacks in survival analysis in a prospective survey (p = 0.029).
   Conclusions: The study findings illustrate the importance of IgG3 associated to 2-months of symptomless in P. vivax infected individuals and open perspectives for the rationale of malaria vaccine designs capable to sustain high levels of IgG3 against polymorphic malaria antigens.
C1 [Versiani, Fernanda G.; Almeida, Maria E. M.; Orlandi, Patricia P.; Mariuba, Luis Andre M.; Soares, Leidiane A.; Souza, Luciana P.; da Silva Balieiro, Antonio A.; Nogueira, Paulo A.] Inst Leonidas e Maria Deane Fiocruz, BR-69057070 Manaus, Amazonas, Brazil.
   [Versiani, Fernanda G.; Versiani, Francivaldo O. L.; Orlandi, Patricia P.; Monteiro, Wuelton M.; Lacerda, Marcus V. G.; Nogueira, Paulo A.] Univ Fed Amazonas, Manaus, Amazonas, Brazil.
   [Melo, Gisely C.; Monteiro, Wuelton M.] Fundacao Med Trop Heitor Vieira Dourado, BR-69040000 Manaus, Amazonas, Brazil.
   [Melo, Gisely C.; Monteiro, Wuelton M.] Univ Estado Amazonas, BR-69040000 Manaus, Amazonas, Brazil.
   [Costa, Fabio T. M.] Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
   [del Portillo, Hernando A.] ICREA Barcelona Ctr Int Hlth Res CRESIB Rossello, Barcelona 08036, Spain.
RP Nogueira, PA (corresponding author), Inst Leonidas e Maria Deane Fiocruz, Rua Teresina 476, BR-69057070 Manaus, Amazonas, Brazil.
EM paulonogueira@amazonia.fiocruz.br
RI Costa, Fabio/E-1181-2012; Nogueira, Paulo/AAK-8822-2020; del Portillo,
   Hernando A/L-2131-2014
OI Costa, Fabio/0000-0001-9969-7300; del Portillo, Hernando
   A/0000-0002-5278-3452
FU CNPq (Program FIOCRUZ-CNPq/Papes V); FAPEAM (Fundacao de Amparo a
   Pesquisa do Estado do Amazonas); Federal University of the Amazonas;
   ICREAICREA Funding Source: Custom
FX This study was supported by funding from CNPq (Program
   FIOCRUZ-CNPq/Papes V) and FAPEAM (Fundacao de Amparo a Pesquisa do
   Estado do Amazonas; Program PIPT - 2009). FGV and MEMA are supported by
   a Masters Scholarship from the Post-Graduate Program in Basic and
   Applied Immunology of the Federal University of the Amazonas.
   FIOCRUZ-ILMD funded logistical support for the study cohort. FTMC is
   enrolled by the Programa Estrategico de Ciencia, Tecnologia & Inovacao
   nas Fundacoes Estaduais de Saude (PECTI/AM Saude) of FAPEAM. FTMC is a
   Level 1D CNPq fellow. PAN and MVGL are Level 2 CNPq fellows.
CR Akpogheneta OJ, 2008, INFECT IMMUN, V76, P1748, DOI 10.1128/IAI.01333-07
   Alexandre MA, 2010, EMERG INFECT DIS, V16, P1611, DOI 10.3201/eid1610.100685
   Baird JK, 2011, ANTIMICROB AGENTS CH, V55, P1827, DOI 10.1128/AAC.01296-10
   Bastos MS, 2007, CLIN VACCINE IMMUNOL, V14, P1249, DOI 10.1128/CVI.00243-07
   Bergmann-Leitner ES, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-315
   BOUHAROUNTAYOUN H, 1995, J EXP MED, V182, P409, DOI 10.1084/jem.182.2.409
   Browder JO, 2008, WORLD DEV, V36, P1469, DOI 10.1016/j.worlddev.2007.08.008
   Bueno LL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021289
   Aguiar ACC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037259
   Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815
   Cavanagh DR, 2004, INFECT IMMUN, V72, P6492, DOI 10.1128/IAI.72.11.6492-6502.2004
   Cavanagh DR, 2001, INFECT IMMUN, V69, P1207, DOI 10.1128/IAI.69.2.1207-1211.2001
   Costa FTM, 2012, INT J PARASITOL, V42, P1099, DOI 10.1016/j.ijpara.2012.08.007
   Cowan GJM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026616
   del Carmen R, 2012, AM J TROP MED HYG, V87, P813, DOI 10.4269/ajtmh.2012.12-0094
   DELPORTILLO HA, 1991, P NATL ACAD SCI USA, V88, P4030, DOI 10.1073/pnas.88.9.4030
   DELPORTILLO HA, 1992, MEM I OSWALDO CRUZ, V87, P77, DOI 10.1590/S0074-02761992000700010
   Druilhe P, 1997, PARASITOL TODAY, V13, P353, DOI 10.1016/S0169-4758(97)01095-8
   DRUILHE P, 1994, IMMUNOL LETT, V41, P115, DOI 10.1016/0165-2478(94)90118-X
   Ellis RD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046094
   Fernandez-Becerra C, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-29
   Fontes CJF, 2010, MALARIAS TREATMENT B
   Galamo CD, 2009, J INFECT DIS, V199, P1151, DOI 10.1086/597426
   Galinski MR, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-S1-S9
   Gama BE, 2011, MEM I OSWALDO CRUZ, V106, P159, DOI 10.1590/S0074-02762011000900020
   Garg S, 2012, EXP PARASITOL, V132, P410, DOI 10.1016/j.exppara.2012.09.018
   HOLDER AA, 1992, MEM I OSWALDO CRUZ, V87, P37, DOI 10.1590/S0074-02761992000700004
   Jafarshad A, 2007, J IMMUNOL, V178, P3099, DOI 10.4049/jimmunol.178.5.3099
   Jouin H, 2001, EUR J IMMUNOL, V31, P539, DOI 10.1002/1521-4141(200102)31:2&lt;539::AID-IMMU539&gt;3.0.CO;2-1
   Kadekoppala M, 2010, INT J PARASITOL, V40, P1155, DOI 10.1016/j.ijpara.2010.04.008
   Kerlin DH, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001772
   Lacerda MVG, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-12
   Lazarou M, 2009, INFECT IMMUN, V77, P5659, DOI 10.1128/IAI.00167-09
   LEVITUS G, 1994, AM J TROP MED HYG, V51, P68, DOI 10.4269/ajtmh.1994.51.68
   Lu F, 2012, KOREAN J PARASITOL, V50, P379, DOI 10.3347/kjp.2012.50.4.379
   Marfurt J, 2012, ANTIMICROB AGENTS CH, V56, P5258, DOI 10.1128/AAC.00283-12
   McCallum FJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003571
   MERTENS F, 1993, AM J TROP MED HYG, V49, P383, DOI 10.4269/ajtmh.1993.49.383
   Miura K, 2009, CLIN VACCINE IMMUNOL, V16, P963, DOI 10.1128/CVI.00042-09
   Moss DK, 2012, INFECT IMMUN, V80, P1280, DOI 10.1128/IAI.05887-11
   Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X
   Nogueira PA, 2006, INFECT IMMUN, V74, P2726, DOI 10.1128/IAI.74.5.2726-2733.2006
   Okenu DMN, 2000, INFECT IMMUN, V68, P5559, DOI 10.1128/IAI.68.10.5559-5566.2000
   Oliveira-Ferreira J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-115
   Perandin F, 2004, J CLIN MICROBIOL, V42, P1214, DOI 10.1128/JCM.42.3.1214-1219.2004
   Price RN, 2009, CURR OPIN INFECT DIS, V22, P430, DOI 10.1097/QCO.0b013e32832f14c1
   Putaporntip C, 2002, P NATL ACAD SCI USA, V99, P16348, DOI 10.1073/pnas.252348999
   Rougemont M, 2004, J CLIN MICROBIOL, V42, P5636, DOI 10.1128/JCM.42.12.5636-5643.2004
   Roussilhon C, 2007, PLOS MED, V4, P1791, DOI 10.1371/journal.pmed.0040320
   Sarthou JL, 1997, INFECT IMMUN, V65, P3271, DOI 10.1128/IAI.65.8.3271-3276.1997
   Scopel KKG, 2007, AM J TROP MED HYG, V76, P1084, DOI 10.4269/ajtmh.2007.76.1084
   Sheehy SH, 2011, MOL THER, V19, P2269, DOI 10.1038/mt.2011.176
   Soares IS, 1999, AM J TROP MED HYG, V60, P357, DOI 10.4269/ajtmh.1999.60.357
   Soares IS, 1997, INFECT IMMUN, V65, P1606, DOI 10.1128/IAI.65.5.1606-1614.1997
   Storti-Melo LM, 2011, AM J TROP MED HYG, V84, P58, DOI 10.4269/ajtmh.2011.10-0044
   Stubbs J, 2011, INFECT IMMUN, V79, P1143, DOI 10.1128/IAI.01034-10
   Tetteh KKA, 2011, VACCINE, V29, P7811, DOI 10.1016/j.vaccine.2011.07.106
   Woodberry T, 2008, J INFECT DIS, V198, P134, DOI 10.1086/588711
NR 58
TC 24
Z9 25
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1475-2875
J9 MALARIA J
JI Malar. J.
PD AUG 27
PY 2013
VL 12
AR 294
DI 10.1186/1475-2875-12-294
PG 12
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 214JU
UT WOS:000324129800001
PM 23977965
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Pohlit, AM
   Lima, RBS
   Frausin, G
   Silva, LFRE
   Lopes, SCP
   Moraes, CB
   Cravo, P
   Lacerda, MVG
   Siqueira, AM
   Freitas, LH
   Costa, FTM
AF Pohlit, Adrian Martin
   Souza Lima, Renata Braga
   Frausin, Gina
   Rocha e Silva, Luiz Francisco
   Pinto Lopes, Stefanie Costa
   Moraes, Carolina Borsoi
   Cravo, Pedro
   Guimaraes Lacerda, Marcus Vinicius
   Siqueira, Andre Machado
   Freitas-Junior, Lucio H.
   Maranhao Costa, Fabio Trindade
TI Amazonian Plant Natural Products: Perspectives for Discovery of New
   Antimalarial Drug Leads
SO MOLECULES
LA English
DT Review
DE herbal remedy; Plasmodium spp.; antimalarials; drug discovery; Amazonian
   plants
ID PLASMODIUM-VIVAX MALARIA; IN-VITRO; EXOERYTHROCYTIC PARASITES;
   LACTATE-DEHYDROGENASE; THERAPEUTIC RESPONSE; FIREFLY LUCIFERASE;
   FALCIPARUM-MALARIA; INDOLE ALKALOIDS; FRENCH-GUIANA; CHLOROQUINE
AB Plasmodium falciparum and P. vivax malaria parasites are now resistant, or showing signs of resistance, to most drugs used in therapy. Novel chemical entities that exhibit new mechanisms of antiplasmodial action are needed. New antimalarials that block transmission of Plasmodium spp. from humans to Anopheles mosquito vectors are key to malaria eradication efforts. Although P. vivax causes a considerable number of malaria cases, its importance has for long been neglected. Vivax malaria can cause severe manifestations and death; hence there is a need for P. vivax-directed research. Plants used in traditional medicine, namely Artemisia annua and Cinchona spp. are the sources of the antimalarial natural products artemisinin and quinine, respectively. Based on these compounds, semi-synthetic artemisinin-derivatives and synthetic quinoline antimalarials have been developed and are the most important drugs in the current therapeutic arsenal for combating malaria. In the Amazon region, where P. vivax predominates, there is a local tradition of using plant-derived preparations to treat malaria. Here, we review the current P. falciparum and P. vivax drug-sensitivity assays, focusing on challenges and perspectives of drug discovery for P. vivax, including tests against hypnozoites. We also present the latest findings of our group and others on the antiplasmodial and antimalarial chemical components from Amazonian plants that may be potential drug leads against malaria.
C1 [Pohlit, Adrian Martin; Souza Lima, Renata Braga; Frausin, Gina; Rocha e Silva, Luiz Francisco] INPA, BR-69067375 Manaus, Amazonas, Brazil.
   [Pinto Lopes, Stefanie Costa; Maranhao Costa, Fabio Trindade] Univ Estadual Campinas UNICAMP, Dept Genet Evolucao & Bioagentes, BR-13083862 Campinas, SP, Brazil.
   [Moraes, Carolina Borsoi; Freitas-Junior, Lucio H.] CNEPM, Lab Nacl Biociencias LNBio, BR-13083970 Campinas, SP, Brazil.
   [Cravo, Pedro] UniEVANGELICA Ctr Univ Anapolis, Programa Mestrado Sociedade Tecnol & Meio Ambient, BR-75083515 Anapolis, GO, Brazil.
   [Cravo, Pedro] LA IHMT Univ Nova Lisboa, Ctr Malaria & Doencas Tropicais, P-1349008 Lisbon, Portugal.
   [Guimaraes Lacerda, Marcus Vinicius; Siqueira, Andre Machado] Fundacao Med Trop Dr Heitor Vieira Dourado, BR-69040000 Manaus, Amazonas, Brazil.
   [Guimaraes Lacerda, Marcus Vinicius; Siqueira, Andre Machado] Univ Estado Amazonas, Programa Posgrad Med Trop, BR-69040000 Manaus, Amazonas, Brazil.
RP Pohlit, AM (corresponding author), INPA, Av Andre Araujo 2936, BR-69067375 Manaus, Amazonas, Brazil.
EM ampohlit@inpa.gov.br; renatabsl@hotmail.com; ginafrausin@gmail.com;
   luizrocha_silva@hotmail.com; stefaniecplopes@gmail.com;
   carolina.borsoi@lnbio.cnpem.br; pedrovcravo@gmail.com;
   marcuslacerda.br@gmail.com; amsiqueira@gmail.com;
   lucio.freitasjunior@lnbio.cnpem.br; fabiotmc72@gmail.com
RI Costa, Fabio/E-1181-2012; Freitas-Junior, Lucio H/C-8677-2011; Pohlit,
   Adrian/M-8122-2017; Lopes, Stefanie/A-8314-2012; Pohlit,
   Adrian/E-8125-2010; Moraes, Carolina Borsoi/I-4408-2014; Cravo, Pedro
   VL/G-3532-2012; Siqueira, Andre M/G-1340-2010
OI Costa, Fabio/0000-0001-9969-7300; Freitas-Junior, Lucio
   H/0000-0002-8904-7897; Pohlit, Adrian/0000-0002-6793-3759; Pohlit,
   Adrian/0000-0002-6793-3759; Moraes, Carolina Borsoi/0000-0002-0689-2770;
   Cravo, Pedro VL/0000-0003-1675-4504; Siqueira, Andre
   M/0000-0003-2208-0294; Lopes, Stefanie/0000-0002-6981-2192
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP,
   Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Fundacao de Amparo a Pesquisa do Estado do Amazonas (FAPEAM, Brazil);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq,
   Brazil)National Council for Scientific and Technological Development
   (CNPq); National Malaria Network, Bionorth Network; Instituto Nacional
   de Tecnologia em Vacinas (CNPq-FAPEMIG, Brazil); Instituto Nacional de
   Tecnologia em Doencas Negligenciadas (CNPq, Brazil); FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); PCI/INPA/MCTI/CNPq
FX This work received financial support from Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP, Brazil), Fundacao de Amparo a Pesquisa
   do Estado do Amazonas (FAPEAM, Brazil; PRONEX), Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil; National Malaria
   Network, Bionorth Network), Instituto Nacional de Tecnologia em Vacinas
   (CNPq-FAPEMIG, Brazil) and Instituto Nacional de Tecnologia em Doencas
   Negligenciadas (CNPq, Brazil). S. C. P. L. is sponsored by FAPESP
   fellowship. L. F. R. S. was supported by a PCI/INPA/MCTI/CNPq
   fellowship. A. M. P. M. V. G. L. and F. T. M. C. are CNPq fellows. F. T.
   M. C. is enrolled at the Programa Estrategico de Ciencia, Tecnologia &
   Inovacao nas Fundacoes Estaduais de Saude (PECTI/AM Saude) from Fundacao
   de Amparo a Pesquisa do Estado do Amazonas (FAPEAM, Brazil). P. C. is a
   fellow of CAPES/PVE in Brazil.
CR Achan J, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-144
   Aguiar ACC, 2012, MEM I OSWALDO CRUZ, V107, P831, DOI 10.1590/S0074-02762012000700001
   Alexandre MA, 2010, EMERG INFECT DIS, V16, P1611, DOI 10.3201/eid1610.100685
   Andrade-Neto VF, 2008, INT J PARASITOL, V38, P1505, DOI 10.1016/j.ijpara.2008.05.007
   Anstey NM, 2009, TRENDS PARASITOL, V25, P220, DOI 10.1016/j.pt.2009.02.003
   Baird JK, 2007, TRENDS PARASITOL, V23, P533, DOI 10.1016/j.pt.2007.08.011
   Baird JK, 2010, LANCET, V376, P1883, DOI 10.1016/S0140-6736(10)61494-8
   Baird JK, 2009, CLIN MICROBIOL REV, V22, P508, DOI 10.1128/CMR.00008-09
   Baird JK, 1997, AM J TROP MED HYG, V56, P627, DOI 10.4269/ajtmh.1997.56.627
   Barcus MJ, 2007, AM J TROP MED HYG, V77, P984, DOI 10.4269/ajtmh.2007.77.984
   Carneiro ALB, 2008, MEM I OSWALDO CRUZ, V103, P31, DOI 10.1590/S0074-02762008000100005
   Bassat Q, 2011, NAT MED, V17, P48, DOI 10.1038/nm0111-48
   Beg MA, 2008, INT J INFECT DIS, V12, P37, DOI 10.1016/j.ijid.2007.04.006
   Bero J, 2011, PLANTA MED, V77, P631, DOI 10.1055/s-0030-1250405
   Bertani S, 2006, J ETHNOPHARMACOL, V108, P155, DOI 10.1016/j.jep.2006.04.017
   BOYD MF, 1935, AM J TROP MED, V16, P133
   Bray PG, 2005, CURR TOP MICROBIOL, V295, P3
   CABRAL JA, 1993, J NAT PROD, V56, P1954, DOI 10.1021/np50101a014
   Cachet N, 2009, ANTIMICROB AGENTS CH, V53, P4393, DOI 10.1128/AAC.00951-09
   Camargo M.R.M., 2011, THESIS U FEDERAL RON
   Carlton JM, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001160
   Cavalcanti BC, 2012, PHARM BIOL, V50, P980, DOI 10.3109/13880209.2012.654921
   Cervantes S, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-1
   Che PL, 2012, ASSAY DRUG DEV TECHN, V10, P61, DOI 10.1089/adt.2011.0378
   Chong CR, 2003, BIOCHEM PHARMACOL, V66, P2201, DOI 10.1016/j.bcp.2003.08.009
   Chotivanich K, 2004, AM J TROP MED HYG, V70, P395, DOI 10.4269/ajtmh.2004.70.395
   Costa FTM, 2012, INT J PARASITOL, V42, P1099, DOI 10.1016/j.ijpara.2012.08.007
   Cui L, 2008, EXP PARASITOL, V120, P80, DOI 10.1016/j.exppara.2008.05.003
   Da Mata A.A., 2003, FLORA MED BRASILIENS
   Pinto ACD, 2010, PLANTA MED, V76, P1473, DOI 10.1055/s-0029-1240938
   Pinto ACD, 2009, EUR J MED CHEM, V44, P2731, DOI 10.1016/j.ejmech.2008.10.025
   de Andrade-Neto VF, 2007, MEM I OSWALDO CRUZ, V102, P359, DOI 10.1590/S0074-02762007000300016
   de Lacerda MVG, 2007, REV SOC BRAS MED TRO, V40, P489, DOI 10.1590/S0037-86822007000400026
   Deharo E, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-S1-S5
   DESJARDINS RE, 1979, ANTIMICROB AGENTS CH, V16, P710, DOI 10.1128/AAC.16.6.710
   Torres ZED, 2013, MOLECULES, V18, P6281, DOI 10.3390/molecules18066281
   Druilhe P, 2001, AM J TROP MED HYG, V64, P233, DOI 10.4269/ajtmh.2001.64.233
   ELISABETSKY E, 1994, PHARMACOL THERAPEUT, V64, P201, DOI 10.1016/0163-7258(94)90039-6
   Enserink M, 2007, SCIENCE, V318, P560, DOI 10.1126/science.318.5850.560
   Feachem RGA, 2010, LANCET, V376, P1566, DOI 10.1016/S0140-6736(10)61270-6
   Gama BE, 2011, MEM I OSWALDO CRUZ, V106, P159, DOI 10.1590/S0074-02762011000900020
   Genton B, 2008, PLOS MED, V5, P881, DOI 10.1371/journal.pmed.0050127
   Gething PW, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001814
   Guerra CA, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000774
   HARINASUTA T, 1965, LANCET, V2, P657
   Harinasuta T., 1962, UNESCO 1 REG S SCI K
   Hastings MD, 2004, J INFECT DIS, V189, P744, DOI 10.1086/381397
   Henrique MC, 2010, QUIM NOVA, V33, P284, DOI 10.1590/S0100-40422010000200010
   HOLLINGDALE MR, 1986, AM J TROP MED HYG, V35, P275, DOI 10.4269/ajtmh.1986.35.275
   HOLLINGDALE MR, 1985, AM J TROP MED HYG, V34, P216, DOI 10.4269/ajtmh.1985.34.216
   Jullian V, 2006, J ETHNOPHARMACOL, V106, P348, DOI 10.1016/j.jep.2006.01.011
   Karl S, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-294
   Kerlin DH, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001772
   Kochar DK, 2009, AM J TROP MED HYG, V80, P194, DOI 10.4269/ajtmh.2009.80.194
   Kochar DK, 2005, EMERG INFECT DIS, V11, P132, DOI 10.3201/eid1101.040519
   Krettli AU, 2009, CURR DRUG TARGETS, V10, P261, DOI 10.2174/138945009787581203
   Krudsood S, 2008, AM J TROP MED HYG, V78, P736, DOI 10.4269/ajtmh.2008.78.736
   Ku MJ, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-118
   Lacerda MVG, 2012, CLIN INFECT DIS, V55, pE67, DOI 10.1093/cid/cis615
   Lampah DA, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001032
   Lima ES, 2013, MOLECULES, V18, P178, DOI 10.3390/molecules18010178
   Santos JDL, 2012, J ETHNOPHARMACOL, V142, P503, DOI 10.1016/j.jep.2012.05.027
   MAKLER MT, 1993, AM J TROP MED HYG, V48, P739, DOI 10.4269/ajtmh.1993.48.739
   *MALERA CONS GROUP, 2011, PLOS MED, V0008
   Malleret B, 2011, SCI REP-UK, V1, DOI 10.1038/srep00118
   Marfurt J, 2011, ANTIMICROB AGENTS CH, V55, P961, DOI 10.1128/AAC.01220-10
   Marti G, 2009, PHYTOCHEMISTRY, V70, P75, DOI 10.1016/j.phytochem.2008.10.005
   MAZIER D, 1984, NATURE, V307, P367, DOI 10.1038/307367a0
   MAZIER D, 1987, EXP PARASITOL, V64, P393, DOI 10.1016/0014-4894(87)90052-X
   Mazier D, 2009, NAT REV DRUG DISCOV, V8, P854, DOI 10.1038/nrd2960
   Meister S, 2011, SCIENCE, V334, P1372, DOI 10.1126/science.1211936
   Milliken W, 1997, PLANTS MALARIA PLANT, P116
   Montoia A., 2013, THESIS U FEDERAL AMA
   Mota ML, 2012, PLANTA MED, V78, P658, DOI 10.1055/s-0031-1298333
   Muhammad I, 2004, J NAT PROD, V67, P772, DOI 10.1021/np030524n
   Neal AT, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-138
   Noedl H, 2002, ANTIMICROB AGENTS CH, V46, P1658, DOI 10.1128/AAC.46.6.1658-1664.2002
   Noedl H, 2003, TRENDS PARASITOL, V19, P175, DOI 10.1016/S1471-4922(03)00028-X
   Oliveira-Ferreira J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-115
   Rodriguez JCP, 2011, MEM I OSWALDO CRUZ, V106, P114, DOI 10.1590/S0074-02762011000900015
   Passemar C, 2011, PHYTOMEDICINE, V18, P1118, DOI 10.1016/j.phymed.2011.03.010
   Perez H, 1997, INT J PHARMACOGN, V35, P227, DOI 10.1076/phbi.35.4.227.13306
   Peters W., 1987, CHEMOTHERAPY DRUG RE
   Phyo AP, 2012, LANCET, V379, P1960, DOI 10.1016/S0140-6736(12)60484-X
   Pinto P.S., 2006, THESIS U FEDERAL AMA
   Pinto P.S., 2013, QUIM NOVA UNPUB
   Plouffe D, 2008, P NATL ACAD SCI USA, V105, P9059, DOI 10.1073/pnas.0802982105
   Pohlit AM, 2012, PHYTOMEDICINE, V19, P1049, DOI 10.1016/j.phymed.2012.06.005
   Pohlit AM, 2009, J BRAZIL CHEM SOC, V20, P1065, DOI 10.1590/S0103-50532009000600010
   Pohlit AM, 2011, PLANTA MED, V77, P618, DOI 10.1055/s-0030-1270949
   Pohlit AM, 2011, PLANTA MED, V77, P598, DOI 10.1055/s-0030-1270723
   Price RN, 2007, AM J TROP MED HYG, V77, P79, DOI 10.4269/ajtmh.2007.77.79
   Price RN, 2012, TRENDS PARASITOL, V28, P522, DOI 10.1016/j.pt.2012.08.005
   Price RN, 2011, CURR OPIN INFECT DIS, V24, P578, DOI 10.1097/QCO.0b013e32834c61e3
   Ratcliff A, 2007, T ROY SOC TROP MED H, V101, P351, DOI 10.1016/j.trstmh.2006.06.008
   Morais Sabrina Kelly Reis de, 2007, Acta Amaz., V37, P99, DOI 10.1590/S0044-59672007000100011
   RIECKMAN.KH, 1968, AM J TROP MED HYG, V17, P661, DOI 10.4269/ajtmh.1968.17.661
   RIECKMANN KH, 1978, LANCET, V1, P22
   RIECKMANN KH, 1989, LANCET, V2, P1183, DOI 10.1016/S0140-6736(89)91792-3
   Silva LFRE, 2012, PHYTOMEDICINE, V20, P71, DOI 10.1016/j.phymed.2012.09.008
   Silva LFRE, 2013, MEM I OSWALDO CRUZ, V108, P501, DOI 10.1590/S0074-02762013000400017
   Silva LFRE, 2011, PHYTOTHER RES, V25, P1181, DOI 10.1002/ptr.3424
   Rodrigues E, 2006, PHYTOTHER RES, V20, P378, DOI 10.1002/ptr.1866
   Roper C, 2004, SCIENCE, V305, P1124, DOI 10.1126/science.1098876
   Roumy V, 2009, PHYTOCHEMISTRY, V70, P305, DOI 10.1016/j.phytochem.2008.10.003
   Ruiz L, 2011, J ETHNOPHARMACOL, V133, P917, DOI 10.1016/j.jep.2010.10.039
   Russell B, 2008, ANTIMICROB AGENTS CH, V52, P1040, DOI 10.1128/AAC.01334-07
   Saito-Ito A, 2001, PARASITOL INT, V50, P249, DOI 10.1016/S1383-5769(01)00091-5
   Nunomura RDS, 2012, QUIM NOVA, V35, P2153, DOI 10.1590/S0100-40422012001100009
   Schmidt TJ, 2012, CURR MED CHEM, V19, P2128
   Schrader FC, 2012, INT J MED MICROBIOL, V302, P165, DOI 10.1016/j.ijmm.2012.07.009
   Sharrock WW, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-94
   Suffredini Ivana Barbosa, 2006, Braz J Infect Dis, V10, P400, DOI 10.1590/S1413-86702006000600008
   Sumawinata IW, 2003, AM J TROP MED HYG, V68, P416, DOI 10.4269/ajtmh.2003.68.416
   Sutanto I, 2009, AM J TROP MED HYG, V81, P338, DOI 10.4269/ajtmh.2009.81.338
   Tan LKK, 2008, LANCET INFECT DIS, V8, P449, DOI 10.1016/S1473-3099(08)70153-1
   Tanaka Y, 2012, TETRAHEDRON, V68, P3669, DOI 10.1016/j.tet.2011.12.076
   Tasanor O, 2002, ACTA TROP, V83, P49, DOI 10.1016/S0001-706X(02)00056-6
   Tjitra E, 2008, PLOS MED, V5, P890, DOI 10.1371/journal.pmed.0050128
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   VANVIANEN PH, 1990, AM J TROP MED HYG, V43, P602, DOI 10.4269/ajtmh.1990.43.602
   Vigneron M, 2005, J ETHNOPHARMACOL, V98, P351, DOI 10.1016/j.jep.2005.01.049
   White NJ, 2012, AM J TROP MED HYG, V87, P785, DOI 10.4269/ajtmh.2012.12-0573
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
   WHO, 2010, GLOB REP ANT DRUG EF, P115
   Wilson DW, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-152
   World Health Organization, 2006, GUID TREATM MAL, P253
   Young M. D., 1959, Bulletin of the World Health Organization, V20, P27
   YOUNG MD, 1961, AM J TROP MED HYG, V10, P317, DOI 10.4269/ajtmh.1961.10.317
NR 129
TC 22
Z9 24
U1 1
U2 43
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD AUG
PY 2013
VL 18
IS 8
BP 9219
EP 9240
DI 10.3390/molecules18089219
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
SC Biochemistry & Molecular Biology; Chemistry
GA 298DL
UT WOS:000330304100034
PM 23917112
OA DOAJ Gold, Green Published, Green Accepted
DA 2020-12-08
ER

PT J
AU Thome, R
   Lopes, SCP
   Costa, FTM
   Verinaud, L
AF Thome, Rodolfo
   Pinto Lopes, Stefanie Costa
   Maranhao Costa, Fabio Trindade
   Verinaud, Liana
TI Chloroquine: Modes of action of an undervalued drug
SO IMMUNOLOGY LETTERS
LA English
DT Review
DE Chloroquine; Autoimmunity; Transplantation; Malaria
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; VERSUS-HOST-DISEASE;
   HUMAN-IMMUNODEFICIENCY-VIRUS; TUMOR-NECROSIS-FACTOR; RESISTANT
   PLASMODIUM-FALCIPARUM; RHEUMATOID-ARTHRITIS; HYDROXYCHLOROQUINE
   RETINOPATHY; QUINONE OXIDOREDUCTASE-2; IN-VITRO; T-CELLS
AB For more than two decades, chloroquine (CQ) was largely and deliberately used as first choice drug for malaria treatment. However, worldwide increasing cases of resistant strains of Plasmodium have hampered its use. Nevertheless, CQ has recently been tested as adjunct therapy in several inflammatory situations, such as rheumatoid arthritis and transplantation procedures, presenting intriguing and promising results. In this review, we discuss recent findings and CQ mechanisms of action vis-a-vis its use as a broad adjunct therapy. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Thome, Rodolfo; Verinaud, Liana] Univ Campinas UNICAMP, Inst Biol, Dept Struct & Funct Biol, Sao Paulo, Brazil.
   [Pinto Lopes, Stefanie Costa; Maranhao Costa, Fabio Trindade] Univ Campinas UNICAMP, Inst Biol, Dept Genet Evolut & Bioagents, Sao Paulo, Brazil.
RP Verinaud, L (corresponding author), Rua Monteiro Lobato,255,CP 6109, BR-13083970 Campinas, SP, Brazil.
EM rodolfo.thome@gmail.com; stefaniecplopes@gmail.com; costaftm@unicamp.br;
   verinaud@unicamp.br
RI Thome, Rodolfo/C-1564-2012; Lopes, Stefanie/A-8314-2012; Costa,
   Fabio/E-1181-2012
OI Thome, Rodolfo/0000-0001-7627-4137; Costa, Fabio/0000-0001-9969-7300;
   Lopes, Stefanie/0000-0002-6981-2192
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP,
   Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [2011/17965-3]; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq, Brazil)National Council for Scientific and
   Technological Development (CNPq); FAPESP scholarshipsFundacao de Amparo
   a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/13191-3]; CNPq fellow
   and is enrolled at the Programa Estrategico de Ciencia, Tecnologia &
   Inovacao nas Fundacoes Estaduais de Saude (PECTI/AM Saude) from Fundacao
   de Amparo a Pesquisa do Estado do Amazonas (FAPEAM, Amazonas, Brazil)
FX This work received financial support from Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP #2011/17965-3, Brazil) and Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil).
   R.T. and S.C.P.L. are sponsored by FAPESP scholarships (#2011/13191-3).
   F.T.M.C. is a CNPq fellow and is enrolled at the Programa Estrategico de
   Ciencia, Tecnologia & Inovacao nas Fundacoes Estaduais de Saude
   (PECTI/AM Saude) from Fundacao de Amparo a Pesquisa do Estado do
   Amazonas (FAPEAM, Amazonas, Brazil). L.V. is sponsored by FAPESP and
   CNPq. The sponsors had no role in data collection, analysis and
   conclusion.
CR Adagu IS, 2001, PARASITOLOGY, V123, P219, DOI 10.1017/S0031182001008344
   Ahn KS, 2007, CANCER RES, V67, P10004, DOI 10.1158/0008-5472.CAN-07-2213
   Alarcon GS, 2007, ANN RHEUM DIS, V66, P1168, DOI 10.1136/ard.2006.068676
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   [Anonymous], 1946, JAMA-J AM MED ASSOC, V130, P1069
   ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302
   Babiker HA, 2001, J INFECT DIS, V183, P1535, DOI 10.1086/320195
   Baird JK, 2009, CLIN MICROBIOL REV, V22, P508, DOI 10.1128/CMR.00008-09
   Ben-Zvi I, 2012, CLIN REV ALLERG IMMU, V42, P145, DOI 10.1007/s12016-010-8243-x
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bernstein H N, 1967, Surv Ophthalmol, V12, P415
   BERNSTEIN HN, 1983, AM J MED, V75, P25, DOI 10.1016/0002-9343(83)91267-6
   Bezerra ELM, 2005, ARTHRITIS RHEUM-US, V52, P3073, DOI 10.1002/art.21358
   Biot C, 1997, J MED CHEM, V40, P3715, DOI 10.1021/jm970401y
   Bondeson J, 1998, GEN PHARMACOL, V30, P357, DOI 10.1016/S0306-3623(97)00269-3
   Bray PG, 1998, MOL PHARMACOL, V54, P170
   Bray PG, 1999, J CELL BIOL, V145, P363, DOI 10.1083/jcb.145.2.363
   Bray PG, 1996, MOL PHARMACOL, V50, P1559
   BUNCH TW, 1984, ARTHRITIS RHEUM, V27, P267, DOI 10.1002/art.1780270304
   CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317
   Castillo CM, 2002, MEM I OSWALDO CRUZ, V97, P559, DOI 10.1590/S0074-02762002000400020
   Chen JW, 2001, J BIOMED SCI, V8, P365, DOI 10.1159/000054056
   Chiang G, 1996, CLIN THER, V18, P1080, DOI 10.1016/S0149-2918(96)80063-4
   Chiu HC, 2009, ANTIMICROB AGENTS CH, V53, P5236, DOI 10.1128/AAC.00555-09
   COATNEY GR, 1963, AM J TROP MED HYG, V12, P121, DOI 10.4269/ajtmh.1963.12.121
   De DY, 1996, AM J TROP MED HYG, V55, P579, DOI 10.4269/ajtmh.1996.55.579
   DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006-2952(74)90174-9
   Demachi-Okamura A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047126
   Di Trani L, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-39
   Djimde A, 2001, NEW ENGL J MED, V344, P257, DOI 10.1056/NEJM200101253440403
   Duraisingh MT, 2005, ACTA TROP, V94, P181, DOI 10.1016/j.actatropica.2005.04.008
   Egan TJ, 2007, CURR OPIN INFECT DIS, V20, P598, DOI 10.1097/QCO.0b013e3282f1673a
   ERTEL W, 1992, ARCH SURG-CHICAGO, V127, P70
   ESDAILE J, 1991, NEW ENGL J MED, V324, P150
   ESDAILE JM, 1995, AM J MED, V98, P156
   Esdaile John M., 2000, Journal of Rheumatology, V27, P2919
   FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001
   Fessler BJ, 2005, ARTHRITIS RHEUM, V52, P1473, DOI 10.1002/art.21039
   Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8
   FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819
   FITCH CD, 1969, P NATL ACAD SCI USA, V64, P1181, DOI 10.1073/pnas.64.4.1181
   FOX RI, 1993, SEMIN ARTHRITIS RHEU, V23, P82, DOI 10.1016/S0049-0172(10)80012-5
   Fredericksen BL, 2002, J VIROL, V76, P11440, DOI 10.1128/JVI.76.22.11440-11446.2002
   Garulli B, 2008, CLIN VACCINE IMMUNOL, V15, P1497, DOI 10.1128/CVI.00166-08
   Gharbi M, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-35
   GIBSON T, 1987, BRIT J RHEUMATOL, V26, P279
   Gilman AL, 1996, BONE MARROW TRANSPL, V17, P1069
   Gilman AL, 2000, BIOL BLOOD MARROW TR, V6, P327, DOI 10.1016/S1083-8791(00)70058-9
   Gladman DD, 1998, J RHEUMATOL, V25, P983
   Goldman FD, 2000, BLOOD, V95, P3460, DOI 10.1182/blood.V95.11.3460.011k26_3460_3466
   Gong X, 2007, CANCER RES, V67, P5380, DOI 10.1158/0008-5472.CAN-07-0323
   Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P654, DOI 10.1073/pnas.93.2.654
   Grierson DJ, 1997, ANN RHEUM DIS, V56, P188, DOI 10.1136/ard.56.3.188
   Guantai Eric, 2010, Current Drug Delivery, V7, P312, DOI 10.2174/156720110793360577
   HARINASUTA T, 1965, LANCET, V2, P657
   Hashimoto M, 2010, J EXP MED, V207, P1135, DOI 10.1084/jem.20092301
   HOBBS HE, 1959, LANCET, V2, P478
   HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0
   Ikeda T, 2012, J DERMATOL, V39, P531, DOI 10.1111/j.1346-8138.2011.01448.x
   Jeong JY, 2002, IMMUNOLOGY, V105, P83, DOI 10.1046/j.0019-2805.2001.01339.x
   Jeong JY, 1997, J IMMUNOL, V158, P4901
   Jiang MC, 1996, BIOCHEM BIOPH RES CO, V226, P1, DOI 10.1006/bbrc.1996.1302
   Kalia S, 2007, DERMATOL THER, V20, P160, DOI 10.1111/j.1529-8019.2007.00131.x
   Karres I, 1998, AM J PHYSIOL-REG I, V274, pR1058
   Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710
   Kreuter A, 2009, ARCH DERMATOL, V145, P244, DOI 10.1001/archdermatol.2008.592
   KROGSTAD DJ, 1986, BIOCHEM PHARMACOL, V35, P547, DOI 10.1016/0006-2952(86)90345-X
   KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302
   KROGSTAD DJ, 1987, SCIENCE, V238, P1283, DOI 10.1126/science.3317830
   Kublin JG, 2003, J INFECT DIS, V187, P1870, DOI 10.1086/375419
   Kuhn A, 2011, J AM ACAD DERMATOL, V65, P54, DOI [10.1016/j.jaad.2010.03.037, 10.1016/j.jaad.2010.06.018, 10.1016/j.jaad.2010.06.017]
   Kuhn Y, 2010, TRAFFIC, V11, P236, DOI 10.1111/j.1600-0854.2009.01018.x
   Kwiek JJ, 2004, BIOCHEMISTRY-US, V43, P4538, DOI 10.1021/bi035923w
   Lakshmanan V, 2005, EMBO J, V24, P2294, DOI 10.1038/sj.emboj.7600681
   Laufer MK, 2006, NEW ENGL J MED, V355, P1959, DOI 10.1056/NEJMoa062032
   Legssyer R, 2003, J INORG BIOCHEM, V94, P36, DOI 10.1016/S0162-0134(02)00633-5
   Lesiak A, 2009, CLIN EXP DERMATOL, V34, P570, DOI 10.1111/j.1365-2230.2008.03006.x
   Leung KKK, 2013, J BIOL CHEM, V288, P11242, DOI 10.1074/jbc.M113.457002
   Levy GD, 1997, ARTHRITIS RHEUM, V40, P1482, DOI 10.1002/art.1780400817
   Levy RA, 2001, LUPUS, V10, P401, DOI 10.1191/096120301678646137
   Li ZM, 2003, INT J BIOCHEM CELL B, V35, P547, DOI 10.1016/S1357-2725(02)00384-9
   Loehberg CR, 2012, BIOCHEM PHARMACOL, V83, P480, DOI 10.1016/j.bcp.2011.11.022
   Long DJ, 2002, J BIOL CHEM, V277, P46131, DOI 10.1074/jbc.M208675200
   Louzada P, 2008, BRAZ J MED BIOL RES, V41, P493, DOI 10.1590/S0100-879X2008005000021
   Macfarlane DE, 1998, J IMMUNOL, V160, P1122
   Madalena BV, 2012, ARQ BRAS OFTALMOL, V75, P170, DOI 10.1590/S0004-27492012000300004
   malERA Consultative Group on Drugs, 2011, PLOS MED
   MARES V, 1974, J CELL BIOL, V63, P665, DOI 10.1083/jcb.63.2.665
   Marmor MF, 2002, OPHTHALMOLOGY, V109, P1377, DOI 10.1016/S0161-6420(02)01168-5
   Marmor MF, 2011, OPHTHALMOLOGY, V118, P415, DOI 10.1016/j.ophtha.2010.11.017
   Martin RE, 2012, ANTIMICROB AGENTS CH, V56, P2283, DOI 10.1128/AAC.00166-12
   Martin RE, 2009, SCIENCE, V325, P1680, DOI 10.1126/science.1175667
   MARTIN SK, 1987, SCIENCE, V235, P899, DOI 10.1126/science.3544220
   Martinson JA, 2010, ANTIMICROB AGENTS CH, V54, P871, DOI 10.1128/AAC.01246-09
   Mavrikakis I, 2003, OPHTHALMOLOGY, V110, P1321, DOI 10.1016/S0161-6420(03)00409-3
   MCCARTY DJ, 1982, JAMA-J AM MED ASSOC, V248, P1718, DOI 10.1001/jama.248.14.1718
   MCCHESNEY EW, 1965, TOXICOL APPL PHARM, V7, P627, DOI 10.1016/0041-008X(65)90050-5
   Misinzo G, 2008, J VIROL, V82, P1128, DOI 10.1128/JVI.01229-07
   Mita T, 2003, AM J TROP MED HYG, V68, P413, DOI 10.4269/ajtmh.2003.68.413
   Momose Y, 2013, J DERMATOL, V40, P94, DOI 10.1111/1346-8138.12005
   MORAND EF, 1992, ANN RHEUM DIS, V51, P1318, DOI 10.1136/ard.51.12.1318
   Mu JB, 2003, MOL MICROBIOL, V49, P977, DOI 10.1046/j.1365-2958.2003.03627.x
   Murray SM, 2010, J VIROL, V84, P12082, DOI 10.1128/JVI.01466-10
   Mwai L, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-106
   Ndiaye M, 2012, AM J TROP MED HYG, V87, P640, DOI 10.4269/ajtmh.2012.11-0709
   Ngo T, 2003, AM J TROP MED HYG, V68, P350, DOI 10.4269/ajtmh.2003.68.350
   Ooi EE, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-39
   Orvedahl A, 2009, CELL DEATH DIFFER, V16, P57, DOI 10.1038/cdd.2008.130
   Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132
   Peel SA, 2001, DRUG RESIST UPDATE, V4, P66, DOI 10.1054/drup.2001.0183
   Perricone C, 2011, AUTOIMMUN REV, V10, P599, DOI 10.1016/j.autrev.2011.04.021
   Piconi S, 2011, BLOOD, V118, P3263, DOI 10.1182/blood-2011-01-329060
   PICOT S, 1993, IMMUNOLOGY, V80, P127
   Plowe Christopher V, 2009, Trans R Soc Trop Med Hyg, V103 Suppl 1, pS11, DOI 10.1016/j.trstmh.2008.11.002
   Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297
   RAINES MF, 1989, INVEST OPHTH VIS SCI, V30, P1726
   Ratcliff A, 2007, T ROY SOC TROP MED H, V101, P351, DOI 10.1016/j.trstmh.2006.06.008
   Ridley RG, 1996, ANTIMICROB AGENTS CH, V40, P1846, DOI 10.1128/AAC.40.8.1846
   RIECKMANN KH, 1989, LANCET, V2, P1183, DOI 10.1016/S0140-6736(89)91792-3
   ROSSI P, 1985, J RHEUMATOL, V12, P629
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Ruebush TK, 2003, AM J TROP MED HYG, V69, P548, DOI 10.4269/ajtmh.2003.69.548
   Ruiz-Irastorza G, 2006, LUPUS, V15, P577, DOI 10.1177/0961203306071872
   Sanchez CP, 1997, J BIOL CHEM, V272, P2652, DOI 10.1074/jbc.272.5.2652
   Savarino A, 2003, LANCET INFECT DIS, V3, P722, DOI 10.1016/S1473-3099(03)00806-5
   Savarino A, 2006, EXPERT OPIN INV DRUG, V15, P1507, DOI 10.1517/13543784.15.12.1507
   SCHULTZ KR, 1995, BLOOD, V86, P4344, DOI 10.1182/blood.V86.11.4344.bloodjournal86114344
   Schultz KR, 1997, LEUKEMIA LYMPHOMA, V24, P201, DOI 10.3109/10428199709039008
   Schultz KR, 2002, BIOL BLOOD MARROW TR, V8, P648, DOI 10.1053/bbmt.2002.v8.abbmt080648
   SCOTT DL, 1989, BRIT J RHEUMATOL, V28, P128
   SHIBATA M, 1983, J GEN VIROL, V64, P1149, DOI 10.1099/0022-1317-64-5-1149
   Sidhu ABS, 2002, SCIENCE, V298, P210, DOI 10.1126/science.1074045
   SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325
   SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J
   Soto J, 2001, AM J TROP MED HYG, V65, P90, DOI 10.4269/ajtmh.2001.65.90
   Soumelis V, 2001, BLOOD, V98, P906, DOI 10.1182/blood.V98.4.906
   SPERBER K, 1995, CLIN THER, V17, P622, DOI 10.1016/0149-2918(95)80039-5
   SPERBER K, 1993, AIDS RES HUM RETROV, V9, P91, DOI 10.1089/aid.1993.9.91
   Sperber K, 1997, CLIN THER, V19, P913, DOI 10.1016/S0149-2918(97)80045-8
   SPERBER K, 1993, J RHEUMATOL, V20, P803
   Sullivan DJ, 1996, P NATL ACAD SCI USA, V93, P11865, DOI 10.1073/pnas.93.21.11865
   Sullivan DJ, 1998, J BIOL CHEM, V273, P31103, DOI 10.1074/jbc.273.47.31103
   Sumawinata IW, 2003, AM J TROP MED HYG, V68, P416, DOI 10.4269/ajtmh.2003.68.416
   Summers RL, 2012, CELL MOL LIFE SCI, V69, P1967, DOI 10.1007/s00018-011-0906-0
   Sundelin SP, 2002, APMIS, V110, P481, DOI 10.1034/j.1600-0463.2002.100606.x
   Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600-0765.2005.00814.x
   Takayanagi H, 1997, BIOCHEM BIOPH RES CO, V240, P279, DOI 10.1006/bbrc.1997.7404
   Tam LS, 2000, J RHEUMATOL, V27, P2142
   TAN EM, 1989, ADV IMMUNOL, V44, P93, DOI 10.1016/S0065-2776(08)60641-0
   Thome R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065913
   Tjitra E, 2008, PLOS MED, V5, P890, DOI 10.1371/journal.pmed.0050128
   vandenBorne BEEM, 1997, J RHEUMATOL, V24, P55
   Weber SM, 2000, J IMMUNOL, V165, P1534, DOI 10.4049/jimmunol.165.3.1534
   Wellems TE, 2001, J INFECT DIS, V184, P770, DOI 10.1086/322858
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
   WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430
   Williams MA, 2007, ANNU REV IMMUNOL, V25, P171, DOI 10.1146/annurev.immunol.25.022106.141548
   World Health Organization, 2010, GLOB REP ANT DRUG EF
   Wunsch S, 1998, J CELL BIOL, V140, P335, DOI 10.1083/jcb.140.2.335
   Wurtz N, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-197
   Yamada H, 2008, ANN RHEUM DIS, V67, P1299, DOI 10.1136/ard.2007.080341
   Yoon YH, 2010, INVEST OPHTH VIS SCI, V51, P6030, DOI 10.1167/iovs.10-5278
   YOSHIMURA A, 1982, J VIROL, V43, P284, DOI 10.1128/JVI.43.1.284-293.1982
NR 163
TC 69
Z9 75
U1 0
U2 39
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0165-2478
EI 1879-0542
J9 IMMUNOL LETT
JI Immunol. Lett.
PD JUN
PY 2013
VL 153
IS 1-2
BP 50
EP 57
DI 10.1016/j.imlet.2013.07.004
PG 8
WC Immunology
SC Immunology
GA 223DD
UT WOS:000324783400009
PM 23891850
DA 2020-12-08
ER

PT J
AU Coelho, HCC
   Lopes, SCP
   Pimentel, JPD
   Nogueira, PA
   Costa, FTM
   Siqueira, AM
   Melo, GC
   Monteiro, WM
   Malheiro, A
   Lacerda, MVG
AF Coelho, Helena Cristina C.
   Lopes, Stefanie C. P.
   Pimentel, Joao Paulo D.
   Nogueira, Paulo A.
   Costa, Fabio T. M.
   Siqueira, Andre M.
   Melo, Gisely C.
   Monteiro, Wuelton M.
   Malheiro, Adriana
   Lacerda, Marcus V. G.
TI Thrombocytopenia in Plasmodium vivax Malaria Is Related to Platelets
   Phagocytosis
SO PLOS ONE
LA English
DT Article
ID FALCIPARUM-MALARIA; INFECTION; TRANSMISSION; POPULATION; MECHANISMS;
   CHILDREN; LIMITS
AB Background: Although thrombocytopenia is a hematological disorder commonly reported in malarial patients, its mechanisms are still poorly understood, with only a few studies focusing on the role of platelets phagocytosis.
   Methods and Findings: Thirty-five malaria vivax patients and eight healthy volunteers (HV) were enrolled in the study. Among vivax malaria patients, thrombocytopenia (<150,000 platelets/mu L) was found in 62.9% (22/35). Mean platelet volume (MPV) was higher in thrombocytopenic patients as compared to non-thrombocytopenic patients (p = 0.017) and a negative correlation was found between platelet count and MPV (r = -0.483; p = 0.003). Platelets from HV or patients were labeled with 5-chloromethyl fluorescein diacetate (CMFDA), incubated with human monocytic cell line (THP-1) and platelet phagocytosis index was analyzed by flow cytometry. The phagocytosis index was higher in thrombocytopenic patients compared to non-thrombocytopenic patients (p = 0.042) and HV (p = 0.048). A negative correlation was observed between platelet count and phagocytosis index (r = -0.402; p = 0.016). Platelet activation was assessed measuring the expression of P-selectin (CD62-P) in platelets' surface by flow cytometry. No significant difference was found in the expression of P-selectin between thrombocytopenic patients and HV (p = 0.092). After evaluating the cytokine profile (IL-2, IL-4, IL-6, IL-10, TNF-alpha, IFN-gamma and IL-17) in the patients' sera, levels of IL-6, IL-10 and IFN-gamma were elevated in malaria patients compared to HV. Moreover, IL-6 and IL-10 values were higher in thrombocytopenic patients than non-thrombocytopenic ones (p = 0.044 and p = 0.017, respectively. In contrast, TNF-alpha levels were not different between the three groups, but a positive correlation was found between TNF-alpha and phagocytosis index (r = -0.305; p = 0.037).
   Conclusion/Significance: Collectively, our findings indicate that platelet phagocytosis may contribute to thrombocytopenia found in vivax malaria. Finally, we believe that this study opens new avenues to explore the mechanisms involved in platelet dysfunction, commonly found in vivax malaria patients.
C1 [Coelho, Helena Cristina C.; Siqueira, Andre M.; Melo, Gisely C.; Lacerda, Marcus V. G.] Univ Estado Amazonas, Manaus, Amazonas, Brazil.
   [Coelho, Helena Cristina C.; Siqueira, Andre M.; Monteiro, Wuelton M.; Lacerda, Marcus V. G.] Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [Lopes, Stefanie C. P.; Costa, Fabio T. M.] Univ Estadual Campinas, Sao Paulo, Brazil.
   [Pimentel, Joao Paulo D.; Nogueira, Paulo A.] Fiocruz MS, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil.
   [Monteiro, Wuelton M.; Malheiro, Adriana] Univ Fed Amazonas, Manaus, Amazonas, Brazil.
   [Pimentel, Joao Paulo D.; Malheiro, Adriana] Fundacao Hematol & Hemoterapia Amazonas, Manaus, Amazonas, Brazil.
RP Lacerda, MVG (corresponding author), Univ Estado Amazonas, Manaus, Amazonas, Brazil.
EM marcuslacerda.br@gmail.com
RI Costa, Fabio/E-1181-2012; Lopes, Stefanie/A-8314-2012; Nogueira,
   Paulo/AAK-8822-2020; Siqueira, Andre M/G-1340-2010
OI Costa, Fabio/0000-0001-9969-7300; Siqueira, Andre M/0000-0003-2208-0294;
   Lopes, Stefanie/0000-0002-6981-2192
FU CAPESCAPES; FAPESP fellowshipFundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP); CNPqNational Council for Scientific and
   Technological Development (CNPq); FAPEAM
FX HCCC received a fellowship from CAPES and SCPL was sponsored by a FAPESP
   fellowship. MVGL and FTMC are CNPq fellows. FTMC is also a fellow from
   Programa Estrategico de Ciencia, Tecnologia & Inovacao nas Fundacoes
   Estaduais de Saude (PECTI/AM-Saude) from Fundacao de Amparo a Pesquisa
   do Estado do Amazonas (FAPEAM, Amazonas - Brazil). This work was
   supported by CNPq and FAPEAM grants. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alecrim MGC, 2000, CLIN ASPECTS RESISTA
   Andrade BB, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-13
   Andrade BB, 2011, MEM I OSWALDO CRUZ, V106, P70, DOI 10.1590/S0074-02762011000900009
   Anstey NM, 2009, TRENDS PARASITOL, V25, P220, DOI 10.1016/j.pt.2009.02.003
   Armah Henry, 2005, Int J Environ Res Public Health, V2, P123, DOI 10.3390/ijerph2005010123
   Badlou BA, 2006, TRANSFUSION, V46, P1432, DOI 10.1111/j.1537-2995.2006.00913.x
   Casals-Pascual C, 2006, AM J TROP MED HYG, V75, P434, DOI 10.4269/ajtmh.2006.75.434
   Cox D, 2010, CELL MOL LIFE SCI, V67, P557, DOI 10.1007/s00018-009-0211-3
   de Mast Q, 2010, BRIT J HAEMATOL, V151, P495, DOI 10.1111/j.1365-2141.2010.08399.x
   de Monbrison F, 2003, T ROY SOC TROP MED H, V97, P387, DOI 10.1016/S0035-9203(03)90065-4
   Echeverri Marcela, 2003, Rev. Inst. Med. trop. S. Paulo, V45, P29, DOI 10.1590/S0036-46652003000100006
   Erhart LM, 2004, AM J TROP MED HYG, V70, P8, DOI 10.4269/ajtmh.2004.70.8
   Gerardin P, 2002, AM J TROP MED HYG, V66, P686, DOI 10.4269/ajtmh.2002.66.686
   Gonzalez B, 2009, INVEST CLIN, V50, P187
   Guerra CA, 2008, PLOS MED, V5, P300, DOI 10.1371/journal.pmed.0050038
   Guerra CA, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000774
   Lacerda MVG, 2011, MEM I OSWALDO CRUZ, V106, P52, DOI 10.1590/S0074-02762011000900007
   Honda S, 2009, AM J TROP MED HYG, V80, P841, DOI 10.4269/ajtmh.2009.80.841
   JAFF MS, 1985, J CLIN PATHOL, V38, P1318, DOI 10.1136/jcp.38.11.1318
   KELTON JG, 1983, J CLIN INVEST, V71, P832, DOI 10.1172/JCI110836
   Klein E, 2012, BLOOD, V119, P910, DOI 10.1182/blood-2011-02-336420
   Kochar DK, 2012, J VECTOR DIS, V49, P191
   Kochar DK, 2010, PLATELETS, V21, P623, DOI 10.3109/09537104.2010.505308
   Kochar DK, 2005, EMERG INFECT DIS, V11, P132, DOI 10.3201/eid1101.040519
   Lacerda MVG, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-12
   Lee SH, 1997, THROMB HAEMOSTASIS, V77, P289
   LOOAREESUWAN S, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P44
   Maina RN, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-S3-S4
   Oliveira-Ferreira J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-115
   Park JW, 2003, ANN TROP MED PARASIT, V97, P339, DOI 10.1179/000349803235002416
   Piguet PF, 2002, APOPTOSIS, V7, P91, DOI 10.1023/A:1014341611412
   Rogier C, 2004, ARCH DIS CHILD, V89, P795, DOI 10.1136/adc.2003.045179
   Saravu K, 2011, ANN TROP MED PARASIT, V105, P593, DOI 10.1179/2047773211Y.0000000013
   SKUDOWITZ RB, 1973, BMJ-BRIT MED J, V2, P515, DOI 10.1136/bmj.2.5865.515
   Sosman JA, 2000, BRIT J HAEMATOL, V111, P104, DOI 10.1046/j.1365-2141.2000.02314.x
   Tacchini-Cottier F, 1998, J IMMUNOL, V160, P6182
   Tanwar GS, 2012, PLATELETS, V23, P211, DOI 10.3109/09537104.2011.607520
   TOUZE JE, 1990, PATHOL BIOL, V38, P678
   Tyagi Padmawati, 1999, Indian Journal of Malariology, V36, P12
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
   Wickramasinghe SN, 2000, BEST PRACT RES CL HA, V13, P277, DOI 10.1053/beha.1999.0072
   Wroczynska A, 2005, INT MARIT HEALTH, V56, P103
   Yamaguchi S, 1997, AM J HEMATOL, V56, P183, DOI 10.1002/(SICI)1096-8652(199711)56:3&lt;183::AID-AJH9&gt;3.0.CO;2-U
   Yeo TW, 2008, P NATL ACAD SCI USA, V105, P17097, DOI 10.1073/pnas.0805782105
NR 44
TC 34
Z9 34
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 28
PY 2013
VL 8
IS 5
AR e63410
DI 10.1371/journal.pone.0063410
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 155FM
UT WOS:000319733000009
PM 23723981
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Shryock, N
   McBerry, C
   Gonzalez, RMS
   Janes, S
   Costa, FTM
   Aliberti, J
AF Shryock, Nathaniel
   McBerry, Cortez
   Gonzalez, Rosa Maria Salazar
   Janes, Steven
   Costa, Fabio T. M.
   Aliberti, Julio
TI Lipoxin A(4) and 15-Epi-Lipoxin A(4) Protect against Experimental
   Cerebral Malaria by Inhibiting IL-12/IFN-gamma in the Brain
SO PLOS ONE
LA English
DT Article
ID IFN-GAMMA; FALCIPARUM-MALARIA; ADJUNCTIVE THERAPY; INTERFERON-GAMMA;
   IL-12 PRODUCTION; STABLE ANALOGS; T-CELLS; INFLAMMATION; ASPIRIN;
   IMMUNOPATHOLOGY
AB Cerebral malaria is caused by infection with Plasmodium falciparum and can lead to severe neurological manifestations and predominantly affects sub-Saharan African children. The pathogenesis of this disease involves unbalanced over-production of pro-inflammatory cytokines. It is clear that signaling though IL-12 receptor is a critical step for development of cerebral malaria, IL-12 genetic deficiency failed to show the same effect, suggesting that there is redundancy among the soluble mediators which leads to immunopathology and death. Consequently, counter-regulatory mediators might protect the host during cerebral malaria. We have previously showed that endogenously produced lipoxins, which are anti-inflammatory mediators generated by 5-lipoxygenase (5-LO)-dependent metabolism of arachidonic acid, limit host damage in a model of mouse toxoplasmosis. We postulated here that lipoxins might also play a counter-regulatory role during cerebral malaria. To test this hypothesis, we infected 5-LO-deficient hosts with P. berghei ANKA strain, which induces a mouse model of cerebral malaria (ECM). Our results show accelerated mortality concomitant with exuberant IL-12 and IFN-gamma production in the absence of 5-lipoxygenase. Moreover, in vivo administration of lipoxin to 5-LO-deficient hosts prevented early mortality and reduced the accumulation of CD8(+)IFN-gamma(+) cells in the brain. Surprisingly, WT animals treated with lipoxin either at the time of infection or 3 days post-inoculum also showed prolonged survival and diminished brain inflammation, indicating that although protective, endogenous lipoxin production is not sufficient to optimally protect the host from brain damage in cerebral malaria. These observations establish 5-LO/LXA(4) as a host protective pathway and suggest a new therapeutic approach against human cerebral malaria (HCM). (255 words).
C1 [Shryock, Nathaniel; McBerry, Cortez; Gonzalez, Rosa Maria Salazar; Janes, Steven; Aliberti, Julio] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA.
   [Costa, Fabio T. M.] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut & Bioagents, Sao Paulo, Brazil.
RP Aliberti, J (corresponding author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA.
EM julio.aliberti@cchmc.org
RI Costa, Fabio/E-1181-2012; Aliberti, Julio/I-7354-2013
OI Costa, Fabio/0000-0001-9969-7300; Aliberti, Julio/0000-0003-3420-8478
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [AI 075038]; NATIONAL
   INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Allergy & Infectious Diseases (NIAID)
   [R01AI075038, R01AI075038, R01AI075038, R01AI075038, R01AI075038,
   R01AI075038] Funding Source: NIH RePORTER
FX This work was funded by National Institutes of Health grant AI 075038
   (JA, NS and CM). FTMC is a Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico fellow and is enrolled at the Programa
   Estrategico de Ciencia, Tecnologia & Inovacao nas Fundacoes Estaduais de
   Saude (PECTI/AM Saude) from Fundacao de Amparoa Pesquisa do Estado do
   Amazonas (Amazonas-Brazil). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Achtman AH, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003515
   Aliberti J, 2002, NAT IMMUNOL, V3, P76, DOI 10.1038/ni745
   Aliberti J, 2005, NAT REV IMMUNOL, V5, P162, DOI 10.1038/nri1547
   Aliberti J, 2002, J EXP MED, V196, P1253, DOI 10.1084/jem.20021183
   Amani V, 2000, EUR J IMMUNOL, V30, P1646, DOI 10.1002/1521-4141(200006)30:6&lt;1646::AID-IMMU1646&gt;3.0.CO;2-0
   Bafica A, 2005, J CLIN INVEST, V115, P1601, DOI 10.1172/JCI23949
   Belnoue E, 2008, PARASITE IMMUNOL, V30, P544, DOI 10.1111/j.1365-3024.2008.01053.x
   Bienvenu AL, 2008, ACTA TROP, V106, P104, DOI 10.1016/j.actatropica.2008.02.001
   Birnbaum Y, 2007, PROSTAG OTH LIPID M, V83, P89, DOI 10.1016/j.prostaglandins.2006.10.003
   Birnbaum Y, 2006, CIRCULATION, V114, P929, DOI 10.1161/CIRCULATIONAHA.106.629907
   Charunwatthana P, 2009, CRIT CARE MED, V37, P516, DOI 10.1097/CCM.0b013e3181958dfd
   Claser C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018720
   Craig AG, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002401
   Day N, 2007, AM J TROP MED HYG, V77, P29
   de Miranda AS, 2011, NEUROSCI LETT, V491, P202, DOI 10.1016/j.neulet.2011.01.038
   DEKOSSODO S, 1993, J IMMUNOL, V151, P4811
   Dondorp AM, 2010, LANCET, V376, P1647, DOI 10.1016/S0140-6736(10)61924-1
   Engwerda CR, 2002, J EXP MED, V195, P1371, DOI 10.1084/jem.20020128
   Faiz MA, 2005, LANCET, V366, P717
   Fauconnier M, 2012, J IMMUNOL, V188, P1905, DOI 10.4049/jimmunol.1101978
   GRAU GE, 1995, SOZ PRAVENTIV MED, V40, P50, DOI 10.1007/BF01615662
   GRAU GE, 1989, P NATL ACAD SCI USA, V86, P5572, DOI 10.1073/pnas.86.14.5572
   GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918
   Herb F, 2008, HUM MOL GENET, V17, P1052, DOI 10.1093/hmg/ddm378
   Higgins SJ, 2011, EXPERT REV ANTI-INFE, V9, P803, DOI [10.1586/ERI.11.96, 10.1586/eri.11.96]
   HOFFMAN SL, 1988, J INFECT DIS, V158, P325, DOI 10.1093/infdis/158.2.325
   Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1
   Hunt NH, 2010, TRENDS PARASITOL, V26, P272, DOI 10.1016/j.pt.2010.03.006
   Idro R, 2005, LANCET NEUROL, V4, P827, DOI 10.1016/S1474-4422(05)70247-7
   John CC, 2008, PEDIATRICS, V122, pE92, DOI 10.1542/peds.2007-3709
   John CC, 2008, AM J TROP MED HYG, V78, P198, DOI 10.4269/ajtmh.2008.78.198
   John CC, 2010, EXPERT REV ANTI-INFE, V8, P997, DOI [10.1586/eri.10.90, 10.1586/ERI.10.90]
   Keri JE, 2000, EUR J DERMATOL, V10, P617
   Lau LS, 2011, J INFECT DIS, V204, P1989, DOI 10.1093/infdis/jir656
   Maddox JF, 1997, J BIOL CHEM, V272, P6972, DOI 10.1074/jbc.272.11.6972
   McBerry C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038384
   Morris T, 2009, J IMMUNOL, V183, P2089, DOI 10.4049/jimmunol.0900477
   Nie CQ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000369
   Palmer CD, 2011, BIOCHEM SOC T, V39, P994, DOI 10.1042/BST0390994
   Penet MF, 2008, P NATL ACAD SCI USA, V105, P1321, DOI 10.1073/pnas.0706867105
   Planche T, 2005, CURR OPIN INFECT DIS, V18, P369, DOI 10.1097/01.qco.0000180161.38530.81
   Prasad K., 2000, COCHRANE DB SYST REV
   Rampengan T H, 1991, Paediatr Indones, V31, P59
   Renia L, 2006, INT J PARASITOL, V36, P547, DOI 10.1016/j.ijpara.2006.02.007
   Rudin W, 1997, AM J PATHOL, V150, P257
   Rudin W, 1997, EUR J IMMUNOL, V27, P810, DOI 10.1002/eji.1830270403
   Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877
   Serghides L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027714
   Serghides L, 2012, PPAR RES, V2012, P1, DOI 10.1155/2012/513865
   Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647
   Serhan CN, 2011, CURR TOP MED CHEM, V11, P629
   SERHAN CN, 1995, BIOCHEMISTRY-US, V34, P14609, DOI 10.1021/bi00044a041
   Takano T, 1998, J CLIN INVEST, V101, P819, DOI 10.1172/JCI1578
   Togbe D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002608
   Van den Steen PE, 2010, AM J RESP CRIT CARE, V181, P957, DOI 10.1164/rccm.200905-0786OC
   Villegas-Mendez A, 2012, J IMMUNOL, V189, P968, DOI 10.4049/jimmunol.1200688
   Villegas-Mendez A, 2011, J IMMUNOL, V187, P2885, DOI 10.4049/jimmunol.1100241
   Walker J, 2011, SHOCK, V36, P410, DOI 10.1097/SHK.0b013e31822798c1
   Willcox ML, 2001, LANCET, V357, P1881, DOI 10.1016/S0140-6736(00)04982-5
   WYLER DJ, 1988, J INFECT DIS, V158, P320, DOI 10.1093/infdis/158.2.320
NR 60
TC 21
Z9 21
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 16
PY 2013
VL 8
IS 4
AR e61882
DI 10.1371/journal.pone.0061882
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 130DR
UT WOS:000317893400127
PM 23613965
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Bitencourt, AR
   Vicentin, EC
   Jimenez, MC
   Ricci, R
   Leite, JA
   Costa, FT
   Ferreira, LC
   Russell, B
   Nosten, F
   Renia, L
   Galinski, MR
   Barnwell, JW
   Rodrigues, MM
   Soares, IS
AF Bitencourt, Amanda R.
   Vicentin, Elaine C.
   Jimenez, Maria C.
   Ricci, Ricardo
   Leite, Juliana A.
   Costa, Fabio T.
   Ferreira, Luis C.
   Russell, Bruce
   Nosten, Francois
   Renia, Laurent
   Galinski, Mary R.
   Barnwell, John W.
   Rodrigues, Mauricio M.
   Soares, Irene S.
TI Antigenicity and Immunogenicity of Plasmodium vivax Merozoite Surface
   Protein-3
SO PLOS ONE
LA English
DT Article
ID LONG SYNTHETIC PEPTIDES; DUFFY BINDING-PROTEIN; BLOOD-STAGE VACCINE;
   C-TERMINAL REGIONS; MALARIA VACCINE; IMMUNE-RESPONSES; CIRCUMSPOROZOITE
   PROTEIN; PROTECTIVE EFFICACY; CANDIDATE MSP1(19); ANTIBODY-RESPONSE
AB A recent clinical trial in African children demonstrated the potential utility of merozoite surface protein (MSP)-3 as a vaccine against Plasmodium falciparum malaria. The present study evaluated the use of Plasmodium vivax MSP-3 (PvMSP-3) as a target antigen in vaccine formulations against malaria caused by P. vivax. Recombinant proteins representing MSP-3 alpha and MSP-3 beta of P. vivax were expressed as soluble histidine-tagged bacterial fusions. Antigenicity during natural infection was evaluated by detecting specific antibodies using sera from individuals living in endemic areas of Brazil. A large proportion of infected individuals presented IgG antibodies to PvMSP-3 alpha (68.2%) and at least 1 recombinant protein representing PvMSP-3 beta (79.1%). In spite of the large responder frequency, reactivity to both antigens was significantly lower than was observed for the immunodominant epitope present on the 19-kDa C-terminal region of PvMSP-1. Immunogenicity of the recombinant proteins was studied in mice in the absence or presence of different adjuvant formulations. PvMSP-3 beta, but not PvMSP-3 alpha, induced a TLR4-independent humoral immune response in the absence of any adjuvant formulation. The immunogenicity of the recombinant antigens were also tested in formulations containing different adjuvants (Alum, Salmonella enterica flagellin, CpG, Quil A, TiterMax (R) and incomplete Freunds adjuvant) and combinations of two adjuvants (Alum plus flagellin, and CpG plus flagellin). Recombinant PvMSP-3 alpha and PvMSP-3 beta elicited higher antibody titers capable of recognizing P. vivax-infected erythrocytes harvested from malaria patients. Our results confirm that P. vivax MSP-3 antigens are immunogenic during natural infection, and the corresponding recombinant proteins may be useful in elucidating their vaccine potential.
C1 [Bitencourt, Amanda R.; Vicentin, Elaine C.; Jimenez, Maria C.; Ricci, Ricardo; Soares, Irene S.] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo, Brazil.
   [Leite, Juliana A.; Costa, Fabio T.] Univ Estadual Campinas, Dept Genet Evolucao & Bioagentes, Inst Biol, Campinas, SP, Brazil.
   [Ferreira, Luis C.] Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, BR-05508 Sao Paulo, Brazil.
   [Russell, Bruce] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Singapore 117595, Singapore.
   [Russell, Bruce; Renia, Laurent] Agcy Sci Technol & Res, Singapore Immunol Network, Biopolis, Singapore, Singapore.
   [Nosten, Francois] Churchill Hosp, Ctr Vaccinol & Trop Med, Oxford OX3 7LJ, England.
   [Nosten, Francois] Mahidol Oxford Univ Trop Med Res Programme, Shoklo Malaria Res Unit, Mae Sot, Thailand.
   [Galinski, Mary R.] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA.
   [Galinski, Mary R.] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30322 USA.
   [Galinski, Mary R.] Emory Univ, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA.
   [Barnwell, John W.] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis, Chamblee, GA USA.
   [Rodrigues, Mauricio M.] Univ Fed Sao Paulo, CTCMOL, Dept Microbiol Imunol & Parasitol, Escola Paulista Med, Sao Paulo, Brazil.
RP Soares, IS (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo, Brazil.
EM isoares@usp.br
RI Russell, Bruce/A-9240-2011; Costa, Fabio/E-1181-2012; Rodrigues,
   Mauricio M./B-8512-2012; Nosten, Francois/AAC-5509-2019; Vicentin,
   Elaine/F-2651-2013; Soares, Irene Silva/C-5974-2012; Leite,
   Juliana/G-2563-2013; Ferreira, Luis/M-3954-2014
OI Russell, Bruce/0000-0003-2333-4348; Costa, Fabio/0000-0001-9969-7300;
   Nosten, Francois/0000-0002-7951-0745; Soares, Irene
   Silva/0000-0002-3336-6856; Ferreira, Luis/0000-0002-4883-1693
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2010/09893-0];
   National Institute for Vaccine Development and Technology (CNPq -
   INCTV); FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP); CNPqNational Council for Scientific and Technological
   Development (CNPq); US National Institutes of Health, National Institute
   for Allergy and Infectious DiseasesUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [1R01AI24710];
   SIgNAgency for Science Technology & Research (ASTAR); Horizontal
   Programme on Infectious Diseases under the Agency for Science,
   Technology and Research (A*STAR, Singapore); Wellcome Trust of Great
   Britain, as part of the Oxford Tropical Medicine Research Programme of
   Wellcome Trust-Mahidol University; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI024710, R01AI024710,
   R01AI024710, R01AI024710, R01AI024710, R01AI024710, R01AI024710,
   R01AI024710, R01AI024710, R01AI024710, R01AI024710, R01AI024710,
   R01AI024710, R01AI024710, R01AI024710, R01AI024710, R01AI024710,
   R01AI024710, R01AI024710, R01AI024710, R01AI024710, R01AI024710,
   R01AI024710] Funding Source: NIH RePORTER
FX This work was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP, 2010/09893-0) and The National Institute
   for Vaccine Development and Technology (CNPq - INCTV). ARB, MCJ and JAL
   were supported by fellowships from FAPESP. ECV, RR, FTC, LCF, MMR and
   ISS were supported by fellowships from CNPq. Support is also
   acknowledged from the US National Institutes of Health, National
   Institute for Allergy and Infectious Diseases to MRG (1R01AI24710), from
   SIgN and from the Horizontal Programme on Infectious Diseases under the
   Agency for Science, Technology and Research (A*STAR, Singapore). SMRU is
   sponsored by The Wellcome Trust of Great Britain, as part of the Oxford
   Tropical Medicine Research Programme of Wellcome Trust-Mahidol
   University. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287
   Arevalo-Herrera M, 2005, AM J TROP MED HYG, V73, P25
   Arevalo-Herrera M, 2011, AM J TROP MED HYG, V84, P35, DOI 10.4269/ajtmh.2011.09-0507
   Barbedo MB, 2007, MEM I OSWALDO CRUZ, V102, P335, DOI 10.1590/S0074-02762007005000040
   Bargieri DY, 2008, VACCINE, V26, P6132, DOI 10.1016/j.vaccine.2008.08.070
   Carlton JM, 2008, NATURE, V455, P757, DOI 10.1038/nature07327
   Ceravolo IP, 2009, CLIN EXP IMMUNOL, V156, P502, DOI 10.1111/j.1365-2249.2009.03931.x
   Coler RN, 2009, PARASITE IMMUNOL, V31, P520, DOI 10.1111/j.1365-3024.2009.01142.x
   Cunha MG, 2001, VACCINE, V20, P385, DOI 10.1016/S0264-410X(01)00359-0
   Ellis RD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008787
   Galinski MR, 1999, MOL BIOCHEM PARASIT, V101, P131, DOI 10.1016/S0166-6851(99)00063-8
   Galinski MR, 2001, MOL BIOCHEM PARASIT, V115, P41, DOI 10.1016/S0166-6851(01)00267-5
   Gentil F, 2010, VACCINE, V28, P6183, DOI 10.1016/j.vaccine.2010.07.017
   Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123
   Herrera S, 2005, AM J TROP MED HYG, V73, P44, DOI 10.4269/ajtmh.2005.73.44
   Herrera S, 2004, INT J PARASITOL, V34, P1535, DOI 10.1016/j.ijpara.2004.10.009
   Herrera S, 2011, AM J TROP MED HYG, V84, P12, DOI 10.4269/ajtmh.2011.09-0516
   Jimenez MCS, 2008, BBA-GEN SUBJECTS, V1780, P983, DOI 10.1016/j.bbagen.2008.03.016
   Lima JC, 2011, VACCINE, V29, P1801, DOI 10.1016/j.vaccine.2010.12.099
   Bouillet LEM, 2011, INFECT IMMUN, V79, P3642, DOI 10.1128/IAI.05048-11
   *MALERA CONS GROUP, 2011, PLOS MED, V0008
   Michon PA, 1998, AM J TROP MED HYG, V59, P597, DOI 10.4269/ajtmh.1998.59.597
   Morais CG, 2005, PARASITOL RES, V95, P420, DOI 10.1007/s00436-005-1314-x
   Morais CG, 2006, AM J TROP MED HYG, V75, P582, DOI 10.4269/ajtmh.2006.75.582
   Mourao LC, 2012, MICROBES INFECT, V14, P730, DOI 10.1016/j.micinf.2012.02.011
   Mullen GED, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002940
   Rayner JC, 2002, PARASITOLOGY, V125, P393, DOI 10.1017/S0031182002002317
   Rayner JC, 2004, INFECT GENET EVOL, V4, P309, DOI 10.1016/j.meegid.2004.03.003
   Ribeiro RS, 2011, MEM I OSWALDO CRUZ, V106, P27, DOI 10.1590/S0074-02762011000900004
   Rodrigues MHC, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-39
   Rodriguesa MHC, 2005, INT J PARASITOL, V35, P185, DOI 10.1016/j.ijpara.2004.11.003
   Rosa DS, 2006, MICROBES INFECT, V8, P2130, DOI 10.1016/j.micinf.2006.03.012
   Russell B, 2011, BLOOD, V118, pE74, DOI 10.1182/blood-2011-04-348748
   Sagara I, 2009, VACCINE, V27, P7292, DOI 10.1016/j.vaccine.2009.10.087
   Singh S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005410
   Sirima SB, 2011, NEW ENGL J MED, V365, P1062, DOI 10.1056/NEJMc1100670
   Soares IS, 1999, AM J TROP MED HYG, V60, P357, DOI 10.4269/ajtmh.1999.60.357
   Soares IS, 1997, INFECT IMMUN, V65, P1606, DOI 10.1128/IAI.65.5.1606-1614.1997
   Storti-Melo LM, 2011, AM J TROP MED HYG, V84, P58, DOI 10.4269/ajtmh.2011.10-0044
   Thera MA, 2011, NEW ENGL J MED, V365, P1004, DOI 10.1056/NEJMoa1008115
   Traore B, 2009, VACCINE, V27, P7299, DOI 10.1016/j.vaccine.2009.08.023
   Valderrama-Aguirre A, 2005, AM J TROP MED HYG, V73, P16, DOI 10.4269/ajtmh.2005.73.16
   Wu Yu-Huan, 2008, P3
NR 43
TC 16
Z9 16
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 14
PY 2013
VL 8
IS 2
AR e56061
DI 10.1371/journal.pone.0056061
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 099EJ
UT WOS:000315602700037
PM 23457498
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Costa, FTM
   Lopes, SCP
   Albrecht, L
   Ataide, R
   Siqueira, AM
   Souza, RM
   Russell, B
   Renia, L
   Marinho, CRF
   Lacerda, MVG
AF Costa, Fabio T. M.
   Lopes, Stefanie C. P.
   Albrecht, Letusa
   Ataide, Ricardo
   Siqueira, Andre M.
   Souza, Rodrigo M.
   Russell, Bruce
   Renia, Laurent
   Marinho, Claudio R. F.
   Lacerda, Marcus V. G.
TI On the pathogenesis of Plasmodium vivax malaria: Perspectives from the
   Brazilian field
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Article
DE Malaria; Plasmodium vivax; Clinical complications; Cytoadhesion;
   Pregnancy; Pathogenesis; Amazon; Brazil
ID RED-BLOOD-CELLS; SPATIAL-DISTRIBUTION; VARIANT GENES; ENDEMIC AREA; LUNG
   INJURY; FALCIPARUM; INFECTION; AMAZON; SUSCEPTIBILITY; PREGNANCY
AB Life-threatening Plasmodium vivax malaria cases, while uncommon, have been reported since the early 20th century. Unfortunately, the pathogenesis of these severe vivax malaria cases is still poorly understood. In Brazil, the proportion of vivax malaria cases has been steadily increasing, as have the number of cases presenting serious clinical complications. The most frequent syndromes associated with severe vivax malaria in Brazil are severe anaemia and acute respiratory distress. Additionally, P. vivax infection may also result in complications associated with pregnancy. Here, we review the latest findings on severe vivax malaria in Brazil. We also discuss how the development of targeted field research infrastructure in Brazil is providing clinical and ex vivo experimental data that benefits local and international efforts to understand the pathogenesis of P. vivax. (C) 2012 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Costa, Fabio T. M.; Lopes, Stefanie C. P.; Albrecht, Letusa] Univ Estadual Campinas UNICAMP, Inst Biol, Dept Genet Evolucao & Bioagentes, BR-13083970 Campinas, SP, Brazil.
   [Marinho, Claudio R. F.] Univ Sao Paulo, Dept Parasitol, Inst Ciencias Biomed ICB 2, BR-05508900 Sao Paulo, Brazil.
   [Siqueira, Andre M.; Lacerda, Marcus V. G.] Fundacao Med Trop Dr Heitor Vieira Dourado, BR-69040000 Manaus, Amazonas, Brazil.
   [Siqueira, Andre M.; Lacerda, Marcus V. G.] Univ Estado Amazonas, Manaus, Amazonas, Brazil.
   [Souza, Rodrigo M.] Univ Fed Acre UFAC, Ctr Multidisciplinar, Cruzeiro Do Sul, AC, Brazil.
   [Russell, Bruce; Renia, Laurent] Agcy Sci Technol & Res, Singapore Immunol Network, Singapore, Singapore.
RP Costa, FTM (corresponding author), Univ Estadual Campinas UNICAMP, Inst Biol, Dept Genet Evolucao & Bioagentes, POB 6109, BR-13083970 Campinas, SP, Brazil.
EM costaftm@unicamp.br; marinho@usp.br; marcuslacerda.br@gmail.com
RI Siqueira, Andre M/G-1340-2010; Costa, Fabio/E-1181-2012; Albrecht,
   Letusa/I-1837-2012; de Souza, Rodrigo Medeiros/F-5564-2016; Russell,
   Bruce/A-9240-2011; Ataide, Ricardo/B-7307-2017; Marinho, Claudio Romero
   Farias/F-7507-2012; Lopes, Stefanie/A-8314-2012; Medeiros de Souza,
   Rodrigo/E-3380-2013
OI Siqueira, Andre M/0000-0003-2208-0294; Costa, Fabio/0000-0001-9969-7300;
   Albrecht, Letusa/0000-0001-6406-2057; de Souza, Rodrigo
   Medeiros/0000-0002-7775-6901; Russell, Bruce/0000-0003-2333-4348;
   Ataide, Ricardo/0000-0002-1014-0432; Marinho, Claudio Romero
   Farias/0000-0002-1227-3845; Lopes, Stefanie/0000-0002-6981-2192
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP,
   Brazil)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq,
   Brazil)National Council for Scientific and Technological Development
   (CNPq); Instituto Nacional de Tecnologia em Vacinas (CNPq-FAPEMIG,
   Brazil); Instituto Nacional de Tecnologia em Doencas Negligenciadas
   (CNPq, Brazil); FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP); CNPqNational Council for Scientific and Technological
   Development (CNPq); Singapore Immunology Network and the Horizontal
   programme on Infectious Diseases, Agency for Science, Technology and
   Research (A*STAR), Singapore
FX This work received financial support from Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP, Brazil), Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil), Instituto
   Nacional de Tecnologia em Vacinas (CNPq-FAPEMIG, Brazil) and Instituto
   Nacional de Tecnologia em Doencas Negligenciadas (CNPq, Brazil).
   S.C.P.L., L.A. and R.A. were sponsored by FAPESP fellowships. R.M.S was
   supported by a CNPq fellowship. MVGL and FTMC are CNPq fellows. FTMC is
   enrolled at the Programa Estrategico de Ciencia, Tecnologia & Inovacao
   nas Fundacoes Estaduais de Saude (PECTI/AM Saude) from Fundacao de
   Amparo a Pesquisa do Estado do Amazonas (FAPEAM, Brazil). L.R. and B.R.
   were supported by core grants to the Singapore Immunology Network and
   the Horizontal programme on Infectious Diseases, Agency for Science,
   Technology and Research (A*STAR), Singapore. The funders had no role in
   study design, data collection and analysis, decision to publish or
   preparation of the manuscript. Special thanks to Dr. Tony Hiroshi
   Katsuragawa (Institut de Pesquisas em Patologias Tropicais - Porto
   Velho, Rondonia, Brazil) for the data on the annual parasitic index and
   the proportion P. vivax cases in Porto Velho.
CR Alexandre MA, 2010, EMERG INFECT DIS, V16, P1611, DOI 10.3201/eid1610.100685
   Alves FP, 2002, AM J TROP MED HYG, V66, P641, DOI 10.4269/ajtmh.2002.66.641
   Andrade BB, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-13
   Andrade BB, 2011, MEM I OSWALDO CRUZ, V106, P70, DOI 10.1590/S0074-02762011000900009
   Anstey NM, 2007, J INFECT DIS, V195, P589, DOI 10.1086/510756
   Anstey NM, 2009, TRENDS PARASITOL, V25, P220, DOI 10.1016/j.pt.2009.02.003
   BERENDT AR, 1990, PARASITOL TODAY, V6, P247, DOI 10.1016/0169-4758(90)90184-6
   Bernabeu M, 2012, CELL MICROBIOL, V14, P386, DOI 10.1111/j.1462-5822.2011.01726.x
   Lanca EFC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035406
   Campos FMF, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-327
   Campos IM, 2011, AM J TROP MED HYG, V84, P929, DOI 10.4269/ajtmh.2011.10-0507
   Carvalho BO, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-178
   Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815
   Cavasini CE, 2007, T ROY SOC TROP MED H, V101, P1042, DOI 10.1016/j.trstmh.2007.04.011
   Chotivanich K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034509
   Chotivanich KT, 1998, AM J TROP MED HYG, V59, P73, DOI 10.4269/ajtmh.1998.59.73
   Collins WE, 2003, AM J TROP MED HYG, V68, P410, DOI 10.4269/ajtmh.2003.68.410
   Chagas ECD, 2009, REV PANAM SALUD PUBL, V26, P203
   da Silva NS, 2010, T ROY SOC TROP MED H, V104, P343, DOI 10.1016/j.trstmh.2009.12.010
   da Silva-Nunes M, 2008, AM J TROP MED HYG, V79, P624, DOI 10.4269/ajtmh.2008.79.624
   Costa KMD, 2010, REV PANAM SALUD PUBL, V28, P353
   del Portillo HA, 2004, INT J PARASITOL, V34, P1547, DOI 10.1016/j.ijpara.2004.10.012
   del Portillo HA, 2001, NATURE, V410, P839, DOI 10.1038/35071118
   Fernandez-Becerra C, 2005, MOL MICROBIOL, V58, P648, DOI 10.1111/j.1365-2958.2005.04850.x
   Fernandez-Becerra C, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-55
   FIELD JW, 1963, MICROSCOPIAL DIAGNOS, P20
   de Santana FS, 2007, EMERG INFECT DIS, V13, P1125, DOI 10.3201/eid1307.061386
   Genton B, 2008, PLOS MED, V5, P881, DOI 10.1371/journal.pmed.0050127
   Saraiva MDG, 2009, REV SOC BRAS MED TRO, V42, P515, DOI 10.1590/S0037-86822009000500008
   GONCALVES MJF, 2004, BRAZIL REV SALUD PUB, V6, P156
   de Lacerda MVG, 2007, REV SOC BRAS MED TRO, V40, P96, DOI 10.1590/S0037-86822007000100023
   Gupta BK, 2010, T ROY SOC TROP MED H, V104, P81, DOI 10.1016/j.trstmh.2009.05.015
   Haldar Kasturi, 2009, Hematology Am Soc Hematol Educ Program, P87, DOI 10.1182/asheducation-2009.1.87
   Handayani S, 2009, J INFECT DIS, V199, P445, DOI 10.1086/596048
   KARUNAWEERA ND, 1992, P NATL ACAD SCI USA, V89, P3200, DOI 10.1073/pnas.89.8.3200
   King CL, 2011, P NATL ACAD SCI USA, V108, P20113, DOI 10.1073/pnas.1109621108
   Kochar DK, 2009, AM J TROP MED HYG, V80, P194, DOI 10.4269/ajtmh.2009.80.194
   Kochar DK, 2010, PLATELETS, V21, P623, DOI 10.3109/09537104.2010.505308
   Lacerda MVG, 2012, CLIN INFECT DIS, V55, pE67, DOI 10.1093/cid/cis615
   Lacerda MVG, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-12
   Lacerda MVG, 2004, ACTA TROP, V90, P187, DOI 10.1016/j.actatropica.2003.12.001
   Lampah DA, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001032
   LEESON HS, 1957, ROY SOC HEALTH J, V77, P694
   LUBITZ JM, 1949, BLOOD, V4, P1168, DOI 10.1182/blood.V4.10.1168.1168
   Manning L, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-107
   MARCELO L, 1994, AM J TROP MED HYG, V51, P16, DOI 10.4269/ajtmh.1994.51.16
   Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452
   Martinez-Espinosa FE, 2004, MEM I OSWALDO CRUZ, V99, P19, DOI 10.1590/S0074-02762004000100003
   McGready R, 2004, AM J TROP MED HYG, V70, P398, DOI 10.4269/ajtmh.2004.70.398
   McGready R, 2012, LANCET INFECT DIS, V12, P388, DOI 10.1016/S1473-3099(11)70339-5
   Mendis K, 2001, AM J TROP MED HYG, V64, P97, DOI 10.4269/ajtmh.2001.64.97
   Mendonca VRR, 2012, INFECT IMMUN, V80, P1445, DOI 10.1128/IAI.05933-11
   Mercereau-Puijalon O, 2008, TRANSFUS CLIN BIOL, V15, P62, DOI 10.1016/j.tracli.2008.04.003
   Mourao LC, 2012, MICROBES INFECT, V14, P730, DOI 10.1016/j.micinf.2012.02.011
   Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X
   NOSTEN F, 1991, T ROY SOC TROP MED H, V85, P424, DOI 10.1016/0035-9203(91)90205-D
   Oliveira-Ferreira J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-115
   Parekh FK, 2010, AM J TROP MED HYG, V83, P973, DOI 10.4269/ajtmh.2010.09-0445
   Price RN, 2007, AM J TROP MED HYG, V77, P79, DOI 10.4269/ajtmh.2007.77.79
   Ramos WM, 2010, BRAZ J INFECT DIS, V14, P410, DOI 10.1590/S1413-86702010000400017
   Rijken MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031411
   Russell B, 2011, BLOOD, V118, pE74, DOI 10.1182/blood-2011-04-348748
   Santana MS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005259
   Santos-Ciminera PD, 2007, EMERG INFECT DIS, V13, P1597, DOI 10.3201/eid1310.070052
   Siqueira AM, 2010, AM J TROP MED HYG, V83, P271, DOI 10.4269/ajtmh.2010.10-0027
   Gil LHS, 2007, MEM I OSWALDO CRUZ, V102, P271, DOI 10.1590/S0074-02762007005000013
   Suwanarusk R, 2004, J INFECT DIS, V189, P190, DOI 10.1086/380468
   Tan LKK, 2008, LANCET INFECT DIS, V8, P449, DOI 10.1016/S1473-3099(08)70153-1
   Tanwar GS, 2011, ANN TROP PAEDIATR, V31, P351, DOI 10.1179/1465328111Y.0000000040
   Tjitra E, 2008, PLOS MED, V5, P890, DOI 10.1371/journal.pmed.0050128
   Udomsangpetch R, 1995, T ROY SOC TROP MED H, V89, P635, DOI 10.1016/0035-9203(95)90422-0
   Udomsangpetch R, 2007, PARASITOL INT, V56, P65, DOI 10.1016/j.parint.2006.12.005
   Valecha N, 2009, AM J TROP MED HYG, V81, P758, DOI 10.4269/ajtmh.2009.09-0348
   Vitor-Silva S, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-230
   WHO, 2011, WORLD MALARIA REPORT 2011, P1
   WYLER DJ, 1983, LYMPHOLOGY, V16, P121
   Yeo TW, 2010, J INFECT DIS, V202, P109, DOI 10.1086/653211
NR 77
TC 34
Z9 34
U1 0
U2 13
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-7519
EI 1879-0135
J9 INT J PARASITOL
JI Int. J. Parasit.
PD NOV
PY 2012
VL 42
IS 12
SI SI
BP 1099
EP 1105
DI 10.1016/j.ijpara.2012.08.007
PG 7
WC Parasitology
SC Parasitology
GA 054OC
UT WOS:000312352100008
PM 23022617
DA 2020-12-08
ER

PT J
AU Russell, B
   Suwanarusk, R
   Malleret, B
   Costa, FTM
   Snounou, G
   Baird, JK
   Nosten, F
   Renia, L
AF Russell, Bruce
   Suwanarusk, Rossarin
   Malleret, Benoit
   Costa, Fabio T. M.
   Snounou, Georges
   Baird, J. Kevin
   Nosten, Francois
   Renia, Laurent
TI Human ex vivo studies on asexual Plasmodium vivax: The best way forward
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Review
DE Plasmodium vivax; Ex vivo; Malaria field studies; Antimalarial
   sensitivity
ID RED-BLOOD-CELLS; CAVEOLA-VESICLE COMPLEXES; HUMAN MALARIA PARASITE;
   DUFFY-BINDING-PROTEIN; IN-VITRO SENSITIVITY; DRUG-SUSCEPTIBILITY;
   INFECTED ERYTHROCYTES; WESTERN BORDER; CORD BLOOD; P. VIVAX
AB The lack of a continuous culture method for Plasmodium vivax has given the impression that investigations on this important species are severely curtailed. However, the use of new or improved ex vivo methods and tools to study fresh and thawed isolates from vivax malaria patients is currently providing useful data on P. vivax, such as sensitivity to antimalarial drugs, invasion mechanisms and pathobiology. This review discusses a practical framework for conducting ex vivo studies on the asexual erythrocytic stages of P. vivax and considers the synergies between ex vivo defined phenotypes, ex vivo derived 'omic' studies and in vivo clinical studies. (C) 2012 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Russell, Bruce; Suwanarusk, Rossarin; Malleret, Benoit; Renia, Laurent] Agcy Sci Technol & Res, Biopolis, Singapore Immunol Network, Singapore, Singapore.
   [Russell, Bruce] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Singapore 117595, Singapore.
   [Costa, Fabio T. M.] Univ Estadual Campinas UNICAMP, Inst Biol, Dept Genet Evolucao & Bioagentes, BR-13083862 Campinas, SP, Brazil.
   [Snounou, Georges] Hop La Pitie Salpetriere, INSERM, Dept Parasitol, UMR S 945, Paris, France.
   [Snounou, Georges] Univ Paris 06, Fac Med Pitie Salpetriere, Paris, France.
   [Baird, J. Kevin] Eijkman Oxford Clin Res Unit, Jakarta, Indonesia.
   [Baird, J. Kevin; Nosten, Francois] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med, Oxford, England.
   [Nosten, Francois] Shoklo Malaria Res Unit, Mae Sot, Tak, Thailand.
RP Russell, B (corresponding author), Agcy Sci Technol & Res, Biopolis, Singapore Immunol Network, Singapore, Singapore.
EM micbmr@nus.edu.sg; renia_laurent@immunol.a-star.edu.sg
RI Malleret, Benoit/E-9159-2011; Costa, Fabio/E-1181-2012; Suwanarusk,
   Rossarin/E-2115-2013; Russell, Bruce/A-9240-2011; Malleret,
   Benoit/AAK-4048-2020; Nosten, Francois/AAC-5509-2019; Snounou,
   Georges/F-3352-2011
OI Malleret, Benoit/0000-0001-9658-7528; Costa, Fabio/0000-0001-9969-7300;
   Suwanarusk, Rossarin/0000-0002-7310-245X; Russell,
   Bruce/0000-0003-2333-4348; Malleret, Benoit/0000-0001-9658-7528; Nosten,
   Francois/0000-0002-7951-0745; Snounou, Georges/0000-0002-6133-6398
FU Horizontal programme on Infectious Diseases, Agency for Science,
   Technology and Research (A*STAR), Singapore
FX This work was supported by core grants to the Singapore Immunology
   network and the Horizontal programme on Infectious Diseases, Agency for
   Science, Technology and Research (A*STAR), Singapore. L.R. and G.S. are
   currently part of an official collaboration between SIgN/A*-STAR and
   Inserm (Laboratoire International Associe, Inserm), France.
CR AIKAWA M, 1975, AM J PATHOL, V79, P285
   Auliff A, 2006, AM J TROP MED HYG, V75, P617, DOI 10.4269/ajtmh.2006.75.617
   Baird JK, 2007, TRENDS PARASITOL, V23, P533, DOI 10.1016/j.pt.2007.08.011
   BARNWELL JW, 1990, EXP PARASITOL, V70, P85, DOI 10.1016/0014-4894(90)90088-T
   BARNWELL JW, 1989, J EXP MED, V169, P1795, DOI 10.1084/jem.169.5.1795
   BASCO LK, 1994, PARASITOL RES, V80, P262, DOI 10.1007/BF00932686
   BASCO LK, 1995, EXP PARASITOL, V80, P260, DOI 10.1006/expr.1995.1032
   Borlon C, 2012, INT J PARASITOL, V42, P155, DOI 10.1016/j.ijpara.2011.10.011
   Bozdech Z, 2008, P NATL ACAD SCI USA, V105, P16290, DOI 10.1073/pnas.0807404105
   Carlton JM, 2008, NATURE, V455, P757, DOI 10.1038/nature07327
   Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815
   Chitnis CE, 2008, TRENDS PARASITOL, V24, P29, DOI 10.1016/j.pt.2007.10.004
   Chotivanich K, 2004, AM J TROP MED HYG, V70, P395, DOI 10.4269/ajtmh.2004.70.395
   Chotivanich K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034509
   Congpuong K, 2002, ACTA TROP, V83, P117, DOI 10.1016/S0001-706X(02)00090-6
   DELPORTILLO HA, 1991, P NATL ACAD SCI USA, V88, P4030, DOI 10.1073/pnas.88.9.4030
   Deplaine G, 2011, BLOOD, V117, pE88, DOI 10.1182/blood-2010-10-312801
   Druilhe P, 2007, ANTIMICROB AGENTS CH, V51, P2112, DOI 10.1128/AAC.01385-06
   FANG XD, 1991, MOL BIOCHEM PARASIT, V44, P125, DOI 10.1016/0166-6851(91)90228-X
   Field J.W., 1938, NOTES CHEMOTHERAPY M
   Galinski MR, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-S1-S9
   GALINSKI MR, 1992, CELL, V69, P1213, DOI 10.1016/0092-8674(92)90642-P
   Galinski MR, 2001, MOL BIOCHEM PARASIT, V115, P41, DOI 10.1016/S0166-6851(01)00267-5
   Grimberg BT, 2007, PLOS MED, V4, P1940, DOI 10.1371/journal.pmed.0040337
   Hamedi Y., 2002, Southeast Asian Journal of Tropical Medicine and Public Health, V33, P512
   Hamedi Y, 2003, T ROY SOC TROP MED H, V97, P435, DOI 10.1016/S0035-9203(03)90080-0
   Handayani S, 2009, J INFECT DIS, V199, P445, DOI 10.1086/596048
   Hasugian AR, 2009, ANTIMICROB AGENTS CH, V53, P1094, DOI 10.1128/AAC.01511-08
   Imwong M, 2011, J INFECT DIS, V203, P207, DOI 10.1093/infdis/jiq024
   Iyer J, 2007, MOL MICROBIOL, V65, P231, DOI 10.1111/j.1365-2958.2007.05791.x
   Kaewpongsri S, 2011, ANTIMICROB AGENTS CH, V55, P1300, DOI 10.1128/AAC.01103-10
   Kocken CHM, 1999, INFECT IMMUN, V67, P43, DOI 10.1128/IAI.67.1.43-49.1999
   Kosaisavee V, 2006, EXP PARASITOL, V114, P34, DOI 10.1016/j.exppara.2006.02.006
   Kosaisavee V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032105
   Lam NYL, 2004, CLIN CHEM, V50, P256, DOI 10.1373/clinchem.2003.026013
   Leimanis ML, 2010, ANTIMICROB AGENTS CH, V54, P2228, DOI 10.1128/AAC.01572-09
   Lek-Uthai U, 2008, ANTIMICROB AGENTS CH, V52, P2435, DOI 10.1128/AAC.00169-08
   Lux D, 2003, WIEN KLIN WOCHENSCHR, V115, P50
   Bouillet LEM, 2011, INFECT IMMUN, V79, P3642, DOI 10.1128/IAI.05048-11
   Malleret B, 2011, SCI REP-UK, V1, DOI 10.1038/srep00118
   Marfurt J, 2011, ANTIMICROB AGENTS CH, V55, P4461, DOI 10.1128/AAC.01375-10
   Meyers RA, 2012, ENCY SUSTAINABILITY, P11134
   MONS B, 1988, EXP PARASITOL, V66, P183, DOI 10.1016/0014-4894(88)90089-6
   MONS B, 1988, INT J PARASITOL, V18, P307, DOI 10.1016/0020-7519(88)90138-5
   Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X
   NICHOLS ME, 1987, J EXP MED, V166, P776, DOI 10.1084/jem.166.3.776
   Phyo AP, 2011, CLIN INFECT DIS, V53, P977, DOI 10.1093/cid/cir631
   POWELL RD, 1974, AM J TROP MED HYG, V23, P1007, DOI 10.4269/ajtmh.1974.23.1007
   Price RN, 2007, AM J TROP MED HYG, V77, P79, DOI 10.4269/ajtmh.2007.77.79
   Rayner JC, 2005, AM J TROP MED HYG, V72, P666, DOI 10.4269/ajtmh.2005.72.666
   RENAPURKAR DM, 1989, CHEMOTHERAPY, V35, P160, DOI 10.1159/000238664
   RIECKMANN KH, 1978, LANCET, V1, P22
   Rijken MJ, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-113
   ROSSAN RN, 1985, AM J TROP MED HYG, V34, P207, DOI 10.4269/ajtmh.1985.34.207
   Rottmann M, 2010, SCIENCE, V329, P1175, DOI 10.1126/science.1193225
   Russell B, 2008, ANTIMICROB AGENTS CH, V52, P1040, DOI 10.1128/AAC.01334-07
   Russell B., 2011, BIONANOTECHNOLOGY, P287
   Russell BM, 2003, ANTIMICROB AGENTS CH, V47, P170, DOI 10.1128/AAC.47.1.170-173.2003
   Russell B, 2011, BLOOD, V118, pE74, DOI 10.1182/blood-2011-04-348748
   Safeukui I, 2008, BLOOD, V112, P2520, DOI 10.1182/blood-2008-03-146779
   Sharrock WW, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-94
   Sriprawat K, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-115
   Stewart VA, 2003, TRENDS PARASITOL, V19, P589, DOI 10.1016/j.pt.2003.10.008
   Suwanarusk R, 2008, J INFECT DIS, V198, P1558, DOI 10.1086/592451
   Suwanarusk R, 2004, J INFECT DIS, V189, P190, DOI 10.1086/380468
   Suwanarusk R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001089
   TANARIYA P, 1995, T ROY SOC TROP MED H, V89, P426, DOI 10.1016/0035-9203(95)90039-X
   Tao ZY, 2011, MALARIA J, V10, DOI 10.1186/1475-2875-10-251
   Tasanor O, 2006, T ROY SOC TROP MED H, V100, P410, DOI 10.1016/j.trstmh.2005.04.024
   Tasanor O, 2002, ACTA TROP, V83, P49, DOI 10.1016/S0001-706X(02)00056-6
   Udomsangpetch R, 1995, T ROY SOC TROP MED H, V89, P635, DOI 10.1016/0035-9203(95)90422-0
   Udomsangpetch R, 2007, PARASITOL INT, V56, P65, DOI 10.1016/j.parint.2006.12.005
   WEED RI, 1969, J CLIN INVEST, V48, P795, DOI 10.1172/JCI106038
   Westenberger SJ, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000653
NR 74
TC 25
Z9 25
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-7519
EI 1879-0135
J9 INT J PARASITOL
JI Int. J. Parasit.
PD NOV
PY 2012
VL 42
IS 12
SI SI
BP 1063
EP 1070
DI 10.1016/j.ijpara.2012.08.010
PG 8
WC Parasitology
SC Parasitology
GA 054OC
UT WOS:000312352100004
PM 23032102
OA Other Gold
DA 2020-12-08
ER

PT J
AU Thome, R
   Francelin, C
   di Gangi, R
   da Costa, TA
   Farias, AS
   Costa, FTM
   Verinaud, L
AF Thome, R.
   Francelin, C.
   di Gangi, R.
   da Costa, T. A.
   Farias, A. S.
   Costa, F. T. M.
   Verinaud, L.
TI Chloroquine treatment reduces the severity of experimental autoimmune
   encephalomyelitis
SO IMMUNOLOGY
LA English
DT Meeting Abstract
CT European Congress of Immunology
CY SEP 05-08, 2012
CL Glasgow, SCOTLAND
C1 [Thome, R.; Francelin, C.; di Gangi, R.; da Costa, T. A.; Verinaud, L.] Univ Estadual Campinas, Inst Biol, Dept Struct & Funct Biol, Campinas, SP, Brazil.
   [Farias, A. S.; Costa, F. T. M.] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut & Bioagents, Campinas, SP, Brazil.
RI da Costa, Thiago Alves/F-8187-2016; Costa, Fabio/E-1181-2012
OI Costa, Fabio/0000-0001-9969-7300
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0019-2805
J9 IMMUNOLOGY
JI Immunology
PD SEP
PY 2012
VL 137
SU 1
SI SI
BP 691
EP 692
PG 2
WC Immunology
SC Immunology
GA 011TW
UT WOS:000309189106080
DA 2020-12-08
ER

PT J
AU Costa, SD
   Golim, MD
   Rossi-Bergmann, B
   Costa, FTM
   Giorgio, S
AF Costa, Solange dos Santos
   Golim, Marjorie de Assis
   Rossi-Bergmann, Bartira
   Maranhao Costa, Fabio Trindade
   Giorgio, Selma
TI Use of In Vivo and In Vitro Systems to Select Leishmania amazonensis
   Expressing Green Fluorescent Protein
SO KOREAN JOURNAL OF PARASITOLOGY
LA English
DT Article
DE Leishmania amazonensis; green fluorescent protein; macrophage; geneticin
ID MARKER; ASSAY; GENE
AB Various Leishmania species were engineered with green fluorescent protein (GFP) using episomal vectors that encoded an antibiotic resistance gene, such as aminoglycoside geneticin sulphate (G418). Most reports of GFP-Leishmania have used the flagellated extracellular promastigote, the stage of parasite detected in the midgut of the sandfly vector; fewer studies have been performed with amastigotes, the stage of parasite detected in mammals. In this study, comparisons were made regarding the efficiency for in vitro G418 selection of GFP-Leishmania amazonensis promastigotes and amastigotes and the use of in vivo G418 selection. The GFP-promastigotes retained episomal plasmid for a prolonged period and G418 treatment was necessary and efficient for in vitro selection. In contrast, GFP-amastigotes showed low retention of the episomal plasmid in the absence of G418 selection and low sensitivity to antibiotics in vitro. The use of protocols for G418 selection using infected BALB/c mice also indicated low sensitivity to antibiotics against amastigotes in cutaneous lesions.
C1 [Costa, Solange dos Santos; Giorgio, Selma] Univ Estadual Campinas, Dept Anim Biol, Inst Biol, BR-13083970 Sao Paulo, Brazil.
   [Golim, Marjorie de Assis] Univ Estadual Campinas, Dept Genet Evolut & Bioagents, Inst Biol, BR-13083970 Sao Paulo, Brazil.
   [Rossi-Bergmann, Bartira] Univ Estadual Paulista, Blood Ctr, Fac Med, Sch Med, Sao Paulo, Brazil.
   [Maranhao Costa, Fabio Trindade] Univ Fed Rio de Janeiro, Carlos Chagas Filho Inst, Rio De Janeiro, Brazil.
RP Giorgio, S (corresponding author), Univ Estadual Campinas, Dept Anim Biol, Inst Biol, Caixa Postal 6109, BR-13083970 Sao Paulo, Brazil.
EM sgiorgio@unicamp.br
RI Rossi-Bergmann, Bartira/ABB-3894-2020; Costa, Fabio/E-1181-2012
OI Costa, Fabio/0000-0001-9969-7300; de Assis Golim,
   Marjorie/0000-0002-4824-9441
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP); Coordenacao de Aperfeicoamento
   de Pessoal de Nivel SuperiorCAPES; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico, BrazilNational Council for Scientific and
   Technological Development (CNPq)
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo, Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior and the Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico, Brazil.
CR Appel KF, 2004, MOL GENET GENOMICS, V271, P595, DOI 10.1007/s00438-004-1008-6
   Arrais-Silva WW, 2006, ACTA TROP, V98, P130, DOI 10.1016/j.actatropica.2006.03.001
   Boeck P, 2006, BIOORGAN MED CHEM, V14, P1538, DOI 10.1016/j.bmc.2005.10.005
   Chan MMY, 2003, PARASITOL RES, V89, P266, DOI 10.1007/s00436-002-0706-4
   Colhone MC, 2004, J PARASITOL, V90, P510, DOI 10.1645/GE-3286
   Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004
   GRIMALDI G, 1993, CLIN MICROBIOL REV, V6, P230, DOI 10.1128/CMR.6.3.230-250.1993
   Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7
   Kain SR, 1999, DRUG DISCOV TODAY, V4, P304, DOI 10.1016/S1359-6446(99)01330-6
   Kamau SW, 2001, ANTIMICROB AGENTS CH, V45, P3654, DOI 10.1128/AAC.45.12.3654-3656.2001
   Mehta SR, 2008, CLIN VACCINE IMMUNOL, V15, P1764, DOI 10.1128/CVI.00270-08
   Misslitz A, 2000, MOL BIOCHEM PARASIT, V107, P251, DOI 10.1016/S0166-6851(00)00195-X
   MURPHY NB, 1993, ANTIMICROB AGENTS CH, V37, P1167, DOI 10.1128/AAC.37.5.1167
   Naumov GN, 1999, J CELL SCI, V112, P1835
   Okuno T, 2003, EXP ANIM TOKYO, V52, P109, DOI 10.1538/expanim.52.109
   Rossi-Bergman B., 1999, Memorias do Instituto Oswaldo Cruz, V94, P74
   Roy G, 2000, MOL BIOCHEM PARASIT, V110, P195, DOI 10.1016/S0166-6851(00)00270-X
   Sereno D, 2001, ANTIMICROB AGENTS CH, V45, P1168, DOI 10.1128/AAC.45.4.1168-1173.2001
   Shimony O, 2008, J MICROBIOL METH, V75, P196, DOI 10.1016/j.mimet.2008.05.026
   Singh N, 2004, AM J TROP MED HYG, V71, P400, DOI 10.4269/ajtmh.2004.71.400
   Singh N, 2009, J ANTIMICROB CHEMOTH, V64, P370, DOI 10.1093/jac/dkp206
   Varela RE, 2009, EXP PARASITOL, V122, P134, DOI 10.1016/j.exppara.2009.02.012
   Wade-Martins R, 1999, NUCLEIC ACIDS RES, V27, P1674, DOI 10.1093/nar/27.7.1674
NR 23
TC 7
Z9 7
U1 1
U2 5
PU KOREAN SOC PARASITOLOGY, SEOUL NATL UNIV COLL MEDI
PI SEOUL
PA DEPT PARASITOLOGY, SEOUL, 00000, SOUTH KOREA
SN 0023-4001
EI 1738-0006
J9 KOREAN J PARASITOL
JI Korean J. Parasitol.
PD DEC
PY 2011
VL 49
IS 4
BP 357
EP 364
DI 10.3347/kjp.2011.49.4.357
PG 8
WC Parasitology
SC Parasitology
GA 875QF
UT WOS:000299048000003
PM 22355202
OA Other Gold, Green Published
DA 2020-12-08
ER

PT J
AU Ferrer, M
   Lopes, S
   Leite, J
   Carvalho, B
   Neiras, W
   Nogueira, P
   Costa, FTM
   Lacerda, MVG
   del Portillo, HA
AF Ferrer, M.
   Lopes, S.
   Leite, J.
   Carvalho, B.
   Neiras, W.
   Nogueira, P.
   Costa, F. T. M.
   Lacerda, M. V. G.
   del Portillo, H. A.
TI Adherence of Plasmodium vivax-infected reticulocytes to the human spleen
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Meeting Abstract
C1 [Ferrer, M.; del Portillo, H. A.] Barcelona Ctr Int Hlth Res CRESIB, Barcelona, Spain.
   [Lopes, S.; Leite, J.; Carvalho, B.; Neiras, W.; Costa, F. T. M.] Univ Estadual Campinas UNICAMP, Dept GenA Tica Evoluciao & Bioagentes, Inst Biol, Campinas, SP, Brazil.
   [Nogueira, P.] Ctr Leonidas & Maria Deane Fiocruz, Manaus, Amazonas, Brazil.
   [Lacerda, M. V. G.] Fdn Med Trop Dr Heitor Vieira Dourado FMT HVD, Manaus, Amazonas, Brazil.
   [del Portillo, H. A.] ICREA, Barcelona, Spain.
RI Costa, Fabio/E-1181-2012; Lopes, Stefanie/A-8314-2012; Nogueira,
   Paulo/AAK-8822-2020
OI Costa, Fabio/0000-0001-9969-7300; 
FU ICREAICREA Funding Source: Custom
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1360-2276
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD OCT
PY 2011
VL 16
SU 1
SI SI
BP 122
EP 122
PG 1
WC Public, Environmental & Occupational Health; Tropical Medicine
SC Public, Environmental & Occupational Health; Tropical Medicine
GA 828RC
UT WOS:000295519100347
DA 2020-12-08
ER

PT J
AU Russell, B
   Suwanarusk, R
   Borlon, C
   Costa, FTM
   Chu, CS
   Rijken, MJ
   Sriprawat, K
   Warter, L
   Koh, EGL
   Malleret, B
   Colin, Y
   Bertrand, O
   Adams, JH
   D'Alessandro, U
   Snounou, G
   Nosten, F
   Renia, L
AF Russell, Bruce
   Suwanarusk, Rossarin
   Borlon, Celine
   Costa, Fabio T. M.
   Chu, Cindy S.
   Rijken, Marcus J.
   Sriprawat, Kanlaya
   Warter, Lucile
   Koh, Esther G. L.
   Malleret, Benoit
   Colin, Yves
   Bertrand, Olivier
   Adams, John H.
   D'Alessandro, Umberto
   Snounou, Georges
   Nosten, Francois
   Renia, Laurent
TI A reliable ex vivo invasion assay of human reticulocytes by Plasmodium
   vivax
SO BLOOD
LA English
DT Article
ID DUFFY-BINDING-PROTEIN; INFECTED ERYTHROCYTES; BLOOD-GROUP; INHIBITORY
   ANTIBODIES; MONOCLONAL-ANTIBODY; LIGAND DOMAIN; MALARIA; SUSCEPTIBILITY;
   RESISTANCE; ROSETTES
AB Currently, there are no reliable RBC invasion assays to guide the discovery of vaccines against Plasmodium vivax, the most prevalent malaria parasite in Asia and South America. Here we describe a protocol for an ex vivo P vivax invasion assay that can be easily deployed in laboratories located in endemic countries. The assay is based on mixing enriched cord blood reticulocytes with matured, trypsin-treated P vivax schizonts concentrated from clinical isolates. The reliability of this assay was demonstrated using a large panel of P vivax isolates freshly collected from patients in Thailand. (Blood. 2011;118(13):e74-e81)
C1 [Russell, Bruce; Suwanarusk, Rossarin; Warter, Lucile; Koh, Esther G. L.; Malleret, Benoit; Renia, Laurent] Agcy Sci Technol & Res, Singapore Immunol Network, Singapore, Singapore.
   [Borlon, Celine; D'Alessandro, Umberto] Inst Trop Med, Dept Parasitol, B-2000 Antwerp, Belgium.
   [Costa, Fabio T. M.] Univ Estadual Campinas, UNICAMP, Dept Genet Evolucao & Bioagentes, Inst Biol, Sao Paulo, Brazil.
   [Chu, Cindy S.; Rijken, Marcus J.; Sriprawat, Kanlaya; Nosten, Francois] Shoklo Malaria Res Unit, Mae Sot, Tak, Thailand.
   [Colin, Yves; Bertrand, Olivier] INSERM, UMR S 665, Paris, France.
   [Colin, Yves; Bertrand, Olivier] Inst Natl Transfus Sanguine, F-75015 Paris, France.
   [Colin, Yves; Bertrand, Olivier] Univ Paris 07, Paris, France.
   [Adams, John H.] Univ S Florida, Coll Publ Hlth, Tampa, FL USA.
   [Snounou, Georges] Univ Paris 06, INSERM, UMR S 945, Hop La Pitie Salpetriere,Dept Parasitol, Paris, France.
   [Snounou, Georges] Univ Paris 06, Fac Med Pitie Salpetriere, Paris, France.
   [Nosten, Francois] Ctr Clin Vaccinol & Trop Med, Oxford, England.
RP Russell, B (corresponding author), Singapore Immunol Network SIgN, Lab Malaria Immunobiol, 8A Biomed Grove, Singapore 138648, Singapore.
EM bruce_russell@immunol.a-star.edu.sg
RI colin, yves/O-1910-2017; Costa, Fabio/E-1181-2012; Suwanarusk,
   Rossarin/E-2115-2013; Adams, John H./ABB-8458-2020; Nosten,
   Francois/AAC-5509-2019; Chu, Cindy S/E-3135-2014; Malleret,
   Benoit/E-9159-2011; Snounou, Georges/F-3352-2011; Adams,
   John/G-1800-2015; Malleret, Benoit/AAK-4048-2020; D'Alessandro,
   Umberto/D-3457-2015; Russell, Bruce/A-9240-2011; Koh, Esther
   GL/E-3921-2013
OI colin, yves/0000-0001-5196-4254; Costa, Fabio/0000-0001-9969-7300;
   Suwanarusk, Rossarin/0000-0002-7310-245X; Adams, John
   H./0000-0003-3707-7979; Nosten, Francois/0000-0002-7951-0745; Chu, Cindy
   S/0000-0001-9465-8214; Malleret, Benoit/0000-0001-9658-7528; Snounou,
   Georges/0000-0002-6133-6398; Adams, John/0000-0003-3707-7979; Malleret,
   Benoit/0000-0001-9658-7528; D'Alessandro, Umberto/0000-0001-6341-5009;
   Russell, Bruce/0000-0003-2333-4348; Rijken, Marcus/0000-0003-0914-5508
FU Wellcome Trust of Great Britain, as part of Wellcome Trust-Mahidol
   UniversityWellcome Trust; Agency for Science Technology and Research
   (A*STAR; Singapore)Agency for Science Technology & Research (ASTAR);
   Wellcome Trust (United Kingdom)Wellcome Trust; ITMDefence Research &
   Development Organisation (DRDO); NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01AI064478, R01AI064478,
   R01AI064478, R01AI064478, R01AI064478, R01AI064478, R01AI064478,
   R01AI064478, R01AI064478, R01AI064478, R01AI064478] Funding Source: NIH
   RePORTER
FX The authors thank all of the patients and staff of the SMRU for their
   contribution to this study. SMRU is sponsored by the Wellcome Trust of
   Great Britain, as part of the Oxford Tropical Medicine Research Program
   of Wellcome Trust-Mahidol University.; This study received funding from
   the Agency for Science Technology and Research (A*STAR; Singapore) and
   the Wellcome Trust (United Kingdom). L. R. and G. S. are currently part
   of an official collaboration between SIgN/A*-STAR and Inserm
   (Laboratoire International Associe, Inserm). C. B. and U. D. were
   supported by ITM Secondary Research Funding (SOFI-B).
CR Babaeekho L, 2009, AM J TROP MED HYG, V80, P112, DOI 10.4269/ajtmh.2009.80.112
   Baird JK, 2007, TRENDS PARASITOL, V23, P533, DOI 10.1016/j.pt.2007.08.011
   Baird JK, 2009, CLIN MICROBIOL REV, V22, P508, DOI 10.1128/CMR.00008-09
   BARNWELL JW, 1989, J EXP MED, V169, P1795, DOI 10.1084/jem.169.5.1795
   Beeson JG, 2007, PLOS MED, V4, P1862, DOI 10.1371/journal.pmed.0040350
   Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815
   Chitnis CE, 2008, TRENDS PARASITOL, V24, P29, DOI 10.1016/j.pt.2007.10.004
   Chootong P, 2010, INFECT IMMUN, V78, P1089, DOI 10.1128/IAI.01036-09
   Chotivanich KT, 1998, AM J TROP MED HYG, V59, P73, DOI 10.4269/ajtmh.1998.59.73
   DAVID PH, 1988, AM J TROP MED HYG, V38, P289, DOI 10.4269/ajtmh.1988.38.289
   Fraser T, 1997, INFECT IMMUN, V65, P2772, DOI 10.1128/IAI.65.7.2772-2777.1997
   Grimberg BT, 2007, PLOS MED, V4, P1940, DOI 10.1371/journal.pmed.0040337
   Guerra CA, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000774
   Kaewpongsri S, 2011, ANTIMICROB AGENTS CH, V55, P1300, DOI 10.1128/AAC.01103-10
   King CL, 2008, P NATL ACAD SCI USA, V105, P8363, DOI 10.1073/pnas.0800371105
   KITCHEN S. F., 1938, AMER JOUR TROP MED, V18, P347
   MILLER LH, 1976, NEW ENGL J MED, V295, P302, DOI 10.1056/NEJM197608052950602
   MONS B, 1988, EXP PARASITOL, V66, P183, DOI 10.1016/0014-4894(88)90089-6
   MONS B, 1988, INT J PARASITOL, V18, P307, DOI 10.1016/0020-7519(88)90138-5
   Narum DL, 2000, INFECT IMMUN, V68, P1964, DOI 10.1128/IAI.68.4.1964-1966.2000
   NICHOLS ME, 1987, J EXP MED, V166, P776, DOI 10.1084/jem.166.3.776
   Ntumngia FB, 2009, AM J TROP MED HYG, V80, P218, DOI 10.4269/ajtmh.2009.80.218
   Price RN, 2007, AM J TROP MED HYG, V77, P79, DOI 10.4269/ajtmh.2007.77.79
   Russell B, 2008, ANTIMICROB AGENTS CH, V52, P1040, DOI 10.1128/AAC.01334-07
   Simpson JA, 1999, T ROY SOC TROP MED H, V93, P165, DOI 10.1016/S0035-9203(99)90295-X
   Sriprawat K, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-115
   Thein SL, 1998, HEMOGLOBIN, V22, P415, DOI 10.3109/03630269809071539
   Udomsangpetch R, 1995, T ROY SOC TROP MED H, V89, P635, DOI 10.1016/0035-9203(95)90422-0
   VanBuskirk KM, 2004, P NATL ACAD SCI USA, V101, P15754, DOI 10.1073/pnas.0405421101
   WAHLGREN M, 1989, PARASITOL TODAY, V5, P183, DOI 10.1016/0169-4758(89)90141-5
   Wasniowska K, 2002, TRANSFUSION MED, V12, P205, DOI 10.1046/j.1365-3148.2002.00373.x
   Xainli J, 2003, INFECT IMMUN, V71, P2508, DOI 10.1128/IAI.71.5.2508-2515.2003
NR 32
TC 90
Z9 90
U1 0
U2 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD SEP 29
PY 2011
VL 118
IS 13
BP E74
EP E81
DI 10.1182/blood-2011-04-348748
PG 8
WC Hematology
SC Hematology
GA 826MW
UT WOS:000295359300002
PM 21768300
OA Green Accepted, Green Published
DA 2020-12-08
ER

PT J
AU Costa, FTM
   Lopes, SCP
   Ferrer, M
   Leite, JA
   Martin-Jaular, L
   Bernabeu, M
   Nogueira, PA
   Mourao, MPG
   Fernandez-Becerra, C
   Lacerda, MVG
   del Portillo, H
AF Costa, Fabio T. M.
   Lopes, Stefanie C. P.
   Ferrer, Mireia
   Leite, Juliana A.
   Martin-Jaular, Lorena
   Bernabeu, Maria
   Nogueira, Paulo A.
   Mourao, Maria Paula G.
   Fernandez-Becerra, Carmen
   Lacerda, Marcus V. G.
   del Portillo, Hernando
TI On cytoadhesion of Plasmodium vivax: raison d'etre?
SO MEMORIAS DO INSTITUTO OSWALDO CRUZ
LA English
DT Article
DE Plasmodium vivax; malaria; cytoadherence; severe disease
ID ANTIGENIC VARIATION; FALCIPARUM-MALARIA; CEREBRAL MALARIA; VARIANT
   GENES; CYTOADHERENCE; PLATELETS; DYSERYTHROPOIESIS; HISTOPATHOLOGY;
   SEQUESTRATION; POPULATION
AB It is generally accepted that Plasmodium vivax, the most widely distributed human malaria parasite, causes mild disease and that this species does not sequester in the deep capillaries of internal organs. Recent evidence, however, has demonstrated that there is severe disease, sometimes resulting in death, exclusively associated with P. vivax and that P. vivax-infected reticulocytes are able to cytoadhere in vitro to different endothelial cells and placental cryosections. Here, we review the scarce and preliminary data on cytoadherence in P. vivax, reinforcing the importance of this phenomenon in this species and highlighting the avenues that it opens for our understanding of the pathology of this neglected human malaria parasite.
C1 [Costa, Fabio T. M.; Lopes, Stefanie C. P.; Leite, Juliana A.] Univ Estadual Campinas, Dept Genet Evolucao & Bioagentes, Inst Biol, Campinas, SP, Brazil.
   [Ferrer, Mireia; Martin-Jaular, Lorena; Bernabeu, Maria; Fernandez-Becerra, Carmen; del Portillo, Hernando] Barcelona Ctr Int Hlth Res, Barcelona, Spain.
   [Nogueira, Paulo A.] Inst Leonidas & Maria Deane Fiocruz, Manaus, Amazonas, Brazil.
   [Mourao, Maria Paula G.; Lacerda, Marcus V. G.] Fundacao Med Trop Doutor Heitor Vieira Dourado, Manaus, Amazonas, Brazil.
   [del Portillo, Hernando] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain.
RP Costa, FTM (corresponding author), Univ Estadual Campinas, Dept Genet Evolucao & Bioagentes, Inst Biol, Campinas, SP, Brazil.
EM costaftm@unicamp.br; hernando.delportillo@cresib.cat
RI Fernandez Becerra, Carmen/L-2069-2014; del Portillo, Hernando
   A/L-2131-2014; Leite, Juliana/G-2563-2013; Lopes, Stefanie/A-8314-2012;
   Costa, Fabio/E-1181-2012
OI Fernandez Becerra, Carmen/0000-0001-5154-0013; del Portillo, Hernando
   A/0000-0002-5278-3452; Costa, Fabio/0000-0001-9969-7300; Bernabeu,
   Maria/0000-0001-7212-6209; Lopes, Stefanie/0000-0002-6981-2192; Martin
   Jaular, Lorena/0000-0002-1511-8576
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   CNPqNational Council for Scientific and Technological Development
   (CNPq); CELLEX FoundationFoundation CELLEX; MICINNSpanish Government;
   ICREAICREA Funding Source: Custom
FX FAPESP, CNPq (FTMC and MVGL), CELLEX Foundation, MICINN (CFB and HAP)
CR Alexandre MA, 2010, EMERG INFECT DIS, V16, P1611, DOI 10.3201/eid1610.100685
   Alonso PL, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000406
   Anstey NM, 2007, J INFECT DIS, V195, P589, DOI 10.1086/510756
   Anstey NM, 2009, TRENDS PARASITOL, V25, P220, DOI 10.1016/j.pt.2009.02.003
   Baird JK, 2007, TRENDS PARASITOL, V23, P533, DOI 10.1016/j.pt.2007.08.011
   BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3
   Bassat Q, 2011, NAT MED, V17, P48, DOI 10.1038/nm0111-48
   Beeson JG, 2002, CELL MOL LIFE SCI, V59, P258, DOI 10.1007/s00018-002-8421-y
   BIGNAMI A, 1889, REFORMA MED, V6, P1334
   BILLINGS F., 1915, Trans. Chicago Path. Soc., V9, P209
   Boyd M. F., 1937, American Journal of Tropical Medicine, V17, P253
   BROWN KN, 1965, NATURE, V208, P1286, DOI 10.1038/2081286a0
   Bruetsch WL, 1932, AM J PSYCHIAT, V12, P19
   Carlton JM, 2008, NATURE, V455, P757, DOI 10.1038/nature07327
   Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815
   Chitnis CE, 2008, TRENDS PARASITOL, V24, P29, DOI 10.1016/j.pt.2007.10.004
   CLARK IA, 1988, BRIT J HAEMATOL, V70, P99, DOI 10.1111/j.1365-2141.1988.tb02440.x
   Clark IA, 2009, TRENDS PARASITOL, V25, P314, DOI 10.1016/j.pt.2009.04.003
   Combes V, 2006, INT J PARASITOL, V36, P541, DOI 10.1016/j.ijpara.2006.02.005
   CORBETT CEP, 1989, J TROP MED HYG, V92, P112
   Cowman AF, 2006, CELL, V124, P755, DOI 10.1016/j.cell.2006.02.006
   DAVID PH, 1988, AM J TROP MED HYG, V38, P289, DOI 10.4269/ajtmh.1988.38.289
   del Portillo HA, 2004, INT J PARASITOL, V34, P1547, DOI 10.1016/j.ijpara.2004.10.012
   del Portillo HA, 2001, NATURE, V410, P839, DOI 10.1038/35071118
   FIELD JW, 1963, MICROSCOPIAL DIAGNOS, P20
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   Grau GE, 2003, J INFECT DIS, V187, P461, DOI 10.1086/367960
   Guerra CA, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-17
   Guerra CA, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000774
   de Lacerda MVG, 2008, REV SOC BRAS MED TRO, V41, P522, DOI 10.1590/S0037-86822008000500021
   HASLER T, 1993, AM J TROP MED HYG, V48, P332, DOI 10.4269/ajtmh.1993.48.332
   Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6
   KITCHEN S. F., 1938, AMER JOUR TROP MED, V18, P347
   Kochar DK, 2009, AM J TROP MED HYG, V80, P194, DOI 10.4269/ajtmh.2009.80.194
   Kochar DK, 2010, PLATELETS, V21, P623, DOI 10.3109/09537104.2010.505308
   Kochar DK, 2005, EMERG INFECT DIS, V11, P132, DOI 10.3201/eid1101.040519
   KROTOSKI WA, 1985, T ROY SOC TROP MED H, V79, P1, DOI 10.1016/0035-9203(85)90221-4
   Lomar André V., 2005, Braz J Infect Dis, V9, P425, DOI 10.1590/S1413-86702005000500011
   Lou JN, 1997, AM J PATHOL, V151, P1397
   MAEGRAITH BG, 1948, PATHOLOGICAL PROCESS
   Mendis K, 2001, AM J TROP MED HYG, V64, P97, DOI 10.4269/ajtmh.2001.64.97
   Mercereau-Puijalon O, 2010, TRANSFUS CLIN BIOL, V17, P176, DOI 10.1016/j.tracli.2010.06.005
   Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a
   MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217
   Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X
   Pasternak ND, 2009, INT J BIOCHEM CELL B, V41, P1463, DOI 10.1016/j.biocel.2008.12.012
   Price RN, 2007, AM J TROP MED HYG, V77, P79, DOI 10.4269/ajtmh.2007.77.79
   Resende M, 2009, INT J PARASITOL, V39, P1195, DOI 10.1016/j.ijpara.2009.02.022
   Santos-Ciminera PD, 2007, ACTA TROP, V102, P38, DOI 10.1016/j.actatropica.2007.02.013
   SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X
   SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1
   Tjitra E, 2008, PLOS MED, V5, P890, DOI 10.1371/journal.pmed.0050128
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   UDAGAMA PV, 1987, INFECT IMMUN, V55, P2604, DOI 10.1128/IAI.55.11.2604-2611.1987
   Udomsangpetch R, 1995, T ROY SOC TROP MED H, V89, P635, DOI 10.1016/0035-9203(95)90422-0
   Valecha N, 2009, AM J TROP MED HYG, V81, P758, DOI 10.4269/ajtmh.2009.09-0348
   Wassmer SC, 2006, J IMMUNOL, V176, P1180, DOI 10.4049/jimmunol.176.2.1180
   Wassmer SC, 2004, J INFECT DIS, V189, P180, DOI 10.1086/380761
   WICKRAMASINGHE SN, 1989, BRIT J HAEMATOL, V72, P91, DOI 10.1111/j.1365-2141.1989.tb07658.x
   WICKRAMASINGHE SN, 1987, BRIT J HAEMATOL, V66, P295, DOI 10.1111/j.1365-2141.1987.tb06913.x
   Yeo TW, 2010, J INFECT DIS, V202, P109, DOI 10.1086/653211
NR 61
TC 21
Z9 21
U1 0
U2 5
PU FUNDACO OSWALDO CRUZ
PI RIO DE JANEIRO, RJ
PA AV BRASIL 4365, 21045-900 RIO DE JANEIRO, RJ, BRAZIL
SN 0074-0276
EI 1678-8060
J9 MEM I OSWALDO CRUZ
JI Mem. Inst. Oswaldo Cruz
PD AUG
PY 2011
VL 106
SU 1
BP 79
EP 84
DI 10.1590/S0074-02762011000900010
PG 6
WC Parasitology; Tropical Medicine
SC Parasitology; Tropical Medicine
GA 814IA
UT WOS:000294440600010
PM 21881760
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Carvalho, BO
   Matsuda, JS
   Luz, SLB
   Martinez-Espinosa, FE
   Leite, JA
   Franzin, F
   Orlandi, PP
   Gregoracci, GB
   Lacerda, MVG
   Nogueira, PA
   Costa, FTM
AF Carvalho, Bruna O.
   Matsuda, Joycenea S.
   Luz, Sergio L. B.
   Martinez-Espinosa, Flor E.
   Leite, Juliana A.
   Franzin, Fernanda
   Orlandi, Patricia P.
   Gregoracci, Gustavo B.
   Lacerda, Marcus V. G.
   Nogueira, Paulo A.
   Costa, Fabio T. M.
TI Gestational malaria associated to Plasmodium vivax and Plasmodium
   falciparum placental mixed-infection followed by foetal loss: a case
   report from an unstable transmission area in Brazil
SO MALARIA JOURNAL
LA English
DT Article
ID CYTOADHESION; AMAZON
AB Gestational malaria is a multi-factorial syndrome leading to poor outcomes for both the mother and foetus. Although an unusual increasing in the number of hospitalizations caused by Plasmodium vivax has been reported in Brazil, mortality is rarely observed. This is a report of a gestational malaria case that occurred in the city of Manaus (Amazonas State, Brazil) and resulted in foetal loss. The patient presented placental mixed-infection by Plasmodium vivax and Plasmodium falciparum after diagnosis by nested-PCR, however microscopic analysis failed to detect P. falciparum in the peripheral blood. Furthermore, as the patient did not receive proper treatment for P. falciparum and hospitalization occurred soon after drug treatment, it seems that P. falciparum pathology was modulated by the concurrent presence of P. vivax. Collectively, this case confirms the tropism towards the placenta by both of these species of parasites, reinforces the notion that co-existence of distinct malaria parasites interferes on diseases' outcomes, and opens discussions regarding diagnostic methods, malaria treatment during pregnancy and prenatal care for women living in unstable transmission areas of malaria, such as the Brazilian Amazon.
C1 [Carvalho, Bruna O.; Leite, Juliana A.; Franzin, Fernanda; Gregoracci, Gustavo B.; Costa, Fabio T. M.] Univ Estadual Campinas UNICAMP, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
   [Carvalho, Bruna O.; Matsuda, Joycenea S.; Luz, Sergio L. B.; Martinez-Espinosa, Flor E.; Orlandi, Patricia P.; Nogueira, Paulo A.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Oswaldo Cruz, Manaus, AM, Brazil.
   [Martinez-Espinosa, Flor E.; Lacerda, Marcus V. G.] Fundacao Med Trop Amazonas FMT AM, Manaus, AM, Brazil.
   [Lacerda, Marcus V. G.] Univ Estado Amazonas, Manaus, AM, Brazil.
   [Lacerda, Marcus V. G.] Ctr Univ Nilton Lins, Manaus, AM, Brazil.
RP Costa, FTM (corresponding author), Univ Estadual Campinas UNICAMP, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
EM fabiotmc72@gmail.com
RI Nogueira, Paulo/AAK-8822-2020; Leite, Juliana/G-2563-2013; Costa,
   Fabio/E-1181-2012; Gregoracci, Gustavo B/E-1848-2013
OI Costa, Fabio/0000-0001-9969-7300; Gregoracci,
   Gustavo/0000-0001-6896-1068
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Fundacao de Amparo a
   Pesquisa do Estado do Amazonas (FAPEAM); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq)
FX Many thanks to Dr. Risoneide da Silva Henriques for giving us the
   placenta sample, and we are grateful to Wanessa C. Souza-Neiras for her
   critical comments. This work received financial support from the
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), the
   Fundacao de Amparo a Pesquisa do Estado do Amazonas (FAPEAM) and the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq).
   BOC and JAL were sponsored by FAPESP fellowships. FTMC is a CNPq fellow.
   The sponsors had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Andrews KT, 2002, PARASITOL RES, V88, P715, DOI 10.1007/s00436-002-0624-5
   Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743
   Carvalho BO, 2010, J INFECT DIS, V202, P638, DOI 10.1086/654815
   Chuangchaiya S, 2010, CLIN EXP IMMUNOL, V160, P233, DOI 10.1111/j.1365-2249.2009.04075.x
   Costa FTM, 2006, BRAZ J MED BIOL RES, V39, P1525, DOI 10.1590/S0100-879X2006001200003
   de Santana FS, 2007, EMERG INFECT DIS, V13, P1125, DOI 10.3201/eid1307.061386
   Kraemer SM, 2006, CURR OPIN MICROBIOL, V9, P374, DOI 10.1016/j.mib.2006.06.006
   Lorenzetti A, 2008, ACTA TROP, V107, P8, DOI 10.1016/j.actatropica.2008.03.012
   Luxemburger C, 1997, T ROY SOC TROP MED H, V91, P256, DOI 10.1016/S0035-9203(97)90066-3
   Mackinnon MJ, 2004, PHILOS T R SOC B, V359, P965, DOI 10.1098/rstb.2003.1414
   Martinez-Espinosa FE, 2004, MEM I OSWALDO CRUZ, V99, P19, DOI 10.1590/S0074-02762004000100003
   Nosten F, 1999, LANCET, V354, P546, DOI 10.1016/S0140-6736(98)09247-2
   Oliveira-Ferreira J, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-115
   Price RN, 2007, AM J TROP MED HYG, V77, P79, DOI 10.4269/ajtmh.2007.77.79
   Rubio J M, 2002, Trans R Soc Trop Med Hyg, V96 Suppl 1, pS199
   Santos-Ciminera PD, 2007, EMERG INFECT DIS, V13, P1597, DOI 10.3201/eid1310.070052
   Scherf A, 2001, CELL MICROBIOL, V3, P125, DOI 10.1046/j.1462-5822.2001.00109.x
   Snounou G, 2004, TRENDS PARASITOL, V20, P333, DOI 10.1016/j.pt.2004.05.004
   Snounou Georges, 2002, Methods Mol Med, V72, P189, DOI 10.1385/1-59259-271-6:189
NR 19
TC 8
Z9 8
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUN 27
PY 2011
VL 10
AR 178
DI 10.1186/1475-2875-10-178
PG 5
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 795IE
UT WOS:000292967100001
PM 21708032
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Kayano, ACAV
   Lopes, SCP
   Bueno, FG
   Cabral, EC
   Souza-Neiras, WC
   Yamauchi, LM
   Foglio, MA
   Eberlin, MN
   Mello, JCP
   Costa, FTM
AF Kayano, Ana Carolina A. V.
   Lopes, Stefanie C. P.
   Bueno, Fernanda G.
   Cabral, Elaine C.
   Souza-Neiras, Wanessa C.
   Yamauchi, Lucy M.
   Foglio, Mary A.
   Eberlin, Marcos N.
   Mello, Joao Carlos P.
   Costa, Fabio T. M.
TI In vitro and in vivo assessment of the anti-malarial activity of
   Caesalpinia pluviosa
SO MALARIA JOURNAL
LA English
DT Article
ID NATURAL BIOACTIVE COMPOUNDS; MULTIDISCIPLINARY APPROACH; ARTEMISININ
   RESISTANCE; SAPPAN LIGNUM; MALARIA; DITERPENOIDS; BOLIVIA; SEARCH;
   GROWTH; DRUGS
AB Background: To overcome the problem of increasing drug resistance, traditional medicines are an important source for potential new anti-malarials. Caesalpinia pluviosa, commonly named "sibipiruna", originates from Brazil and possess multiple therapeutic properties, including anti-malarial activity.
   Methods: Crude extract (CE) was obtained from stem bark by purification using different solvents, resulting in seven fractions. An MTT assay was performed to evaluate cytotoxicity in MCF-7 cells. The CE and its fractions were tested in vitro against chloroquine-sensitive (3D7) and -resistant (S20) strains of Plasmodium falciparum and in vivo in Plasmodium chabaudi-infected mice. In vitro interaction with artesunate and the active C. pluviosa fractions was assessed, and mass spectrometry analyses were conducted.
   Results: At non-toxic concentrations, the 100% ethanolic (F4) and 50% methanolic (F5) fractions possessed significant anti-malarial activity against both 3D7 and S20 strains. Drug interaction assays with artesunate showed a synergistic interaction with the F4. Four days of treatment with this fraction significantly inhibited parasitaemia in mice in a dose-dependent manner. Mass spectrometry analyses revealed the presence of an ion corresponding to m/z 303.0450, suggesting the presence of quercetin. However, a second set of analyses, with a quercetin standard, showed distinct ions of m/z 137 and 153.
   Conclusions: The findings show that the F4 fraction of C. pluviosa exhibits anti-malarial activity in vitro at non-toxic concentrations, which was potentiated in the presence of artesunate. Moreover, this anti-malarial activity was also sustained in vivo after treatment of infected mice. Finally, mass spectrometry analyses suggest that a new compound, most likely an isomer of quercetin, is responsible for the anti-malarial activity of the F4.
C1 [Kayano, Ana Carolina A. V.; Lopes, Stefanie C. P.; Souza-Neiras, Wanessa C.; Costa, Fabio T. M.] Univ Campinas UNICAMP, Inst Biol, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
   [Bueno, Fernanda G.; Mello, Joao Carlos P.] Univ Estadual Maringa, Dept Farm, Maringa, Parana, Brazil.
   [Cabral, Elaine C.; Eberlin, Marcos N.] Univ Estadual Campinas, Inst Quim, Thomson Mass Spectrometry Lab, Campinas, SP, Brazil.
   [Yamauchi, Lucy M.] Univ Estadual Londrina, Dept Microbiol, Ctr Ciencias Biol, Londrina, PR, Brazil.
   [Foglio, Mary A.] Univ Estadual Campinas, Ctr Pluridisciplinar Pesquisas Quim Biol & Agr CP, Div Fotoquim, Campinas, SP, Brazil.
RP Costa, FTM (corresponding author), Univ Campinas UNICAMP, Inst Biol, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
EM costaftm@unicamp.br
RI Cabral, Elaine/H-7891-2013; Foglio, mary A./B-9149-2012; Foglio,
   Mary/AAV-2249-2020; Yamauchi, Lucy M/O-1859-2016; Eberlin,
   Marcos/B-8106-2012; de Mello, Joao Carlos P/B-9418-2013; Lopes,
   Stefanie/A-8314-2012; Cabral, Elaine/E-1552-2015; Costa,
   Fabio/E-1181-2012
OI Cabral, Elaine/0000-0001-9261-9844; Foglio, mary A./0000-0001-7715-4452;
   Yamauchi, Lucy M/0000-0003-2241-8814; de Mello, Joao Carlos
   P/0000-0002-7532-3395; Cabral, Elaine/0000-0001-5945-3125; Costa,
   Fabio/0000-0001-9969-7300; Lopes, Stefanie/0000-0002-6981-2192
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desen-volvimento Cientifico e Tecnologico (CNPq)National Council for
   Scientific and Technological Development (CNPq); Instituto do Milenio de
   Desenvolvimento e Tecnologia em Vacinas, Instituto Nacional de
   Tecnologia em Vacinas (CNPq-FAPEMIG); CNPq-Doencas Negligenciadas
   [576128/2008-2]; CNPq-UniversalNational Council for Scientific and
   Technological Development (CNPq) [472913/2010-7]; FAPESPFundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); CNPqNational Council
   for Scientific and Technological Development (CNPq); CAPESCAPES
FX Special thanks to Andre Batista Silva and Andre Spanhol for assistance
   in the extraction and purification process of plant extracts. This work
   received financial support from the Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP), the Conselho Nacional de Desen-volvimento
   Cientifico e Tecnologico (CNPq), Instituto do Milenio de Desenvolvimento
   e Tecnologia em Vacinas, Instituto Nacional de Tecnologia em Vacinas
   (CNPq-FAPEMIG), CNPq-Doencas Negligenciadas (Grant no. 576128/2008-2)
   and CNPq-Universal (Grant no. 472913/2010-7). ACAVK was sponsored by
   FAPESP, and SCPL and WCSN received fellowships from CNPq and CAPES
   foundation (PNPD), respectively. FTMC is a CNPq fellow. The sponsors had
   no role in study design, data collection and analysis, the decision to
   publish, or preparation of the manuscript.
CR Arif T, 2009, J ETHNOPHARMACOL, V123, P177, DOI 10.1016/j.jep.2009.02.040
   Baelmans R, 2000, J ETHNOPHARMACOL, V73, P271, DOI 10.1016/S0378-8741(00)00330-5
   Bahia MV, 2005, J BRAZIL CHEM SOC, V16, P1402, DOI 10.1590/S0103-50532005000800017
   BERENBAUM MC, 1978, J INFECT DIS, V137, P122, DOI 10.1093/infdis/137.2.122
   Bero J, 2009, J PHARM PHARMACOL, V61, P1401, DOI [10.1211/jpp/61.11.0001, 10.1211/jpp.61.11.0001]
   Camacho MD, 2002, J NAT PROD, V65, P1457, DOI 10.1021/np010419i
   Carmargo Luiz Ma, 2009, Ther Clin Risk Manag, V5, P311
   Chiang LC, 2003, J ANTIMICROB CHEMOTH, V52, P194, DOI 10.1093/jac/dkg291
   Das B, 2010, BIOORG MED CHEM LETT, V20, P2847, DOI 10.1016/j.bmcl.2010.03.048
   Das B, 2009, CHEM PHARM BULL, V57, P1139, DOI 10.1248/cpb.57.1139
   Deharo E, 2001, J ETHNOPHARMACOL, V77, P91, DOI 10.1016/S0378-8741(01)00270-7
   Dell'Agli M, 2009, J ETHNOPHARMACOL, V125, P279, DOI 10.1016/j.jep.2009.06.025
   DISANTI SM, 1987, REV INST MED TROP SP, V29, P142, DOI 10.1590/S0036-46651987000300005
   Dondorp AM, 2009, NEW ENGL J MED, V361, P455, DOI 10.1056/NEJMoa0808859
   Ekland EH, 2008, INT J PARASITOL, V38, P743, DOI 10.1016/j.ijpara.2008.03.004
   Enserink M, 2010, SCIENCE, V328, P844, DOI 10.1126/science.328.5980.844
   Fu LC, 2008, MOLECULES, V13, P1923, DOI 10.3390/molecules13081923
   Garavito G, 2006, J ETHNOPHARMACOL, V107, P460, DOI 10.1016/j.jep.2006.03.033
   Gupta S, 2002, ANTIMICROB AGENTS CH, V46, P1510, DOI 10.1128/AAC.46.5.1510-1515.2002
   Jiang RW, 2001, J NAT PROD, V64, P1266, DOI 10.1021/np010174+
   Le Bras J, 2003, FUND CLIN PHARMACOL, V17, P147, DOI 10.1046/j.1472-8206.2003.00164.x
   Liu AL, 2009, PLANTA MED, V75, P337, DOI 10.1055/s-0028-1112208
   Lopes SCP, 2009, ANTIMICROB AGENTS CH, V53, P2149, DOI 10.1128/AAC.00693-08
   Mackinnon MJ, 2010, SCIENCE, V328, P866, DOI 10.1126/science.1185410
   MANDAL S, ECAM 2009
   MCPHERSON DD, 1985, PHYTOCHEMISTRY, V25, P167, DOI 10.1016/S0031-9422(00)94522-9
   Mishra K, 2010, EXP PARASITOL, V124, P421, DOI 10.1016/j.exppara.2009.12.007
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Muregi Francis W, 2010, Curr Drug Discov Technol, V7, P280
   NAGAI M, 1987, CHEM PHARM BULL, V35, P3002
   Noedl H, 2010, CLIN INFECT DIS, V51, pE82, DOI 10.1086/657120
   Noedl H, 2008, NEW ENGL J MED, V359, P2619, DOI 10.1056/NEJMc0805011
   PARLATAN A, 2008, INT J FOOD SCI NUTR, V26, P1
   Pawar C R, 2010, Pak J Pharm Sci, V23, P423
   PETERS W, 1992, ANN TROP MED PARASIT, V86, P455, DOI 10.1080/00034983.1992.11812694
   PRASAD GR, 1978, INDIAN J PHARM SCI, V40, P103
   Rao YK, 2005, J ETHNOPHARMACOL, V100, P249, DOI 10.1016/j.jep.2005.02.039
   Rodrigues LA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011593
   Sampaio FC, 2009, J ETHNOPHARMACOL, V124, P289, DOI 10.1016/j.jep.2009.04.034
   Saralamba S, 2011, P NATL ACAD SCI USA, V108, P397, DOI 10.1073/pnas.1006113108
   Schlichtherle S, 2000, Strabismus, V8, P291, DOI 10.1076/stra.8.4.291.685
   Shukla S, 2009, FOOD CHEM TOXICOL, V47, P1848, DOI 10.1016/j.fct.2009.04.040
   SIXSMITH DG, 1984, AM J TROP MED HYG, V33, P772, DOI 10.4269/ajtmh.1984.33.772
   Snounou G, 2005, TRENDS PARASITOL, V21, P456, DOI 10.1016/j.pt.2005.08.002
   Soh PN, 2009, ANTIMICROB AGENTS CH, V53, P1100, DOI 10.1128/AAC.01175-08
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Tan XJ, 2008, J PHARMACEUT BIOMED, V47, P847, DOI 10.1016/j.jpba.2008.04.010
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Ueda H, 2001, PHYTOMEDICINE, V8, P377, DOI 10.1078/0944-7113-00043
   WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700
   Wu ZH, 2010, J ASIAN NAT PROD RES, V12, P781, DOI 10.1080/10286020.2010.504661
   Yodsaoue O, 2010, PHYTOCHEMISTRY, V71, P1756, DOI 10.1016/j.phytochem.2010.06.016
NR 52
TC 14
Z9 15
U1 0
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2875
J9 MALARIA J
JI Malar. J.
PD MAY 2
PY 2011
VL 10
AR 112
DI 10.1186/1475-2875-10-112
PG 11
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 777EJ
UT WOS:000291598300001
PM 21535894
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Farias, AS
   Talaisys, RL
   Blanco, YC
   Lopes, SCP
   Longhini, ALF
   Pradella, F
   Santos, LMB
   Costa, FTM
AF Farias, Alessandro S.
   Talaisys, Rafael L.
   Blanco, Yara C.
   Lopes, Stefanie C. P.
   Longhini, Ana Leda F.
   Pradella, Fernando
   Santos, Leonilda M. B.
   Costa, Fabio T. M.
TI Regulatory T Cell Induction during Plasmodium chabaudi Infection
   Modifies the Clinical Course of Experimental Autoimmune
   Encephalomyelitis
SO PLOS ONE
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; MULTIPLE-SCLEROSIS; TGF-BETA; SELF-TOLERANCE;
   IMMUNE EVASION; TH17 CELLS; MALARIA; EFFECTOR; DISEASE; INFLAMMATION
AB Background: Experimental autoimmune encephalomyelitis (EAE) is used as an animal model for human multiple sclerosis (MS), which is an inflammatory demyelinating autoimmune disease of the central nervous system characterized by activation of Th1 and/or Th17 cells. Human autoimmune diseases can be either exacerbated or suppressed by infectious agents. Recent studies have shown that regulatory T cells play a crucial role in the escape mechanism of Plasmodium spp. both in humans and in experimental models. These cells suppress the Th1 response against the parasite and prevent its elimination. Regulatory T cells have been largely associated with protection or amelioration in several autoimmune diseases, mainly by their capacity to suppress proinflammatory response.
   Methodology/Principal Findings: In this study, we verified that CD4(+)CD25(+) regulatory T cells (T regs) generated during malaria infection (6 days after EAE induction) interfere with the evolution of EAE. We observed a positive correlation between the reduction of EAE clinical symptoms and an increase of parasitemia levels. Suppression of the disease was also accompanied by a decrease in the expression of IL-17 and IFN-gamma and increases in the expression of IL-10 and TGF-beta 1 relative to EAE control mice. The adoptive transfer of CD4(+)CD25(+) cells from P. chabaudi-infected mice reduced the clinical evolution of EAE, confirming the role of these T regs.
   Conclusions/Significance: These data corroborate previous findings showing that infections interfere with the prevalence and evolution of autoimmune diseases by inducing regulatory T cells, which regulate EAE in an apparently non-specific manner.
C1 [Farias, Alessandro S.; Talaisys, Rafael L.; Blanco, Yara C.; Lopes, Stefanie C. P.; Longhini, Ana Leda F.; Pradella, Fernando; Santos, Leonilda M. B.; Costa, Fabio T. M.] Univ Estadual Campinas UNICAMP, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
RP Farias, AS (corresponding author), Univ Estadual Campinas UNICAMP, Dept Genet Evolucao & Bioagentes, Campinas, SP, Brazil.
EM asfarias@unicamp.br; costaftm@unicamp.br
RI Costa, Fabio/E-1181-2012; Farias, Alessandro/AAH-2228-2020; Farias,
   Alessandro/C-6879-2012; Lopes, Stefanie/A-8314-2012
OI Costa, Fabio/0000-0001-9969-7300; Farias,
   Alessandro/0000-0001-6759-1819; Farias, Alessandro/0000-0001-6759-1819;
   Lopes, Stefanie/0000-0002-6981-2192
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2009/15620-9];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Academy of Sciences for the Developing World (TWAS) [05-049
   RG/BIO/LA]; National Institute for Vaccine Development and Technology
   (CNPq-INCTV); Rede de Malaria (CNPq)National Council for Scientific and
   Technological Development (CNPq); Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)CAPES
FX This work was supported financially by the Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP), the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq) and The Academy of
   Sciences for the Developing World (TWAS; Grant # 05-049 RG/BIO/LA), The
   National Institute for Vaccine Development and Technology (CNPq-INCTV)
   and Rede de Malaria (CNPq). ASF was supported by a FAPESP fellowship (#
   2009/15620-9). RLT, YCB and ALFL received a Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES) fellowship and SCPL
   was supported by CNPq. The funders had no role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Anderton SM, 2008, CURR OPIN NEUROL, V21, P248, DOI 10.1097/WCO.0b013e3282febf58
   Bach JF, 2001, J AUTOIMMUN, V16, P347, DOI 10.1006/jaut.2000.0478
   Bettini M, 2009, CURR OPIN IMMUNOL, V21, P612, DOI 10.1016/j.coi.2009.09.011
   Blanco YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003126
   BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0
   BUENO LL, PLOS ONE, V5, pE9623
   Cambos M, 2008, INT J PARASITOL, V38, P229, DOI 10.1016/j.ijpara.2007.07.006
   Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152
   Farias AS, 2007, NEUROIMMUNOMODULAT, V14, P32, DOI 10.1159/000107286
   Feger U, 2007, CLIN EXP IMMUNOL, V147, P412, DOI 10.1111/j.1365-2249.2006.03271.x
   Finney OC, 2009, EUR J IMMUNOL, V39, P1288, DOI 10.1002/eji.200839112
   Furtado GD, 2001, IMMUNOL REV, V182, P122
   Hafler DA, 2005, IMMUNOL REV, V204, P208, DOI 10.1111/j.0105-2896.2005.00240.x
   Hauser SL, 2006, NEURON, V52, P61, DOI 10.1016/j.neuron.2006.09.011
   Hisaeda H, 2005, INT J BIOCHEM CELL B, V37, P700, DOI 10.1016/j.biocel.2004.10.009
   Korn T, 2007, SEMIN IMMUNOL, V19, P362, DOI 10.1016/j.smim.2007.10.007
   Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564
   LEHMANN D, 1992, J AUTOIMMUN, V5, P675, DOI 10.1016/0896-8411(92)90185-S
   Liu YZ, 2008, NAT IMMUNOL, V9, P632, DOI 10.1038/ni.1607
   McGeachy MJ, 2005, J IMMUNOL, V175, P3025, DOI 10.4049/jimmunol.175.5.3025
   Minigo G, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000402
   Nie CQ, 2007, INFECT IMMUN, V75, P2275, DOI 10.1128/IAI.01783-06
   O'Connor RA, 2008, J IMMUNOL, V181, P3750, DOI 10.4049/jimmunol.181.6.3750
   O'Connor RA, 2008, J NEUROIMMUNOL, V193, P1, DOI 10.1016/j.jneuroim.2007.11.016
   Olivares-Villagomez D, 1998, J EXP MED, V188, P1883, DOI 10.1084/jem.188.10.1883
   Omer FM, 2003, J EXP MED, V198, P1817, DOI 10.1084/jem.20030713
   Peacock JW, 2003, EUR J IMMUNOL, V33, P1849, DOI 10.1002/eji.200323148
   Riley EM, 2006, PARASITE IMMUNOL, V28, P35, DOI 10.1111/j.1365-3024.2006.00775.x
   Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x
   Scholzen A, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000543
   Strauch UG, 2005, GUT, V54, P1546, DOI 10.1136/gut.2004.059451
   Tadokoro CE, 2004, J AUTOIMMUN, V23, P103, DOI 10.1016/j.jaut.2004.05.003
   Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572
   Thornton AM, 2000, J IMMUNOL, V164, P183, DOI 10.4049/jimmunol.164.1.183
   Todryk SM, 2009, EUR J IMMUNOL, V39, P3042, DOI 10.1002/eji.200939434
   Walther M, 2005, IMMUNITY, V23, P287, DOI 10.1016/j.immuni.2005.08.006
   Walther M, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000364
   Wing K, 2010, NAT IMMUNOL, V11, P7, DOI 10.1038/ni.1818
NR 38
TC 21
Z9 24
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 25
PY 2011
VL 6
IS 3
AR e17849
DI 10.1371/journal.pone.0017849
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 740SE
UT WOS:000288813900014
PM 21464982
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Martins, D
   Costa, FTM
   Brocchi, M
   Duran, N
AF Martins, D.
   Costa, F. T. M.
   Brocchi, M.
   Duran, N.
TI Evaluation of the antibacterial activity of
   poly-(D,L-lactide-co-glycolide) nanoparticles containing violacein
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE Polymeric nanoparticles; Violacein; Antibiotics; Antibacterial activity;
   Staphylococcus aureus; Solubility; Encapsulation
ID RESISTANT STAPHYLOCOCCUS-AUREUS; CHROMOBACTERIUM-VIOLACEUM;
   BETA-CYCLODEXTRIN; CANCER CELLS; IN-VITRO; CYTOTOXICITY; DELIVERY;
   MICROENCAPSULATION; SYSTEMS; VIVO
AB Since violacein-an antibiotic, antiviral, and antiparasitic compound-exhibits poor solubility in water, polymeric poly-(D,L-lactide-co-glycolide)nanoparticles containing this compound improved its solubility and biological activity. The nanoparticles were prepared by the nanoprecipitation method and characterized in terms of average diameter, zeta potential, drug loading, polymer recovery, in vitro release kinetic, and in vitro antibacterial activity. Nanoparticles with diameters between 116 and 139 nm and negative-charged outer surfaces were obtained. Drug-loading efficiency and polymer recovery were 87 and 93%, respectively. In vitro release kinetics assays showed that violacein loaded in these nanoparticles has sustained release behavior until 5 days. Both free and nanoparticles-loaded violacein exhibited in vitro antibacterial activity against Staphylococcus aureus ATCC 29213 and ATCC 25923 strains and exhibiting around two to five times lower minimum inhibitory concentration (MIC) than free violacein, respectively. The encapsulated violacein was efficient against methicilin-resistant Staphylococcus aureus (MRSA) strains. No significant activity against Escherichia coli and Salmonella enterica was found.
C1 [Martins, D.] Univ Estadual Campinas, Chem Inst, Biol Chem Lab, BR-13083970 Campinas, SP, Brazil.
   [Costa, F. T. M.; Brocchi, M.; Duran, N.] Univ Estadual Campinas, Inst Biol, Dept Genet Evolut & Bioagents, BR-13083860 Campinas, SP, Brazil.
RP Duran, N (corresponding author), Univ Estadual Campinas, Chem Inst, Biol Chem Lab, CP 6154, BR-13083970 Campinas, SP, Brazil.
EM duran@iqm.unicamp.br
RI Brocchi, Marcelo/E-3723-2012; Costa, Fabio/E-1181-2012
OI Costa, Fabio/0000-0001-9969-7300; Duran, Nelson/0000-0001-8372-5143
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [06/58826-8]; CNPqNational Council for Scientific and Technological
   Development (CNPq); MCT/PADCT/IMMP; Brazilian Nanobiotechnology Network
FX This study was supported by FAPESP, CNPq, MCT/PADCT/IMMP, and the
   Brazilian Nanobiotechnology Network (CNPq/MCT). Dorival Martins held a
   fellowship from FAPESP, project number 06/58826-8.
CR Bromberg N, 2005, J ENZYM INHIB MED CH, V20, P449, DOI 10.1080/14756360500273052
   Bromberg N, 2010, CHEM-BIOL INTERACT, V186, P43, DOI 10.1016/j.cbi.2010.04.016
   *CLSI, 2003, CLSI
   Cui F, 2006, J CONTROL RELEASE, V114, P242, DOI 10.1016/j.jconrel.2006.05.013
   Cury GG, 2009, BRAZ J INFECT DIS, V13, P165, DOI 10.1590/S1413-86702009000300002
   de Carvalho DD, 2006, TOXICOL IN VITRO, V20, P1514, DOI 10.1016/j.tiv.2006.06.007
   de Souza Ana Olivia, 1999, Revista do Instituto Adolfo Lutz, V58, P59
   DEMLING RH, 2007, J BURNS WOUNDS, V7, P89
   Duran N, 2007, PHARMAZIE, V62, P287, DOI 10.1691/ph.2007.4.6058
   Duran N, 2003, CAN J PHYSIOL PHARM, V81, P387, DOI 10.1139/Y03-033
   Duran N, 2001, CRIT REV MICROBIOL, V27, P201, DOI 10.1080/20014091096747
   Duran N, 2008, ARCH PHARM RES, V31, P1509, DOI 10.1007/s12272-001-2137-7
   Duran N, 2007, BIOTECHNOL APPL BIOC, V48, P127, DOI 10.1042/BA20070115
   Duran N, 2007, J BIOMED NANOTECHNOL, V3, P203, DOI 10.1166/jbn.2007.022
   Ferreira CV, 2004, BLOOD, V104, P1459, DOI 10.1182/blood-2004-02-0594
   Gimenez IF, 2005, J BIOMED NANOTECHNOL, V1, P352, DOI 10.1166/jbn.2005.041
   Har-el YE, 2007, CURR NANOSCI, V3, P329, DOI 10.2174/157341307782418612
   Jain KK, 2008, TECHNOL CANCER RES T, V7, P1
   Kodach LL, 2006, CARCINOGENESIS, V27, P508, DOI 10.1093/carcin/bgi307
   Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2
   Lopes SCP, 2009, ANTIMICROB AGENTS CH, V53, P2149, DOI 10.1128/AAC.00693-08
   Marcato PD, 2008, J NANOSCI NANOTECHNO, V8, P2216, DOI 10.1166/jnn.2008.274
   McClelland M, 2001, NATURE, V413, P852, DOI 10.1038/35101614
   Melo PS, 2009, J BIOMED NANOTECHNOL, V5, P192, DOI 10.1166/jbn.2009.1018
   Mosqueira VCF, 2000, J PHARM SCI-US, V89, P614, DOI 10.1002/(SICI)1520-6017(200005)89:5<614::AID-JPS7>3.0.CO;2-7
   Murray CK, 2008, CRIT CARE MED, V36, pS358, DOI 10.1097/CCM.0b013e31817e2ffc
   Nair LS, 2007, PROG POLYM SCI, V32, P762, DOI 10.1016/j.progpolymsci.2007.05.017
   Powell JP, 2008, EXPERT REV ANTI-INFE, V6, P299, DOI 10.1586/14787210.6.3.299
   Rettori D, 1998, WORLD J MICROB BIOT, V14, P685, DOI 10.1023/A:1008809504504
   Schaffazick SR, 2003, QUIM NOVA, V26, P726, DOI 10.1590/S0100-40422003000500017
   Sievert DM, 2008, CLIN INFECT DIS, V46, P668, DOI 10.1086/527392
   Soares MJD, 2001, J MED MICROBIOL, V50, P732, DOI 10.1099/0022-1317-50-8-732
   World Health Organization, 2008, WHO
   Zhang YQ, 2003, MOL MICROBIOL, V49, P1577, DOI 10.1046/j.1365-2958.2003.03671.x
NR 34
TC 17
Z9 17
U1 0
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388-0764
J9 J NANOPART RES
JI J. Nanopart. Res.
PD JAN
PY 2011
VL 13
IS 1
BP 355
EP 363
DI 10.1007/s11051-010-0037-9
PG 9
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA 712LA
UT WOS:000286667000035
DA 2020-12-08
ER

PT J
AU Gentil, F
   Bargieri, DY
   Leite, JA
   Francoso, KS
   Patricio, MBM
   Espindola, NM
   Vaz, AJ
   Palatnik-de-Sousa, CB
   Rodrigues, MM
   Costa, FTM
   Soares, IS
AF Gentil, Fernanda
   Bargieri, Daniel Y.
   Leite, Juliana A.
   Francoso, Katia S.
   Patricio, Mariana B. M.
   Espindola, Noeli M.
   Vaz, Adelaide J.
   Palatnik-de-Sousa, Clarisa B.
   Rodrigues, Mauricio M.
   Costa, Fabio T. M.
   Soares, Irene S.
TI A recombinant vaccine based on domain II of Plasmodium vivax Apical
   Membrane Antigen 1 induces high antibody titres in mice
SO VACCINE
LA English
DT Article
DE Malaria; Plasmodium vivax; Recombinant vaccine
ID MEROZOITE SURFACE PROTEIN-1; HIGH-LEVEL EXPRESSION; ERYTHROCYTE
   INVASION; COMPARATIVE RECOGNITION; SALMONELLA-TYPHIMURIUM;
   MONOCLONAL-ANTIBODY; GENETIC DIVERSITY; FLIC FLAGELLIN; MALARIA;
   CANDIDATE
AB The Apical Membrane Antigen 1 (AMA-1) is considered a promising candidate for development of a malaria vaccine against asexual stages of Plasmodium. We recently identified domain II (DII) of Plasmodium vivax AMA-1 (PvAMA-1) as a highly immunogenic region recognised by IgG antibodies present in many individuals during patent infection with P. vivax. The present study was designed to evaluate the immunogenic properties of a bacterial recombinant protein containing PvAMA-1 DII. To accomplish this, the recombinant protein was administered to mice in the presence of each of the following six adjuvants: Complete/Incomplete Freund's Adjuvant (CFA/IFA), aluminium hydroxide (Alum), Quil A, QS21 saponin, CpG-ODN 1826 and TiterMax. We found that recombinant DII was highly immunogenic in BALB/c mice when administered in the presence of any of the tested adjuvants. Importantly, we show that DII-specific antibodies recognised the native AMA-1 protein expressed on the surface of P. vivax merozoites isolated from the blood of infected patients. These results demonstrate that a recombinant protein containing PvAMA-1 DII is immunogenic when administered in different adjuvant formulations, and indicate that this region of the AMA-1 protein should continue to be evaluated as part of a subunit vaccine against vivax malaria. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Gentil, Fernanda; Francoso, Katia S.; Patricio, Mariana B. M.; Espindola, Noeli M.; Vaz, Adelaide J.; Soares, Irene S.] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, BR-05508900 Sao Paulo, Brazil.
   [Bargieri, Daniel Y.; Rodrigues, Mauricio M.] Univ Fed Sao Paulo, Escola Paulista Med, CINTERGEN, BR-04044010 Sao Paulo, Brazil.
   [Leite, Juliana A.; Costa, Fabio T. M.] Univ Estadual Campinas, Dept Genet Evolucao & Bioagentes, Inst Biol, BR-13083862 Campinas, SP, Brazil.
   [Palatnik-de-Sousa, Clarisa B.] Univ Fed Rio de Janeiro, Inst Microbiol Prof Paulo de Goes, BR-21941902 Rio De Janeiro, Brazil.
RP Soares, IS (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Av Prof Lineu Prestes 580,Cidade Univ, BR-05508900 Sao Paulo, Brazil.
EM isoares@usp.br
RI Francoso, Katia Sanches/M-4088-2019; Soares, Irene Silva/C-5974-2012;
   Costa, Fabio/E-1181-2012; Rodrigues, Mauricio M./B-8512-2012; Leite,
   Juliana/G-2563-2013; Bargieri, Daniel Youssef/A-4461-2013
OI Francoso, Katia Sanches/0000-0003-1494-2405; Soares, Irene
   Silva/0000-0002-3336-6856; Costa, Fabio/0000-0001-9969-7300; Bargieri,
   Daniel Youssef/0000-0003-2564-3742; Palatnik-de-Sousa, Clarisa
   B./0000-0002-6231-0608
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2006/02832-0];
   Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)Carlos
   Chagas Filho Foundation for Research Support of the State of Rio de
   Janeiro (FAPERJ); The National Institute for Vaccine Development and
   Technology; CNPqNational Council for Scientific and Technological
   Development (CNPq); CAPESCAPES; FAPESPFundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP)
FX This work was supported by grants from Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP, 2006/02832-0), Fundacao de Amparo a
   Pesquisa do Estado do Rio de Janeiro (FAPERJ) and The National Institute
   for Vaccine Development and Technology (CNPq - INCTV). The authors would
   like to thank Dr. Jose Paz Parente from Nucleo de Pesquisas em Produtos
   Naturais da Universidade Federal do Rio de Janeiro (NPPN-UFRJ) for
   isolation of QS21 saponin and Elaine Cristina Vicentin (FCF-USP) for
   help in the finalization of the experiments with TLR4 knockout mice.
   CBPT, MMR, FTMC and ISS are supported by fellowships from CNPq. FG was
   supported by fellowships from CAPES. DYB, JAL, MBMP and NME were
   supported by fellowships from FAPESP.
CR Anders RF, 1998, VACCINE, V16, P240, DOI 10.1016/S0264-410X(97)88331-4
   Anstey NM, 2009, TRENDS PARASITOL, V25, P220, DOI 10.1016/j.pt.2009.02.003
   Baird JK, 2007, TRENDS PARASITOL, V23, P533, DOI 10.1016/j.pt.2007.08.011
   Barbedo MB, 2007, MEM I OSWALDO CRUZ, V102, P335, DOI 10.1590/S0074-02762007005000040
   Bargieri DY, 2010, VACCINE, V28, P2818, DOI 10.1016/j.vaccine.2010.02.004
   Bargieri DY, 2008, VACCINE, V26, P6132, DOI 10.1016/j.vaccine.2008.08.070
   Chesne-Seck ML, 2005, MOL BIOCHEM PARASIT, V144, P55, DOI 10.1016/j.molbiopara.2005.07.007
   Chitnis CE, 2008, TRENDS PARASITOL, V24, P29, DOI 10.1016/j.pt.2007.10.004
   Collins CR, 2007, J BIOL CHEM, V282, P7431, DOI 10.1074/jbc.M610562200
   Collins CR, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000273
   Crewther PE, 1996, INFECT IMMUN, V64, P3310, DOI 10.1128/IAI.64.8.3310-3317.1996
   Donahue CG, 2000, MOL BIOCHEM PARASIT, V111, P15, DOI 10.1016/S0166-6851(00)00289-9
   Dutta S, 2002, INFECT IMMUN, V70, P3101, DOI 10.1128/IAI.70.6.3101-3110.2002
   Dutta S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008138
   Figtree M, 2000, MOL BIOCHEM PARASIT, V108, P53, DOI 10.1016/S0166-6851(00)00204-8
   Gaffar FR, 2004, INFECT IMMUN, V72, P2947, DOI 10.1128/IAI.72.5.2947-2955.2004
   Galinski MR, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-S1-S9
   Greenwood BM, 2008, TRENDS PARASITOL, V24, P449, DOI 10.1016/j.pt.2008.07.002
   Grynberg P, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-123
   Gunasekera AM, 2007, MOL BIOL EVOL, V24, P939, DOI 10.1093/molbev/msm013
   Hehl AB, 2000, INFECT IMMUN, V68, P7078, DOI 10.1128/IAI.68.12.7078-7086.2000
   Herrera S, 2007, TRENDS PARASITOL, V23, P122, DOI 10.1016/j.pt.2007.01.008
   Hodder AN, 1996, J BIOL CHEM, V271, P29446, DOI 10.1074/jbc.271.46.29446
   Hodder AN, 2001, INFECT IMMUN, V69, P3286, DOI 10.1128/IAI.69.5.3286-3294.2001
   Kennedy MC, 2002, INFECT IMMUN, V70, P6948, DOI 10.1128/IAI.70.12.6948-6960.2002
   Kocken CHM, 1999, INFECT IMMUN, V67, P43, DOI 10.1128/IAI.67.1.43-49.1999
   Kocken CHM, 1998, J BIOL CHEM, V273, P15119, DOI 10.1074/jbc.273.24.15119
   Kocken CHM, 2002, INFECT IMMUN, V70, P4471, DOI 10.1128/IAI.70.8.4471-4476.2002
   Lalitha PV, 2008, VACCINE, V26, P4526, DOI 10.1016/j.vaccine.2008.06.031
   Lalitha PV, 2004, INFECT IMMUN, V72, P4464, DOI 10.1128/IAI.72.8.4464-4470.2004
   Li F, 2002, J BIOL CHEM, V277, P50303, DOI 10.1074/jbc.M207985200
   Mitchell GH, 2004, INFECT IMMUN, V72, P154, DOI 10.1128/IAI.72.1.154-158.2004
   Morais CG, 2006, AM J TROP MED HYG, V75, P582, DOI 10.4269/ajtmh.2006.75.582
   Mufalo BC, 2008, MICROBES INFECT, V10, P1266, DOI 10.1016/j.micinf.2008.07.023
   NARUM DL, 1994, MOL BIOCHEM PARASIT, V67, P59, DOI 10.1016/0166-6851(94)90096-5
   Narum DL, 2000, INFECT IMMUN, V68, P2899, DOI 10.1128/IAI.68.5.2899-2906.2000
   Oliveira-Freitas E, 2006, VACCINE, V24, P3909, DOI 10.1016/j.vaccine.2006.02.034
   Pizarro JC, 2005, SCIENCE, V308, P408, DOI 10.1126/science.1107449
   Polley SD, 2004, VACCINE, V23, P718, DOI 10.1016/j.vaccine.2004.05.031
   Polley SD, 2004, TRENDS PARASITOL, V20, P99, DOI 10.1016/j.pt.2003.12.003
   Price RN, 2007, AM J TROP MED HYG, V77, P79, DOI 10.4269/ajtmh.2007.77.79
   Putaporntip C, 2009, INFECT GENET EVOL, V9, P1295, DOI 10.1016/j.meegid.2009.07.005
   Rajesh V, 2007, EXP PARASITOL, V116, P252, DOI 10.1016/j.exppara.2007.01.006
   Remarque EJ, 2008, TRENDS PARASITOL, V24, P74, DOI 10.1016/j.pt.2007.12.002
   Rodriguesa MHC, 2005, INT J PARASITOL, V35, P185, DOI 10.1016/j.ijpara.2004.11.003
   Rogers WO, 1999, VACCINE, V17, P3136, DOI 10.1016/S0264-410X(99)00146-2
   Silvie O, 2004, J BIOL CHEM, V279, P9490, DOI 10.1074/jbc.M311331200
   Tan LKK, 2008, LANCET INFECT DIS, V8, P449, DOI 10.1016/S1473-3099(08)70153-1
   THOMAS AW, 1984, MOL BIOCHEM PARASIT, V13, P187, DOI 10.1016/0166-6851(84)90112-9
   Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x
   Wickramarachchi T, 2006, INFECT IMMUN, V74, P798, DOI 10.1128/IAI.74.1.798-801.2006
NR 51
TC 27
Z9 27
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD AUG 31
PY 2010
VL 28
IS 38
BP 6183
EP 6190
DI 10.1016/j.vaccine.2010.07.017
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 654EG
UT WOS:000282150700011
PM 20654667
DA 2020-12-08
ER

PT J
AU Carvalho, BO
   Lopes, SCP
   Nogueira, PA
   Orlandi, PP
   Bargieri, DY
   Blanco, YC
   Mamoni, R
   Leite, JA
   Rodrigues, MM
   Soares, IS
   Oliveira, TR
   Wunderlich, G
   Lacerda, MVG
   del Portillo, HA
   Araujo, MOG
   Russell, B
   Suwanarusk, R
   Snounou, G
   Renia, L
   Costa, FTM
AF Carvalho, Bruna O.
   Lopes, Stefanie C. P.
   Nogueira, Paulo A.
   Orlandi, Patricia P.
   Bargieri, Daniel Y.
   Blanco, Yara C.
   Mamoni, Ronei
   Leite, Juliana A.
   Rodrigues, Mauricio M.
   Soares, Irene S.
   Oliveira, Tatiane R.
   Wunderlich, Gerhard
   Lacerda, Marcus V. G.
   del Portillo, Hernando A.
   Araujo, Maria O. G.
   Russell, Bruce
   Suwanarusk, Rossarin
   Snounou, Georges
   Renia, Laurent
   Costa, Fabio T. M.
TI On the Cytoadhesion of Plasmodium vivax-Infected Erythrocytes
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID CHONDROITIN SULFATE-A; RED-BLOOD-CELLS; IN-VITRO MODEL; ANTIGENIC
   VARIATION; ENDOTHELIAL-CELLS; LUNG INJURY; FALCIPARUM; MALARIA;
   PARASITES; ADHESION
AB Background. Plasmodium falciparum and Plasmodium vivax are responsible for most of the global burden of malaria. Although the accentuated pathogenicity of P. falciparum occurs because of sequestration of the mature erythrocytic forms in the microvasculature, this phenomenon has not yet been noted in P. vivax. The increasing number of severe manifestations of P. vivax infections, similar to those observed for severe falciparum malaria, suggests that key pathogenic mechanisms (eg, cytoadherence) might be shared by the 2 parasites.
   Methods. Mature P. vivax-infected erythrocytes (Pv-iEs) were isolated from blood samples collected from 34 infected patients. Pv-iEs enriched on Percoll gradients were used in cytoadhesion assays with human lung endothelial cells, Saimiri brain endothelial cells, and placental cryosections.
   Results. Pv-iEs were able to cytoadhere under static and flow conditions to cells expressing endothelial receptors known to mediate the cytoadhesion of P. falciparum. Although Pv-iE cytoadhesion levels were 10-fold lower than those observed for P. falciparum-infected erythrocytes, the strength of the interaction was similar. Cytoadhesion of Pv-iEs was in part mediated by VIR proteins, encoded by P. vivax variant genes (vir), given that specific antisera inhibited the Pv-iE-endothelial cell interaction.
   Conclusions. These observations prompt a modification of the current paradigms of the pathogenesis of malaria and clear the way to investigate the pathophysiology of P. vivax infections.
C1 [Carvalho, Bruna O.; Lopes, Stefanie C. P.; Blanco, Yara C.; Mamoni, Ronei; Leite, Juliana A.; Costa, Fabio T. M.] Univ Estadual Campinas, Inst Biol, Dept Genet Evolucao & Bioagentes, BR-13083970 Campinas, SP, Brazil.
   [Carvalho, Bruna O.; Nogueira, Paulo A.; Orlandi, Patricia P.] Fiocruz MS, Inst Leonidas & Maria Deane, Rio De Janeiro, Brazil.
   [Lacerda, Marcus V. G.] Univ Estado Amazonas, Manaus, Amazonas, Brazil.
   [Bargieri, Daniel Y.; Rodrigues, Mauricio M.] Univ Fed Sao Paulo, Ctr Interdisciplinar Terapia Genica, Sao Paulo, Brazil.
   [Bargieri, Daniel Y.; Rodrigues, Mauricio M.] Univ Fed Sao Paulo, Dept Microbiol Imunol & Parasitol, Sao Paulo, Brazil.
   [Soares, Irene S.; Oliveira, Tatiane R.] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo, Brazil.
   [Wunderlich, Gerhard] Univ Sao Paulo, Dept Parasitol, Inst Ciencias Biol, Sao Paulo, Brazil.
   [Araujo, Maria O. G.] Univ Brasilia, Brasilia, DF, Brazil.
   [del Portillo, Hernando A.] Barcelona Ctr Int Hlth Res, Barcelona, Spain.
   [del Portillo, Hernando A.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain.
   [Russell, Bruce; Suwanarusk, Rossarin; Snounou, Georges; Renia, Laurent] Natl Univ Singapore, Singapore Immunol Network, Agcy Sci Technol & Res, Singapore 117548, Singapore.
   [Snounou, Georges] Natl Univ Singapore, Dept Microbiol, Singapore 117548, Singapore.
   [Snounou, Georges] INSERM, Unite Mixte Rech S945, Paris, France.
   [Snounou, Georges] Univ Paris 06, Fac Med Pitie Salpetriere, Paris, France.
RP Costa, FTM (corresponding author), Univ Estadual Campinas, Inst Biol, Dept Genet Evolucao & Bioagentes, POB 6109, BR-13083970 Campinas, SP, Brazil.
EM costaftm@unicamp.br
RI Rodrigues, Mauricio M./B-8512-2012; Mamoni, Ronei/F-7421-2012; Costa,
   Fabio/E-1181-2012; Leite, Juliana/G-2563-2013; Bargieri, Daniel
   Youssef/A-4461-2013; Snounou, Georges/F-3352-2011; Russell,
   Bruce/A-9240-2011; Wunderlich, Gerhard/G-8245-2012; Lopes,
   Stefanie/A-8314-2012; Nogueira, Paulo/AAK-8822-2020; ,
   RENIA/E-2117-2011; del Portillo, Hernando A/L-2131-2014; Soares, Irene
   Silva/C-5974-2012; Suwanarusk, Rossarin/E-2115-2013
OI Costa, Fabio/0000-0001-9969-7300; Bargieri, Daniel
   Youssef/0000-0003-2564-3742; Snounou, Georges/0000-0002-6133-6398;
   Russell, Bruce/0000-0003-2333-4348; Wunderlich,
   Gerhard/0000-0003-1724-0337; , RENIA/0000-0003-0349-1557; del Portillo,
   Hernando A/0000-0002-5278-3452; Soares, Irene Silva/0000-0002-3336-6856;
   Suwanarusk, Rossarin/0000-0002-7310-245X; Lopes,
   Stefanie/0000-0002-6981-2192
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [04/00638-6,
   05/60569-0, 09/52013-3]; Conselho Nacional de Desenvolvimento Cientifico
   e Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Instituto Nacional de Tecnologia em Vacinas
   (CNPq-FAPEMIG); Doencas Negligenciadas [576128/2008-2]; CNPqNational
   Council for Scientific and Technological Development (CNPq); Coordenacao
   de Aperfeicoamento de Pessoal de Nivel; Agency for Science, Technology,
   and Research, SingaporeAgency for Science Technology & Research (ASTAR);
   Institut National de la Sante et de la Recherche Medicale,
   FranceInstitut National de la Sante et de la Recherche Medicale
   (Inserm); ICREAICREA Funding Source: Custom
FX Financial support: This work received financial support from the
   Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; grant
   04/00638-6) and Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq) grants-Instituto do Milenio de Desenvolvimento e
   Tecnologia em Vacinas, Instituto Nacional de Tecnologia em Vacinas
   (CNPq-FAPEMIG), and Doencas Negligenciadas (576128/2008-2). B.O.C. and
   J.A.L. were sponsored by FAPESP fellowships (grants 05/60569-0 and
   09/52013-3). S.C.P.L. and R.M. were supported by CNPq, and Y.C.B.
   received a Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   fellowship. M.M.R., I.S.S., G.W., and F.T.M.C. are CNPq fellows. L.R.
   was supported by the Agency for Science, Technology, and Research,
   Singapore, and G.S. was supported by the Institut National de la Sante
   et de la Recherche Medicale, France.
CR Andrews KT, 2005, INT J PARASITOL, V35, P1127, DOI 10.1016/j.ijpara.2005.05.007
   Anstey NM, 2007, J INFECT DIS, V195, P589, DOI 10.1086/510756
   Anstey NM, 2009, TRENDS PARASITOL, V25, P220, DOI 10.1016/j.pt.2009.02.003
   Avril M, 2004, MICROBES INFECT, V6, P249, DOI 10.1016/j.micinf.2003.12.007
   Bargieri DY, 2008, VACCINE, V26, P6132, DOI 10.1016/j.vaccine.2008.08.070
   Carlton JM, 2008, NATURE, V455, P757, DOI 10.1038/nature07327
   Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660
   COOKE BM, 1994, BRIT J HAEMATOL, V87, P162, DOI 10.1111/j.1365-2141.1994.tb04887.x
   Costa FTM, 2003, J INFECT DIS, V188, P153, DOI 10.1086/375800
   Cserti CM, 2007, BLOOD, V110, P2250, DOI 10.1182/blood-2007-03-077602
   del Portillo HA, 2001, NATURE, V410, P839, DOI 10.1038/35071118
   DISANTI SM, 1987, REV INST MED TROP SP, V29, P142, DOI 10.1590/S0036-46651987000300005
   Duffy PE, 2007, PARASITOLOGY, V134, P1877, DOI 10.1017/S0031182007000170
   Fairhurst RM, 2006, CURR OPIN HEMATOL, V13, P124, DOI 10.1097/01.moh.0000219655.73162.42
   Fernandez V., 2004, METHODS MALARIA RES, P26
   Fernandez-Becerra C, 2005, MOL MICROBIOL, V58, P648, DOI 10.1111/j.1365-2958.2005.04850.x
   Field J., 1956, MICROSCOPIC DIAGNOSI, V2
   FREMOUNT HN, 1974, J PARASITOL, V60, P534, DOI 10.2307/3278382
   Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097
   GAY F, 1995, J IMMUNOL METHODS, V184, P15, DOI 10.1016/0022-1759(95)00070-Q
   Genton B, 2008, PLOS MED, V5, P881, DOI 10.1371/journal.pmed.0050127
   HASLER T, 1993, AM J TROP MED HYG, V48, P332, DOI 10.4269/ajtmh.1993.48.332
   IHALAMULLA RL, 1987, T ROY SOC TROP MED H, V81, P25, DOI 10.1016/0035-9203(87)90271-9
   Kochar DK, 2005, EMERG INFECT DIS, V11, P132, DOI 10.3201/eid1101.040519
   Kroll MH, 1996, BLOOD, V88, P1525
   Kyes S, 2001, ANNU REV MICROBIOL, V55, P673, DOI 10.1146/annurev.micro.55.1.673
   Mendis K, 2001, AM J TROP MED HYG, V64, P97, DOI 10.4269/ajtmh.2001.64.97
   Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a
   Muanza K, 1996, RES IMMUNOL, V147, P149, DOI 10.1016/0923-2494(96)83167-1
   Nosten F, 1999, LANCET, V354, P546, DOI 10.1016/S0140-6736(98)09247-2
   Noviyanti R, 2001, MOL BIOCHEM PARASIT, V114, P227, DOI 10.1016/S0166-6851(01)00266-3
   Oliveira TR, 2006, MALARIA J, V5, DOI 10.1186/1475-2875-5-83
   Pouvelle B, 1998, INFECT IMMUN, V66, P4950, DOI 10.1128/IAI.66.10.4950-4956.1998
   Pouvelle B, 2003, J INFECT DIS, V187, P292, DOI 10.1086/346050
   Resende M, 2009, INT J PARASITOL, V39, P1195, DOI 10.1016/j.ijpara.2009.02.022
   RUDOLF G. de M., 1927, JOUR TROP MED HYG, V30, P1
   Scherf A, 2008, ANNU REV MICROBIOL, V62, P445, DOI 10.1146/annurev.micro.61.080706.093134
   Snounou Georges, 2002, Methods Mol Med, V72, P189, DOI 10.1385/1-59259-271-6:189
   Tan LKK, 2008, LANCET INFECT DIS, V8, P449, DOI 10.1016/S1473-3099(08)70153-1
   Tjitra E, 2008, PLOS MED, V5, P890, DOI 10.1371/journal.pmed.0050128
NR 40
TC 179
Z9 180
U1 0
U2 23
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD AUG 15
PY 2010
VL 202
IS 4
BP 638
EP 647
DI 10.1086/654815
PG 10
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 625HR
UT WOS:000279886600017
PM 20617923
OA Bronze
DA 2020-12-08
ER

PT J
AU Bargieri, DY
   Leite, JA
   Lopes, SCP
   Sbrogio-Almeida, ME
   Braga, CJM
   Ferreira, LCS
   Soares, IS
   Costa, FTM
   Rodrigues, MM
AF Bargieri, Daniel Y.
   Leite, Juliana A.
   Lopes, Stefanie C. P.
   Sbrogio-Almeida, Maria Elisabete
   Braga, Catarina J. M.
   Ferreira, Luis C. S.
   Soares, Irene S.
   Costa, Fabio T. M.
   Rodrigues, Mauricio M.
TI Immunogenic properties of a recombinant fusion protein containing the
   C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1
   and the innate immunity agonist FliC flagellin of Salmonella Typhimurium
SO VACCINE
LA English
DT Article
DE P. falciparum; Vaccine; Flagellin; TLR5
ID TOLL-LIKE RECEPTOR-5; MALARIA VACCINE; BACTERIAL FLAGELLIN; ADJUVANT
   ACTIVITY; AOTUS MONKEYS; MONOCLONAL-ANTIBODIES; PROTECTIVE IMMUNITY;
   ADAPTIVE IMMUNITY; INFLUENZA VACCINE; DNA VACCINE
AB In a recent study, we demonstrated the immunogenic properties of a new malaria vaccine polypeptide based on a 19 kDa C-terminal fragment of the merozoite surface protein-1 (MSP1(19)) from Plasmodium vivax and an innate immunity agonist, the Salmonella enterica serovar Typhimurium flagellin (FliC). Herein, we tested whether the same strategy, based on the MSP1(19) component of the deadly malaria parasite Plasmodium falciparum, could also generate a fusion polypeptide with enhanced immunogenicity. The His(6)FliC-MSP1(19) fusion protein was expressed from a recombinant Escherichia coli and showed preserved in vitro TLR5-binding activity. In contrast to animals injected with His(6)MSP1(19), mice subcutaneously immunised with the recombinant His6FliC-MSP1(19) developed strong MSP1(19)-specific systemic antibody responses with a prevailing IgG1 subclass. Incorporation of other adjuvants, such as CpG ODN 1826, complete and incomplete Freund's adjuvants or Quil-A, improved the IgG responses after the second, but not the third, immunising dose. It also resulted in a more balanced IgG subclass response, as evaluated by the IgG1/IgG2c ratio, and higher cell-mediated immune response, as determined by the detection of antigen-specific interferon-gamma secretion by immune spleen cells. MSP19-specific antibodies recognised not only the recombinant protein, but also the native protein expressed on the surface of P. falciparum parasites. Finally, sera from rabbits immunised with the fusion protein alone inhibited the in vitro growth of three different P. falciparum strains. In summary, these results extend our previous observations and further demonstrate that fusion of the innate immunity agonist FliC to Plasmodium antigens is a promising alternative to improve their immunogenicity. (c) 2010 Elsevier Ltd. All rights reserved.
C1 [Bargieri, Daniel Y.; Rodrigues, Mauricio M.] Univ Fed Sao Paulo, CINTERGEN, Escola Paulista Med, BR-04044010 Sao Paulo, Brazil.
   [Bargieri, Daniel Y.; Rodrigues, Mauricio M.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, BR-04044010 Sao Paulo, Brazil.
   [Leite, Juliana A.; Lopes, Stefanie C. P.; Costa, Fabio T. M.] Univ Estadual Campinas, Inst Biol, Dept Genet Evolucao & Bioagentes, BR-13083970 Campinas, SP, Brazil.
   [Sbrogio-Almeida, Maria Elisabete] Lab Ctr Biotecnol, Inst Butantan, BR-05503900 Sao Paulo, Brazil.
   [Braga, Catarina J. M.; Ferreira, Luis C. S.] Univ Sao Paulo, Dept Microbiol, Inst Ciencias Biomed, BR-05508900 Sao Paulo, Brazil.
   [Soares, Irene S.] Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, BR-05508900 Sao Paulo, Brazil.
RP Rodrigues, MM (corresponding author), Univ Fed Sao Paulo, CINTERGEN, Escola Paulista Med, Rua Mirassol 207, BR-04044010 Sao Paulo, Brazil.
EM mrodrigues@unifesp.br
RI Ferreira, Luis Carlos S/M-3954-2014; Costa, Fabio/E-1181-2012; Leite,
   Juliana/G-2563-2013; Bargieri, Daniel Youssef/A-4461-2013; Lopes,
   Stefanie/A-8314-2012; Rodrigues, Mauricio M./B-8512-2012; Soares, Irene
   Silva/C-5974-2012
OI Ferreira, Luis Carlos S/0000-0002-4883-1693; Costa,
   Fabio/0000-0001-9969-7300; Bargieri, Daniel Youssef/0000-0003-2564-3742;
   Soares, Irene Silva/0000-0002-3336-6856; Lopes,
   Stefanie/0000-0002-6981-2192
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Millennium Institute
   for Vaccine Development and Technology [CNPq 420067/2005-1]; National
   Institute for Vaccine Development and Technology (CNPq - INCTV); Rede de
   Malaria (CNPq)National Council for Scientific and Technological
   Development (CNPq); FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP)
FX This work was supported by grants from the Fundacao de Amparo a Pesquisa
   do Estado de Sao Paulo (FAPESP), the Millennium Institute for Vaccine
   Development and Technology (CNPq 420067/2005-1), the National Institute
   for Vaccine Development and Technology (CNPq - INCTV), and Rede de
   Malaria (CNPq). DYB, JAL, SCPL and CJMB were supported by fellowships
   from FAPESP. MES-A, LCSF, ISS, FTMC and MMR were supported by
   fellowships from CNPq.
CR Abdulla S, 2008, NEW ENGL J MED, V359, P2533, DOI 10.1056/NEJMoa0807773
   Adar Y, 2009, VACCINE, V27, P2099, DOI 10.1016/j.vaccine.2009.02.011
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   AREGAWI M, 2008, WORLD MALARIA REPORT
   Bargieri DY, 2008, VACCINE, V26, P6132, DOI 10.1016/j.vaccine.2008.08.070
   Bates JT, 2009, J IMMUNOL, V182, P7539, DOI 10.4049/jimmunol.0804225
   Beeson JG, 2008, TRENDS PARASITOL, V24, P578, DOI 10.1016/j.pt.2008.08.008
   Bejon P, 2008, NEW ENGL J MED, V359, P2521, DOI 10.1056/NEJMoa0807381
   Ben-Yedidia T, 1999, INFECT IMMUN, V67, P4360, DOI 10.1128/IAI.67.9.4360-4366.1999
   Bergmann-Leitner ES, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-183
   BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379
   Braga CJM, 2009, INFECT IMMUN, V77, P1700, DOI 10.1128/IAI.01470-08
   Chang SP, 1996, INFECT IMMUN, V64, P253, DOI 10.1128/IAI.64.1.253-261.1996
   Chauhan N, 2005, MOL CELL BIOCHEM, V276, P1, DOI 10.1007/s11010-005-2240-z
   Combe A, 2009, CELL HOST MICROBE, V5, P386, DOI 10.1016/j.chom.2009.03.008
   Cuadros C, 2004, INFECT IMMUN, V72, P2810, DOI 10.1128/IAI.72.5.2810-2816.2004
   Cunha MG, 2001, VACCINE, V20, P385, DOI 10.1016/S0264-410X(01)00359-0
   Darko CA, 2005, INFECT IMMUN, V73, P287, DOI 10.1128/IAI.73.1.287-297.2005
   DIGGS CL, 1993, PARASITOL TODAY, V9, P300, DOI 10.1016/0169-4758(93)90130-8
   DISANTI SM, 1987, REV INST MED TROP SP, V29, P142, DOI 10.1590/S0036-46651987000300005
   Doolan DL, 2006, CURR MOL MED, V6, P169, DOI 10.2174/156652406776055249
   Douki JBL, 2002, BLOOD, V100, P1478, DOI 10.1182/blood-2002-01-0315
   Franchi L, 2006, NAT IMMUNOL, V7, P576, DOI 10.1038/ni1346
   Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106
   Holder AA, 2009, PARASITOLOGY, V136, P1445, DOI 10.1017/S0031182009990515
   Honko AN, 2006, INFECT IMMUN, V74, P1113, DOI 10.1128/IAI.74.2.1113-1120.2006
   Huleatt JW, 2008, VACCINE, V26, P201, DOI 10.1016/j.vaccine.2007.10.062
   Huleatt JW, 2007, VACCINE, V25, P763, DOI 10.1016/j.vaccine.2006.08.013
   Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359
   KULANE A, 1992, AM J TROP MED HYG, V46, P589, DOI 10.4269/ajtmh.1992.46.589
   KUMAR S, 1995, MOL MED, V1, P325, DOI 10.1007/BF03401557
   Lamkanfi M, 2007, J IMMUNOL, V178, P8022, DOI 10.4049/jimmunol.178.12.8022
   Le Moigne V, 2008, MOL IMMUNOL, V45, P2499, DOI 10.1016/j.molimm.2008.01.005
   Lee SE, 2006, INFECT IMMUN, V74, P694, DOI 10.1128/IAI.74.1.694-702.2006
   Ljungstrom I.PerlmannH, 2004, METHODS MALARIA RES
   Lyon JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002830
   McDonald WF, 2007, J INFECT DIS, V195, P1607, DOI 10.1086/517613
   Means TK, 2003, J IMMUNOL, V170, P5165, DOI 10.4049/jimmunol.170.10.5165
   Miao EA, 2006, NAT IMMUNOL, V7, P569, DOI 10.1038/ni1344
   Mizel SB, 2009, CLIN VACCINE IMMUNOL, V16, P21, DOI 10.1128/CVI.00333-08
   O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403
   O'Donnell RA, 2000, NAT MED, V6, P91, DOI 10.1038/71595
   Ogutu BR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004708
   Patino Jose A. Guevara, 1997, Journal of Experimental Medicine, V186, P1689, DOI 10.1084/jem.186.10.1689
   Pino O, 2005, INFECT IMMUN, V73, P6763, DOI 10.1128/IAI.73.10.6763-6770.2005
   Reed ZH, 2009, VACCINE, V27, P1651, DOI 10.1016/j.vaccine.2008.10.093
   Ren T, 2006, PLOS PATHOG, V2, P175, DOI 10.1371/journal.ppat.0020018
   Renia L, 2008, PARASITE, V15, P379, DOI 10.1051/parasite/2008153379
   Rodrigues MM, 1999, INFECT IMMUN, V67, P3855, DOI 10.1128/IAI.67.8.3855-3863.1999
   Sanders CJ, 2009, EUR J IMMUNOL, V39, P359, DOI 10.1002/eji.200838804
   Schmitt CK, 1996, J BACTERIOL, V178, P2911, DOI 10.1128/jb.178.10.2911-2915.1996
   Singh S, 2006, INFECT IMMUN, V74, P4573, DOI 10.1128/IAI.01679-05
   Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011
   Song LZ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002257
   Stowers AW, 2002, P NATL ACAD SCI USA, V99, P339, DOI 10.1073/pnas.012590199
   Stowers AW, 2001, INFECT IMMUN, V69, P1536, DOI 10.1128/IAI.69.3.1536-1546.2001
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Vicente-Suarez I, 2007, EUR J IMMUNOL, V37, P3164, DOI 10.1002/eji.200737306
   Vinzing M, 2008, J IMMUNOL, V180, P6808, DOI 10.4049/jimmunol.180.10.6808
   Weimer ET, 2009, INFECT IMMUN, V77, P2356, DOI 10.1128/IAI.00054-09
   White NJ, 2004, J CLIN INVEST, V113, P1084, DOI 10.1172/JCI21682
   Yazdani SS, 2006, CURR MOL MED, V6, P187, DOI 10.2174/156652406776055212
   Zamboni DS, 2006, NAT IMMUNOL, V7, P318, DOI 10.1038/ni1305
NR 63
TC 26
Z9 31
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 1
PY 2010
VL 28
IS 16
BP 2818
EP 2826
DI 10.1016/j.vaccine.2010.02.004
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 587EJ
UT WOS:000276972100005
PM 20170765
DA 2020-12-08
ER

PT J
AU Albrecht, L
   Castineiras, C
   Carvalho, BO
   Ladeia-Andrade, S
   da Silva, NS
   Hoffmann, EHE
   dalla Martha, RC
   Costa, FTM
   Wunderlich, G
AF Albrecht, Letusa
   Castineiras, Catarina
   Carvalho, Bruna O.
   Ladeia-Andrade, Simone
   da Silva, Natal Santos
   Hoffmann, Erika H. E.
   dalla Martha, Rosimeire C.
   Costa, Fabio T. M.
   Wunderlich, Gerhard
TI The South American Plasmodium falciparum var gene repertoire is limited,
   highly shared and possibly lacks several antigenic types
SO GENE
LA English
DT Article
DE Antigenic variation; var; PfEMP1
ID ECTOPIC RECOMBINATION; IMMUNE EVASION; AMAZON REGION; MALARIA; SURFACE;
   DIVERSITY; TRANSCRIPTION; POPULATIONS; PFEMP1; BRAZIL
AB The Plasmodium falciparum var gene family encodes large variant antigens, which are important virulence factors, and also targets of the humoral host response. The frequently observed mild outcomes of falciparum malaria in many places of the Amazon area prompted us to ask whether a globally restricted variant (var) gene repertoire is present in currently circulating and older isolates of this area. By exhaustive analysis of var gene tags from 89 isolates and clones taken during many years from all over the Brazilian Amazon, we estimate that there are probably no more than 350-430 distinct sequence types, less than for any similar sized area studied so far. Detailed analysis of the var tags from genetically distinct clones obtained from single isolates revealed restricted and redundant repertoires suggesting either a low incidence of infective bites or restricted variant gene diversity in inoculated parasites. Additionally, we found a structuring of var gene repertoires observed as a higher pairwise typing sharing in isolates from the same microregion compared to isolates from different regions. Fine analysis of translated var tags revealed that certain Distinct Sequence Identifiers (DSIDs) were differently represented in Brazilian/South American isolates when compared to datasets from other continents. By global alignment of worldwide var DBL alpha sequences and sorting in groups with more than 76% identity, 125 clusters were formed and more than half of all genes were found in nine clusters with 50 or more sequences. While Brazilian/South American sequences were represented only in 64 groups, African sequences were found in the majority of clusters. DSID type 1 related sequences accumulated almost completely in one single cluster, indicating that limited recombination occurs in these specific var gene types. These data demonstrate the so far highest pairwise type sharing values for the var gene family in isolates from all over an entire subcontinent. The apparent lack of specific sequences types suggests that the P. falciparum transmission dynamics in the whole Amazon are probably different from any other endemic region studied and possibly interfere with the parasite's ability to efficiently diversify its variant gene repertoires. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Albrecht, Letusa; Castineiras, Catarina; Ladeia-Andrade, Simone; da Silva, Natal Santos; Wunderlich, Gerhard] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, BR-05508900 Sao Paulo, Brazil.
   [Carvalho, Bruna O.; Costa, Fabio T. M.] Univ Estadual Campinas, UNICAMP, Inst Biol, Dept Genet Evolut & Bioagents, Campinas, SP, Brazil.
   [Hoffmann, Erika H. E.] Univ Sao Paulo, Inst Trop Med, BR-05508900 Sao Paulo, Brazil.
   [dalla Martha, Rosimeire C.] Ctr Res Trop Med CEPEM, Porto Velho, Brazil.
RP Wunderlich, G (corresponding author), Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Av Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, Brazil.
EM gwunder@usp.br
RI da Silva, Natal Santos/E-9579-2015; Wunderlich, Gerhard/G-8245-2012;
   Albrecht, Letusa/I-1837-2012; da Silva, Natal Santos/Y-1913-2019; Costa,
   Fabio/E-1181-2012
OI da Silva, Natal Santos/0000-0002-0856-1748; Wunderlich,
   Gerhard/0000-0003-1724-0337; Albrecht, Letusa/0000-0001-6406-2057; da
   Silva, Natal Santos/0000-0002-0856-1748; Costa,
   Fabio/0000-0001-9969-7300; ladeia-andrade, simone/0000-0003-0912-5937
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   CNPqNational Council for Scientific and Technological Development (CNPq)
FX The authors thank Wolfgang Fischer and Marcio Yamamoto for help with
   sequencing. LA and BC received a FAPESP postgraduate fellowship, CC
   received a CNPq fellowship. This work was supported by a FAPESP grant to
   GW. FTMC and GW are CNPq fellows.
CR Albrecht L, 2006, MOL BIOCHEM PARASIT, V150, P157, DOI 10.1016/j.molbiopara.2006.07.007
   Alves FP, 2002, AM J TROP MED HYG, V66, P641, DOI 10.4269/ajtmh.2002.66.641
   Arez AP, 1999, PARASITOLOGY, V118, P347, DOI 10.1017/S0031182099003972
   Barry AE, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030034
   BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3
   BOYLE JS, 1995, TRENDS GENET, V11, P8, DOI 10.1016/S0168-9525(00)88977-5
   Bull PC, 2007, MOL BIOCHEM PARASIT, V154, P98, DOI 10.1016/j.molbiopara.2007.03.011
   Bull PC, 2005, PLOS PATHOG, V1, P202, DOI 10.1371/journal.ppat.0010026
   Cham GKK, 2009, J IMMUNOL, V183, P3356, DOI 10.4049/jimmunol.0901331
   Colwell RK, 2006, STAT ESTIMATION SPEC
   Craig A, 2001, MOL BIOCHEM PARASIT, V115, P129, DOI 10.1016/S0166-6851(01)00275-4
   da Silva-Nunes M, 2007, MEM I OSWALDO CRUZ, V102, P341, DOI 10.1590/S0074-02762007005000051
   Duffy MF, 2009, J MOL BIOL, V389, P453, DOI 10.1016/j.jmb.2009.04.032
   Durham AM, 2005, BIOINFORMATICS, V21, P2812, DOI 10.1093/bioinformatics/bti424
   Fowler EV, 2002, MOL BIOCHEM PARASIT, V120, P117, DOI 10.1016/S0166-6851(01)00443-1
   Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531
   Hoffmann EHE, 2006, GENE, V376, P224, DOI 10.1016/j.gene.2006.03.011
   Jensen ATR, 2004, J EXP MED, V199, P1179, DOI 10.1084/jem.20040274
   Kaestli M, 2006, J INFECT DIS, V193, P1567, DOI 10.1086/503776
   Kirchgatter K, 2002, MOL MED, V8, P16, DOI 10.1007/BF03401999
   Kraemer SM, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-45
   Kyriacou HM, 2006, MOL BIOCHEM PARASIT, V150, P211, DOI 10.1016/j.molbiopara.2006.08.005
   Ladeia-Andrade S, 2007, MEM I OSWALDO CRUZ, V102, P943, DOI 10.1590/S0074-02762007000800009
   Larkin MA, 2007, BIOINFORMATICS, V23, P2947, DOI 10.1093/bioinformatics/btm404
   LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567
   Machado RLD, 2004, J INFECT DIS, V190, P1547, DOI 10.1086/424601
   MARCELO L, 1994, AM J TROP MED HYG, V51, P16, DOI 10.4269/ajtmh.1994.51.16
   Marsh K, 2006, PARASITE IMMUNOL, V28, P51, DOI 10.1111/j.1365-3024.2006.00808.x
   Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a
   Moll K., 2008, METHODS MALARIA RES
   Normark J, 2007, P NATL ACAD SCI USA, V104, P15835, DOI 10.1073/pnas.0610485104
   Peters J, 2002, P NATL ACAD SCI USA, V99, P10689, DOI 10.1073/pnas.162349899
   Razakandrainibe FG, 2005, P NATL ACAD SCI USA, V102, P17388, DOI 10.1073/pnas.0508871102
   ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0
   Roussilhon C, 2007, PLOS MED, V4, P1791, DOI 10.1371/journal.pmed.0040320
   SAWYER D R, 1986, Southeast Asian Journal of Tropical Medicine and Public Health, V17, P342
   Scherf A, 2006, CELL, V124, P251, DOI 10.1016/j.cell.2006.01.004
   Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418
   Tami A, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-7
   Taylor HM, 2000, MOL BIOCHEM PARASIT, V105, P13, DOI 10.1016/S0166-6851(99)00159-0
   Taylor HM, 2000, MOL BIOCHEM PARASIT, V110, P391, DOI 10.1016/S0166-6851(00)00286-3
   Ward CP, 1999, MOL BIOCHEM PARASIT, V102, P167, DOI 10.1016/S0166-6851(99)00106-1
NR 42
TC 19
Z9 19
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD MAR 15
PY 2010
VL 453
IS 1-2
BP 37
EP 44
DI 10.1016/j.gene.2010.01.001
PG 8
WC Genetics & Heredity
SC Genetics & Heredity
GA 573UA
UT WOS:000275939200004
PM 20079817
DA 2020-12-08
ER

PT J
AU Gameiro, J
   Nagib, PRA
   Andrade, CF
   Villa-Verde, DMS
   Silva-Barbosa, SD
   Savino, W
   Costa, FTM
   Verinaud, L
AF Gameiro, Jacy
   Nagib, Patricia R. A.
   Andrade, Carolina F.
   Villa-Verde, Dea M. S.
   Silva-Barbosa, Suse D.
   Savino, Wilson
   Costa, Fabio T. M.
   Verinaud, Liana
TI Changes in cell migration-related molecules expressed by thymic
   microenvironment during experimental Plasmodium berghei infection:
   consequences on thymocyte development
SO IMMUNOLOGY
LA English
DT Article
DE chemokines; extracellular matrix; Plasmodium berghei; T-cell
   development; thymus
ID TRYPANOSOMA-CRUZI INFECTION; REGULATORY T-CELLS; EXTRACELLULAR-MATRIX;
   MALARIA PATHOGENESIS; CHABAUDI-CHABAUDI; NKT CELLS; FIBRONECTIN; MICE;
   DIFFERENTIATION; CHEMOKINES
AB P>We previously showed alterations in the thymus during experimental infection with Plasmodium berghei. Such alterations comprised histological changes, with loss of cortical-medullary limits, and the intrathymic presence of parasites. As the combination of chemokines, adhesion molecules and extracellular matrix (ECM) is critical to appropriate thymocyte development, we analysed the thymic expression of ECM ligands and receptors, as well as chemokines and their respective receptors during the experimental P. berghei infection. Increased expression of ECM components was observed in thymi from infected mice. In contrast, down-regulated surface expression of fibronectin and laminin receptors was observed in thymocytes from these animals. Moreover, in thymi from infected mice there was increased CXCL12 and CXCR4, and a decreased expression of CCL25 and CCR9. An altered thymocyte migration towards ECM elements and chemokines was seen when the thymi from infected mice were analysed. Evaluation of ex vivo migration patterns of CD4/CD8-defined thymocyte subpopulations revealed that double-negative (DN), and CD4+ and CD8+ single-positive (SP) cells from P. berghei-infected mice have higher migratory responses compared with controls. Interestingly, increased numbers of DN and SP subpopulations were found in the spleens of infected mice. Overall, we show that the thymic atrophy observed in P. berghei-infected mice is accompanied by thymic microenvironmental changes that comprise altered expression of thymocyte migration-related molecules of the ECM and chemokine protein families, which in turn can alter the thymocyte migration pattern. These thymic disturbances may have consequences for the control of the immune response against this protozoan.
C1 [Gameiro, Jacy; Nagib, Patricia R. A.; Andrade, Carolina F.; Verinaud, Liana] Univ Estadual Campinas, UNICAMP, Dept Anat Cell Biol & Physiol, Inst Biol, Sao Paulo, Brazil.
   [Villa-Verde, Dea M. S.; Savino, Wilson] Fundacao Oswaldo Cruz, Inst Oswaldo Cruz, Lab Thymus Res, Rio De Janeiro, Brazil.
   [Silva-Barbosa, Suse D.] Brazilian Natl Canc Inst, Ctr Bone Marrow Transplantat, Rio De Janeiro, Brazil.
   [Costa, Fabio T. M.] Univ Estadual Campinas, UNICAMP, Dept Genet & Evolut, Inst Biol, Rio De Janeiro, Brazil.
RP Verinaud, L (corresponding author), Univ Estadual Campinas, Dept Anat Biol Celular & Fisiol, Inst Biol, Cidade Univ Zeferino Vaz S-N, BR-13084970 Sao Paulo, Brazil.
EM verinaud@unicamp.br
RI Verinaud, Liana/B-8985-2012; Villa-Verde, Dea M.S./Q-1238-2016; Gameiro,
   Jacy JG/N-8543-2018; Costa, Fabio/E-1181-2012; Francelin,
   Carolina/AAZ-9572-2020
OI Villa-Verde, Dea M.S./0000-0002-2685-5512; Costa,
   Fabio/0000-0001-9969-7300; Francelin, Carolina/0000-0001-7439-3124;
   Gameiro, Jacy/0000-0001-9244-3623
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [04/03599-1]; Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National
   Council for Scientific and Technological Development (CNPq)
   [14229/2005-1]; State University of Campinas (UNICAMP)
FX We sincerely thank Ana Leda Longhini from Centro Integrado de Pesquisas
   Onco-hematologicas na Infancia (CIPOI/UNICAMP). This work was supported
   by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), grant
   number #04/03599-1. P.R.A.N. was a recipient of a doctoral fellowship
   from Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq
   #14229/2005-1) and State University of Campinas (UNICAMP). F.T.M.C. and
   W.S. are recipients of a research scholarship from CNPq.
CR Andrade CF, 2008, CELL IMMUNOL, V253, P1, DOI 10.1016/j.cellimm.2008.06.001
   Ciofani M, 2007, ANNU REV CELL DEV BI, V23, P463, DOI 10.1146/annurev.cellbio.23.090506.123547
   Collins TJ, 2007, BIOTECHNIQUES, V43, P25
   Cotta-De-Almeida V, 2004, EUR J IMMUNOL, V34, P1578, DOI 10.1002/eji.200324765
   Cotta-De-Almeida V, 2003, EUR J IMMUNOL, V33, P2439, DOI 10.1002/eji.200323860
   Farouk SE, 2004, EUR J IMMUNOL, V34, P2248, DOI 10.1002/eji.200424861
   Fonseca L, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-77
   Fu WX, 2004, CELL MOL IMMUNOL, V1, P266
   Garly ML, 2008, J PEDIATR-US, V153, P683, DOI 10.1016/j.jpeds.2008.04.069
   Hansen DS, 2003, IMMUNITY, V18, P391, DOI 10.1016/S1074-7613(03)00052-9
   Hernandez-Lopez C, 2002, BLOOD, V99, P546, DOI 10.1182/blood.V99.2.546
   HO M, 1994, INFECT IMMUN, V62, P855, DOI 10.1128/IAI.62.3.855-862.1994
   Kierszenbaum F, 1999, CLIN MICROBIOL REV, V12, P210, DOI 10.1128/CMR.12.2.210
   Marsh K, 2006, PARASITE IMMUNOL, V28, P51, DOI 10.1111/j.1365-3024.2006.00808.x
   Mendes-da-Cruz DA, 2003, MICROBES INFECT, V5, P825, DOI 10.1016/S1286-4579(03)00156-4
   Mendes-Da-Cruz DA, 2008, J IMMUNOL, V180, P4639, DOI 10.4049/jimmunol.180.7.4639
   Mendes-da-Cruz DA, 2006, EUR J IMMUNOL, V36, P1486, DOI 10.1002/eji.200535629
   Overbergh L, 2003, J Biomol Tech, V14, P33
   Pelletier AJ, 2000, BLOOD, V96, P2682
   Petrie HT, 2007, ANNU REV IMMUNOL, V25, P649, DOI 10.1146/annurev.immunol.23.021704.115715
   Plotkin J, 2003, J IMMUNOL, V171, P4521, DOI 10.4049/jimmunol.171.9.4521
   Savino W, 2004, J LEUKOCYTE BIOL, V75, P951, DOI 10.1189/jlb.1003455
   SAVINO W, 1993, IMMUNOL TODAY, V14, P158, DOI 10.1016/0167-5699(93)90278-S
   Savino W, 2002, TRENDS IMMUNOL, V23, P305, DOI 10.1016/S1471-4906(02)02224-X
   Savino W, 2000, ENDOCR REV, V21, P412, DOI 10.1210/er.21.4.412
   Savino W, 2006, PLOS PATHOG, V2, P472, DOI 10.1371/journal.ppat.0020062
   Schofield L, 2005, NAT REV IMMUNOL, V5, P722, DOI 10.1038/nri1686
   Seixas E, 2005, EXP PARASITOL, V110, P394, DOI 10.1016/j.exppara.2005.03.024
   Soulard V, 2007, INFECT IMMUN, V75, P2511, DOI 10.1128/IAI.01818-06
   Takayama E, 1998, IMMUNOLOGY, V95, P553
   Thomson CW, 2006, IMMUNOL RES, V35, P163, DOI 10.1385/IR:35:1:163
   Youn BS, 2002, APOPTOSIS, V7, P271, DOI 10.1023/A:1015320321511
   Zhang D, 2007, BLOOD, V109, P4071, DOI 10.1182/blood-2006-10-050625
NR 33
TC 10
Z9 11
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0019-2805
EI 1365-2567
J9 IMMUNOLOGY
JI Immunology
PD FEB
PY 2010
VL 129
IS 2
BP 248
EP 256
DI 10.1111/j.1365-2567.2009.03177.x
PG 9
WC Immunology
SC Immunology
GA 541YQ
UT WOS:000273458000010
PM 19824923
OA Green Published
DA 2020-12-08
ER

PT J
AU Duran, N
   Marcato, PD
   De Conti, R
   Alves, OL
   Costa, FTM
   Brocchi, M
AF Duran, Nelson
   Marcato, Priscyla D.
   De Conti, Roseli
   Alves, Oswaldo L.
   Costa, Fabio T. M.
   Brocchi, Marcelo
TI Potential Use of Silver Nanoparticles on Pathogenic Bacteria, their
   Toxicity and Possible Mechanisms of Action
SO JOURNAL OF THE BRAZILIAN CHEMICAL SOCIETY
LA English
DT Review
DE silver nanoparticles; silver ions; antimicrobial activity; toxicity
ID IN-VITRO CYTOTOXICITY; ESCHERICHIA-COLI; EXTRACELLULAR BIOSYNTHESIS;
   ANTIBACTERIAL ACTIVITY; STAPHYLOCOCCUS-AUREUS; INHALATION EXPOSURE;
   TEXTILE FABRICS; RESISTANCE; PARTICLES; MODEL
AB The antimicrobial properties of silver have been known for thousands of years. Recently, silver nanoparticles have gained attention because of their antimicrobial activity which offers the possibility of their use for medical and hygiene purposes. Indeed, silver nanoparticles in different formulations and with different shapes and sizes exhibit variable antimicrobial activity. However, the mechanisms of antimicrobial activity of silver ions and silver nanoparticles, and their toxicity to human tissues are not fully characterized. This review evaluates the potential use of silver nanoparticles to control pathogens with emphasis on their action against pathogenic bacteria, their toxicity and possible mechanisms of action.
C1 [Duran, Nelson; Marcato, Priscyla D.; De Conti, Roseli; Alves, Oswaldo L.] Univ Estadual Campinas, Inst Quim, BR-13083970 Campinas, SP, Brazil.
   [Costa, Fabio T. M.; Brocchi, Marcelo] Univ Estadual Campinas, Inst Biol, BR-13083970 Campinas, SP, Brazil.
RP Duran, N (corresponding author), Univ Estadual Campinas, Inst Quim, BR-13083970 Campinas, SP, Brazil.
EM duran@iqm.unicamp.br
RI Brocchi, Marcelo/E-3723-2012; Alves, Oswaldo L./J-7124-2012; Marcato,
   Priscyla/D-4371-2012; Costa, Fabio/E-1181-2012
OI Alves, Oswaldo L./0000-0002-1518-2092; Costa, Fabio/0000-0001-9969-7300;
   Duran, Nelson/0000-0001-8372-5143; Marcato Gaspari, Priscyla
   Daniely/0000-0003-0378-9580
FU FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP);
   CAPESCAPES; Brazilian Network of Nanocosmetics (CNPq/MCT)National
   Council for Scientific and Technological Development (CNPq)
FX Support from FAPESP, CAPES and the Brazilian Network of Nanocosmetics
   (CNPq/MCT) are acknowledged.
CR Alt V, 2004, BIOMATERIALS, V25, P4383, DOI 10.1016/j.biomaterials.2003.10.078
   Arora S, 2009, TOXICOL APPL PHARM, V236, P310, DOI 10.1016/j.taap.2009.02.020
   Asharani PV, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/25/255102
   AshaRani PV, 2009, ACS NANO, V3, P279, DOI 10.1021/nn800596w
   Baker C, 2005, J NANOSCI NANOTECHNO, V5, P244, DOI 10.1166/jnn.2005.034
   Balaji DS, 2009, COLLOID SURFACE B, V68, P88, DOI 10.1016/j.colsurfb.2008.09.022
   Basavaraja S, 2008, MATER RES BULL, V43, P1164, DOI 10.1016/j.materresbull.2007.06.020
   Birla SS, 2009, LETT APPL MICROBIOL, V48, P173, DOI 10.1111/j.1472-765X.2008.02510.x
   Borm PJA, 2004, J NANOSCI NANOTECHNO, V4, P521, DOI 10.1166/jnn.2004.081
   Braydich-Stolle L, 2005, TOXICOL SCI, V88, P412, DOI 10.1093/toxsci/kfi256
   Burd A, 2007, WOUND REPAIR REGEN, V15, P94, DOI 10.1111/j.1524-475X.2006.00190.x
   Carlson C, 2008, J PHYS CHEM B, V112, P13608, DOI 10.1021/jp712087m
   Chen X, 2008, TOXICOL LETT, V176, P1, DOI 10.1016/j.toxlet.2007.10.004
   Chen Yuxiang, 2003, Current Gene Therapy, V3, P273, DOI 10.2174/1566523034578339
   Choi O, 2008, ENVIRON SCI TECHNOL, V42, P4583, DOI 10.1021/es703238h
   Chopra I, 2007, J ANTIMICROB CHEMOTH, V59, P587, DOI 10.1093/jac/dkm006
   de Souza A, 2006, CURR SCI INDIA, V91, P926
   DURAN N, 2008, NANOTOXICOLOGY, V2, pS32
   Duran N, 2007, J BIOMED NANOTECHNOL, V3, P203, DOI 10.1166/jbn.2007.022
   Duran Nelson, 2005, J Nanobiotechnology, V3, P8, DOI 10.1186/1477-3155-3-8
   Duran N, 2010, J NANOPART RES, V12, P285, DOI 10.1007/s11051-009-9606-1
   El-Ansary A, 2009, J TOXICOL-US, V2009, DOI 10.1155/2009/754810
   Feng QL, 2000, J BIOMED MATER RES, V52, P662, DOI 10.1002/1097-4636(20001215)52:4<662::AID-JBM10>3.0.CO;2-3
   Gade AK, 2008, J BIOBASED MATER BIO, V2, P243, DOI 10.1166/jbmb.2008.401
   Gogoi SK, 2006, LANGMUIR, V22, P9322, DOI 10.1021/la060661v
   Hussain SM, 2006, TOXICOL SCI, V92, P456, DOI 10.1093/toxsci/kfl020
   Hussain SM, 2009, TOXICOL SCI, V108, P223, DOI 10.1093/toxsci/kfp032
   Hussain SM, 2005, TOXICOL IN VITRO, V19, P975, DOI 10.1016/j.tiv.2005.06.034
   Ingle A, 2008, CURR NANOSCI, V4, P141, DOI 10.2174/157341308784340804
   JANI P, 1990, J PHARM PHARMACOL, V42, P821, DOI 10.1111/j.2042-7158.1990.tb07033.x
   Jung WK, 2008, APPL ENVIRON MICROB, V74, P2171, DOI 10.1128/AEM.02001-07
   Kalishwaralal K, 2008, MATER LETT, V62, P4411, DOI 10.1016/j.matlet.2008.06.051
   Kim JS, 2007, NANOMED-NANOTECHNOL, V3, P95, DOI 10.1016/j.nano.2006.12.001
   Kreilgaard M, 2002, ADV DRUG DELIVER REV, V54, pS77, DOI 10.1016/S0169-409X(02)00116-3
   Lee KJ, 2007, ACS NANO, V1, P133, DOI 10.1021/nn700048y
   Li P, 2005, NANOTECHNOLOGY, V16, P1912, DOI 10.1088/0957-4484/16/9/082
   Liau SY, 1997, LETT APPL MICROBIOL, V25, P279, DOI 10.1046/j.1472-765X.1997.00219.x
   Liong M, 2009, ADV MATER, V21, P1684, DOI 10.1002/adma.200802646
   Lok CN, 2007, J BIOL INORG CHEM, V12, P527, DOI 10.1007/s00775-007-0208-z
   Lok CN, 2006, J PROTEOME RES, V5, P916, DOI 10.1021/pr0504079
   Maliszewska I, 2009, J PHYS CONF SER, V146, DOI 10.1088/1742-6596/146/1/012024
   MARCATO PD, 2008, P 7 BRAZ MRS M SBPMA
   Marcato PD, 2008, J NANOSCI NANOTECHNO, V8, P2216, DOI 10.1166/jnn.2008.274
   Matsumura Y, 2003, APPL ENVIRON MICROB, V69, P4278, DOI 10.1128/AEM.69.7.4278-4281.2003
   Melaiye A, 2005, EXPERT OPIN THER PAT, V15, P125, DOI 10.1517/13543776.15.2.125
   Mohan YM, 2007, POLYMER, V48, P158, DOI 10.1016/j.polymer.2006.10.045
   Mohanpuria P, 2008, J NANOPART RES, V10, P507, DOI 10.1007/s11051-007-9275-x
   Monarca S, 1997, SCI TOTAL ENVIRON, V205, P137, DOI 10.1016/S0048-9697(97)00194-0
   Morones JR, 2005, NANOTECHNOLOGY, V16, P2346, DOI 10.1088/0957-4484/16/10/059
   Mukherjee P, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/7/075103
   Nanda A, 2009, NANOMED-NANOTECHNOL, V5, P452, DOI 10.1016/j.nano.2009.01.012
   Navarro E, 2008, ENVIRON SCI TECHNOL, V42, P8959, DOI 10.1021/es801785m
   Oberdorster G, 2001, INT ARCH OCC ENV HEA, V74, P1
   Oberdorster G, 2002, J TOXICOL ENV HEAL A, V65, P1531, DOI 10.1080/00984100290071658
   Oberdorster G, 2004, INHAL TOXICOL, V16, P437, DOI 10.1080/08958370490439597
   Pal S, 2007, APPL ENVIRON MICROB, V73, P1712, DOI 10.1128/AEM.02218-06
   Panacek A, 2006, J PHYS CHEM B, V110, P16248, DOI 10.1021/jp063826h
   Panyala NR, 2008, J APPL BIOMED, V6, P117, DOI 10.32725/jab.2008.015
   Parikh RY, 2008, CHEMBIOCHEM, V9, P1415, DOI 10.1002/cbic.200700592
   Patil SS, 2009, SYNTH REACT INORG M, V39, P65, DOI 10.1080/15533170902762587
   Raffi M, 2008, J MATER SCI TECHNOL, V24, P192
   Rahman MF, 2009, TOXICOL LETT, V187, P15, DOI 10.1016/j.toxlet.2009.01.020
   Sadowski Z, 2008, MATER SCI-POLAND, V26, P419
   Shahverdi AR, 2007, NANOMED-NANOTECHNOL, V3, P168, DOI 10.1016/j.nano.2007.02.001
   Shankar SS, 2004, J COLLOID INTERF SCI, V275, P496, DOI 10.1016/j.jcis.2004.03.003
   Sharma VK, 2009, ADV COLLOID INTERFAC, V145, P83, DOI 10.1016/j.cis.2008.09.002
   Silver S, 2003, FEMS MICROBIOL REV, V27, P341, DOI 10.1016/S0168-6445(03)00047-0
   Silver S, 2006, J IND MICROBIOL BIOT, V33, P627, DOI 10.1007/s10295-006-0139-7
   Sondi I, 2004, J COLLOID INTERF SCI, V275, P177, DOI 10.1016/j.jcis.2004.02.012
   Song JY, 2009, BIOPROC BIOSYST ENG, V32, P79, DOI 10.1007/s00449-008-0224-6
   Soto KF, 2005, J NANOPART RES, V7, P145, DOI 10.1007/s11051-005-3473-1
   Sun L, 2008, J BIOMED NANOTECHNOL, V4, P149, DOI 10.1166/jbn.2008.012
   Sung JH, 2008, INHAL TOXICOL, V20, P567, DOI [10.1080/08958370701874671, 10.1080/08958370701874671 ]
   Sung JH, 2009, TOXICOL SCI, V108, P452, DOI 10.1093/toxsci/kfn246
   Takenaka S, 2001, ENVIRON HEALTH PERSP, V109, P547, DOI 10.2307/3454667
   Teeguarden JG, 2007, TOXICOL SCI, V95, P300, DOI 10.1093/toxsci/kfl165
   Tenover FC, 2006, AM J INFECT CONTROL, V34, pS3, DOI 10.1016/j.ajic.2006.05.219
   Totaro Pasquale, 2009, Interact Cardiovasc Thorac Surg, V8, P153, DOI 10.1510/icvts.2008.188870
   Vigneshwaran N, 2007, LANGMUIR, V23, P7113, DOI 10.1021/la063627p
   Wei QS, 2007, SCI CHINA SER B, V50, P418, DOI 10.1007/s11426-007-0028-6
   White RJ, 2001, BR J NURS S2, V10, pS3, DOI DOI 10.12968/BJON.2001.10.SUP4.16079
   Yen HJ, 2009, SMALL, V5, P1553, DOI 10.1002/smll.200900126
NR 82
TC 240
Z9 249
U1 2
U2 103
PU SOC BRASILEIRA QUIMICA
PI SAO PAULO
PA CAIXA POSTAL 26037, 05599-970 SAO PAULO, BRAZIL
SN 0103-5053
EI 1678-4790
J9 J BRAZIL CHEM SOC
JI J. Braz. Chem. Soc.
PY 2010
VL 21
IS 6
BP 949
EP 959
DI 10.1590/S0103-50532010000600002
PG 11
WC Chemistry, Multidisciplinary
SC Chemistry
GA 610PJ
UT WOS:000278745400002
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Duran, N
   Marcato, PD
   Teixeira, Z
   Duran, M
   Costa, FTM
   Brocchi, M
AF Duran, Nelson
   Marcato, Priscyla D.
   Teixeira, Zaine
   Duran, Marcela
   Costa, Fabio T. M.
   Brocchi, Marcelo
TI State of the Art of Nanobiotechnology Applications in Neglected Diseases
SO CURRENT NANOSCIENCE
LA English
DT Review
DE Neglected diseases; nanobiotechnology; malaria; schistosomiasis;
   leishmaniasis; trypanosomiasis; tuberculosis; filarial infection;
   leprosy
ID SOLID LIPID NANOPARTICLES; DRUG-DELIVERY SYSTEM; IN-VIVO DISTRIBUTION;
   AMPHOTERICIN-B; PLASMODIUM-FALCIPARUM; TRYPANOCIDAL ACTIVITY;
   ANTITUBERCULAR DRUGS; BEARING LIPOSOMES; PHYSICOCHEMICAL
   CHARACTERIZATION; ANTILEISHMANIAL PROPERTIES
AB The neglected diseases have not received any especial public and private attention in the last years, as for example, some parasitic diseases. Considerable amounts of private and public money are needed to apply nanobiotechnology for the treatment of neglected diseases. This review focuses on malaria, leishmaniasis, schistosomiasis, trypanosomiasis, tuberculosis, leprosy and filiarasis, and onchocerciasis where liposomes, polymeric nanoparticles or nanostructured lipid carriers have been applied. These nanocarrier systems have shown promissing results in the treatment of many neglected diseases with diminished toxicity and increased efficacy as well as a prolonged release with a reduced number of dosages. Despite these promising results, few nanocarriers have been used in clinical tests. As far as we know, these references are a minority compared to the number of studies of drug delivery systems that have been published in the last years. Therefore, the challenge for the researchers in this area is to generate interest amongst the governments and industries for the treatment of neglected diseases.
C1 [Duran, Nelson; Marcato, Priscyla D.; Teixeira, Zaine; Duran, Marcela] Univ Estadual Campinas, Inst Quim, Biol Chem Lab, BR-13083070 Campinas, SP, Brazil.
   [Costa, Fabio T. M.; Brocchi, Marcelo] Univ Estadual Campinas, Univ Estadual Campinas, Dept Gene Evolut & Bioagents, Ist Biol, BR-13083862 Campinas, SP, Brazil.
RP Duran, N (corresponding author), Univ Estadual Campinas, Inst Quim, Biol Chem Lab, CP 6154, BR-13083070 Campinas, SP, Brazil.
EM duran@iqm.unicamp.br
RI Marcato, Priscyla/D-4371-2012; Brocchi, Marcelo/E-3723-2012; Camargo,
   Zaine/AAG-3655-2020; Costa, Fabio/E-1181-2012
OI Camargo, Zaine/0000-0002-3586-7304; Costa, Fabio/0000-0001-9969-7300;
   Duran, Nelson/0000-0001-8372-5143; Marcato Gaspari, Priscyla
   Daniely/0000-0003-0378-9580
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPESPFundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP); CAPESCAPES; Brazilian Network of Nanocosmetics
   (CNPq/MCT)National Council for Scientific and Technological Development
   (CNPq)
FX The support from CNPq, FAPESP, CAPES and the Brazilian Network of
   Nanocosmetics (CNPq/MCT) are acknowledged.
CR Adler-Moore JP, 1993, J LIPOSOME RES, V3, P429, DOI DOI 10.3109/08982109309150729
   AGATHAT W, 2003, J PHARM PHARM SCI, V6, P67
   Agrawal AK, 2000, ADV DRUG DELIVER REV, V41, P135, DOI 10.1016/S0169-409X(99)00061-7
   Ahmad Z, 2007, NANOMED-NANOTECHNOL, V3, P239, DOI 10.1016/j.nano.2007.05.001
   Ahmad Z, 2006, INT J ANTIMICROB AG, V27, P409, DOI 10.1016/j.ijantimicag.2005.12.009
   Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6
   ALVING C R, 1986, Parasitology Today, V2, P101, DOI 10.1016/0169-4758(86)90039-6
   ALVING CR, 1984, ANN TROP MED PARASIT, V78, P279, DOI 10.1080/00034983.1984.11811817
   Amarji B, 2007, J BIOMED NANOTECHNOL, V3, P264, DOI 10.1166/jbn.2007.029
   Amato VS, 2004, ACTA TROP, V92, P127, DOI 10.1016/j.actatropica.2004.06.006
   Antimisiaris SG, 2005, INT J PHARMACEUT, V289, P151, DOI 10.1016/j.ijpharm.2004.11.002
   Antimisiaris SG, 2003, J PHARM PHARMACOL, V55, P647, DOI 10.1211/002235703765344559
   Bajpai AK, 2006, J MATER SCI-MATER M, V17, P345, DOI 10.1007/s10856-006-8235-9
   Bajpai P, 2005, J DRUG TARGET, V13, P375, DOI 10.1080/10611860500285439
   Banerjee A, 2008, J ANTIMICROB CHEMOTH, V61, P103, DOI 10.1093/jac/dkm396
   BANERJEE G, 1994, BIOCHEM MED METAB B, V53, P1, DOI 10.1006/bmmb.1994.1050
   Banerjee G, 1996, J ANTIMICROB CHEMOTH, V38, P145, DOI 10.1093/jac/38.1.145
   Banerjee G, 1998, ANTIMICROB AGENTS CH, V42, P348
   Barratt G, 2007, INT J NANOMED, V2, P301
   BERMAN JD, 1986, ANTIMICROB AGENTS CH, V30, P847, DOI 10.1128/AAC.30.6.847
   Bhadra D, 2005, J DRUG DELIV SCI TEC, V15, P65, DOI 10.1016/S1773-2247(05)50008-X
   Bhavane R, 2007, INT J NANOMED, V2, P407
   Bisht V, 2005, CURR APPL PHYS, V5, P189, DOI 10.1016/j.cap.2004.06.011
   Bivas-Benita M, 2004, VACCINE, V22, P1609, DOI 10.1016/j.vaccine.2003.09.044
   de Araujo SC, 2007, INT J PHARMACEUT, V337, P307, DOI 10.1016/j.ijpharm.2007.01.009
   Chakraborty R, 1999, BIOCHEM J, V340, P393, DOI 10.1042/0264-6021:3400393
   Chambers MA, 2004, VACCINE, V22, P1063, DOI 10.1016/j.vaccine.2003.05.002
   Chimanuka B, 2002, J PHARMACEUT BIOMED, V28, P13, DOI 10.1016/S0731-7085(01)00611-2
   Chono S, 2006, J DRUG TARGET, V14, P557, DOI 10.1080/10611860600834375
   Christensen D, 2007, EXPERT REV VACCINES, V6, P785, DOI 10.1586/14760584.6.5.785
   Costa FTM, 2006, BRAZ J MED BIOL RES, V39, P1525, DOI 10.1590/S0100-879X2006001200003
   COSTA FTM, 2006, Patent No. 05063990
   COUVREUR P, 1979, J PHARM PHARMACOL, V31, P331, DOI 10.1111/j.2042-7158.1979.tb13510.x
   Couvreur P, 2006, PHARM RES-DORDR, V23, P1417, DOI 10.1007/s11095-006-0284-8
   DAS N, 1990, BIOCHEM MED METAB B, V43, P133, DOI 10.1016/0885-4505(90)90018-V
   Dasgupta D, 2002, J BIOCHEM, V132, P23, DOI 10.1093/oxfordjournals.jbchem.a003194
   Date AA, 2007, ADV DRUG DELIVER REV, V59, P505, DOI 10.1016/j.addr.2007.04.009
   de Oliveira FB, 2006, J BRAZIL CHEM SOC, V17, P1642, DOI 10.1590/S0103-50532006000800023
   De Souza A. O., 2002, ARBS Annual Review of Biomedical Sciences, V4, P53
   de Souza Ana Olivia, 1999, Revista do Instituto Adolfo Lutz, V58, P59
   De Souza AO, 2005, J CHIL CHEM SOC, V50, P591, DOI 10.4067/S0717-97072005000300012
   de Souza AO, 2004, J BRAZIL CHEM SOC, V15, P682, DOI 10.1590/S0103-50532004000500012
   de Souza AO, 2002, J ANTIMICROB CHEMOTH, V50, P629, DOI 10.1093/jac/dkf188
   De Souza AO, 1998, J ANTIMICROB CHEMOTH, V42, P407, DOI 10.1093/jac/42.3.407
   de Souza AO, 2001, EUR J MED CHEM, V36, P843, DOI 10.1016/S0223-5234(01)01263-6
   de Steenwinkel JEM, 2007, J ANTIMICROB CHEMOTH, V60, P1064, DOI 10.1093/jac/dkm341
   DeConti R, 1996, EUR J MED CHEM, V31, P915, DOI 10.1016/S0223-5234(97)89856-X
   DESOUZA AO, 2009, OPEN J PHARM S UNPUB
   Duran N, 2006, J CHEMOTHERAPY, V18, P473, DOI 10.1179/joc.2006.18.5.473
   Duran N, 2001, CRIT REV MICROBIOL, V27, P201, DOI 10.1080/20014091096747
   DURAN N, 1989, Anais da Academia Brasileira de Ciencias, V61, P31
   Duran N, 2008, ARCH PHARM RES, V31, P1509, DOI 10.1007/s12272-001-2137-7
   DURAN N, 2004, BRAZILIAN NANOBIOTEC
   Duran N, 1991, MEM I O CRUZ S1, V86, P29
   DURAN N, 2004, Patent No. 01001990
   Duran N, 2007, BIOTECHNOL APPL BIOC, V48, P127, DOI 10.1042/BA20070115
   Ehrenberg JP, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-119
   El-Ridy MS, 2007, INT J PHARMACEUT, V330, P82, DOI 10.1016/j.ijpharm.2006.09.017
   Feng ZQ, 2004, CHINESE MED J-PEKING, V117, P83
   Flaig RM, 2005, J DRUG DELIV SCI TEC, V15, P59, DOI 10.1016/S1773-2247(05)50007-8
   Fogera F, 2006, INT J PHARMACEUT, V319, P139, DOI 10.1016/j.ijpharm.2006.03.034
   Frezard F, 2005, QUIM NOVA, V28, P511, DOI 10.1590/S0100-40422005000300025
   Mosqueira VCF, 2006, J NANOSCI NANOTECHNO, V6, P3193, DOI 10.1166/jnn.2006.444
   Gabriels M, 2003, J PHARMACEUT BIOMED, V31, P655, DOI 10.1016/S0731-7085(02)00678-7
   GASPAR R, 1992, ANN TROP MED PARASIT, V86, P41, DOI 10.1080/00034983.1992.11812629
   GASPAR R, 1991, INT J PHARM, V68, P111, DOI 10.1016/0378-5173(91)90133-9
   Gill S, 2007, J BIOMED NANOTECHNOL, V3, P107, DOI 10.1166/jbn.2007.015
   Golenser J, 2006, INT J PARASITOL, V36, P1427, DOI 10.1016/j.ijpara.2006.07.011
   Gonzalez-Martin G, 2000, EUR J PHARM BIOPHARM, V49, P137, DOI 10.1016/S0939-6411(99)00076-4
   Green S, 1995, ADV EXP MED BIOL, V383, P83
   Gupta Y, 2007, J PHARM PHARMACOL, V59, P935, DOI 10.1211/jpp.59.7.0004
   GURU PY, 1989, FEBS LETT, V245, P204, DOI 10.1016/0014-5793(89)80222-4
   Heurtault B, 2001, ANN TROP MED PARASIT, V95, P529, DOI 10.1080/00034980120067226
   Hien TT, 2004, ANTIMICROB AGENTS CH, V48, P4234, DOI 10.1128/AAC.48.11.4234-4239.2004
   JOSHI M, 2005, P 1 IND JAP INT C AD, V1, P110
   KARAJGI JS, 1994, J MICROENCAPSUL, V11, P539, DOI 10.3109/02652049409034992
   Kayser O, 2005, CURR PHARM BIOTECHNO, V6, P3
   Kayser O, 2003, EXPERT OPIN INV DRUG, V12, P197, DOI 10.1517/13543784.12.2.197
   Kisich KO, 2007, INT J PHARM, V345, P154, DOI 10.1016/j.ijpharm.2007.05.062
   Kole L, 1999, J INFECT DIS, V180, P811, DOI 10.1086/314929
   Kumar PV, 2006, J DRUG TARGET, V14, P546, DOI 10.1080/10611860600825159
   LABHASETWAR VD, 1990, J CONTROL RELEASE, V12, P113, DOI 10.1016/0168-3659(90)90087-A
   Lala S, 2004, J DRUG TARGET, V12, P165, DOI 10.1080/10611860410001712696
   Lala S, 2006, J DRUG TARGET, V14, P171, DOI 10.1080/10611860600649765
   Leite EA, 2007, LIFE SCI, V80, P1327, DOI 10.1016/j.lfs.2006.12.019
   Leon LL, 2001, J ANTIMICROB CHEMOTH, V48, P449, DOI 10.1093/jac/48.3.449
   LESLIE TA, 1993, CURR OPIN INFECT DIS, V6, P658, DOI 10.1097/00001432-199310000-00008
   Longmuir KJ, 2006, PHARM RES, V23, P759, DOI 10.1007/s11095-006-9609-x
   LOPES SCP, 2006, 22 ANN M BRAZ SOC PR, P195
   Mainardes RM, 2006, J NANOSCI NANOTECHNO, V6, P3057, DOI 10.1166/jnn.2006.487
   MBELA TKM, 1992, INT J PHARMACEUT, V79, P29, DOI 10.1016/0378-5173(92)90090-O
   Meshnick SR, 2002, INT J PARASITOL, V32, P1655, DOI 10.1016/S0020-7519(02)00194-7
   Mohamed F, 2008, J PHARM SCI-US, V97, P71, DOI 10.1002/jps.21082
   Molina J, 2001, J ANTIMICROB CHEMOTH, V47, P101, DOI 10.1093/jac/47.1.101
   Morilla MJ, 2005, J CONTROL RELEASE, V103, P599, DOI 10.1016/j.jconrel.2004.12.012
   Morilla MJ, 2004, INT J PHARMACEUT, V278, P311, DOI 10.1016/j.ijpharm.2004.03.025
   Mosqueira VCF, 2004, ANTIMICROB AGENTS CH, V48, P1222, DOI 10.1128/AAC.48.4.1222-1228.2004
   Mourao SC, 2005, INT J PHARMACEUT, V295, P157, DOI 10.1016/j.ijpharm.2005.02.009
   Mukherjee S, 2004, J INFECT DIS, V189, P1024, DOI 10.1086/382048
   Muller RH, 2002, ADV DRUG DELIVER REV, V54, pS131, DOI 10.1016/S0169-409X(02)00118-7
   Muller RH, 2000, EUR J PHARM BIOPHARM, V50, P161, DOI 10.1016/S0939-6411(00)00087-4
   Nahar M, 2006, CRIT REV THER DRUG, V23, P259, DOI 10.1615/CritRevTherDrugCarrierSyst.v23.i4.10
   NEW RRC, 1980, ACTA TROP, V37, P253
   Olbrich C, 2002, J DRUG TARGET, V10, P387, DOI 10.1080/1061186021000001832
   OWAIS M, 1995, ANTIMICROB AGENTS CH, V39, P180, DOI 10.1128/AAC.39.1.180
   Owais M, 2003, J DRUG TARGET, V11, P247, DOI 10.1080/10611860310001620707
   Pal S, 2004, ANTIMICROB AGENTS CH, V48, P3591, DOI 10.1128/AAC.48.9.3591-3593.2004
   Pandey R, 2005, TUBERCULOSIS, V85, P415, DOI 10.1016/j.tube.2005.08.009
   Pandey R, 2006, J ANTIMICROB CHEMOTH, V57, P1146, DOI 10.1093/jac/dkl128
   Panyam J, 2003, ADV DRUG DELIVER REV, V55, P329, DOI 10.1016/S0169-409X(02)00228-4
   Papagiannaros A, 2005, BIOMED PHARMACOTHER, V59, P545, DOI 10.1016/j.biopha.2005.06.011
   Patel VB, 1999, PHARMAZIE, V54, P448
   Patel VB, 1999, J MICROENCAPSUL, V16, P357
   Paul M, 1998, J DRUG TARGET, V5, P481, DOI 10.3109/10611869808997874
   Pinero J, 2006, ACTA TROP, V98, P59, DOI 10.1016/j.actatropica.2006.02.001
   Postma NS, 1999, J PHARMACOL EXP THER, V288, P114
   Renslo AR, 2006, NAT CHEM BIOL, V2, P701, DOI 10.1038/nchembio837
   Richards RL, 1998, INFECT IMMUN, V66, P2859, DOI 10.1128/IAI.66.6.2859-2865.1998
   Rosada RS, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-38
   Sanchez G, 2002, BIOL RES, V35, P39, DOI 10.4067/S0716-97602002000100007
   Sarkar S, 2002, J DRUG TARGET, V10, P573, DOI 10.1080/106118021000072681
   Schettini DA, 2006, INT J PHARMACEUT, V315, P140, DOI 10.1016/j.ijpharm.2006.01.048
   Schwinte P, 2003, J INCL PHENOM MACRO, V47, P109, DOI 10.1023/B:JIPH.0000011734.89838.bc
   SESSA G, 1968, J LIPID RES, V9, P310
   Sharma A, 2004, INT J ANTIMICROB AG, V24, P599, DOI 10.1016/j.ijantimicag.2004.07.010
   Singh KK, 2008, INT J PHARMACEUT, V347, P136, DOI 10.1016/j.ijpharm.2007.06.035
   Sinha J, 2000, DRUG DELIV, V7, P209
   Soppimath KS, 2001, J CONTROL RELEASE, V70, P1, DOI 10.1016/s0168-3659(00)00339-4
   Sosunov V, 2007, J ANTIMICROB CHEMOTH, V59, P919, DOI 10.1093/jac/dkm053
   Sung JC, 2007, TRENDS BIOTECHNOL, V25, P563, DOI 10.1016/j.tibtech.2007.09.005
   Talisuna AO, 2004, CLIN MICROBIOL REV, V17, P235, DOI 10.1128/CMR.17.1.235-254.2004
   Troshkina OA, 2007, APPL BIOCHEM MICRO+, V43, P41, DOI 10.1134/S0003683807010073
   Tyagi R, 2005, J DRUG TARGET, V13, P161, DOI 10.1080/10611860500046732
   Urbina JA, 2001, CURR OPIN INFECT DIS, V14, P733, DOI 10.1097/00001432-200112000-00012
   White NJ, 2004, J CLIN INVEST, V113, P1084, DOI 10.1172/JCI21682
   Yardley V, 2000, INT J ANTIMICROB AG, V13, P243, DOI 10.1016/S0924-8579(99)00133-8
   Yardley V, 1999, AM J TROP MED HYG, V61, P193, DOI 10.4269/ajtmh.1999.61.193
   YOSHIHARA E, 1987, LIFE SCI, V40, P2153, DOI 10.1016/0024-3205(87)90005-1
   Zagana P, 2007, BIOMED PHARMACOTHER, V61, P499, DOI 10.1016/j.biopha.2007.05.005
   Zahoor A, 2005, INT J ANTIMICROB AG, V26, P298, DOI 10.1016/j.ijantimicag.2005.07.012
NR 140
TC 19
Z9 19
U1 0
U2 25
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573-4137
EI 1875-6786
J9 CURR NANOSCI
JI Curr. Nanosci.
PD NOV
PY 2009
VL 5
IS 4
BP 396
EP 408
DI 10.2174/157341309789378069
PG 13
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology;
   Materials Science, Multidisciplinary
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics; Materials Science
GA 514IB
UT WOS:000271386500002
DA 2020-12-08
ER

PT J
AU Duran, N
   Gowen, BB
   Costa, FTM
   Justo, GZ
   Brocchi, M
   Nunes, OS
   Nunes, IS
AF Duran, Nelson
   Gowen, Brian B.
   Costa, Fabio T. M.
   Justo, Giselle Z.
   Brocchi, Marcelo
   Nunes, Odilon S.
   Nunes, Iseu S.
TI A biotechnological product and its potential as a new immunomodulator
   for treatment of animal phlebovirus infection: Punta Toro virus
SO ANTIVIRAL RESEARCH
LA English
DT Article
DE Immunomodulator; Virus; Punta Toro virus; P-MAPA
ID PROTECTIVE IMMUNITY; AGGREGATED POLYMER; IN-VITRO;
   7-THIA-8-OXOGUANOSINE; PROLIFERATION; BUNYAVIRIDAE; INHIBITION;
   INDUCTION; HAMSTERS; MICE
AB Intracellular pathogens with widespread drug-resistance contribute substantially to the increasing rates in morbidity and mortality due to emerging and reemerging diseases. Thus, the development of new drugs, including those that can enhance the immune response, is urgently needed. The immunomodulator, P-MAPA, a proteinaceous aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride derived from Aspergillus oryzae, have been shown to induce antitumor activities. The ability of this compound to elicit protective immunity against viral infections has not been fully explored. Here, we report findings on the use of P-MAPA as an antiviral agent in a mouse model of acute phleboviral (Punta Toro virus) disease. A dose administered i.p. 24 h post-infectious challenge (100 mg/kg dose of P-MAPA) was remarkably effective at preventing death due to Punta Toro virus infection. This dose also reduced systemic viral burden and liver discoloration assayed on day 3 of infection. Taken together, our findings indicate that non-specific immunotherapy with P-MAPA appears to be an effective treatment for blocking Punta Toro virus-induced disease and suggest that further exploration with other viral disease models is warranted. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Duran, Nelson] Univ Estadual Campinas, Inst Quim, Biol Chem Lab, BR-13083970 Campinas, SP, Brazil.
   [Gowen, Brian B.] Utah State Univ, Inst Antiviral Res, Logan, UT 84322 USA.
   [Costa, Fabio T. M.] Univ Estadual Campinas, Inst Biol, Dept Parasitol, BR-13083970 Campinas, SP, Brazil.
   [Justo, Giselle Z.] Univ Fed Sao Paulo, Dept Biochem, Sao Paulo, Brazil.
   [Brocchi, Marcelo] Univ Estadual Campinas, Inst Biol, Genom & Mol Biol Lab, BR-13083970 Campinas, SP, Brazil.
RP Duran, N (corresponding author), Univ Estadual Campinas, Inst Quim, Biol Chem Lab, CP 6154, BR-13083970 Campinas, SP, Brazil.
EM duran@iqm.unicamp.br
RI Justo, Giselle/E-9424-2012; Costa, Fabio/E-1181-2012; Brocchi,
   Marcelo/E-3723-2012
OI Costa, Fabio/0000-0001-9969-7300; NUNES, ISEU/0000-0002-2818-3107;
   Duran, Nelson/0000-0001-8372-5143
FU Farmabrasilis (Campinas, S.P., Brazil); National Institute of Allergy
   and Infectious Diseases-USA (NIAID), Virology BranchUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [N01-AI-15435]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [N01AI015435] Funding Source: NIH RePORTER
FX Support by Farmabrasilis (Campinas, S.P., Brazil) and by National
   Institute of Allergy and Infectious Diseases-USA (NIAID) Contract
   N01-AI-15435, Virology Branch, is acknowledged.
CR *AMPL, 2008, HEM BIOPH
   ANDERSON GW, 1990, ARCH VIROL, V114, P203, DOI 10.1007/BF01310749
   Bromberg N, 2006, NITRIC OXIDE-BIOL CH, V14, pA37, DOI 10.1016/j.niox.2006.04.126
   Colic M, 2000, INT J IMMUNOPHARMACO, V22, P203, DOI 10.1016/S0192-0561(99)00077-6
   Dow SW, 1999, J IMMUNOL, V163, P1552
   DURAN N, 1990, BRAZ J MED BIOL RES, V23, P1303
   DURAN N, 1990, BRAZ J MED BIOL RES, V23, P1289
   Duran N., 1993, Drugs of the Future, V18, P327
   DURAN N, 1999, INT J MOL MED S1, V4, pS49
   DURAN N, 1999, INT J MOL MED S1, V4, P280
   *FARM, 2009, P MAPA TOX SAF
   *FARM, 2009, P MAPA CLIN TRIAL PH
   Fisher AF, 2003, AM J TROP MED HYG, V69, P269, DOI 10.4269/ajtmh.2003.69.269
   GABRIELSEN B, 1992, J NAT PROD, V55, P1569, DOI 10.1021/np50089a003
   Gowen BB, 2006, ANTIVIR RES, V69, P165, DOI 10.1016/j.antiviral.2005.12.002
   Gowen BB, 2008, ANTIVIR RES, V77, P215, DOI 10.1016/j.antiviral.2007.12.002
   Gowen BB, 2007, ANTIMICROB AGENTS CH, V51, P3168, DOI 10.1128/AAC.00356-07
   Gowen BB, 2007, J IMMUNOL, V178, P5200, DOI 10.4049/jimmunol.178.8.5200
   Gowen BB, 2006, ANTIMICROB AGENTS CH, V50, P2023, DOI 10.1128/AAC.01473-05
   Gowen BB, 2008, FASEB J, V22
   Justo GZ, 2003, IMMUNOPHARM IMMUNOT, V25, P305, DOI 10.1081/IPH-120024499
   Justo GZ, 2000, EUR J PHARMACOL, V388, P219, DOI 10.1016/S0014-2999(99)00851-1
   JUSTO GZ, 1999, INT J MOL MED S1, V49, pS49
   JUSTO GZ, 1999, INT J MOL MED S1, V49, P279
   MEAD JR, 1991, ANTIVIR RES, V15, P331, DOI 10.1016/0166-3542(91)90014-I
   MELO A, 2001, HUMAN EXP TOXICOL, V20, P38
   *NCI, 2007, PHAS 1 2 STUD 3 DIM
   Neyts J, 1996, ANTIVIR RES, V30, P125, DOI 10.1016/0166-3542(96)89697-5
   Nunes I, 2008, INT C DRUG DES DISC
   NUNES IS, 2004, Patent No. 10978683
   PILAT DY, 1987, MICROB PATHOG, V3, P409
   REED LJ, 1938, AM J HYG, V27
   Romani L, 1997, CLIN MICROBIOL REV, V10, P611, DOI 10.1128/CMR.10.4.611
   Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001
   Santos M, 2004, J CLIN ONCOL, V22, p441S
   Sellins K, 2005, MOL THER, V12, P451, DOI 10.1016/j.ymthe.2005.04.008
   SIDWELL RW, 1994, ANTIVIR RES, V25, P105, DOI 10.1016/0166-3542(94)90100-7
   SIDWELL RW, 1992, ANN NY ACAD SCI, V653, P344, DOI 10.1111/j.1749-6632.1992.tb19661.x
   SIDWELL RW, 1988, ANTIVIR RES, V10, P193, DOI 10.1016/0166-3542(88)90031-9
   SIDWELL RW, 1988, ANTIMICROB AGENTS CH, V32, P331, DOI 10.1128/AAC.32.3.331
   SMEE D F, 1991, Antiviral Chemistry and Chemotherapy, V2, P93
   Smee DF, 1990, ANTIVIR CHEM CHEMOTH, V1, P211, DOI 10.1177/095632029000100305
   SMEE DF, 1991, ANTIVIR RES, V15, P229, DOI 10.1016/0166-3542(91)90069-4
   Smee DF, 1996, CHEMOTHERAPY, V42, P286, DOI 10.1159/000239457
   Vroegop SM, 1999, INT J IMMUNOPHARMACO, V21, P391, DOI 10.1016/S0192-0561(99)00019-3
NR 45
TC 6
Z9 7
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0166-3542
EI 1872-9096
J9 ANTIVIR RES
JI Antiviral Res.
PD AUG
PY 2009
VL 83
IS 2
BP 143
EP 147
DI 10.1016/j.antiviral.2009.04.006
PG 5
WC Pharmacology & Pharmacy; Virology
SC Pharmacology & Pharmacy; Virology
GA 470SH
UT WOS:000267999700006
PM 19393266
DA 2020-12-08
ER

PT J
AU Rezende, AC
   Peroni, D
   Vieira, AS
   Rogerio, F
   Talaisys, RL
   Costa, FTM
   Langone, F
   Skaper, SD
   Negro, A
AF Rezende, Alexandre C.
   Peroni, Daniele
   Vieira, Andre S.
   Rogerio, Fabio
   Talaisys, Rafael L.
   Costa, Fabio T. M.
   Langone, Francesco
   Skaper, Stephen D.
   Negro, Alessandro
TI Ciliary neurotrophic factor fused to a protein transduction domain
   retains full neuroprotective activity in the absence of cytokine-like
   side effects
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE ciliary neurotrophic factor; fusion protein; motor neuron;
   neuroprotection; protein transduction domain; weight loss
ID AXOTOMIZED FACIAL MOTONEURONS; PROGRESSIVE MOTOR NEURONOPATHY;
   AMYOTROPHIC-LATERAL-SCLEROSIS; SCIATIC-NERVE TRANSECTION; ACUTE-PHASE
   RESPONSE; IN-VIVO; NEURONOTROPHIC FACTOR; FACTOR PREVENTS; NEONATAL RAT;
   FACTOR CNTF
AB Ciliary neurotrophic factor (CNTF) is a multifunctional cytokine that can regulate the survival and differentiation of many types of developing and adult neurons. CNTF prevents the degeneration of motor neurons after axotomy and in mouse mutant progressive motor neuronopathy, which has encouraged trials of CNTF for human motor neuron disease. Given systemically, however, CNTF causes severe side effects, including cachexia and a marked immune response, which has limited its clinical application. The present work describes a novel approach for administering recombinant human CNTF (rhCNTF) while conserving neurotrophic activity and avoiding deleterious side effects. rhCNTF was fused to a protein transduction domain derived from the human immunodeficiency virus-1 TAT (transactivator) protein. The resulting fusion protein (TAT-CNTF) crosses the plasma membrane within minutes and displays a nuclear localization. TAT-CNTF was equipotent to rhCNTF in supporting the survival of cultured chicken embryo dorsal root ganglion neurons. Local or subcutaneous administration of TAT-CNTF, like rhCNTF rescued motor neurons from death in neonatal rats subjected to sciatic nerve transection. In contrast to subcutaneous rhCNTF, which caused a 20-30% decrease in body weight in neonatal rats between postnatal days 2 and 7 together with a considerable fat mobilization in brown adipose tissue, TAT-CNTF lacked such side effects. Together, these results indicate that rhCNTF fused with the protein transduction domain/TAT retains neurotrophic activity in the absence of CNTFs cytokine-like side effects and may be a promising candidate for the treatment of motor neuron and other neurodegenerative diseases.
C1 [Peroni, Daniele; Negro, Alessandro] Univ Padua, CRIBI, Dept Vet Sci, I-35121 Padua, Italy.
   [Skaper, Stephen D.] Univ Padua, CRIBI, Dept Pharmacol, I-35121 Padua, Italy.
   [Skaper, Stephen D.] Univ Padua, CRIBI, Dept Anesthesiol, I-35121 Padua, Italy.
   [Rezende, Alexandre C.; Vieira, Andre S.; Rogerio, Fabio; Langone, Francesco] Univ Estadual Campinas, Dept Physiol & Biophys, Campinas, SP, Brazil.
   [Talaisys, Rafael L.; Costa, Fabio T. M.] Univ Estadual Campinas, Dept Microbiol & Immunol, Campinas, SP, Brazil.
RP Negro, A (corresponding author), Univ Padua, CRIBI, Dept Vet Sci, Via G Colombo 3, I-35121 Padua, Italy.
EM alessandro.negro@unipd.it
RI Costa, Fabio/E-1181-2012; Rogerio, Fabio/B-9391-2013; Vieira,
   Andre/A-3819-2013
OI Costa, Fabio/0000-0001-9969-7300; Vieira, Andre/0000-0001-5318-8957;
   Rogerio, Fabio/0000-0001-5712-7617; Peroni, Daniele/0000-0002-0862-266X
FU Foundation for the Support of Research of the State of Sao Paolo
   (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
   [05/54613-7, 04/14210-8]; Brazilian Council for Research (CnPq)National
   Council for Scientific and Technological Development (CNPq)
   [473909/2004-9]; ASV [05/57335-6]
FX This work was supported by grants from Foundation for the Support of
   Research of the State of Sao Paolo (FAPESP: Grant 05/54613-7) and
   Brazilian Council for Research (CnPq: Grant 473909/2004-9). ACR was
   supported by a scholarships from FAPESP and ASV by Grants 04/14210-8 and
   05/57335-6, respectively.
CR Alonzi T, 2001, MOL CELL NEUROSCI, V18, P270, DOI 10.1006/mcne.2001.1018
   Anderson KD, 2003, J NEUROENDOCRINOL, V15, P649, DOI 10.1046/j.1365-2826.2003.01043.x
   ARAKAWA Y, 1990, J NEUROSCI, V10, P3507
   Bajetto A, 1999, BRAIN RES, V818, P565, DOI 10.1016/S0006-8993(98)01308-0
   BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x
   BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2
   CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778
   CAZZOLA F, 1993, HYBRIDOMA, V12, P259, DOI 10.1089/hyb.1993.12.259
   CHEN H, 1995, SCIENCE, V84, P491
   CURTIS R, 1993, NATURE, V365, P253, DOI 10.1038/365253a0
   DITTRICH F, 1994, ANN NEUROL, V35, P151, DOI 10.1002/ana.410350206
   Dolcet X, 2001, MOL CELL NEUROSCI, V18, P619, DOI 10.1006/mcne.2001.1058
   Duff E, 2004, APOPTOSIS, V9, P629, DOI 10.1023/B:APPT.0000038042.31683.7b
   ERNSBERGER U, 1989, NEURON, V2, P1275, DOI 10.1016/0896-6273(89)90312-7
   Espat NJ, 1996, AM J PHYSIOL-REG I, V271, pR185
   Ettinger MP, 2003, JAMA-J AM MED ASSOC, V289, P1826, DOI 10.1001/jama.289.14.1826
   FANTUZZI G, 1995, CYTOKINE, V7, P150, DOI 10.1006/cyto.1995.1020
   GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7
   Gloaguen I, 1997, P NATL ACAD SCI USA, V94, P6456, DOI 10.1073/pnas.94.12.6456
   Gump JM, 2007, TRENDS MOL MED, V13, P443, DOI 10.1016/j.molmed.2007.08.002
   Haas CA, 1999, J NEUROBIOL, V41, P559, DOI 10.1002/(SICI)1097-4695(199912)41:4<559::AID-NEU11>3.0.CO;2-A
   HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777
   Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297
   Henderson JT, 1996, CYTOKINE, V8, P784, DOI 10.1006/cyto.1996.0104
   HENDERSON JT, 1994, J CLIN INVEST, V93, P2632, DOI 10.1172/JCI117276
   Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1
   Kaur N, 2002, CELL SIGNAL, V14, P419, DOI 10.1016/S0898-6568(01)00280-7
   Kirsch M, 2003, MOL CELL NEUROSCI, V24, P130, DOI 10.1016/S1044-7431(03)00130-1
   KWON YW, 1994, NEUROREPORT, V5, P789, DOI 10.1097/00001756-199403000-00013
   Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298
   Lelievre E, 2001, J BIOL CHEM, V276, P22476, DOI 10.1074/jbc.M101681200
   Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909
   Liu QS, 2007, EUR J PHARMACOL, V563, P77, DOI 10.1016/j.ejphar.2007.02.034
   LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320
   MCDONALD NQ, 1995, EMBO J, V14, P2689, DOI 10.1002/j.1460-2075.1995.tb07269.x
   Miller RG, 1996, NEUROLOGY, V47, P1329, DOI 10.1212/WNL.47.5.1329
   Miller RG, 1996, ANN NEUROL, V39, P256, DOI 10.1002/ana.410390215
   Negro A, 1997, PROTEIN ENG, V10, P1077, DOI 10.1093/protein/10.9.1077
   NEGRO A, 1991, J NEUROSCI RES, V29, P251, DOI 10.1002/jnr.490290216
   Oliveira ALR, 2002, J COMP NEUROL, V447, P381, DOI 10.1002/cne.10248
   OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743
   Ott V, 2004, MOL CELL ENDOCRINOL, V224, P21, DOI 10.1016/j.mce.2004.07.006
   Pan WH, 1999, NEUROSCI LETT, V263, P69, DOI 10.1016/S0304-3940(99)00083-X
   PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776
   Peroni D, 2007, NEUROSCI LETT, V421, P110, DOI 10.1016/j.neulet.2007.05.046
   POLLIN MM, 1991, DEVELOPMENT, V112, P83
   Rezende ACS, 2008, BRAZ J MED BIOL RES, V41, P1024, DOI 10.1590/S0100-879X2008005000052
   Rogerio F, 2002, BRAIN RES, V926, P33, DOI 10.1016/S0006-8993(01)03286-3
   SAGOT Y, 1995, EUR J NEUROSCI, V7, P1313, DOI 10.1111/j.1460-9568.1995.tb01122.x
   SCHMALBRUCH H, 1987, ANAT REC, V219, P323, DOI 10.1002/ar.1092190314
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0
   SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0
   SHAPIRO L, 1993, P NATL ACAD SCI USA, V90, P8614, DOI 10.1073/pnas.90.18.8614
   SKAPER SD, 1990, METHODS NEUROSCIENCE, V2, P17
   STOCKLI KA, 1991, J CELL BIOL, V115, P447, DOI 10.1083/jcb.115.2.447
   TAGA T, 1992, FASEB J, V6, P3387
   Turner MR, 2001, SEMIN NEUROL, V21, P167, DOI 10.1055/s-2001-15262
   Watt JA, 2006, EXP NEUROL, V197, P206, DOI 10.1016/j.expneurol.2005.09.009
   Watt MJ, 2006, NAT MED, V12, P541, DOI 10.1038/nm1383
   Xu B, 1998, ENDOCRINOLOGY, V139, P466, DOI 10.1210/en.139.2.466
   ZHANG F, 1995, J NEUROSCI RES, V40, P564, DOI 10.1002/jnr.490400416
   Zvonic S, 2005, J BIOL CHEM, V280, P33856, DOI 10.1074/jbc.M508020200
   Zvonic S, 2003, BIOCHEM BIOPH RES CO, V302, P359, DOI 10.1016/S0006-291X(03)00179-7
   Zvonic S, 2003, J BIOL CHEM, V278, P2228, DOI 10.1074/jbc.M205871200
NR 65
TC 6
Z9 7
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD JUN
PY 2009
VL 109
IS 6
BP 1680
EP 1690
DI 10.1111/j.1471-4159.2009.06091.x
PG 11
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 448ND
UT WOS:000266268400011
PM 19457136
OA Bronze
DA 2020-12-08
ER

PT J
AU Lopes, SCP
   Blanco, YC
   Justo, GZ
   Nogueira, PA
   Rodrigues, FLS
   Goelnitz, U
   Wunderlich, G
   Facchini, G
   Brocchi, M
   Duran, N
   Costa, FTM
AF Lopes, Stefanie C. P.
   Blanco, Yara C.
   Justo, Giselle Z.
   Nogueira, Paulo A.
   Rodrigues, Francisco L. S.
   Goelnitz, Uta
   Wunderlich, Gerhard
   Facchini, Gustavo
   Brocchi, Marcelo
   Duran, Nelson
   Costa, Fabio T. M.
TI Violacein Extracted from Chromobacterium violaceum Inhibits Plasmodium
   Growth In Vitro and In Vivo
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID CANCER CELLS; FALCIPARUM; APOPTOSIS; CYTOTOXICITY; MALARIA
AB Violacein is a violet pigment extracted from the gram-negative bacterium Chromobacterium violaceum. It presents bactericidal, tumoricidal, trypanocidal, and antileishmanial activities. We show that micromolar concentrations efficiently killed chloroquine-sensitive and -resistant Plasmodium falciparum strains in vitro; inhibited parasitemia in vivo, even after parasite establishment; and protected Plasmodium chabaudi chabaudi-infected mice from a lethal challenge.
C1 [Costa, Fabio T. M.] Univ Estadual Campinas, UNICAMP, Dept Parasitol, Inst Biol, BR-13083970 Campinas, SP, Brazil.
   [Lopes, Stefanie C. P.; Blanco, Yara C.; Brocchi, Marcelo; Costa, Fabio T. M.] Univ Estadual Campinas, UNICAMP, Dept Microbiol & Imunol, Inst Biol, BR-13083970 Campinas, SP, Brazil.
   [Justo, Giselle Z.] Univ Fed Sao Paulo, UNIFESP, Dept Bioquim, BR-04044020 Sao Paulo, Brazil.
   [Nogueira, Paulo A.; Rodrigues, Francisco L. S.] CEPEM, IPEPATRO, BR-78900970 Porto Velho, RO, Brazil.
   [Goelnitz, Uta; Wunderlich, Gerhard] Univ Sao Paulo, Dept Parasitol, ICB2, Sao Paulo, Brazil.
   [Facchini, Gustavo] Univ Estadual Campinas, Dept Fisiol & Biofis, Inst Biol, BR-13083970 Campinas, SP, Brazil.
   [Duran, Nelson] Univ Estadual Campinas, Lab Quim Biol, Inst Quim, BR-13083970 Campinas, SP, Brazil.
RP Costa, FTM (corresponding author), Univ Estadual Campinas, UNICAMP, Dept Parasitol, Inst Biol, POB 6109, BR-13083970 Campinas, SP, Brazil.
EM costaftm@unicamp.br
RI Lopes, Stefanie/A-8314-2012; Costa, Fabio/E-1181-2012; Wunderlich,
   Gerhard/G-8245-2012; Nogueira, Paulo/AAK-8822-2020; Justo,
   Giselle/E-9424-2012; Brocchi, Marcelo/E-3723-2012
OI Costa, Fabio/0000-0001-9969-7300; Wunderlich,
   Gerhard/0000-0003-1724-0337; Lopes, Stefanie/0000-0002-6981-2192; Duran,
   Nelson/0000-0001-8372-5143
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2004/00638-6];
   Conselho Nacional de Desenvolvimento Cientfico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [470587/2006-7]; Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior (CAPES)CAPES
FX This work was supported by the Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo (FAPESP; grant 2004/00638-6) and the Conselho Nacional de
   Desenvolvimento Cientfico e Tecnologico (CNPq; grant 470587/2006-7). S.
   C. P. L. and Y.C.B. were supported by the Coordenacao de Aperfeicoamento
   de Pessoal de Nivel Superior (CAPES), and U. G. and G. F. were sponsored
   by FAPESP and CNPq fellowships, respectively. F. T. M. C., M. B., and G.
   W. are CNPq fellows. We thank Hernando Del Portillo (Department of
   Parasitology, ICB, USP, Sao Paulo, SP, Brazil) and Maria Regina
   D'Imperio Lima (Department of Immunology, ICB, USP, Sao Paulo, SP,
   Brazil) for kindly providing P. chabaudi chabaudi strains AS and AJ,
   respectively, and Lindsay Ann Pirrit for revising the English. Many
   thanks to Carmen L. Lopes and Zeci S. Costa (in memoriam).
CR de Carvalho DD, 2006, TOXICOL IN VITRO, V20, P1514, DOI 10.1016/j.tiv.2006.06.007
   DISANTI SM, 1987, REV INST MED TROP SP, V29, P142, DOI 10.1590/S0036-46651987000300005
   Duran N, 2001, CRIT REV MICROBIOL, V27, P201, DOI 10.1080/20014091096747
   DURAN N, 1989, Anais da Academia Brasileira de Ciencias, V61, P31
   Duran N, 2007, BIOTECHNOL APPL BIOC, V48, P127, DOI 10.1042/BA20070115
   FERNANDEZ V, 2004, METHODS MALARIA RES, P24
   Ferreira CV, 2004, BLOOD, V104, P1459, DOI 10.1182/blood-2004-02-0594
   Kodach LL, 2006, CARCINOGENESIS, V27, P508, DOI 10.1093/carcin/bgi307
   Leon LL, 2001, J ANTIMICROB CHEMOTH, V48, P449, DOI 10.1093/jac/48.3.449
   Melo PD, 2000, IN VITRO CELL DEV-AN, V36, P539
   Melo PS, 2003, TOXICOLOGY, V186, P217, DOI 10.1016/S0300-483X(02)00751-5
   Rettori D, 1998, WORLD J MICROB BIOT, V14, P685, DOI 10.1023/A:1008809504504
   Schmidt BA, 2004, METHODS MALARIA RES, P87
   Snounou G, 2005, TRENDS PARASITOL, V21, P456, DOI 10.1016/j.pt.2005.08.002
   Talisuna AO, 2007, AM J TROP MED HYG, V77, P170
   WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700
NR 16
TC 55
Z9 57
U1 1
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD MAY 1
PY 2009
VL 53
IS 5
BP 2149
EP 2152
DI 10.1128/AAC.00693-08
PG 4
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA 438AQ
UT WOS:000265528700060
PM 19273690
OA Green Published, Other Gold
DA 2020-12-08
ER

PT J
AU Belnoue, E
   Voza, T
   Costa, FTM
   Gruner, AC
   Mauduit, M
   Rosa, DS
   Depinay, N
   Kayibanda, M
   Vigario, AM
   Mazier, D
   Snounou, G
   Sinnis, P
   Renia, L
AF Belnoue, Elodie
   Voza, Tatiana
   Costa, Fabio T. M.
   Gruener, Anne Charlotte
   Mauduit, Marjorie
   Rosa, Daniela Santoro
   Depinay, Nadya
   Kayibanda, Michele
   Vigario, Ana Margarida
   Mazier, Dominique
   Snounou, Georges
   Sinnis, Photini
   Renia, Laurent
TI Vaccination with Live Plasmodium yoelii Blood Stage Parasites under
   Chloroquine Cover Induces Cross-Stage Immunity against Malaria Liver
   Stage
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; LIFE-CYCLE; PROTECTIVE IMMUNITY;
   INTERFERON-GAMMA; FALCIPARUM SPOROZOITES; PREERYTHROCYTIC STAGES;
   HEPATIC STAGES; T-CELLS; IN-VIVO; MICE
AB Immunity to malaria has long been thought to be stage-specific. In this study we show that immunization of BALB/c mice with live erythrocytes infected with nonlethal strains of Plasmodium yoelii under curative chloroquine cover conferred protection not only against challenge by blood stage parasites but also against sporozoite challenge. This cross-stage protection was dose-dependent and long lasting. CD4(+) and CD8(+) T cells inhibited malaria liver but not blood stage. Their effect was mediated partially by IFN-gamma, and was completely dependent of NO. Abs against both pre-erythrocytic and blood parasites were elicited and were essential for protection against blood stage and liver stage parasites. Our results suggest that Ags shared by liver and blood stage parasites can be the foundation for a malaria vaccine that would provide effective protection against both pre-erythrocytic and erythrocytic asexual parasites found in the mammalian host. The Journal of Immunology, 2008, 181: 8552-8558.
C1 [Gruener, Anne Charlotte; Renia, Laurent] Agcy Sci Technol & Res, Singapore Immunol Network, Singapore 138648, Singapore.
   [Belnoue, Elodie; Costa, Fabio T. M.; Gruener, Anne Charlotte; Mauduit, Marjorie; Rosa, Daniela Santoro; Depinay, Nadya; Kayibanda, Michele; Vigario, Ana Margarida; Renia, Laurent] Univ Paris 05, CNRS, Dept Immunol, Inst Cochin,Unite Mixte Rech 8104, Paris, France.
   [Belnoue, Elodie; Costa, Fabio T. M.; Gruener, Anne Charlotte; Mauduit, Marjorie; Rosa, Daniela Santoro; Depinay, Nadya; Kayibanda, Michele; Vigario, Ana Margarida; Renia, Laurent] INSERM, U567, F-75654 Paris 13, France.
   [Mazier, Dominique; Snounou, Georges] INSERM, U511, F-75654 Paris 13, France.
   [Snounou, Georges; Sinnis, Photini] Univ Paris 06, Fac Med Pitie Salpetriere, F-75252 Paris 05, France.
   [Mazier, Dominique] Ctr Hosp Univ Pitie Salpetriere, AP HP, Paris, France.
   [Voza, Tatiana; Snounou, Georges] Museum Natl Hist Nat, Inst Fed Res 101, CNRS,Unite Sci Museum 0307, Equipe Parasitol Comparee & Modeles Expt, F-75231 Paris, France.
   [Voza, Tatiana; Sinnis, Photini] NYU, Sch Med, Dept Med Parasitol, New York, NY 10010 USA.
   [Costa, Fabio T. M.] Univ Estadual Campinas, Dept Parasitol, Campinas, SP, Brazil.
RP Renia, L (corresponding author), Agcy Sci Technol & Res, Singapore Immunol Network, Immunos 3-15,8A Biomed Grove, Singapore 138648, Singapore.
EM renia_laurent@immunol.a-star.edu.sg
RI Costa, Fabio/E-1181-2012; , RENIA/E-2117-2011; Rosa, Daniela
   S/D-2190-2012; Gruner, Anne Charlotte/C-1841-2012; Snounou,
   Georges/F-3352-2011
OI Costa, Fabio/0000-0001-9969-7300; , RENIA/0000-0003-0349-1557; Rosa,
   Daniela S/0000-0003-4536-891X; Snounou, Georges/0000-0002-6133-6398;
   Vigario, Ana Margarida/0000-0001-5679-1196
FU Institut National de la Sante et de In Recherche Medicale; Coordination
   for the Improvement of Higher Education Personnel (CAPES) Foundation
   BrazilCAPES [BEX 0446/98-0]; Minisetre de la Recherche et de la
   Technologie France; Junta Nacional de Investigacao Cientifica e
   Tecnologica Portugal [BD/9255/96]; National Institutes of HealthUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [T32 A107180, R01 AI056840]; NATIONAL INSTITUTE OF
   ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Allergy & Infectious Diseases (NIAID) [R01AI056840,
   T32AI007180, T32AI007180, T32AI007180, T32AI007180, T32AI007180,
   T32AI007180, T32AI007180, T32AI007180, T32AI007180, R01AI056840,
   R01AI056840, T32AI007180, T32AI007180, T32AI007180, T32AI007180,
   T32AI007180, T32AI007180, R01AI056840, T32AI007180, R01AI056840,
   T32AI007180, T32AI007180, T32AI007180, T32AI007180, R01AI056840,
   R01AI056840, T32AI007180, R01AI056840, R01AI056840, T32AI007180,
   T32AI007180, T32AI007180, T32AI007180, T32AI007180, T32AI007180,
   R01AI056840, T32AI007180, R01AI056840, T32AI007180, T32AI007180,
   T32AI007180, T32AI007180, T32AI007180] Funding Source: NIH RePORTER
FX This work was supported by Institut National de la Sante et de In
   Recherche Medicale. F.T.M.C. was supported by fellowship BEX 0446/98-0
   from Coordination for the Improvement of Higher Education Personnel
   (CAPES) Foundation Brazil. E.B. was supported by a fellowship from
   Minisetre de la Recherche et de la Technologie France. A.M.V. was
   supported by Fellowship BD/9255/96 from Junta Nacional de Investigacao
   Cientifica e Tecnologica Portugal. T.V. was supported by Training Grant
   T32 A107180 and P.S. by Grant R01 AI056840 from the National Institutes
   of Health.
CR Belnoue E, 2004, J IMMUNOL, V172, P2487, DOI 10.4049/jimmunol.172.4.2487
   BOYD MARK F., 1936, AMER JOUR TROP MED, V16, P317
   CAMBIE G, 1994, PARASITE, V1, P219, DOI 10.1051/parasite/1994013219
   CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229
   Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107
   Franke-Fayard B, 2004, MOL BIOCHEM PARASIT, V137, P23, DOI 10.1016/j.molbiopara.2004.04.007
   Gruner AC, 2005, MOL BIOCHEM PARASIT, V142, P184, DOI 10.1016/j.molbiopara.2005.03.019
   Gruner AC, 2003, TRENDS PARASITOL, V19, P74, DOI 10.1016/S1471-4922(02)00067-3
   Gruner AC, 2001, MOL BIOCHEM PARASIT, V112, P253, DOI 10.1016/S0166-6851(00)00373-X
   Gruner AC, 2001, J INFECT DIS, V184, P892, DOI 10.1086/323394
   Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717
   Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409
   Hulier E, 1996, MOL BIOCHEM PARASIT, V77, P127, DOI 10.1016/0166-6851(96)02584-4
   Kaiser K, 2004, MOL MICROBIOL, V51, P1221, DOI 10.1046/j.1365-2958.2003.03909.x
   Langhorne J, 1998, P NATL ACAD SCI USA, V95, P1730, DOI 10.1073/pnas.95.4.1730
   Marussig M, 1997, INT IMMUNOL, V9, P1817, DOI 10.1093/intimm/9.12.1817
   MELLOUK S, 1991, J IMMUNOL, V146, P3971
   Mueller AK, 2005, NATURE, V433, P164, DOI 10.1038/nature03188
   Mueller AK, 2005, P NATL ACAD SCI USA, V102, P3022, DOI 10.1073/pnas.0408442102
   Mueller AK, 2007, AM J PATHOL, V171, P107, DOI 10.2353/ajpath.2007.060792
   NUDELMAN S, 1989, J IMMUNOL, V143, P996
   NUSSENZWEIG RS, 1969, NATURE, V222, P488, DOI 10.1038/222488a0
   NUSSENZWEIG RS, 1972, AM J TROP MED HYG, V21, P722, DOI 10.4269/ajtmh.1972.21.722
   NUSSLER A, 1991, INT IMMUNOL, V3, P317, DOI 10.1093/intimm/3.4.317
   NUSSLER A, 1991, EUR J IMMUNOL, V21, P227, DOI 10.1002/eji.1830210134
   NUSSLER AK, 1993, EUR J IMMUNOL, V23, P882, DOI 10.1002/eji.1830230417
   OCAGNAMORGNER C, 2003, J EXP MED, V197, P143
   ORJIH A, 1987, CLIN EXP IMMUNOL, V61, P67
   Owusu-Agyei S, 2001, AM J TROP MED HYG, V65, P197, DOI 10.4269/ajtmh.2001.65.197
   PIED S, 1992, J IMMUNOL, V148, P197
   PIED S, 1991, PARASITE IMMUNOL, V13, P211, DOI 10.1111/j.1365-3024.1991.tb00276.x
   Pombo DJ, 2002, LANCET, V360, P610, DOI 10.1016/S0140-6736(02)09784-2
   Preiser P, 2004, INFECT IMMUN, V72, P3604, DOI 10.1128/IAI.72.6.3604-3608.2004
   Preiser PR, 2002, SCIENCE, V295, P342, DOI 10.1126/science.1064938
   RENIA L, 1990, EUR J IMMUNOL, V20, P1445, DOI 10.1002/eji.1830200706
   Renia L, 1997, INFECT IMMUN, V65, P4419
   Renia L, 2006, EXPERT REV VACCINES, V5, P473, DOI 10.1586/14760584.5.4.473
   RICHARDS WHG, 1977, PARASITOLOGY, V74, P191, DOI 10.1017/S0031182000047685
   ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0
   Sacci JB, 2005, MOL BIOCHEM PARASIT, V142, P177, DOI 10.1016/j.molbiopara.2005.03.018
   Sagara I, 2002, AM J TROP MED HYG, V66, P310, DOI 10.4269/ajtmh.2002.66.310
   SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P10700, DOI 10.1073/pnas.91.22.10700
   SEGUIN MC, 1994, J EXP MED, V180, P353, DOI 10.1084/jem.180.1.353
   Silvie O, 2004, J BIOL CHEM, V279, P9490, DOI 10.1074/jbc.M311331200
   SKARLATOS S, 1995, J DRUG TARGET, V3, P9, DOI 10.3109/10611869509015927
   SZABO C, 1994, P NATL ACAD SCI USA, V91, P12472, DOI 10.1073/pnas.91.26.12472
   SZARFMAN A, 1988, PARASITE IMMUNOL, V10, P339, DOI 10.1111/j.1365-3024.1988.tb00225.x
   Tarun AS, 2008, P NATL ACAD SCI USA, V105, P305, DOI 10.1073/pnas.0710780104
   Ting LM, 2008, NAT MED, V14, P954, DOI 10.1038/nm.1867
   van Dijk MR, 2005, P NATL ACAD SCI USA, V102, P12194, DOI 10.1073/pnas.0500925102
   VANDERHEYDE HC, 1994, J IMMUNOL, V152, P4557
   Voza T, 2005, INFECT IMMUN, V73, P4777, DOI 10.1128/IAI.73.8.4777-4786.2005
   Wang QA, 2004, MOL BIOCHEM PARASIT, V137, P161, DOI 10.1016/j.molbiopara.2004.06.001
   WYSOCKA M, 1995, EUR J IMMUNOL, V25, P672, DOI 10.1002/eji.1830250307
   Yamauchi LM, 2007, CELL MICROBIOL, V9, P1215, DOI 10.1111/j.1462-5822.2006.00861.x
NR 55
TC 67
Z9 67
U1 0
U2 5
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD DEC 15
PY 2008
VL 181
IS 12
BP 8552
EP 8558
DI 10.4049/jimmunol.181.12.8552
PG 7
WC Immunology
SC Immunology
GA 382CQ
UT WOS:000261583000044
PM 19050274
OA Green Accepted, Bronze
DA 2020-12-08
ER

PT J
AU Murad, AM
   Noronha, EF
   Miller, RNG
   Costa, FT
   Pereira, CD
   Mehta, A
   Caldas, RA
   Franco, OL
AF Murad, Andre M.
   Noronha, Eliane F.
   Miller, Robert N. G.
   Costa, Fabio T.
   Pereira, Caroline D.
   Mehta, Angela
   Caldas, Ruy A.
   Franco, Octavio L.
TI Proteomic analysis of Metarhizium anisopliae secretion in the presence
   of the insect pest Callosobruchus maculatus
SO MICROBIOLOGY-SGM
LA English
DT Article
ID TRUNCATUS HORN COLEOPTERA; ENTOMOPATHOGENIC FUNGI; BEAUVERIA-BASSIANA;
   BIOLOGICAL-CONTROL; SACCHAROMYCES-CEREVISIAE; TRICHODERMA-ATROVIRIDE;
   ASPERGILLUS-NIGER; PROTEIN; GENE; COWPEA
AB Crop improvement in agriculture generally focuses on yield, seed quality and nutritional characteristics, as opposed to resistance to biotic stresses. Consequently, natural antifeedant toxins are often rare in seed material, with commercial crops being prone to insect pest predation. In the specific case of cowpea (Vigna unguiculata), smallholder cropping is affected by insect pests that reproduce inside the stored seeds. Entomopathogenic organisms can offer an alternative to conventional pesticides for pest control, producing hydrolases that degrade insect exoskeleton. In this study, protein secretions of the ascomycete Metarhizium anisopliae, which conferred bioinsecticidal activity against Callosobruchus maculatus, were characterized via 2D electrophoresis and mass spectrometry. Proteases, reductases and acetyltransferase enzymes were detected. These may be involved in degradation and nutrient uptake from dehydrated C. maculatus. Proteins identified in this work allowed description of metabolic pathways. Their potential applications in biotechnology include both novel compound development and production of genetically modified plants resistant to insect pests.
C1 [Murad, Andre M.; Noronha, Eliane F.; Miller, Robert N. G.; Costa, Fabio T.; Pereira, Caroline D.; Caldas, Ruy A.; Franco, Octavio L.] Posgrad Ciencias Genom & Biotecnol UCB, Ctr Anal Prote & Bioquim, Brasilia, DF, Brazil.
   [Mehta, Angela] Embrapa Recursos Genet & Biotecnol, Brasilia, DF, Brazil.
   [Franco, Octavio L.] Univ Fed Juiz de Fora, Juiz De Fora, MG, Brazil.
RP Franco, OL (corresponding author), Posgrad Ciencias Genom & Biotecnol UCB, Ctr Anal Prote & Bioquim, Brasilia, DF, Brazil.
EM ocfranco@pos.ucb.br
RI Franco, Octavio L/T-3020-2017; Costa, Fabio/E-1181-2012; Miller, Robert
   N G/C-6272-2013; , Andre/S-7486-2019; Mehta, Angela/AAD-1197-2019
OI Costa, Fabio/0000-0001-9969-7300; Miller, Robert N
   G/0000-0002-5798-4552; , Andre/0000-0002-7055-9462; Mehta,
   Angela/0000-0002-5348-5123; Franco, Octavio/0000-0001-9546-0525
FU Fundacao Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES; Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq)National Council for Scientific and Technological
   Development (CNPq); Fundacao de Amparo a Pesquisa do Estado de Minas
   Gerais (FAPEMIG)Minas Gerais State Research Foundation (FAPEMIG);
   Universidade Catolica de Brasilia (UCB)UCB Pharma SA
FX The Fundacao Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq), Fundacao de Amparo a Pesquisa do Estado de Minas Gerais
   (FAPEMIG) and Universidade Catolica de Brasilia (UCB) supported this
   work. The authors thank Dr Carlos Bloch Jr and Dr Luciano Paulino Silva
   at Embrapa Recursos Geneticos e Biotecnologia for provision and
   coordination of mass spectrometry activities.
CR Adane K, 1996, J STORED PROD RES, V32, P105, DOI 10.1016/0022-474X(96)00009-4
   Albrecht EB, 2000, MOL BIOL CELL, V11, P873, DOI 10.1091/mbc.11.3.873
   Banks IR, 2005, EUKARYOT CELL, V4, P1902, DOI 10.1128/EC.4.11.1902-1912.2005
   Becker Norbert, 1998, Israel Journal of Entomology, V32, P63
   BIDOCHKA MJ, 1994, J INVERTEBR PATHOL, V63, P7, DOI 10.1006/jipa.1994.1002
   Bourassa C, 2001, J INVERTEBR PATHOL, V77, P75, DOI 10.1006/jipa.2000.4986
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brunner K, 2005, APPL ENVIRON MICROB, V71, P3959, DOI 10.1128/AEM.71.7.3959-3965.2005
   Carberry S, 2006, BIOCHEM BIOPH RES CO, V341, P1096, DOI 10.1016/j.bbrc.2006.01.078
   Cherry AJ, 2005, J STORED PROD RES, V41, P295, DOI 10.1016/j.jspr.2004.04.002
   CREDLAND PF, 1986, ECOL ENTOMOL, V11, P41, DOI 10.1111/j.1365-2311.1986.tb00278.x
   CRONIN VB, 1991, BIOCHEM J, V277, P335, DOI 10.1042/bj2770335
   Delincee H, 1998, RADIAT PHYS CHEM, V52, P43, DOI 10.1016/S0969-806X(98)00071-1
   DESTRUELLE M, 1994, MOL CELL BIOL, V14, P2740, DOI 10.1128/MCB.14.4.2740
   EINERHAND AWC, 1991, EUR J BIOCHEM, V200, P113, DOI 10.1111/j.1432-1033.1991.tb21056.x
   Galvan TL, 2006, PEST MANAG SCI, V62, P797, DOI 10.1002/ps.1223
   GERMANN UA, 1988, J BIOL CHEM, V263, P885
   GilNavarro I, 1997, J BACTERIOL, V179, P4992, DOI 10.1128/jb.179.16.4992-4999.1997
   GORG A, 1988, ELECTROPHORESIS, V9, P531, DOI 10.1002/elps.1150090913
   Grinyer J, 2005, CURR GENET, V47, P381, DOI 10.1007/s00294-005-0575-3
   Grinyer J, 2004, CURR GENET, V45, P163, DOI 10.1007/s00294-003-0474-4
   HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011
   Hess DC, 2006, PLOS BIOL, V4, P2012, DOI 10.1371/journal.pbio.0040351
   Jackai LEN, 1997, ADV COWPEA RES, P240
   Jenkins J, 1996, ACTA CRYSTALLOGR D, V52, P402, DOI 10.1107/S0907444995012698
   Kang SC, 1999, J INVERTEBR PATHOL, V73, P276, DOI 10.1006/jipa.1999.4843
   Kassa A, 2002, BIOCONTROL SCI TECHN, V12, P727, DOI 10.1080/0958315021000039905
   KAYA HK, 1993, ANNU REV ENTOMOL, V38, P181, DOI 10.1146/annurev.en.38.010193.001145
   Kneip C, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-55
   Kolkman A, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100069
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEGNER EF, 1995, J VECTOR ECOL, V20, P59
   Lesage G, 2006, MICROBIOL MOL BIOL R, V70, P317, DOI 10.1128/MMBR.00038-05
   Lomako J, 2004, BBA-GEN SUBJECTS, V1673, P45, DOI 10.1016/j.bbagen.2004.03.017
   Lorito M, 1998, P NATL ACAD SCI USA, V95, P7860, DOI 10.1073/pnas.95.14.7860
   MARZLUF GA, 1981, MICROBIOL REV, V45, P437, DOI 10.1128/MMBR.45.3.437-461.1981
   Murad AM, 2006, COMP BIOCHEM PHYS C, V142, P365, DOI 10.1016/j.cbpc.2005.11.016
   Murad AM, 2007, COMP BIOCHEM PHYS C, V145, P333, DOI 10.1016/j.cbpc.2007.01.010
   Nahar P, 2004, J INVERTEBR PATHOL, V85, P80, DOI 10.1016/j.jip.2003.11.006
   Rice WC, 1999, J ECON ENTOMOL, V92, P691, DOI 10.1093/jee/92.3.691
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   Sorensen TK, 2003, BBA-GEN SUBJECTS, V1619, P89, DOI 10.1016/S0304-4165(02)00445-2
   StLeger RJ, 1996, APPL ENVIRON MICROB, V62, P1257, DOI 10.1128/AEM.62.4.1257-1264.1996
   STLEGER RJ, 1987, ARCH BIOCHEM BIOPHYS, V253, P221
   STLEGER RJ, 1986, J GEN MICROBIOL, V132, P1509
   STLEGER RJ, 1994, ARCH BIOCHEM BIOPHYS, V313, P1, DOI 10.1006/abbi.1994.1350
   Suarez MB, 2005, FUNGAL GENET BIOL, V42, P924, DOI 10.1016/j.fgb.2005.08.002
NR 47
TC 22
Z9 22
U1 1
U2 15
PU SOC GENERAL MICROBIOLOGY
PI READING
PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG,
   BERKS, ENGLAND
SN 1350-0872
J9 MICROBIOL-SGM
JI Microbiology-(UK)
PD DEC
PY 2008
VL 154
BP 3766
EP 3774
DI 10.1099/mic.0.2008/022913-0
PN 12
PG 9
WC Microbiology
SC Microbiology
GA 387TO
UT WOS:000261974700016
PM 19047744
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Bargieri, DY
   Rosa, DS
   Braga, CJM
   Carvalho, BO
   Costa, FTM
   Espindola, NM
   Vaz, AJ
   Soares, IS
   Ferreira, LCS
   Rodrigues, MM
AF Bargieri, Daniel Y.
   Rosa, Daniela S.
   Braga, Catarina J. M.
   Carvalho, Bruna O.
   Costa, Fabio T. M.
   Espindola, Noeli Maria
   Vaz, Adelaide Jose
   Soares, Irene S.
   Ferreira, Luis C. S.
   Rodrigues, Mauricio M.
TI New malaria vaccine candidates based on the Plasmodium vivax Merozoite
   Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC
   flagellin
SO VACCINE
LA English
DT Article
DE P vivax; Vaccine; Flagellin; FliC; TLR5; CpG ODN; TLR9
ID TRANSMISSION-BLOCKING ACTIVITY; DUFFY-BINDING-PROTEIN; CARBOXYL-TERMINAL
   FRAGMENT; RECOMBINANT PROTEIN; AOTUS MONKEYS; PROTECTIVE IMMUNITY;
   ESCHERICHIA-COLI; ANTIBODY TITER; ADJUVANT ACTIVITY; FUSION PROTEINS
AB The present study evaluated the immunogenicity of new malaria vaccine formulations based on the 19 kDa C-terminal fragment of Plasmodium vivax Merozoite Surface Protein-1 (MSP1(19)) and the Salmonella enterica serovar Typhimurium flagellin (FIiC), a Toll-like receptor 5 (TLR5) agonist. FHC was used as an adjuvant either admixed or genetically linked to the P. vivax MSP1(19) and administered to C57BL/6 mice via parenteral (s.c.) or mucosal (i.n.) routes. The recombinant fusion protein preserved MSP1(19) epitopes recognized by Sera collected from P. vivax infected humans and TLR5 agonist activity. Mice parenterally immunized with recombinant P vivax MSPI 19 in the presence of FliC, either admixed or genetically linked, elicited strong and long-lasting MSP1 (19)-specific systemic antibody responses with a prevailing IgG1 subclass response. Incorporation of another TLR agonist, CpG ODN 1826, resulted in a more balanced response, as evaluated by the IgG1/IgG2c ratio, and higher cell-mediated immune response measured by interferon-gamma secretion. Finally, we show that MSPI 19-specific antibodies recognized the native protein expressed on the surface of P. vivax parasites harvested from infected humans. The present report proposes a new class of malaria vaccine formulation based on the use of malaria antigens and the innate immunity agonist FliC. it contains intrinsic adjuvant properties and enhanced ability to induce specific humoral and cellular immune responses when administered alone or in combination with other adjuvants. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Bargieri, Daniel Y.; Rosa, Daniela S.; Rodrigues, Mauricio M.] Univ Fed Sao Paulo, Escola Paulista Med, CINTERGEN, BR-04044010 Sao Paulo, Brazil.
   [Bargieri, Daniel Y.; Rodrigues, Mauricio M.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, BR-04044010 Sao Paulo, Brazil.
   [Braga, Catarina J. M.; Ferreira, Luis C. S.] Univ Sao Paulo, Inst Ciencias Biomed, Dept Microbiol, BR-05508900 Sao Paulo, Brazil.
   [Carvalho, Bruna O.; Costa, Fabio T. M.] Univ Estadual Campinas, Inst Biol, Dept Parasitol, BR-13083970 Campinas, SP, Brazil.
   [Espindola, Noeli Maria; Vaz, Adelaide Jose; Soares, Irene S.] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, BR-05508900 Sao Paulo, Brazil.
RP Rodrigues, MM (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, CINTERGEN, Rua Mirassol 207, BR-04044010 Sao Paulo, Brazil.
EM mrodrigues@unifesp.br
RI Soares, Irene Silva/C-5974-2012; Costa, Fabio/E-1181-2012; Ferreira,
   Luis Carlos S/M-3954-2014; Bargieri, Daniel Youssef/A-4461-2013;
   Rodrigues, Mauricio M./B-8512-2012; Rosa, Daniela S/D-2190-2012
OI Soares, Irene Silva/0000-0002-3336-6856; Costa,
   Fabio/0000-0001-9969-7300; Ferreira, Luis Carlos S/0000-0002-4883-1693;
   Bargieri, Daniel Youssef/0000-0003-2564-3742; Rosa, Daniela
   S/0000-0003-4536-891X
FU Fundacao de Amparo A Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP); Fundacao de Amparo A Pesquisa
   do Estado do Rio de JaneiroCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); The Millennium
   Institute for Vaccine Development and Technology [CNPq-420067/2005-1];
   DYB; DSR; CJMB; BOC; NME; FAPESR; FTMC; AJV; LCSF; ISS; MMR;
   CNPqNational Council for Scientific and Technological Development (CNPq)
FX This work was Supported by grants from Fundacao de Amparo A Pesquisa do
   Estado de Sao Paulo, Fundacao de Amparo A Pesquisa do Estado do Rio de
   Janeiro, and The Millennium Institute for Vaccine Development and
   Technology (CNPq-420067/2005-1). DYB, DSR, CJMB, BOC, NME were supported
   by fellowships from FAPESR FTMC, AJV, LCSF, ISS, MMR were supported by
   fellowships from CNPq.
CR Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Applequist SE, 2005, J IMMUNOL, V175, P3882, DOI 10.4049/jimmunol.175.6.3882
   Arevalo-Herrera M, 2005, AM J TROP MED HYG, V73, P32, DOI 10.4269/ajtmh.2005.73.32
   Arevalo-Herrera M, 2005, AM J TROP MED HYG, V73, P25
   Baird JK, 2007, TRENDS PARASITOL, V23, P533, DOI 10.1016/j.pt.2007.08.011
   Baird JK, 2004, ANTIMICROB AGENTS CH, V48, P4075, DOI 10.1128/AAC.48.11.4075-4083.2004
   Bargieri DY, 2007, MEM I OSWALDO CRUZ, V102, P313, DOI 10.1590/S0074-02762007005000039
   Barnwell JW, 1999, EXP PARASITOL, V91, P238, DOI 10.1006/expr.1998.4372
   BATES MD, 1988, PARASITE IMMUNOL, V10, P1, DOI 10.1111/j.1365-3024.1988.tb00199.x
   BLACKMAN MJ, 1990, J EXP MED, V172, P379, DOI 10.1084/jem.172.1.379
   Caraballo JR, 2007, VACCINE, V25, P3713, DOI 10.1016/j.vaccine.2006.12.041
   Castellanos A, 2007, MEM I OSWALDO CRUZ, V102, P411, DOI 10.1590/S0074-02762007005000047
   Chitnis CE, 2008, TRENDS PARASITOL, V24, P29, DOI 10.1016/j.pt.2007.10.004
   Collins WE, 2006, AM J TROP MED HYG, V74, P215, DOI 10.4269/ajtmh.2006.74.215
   Cuadros C, 2004, INFECT IMMUN, V72, P2810, DOI 10.1128/IAI.72.5.2810-2816.2004
   Cunha MG, 2001, VACCINE, V20, P385, DOI 10.1016/S0264-410X(01)00359-0
   Cunningham AF, 2004, EUR J IMMUNOL, V34, P2986, DOI 10.1002/eji.200425403
   DALY TM, 1993, INFECT IMMUN, V61, P2462, DOI 10.1128/IAI.61.6.2462-2467.1993
   Darko CA, 2005, INFECT IMMUN, V73, P287, DOI 10.1128/IAI.73.1.287-297.2005
   Devi YS, 2007, VACCINE, V25, P5166, DOI 10.1016/j.vaccine.2007.04.080
   Didierlaurent A, 2004, J IMMUNOL, V172, P6922, DOI 10.4049/jimmunol.172.11.6922
   Dutta S, 2001, INFECT IMMUN, V69, P5464, DOI 10.1128/IAI.69.9.5464-5470.2001
   Dutta S, 2005, INFECT IMMUN, V73, P5936, DOI 10.1128/IAI.73.9.5936-5944.2005
   Franchi L, 2006, NAT IMMUNOL, V7, P576, DOI 10.1038/ni1346
   Grimberg BT, 2007, PLOS MED, V4, P1940, DOI 10.1371/journal.pmed.0040337
   Herrera S, 2005, AM J TROP MED HYG, V73, P3, DOI 10.4269/ajtmh.2005.73.3
   Herrera S, 2007, TRENDS PARASITOL, V23, P122, DOI 10.1016/j.pt.2007.01.008
   Hirunpetcharat C, 1997, J IMMUNOL, V159, P3400
   Honko AN, 2006, INFECT IMMUN, V74, P1113, DOI 10.1128/IAI.74.2.1113-1120.2006
   Huaman MC, 2008, J IMMUNOL, V180, P1451, DOI 10.4049/jimmunol.180.3.1451
   Huleatt JW, 2008, VACCINE, V26, P201, DOI 10.1016/j.vaccine.2007.10.062
   Huleatt JW, 2007, VACCINE, V25, P763, DOI 10.1016/j.vaccine.2006.08.013
   Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359
   Klinman DM, 2004, NAT REV IMMUNOL, V4, P248, DOI 10.1038/nri1329
   Kocken CHM, 1999, INFECT IMMUN, V67, P43, DOI 10.1128/IAI.67.1.43-49.1999
   Lee SE, 2006, INFECT IMMUN, V74, P694, DOI 10.1128/IAI.74.1.694-702.2006
   LING IT, 1994, PARASITE IMMUNOL, V16, P63, DOI 10.1111/j.1365-3024.1994.tb00324.x
   Ljungstrom I.PerlmannH, 2004, METHODS MALARIA RES
   MAJARIAN WR, 1984, J IMMUNOL, V132, P3131
   Malkin Elissa, 2007, PLoS Clin Trials, V2, pe12, DOI 10.1371/journal.pctr.0020012
   Malkin EM, 2005, VACCINE, V23, P3131, DOI 10.1016/j.vaccine.2004.12.019
   McDonald WF, 2007, J INFECT DIS, V195, P1607, DOI 10.1086/517613
   Miao EA, 2006, NAT IMMUNOL, V7, P569, DOI 10.1038/ni1344
   Miura K, 2007, MALARIA J, V6, DOI 10.1186/1475-2875-6-107
   Molofsky AB, 2006, J EXP MED, V203, P1093, DOI 10.1084/jem.20051659
   O'Donnell RA, 2000, NAT MED, V6, P91, DOI 10.1038/71595
   Oliveira-Ferreira J, 2004, VACCINE, V22, P2023, DOI 10.1016/j.vaccine.2003.07.021
   Perera KLRL, 1998, INFECT IMMUN, V66, P1500, DOI 10.1128/IAI.66.4.1500-1506.1998
   Pino O, 2005, INFECT IMMUN, V73, P6763, DOI 10.1128/IAI.73.10.6763-6770.2005
   Price RN, 2007, AM J TROP MED HYG, V77, P79, DOI 10.4269/ajtmh.2007.77.79
   Ramjanee S, 2007, VACCINE, V25, P886, DOI 10.1016/j.vaccine.2006.09.035
   Ren T, 2006, PLOS PATHOG, V2, P175, DOI 10.1371/journal.ppat.0020018
   Rodrigues MHC, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-39
   Rodrigues MM, 1999, INFECT IMMUN, V67, P3855, DOI 10.1128/IAI.67.8.3855-3863.1999
   Rogers WO, 1999, VACCINE, V17, P3136, DOI 10.1016/S0264-410X(99)00146-2
   Rosa DS, 2006, MICROBES INFECT, V8, P2130, DOI 10.1016/j.micinf.2006.03.012
   Rosa DS, 2004, IMMUNOL LETT, V92, P259, DOI 10.1016/j.imlet.2004.01.006
   Rotman HL, 1998, J IMMUNOL, V161, P1908
   Sachdeva S, 2004, INFECT IMMUN, V72, P5775, DOI 10.1128/IAI.72.10.5775-5782.2004
   Saul A, 2007, PARASITE IMMUNOL, V29, P525, DOI 10.1111/j.1365-3024.2007.00971.x
   Schmitt CK, 1996, J BACTERIOL, V178, P2911, DOI 10.1128/jb.178.10.2911-2915.1996
   Singh S, 2006, INFECT IMMUN, V74, P4573, DOI 10.1128/IAI.01679-05
   Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011
   Soares IS, 1999, MOL MED, V5, P459
   Soares IS, 1999, AM J TROP MED HYG, V60, P357, DOI 10.4269/ajtmh.1999.60.357
   Soares IS, 1997, INFECT IMMUN, V65, P1606, DOI 10.1128/IAI.65.5.1606-1614.1997
   Valderrama-Aguirre A, 2005, AM J TROP MED HYG, V73, P16, DOI 10.4269/ajtmh.2005.73.16
   Valero LMS, 1998, INFECT IMMUN, V66, P3925, DOI 10.1128/IAI.66.8.3925-3930.1998
   Vicente-Suarez I, 2007, EUR J IMMUNOL, V37, P3164, DOI 10.1002/eji.200737306
NR 69
TC 76
Z9 85
U1 0
U2 10
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD NOV 11
PY 2008
VL 26
IS 48
BP 6132
EP 6142
DI 10.1016/j.vaccine.2008.08.070
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 381LS
UT WOS:000261538200014
PM 18804504
DA 2020-12-08
ER

PT J
AU Mufalo, BC
   Gentil, F
   Bargieri, DY
   Costa, FTM
   Rodrigues, MM
   Soares, IS
AF Mufalo, Bruno C.
   Gentil, Fernanda
   Bargieri, Daniel Y.
   Costa, Fabio T. M.
   Rodrigues, Mauricio M.
   Soares, Irene S.
TI Plasmodium vivax apical membrane antigen-1: comparative recognition of
   different domains by antibodies induced during natural human infection
SO MICROBES AND INFECTION
LA English
DT Article
DE Malaria; Plasmodium vivax; Apical Membrane Antigen-1
ID MALARIA VACCINE CANDIDATE; MEROZOITE SURFACE PROTEIN-1; ERYTHROCYTE
   INVASION; MONOCLONAL-ANTIBODY; FULL-LENGTH; HOMOLOG; INDIVIDUALS;
   PF83/AMA-1; RESPONSES; MSP1(19)
AB The Apical Membrane Antigen-1 (AMA-1) of Plasmodium sp. has been suggested as a vaccine candidate against malaria. This protein seems to be involved in merozoite invasion and its extra-cellular portion contains three distinct domains: DI, DII, and DIII. Previously, we described that Plasmodium vivax AMA-1 (PvAMA-1) ectodomain is highly immunogenic in natural human infections. Here, we expressed each domain, separately or in combination (DI-II or DII-III), as bacterial recombinant proteins to map immunodominant epitopes within the PvAMA-1 ectodomain. IgG recognition was assessed by ELISA using sera of P. vivax-infected individuals collected from endemic regions of Brazil or antibodies raised in immunized mice. The frequencies of responders to recombinant proteins containing the DII were higher than the others and similar to the ones observed against the PvAMA-1 ectodomain. Moreover, ELISA inhibition assays using the PvAMA-1 ectodomain as substrate revealed the presence of many common epitopes within DI-II that are recognized by human immune antibodies. Finally, immunization of mice with the PvAMA-1 ectodomain induced high levels of antibodies predominantly to DI-II. Together, our results indicate that DII is particularly immunogenic during natural human infections, thus indicating that this region could be used as part of an experimental sub-unit vaccine to prevent vivax malaria. (C) 2008 Elsevier Masson SAS. All rights reserved.
C1 [Mufalo, Bruno C.; Gentil, Fernanda; Soares, Irene S.] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, BR-05508900 Sao Paulo, Brazil.
   [Bargieri, Daniel Y.; Rodrigues, Mauricio M.] Univ Fed Sao Paulo, Escola Paulista Med, CINTERGEN, BR-04044010 Sao Paulo, Brazil.
   [Costa, Fabio T. M.] Univ Estadual Campinas, Inst Biol, Dept Parasitol, BR-13083970 Campinas, SP, Brazil.
RP Soares, IS (corresponding author), Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Ave Prof Lineu Prestes 580, BR-05508900 Sao Paulo, Brazil.
EM isoares@usp.br
RI Soares, Irene Silva/C-5974-2012; Bargieri, Daniel Youssef/A-4461-2013;
   Costa, Fabio/E-1181-2012; Rodrigues, Mauricio M./B-8512-2012
OI Soares, Irene Silva/0000-0002-3336-6856; Bargieri, Daniel
   Youssef/0000-0003-2564-3742; Costa, Fabio/0000-0001-9969-7300; 
FU Fundacao de Amparo Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2004/00768-7];
   Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de
   Janeiro (FAPERJ)Carlos Chagas Filho Foundation for Research Support of
   the State of Rio de Janeiro (FAPERJ) [E-26/110.305/2007]; Millennium
   Institute for Vaccine Development and Technology (CNPq)National Council
   for Scientific and Technological Development (CNPq) [420067/2005-1];
   CAPESCAPES
FX This work was supported by grants from Fundacao de Amparo Pesquisa do
   Estado de Sao Paulo (FAPESP, 2004/00768-7), Fundacao Carlos Chagas Filho
   de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ,
   E-26/110.305/2007) and The Millennium Institute for Vaccine Development
   and Technology (CNPq, 420067/2005-1). BCM, FTMC, MMR and ISS are
   supported by fellowships from CNPq. FG and DYB are supported by
   fellowships from CAPES and FAPESP, respectively.
CR Bai T, 2005, P NATL ACAD SCI USA, V102, P12736, DOI 10.1073/pnas.0501808102
   Baird JK, 2007, TRENDS PARASITOL, V23, P533, DOI 10.1016/j.pt.2007.08.011
   Bannister LH, 2003, J CELL SCI, V116, P3825, DOI 10.1242/jcs.00665
   CHENG Q, 1994, MOL BIOCHEM PARASIT, V65, P183, DOI 10.1016/0166-6851(94)90127-9
   Collins CR, 2007, J BIOL CHEM, V282, P7431, DOI 10.1074/jbc.M610562200
   Cunha MG, 2001, VACCINE, V20, P385, DOI 10.1016/S0264-410X(01)00359-0
   Donahue CG, 2000, MOL BIOCHEM PARASIT, V111, P15, DOI 10.1016/S0166-6851(00)00289-9
   Feng ZP, 2005, J MOL BIOL, V350, P641, DOI 10.1016/j.jmb.2005.05.011
   Figtree M, 2000, MOL BIOCHEM PARASIT, V108, P53, DOI 10.1016/S0166-6851(00)00204-8
   Fraser TS, 2001, MOL BIOCHEM PARASIT, V117, P49, DOI 10.1016/S0166-6851(01)00326-7
   Gaffar FR, 2004, INFECT IMMUN, V72, P2947, DOI 10.1128/IAI.72.5.2947-2955.2004
   Gunasekera AM, 2007, MOL BIOL EVOL, V24, P939, DOI 10.1093/molbev/msm013
   Healer J, 2002, INFECT IMMUN, V70, P5751, DOI 10.1128/IAI.70.10.5751-5758.2002
   Healer J, 2005, INFECT IMMUN, V73, P2444, DOI 10.1128/IAI.73.4.2444-2451.2005
   Hehl AB, 2000, INFECT IMMUN, V68, P7078, DOI 10.1128/IAI.68.12.7078-7086.2000
   Hodder AN, 1996, J BIOL CHEM, V271, P29446, DOI 10.1074/jbc.271.46.29446
   Igonet S, 2007, J MOL BIOL, V366, P1523, DOI 10.1016/j.jmb.2006.12.028
   Lalitha PV, 2004, INFECT IMMUN, V72, P4464, DOI 10.1128/IAI.72.8.4464-4470.2004
   Nair M, 2002, J MOL BIOL, V322, P741, DOI 10.1016/S0022-2836(02)00806-9
   NARUM DL, 1994, MOL BIOCHEM PARASIT, V67, P59, DOI 10.1016/0166-6851(94)90096-5
   PETERSON MG, 1989, MOL CELL BIOL, V9, P3151, DOI 10.1128/MCB.9.7.3151
   Pizarro JC, 2005, SCIENCE, V308, P408, DOI 10.1126/science.1107449
   Remarque EJ, 2008, TRENDS PARASITOL, V24, P74, DOI 10.1016/j.pt.2007.12.002
   Rodrigues MHC, 2003, MALARIA J, V2, DOI 10.1186/1475-2875-2-39
   Rodriguesa MHC, 2005, INT J PARASITOL, V35, P185, DOI 10.1016/j.ijpara.2004.11.003
   Rosa DS, 2006, MICROBES INFECT, V8, P2130, DOI 10.1016/j.micinf.2006.03.012
   Soares IS, 1997, INFECT IMMUN, V65, P1606, DOI 10.1128/IAI.65.5.1606-1614.1997
   THOMAS AW, 1994, AM J TROP MED HYG, V51, P730, DOI 10.4269/ajtmh.1994.51.730
   Triglia T, 2000, MOL MICROBIOL, V38, P706, DOI 10.1046/j.1365-2958.2000.02175.x
   WATERS AP, 1990, J BIOL CHEM, V265, P17974
   Wickramarachchi T, 2006, INFECT IMMUN, V74, P798, DOI 10.1128/IAI.74.1.798-801.2006
NR 31
TC 31
Z9 31
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD OCT
PY 2008
VL 10
IS 12-13
BP 1266
EP 1273
DI 10.1016/j.micinf.2008.07.023
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 379BB
UT WOS:000261368400006
PM 18692152
DA 2020-12-08
ER

PT J
AU Blanco, YC
   Farias, AS
   Goelnitz, U
   Lopes, SCP
   Arrais-Silva, WW
   Carvalho, BO
   Amino, R
   Wunderlich, G
   Santos, LMB
   Giorgio, S
   Costa, FTM
AF Blanco, Yara C.
   Farias, Alessandro S.
   Goelnitz, Uta
   Lopes, Stefanie C. P.
   Arrais-Silva, Wagner W.
   Carvalho, Bruna O.
   Amino, Rogerio
   Wunderlich, Gerhard
   Santos, Leonilda M. B.
   Giorgio, Selma
   Costa, Fabio T. M.
TI Hyperbaric Oxygen Prevents Early Death Caused by Experimental Cerebral
   Malaria
SO PLOS ONE
LA English
DT Article
ID NECROSIS-FACTOR-ALPHA; SEVERE FALCIPARUM-MALARIA; T-CELLS;
   INTERFERON-GAMMA; BRAIN TRAUMA; ISCHEMIA; CYTOKINES; EXPRESSION;
   PRESSURE; THERAPY
AB Background: Cerebral malaria (CM) is a syndrome characterized by neurological signs, seizures and coma. Despite the fact that CM presents similarities with cerebral stroke, few studies have focused on new supportive therapies for the disease. Hyperbaric oxygen (HBO) therapy has been successfully used in patients with numerous brain disorders such as stroke, migraine and atherosclerosis.
   Methodology/Principal Findings: C57BL/6 mice infected with Plasmodium berghei ANKA (PbA) were exposed to daily doses of HBO (100% O-2, 3.0 ATA, 1-2 h per day) in conditions well-tolerated by humans and animals, before or after parasite establishment. Cumulative survival analyses demonstrated that HBO therapy protected 50% of PbA-infected mice and delayed CM-specific neurological signs when administrated after patent parasitemia. Pressurized oxygen therapy reduced peripheral parasitemia, expression of TNF-alpha, IFN-gamma and IL-10 mRNA levels and percentage of gamma delta and alpha beta CD4(+) and CD8(+) T lymphocytes sequestered in mice brains, thus resulting in a reduction of blood-brain barrier (BBB)dysfunction and hypothermia.
   Conclusions/Significance: The data presented here is the first indication that HBO treatment could be used as supportive therapy, perhaps in association with neuroprotective drugs, to prevent CM clinical outcomes, including death.
C1 [Blanco, Yara C.; Farias, Alessandro S.; Lopes, Stefanie C. P.; Carvalho, Bruna O.; Santos, Leonilda M. B.; Costa, Fabio T. M.] State Univ Campinas UNICAMP, Dept Microbiol & Immunol, Campinas, SP, Brazil.
   [Blanco, Yara C.; Lopes, Stefanie C. P.; Arrais-Silva, Wagner W.; Carvalho, Bruna O.; Giorgio, Selma; Costa, Fabio T. M.] State Univ Campinas UNICAMP, Dept Parasitol, Sao Paulo, Brazil.
   [Goelnitz, Uta; Wunderlich, Gerhard] Univ Sao Paulo, Dept Parasitol ICB, Sao Paulo, Brazil.
   [Amino, Rogerio] Fed Univ Sao Paulo UNIFESP, Dept Biochem, Sao Paulo, Brazil.
RP Blanco, YC (corresponding author), State Univ Campinas UNICAMP, Dept Microbiol & Immunol, Campinas, SP, Brazil.
EM costaftm@unicamp.br
RI Costa, Fabio/E-1181-2012; Farias, Alessandro/C-6879-2012; Wunderlich,
   Gerhard/G-8245-2012; Giorgio, Selma/A-6701-2013; Farias,
   Alessandro/AAH-2228-2020; Lopes, Stefanie/A-8314-2012
OI Costa, Fabio/0000-0001-9969-7300; Farias,
   Alessandro/0000-0001-6759-1819; Wunderlich, Gerhard/0000-0003-1724-0337;
   Farias, Alessandro/0000-0001-6759-1819; Lopes,
   Stefanie/0000-0002-6981-2192; Amino, Rogerio/0000-0002-8086-2932
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2004/00638-6];
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)CAPES
FX This work was supported by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP), grant n 2004/00638-6, and from Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq). YCB, WWA, ASF and SCPL
   were supported by Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES), and UG was sponsored by a FAPESP fellowship. GW, SG
   and FTMC are CNPq fellows.
CR Al-Waili NS, 2006, THESCIENTIFICWORLDJO, V6, P425, DOI 10.1100/tsw.2006.78
   Al-Waili NS, 2005, ADV THER, V22, P659, DOI 10.1007/BF02849960
   Arrais-Silva WW, 2006, ACTA TROP, V98, P130, DOI 10.1016/j.actatropica.2006.03.001
   Arrais-Silva WW, 2005, PARASITOL INT, V54, P1, DOI 10.1016/j.parint.2004.07.002
   Belnoue E, 2002, J IMMUNOL, V169, P6369, DOI 10.4049/jimmunol.169.11.6369
   Benson RM, 2003, CLIN EXP IMMUNOL, V134, P57, DOI 10.1046/j.1365-2249.2003.02248.x
   Buras JA, 2000, AM J PHYSIOL-CELL PH, V278, pC292
   Calvert JW, 2002, BRAIN RES, V951, P1, DOI 10.1016/S0006-8993(02)03094-9
   Carter JA, 2005, TROP MED INT HEALTH, V10, P3, DOI 10.1111/j.1365-3156.2004.01345.x
   Day NPJ, 1999, J INFECT DIS, V180, P1288, DOI 10.1086/315016
   DEKOSSODO S, 1993, J IMMUNOL, V151, P4811
   Engwerda C, 2005, CURR TOP MICROBIOL, V297, P103
   GADD MA, 1990, CRIT CARE MED, V18, P974, DOI 10.1097/00003246-199009000-00014
   Gillman BM, 2004, INFECT IMMUN, V72, P6359, DOI 10.1128/IAI.72.11.6359-6366.2004
   Gramaglia I, 2006, NAT MED, V12, P1417, DOI 10.1038/nm1499
   Granowitz EV, 2002, UNDERSEA HYPERBAR M, V29, P216
   GUDEWICZ TM, 1987, AVIAT SPACE ENVIR MD, V58, P673
   Hermsen CC, 1997, PARASITE IMMUNOL, V19, P571, DOI 10.1046/j.1365-3024.1997.d01-175.x
   Hink J, 2001, MED HYPOTHESES, V57, P764, DOI 10.1054/mehy.2001.1488
   Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1
   Idro R, 2005, LANCET NEUROL, V4, P827, DOI 10.1016/S1474-4422(05)70247-7
   IRANI DN, 1991, J IMMUNOL METHODS, V139, P223, DOI 10.1016/0022-1759(91)90192-I
   Jennings VM, 1997, INFECT IMMUN, V65, P4883, DOI 10.1128/IAI.65.11.4883-4887.1997
   Jennings VM, 1998, INFECT IMMUN, V66, P5972, DOI 10.1128/IAI.66.12.5972-5979.1998
   Kaide CG, 2008, EMERG MED CLIN N AM, V26, P571, DOI 10.1016/j.emc.2008.01.005
   Kaiser K, 2006, J INFECT DIS, V193, P987, DOI 10.1086/500844
   KAPP JP, 1981, SURG NEUROL, V15, P43, DOI 10.1016/S0090-3019(81)80089-4
   Lahat N, 1995, CLIN EXP IMMUNOL, V102, P655
   Lee CC, 2006, J BIOMED SCI, V13, P143, DOI 10.1007/s11373-005-9037-7
   Li Y, 2005, EXP NEUROL, V191, P198, DOI 10.1016/j.expneurol.2004.08.036
   Lou M, 2004, STROKE, V35, P578, DOI 10.1161/01.STR.0000111599.77426.A0
   Medana IM, 1997, AM J PATHOL, V150, P1473
   Medana IM, 2006, INT J PARASITOL, V36, P555, DOI 10.1016/j.ijpara.2006.02.004
   Newton CRJC, 1998, PHARMACOL THERAPEUT, V79, P1, DOI 10.1016/S0163-7258(98)00008-4
   NEWTON CRJC, 1994, ARCH DIS CHILD, V70, P281, DOI 10.1136/adc.70.4.281
   Newton CRJC, 1996, PEDIATR NEUROL, V15, P41, DOI 10.1016/0887-8994(96)00115-4
   Niklas A, 2004, J NEUROL SCI, V219, P77, DOI 10.1016/j.jns.2003.12.013
   Nitcheu J, 2003, J IMMUNOL, V170, P2221, DOI 10.4049/jimmunol.170.4.2221
   Ohganli Y, 2008, BRAIN RES BULL, V75, P668, DOI 10.1016/j.brainresbull.2007.11.002
   Ostrowski RP, 2005, J CEREBR BLOOD F MET, V25, P554, DOI 10.1038/sj.jcbfm.9600048
   Overbergh L, 2003, J Biomol Tech, V14, P33
   PARK MK, 1992, CLIN INFECT DIS, V14, P720, DOI 10.1093/clinids/14.3.720
   Patankar TF, 2002, RADIOLOGY, V224, P811, DOI 10.1148/radiol.2243010588
   Piguet PF, 2001, AM J PATHOL, V159, P733, DOI 10.1016/S0002-9440(10)61744-0
   PONGPONRATN E, 1991, AM J TROP MED HYG, V44, P168, DOI 10.4269/ajtmh.1991.44.168
   Prakash D, 2006, J INFECT DIS, V194, P198, DOI 10.1086/504720
   REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447
   RENCRICCA NJ, 1981, AVIAT SPACE ENVIR MD, V52, P85
   Renia L, 2006, INT J PARASITOL, V36, P547, DOI 10.1016/j.ijpara.2006.02.007
   Rockswold SB, 2001, J NEUROSURG, V94, P403, DOI 10.3171/jns.2001.94.3.0403
   Rudin W, 1997, EUR J IMMUNOL, V27, P810, DOI 10.1002/eji.1830270403
   Schabitz WR, 2004, STROKE, V35, P1175, DOI 10.1161/01.STR.0000125868.86298.8e
   Sobolewski P, 2005, INFECT IMMUN, V73, P6704, DOI 10.1128/IAI.73.10.6704-6710.2005
   Taylor TE, 2004, NAT MED, V10, P143, DOI 10.1038/nm986
   Thackham JA, 2008, WOUND REPAIR REGEN, V16, P321, DOI 10.1111/j.1524-475X.2008.00372.x
   Veltkamp R, 2005, BRAIN RES, V1037, P134, DOI 10.1016/j.brainres.2005.01.006
   Veltkamp R, 2005, STROKE, V36, P1679, DOI 10.1161/01.STR.0000173408.94728.79
   WARRELL DA, 1988, LANCET, V2, P534
   Wassmer SC, 2005, PLOS MED, V2, P885, DOI 10.1371/journal.pmed.0020245
   WHITE NJ, 1985, LANCET, V1, P776
   Yang ZJ, 2001, EUR J APPL PHYSIOL, V85, P96, DOI 10.1007/s004210100391
   Yin DL, 2003, J CEREBR BLOOD F MET, V23, P855, DOI 10.1097/01.WCB.0000073946.29308.55
   Yin W, 2002, BRAIN RES, V926, P165, DOI 10.1016/S0006-8993(01)03304-2
   Zhang QX, 2008, J INVEST DERMATOL, V128, P2102, DOI 10.1038/jid.2008.53
NR 64
TC 24
Z9 24
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 4
PY 2008
VL 3
IS 9
AR e3126
DI 10.1371/journal.pone.0003126
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 422HU
UT WOS:000264419100001
PM 18769544
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Andrade, CF
   Gameiro, J
   Nagib, PRA
   Carvalho, BO
   Talaisys, RL
   Costa, FTM
   Verinaud, L
AF Andrade, C. F.
   Gameiro, J.
   Nagib, P. R. A.
   Carvalho, B. O.
   Talaisys, R. L.
   Costa, F. T. M.
   Verinaud, L.
TI Thymic alterations in Plasmodium berghei-infected mice
SO CELLULAR IMMUNOLOGY
LA English
DT Article
DE Plasmodium berghei; thymus; thymic atrophy; T-cell generation
ID LIVER STAGES; T-CELLS; RESPONSES; NK65
AB The primary function of the thymus is to develop immature T-cells into cells that further in the periphery will be able to carry out immune functions. The Literature has shown that thymus can be a target for many pathogens and severe structural alterations take place in this organ during infectious diseases. Here, we investigated if thymus is also a target organ during experimental malaria infection by analyzing the presence of parasites inside the organ and histological alterations in thymuses from Plasmodium berghei NK65-infected BALB/c. After 14 days of infection, parasites were found inside the thymus that presented a profound atrophy with total loss of its architecture. We propose that the presence of parasites in the thymus induces histological modifications that alter the microenvironment, impairing by consequence the successful T cell development. Additional studies are currently being developed in our laboratory to verify if such thymic alterations can influence the systemic immune response to the parasite. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Andrade, C. F.; Gameiro, J.; Nagib, P. R. A.; Verinaud, L.] Univ Estadual Campinas, Inst Biol, Dept Microbiol & Immunol, Sao Paulo, Brazil.
   [Carvalho, B. O.; Talaisys, R. L.; Costa, F. T. M.] Univ Estadual Campinas, Inst Biol, Dept Parasitol, Sao Paulo, Brazil.
RP Verinaud, L (corresponding author), Univ Estadual Campinas, Dept Microbiol & Imunol, Vaz S-N, BR-13084970 Campinas, SP, Brazil.
EM verinaud@unicamp.br
RI Verinaud, Liana/B-8985-2012; Costa, Fabio/E-1181-2012; Francelin,
   Carolina/AAZ-9572-2020; Gameiro, Jacy JG/N-8543-2018
OI Costa, Fabio/0000-0001-9969-7300; Francelin,
   Carolina/0000-0001-7439-3124; Gameiro, Jacy/0000-0001-9244-3623
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [05/59774-9, 04/03599-1];
   Conselho Nacional de Desenvolvimento Cientificoe Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq)
FX We thank Dr. Nobuko Yoshida from Department of Microbiology, Immunology
   and Parasitology, UNIFESP, Sao Paulo, SP, Brazil who kindly provided P.
   berghei NK65 parasites. This work was supported by grants from Fundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (#05/59774-9 & 04/03599-1)
   and Conselho Nacional de Desenvolvimento Cientificoe Tecnologico (CNPq).
CR Brito VN, 2003, MED MYCOL, V41, P83, DOI 10.1080/714043902
   Ciofani M, 2007, ANNU REV CELL DEV BI, V23, P463, DOI 10.1146/annurev.cellbio.23.090506.123547
   Cotta-De-Almeida V, 2003, EUR J IMMUNOL, V33, P2439, DOI 10.1002/eji.200323860
   Hong R, 2001, Chest Surg Clin N Am, V11, P295
   Jamieson BD, 1999, IMMUNITY, V10, P569, DOI 10.1016/S1074-7613(00)80056-4
   Jarra W, 1998, INFECT IMMUN, V66, P3783, DOI 10.1128/IAI.66.8.3783-3787.1998
   Long TTA, 2003, INT J PARASITOL, V33, P175, DOI 10.1016/S0020-7519(02)00261-8
   Morrot A, 2004, INT J PARASITOL, V34, P1529, DOI 10.1016/j.ijpara.2004.10.001
   Nakazawa S, 2005, EXP PARASITOL, V111, P59, DOI 10.1016/j.exppara.2005.05.002
   Petrie HT, 2007, ANNU REV IMMUNOL, V25, P649, DOI 10.1146/annurev.immunol.23.021704.115715
   SAVINO W, 1989, EUR J IMMUNOL, V19, P1727, DOI 10.1002/eji.1830190930
   SAVINO W, 1986, AM J PATHOL, V122, P302
   Savino W, 2006, PLOS PATHOG, V2, P472, DOI 10.1371/journal.ppat.0020062
   Schofield L, 2005, NAT REV IMMUNOL, V5, P722, DOI 10.1038/nri1686
   Seixas E, 2005, EXP PARASITOL, V110, P394, DOI 10.1016/j.exppara.2005.03.024
   Shanker A, 2004, IMMUNOL LETT, V91, P79, DOI 10.1016/j.imlet.2003.12.012
   Sodora DL, 2002, J VIROL, V76, P9981, DOI 10.1128/JVI.76.19.9981-9990.2002
   Souto PCS, 2003, MED MICROBIOL IMMUN, V192, P225, DOI 10.1007/s00430-003-0180-3
   Suster S, 1997, HISTOLOGY PATHOLOGIS, P687
   Tsuji M, 2003, TRENDS PARASITOL, V19, P88, DOI 10.1016/S1471-4922(02)00053-3
NR 20
TC 18
Z9 19
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
EI 1090-2163
J9 CELL IMMUNOL
JI Cell. Immunol.
PY 2008
VL 253
IS 1-2
BP 1
EP 4
DI 10.1016/j.cellimm.2008.06.001
PG 4
WC Cell Biology; Immunology
SC Cell Biology; Immunology
GA 354DB
UT WOS:000259618000001
PM 18635160
DA 2020-12-08
ER

PT J
AU Blanco, YC
   Lopes, SCP
   Vieira, AS
   Arrais-Silva, WW
   Carvalho, BOE
   Langone, F
   Giorgio, S
   Costa, FTM
AF Blanco, Yara C.
   Lopes, Stefanie C. P.
   Vieira, Andre S.
   Arrais-Silva, Wagner W.
   Carvalho, Bruna Oliveira E.
   Langone, Francesco
   Giorgio, Selma
   Costa, Fabio T. M.
TI Hyperbaric oxygen therapy: a new approach to treat cerebral malaria?
SO INTERNATIONAL JOURNAL FOR PARASITOLOGY
LA English
DT Meeting Abstract
CT 3rd Molecular Approaches to Malaria Meeting (MAM 2008)
CY FEB 03-07, 2008
CL Lorne, AUSTRALIA
SP BioMalPar, Boehringer Ingelheim Foods, Burroughs Wellcome Fund, Fdn Natl Inst Hlth, PATH Malaria Vaccine Initiative, Walter & Eliza Hall Inst Med Res, Wellcome Trust, ARC/NHMRC Net Parasitol, Australian Soc Biochem & Molecular Biol, Lorne Protein Conf, GlaxoSmithKline
C1 [Blanco, Yara C.; Lopes, Stefanie C. P.; Carvalho, Bruna Oliveira E.; Costa, Fabio T. M.] Univ Estadual Campinas, Dept Microbiol & Immunol, Campinas, SP, Brazil.
   Univ Estadual Campinas, Dept Parasitol, Campinas, Brazil.
   [Vieira, Andre S.; Langone, Francesco] Univ Estadual Campinas, Dept Physiol & Biophys, Campinas, Brazil.
RI Giorgio, Selma/A-6701-2013; Costa, Fabio/E-1181-2012
OI Costa, Fabio/0000-0001-9969-7300
NR 0
TC 0
Z9 0
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0020-7519
J9 INT J PARASITOL
JI Int. J. Parasit.
PD JAN
PY 2008
VL 38
SU 1
BP S54
EP S54
PG 1
WC Parasitology
SC Parasitology
GA 262CW
UT WOS:000253127600132
DA 2020-12-08
ER

PT J
AU Egima, CM
   Macedo, SF
   Sasso, GRS
   Covarrubias, C
   Cortez, M
   Maeda, FY
   Costa, FT
   Yoshida, N
AF Egima, Claudia M.
   Macedo, Silene F.
   Sasso, Gisela R. S.
   Covarrubias, Charles
   Cortez, Mauro
   Maeda, Fernando Y.
   Costa, Fabio T.
   Yoshida, Nobuko
TI Co-infection with Trypanosoma cruzi protects mice against early death by
   neurological or pulmonary disorders induced by Plasmodium berghei ANKA
SO MALARIA JOURNAL
LA English
DT Article
ID METACYCLIC TRYPOMASTIGOTES; SCHISTOSOMA-MANSONI; SURFACE-ANTIGENS;
   MALARIA; FALCIPARUM; INFECTION; CHILDREN; DISEASE; EDEMA; CELLS
AB Objective: The objective of this study was to investigate whether the infection of C57BL/ 6 mice by P. berghei ANKA, which causes severe malaria, was modulated by co-infection with Trypanosoma cruzi.
   Methods: Groups of C57BL/ 6 mice were infected either with P. berghei ANKA, T. cruzi strain G, or with both parasites. The presence of parasites was checked by microscopic examination of blood samples. Symptoms of neurological or respiratory disorders, as well as mortality, were registered. Breakdown of the blood brain barrier was determined by injecting the dye Evans blue. Histological sections of the lung were prepared and stained with hematoxilin-eosin.
   Results: All mice infected only with P. berghei ANKA died within 7-11 days post-infection, either with symptoms of cerebral malaria or with respiratory abnormalities. The animals co- infected with T. cruzi strain G survived longer, without any of the referred to symptoms. Protection against the early death by severe malaria was effective when mice were given T. cruzi 15 days before P. berghei inoculation. Breakdown of the blood brain barrier and extensive pulmonary oedema, caused by malaria parasites, were much less pronounced in co- infected mice. The degree of protection to severe malaria and early death, conferred by co- infection with T. cruzi, was comparable to that conferred by treatment with anti-CD8 antibodies.
   Conclusion: Co-infection with T. cruzi protects C57BL/ 6 against the early death by malaria infection, by partially preventing either the breakdown of the blood brain, and cerebral malaria as a consequence, or the pulmonary oedema.
C1 Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Dept Morfol, Sao Paulo, Brazil.
   Univ Estadual Campinas, Inst Biol, Dept Parasitol, Campinas, SP, Brazil.
RP Yoshida, N (corresponding author), Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, Sao Paulo, Brazil.
EM c.egima@uol.com.br; silene@ecb.epm.br; gisela.morf@epm.br;
   charlesccf@ecb.epm.br; mauroptex@ecb.epm.br; fernando.maeda@unifesp.br;
   costaftm@unicamp.br; nyoshida@ecb.epm.br
RI Veliz, Mauro Javier Cortez/Q-8227-2019; Maeda, Fernando
   Yukio/H-5149-2016; Yoshida, Nobuko/AAL-6082-2020; Costa,
   Fabio/E-1181-2012; Veliz, Mauro Javier Cortez/J-3119-2012
OI Veliz, Mauro Javier Cortez/0000-0001-6536-4647; Yoshida,
   Nobuko/0000-0002-3925-8557; Costa, Fabio/0000-0001-9969-7300; Veliz,
   Mauro Javier Cortez/0000-0001-6536-4647; Sasso, Gisela Rodrigues da
   Silva/0000-0002-6583-1329
CR Belnoue E, 2002, J IMMUNOL, V169, P6369, DOI 10.4049/jimmunol.169.11.6369
   Boulos Marcos, 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P93
   Briand V, 2005, AM J TROP MED HYG, V72, P702, DOI 10.4269/ajtmh.2005.72.702
   BUCK AA, 1978, TROPENMED PARASITOL, V29, P253
   Chadee DD, 2003, TROP MED INT HEALTH, V8, P140, DOI 10.1046/j.1365-3156.2003.01001.x
   CHAROENPAN P, 1990, CHEST, V97, P1190, DOI 10.1378/chest.97.5.1190
   COOK IF, 1985, J TROP MED HYG, V88, P261
   Coura JR, 2002, TRENDS PARASITOL, V18, P171, DOI 10.1016/S1471-4922(01)02200-0
   Druilhe P, 2005, TRENDS PARASITOL, V21, P359, DOI 10.1016/j.pt.2005.06.011
   Graham AL, 2005, J INFECT DIS, V191, P410, DOI 10.1086/426871
   GREENWOOD BM, 1972, LANCET, V1, P169
   Helmby H, 1998, INFECT IMMUN, V66, P5167, DOI 10.1128/IAI.66.11.5167-5174.1998
   KRETTLI AU, 1977, J PROTOZOOL, V24, P514, DOI 10.1111/j.1550-7408.1977.tb01003.x
   Legesse M, 2004, ACTA TROP, V91, P161, DOI 10.1016/j.actatropica.2004.04.002
   PECANHA LMT, 1988, ANN TROP MED PARASIT, V82, P429, DOI 10.1080/00034983.1988.11812272
   Petney TN, 1998, INT J PARASITOL, V28, P377, DOI 10.1016/S0020-7519(97)00189-6
   Ravindran B, 1998, T ROY SOC TROP MED H, V92, P21, DOI 10.1016/S0035-9203(98)90937-3
   SUN J, 1993, AM J TROP MED HYG, V48, P161, DOI 10.4269/ajtmh.1993.48.161
   TEIXEIRA MMG, 1986, MOL BIOCHEM PARASIT, V18, P271, DOI 10.1016/0166-6851(86)90085-X
   THUMWOOD CM, 1988, PARASITOLOGY, V96, P579, DOI 10.1017/S0031182000080203
   Tshikuka JG, 1996, ANN TROP MED PARASIT, V90, P277, DOI 10.1080/00034983.1996.11813053
   Voza T, 2005, INFECT IMMUN, V73, P4777, DOI 10.1128/IAI.73.8.4777-4786.2005
   WHITTLE HC, 1984, NATURE, V312, P449, DOI 10.1038/312449a0
   YOSHIDA N, 1983, INFECT IMMUN, V40, P836, DOI 10.1128/IAI.40.2.836-839.1983
NR 24
TC 7
Z9 7
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2875
J9 MALARIA J
JI Malar. J.
PD JUL 9
PY 2007
VL 6
AR 90
DI 10.1186/1475-2875-6-90
PG 6
WC Infectious Diseases; Parasitology; Tropical Medicine
SC Infectious Diseases; Parasitology; Tropical Medicine
GA 208DM
UT WOS:000249300000001
PM 17620126
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Farias, LR
   Costa, FT
   Souza, LA
   Pelegrini, PB
   Grossi-de-Sa, MF
   Neto, SM
   Bloch, C
   Laumann, RA
   Noronha, EF
   Franco, OL
AF Farias, L. R.
   Costa, F. T.
   Souza, L. A.
   Pelegrini, P. B.
   Grossi-de-Sa, M. F.
   Neto, S. M.
   Bloch, C., Jr.
   Laumann, R. A.
   Noronha, E. F.
   Franco, O. L.
TI Isolation of a novel Carica papaya alpha-amylase inhibitor with
   deleterious activity toward Callosobruchus maculatus
SO PESTICIDE BIOCHEMISTRY AND PHYSIOLOGY
LA English
DT Article
DE Callosobruchus maculatus; alpha-amylase inhibitors; Carica papaya; plant
   defense
ID AMINO-ACID-SEQUENCES; AMYLASE/SUBTILISIN INHIBITOR; GAMMA-THIONINS;
   FINGER MILLET; WHEAT; INSECT; PURIFICATION; EXPRESSION; PROTEINS;
   BINDING
AB Cowpea (Vigna unguiculata) is a subsistence crop for small and poor farmers from Latin America and Africa. This culture is commonly damaged by cowpea weevil (Callosobruchus maculatus), which burrow into stored seeds to fed on. Due to impact of larval predation, several plant defense studies have been developed, indicating that alpha-amylase inhibitors are able to impede and/or reduce bruchids digestive process. In this report, a novel alpha-amylase inhibitor from papaya seeds (Carica papaya) with activity against cowpea weevil enzymes was purified and biochemical characterized. Peeled seeds were macerated and extracted with a 0.6 M NaCl and 0.1% HCl solution. Crude extract was precipitated with ammonium sulphate (100%). After dialyses, this rich fraction was applied onto a CM-Cellulose column and retained peak was submitted to an analytic reversed-phase column HPLC (Vydac C-18TP) yielding several peaks. Only one fraction, with molecular mass of 4562 Da, showed significant inhibitory activity against C. maculatus alpha-amylases. Otherwise, no inhibitory activities against mammalian alpha-amylases were observed. Bioassays using artificial seeds containing C. papaya alpha-amylase inhibitor rich fraction (0.5% and 1.0%) were also conduced showing that alpha-amylase inhibitors were able to increase larval mortality (50%) and also decrease insect fecundity and adult longevity. These results showed the presence of an alpha-amylase inhibitor from C. papaya seeds with high specificity to insect enzymes, indicating that this inhibitor probably could be used, through genetic engineering, in the construction of transgenic plants with enhanced resistance toward cowpea weevil. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Brasilia, Ctr Anal Proteom & Bioquim, Programa Posgrad Ciencias Genom & Biotecnol, BR-70910900 Brasilia, DF, Brazil.
   EMBRAPA, Cenargen, Brasilia, DF, Brazil.
RP Franco, OL (corresponding author), Univ Brasilia, Ctr Anal Proteom & Bioquim, Programa Posgrad Ciencias Genom & Biotecnol, BR-70910900 Brasilia, DF, Brazil.
EM ocfranco@pos.ucb.br
RI laumann, raul/AAC-4416-2019; Franco, Octavio L/T-3020-2017; Bloch,
   Carlos/S-8375-2019; Pelegrini, Patr\\xc3\\xadcia/U-2882-2019; Costa,
   Fabio/E-1181-2012; Grossi-de-Sa, Maria Fatima/N-7856-2017; Laumann,
   Raul/C-4026-2013
OI laumann, raul/0000-0003-3531-2613; Costa, Fabio/0000-0001-9969-7300;
   Laumann, Raul/0000-0003-3531-2613; Franco, Octavio/0000-0001-9546-0525;
   Neto, Simone Maria/0000-0002-7690-8184; GROSSI-DE-SA, MARIA
   FATIMA/0000-0001-8184-9599
CR ABE J, 1993, BIOCHEM J, V293, P151, DOI 10.1042/bj2930151
   AZARKAN M, 2006, BIOCHIM BIOPHYS ACTA, V1746, P1063
   BALESTRIERI C, 1990, EUR J BIOCHEM, V193, P183, DOI 10.1111/j.1432-1033.1990.tb19321.x
   BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5
   Bloch C, 1998, PROTEINS, V32, P334, DOI 10.1002/(SICI)1097-0134(19980815)32:3<334::AID-PROT9>3.0.CO;2-H
   BLOCH C, 1991, FEBS LETT, V279, P101, DOI 10.1016/0014-5793(91)80261-Z
   BUONOCORE V, 1976, BIOCHEM J, V153, P621, DOI 10.1042/bj1530621
   CAMPOS FAP, 1983, FEBS LETT, V152, P300, DOI 10.1016/0014-5793(83)80400-1
   Carlini CR, 2002, TOXICON, V40, P1515, DOI 10.1016/S0041-0101(02)00240-4
   Castro MD, 1996, PROTEIN PEPTIDE LETT, V3, P267
   CHAGOLLALOPEZ A, 1994, J BIOL CHEM, V269, P23675
   Dayler CSA, 2005, FEBS LETT, V579, P5616, DOI 10.1016/j.febslet.2005.09.030
   deSa MFG, 1997, PLANTA, V203, P295, DOI 10.1007/s004250050195
   Dias SC, 2005, PROTEIN J, V24, P113, DOI 10.1007/s10930-004-1518-4
   Feng GH, 1996, INSECT BIOCHEM MOLEC, V26, P419, DOI 10.1016/0965-1748(95)00087-9
   Franco OL, 2005, J AGR FOOD CHEM, V53, P1585, DOI 10.1021/jf049343x
   Franco OL, 2002, EUR J BIOCHEM, V269, P397, DOI 10.1046/j.0014-2956.2001.02656.x
   Franco OL, 2000, EUR J BIOCHEM, V267, P2166, DOI 10.1046/j.1432-1327.2000.01199.x
   Giri AP, 1998, PHYTOCHEMISTRY, V47, P197, DOI 10.1016/S0031-9422(97)00570-0
   HARSAWASDI C, 2000, BIOSCI BIOTECH BIOCH, V64, P1041
   Iulek J, 2000, INT J BIOCHEM CELL B, V32, P1195, DOI 10.1016/S1357-2725(00)00053-4
   Kim MJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P277, DOI 10.1006/abbi.1999.1423
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   MARSHALL JJ, 1975, J BIOL CHEM, V250, P8030
   Melo FR, 1999, PROTEIN PEPTIDE LETT, V6, P385
   Melo FR, 2002, PROTEINS, V48, P311, DOI 10.1002/prot.10142
   MENDEZ E, 1990, EUR J BIOCHEM, V194, P533, DOI 10.1111/j.1432-1033.1990.tb15649.x
   MORENO J, 1989, P NATL ACAD SCI USA, V86, P7885, DOI 10.1073/pnas.86.20.7885
   Morton RL, 2000, P NATL ACAD SCI USA, V97, P3820, DOI 10.1073/pnas.070054597
   Payan F., 2005, BIOCHIM BIOPHYS ACTA, V1696, P171
   Pelegrini PB, 2006, ARCH INSECT BIOCHEM, V61, P77, DOI 10.1002/arch.20099
   Pelegrini PB, 2005, INT J BIOCHEM CELL B, V37, P2239, DOI 10.1016/j.biocel.2005.06.011
   RICHARDSON M, 1990, METHODS PLANT BIOCH, V5, P261
   Romagnoli S, 2003, BIOCHEMISTRY-US, V42, P12503, DOI 10.1021/bi034762t
   RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233
   SANCHEZMONGE R, 1992, BIOCHEM J, V281, P401, DOI 10.1042/bj2810401
   SHADE RE, 1994, BIO-TECHNOL, V12, P793, DOI 10.1038/nbt0894-793
   SILANO V., 1987, ENZYMES THEIR ROLE C, P141
   Sivakumar S, 2006, PESTIC BIOCHEM PHYS, V85, P155, DOI 10.1016/j.pestbp.2005.11.008
   Song XM, 2005, PLANT MOL BIOL, V57, P13, DOI 10.1007/s11103-004-6637-y
   Strobl S, 1998, J MOL BIOL, V278, P617, DOI 10.1006/jmbi.1998.1667
   TAKASE K, 1994, BIOCHEMISTRY-US, V33, P7925, DOI 10.1021/bi00191a020
   Thevissen K, 1996, J BIOL CHEM, V271, P15018, DOI 10.1074/jbc.271.25.15018
   Vila-Perello M, 2003, FEBS LETT, V536, P215, DOI 10.1016/S0014-5793(03)00053-X
   Wijaya R, 2000, PLANT SCI, V159, P243, DOI 10.1016/S0168-9452(00)00348-4
   Yamagata H, 1998, BIOSCI BIOTECH BIOCH, V62, P978, DOI 10.1271/bbb.62.978
   Young NM, 1999, FEBS LETT, V446, P203, DOI 10.1016/S0014-5793(99)00212-4
NR 47
TC 22
Z9 28
U1 1
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0048-3575
EI 1095-9939
J9 PESTIC BIOCHEM PHYS
JI Pest. Biochem. Physiol.
PD MAR
PY 2007
VL 87
IS 3
BP 255
EP 260
DI 10.1016/j.pestbp.2006.08.004
PG 6
WC Biochemistry & Molecular Biology; Entomology; Physiology
SC Biochemistry & Molecular Biology; Entomology; Physiology
GA 142NS
UT WOS:000244657300009
OA Green Published
DA 2020-12-08
ER

PT J
AU Costa, FTM
   Avril, M
   Nogueira, PA
   Gysin, J
AF Costa, F. T. M.
   Avril, M.
   Nogueira, P. A.
   Gysin, J.
TI Cytoadhesion of Plasmodium falciparum-infected erythrocytes and the
   infected placenta: a two-way pathway
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article
DE Plasmodium falciparum; cytoadhesion; pregnancy-associated malaria;
   var2(CSA) gene
ID CHONDROITIN-SULFATE-A; PREGNANCY-ASSOCIATED MALARIA; MICROVASCULAR
   ENDOTHELIAL-CELLS; VARIANT SURFACE-ANTIGEN; CSA-BINDING PARASITES;
   FUNCTIONAL SPECIALIZATION; INHIBIT BINDING; IFN-GAMMA; IN-VITRO; VAR
   GENE
AB Malaria is undoubtedly the world's most devastating parasitic disease, affecting 300 to 500 million people every year. Some cases of Plasmodium falciparum infection progress to the deadly forms of the disease responsible for I to 3 million deaths annually. P. falciparum-infected erythrocytes adhere to host receptors in the deep microvasculature of several organs. The cytoadhesion of infected erythrocytes to placental syncytiotrophoblast receptors leads to pregnancy-associated malaria (PAM). This specific maternal-fetal syndrome causes maternal anemia, low birth weight and the death of 62,000 to 363,000 infants per year in sub-Saharan Africa, and thus has a poor outcome for both mother and fetus. However, PAM and non-PAM parasites have been shown to differ antigenically and genetically. After multiple pregnancies, women from different geographical areas develop adhesion-blocking antibodies that protect against placental parasitemia and clinical symptoms of PAM. The recent description of a new parasite ligand encoded by the var2(CSA) gene as the only gene up-regulated in PAM parasites renders the development of an anti-PAM vaccine more feasible. The search for a vaccine to prevent P. falciparum sequestration in the placenta by eliciting adhesion-blocking antibodies and a cellular immune response, and the development of new methods for evaluating such antibodies should be key priorities in mother-child health programs in areas of endemic malaria. This review summarizes the main molecular, immunological and physiopathological aspects of PAM, including findings related to new targets in the P. falciparum var gene family. Finally, we focus on a new methodology for mimicking cytoadhesion under blood flow conditions in human placental tissue.
C1 Univ Estadual Campinas, Inst Biol, Dept Microbiol & Imunol, BR-13083862 Campinas, SP, Brazil.
   Univ Estadual Campinas, Inst Biol, Dept Parasitol, BR-13083862 Campinas, SP, Brazil.
   Univ Aix Marseille 2, Inst Pasteur, Unite Parasitol Expt, Marseille, France.
   Ctr Pesquisa Med Trop, Port Velho, RO, Brazil.
RP Costa, FTM (corresponding author), Univ Estadual Campinas, Inst Biol, Dept Microbiol & Imunol, BR-13083862 Campinas, SP, Brazil.
EM costaftm@unicamp.br
RI Costa, Fabio/E-1181-2012
OI Costa, Fabio/0000-0001-9969-7300
CR Achur RN, 2003, J BIOL CHEM, V278, P11705, DOI 10.1074/jbc.M211015200
   Achur RN, 2000, J BIOL CHEM, V275, P40344, DOI 10.1074/jbc.M006398200
   Agbor-Enoh ST, 2003, INFECT IMMUN, V71, P2455, DOI 10.1128/IAI.71.5.2455-2461.2003
   Alkhalil A, 2000, J BIOL CHEM, V275, P40357, DOI 10.1074/jbc.M006399200
   Andrews KT, 2005, INFECT IMMUN, V73, P4288, DOI 10.1128/IAI.73.7.4288-4294.2005
   Andrews KT, 2003, MOL MICROBIOL, V49, P655, DOI 10.1046/j.1365-2958.2003.03595.x
   Avril M, 2004, MICROBES INFECT, V6, P249, DOI 10.1016/j.micinf.2003.12.007
   AVRIL M, 2006, IN PRESS MICROBES IN
   Beeson JG, 2005, CURR TOP MICROBIOL, V297, P187
   Bir N, 2006, INFECT IMMUN, V74, P5955, DOI 10.1128/IAI.00481-06
   Brustoski K, 2005, J IMMUNOL, V174, P1738, DOI 10.4049/jimmunol.174.3.1738
   Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743
   Chaisavaneeyakorn S, 2005, INFECT IMMUN, V73, P3287, DOI 10.1128/IAI.73.6.3287-3293.2005
   COOKE BM, 1995, PARASITOL TODAY, V11, P282, DOI 10.1016/0169-4758(95)80040-9
   DAVID PH, 1983, P NATL ACAD SCI-BIOL, V80, P5075, DOI 10.1073/pnas.80.16.5075
   Davison BB, 2005, J INFECT DIS, V191, P1940, DOI 10.1086/430004
   del Portillo HA, 2001, NATURE, V410, P839, DOI 10.1038/35071118
   Diouf I, 2004, J INFECT DIS, V189, P2235, DOI 10.1086/420791
   Duffy PE, 2005, CURR TOP MICROBIOL, V295, P169
   Duffy PE, 2003, INFECT IMMUN, V71, P6620, DOI 10.1128/IAI.71.11.6620-6623.2003
   Elliott SR, 2005, INFECT IMMUN, V73, P2848, DOI 10.1128/IAI.73.5.2848-2856.2005
   Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531
   Fried M, 1998, J IMMUNOL, V160, P2523
   Fried M, 2004, PROTEOMICS, V4, P1086, DOI 10.1002/pmic.200300666
   Fried M, 2006, EXP PARASITOL, V113, P36, DOI 10.1016/j.exppara.2005.12.003
   Fusai T, 2000, MOL BIOCHEM PARASIT, V108, P25, DOI 10.1016/S0166-6851(00)00199-7
   Gamain B, 2005, J INFECT DIS, V191, P1010, DOI 10.1086/428137
   Gamain B, 2004, MOL MICROBIOL, V53, P445, DOI 10.1111/j.1365-2958.2004.04145.x
   Gamain B, 2002, P NATL ACAD SCI USA, V99, P10020, DOI 10.1073/pnas.152321599
   GAY F, 1995, J IMMUNOL METHODS, V184, P15, DOI 10.1016/0022-1759(95)00070-Q
   Gysin J, 1999, INFECT IMMUN, V67, P6596
   GYSIN J, 1992, EXP PARASITOL, V75, P390, DOI 10.1016/0014-4894(92)90252-6
   Gysin J, 1997, MOL BIOCHEM PARASIT, V88, P267, DOI 10.1016/S0166-6851(97)00082-0
   Kraemer SM, 2003, MOL MICROBIOL, V50, P1527, DOI 10.1046/j.1365-2958.2003.03814.x
   LeHesran JY, 1997, AM J EPIDEMIOL, V146, P826, DOI 10.1093/oxfordjournals.aje.a009200
   Martinez-Espinosa FE, 2004, MEM I OSWALDO CRUZ, V99, P19, DOI 10.1590/S0074-02762004000100003
   McGready R, 2004, AM J TROP MED HYG, V70, P398, DOI 10.4269/ajtmh.2004.70.398
   Megnekou R, 2005, INFECT IMMUN, V73, P4112, DOI 10.1128/IAI.73.7.4112-4118.2005
   Moore JM, 1999, J INFECT DIS, V179, P1218, DOI 10.1086/314737
   Mutabingwa TK, 2005, PLOS MED, V2, P1260, DOI 10.1371/journal.pmed.0020407
   Muthusamy A, 2004, AM J PATHOL, V164, P2013, DOI 10.1016/S0002-9440(10)63761-3
   Nosten F, 1999, LANCET, V354, P546, DOI 10.1016/S0140-6736(98)09247-2
   O'Neil-Dunne I, 2001, INFECT IMMUN, V69, P7487, DOI 10.1128/IAI.69.12.7487-7492.2001
   Ordi J, 1998, AM J SURG PATHOL, V22, P1006, DOI 10.1097/00000478-199808000-00011
   Pouvelle B, 1998, INFECT IMMUN, V66, P4950, DOI 10.1128/IAI.66.10.4950-4956.1998
   Pouvelle B, 1997, MOL MED, V3, P508, DOI 10.1007/BF03401697
   Pouvelle B, 2003, J INFECT DIS, V187, P292, DOI 10.1086/346050
   Robinson BA, 2003, MOL MICROBIOL, V47, P1265, DOI 10.1046/j.1365-2958.2003.03378.x
   ROGERSON SJ, 1995, J EXP MED, V182, P15, DOI 10.1084/jem.182.1.15
   Salanti A, 2004, J EXP MED, V200, P1197, DOI 10.1084/jem.20041579
   Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x
   Schofield L, 2005, NAT REV IMMUNOL, V5, P722, DOI 10.1038/nri1686
   Staalsoe T, 2004, LANCET, V363, P283, DOI 10.1016/S0140-6736(03)15386-X
   Staalsoe T, 2001, J INFECT DIS, V184, P618, DOI 10.1086/322809
   Suguitan AL, 2003, J INFECT DIS, V188, P1074
   Taylor DW, 2004, INFECT IMMUN, V72, P1603, DOI 10.1128/IAI.72.3.1603-1607.2004
   Todryk SM, 2005, IMMUNOLOGY, V115, P163, DOI 10.1111/j.1365-2567.2005.02154.x
   Viebig NK, 2006, EXP PARASITOL, V112, P121, DOI 10.1016/j.exppara.2005.09.007
   Viebig NK, 2005, EMBO REP, V6, P775, DOI 10.1038/sj.embor.7400466
   WAHLGREN M, 1999, MALARIA MOL CLIN ASP, P289
   Winter Gerhard, 2004, Molecular & Biochemical Parasitology, V134, P37, DOI 10.1016/j.molbiopara.2003.11.002
NR 61
TC 15
Z9 16
U1 0
U2 2
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD DEC
PY 2006
VL 39
IS 12
BP 1525
EP 1536
DI 10.1590/S0100-879X2006001200003
PG 12
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 120RJ
UT WOS:000243103300003
PM 17160261
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU de Carvalho, DD
   Costa, FTM
   Duran, N
   Haun, M
AF de Carvalho, Daniela D.
   Costa, Fabio T. M.
   Duran, Nelson
   Haun, Marcela
TI Cytotoxic activity of violacein in human colon cancer cells
SO TOXICOLOGY IN VITRO
LA English
DT Article
DE violacein; reactive oxygen species; colon cancer cell death; apoptosis
ID OXIDATIVE STRESS; INCLUSION COMPLEX; CYTOCHROME-C; APOPTOSIS; INDUCTION;
   BETA; MITOCHONDRIA; REQUIREMENT; GENERATION; RELEASE
AB Several studies have shown that violacein, a purple pigment extracted from Chromobacterium violaceum, is capable to induce apoptosis in a variety of cancer cells, including those leukemia cell lines. Herein, we examined the effects of violacein on reactive oxygen species (ROS) production during the apoptotic colon cancer cell death. We demonstrate that violacein mediates ROS production followed by activation of Caspase-3, release of cytochrome c, and calcium release to citosol in Caco-2 cells. Moreover, presence of ROS scavengers such as N-acetyl-cysteine (NAC) diminishes ROS cytotoxicity induced by violacein in Caco-2 cells, indicating that violacein mediates cellular critical mechanisms in the triggering of apoptotic tumor cell death. These data also imply that violacein-induced ROS are collectively key mediators of mitochondrial membrane collapse, leading to cytochrome c release, and culminating in tumor apoptosis. Unlike in Caco-2 cells, violacein was incapable of increasing ROS levels in HT29 cells, suggesting the existence of violacein cell-type specific mechanisms. Those findings bring light to the violacein cytotoxic mechanism studies, indicating that oxidative stress play a role in the violacein-induced cytotoxicity. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Estadual Campinas, UNICAMP, IB, Dept Bioquim, Campinas, SP, Brazil.
   Univ Estadual Campinas, UNICAMP, IB, Dept Parasitol, Campinas, SP, Brazil.
   Univ Estadual Campinas, UNICAMP, IB, Dept Microbiol & Immunol, Campinas, SP, Brazil.
   Univ Estadual Campinas, UNICAMP, Inst Quim, Lab Quim Biol, Campinas, SP, Brazil.
RP de Carvalho, DD (corresponding author), Univ Estadual Campinas, UNICAMP, IB, Dept Bioquim, Campinas, SP, Brazil.
EM ddc@unicamp.br
RI Costa, Fabio/E-1181-2012; de Carvalho, Daniela/G-9453-2019; Carvalho,
   Daniela/L-1944-2013
OI Costa, Fabio/0000-0001-9969-7300; Carvalho, Daniela/0000-0002-2479-949X;
   Duran, Nelson/0000-0001-8372-5143
CR Battu S, 1998, ANTICANCER RES, V18, P3579
   Bromberg N, 2005, J ENZYM INHIB MED CH, V20, P449, DOI 10.1080/14756360500273052
   BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   De Azevedo MBM, 2000, J INCL PHENOM MACRO, V37, P67, DOI 10.1023/A:1008186706573
   De Azevedo MBM, 2000, J INCL PHENOM MACRO, V37, P93, DOI 10.1023/A:1008138807481
   DURAN N, 1994, WORLD J MICROB BIOT, V10, P686, DOI 10.1007/BF00327960
   Duran N, 2001, CRIT REV MICROBIOL, V27, P201, DOI 10.1080/20014091096747
   DURAN N, 1983, AN ACAD BRAS CIENC, V55, P231
   Ferreira CV, 2004, BLOOD, V104, P1459, DOI 10.1182/blood-2004-02-0594
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Friesen C, 1999, CELL DEATH DIFFER, V6, P471, DOI 10.1038/sj.cdd.4400512
   Garcia-Ruiz C, 2000, FASEB J, V14, P847
   Gibson BW, 2005, INT J BIOCHEM CELL B, V37, P927, DOI 10.1016/j.biocel.2004.11.013
   Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com
   Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132
   Kodach LL, 2006, CARCINOGENESIS, V27, P508, DOI 10.1093/carcin/bgi307
   Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9
   Melo PD, 2000, IN VITRO CELL DEV-AN, V36, P539
   Melo PS, 2003, TOXICOLOGY, V186, P217, DOI 10.1016/S0300-483X(02)00751-5
   Noda T, 2001, FASEB J, V15, P2131, DOI 10.1096/fj.01-0131com
   Rettori D, 1998, WORLD J MICROB BIOT, V14, P685, DOI 10.1023/A:1008809504504
   Saraiva VS, 2004, MELANOMA RES, V14, P421, DOI 10.1097/00008390-200410000-00014
   Saris NEL, 2005, BIOCHEMISTRY-MOSCOW+, V70, P187, DOI 10.1007/s10541-005-0100-9
   SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296
   Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489
   van Kooten TG, 1999, J BIOMED MATER RES, V46, P33, DOI 10.1002/(SICI)1097-4636(199907)46:1<33::AID-JBM4>3.0.CO;2-K
   Wedgwood S, 2001, AM J PHYSIOL-LUNG C, V281, pL1058
   Yan LJ, 1997, P NATL ACAD SCI USA, V94, P11168, DOI 10.1073/pnas.94.21.11168
NR 29
TC 54
Z9 54
U1 0
U2 16
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-2333
J9 TOXICOL IN VITRO
JI Toxicol. Vitro
PD DEC
PY 2006
VL 20
IS 8
BP 1514
EP 1521
DI 10.1016/j.tiv.2006.06.007
PG 8
WC Toxicology
SC Toxicology
GA 106XU
UT WOS:000242136100030
PM 16889929
DA 2020-12-08
ER

PT J
AU Layez, C
   Nogueira, P
   Combes, V
   Costa, FTM
   Juhan-Vague, I
   da Silva, LHP
   Gysin, J
AF Layez, C
   Nogueira, P
   Combes, V
   Costa, FTM
   Juhan-Vague, I
   da Silva, LHP
   Gysin, J
TI Plasmodium falciparum rhoptry protein RSP2 triggers destruction of the
   erythroid lineage
SO BLOOD
LA English
DT Article
ID BLOOD-CELL DEFORMABILITY; INFECTED ERYTHROCYTES; BONE-MARROW; MALARIA
   INFECTION; ENDOTHELIAL-CELLS; IMMUNE-RESPONSE; ANEMIA; SURFACE;
   CHONDROITIN-4-SULFATE; ERYTHROPHAGOCYTOSIS
AB The destruction of erythrocytes and defects in erythropoiesis are among the most frequently observed causes of morbidity in severe Plasmodium falciparum malaria. The molecular mechanisms involved remain unclear, despite extensive investigation. We show here, for the first time, that tagging with the parasite rhoptry protein ring surface protein 2 (RSP2) is not restricted to the surfaces of normal erythrocytes, as previously reported, but that it extends to erythroid precursor cells in the bone marrow of anemic malaria patients. Monoclonal mouse antibodies and human sera from patients with severe anemia, reacting with RSP2-tagged erythrocytes, induced cell destruction by phagocytosis and complement activation in vitro. Our observations reveal a new parasite mechanism implicated in the destruction of normal erythrocytes and probably dyserythropoiesis in malaria patients. These data suggest that the tagging of host cells with RSP2 may trigger anemia in falciparum malaria.
C1 Univ Mediterranee, URA, Unite Parasitol Expt, Inst Pasteur,EA3282,IFR48,Fac Med, F-13385 Marseille, France.
   CEPEM, Unidade Imunol & Parasitol Expt, BR-364 Rondonia, Brazil.
   Univ Estadual Campinas, Dept Parasitol, Campinas, Brazil.
   Univ Mediterranee, Fac Med, Hematol Lab, F-13385 Marseille, France.
RP Gysin, J (corresponding author), Univ Mediterranee, URA, Unite Parasitol Expt, Inst Pasteur,EA3282,IFR48,Fac Med, 27 Bd Jean Moulin, F-13385 Marseille, France.
EM gysin@medecine.univ-mrs.fr
RI Costa, Fabio/E-1181-2012; Nogueira, Paulo/AAK-8822-2020
OI Costa, Fabio/0000-0001-9969-7300; Combes, Valery/0000-0003-2178-3596
CR ABDALLA S, 1980, BRIT J HAEMATOL, V46, P171, DOI 10.1111/j.1365-2141.1980.tb05956.x
   Andrews KT, 2003, MOL MICROBIOL, V49, P655, DOI 10.1046/j.1365-2958.2003.03595.x
   Baldi DL, 2000, EMBO J, V19, P2435, DOI 10.1093/emboj/19.11.2435
   Baldi DL, 2002, INFECT IMMUN, V70, P5236, DOI 10.1128/IAI.70.9.5236-5245.2002
   Baum J, 2002, MOL BIOL EVOL, V19, P223, DOI 10.1093/oxfordjournals.molbev.a004075
   CHEN P, 1980, Southeast Asian Journal of Tropical Medicine and Public Health, V11, P435
   Dondorp AM, 2000, PARASITOL TODAY, V16, P228, DOI 10.1016/S0169-4758(00)01666-5
   Dondorp AM, 1999, AM J TROP MED HYG, V60, P733, DOI 10.4269/ajtmh.1999.60.733
   Douki JBL, 2003, BLOOD, V101, P5025, DOI 10.1182/blood-2002-12-3710
   Ekvall H, 2003, CURR OPIN HEMATOL, V10, P108, DOI 10.1097/00062752-200303000-00002
   FACER CA, 1981, LANCET, V1, P897
   FRIEDMAN MJ, 1984, J CELL BIOL, V98, P1672, DOI 10.1083/jcb.98.5.1672
   Goka BQ, 2001, T ROY SOC TROP MED H, V95, P545, DOI 10.1016/S0035-9203(01)90036-7
   GROUX H, 1990, RES IMMUNOL, V141, P529, DOI 10.1016/0923-2494(90)90021-P
   Gysin J, 1999, INFECT IMMUN, V67, P6596
   Gysin J, 1996, RES IMMUNOL, V147, P397, DOI 10.1016/0923-2494(96)82048-7
   Holm I, 1997, MOL BIOCHEM PARASIT, V89, P313, DOI 10.1016/S0166-6851(97)00128-X
   KNUTTGEN HJ, 1987, ANN TROP MED PARASIT, V81, P567
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   Letestu R, 2003, ANN BIOL CLIN-PARIS, V61, P655
   LOOAREESUWAN S, 1987, BRIT J HAEMATOL, V67, P473, DOI 10.1111/j.1365-2141.1987.tb06171.x
   LOOAREESUWAN S, 1991, ACTA TROP, V48, P263, DOI 10.1016/0001-706X(91)90014-B
   MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045
   ODUOLA AMJ, 1988, EXP PARASITOL, V67, P354, DOI 10.1016/0014-4894(88)90082-3
   OKANO H, 1981, J CANCER RES CLIN, V102, P49, DOI 10.1007/BF00410534
   Omodeo-Sale F, 2005, EUR J HAEMATOL, V74, P324, DOI 10.1111/j.1600-0609.2004.00352.x
   PERRIN LH, 1984, CLIN EXP IMMUNOL, V56, P67
   PHILLIPS RE, 1992, BAILLIERE CLIN HAEM, V5, P315, DOI 10.1016/S0950-3536(11)80022-3
   Pouvelle B, 2000, NAT MED, V6, P1264
   Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X
   Rogerson SJ, 2003, AM J TROP MED HYG, V68, P115, DOI 10.4269/ajtmh.2003.68.1.0680115
   SABCHAREON A, 1991, AM J TROP MED HYG, V45, P297, DOI 10.4269/ajtmh.1991.45.297
   Saul Allan, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P656
   Stowers A, 1997, INFECT IMMUN, V65, P2329, DOI 10.1128/IAI.65.6.2329-2338.1997
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Waitumbi JN, 2000, BLOOD, V95, P1481, DOI 10.1182/blood.V95.4.1481.004k15_1481_1486
   WEATHERALL DJ, 1983, CIBA F SYMP, V94, P74
   Wickramasinghe SN, 2000, BEST PRACT RES CL HA, V13, P277, DOI 10.1053/beha.1999.0072
NR 38
TC 37
Z9 37
U1 0
U2 1
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD NOV 15
PY 2005
VL 106
IS 10
BP 3632
EP 3638
DI 10.1182/blood-2005-04-1574
PG 7
WC Hematology
SC Hematology
GA 982US
UT WOS:000233187700053
PM 16046531
DA 2020-12-08
ER

PT J
AU Avril, M
   Traore, B
   Costa, FTM
   Lepolard, C
   Gysin, J
AF Avril, M
   Traore, B
   Costa, FTM
   Lepolard, C
   Gysin, J
TI Placenta cryosections for study of the adhesion of Plasmodium
   falciparum-infected erythrocytes to chondroitin sulfate A in flow
   conditions
SO MICROBES AND INFECTION
LA English
DT Article
DE Plasmodium falciparum; cytoadhesion; inhibitors; chondroitin sulfate A;
   placenta model; flow conditions
ID MICROVASCULAR ENDOTHELIAL-CELLS; RED-BLOOD-CELLS; SAIMIRI-SCIUREUS;
   MALARIA; CYTOADHESION; ANTIBODIES; RECEPTOR; SEQUESTRATION;
   PROTEOGLYCAN; ADHERENCE
AB The adhesion of Plasmodium falciparum-infected erythrocytes (IEs) to chondroitin-4-sulfate (CSA) via the PfEMPI-CSA parasite ligand domain is correlated with placental malaria in primigravidae. The recent identification of parasite genes encoding CSA adhesion molecules and the development of pan-reactive monoclonal antibodies against the pf(CSA) ligand have opened up new avenues for the development of anti-IE sequestration therapies for the prevention of placental malaria. A model closely mimicking placental sequestration of IEs during pregnancy is needed for the preclinical and clinical evaluation of candidate molecules for the induction of antibodies that could protect pregnant women from placental malaria. We found that normal placenta cryosections were a specific and highly consistent support for the binding of IEs to CSA in flow conditions under physiological conditions. This model makes possible the quantitative and qualitative analysis of IE adhesion. We identified distinct CSA-binding phenotypes within the FCR3(CSA)-selected parasites in flow analyses, but not in static analyses. We also analyzed inhibitors of placental parasite binding such as soluble CSA and antibodies directed against the pf(CSA) ligand. Our data demonstrate that placenta cryosections could be used to standardize assays between laboratories, potentially advancing the development of therapies against placental malaria. (C) 2003 Elsevier SAS. All rights reserved.
C1 Univ Aix Marseille 2, Fac Med, Unite Parasitol Expt URA IPP UNIV MED EA 3282, F-13385 Marseille 5, France.
   Fac Med, Dept Epidemiol Affect Parasitaires, Bamako, Mali.
   Univ Estadual Campinas, Inst Biol, Dept Parasitol, Campinas, SP, Brazil.
RP Gysin, J (corresponding author), Univ Aix Marseille 2, Fac Med, Unite Parasitol Expt URA IPP UNIV MED EA 3282, IFR 48,27 Blvd Jean Moulin, F-13385 Marseille 5, France.
EM gysin@medecine.univ-mrs.fr
RI catherine, lepolard/P-5653-2016; Costa, Fabio/E-1181-2012
OI Costa, Fabio/0000-0001-9969-7300
CR Andrews KT, 2003, MOL MICROBIOL, V49, P655, DOI 10.1046/j.1365-2958.2003.03595.x
   Beeson JG, 2001, TRENDS PARASITOL, V17, P331, DOI 10.1016/S1471-4922(01)01917-1
   Chien S., 1969, ADVAN MICROCIRCULATI, V2, P89
   CHIEN S, 1972, PRESENT STATE BLOOD
   Cooke BM, 1996, BLOOD, V88, P4040, DOI 10.1182/blood.V88.10.4040.bloodjournal88104040
   Cooke Brian M, 2002, Methods Mol Med, V72, P561, DOI 10.1385/1-59259-271-6:561
   Cooke Brian M, 2002, Methods Mol Med, V72, P571, DOI 10.1385/1-59259-271-6:571
   Costa FTM, 2003, J INFECT DIS, V188, P153, DOI 10.1086/375800
   Douki JBL, 2003, BLOOD, V101, P5025, DOI 10.1182/blood-2002-12-3710
   Douki JBL, 2002, BLOOD, V100, P1478, DOI 10.1182/blood-2002-01-0315
   Fried M, 2000, EXP PARASITOL, V95, P75, DOI 10.1006/expr.2000.4510
   Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502
   Fried M, 1998, NATURE, V395, P851, DOI 10.1038/27570
   Fusai T, 2000, MOL BIOCHEM PARASIT, V108, P25, DOI 10.1016/S0166-6851(00)00199-7
   GAY F, 1995, J IMMUNOL METHODS, V184, P15, DOI 10.1016/0022-1759(95)00070-Q
   Gysin J, 1999, INFECT IMMUN, V67, P6596
   GYSIN J, 1980, J PARASITOL, V66, P1003, DOI 10.2307/3280405
   GYSIN J, 1983, AM J TROP MED HYG, V32, P461, DOI 10.4269/ajtmh.1983.32.461
   Pouvelle B, 2000, NAT MED, V6, P1264
   Pouvelle B, 1998, INFECT IMMUN, V66, P4950, DOI 10.1128/IAI.66.10.4950-4956.1998
   Pouvelle B, 2003, J INFECT DIS, V187, P292, DOI 10.1086/346050
   Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X
   Rogerson SJ, 1997, EXP PARASITOL, V86, P8, DOI 10.1006/expr.1996.4142
   Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x
   Trager W, 1997, INT J PARASITOL, V27, P989, DOI 10.1016/S0020-7519(97)00080-5
NR 25
TC 21
Z9 21
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1286-4579
EI 1769-714X
J9 MICROBES INFECT
JI Microbes Infect.
PD MAR
PY 2004
VL 6
IS 3
BP 249
EP 255
DI 10.1016/j.micinf.2003.12.007
PG 7
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 805UV
UT WOS:000220392100001
PM 15026011
DA 2020-12-08
ER

PT J
AU Belnoue, E
   Costa, FTM
   Frankenberg, T
   Vigario, AM
   Voza, T
   Leroy, N
   Rodrigues, MM
   Landau, I
   Snounou, G
   Renia, L
AF Belnoue, E
   Costa, FTM
   Frankenberg, T
   Vigario, AM
   Voza, T
   Leroy, N
   Rodrigues, MM
   Landau, I
   Snounou, G
   Renia, L
TI Protective T cell immunity against malaria liver stage after vaccination
   with live sporozoites under chloroquine treatment
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID BERGHEI-ANOPHELES-STEPHENSI; PLASMODIUM-BERGHEI; IRRADIATED SPOROZOITES;
   PREERYTHROCYTIC STAGES; CAUSAL PROPHYLAXIS; IFN-GAMMA; YOELII; BLOOD;
   MICE; FALCIPARUM
AB In this study we present the first systematic analysis of the immunity induced by normal Plasmodium yoelii sporozoites in mice. Immunization With sporozoites, which was conducted under chloroquine treatment to minimize the influence of blood stage parasites, induced a strong protection against a subsequent sporozoite and, to a lesser extent, against infected RBC challenges. The protection induced by this immunization protocol proved to be very effective. Induction of this protective immunity depended on the presence of liver stage parasites, as primaquine treatment concurrent with sporozoite immunization abrogated protection. Protection was not found to be mediated by the Abs elicited against pre-erythrocytic and blood stage parasites, as demonstrated by inhibition assays of sporozoite penetration or development in vitro and in vivo assays of sporozoite infectivity or blood stage parasite development. CD4(+) and CD8(+) T cells were, however, responsible for the protection through the induction of IFN-gamma and NO. The Journal of Immunology, 2004, 172: 2487-2495.
C1 Univ Paris 05, Inst Cochin,Hop Cochin, Dept Immunol,INSERM, Unite 567,CNRS, F-75014 Paris, France.
   Univ Estadual Campinas, Dept Parasitol, Campinas, Brazil.
   Museum Natl Hist Nat, F-75231 Paris, France.
   Univ Fed Sao Paulo, Dept Microbiol Imunol & Parasitol, Sao Paulo, Brazil.
   Inst Pasteur, Unite Parasitol Biomed, Paris, France.
   Inst Pasteur, CNRS, Paris, France.
RP Renia, L (corresponding author), Univ Paris 05, Inst Cochin,Hop Cochin, Dept Immunol,INSERM, Unite 567,CNRS, Batiment Gustave Roussy,27 Rue Fbg St Jacques, F-75014 Paris, France.
EM renia@cochin.inserm.fr
RI Rodrigues, Mauricio M./B-8512-2012; Snounou, Georges/F-3352-2011; Costa,
   Fabio/E-1181-2012; , RENIA/E-2117-2011
OI Snounou, Georges/0000-0002-6133-6398; Costa, Fabio/0000-0001-9969-7300;
   , RENIA/0000-0003-0349-1557; Vigario, Ana Margarida/0000-0001-5679-1196
CR Amante FH, 1997, PARASITE IMMUNOL, V19, P111, DOI 10.1046/j.1365-3024.1997.d01-187.x
   BAIRD JK, 1991, AM J TROP MED HYG, V44, P640, DOI 10.4269/ajtmh.1991.44.640
   BEAUDOIN RL, 1977, EXP PARASITOL, V42, P1, DOI 10.1016/0014-4894(77)90054-6
   BOULARD Y, 1983, ANN TROP MED PARASIT, V77, P555, DOI 10.1080/00034983.1983.11811754
   BOYD MF, 1941, S HUMAN MALARIA, P163
   BRADLEYMOORE AM, 1985, ANN TROP MED PARASIT, V79, P549, DOI 10.1080/00034983.1985.11811962
   CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229
   Cotgreave I A, 1997, Adv Pharmacol, V38, P205
   Dieye A, 1997, PARASITOL TODAY, V13, P48, DOI 10.1016/S0169-4758(96)20062-6
   Doolan DL, 2000, J IMMUNOL, V165, P1453, DOI 10.4049/jimmunol.165.3.1453
   DRUILHE P, 1998, MALARIA PARASITE BIO, P513
   FINK E, 1974, B WORLD HEALTH ORGAN, V50, P213
   Fryauff DJ, 1997, AM J TROP MED HYG, V56, P137, DOI 10.4269/ajtmh.1997.56.137
   GOLENSER J, 1977, CLIN EXP IMMUNOL, V29, P43
   HOFFMAN SL, 1989, J IMMUNOL, V142, P1299
   Hulier E, 1996, MOL BIOCHEM PARASIT, V77, P127, DOI 10.1016/0166-6851(96)02584-4
   KARUNAKARAN CS, 1980, J TROP MED HYG, V83, P195
   LANDAU I, 1968, CR ACAD SCI D NAT, V266, P1730
   LANDAU I, 1968, Cahiers de la Maboke, V6, P63
   LANDAU I, 1966, T ROY SOC TROP MED H, V60, P633, DOI 10.1016/0035-9203(66)90010-1
   Makobongo MO, 2003, P NATL ACAD SCI USA, V100, P2628, DOI 10.1073/pnas.0337629100
   Mazier D, 1993, Parassitologia, V35 Suppl, P59
   MELLOUK S, 1991, J IMMUNOL, V146, P3971
   MELLOUK S, 1990, LANCET, V335, P721, DOI 10.1016/0140-6736(90)90832-P
   MOST H, 1975, AM J TROP MED HYG, V24, P179, DOI 10.4269/ajtmh.1975.24.179
   MURPHY GS, 1993, LANCET, V341, P96, DOI 10.1016/0140-6736(93)92568-E
   NARDIN EH, 1993, ANNU REV IMMUNOL, V11, P687, DOI 10.1146/annurev.iy.11.040193.003351
   NUSSLER A, 1989, TROP MED PARASITOL, V40, P468
   NUSSLER A, 1991, INT IMMUNOL, V3, P317, DOI 10.1093/intimm/3.4.317
   NUSSLER AK, 1993, EUR J IMMUNOL, V23, P882, DOI 10.1002/eji.1830230417
   Ocana-Morgner C, 2003, J EXP MED, V197, P143, DOI 10.1084/jem.20021072
   ORJIH AU, 1982, T ROY SOC TROP MED H, V76, P57, DOI 10.1016/0035-9203(82)90019-0
   ORJIH AU, 1979, CLIN EXP IMMUNOL, V38, P1
   Peters W., 1974, Advances Parasit, V12, P69, DOI 10.1016/S0065-308X(08)60387-5
   PIED S, 1992, J IMMUNOL, V148, P197
   RENIA L, 1990, EUR J IMMUNOL, V20, P1445, DOI 10.1002/eji.1830200706
   SCHELLER LF, 1995, P NATL ACAD SCI USA, V92, P4066, DOI 10.1073/pnas.92.9.4066
   SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P10700, DOI 10.1073/pnas.91.22.10700
   SHEAR HL, 1989, J IMMUNOL, V143, P2038
   Silvie O, 2002, PARASITE IMMUNOL, V24, P221, DOI 10.1046/j.1365-3024.2002.00450.x
   Sokhna CS, 2000, AM J TROP MED HYG, V62, P266, DOI 10.4269/ajtmh.2000.62.266
   SOUTHAN GJ, 1995, BRIT J PHARMACOL, V114, P510, DOI 10.1111/j.1476-5381.1995.tb13256.x
   SUHRBIER A, 1990, INFECT IMMUN, V58, P2834, DOI 10.1128/IAI.58.9.2834-2839.1990
   SUI H, 1993, EUR J IMMUNOL, V259, P1742
   TIEGS G, 1989, BIOCHEM PHARMACOL, V38, P627, DOI 10.1016/0006-2952(89)90208-6
   VANDERBERG JP, 1968, J PARASITOL, V54, P1009, DOI 10.2307/3277136
   vanderHeyde HC, 1997, EXP PARASITOL, V85, P206, DOI 10.1006/expr.1996.4132
   WETSTEYN JCFM, 1995, BRIT J CLIN PHARMACO, V39, P696, DOI 10.1111/j.1365-2125.1995.tb05731.x
   Wipasa J, 2002, J IMMUNOL, V169, P944, DOI 10.4049/jimmunol.169.2.944
   WYSOCKA M, 1995, EUR J IMMUNOL, V25, P672, DOI 10.1002/eji.1830250307
NR 50
TC 165
Z9 168
U1 0
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD FEB 15
PY 2004
VL 172
IS 4
BP 2487
EP 2495
DI 10.4049/jimmunol.172.4.2487
PG 9
WC Immunology
SC Immunology
GA 771LZ
UT WOS:000188788600062
PM 14764721
OA Bronze
DA 2020-12-08
ER

PT J
AU Costa, FTM
   Fusai, T
   Parzy, D
   Sterkers, Y
   Torrentino, M
   Douki, JBL
   Traore, B
   Petres, S
   Scherf, A
   Gysin, J
AF Costa, FTM
   Fusai, T
   Parzy, D
   Sterkers, Y
   Torrentino, M
   Douki, JBL
   Traore, B
   Petres, S
   Scherf, A
   Gysin, J
TI Immunization with recombinant duffy binding-like-gamma 3 induces
   pan-reactive and adhesion-blocking antibodies against placental
   chondroitin sulfate A-binding Plasmodium falciparum parasites
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
ID IN-VITRO MODEL; INFECTED ERYTHROCYTES; ENDOTHELIAL-CELLS; MATERNAL
   MALARIA; SAIMIRI-SCIUREUS; BIRTH-WEIGHT; BLOOD STAGES; PREGNANCY;
   PROTECTION; RECEPTOR
AB Maternal malaria is associated with the sequestration, in the placenta, of Plasmodium falciparum-infected erythrocytes onto chondroitin sulfate A (CSA), via the duffy binding-like (DBL)-gamma3 domain of the P. falciparum erythrocyte membrane protein 1 (PfEMP1(CSA)) (DBL-gamma3(CSA)). The production of antibodies against CSA-binding infected erythrocytes (IEsCSA) is correlated with resistance to maternal malaria in multiparous women. We produced recombinant DBL-gamma(3)(CSA) (rDBL-gamma3(CSA)) in insect cells, corresponding to 2 variant DBL-gamma3(CSA) subtypes that mediate binding to CSA in laboratory lines and placental isolates. Both recombinant cysteine-rich DBL-gamma3(CSA) domains blocked IEsCSA binding to CSA. Immunization of mice, with the rDBL-gamma3(CSA)-FCR3 and rDBL-gamma3(CSA)-3D7 domains, resulted in the generation of antibodies recognizing homologous and heterologous rDBL-gamma3(CSA), a finding indicating conserved epitopes inducing a pan-reactive immune response. Mouse monoclonal antibodies (MAbs) against both recombinant proteins were pan-reactive with various IEsCSA. One MAb efficiently inhibited and reversed IECSA cytoadhesion to endothelial cells in vitro. Thus, DBL-gamma3(CSA) is the target of inhibitory and pan-reactive antibodies. Saimiri sciureus monkeys immunized with FCR3-rDBL-gamma3(CSA) developed pan-reactive and inhibitory antibodies, a finding suggesting that the development of a vaccine to prevent maternal malaria is feasible.
C1 Univ Aix Marseille 2, Fac Med, EA 3282, Unite Parasitol Expt, F-13385 Marseille 5, France.
   Univ Aix Marseille 2, Fac Med, Unite Parasitol, F-13385 Marseille 5, France.
   Inst Pasteur, Dept Biol Struct & Chim, Unite Biol Interact Hote Parasite, Paris, France.
   Inst Pasteur, Dept Biol Struct & Chim, Plateau Tech Genom Struct, Paris, France.
RP Gysin, J (corresponding author), Univ Aix Marseille 2, Fac Med, EA 3282, Unite Parasitol Expt, 27 Blvd Jean Moulin, F-13385 Marseille 5, France.
EM gysin@medecine.univ-mrs.fr
RI Scherf, Artur/A-9674-2014; Costa, Fabio/E-1181-2012
OI Costa, Fabio/0000-0001-9969-7300; petres, stephane/0000-0002-4716-565X
CR Baruch DI, 2002, P NATL ACAD SCI USA, V99, P3860, DOI 10.1073/pnas.022018399
   BOUHAROUNTAYOUN H, 1990, J EXP MED, V172, P1633, DOI 10.1084/jem.172.6.1633
   BRABIN BJ, 1983, B WORLD HEALTH ORGAN, V61, P1005
   Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743
   Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660
   Chen QJ, 2000, CLIN MICROBIOL REV, V13, P439, DOI 10.1128/CMR.13.3.439-450.2000
   Craig A, 2000, TRENDS MICROBIOL, V8, P350, DOI 10.1016/S0966-842X(00)01808-4
   Douki JBL, 2002, BLOOD, V100, P1478, DOI 10.1182/blood-2002-01-0315
   Flick K, 2001, SCIENCE, V293, P2098, DOI 10.1126/science.1062891
   Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531
   Fried M, 1998, J MOL MED-JMM, V76, P162, DOI 10.1007/s001090050205
   Fried M, 2002, MOL BIOCHEM PARASIT, V122, P201, DOI 10.1016/S0166-6851(02)00103-2
   Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502
   Galfre G, 1981, Methods Enzymol, V73, P3
   GAY F, 1995, J IMMUNOL METHODS, V184, P15, DOI 10.1016/0022-1759(95)00070-Q
   GROUX H, 1990, RES IMMUNOL, V141, P529, DOI 10.1016/0923-2494(90)90021-P
   Gysin J, 1999, INFECT IMMUN, V67, P6596
   GYSIN J, 1980, J PARASITOL, V66, P1003, DOI 10.2307/3280405
   GYSIN J, 1983, AM J TROP MED HYG, V32, P461, DOI 10.4269/ajtmh.1983.32.461
   GYSIN J, 1992, MEM I OSWALDO CRUZ, V87, P145, DOI 10.1590/S0074-02761992000900023
   Gysin Jurg, 1998, P419
   Maubert B, 2000, PARASITE IMMUNOL, V22, P191, DOI 10.1046/j.1365-3024.2000.00292.x
   MCGREGOR IA, 1983, T ROY SOC TROP MED H, V77, P232, DOI 10.1016/0035-9203(83)90081-0
   MENENDEZ C, 1995, PARASITOL TODAY, V11, P178, DOI 10.1016/0169-4758(95)80151-0
   MOISSON P, 1993, CURRENT PRIMATOLOGY, V3, P263
   Muanza K, 1996, RES IMMUNOL, V147, P149, DOI 10.1016/0923-2494(96)83167-1
   O'Neil-Dunne I, 2001, INFECT IMMUN, V69, P7487, DOI 10.1128/IAI.69.12.7487-7492.2001
   Parzy D, 2000, MICROBES INFECT, V2, P779, DOI 10.1016/S1286-4579(00)90357-5
   Pouvelle B, 1998, INFECT IMMUN, V66, P4950, DOI 10.1128/IAI.66.10.4950-4956.1998
   Pouvelle B, 1997, MOL MED, V3, P508, DOI 10.1007/BF03401697
   Pouvelle B, 2003, J INFECT DIS, V187, P292, DOI 10.1086/346050
   Reeder JC, 1999, P NATL ACAD SCI USA, V96, P5198, DOI 10.1073/pnas.96.9.5198
   Ricke CH, 2000, J IMMUNOL, V165, P3309, DOI 10.4049/jimmunol.165.6.3309
   Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X
   Rowe JA, 2002, J INFECT DIS, V185, P1207, DOI 10.1086/339684
   Salanti A, 2002, MOL BIOCHEM PARASIT, V122, P111, DOI 10.1016/S0166-6851(02)00080-4
   Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418
   Smith JD, 2000, P NATL ACAD SCI USA, V97, P1766, DOI 10.1073/pnas.040545897
   Staalsoe T, 2001, J INFECT DIS, V184, P618, DOI 10.1086/322809
   Steketee RW, 1996, AM J TROP MED HYG, V55, P33, DOI 10.4269/ajtmh.1996.55.33
   Taylor HM, 2000, MOL BIOCHEM PARASIT, V110, P391, DOI 10.1016/S0166-6851(00)00286-3
   TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840
   Vazquez-Macias A, 2002, MOL MICROBIOL, V45, P155, DOI 10.1046/j.1365-2958.2002.02999.x
NR 43
TC 34
Z9 34
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
EI 1537-6613
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUL 1
PY 2003
VL 188
IS 1
BP 153
EP 164
DI 10.1086/375800
PG 12
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 696UK
UT WOS:000183905800022
PM 12825185
OA Bronze
DA 2020-12-08
ER

PT J
AU Douki, JBL
   Sterkers, Y
   Lepolard, C
   Traore, B
   Costa, FTM
   Scherf, A
   Gysin, J
AF Douki, JBL
   Sterkers, Y
   Lepolard, C
   Traore, B
   Costa, FTM
   Scherf, A
   Gysin, J
TI Adhesion of normal and Plasmodium falciparum ring-infected erythrocytes
   to endothelial cells and the placenta involves the rhoptry-derived ring
   surface protein-2
SO BLOOD
LA English
DT Article
ID CHONDROITIN SULFATE; IN-VITRO; MONOCLONAL-ANTIBODIES; SAIMIRI MONKEYS;
   MALARIA; SEQUESTRATION; ANTIGEN; CYTOADHESION; RECEPTOR; EPITOPES
AB Recent findings have challenged the current view of Plasmodium falciparum (P falciparum) blood-stage biology by demonstrating the cytoadhesion of early ring-stage-infected erythrocytes (rIEs) to host endothelial cells and placental syncytiotrophoblasts. The adhesion of rIEs was observed only in parasites that bind to the placenta via chondroitin sulfate A (CSA). In this work, a panel of mouse monoclonal antibodies (mAbs) that specifically inhibit cytoadhesion of rIEs but not of mature IEs was generated. The previously described ring surface protein 2 (RSP-2), a 42-kDa protein, was identified as the target of the ring-stage-specific mAbs. Time course surface fluorescence experiments revealed a short overlap (approximately 4 hours) of expression between RSP-2 and P falciparum erythrocyte membrane protein 1 (PfEMP1). Their consecutive expression enables IEs to adhere to endothelial cells during the entire blood-stage cycle. During this study, a new phenotype was detected in parasite cultures, the adhesion of normal erythrocytes (nEs) to endothelial cells. All adherent nEs were coated with RSP-2. Immunolocalization studies show that RSP-2 is a rhoptry-derived protein that is discharged onto the erythrocyte membrane during contact with merozoites. Our results identify RSP-2 as a key molecule in sequestration of young bloodstage forms and nEs to endothelial cells. (C) 2003 by The American Society of Hematology.
C1 Univ Aix Marseille 2, Fac Med, URA IPP UNIV MED EA 3282, Unite Parasitol Expt, F-13385 Marseille 5, France.
   Inst Pasteur, Unite Biol Interact Hote Parasite, Paris, France.
RP Gysin, J (corresponding author), Univ Aix Marseille 2, Fac Med, URA IPP UNIV MED EA 3282, Unite Parasitol Expt, F-13385 Marseille 5, France.
EM gysin@medecine.univ-mrs.fr
RI Costa, Fabio/E-1181-2012; Scherf, Artur/A-9674-2014; catherine,
   lepolard/P-5653-2016
OI Costa, Fabio/0000-0001-9969-7300; 
CR Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497
   Cooke BM, 1996, BLOOD, V88, P4040, DOI 10.1182/blood.V88.10.4040.bloodjournal88104040
   Douki JBL, 2002, BLOOD, V100, P1478, DOI 10.1182/blood-2002-01-0315
   Galfre G, 1981, Methods Enzymol, V73, P3
   GAY F, 1995, J IMMUNOL METHODS, V184, P15, DOI 10.1016/0022-1759(95)00070-Q
   Gysin J, 1999, INFECT IMMUN, V67, P6596
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567
   Pouvelle B, 2000, NAT MED, V6, P1264
   Pouvelle B, 1997, MOL MED, V3, P508, DOI 10.1007/BF03401697
   Pouvelle B, 2003, J INFECT DIS, V187, P292, DOI 10.1086/346050
   Pradines B, 2000, AM J TROP MED HYG, V62, P82, DOI 10.4269/ajtmh.2000.62.82
   Preiser PR, 1999, NATURE, V398, P618, DOI 10.1038/19309
   RIDLEY RG, 1990, PARASITOLOGY, V101, P187, DOI 10.1017/S0031182000063228
   Scherf A, 2001, CELL MICROBIOL, V3, P125, DOI 10.1046/j.1462-5822.2001.00109.x
   SCHOFIELD L, 1986, MOL BIOCHEM PARASIT, V18, P183, DOI 10.1016/0166-6851(86)90037-X
   Shulman CE, 1996, T ROY SOC TROP MED H, V90, P535, DOI 10.1016/S0035-9203(96)90312-0
   Silamut K, 1999, AM J PATHOL, V155, P395, DOI 10.1016/S0002-9440(10)65136-X
   Wahlgren M, 1999, CELL, V96, P603, DOI 10.1016/S0092-8674(00)80569-3
NR 19
TC 32
Z9 32
U1 0
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD JUN 15
PY 2003
VL 101
IS 12
BP 5025
EP 5032
DI 10.1182/blood-2002-12-3710
PG 8
WC Hematology
SC Hematology
GA 689FV
UT WOS:000183481700065
PM 12609837
DA 2020-12-08
ER

PT J
AU Belnoue, E
   Costa, FTM
   Vigario, AM
   Voza, T
   Gonnet, F
   Landau, I
   van Rooijen, N
   Mack, M
   Kuziel, WA
   Renia, L
AF Belnoue, E
   Costa, FTM
   Vigario, AM
   Voza, T
   Gonnet, F
   Landau, I
   van Rooijen, N
   Mack, M
   Kuziel, WA
   Renia, L
TI Chemokine receptor CCR2 is not essential for the development of
   experimental cerebral malaria
SO INFECTION AND IMMUNITY
LA English
DT Article
ID CD8(+) T-CELLS; IFN-GAMMA; MICE; SEQUESTRATION; INFECTION; BRAIN;
   PATHOLOGY; PATHOGENESIS; EXPRESSION; RESPONSES
AB Infection with Plasmodium berghei ANKA induces cerebral malaria in susceptible mice. Brain-sequestered CD8(+) T cells are responsible for this pathology. We have evaluated the role of CCR2, a chemokine receptor expressed on CD8(+) T cells. Infected CCR2-deficient mice were as susceptible to cerebral malaria as wild-type mice were, and CD8(+) T-cell migration to the brain was not abolished.
C1 Univ Paris 05, CNRS UMR 8104,Hop Cochin, INSERM U567,Inst Cochin Genet Mol, Dept Immunol, F-75014 Paris, France.
   Museum Natl Hist Nat, F-75231 Paris, France.
   Vrije Univ Amsterdam, Fac Med, Dept Cell Biol & Immunol, NL-1081 BT Amsterdam, Netherlands.
   Univ Munich, Med Policlin, D-80336 Munich, Germany.
   Univ Texas, Dept Microbiol, Austin, TX 78712 USA.
   Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA.
RP Renia, L (corresponding author), Univ Paris 05, CNRS UMR 8104,Hop Cochin, INSERM U567,Inst Cochin Genet Mol, Dept Immunol, Batiment Gustave Roussy,27 Rue Fbg St Jacques, F-75014 Paris, France.
RI Van Rooijen, Nico/Z-1578-2019; Costa, Fabio/E-1181-2012; ,
   RENIA/E-2117-2011
OI Costa, Fabio/0000-0001-9969-7300; , RENIA/0000-0003-0349-1557; Vigario,
   Ana Margarida/0000-0001-5679-1196
CR Amani V, 2000, EUR J IMMUNOL, V30, P1646, DOI 10.1002/1521-4141(200006)30:6&lt;1646::AID-IMMU1646&gt;3.0.CO;2-0
   Belnoue E, 2002, J IMMUNOL, V169, P6369, DOI 10.4049/jimmunol.169.11.6369
   BENOUE E, IN PRESS BLOOD
   BERENDT AR, 1994, PARASITOL TODAY, V10, P412, DOI 10.1016/0169-4758(94)90238-0
   Berger O, 1999, MOL MED, V5, P795, DOI 10.1007/BF03401992
   Blease K, 2000, J IMMUNOL, V165, P2603, DOI 10.4049/jimmunol.165.5.2603
   Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798
   Fife BT, 2000, J EXP MED, V192, P899, DOI 10.1084/jem.192.6.899
   Grau GE, 2003, J INFECT DIS, V187, P461, DOI 10.1086/367960
   Hearn J, 2000, INFECT IMMUN, V68, P5364, DOI 10.1128/IAI.68.9.5364-5376.2000
   Hesselgesser J, 1999, J NEUROVIROL, V5, P13, DOI 10.3109/13550289909029741
   Jennings VM, 1997, INFECT IMMUN, V65, P4883, DOI 10.1128/IAI.65.11.4883-4887.1997
   Kurihara T, 1997, J EXP MED, V186, P1757, DOI 10.1084/jem.186.10.1757
   Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053
   LOPEZ AF, 1984, BRIT J HAEMATOL, V57, P489, DOI 10.1111/j.1365-2141.1984.tb02923.x
   Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001
   Mack M, 2001, J IMMUNOL, V166, P4697, DOI 10.4049/jimmunol.166.7.4697
   MACPHERSON GG, 1985, AM J PATHOL, V119, P385
   Nansen A, 2000, EUR J IMMUNOL, V30, P1797, DOI 10.1002/1521-4141(200007)30:7<1797::AID-IMMU1797>3.0.CO;2-B
   NEILL AL, 1992, PARASITOLOGY, V105, P165, DOI 10.1017/S0031182000074072
   PATNAIK JK, 1994, AM J TROP MED HYG, V51, P642, DOI 10.4269/ajtmh.1994.51.642
   REST JR, 1982, T ROY SOC TROP MED H, V76, P410, DOI 10.1016/0035-9203(82)90203-6
   Sato N, 1999, J IMMUNOL, V163, P5519
   Sato N, 2000, J EXP MED, V192, P205, DOI 10.1084/jem.192.2.205
   Silamut K, 1999, AM J PATHOL, V155, P395, DOI 10.1016/S0002-9440(10)65136-X
   Traynor TR, 2000, J IMMUNOL, V164, P2021, DOI 10.4049/jimmunol.164.4.2021
   vanRooijen N, 1996, J IMMUNOL METHODS, V193, P93, DOI 10.1016/0022-1759(96)00056-7
   Vigario AM, 2001, BLOOD, V97, P3966, DOI 10.1182/blood.V97.12.3966
   Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X
NR 29
TC 30
Z9 32
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
J9 INFECT IMMUN
JI Infect. Immun.
PD JUN
PY 2003
VL 71
IS 6
BP 3648
EP 3651
DI 10.1128/IAI.71.6.3648-3651.2003
PG 4
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 682WX
UT WOS:000183116300083
PM 12761155
OA Green Published, Bronze
DA 2020-12-08
ER

PT J
AU Douki, JBL
   Traore, B
   Costa, FTM
   Fusai, T
   Pouvelle, B
   Sterkers, Y
   Scherf, A
   Gysin, J
AF Douki, JBL
   Traore, B
   Costa, FTM
   Fusai, T
   Pouvelle, B
   Sterkers, Y
   Scherf, A
   Gysin, J
TI Sequestration of Plasmodium falciparum-infected erythrocytes to
   chondroitin sulfate A, a receptor for maternal malaria: monoclonal
   antibodies against the native parasite ligand reveal pan-reactive
   epitopes in placental isolates
SO BLOOD
LA English
DT Article
ID MICROVASCULAR ENDOTHELIAL-CELLS; VARIANT ANTIGENS; ADHESION; SURFACE;
   CYTOADHESION; ADHERENCE; FAMILY
AB Plasmodium falciparum parasites express variant adhesion molecules on the surface of infected erythrocytes (IEs), which act as targets for natural protection. Recently it was shown that IE sequestration in the placenta is mediated by binding to chondroitin sulfate A via the duffy binding-like (DBL)-gamma3 domain of P falciparum erythrocyte membrane protein 1 (PfEM1(CSA)). Conventional immunization procedures rarely result in the successful production of monoclonal antibodies (mAbs) against such conformational vaccine candidates. Here, we show that this difficulty can be overcome by rendering Balb/c mice B cells tolerant to the surface of human erythrocytes or Chinese hamster ovary (CHO) cells before injecting P falciparum, IEs or transfected CHO cells expressing the chondroltin sulfate A (CSA)-binding domain (DBL-gamma3) of the FCR3 var(CSA) gene. We fused spleen cells with P3U1 cells and obtained between 20% and 60% mAbs that specifically label the surface of mature infected erythrocytes of the CSA phenotype (mIE(CSA)) but not of other adhesive phenotypes. Surprisingly, 70.8% of the 43 mAbs analyzed in this work were IgM. All mAbs immunoprecipitated PfEMP1(CSA) from extracts of I-125 surface-labeled IECSA. Several mAbs bound efficiently to the surface of CSA-binding parasites from different geographic areas and to placental isolates from West Africa. The cross-reactive mAbs are directed against the DBL-gamma3(CSA), demonstrating that this domain, which mediates CSA binding, is able to Induce a pan-reactive immune response. This work is an important step toward the development of a DBL-gamma3-based vaccine that could protect pregnant women from pathogenesis. (C) 2002 by The American Society of Hematology.
C1 Univ Mediterranee, Fac Med, Unite Parasitol Expt, URA IPP IMTSSA, F-13385 Marseille 5, France.
   Inst Pasteur, Unite Biol Interact Hote Parasite, Paris, France.
RP Gysin, J (corresponding author), Univ Mediterranee, Fac Med, Unite Parasitol Expt, URA IPP IMTSSA, EA3282, F-13385 Marseille 5, France.
RI Scherf, Artur/A-9674-2014; Costa, Fabio/E-1181-2012
OI Costa, Fabio/0000-0001-9969-7300
CR Beeson JG, 2000, NAT MED, V6, P86, DOI 10.1038/71582
   Buffet PA, 1999, P NATL ACAD SCI USA, V96, P12743, DOI 10.1073/pnas.96.22.12743
   Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358
   Chen QJ, 2000, J EXP MED, V192, P1, DOI 10.1084/jem.192.1.1
   Craig A, 2000, TRENDS MICROBIOL, V8, P350, DOI 10.1016/S0966-842X(00)01808-4
   Craig A, 2001, MOL BIOCHEM PARASIT, V115, P129, DOI 10.1016/S0166-6851(01)00275-4
   Duffy Patrick E., 2001, Trends in Parasitology, V17, P354, DOI 10.1016/S1471-4922(01)02022-0
   Duffy PE, 2001, SCIENCE, V293, P2009, DOI 10.1126/science.1065302
   Fernandez V, 1999, J EXP MED, V190, P1393, DOI 10.1084/jem.190.10.1393
   Flick K, 2001, SCIENCE, V293, P2098, DOI 10.1126/science.1062891
   Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502
   Fusai T, 2000, MOL BIOCHEM PARASIT, V108, P25, DOI 10.1016/S0166-6851(00)00199-7
   Galfre G, 1981, Methods Enzymol, V73, P3
   Gamain B, 2001, P NATL ACAD SCI USA, V98, P2664, DOI 10.1073/pnas.041602598
   GAY F, 1995, J IMMUNOL METHODS, V184, P15, DOI 10.1016/0022-1759(95)00070-Q
   Gysin J, 1999, INFECT IMMUN, V67, P6596
   HEIDRICH HG, 1982, J PARASITOL, V68, P443, DOI 10.2307/3280956
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   Kyes SA, 1999, P NATL ACAD SCI USA, V96, P9333, DOI 10.1073/pnas.96.16.9333
   LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287
   MILLER LH, 1977, J EXP MED, V146, P277, DOI 10.1084/jem.146.1.277
   Parzy D, 2000, MICROBES INFECT, V2, P779, DOI 10.1016/S1286-4579(00)90357-5
   PERLMANN H, 1989, IMMUNOL REV, V112, P115, DOI 10.1111/j.1600-065X.1989.tb00555.x
   Pouvelle B, 2000, NAT MED, V6, P1264
   Pouvelle B, 1998, INFECT IMMUN, V66, P4950, DOI 10.1128/IAI.66.10.4950-4956.1998
   Robert C, 1995, RES IMMUNOL, V146, P383, DOI 10.1016/0923-2494(96)81042-X
   Scherf A, 2001, CELL MICROBIOL, V3, P125, DOI 10.1046/j.1462-5822.2001.00109.x
   Taramelli D, 1998, T ROY SOC TROP MED H, V92, P57, DOI 10.1016/S0035-9203(98)90954-3
NR 28
TC 50
Z9 51
U1 0
U2 0
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD AUG 15
PY 2002
VL 100
IS 4
BP 1478
EP 1483
DI 10.1182/blood-2002-01-0315
PG 6
WC Hematology
SC Hematology
GA 582RG
UT WOS:000177364500049
PM 12149234
DA 2020-12-08
ER

PT J
AU Costa, FTE
   Pinto, JR
   Carvalho, F
   Galvao, MJ
AF Costa, FTE
   Pinto, JR
   Carvalho, F
   Galvao, MJ
TI An early case of de novo membranous nephropathy in a renal transplant
   patient
SO TRANSPLANTATION PROCEEDINGS
LA English
DT Article; Proceedings Paper
CT 6th Congress of the Catalan-Transplantation-Society
CY JAN 21-24, 2001
CL BARCELONA, SPAIN
SP Catalon Transplantat Soc
ID GLOMERULONEPHRITIS
C1 Unidade Transplante, Lisbon, Portugal.
   Serv Nefrol, Lisbon, Portugal.
   Hosp Curra Cabral, Lisbon, Portugal.
RP Costa, FTE (corresponding author), Rua Prof Mira Fernandes 16,40 ESQ, P-1900380 Lisbon, Portugal.
RI Costa, Fabio/E-1181-2012
OI Costa, Fabio/0000-0001-9969-7300
CR COLLIN P, 1976, KIDNEY INT, V10, P336
   DAVISON AM, 1992, NEPHROL DIAL TRANSPL, V7, P114
   DYER PA, 1980, TISSUE ANTIGENS, V15, P505
   KLOUDA PT, 1979, LANCET, V2, P770, DOI 10.1016/S0140-6736(79)92118-4
   Kotanko P, 1997, TRANSPLANTATION, V63, P1045, DOI 10.1097/00007890-199704270-00001
   SCHWARZ A, 1994, TRANSPLANTATION, V58, P650
NR 6
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0041-1345
J9 TRANSPLANT P
JI Transplant. Proc.
PD FEB
PY 2002
VL 34
IS 1
BP 364
EP 364
AR PII S0041-1345(01)02803-2
DI 10.1016/S0041-1345(01)02803-2
PG 1
WC Immunology; Surgery; Transplantation
SC Immunology; Surgery; Transplantation
GA 541HP
UT WOS:000174979400167
PM 11959328
DA 2020-12-08
ER

PT J
AU Preiser, PR
   Khan, S
   Costa, FTM
   Jarra, W
   Belnoue, E
   Ogun, S
   Holder, AA
   Voza, T
   Landau, I
   Snounou, G
   Renia, L
AF Preiser, PR
   Khan, S
   Costa, FTM
   Jarra, W
   Belnoue, E
   Ogun, S
   Holder, AA
   Voza, T
   Landau, I
   Snounou, G
   Renia, L
TI Stage-specific transcription of distinct repertoires of a multigene
   family during plasmodium life cycle
SO SCIENCE
LA English
DT Article
ID YOELII RHOPTRY PROTEIN; MALARIA PARASITE; RODENT MALARIA; FALCIPARUM;
   VIVAX; GENE; IDENTIFICATION; MEROZOITES; SELECTION; INVASION
AB Members of a multigene family in the rodent malaria parasite Plasmodium yoelii yoelli code for 235-kilodalton proteins (Py235) that are located in the merozoite apical complex, are implicated in virulence, and may determine red blood cell specificity. We show that distinct subsets of py235 genes are expressed in sporozoites and hepatic and erythrocytic stages, Antibodies to Py235 inhibited sporozoite invasion of hepatocytes, The switch in expression profile occurred immediately after transition from one stage to another, The results suggest that this differential expression is driven by strong biological requirements and provide evidence that hepatic and erythrocytic merozoites differ.
C1 Natl Inst Med Res, Div Parasitol, London NW7 1AA, England.
   Univ Paris 05, Hop Cochin, Inst Cochin Genet Mol, Dept Immunol,INSERM,U445, F-75014 Paris, France.
   Natl Museum Nat Hist, Lab Biol Parasitaire, F-75231 Paris, France.
   Inst Pasteur, Unite Parasitol Biomed, F-75724 Paris 15, France.
RP Preiser, PR (corresponding author), Natl Inst Med Res, Div Parasitol, Ridgeway, London NW7 1AA, England.
RI Holder, Anthony A/A-7554-2013; Preiser, Peter R/A-2201-2011; Snounou,
   Georges/F-3352-2011; , RENIA/E-2117-2011; Costa, Fabio/E-1181-2012
OI Holder, Anthony A/0000-0002-8490-6058; Snounou,
   Georges/0000-0002-6133-6398; , RENIA/0000-0003-0349-1557; Costa,
   Fabio/0000-0001-9969-7300; Khan, Shahid/0000-0002-0533-4670; ,
   Peter/0000-0003-4331-7000
FU Medical Research CouncilMedical Research Council UK (MRC)
   [MC_U117532067] Funding Source: Medline
CR Barry JD, 2001, ADV PARASIT, V49, P1, DOI 10.1016/S0065-308X(01)49037-3
   Borst P, 2001, MOL BIOCHEM PARASIT, V114, P17, DOI 10.1016/S0166-6851(01)00243-2
   Chen QJ, 1998, NATURE, V394, P392, DOI 10.1038/28660
   FREEMAN RR, 1980, NATURE, V284, P366, DOI 10.1038/284366a0
   GALINSKI MR, 1992, CELL, V69, P1213, DOI 10.1016/0092-8674(92)90642-P
   Galinski MR, 2000, MOL BIOCHEM PARASIT, V108, P257, DOI 10.1016/S0166-6851(00)00219-X
   Galinski MR, 1996, PARASITOL TODAY, V12, P20, DOI 10.1016/0169-4758(96)80641-7
   Hayward RE, 1999, P NATL ACAD SCI USA, V96, P4563, DOI 10.1073/pnas.96.8.4563
   HOLDER AA, 1984, PHILOS T ROY SOC B, V307, P171, DOI 10.1098/rstb.1984.0117
   Holder AA, 1981, NATURE, V294, P361, DOI 10.1038/294361a0
   KEEN J, 1990, MOL BIOCHEM PARASIT, V42, P241, DOI 10.1016/0166-6851(90)90167-K
   KEEN JK, 1994, MOL BIOCHEM PARASIT, V65, P171, DOI 10.1016/0166-6851(94)90125-2
   Khan SM, 2001, MOL BIOCHEM PARASIT, V114, P197, DOI 10.1016/S0166-6851(01)00253-5
   Landau Irene, 1998, P401
   Marussig M, 1997, INT IMMUNOL, V9, P1817, DOI 10.1093/intimm/9.12.1817
   Narum DL, 2001, MOL BIOCHEM PARASIT, V112, P193, DOI 10.1016/S0166-6851(00)00363-7
   Ogun SA, 1996, MOL BIOCHEM PARASIT, V76, P321, DOI 10.1016/0166-6851(95)02540-5
   OGUN SA, 1994, EXP PARASITOL, V79, P270, DOI 10.1006/expr.1994.1090
   Owen CA, 1999, MOL BIOCHEM PARASIT, V99, P183, DOI 10.1016/S0166-6851(99)00015-8
   Preiser PR, 1998, EXP PARASITOL, V89, P50, DOI 10.1006/expr.1998.4259
   Preiser PR, 1999, NATURE, V398, P618, DOI 10.1038/19309
   Preiser PR, 1996, EMBO J, V15, P684, DOI 10.1002/j.1460-2075.1996.tb00401.x
   PREISER PR, UNPUB
   Rayner JC, 2000, P NATL ACAD SCI USA, V97, P9648, DOI 10.1073/pnas.160469097
   RENIA L, 1990, EUR J IMMUNOL, V20, P1445, DOI 10.1002/eji.1830200706
   RENIA L, UNPUB
   Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418
   Sinha KA, 1996, MOL BIOCHEM PARASIT, V76, P329, DOI 10.1016/0166-6851(95)02546-4
   Snounou G, 2000, PARASITOL TODAY, V16, P28, DOI 10.1016/S0169-4758(99)01546-X
   SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V58, P283, DOI 10.1016/0166-6851(93)90050-8
   Taylor HM, 2001, INFECT IMMUN, V69, P3635, DOI 10.1128/IAI.69.6.3635-3645.2001
   Thompson J, 1999, MOL MICROBIOL, V31, P253, DOI 10.1046/j.1365-2958.1999.01167.x
   Triglia T, 2001, INFECT IMMUN, V69, P1084, DOI 10.1128/IAI.69.2.1084-1092.2001
NR 33
TC 59
Z9 61
U1 0
U2 12
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD JAN 11
PY 2002
VL 295
IS 5553
BP 342
EP 345
DI 10.1126/science.1064938
PG 4
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 511RD
UT WOS:000173278600054
PM 11786645
DA 2020-12-08
ER

PT J
AU Costa, FTM
   Snounou, G
   Letourneur, F
   Lebrun, N
   Landau, I
   Renia, L
AF Costa, FTM
   Snounou, G
   Letourneur, F
   Lebrun, N
   Landau, I
   Renia, L
TI The primary structure of the circumsporozoite protein of Plasmodium
   atheruri, a malaria parasite of the African porcupine Atherurus
   africanus
SO MOLECULAR AND BIOCHEMICAL PARASITOLOGY
LA English
DT Article
DE circumsporozoite protein; Plasmodium artheruri; sequence
ID INVITRO; RECOMBINANT; SPOROZOITES; BERGHEI; PEPTIDE; CELLS
C1 Univ Paris 05, Hop Cochin, Inst Cochin Genet Mol, INSERM,U445, F-75014 Paris, France.
   Univ Fed Sao Paulo, Dept Microbiol Immunol & Parasitol, Sao Paulo, SP, Brazil.
   Inst Pasteur, Unite Parasitol Biomed, F-75724 Paris 15, France.
   Univ Paris 05, Inst Cochin Genet Mol, Lab Commun Sequencage, Paris, France.
   Museum Natl Hist Nat, Lab Biol Parasitaire, F-75231 Paris 05, France.
RP Renia, L (corresponding author), Univ Paris 05, Hop Cochin, Inst Cochin Genet Mol, INSERM,U445, 27 Rue Du Faubourg St Jacques, F-75014 Paris, France.
EM renia@icgm.cochin.inserm.fr
RI Costa, Fabio/E-1181-2012; , RENIA/E-2117-2011; Snounou,
   Georges/F-3352-2011
OI Costa, Fabio/0000-0001-9969-7300; , RENIA/0000-0003-0349-1557; Snounou,
   Georges/0000-0002-6133-6398
CR ESCALANTE AA, 1995, MOL BIOL EVOL, V12, P616
   Frevert Ute, 1998, P73
   HOLLINGDALE MR, 1982, J IMMUNOL, V128, P1929
   HOLLINGDALE MR, 1983, AM J TROP MED HYG, V32, P24, DOI 10.4269/ajtmh.1983.32.24
   Killick-Kendrick R., 1978, P1
   LANDAU I, 1969, T ROY SOC TROP MED H, V63, P8
   LANDAU I, 1983, ANN PARASIT HUM COMP, V58, P523, DOI 10.1051/parasite/1983586523
   MAZIER D, 1986, SCIENCE, V231, P156, DOI 10.1126/science.3510455
   McCutchan TF, 1996, P NATL ACAD SCI USA, V93, P11889, DOI 10.1073/pnas.93.21.11889
   Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0
   MORAN P, 1994, J CELL BIOL, V125, P333, DOI 10.1083/jcb.125.2.333
   Pyper WR, 1998, MOL BIOCHEM PARASIT, V94, P287, DOI 10.1016/S0166-6851(98)00069-3
   RENIA L, 1991, P NATL ACAD SCI USA, V88, P7963, DOI 10.1073/pnas.88.18.7963
   RODRIGUES MM, 1991, INT IMMUNOL, V3, P579, DOI 10.1093/intimm/3.6.579
   SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297
   Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202
   SUHRBIER A, 1988, EUR J CELL BIOL, V46, P25
   VAN DEN BERGHE L, 1958, Ann Soc Belg Med Trop (1920), V38, P971
   VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683
   WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763
NR 20
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0166-6851
EI 1872-9428
J9 MOL BIOCHEM PARASIT
JI Mol. Biochem. Parasitol.
PD APR 25
PY 2001
VL 114
IS 1
BP 125
EP 127
DI 10.1016/S0166-6851(01)00248-1
PG 3
WC Biochemistry & Molecular Biology; Parasitology
SC Biochemistry & Molecular Biology; Parasitology
GA 433ZW
UT WOS:000168791500014
PM 11356522
DA 2020-12-08
ER

PT J
AU Bau, CHD
   Spode, A
   Ponso, AC
   Elias, EP
   Garcia, CED
   Costa, FT
   Hutz, MH
AF Bau, CHD
   Spode, A
   Ponso, AC
   Elias, EP
   Garcia, CED
   Costa, FT
   Hutz, MH
TI Heterogeneity in early onset alcoholism suggests a third group of
   alcoholics
SO ALCOHOL
LA English
DT Article
DE heterogeneity in alcoholism; cluster analysis; types of alcoholics;
   personality; temperament; life events; novelty seeking; harm avoidance
ID DOPAMINE-D4 RECEPTOR GENE; PERSONALITY; TYPOLOGY; CLASSIFICATION;
   SUBTYPES; TYPE-1; AGE
AB Data fi-om 141 Brazilian male alcoholics were investigated with the objective of further exploring the heterogeneity of alcoholism and to replicate previous studies. A set of seven variables was studied by different cluster analyses to test hypotheses with two, three, and four groups. The results suggested that the best solution showed three groups of alcoholics, two of them similar to those previously described and a third relatively similar to type 2, but with lower scores in harm avoidance, more positive impact of life events, higher proportion of alcoholic relatives, less frequent use of antianxiety drugs, and less delirium tremens. These results reinforced the model with three groups and may be useful in the delineation of new etiology and treatment studies. (C) 2001 Elsevier Science Inc. All rights reserved.
C1 Univ Fed Rio Grande do Sul, Dept Genet, Inst Biociencias, BR-91501970 Porto Alegre, RS, Brazil.
RP Bau, CHD (corresponding author), Univ Fed Rio Grande do Sul, Dept Genet, Inst Biociencias, Ave Bento Goncalves 9500,Caixa Postal 15053, BR-91501970 Porto Alegre, RS, Brazil.
EM bau@if.ufrgs.br
RI Bau, Claiton Henrique Dotto/C-9980-2013; Costa, Fabio/E-1181-2012; Hutz,
   Mara H/I-4070-2012
OI Bau, Claiton Henrique Dotto/0000-0001-5644-3845; Costa,
   Fabio/0000-0001-9969-7300; Hutz, Mara/0000-0002-9146-1229
CR Allen JP, 1997, J STUD ALCOHOL, V58, P7
   American Psychiatric Association, 1987, DIAGN STAT MAN MENT
   BABOR TF, 1992, ARCH GEN PSYCHIAT, V49, P599
   Babor TF, 1996, ALCOHOL HEALTH RES W, V20, P6
   Bau CHD, 1999, PSYCHIATR GENET, V9, P139, DOI 10.1097/00041444-199909000-00005
   BAU CHD, 1995, ADDICTION, V90, P693, DOI 10.1046/j.1360-0443.1995.90569310.x
   BROWN J, 1994, ANN NY ACAD SCI, V708, P1
   BUCHOLZ KK, 1994, J STUD ALCOHOL, V55, P149, DOI 10.15288/jsa.1994.55.149
   CLONINGER CR, 1987, ARCH GEN PSYCHIAT, V44, P573
   CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604
   CLONINGER CR, 1981, ARCH GEN PSYCHIAT, V38, P861
   Everitt B.S., 1980, CLUSTER ANAL
   EVERITT BS, 1992, ANAL CONTINGENCY
   Hauser J, 1997, DRUG ALCOHOL DEPEN, V48, P243, DOI 10.1016/S0376-8716(97)00130-0
   IRWIN M, 1990, ARCH GEN PSYCHIAT, V47, P320
   JELLINEK E M, 1960, Can Med Assoc J, V83, P1341
   LITT MD, 1992, ARCH GEN PSYCHIAT, V49, P609
   MEZZICH A, 1993, ALCOHOL CLIN EXP RES, V17, P767, DOI 10.1111/j.1530-0277.1993.tb00838.x
   MOREY LC, 1984, J ABNORM PSYCHOL, V93, P408, DOI 10.1037/0021-843X.93.4.408
   Roman T, 1999, ADDICT BIOL, V4, P203, DOI 10.1080/13556219971713
   SARASON IG, 1978, J CONSULT CLIN PSYCH, V46, P932, DOI 10.1037/0022-006X.46.5.932
   VAILLANT GE, 1994, ADDICTION, V89, P1049, DOI 10.1111/j.1360-0443.1994.tb02776.x
   Zucker RA, 1996, ALCOHOL HEALTH RES W, V20, P46
NR 23
TC 7
Z9 9
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0741-8329
EI 1873-6823
J9 ALCOHOL
JI Alcohol
PD JAN
PY 2001
VL 23
IS 1
BP 9
EP 13
DI 10.1016/S0741-8329(00)00120-8
PG 5
WC Substance Abuse; Pharmacology & Pharmacy; Toxicology
SC Substance Abuse; Pharmacology & Pharmacy; Toxicology
GA 418FN
UT WOS:000167880400002
PM 11282446
DA 2020-12-08
ER

PT J
AU Bau, CHD
   Almeida, S
   Costa, FT
   Garcia, CED
   Elias, EP
   Ponso, AC
   Spode, A
   Hutz, MH
AF Bau, CHD
   Almeida, S
   Costa, FT
   Garcia, CED
   Elias, EP
   Ponso, AC
   Spode, A
   Hutz, MH
TI DRD4 and DAT1 as modifying genes in alcoholism: interaction with novelty
   seeking on level of alcohol consumption
SO MOLECULAR PSYCHIATRY
LA English
DT Editorial Material
ID DEFICIT HYPERACTIVITY DISORDER; DOPAMINE-D4 RECEPTOR GENE; ASSOCIATION;
   POLYMORPHISM; POPULATION
C1 Univ Fed Rio Grande Sul, Biosci Inst, Dept Genet, BR-91501970 Porto Alegre, RS, Brazil.
RP Bau, CHD (corresponding author), Univ Fed Rio Grande Sul, Biosci Inst, Dept Genet, Postal Box 15053, BR-91501970 Porto Alegre, RS, Brazil.
RI Almeida, Silvana/C-6045-2017; Bau, Claiton Henrique Dotto/C-9980-2013;
   Costa, Fabio/E-1181-2012; Hutz, Mara H/I-4070-2012
OI Almeida, Silvana/0000-0001-7959-3723; Bau, Claiton Henrique
   Dotto/0000-0001-5644-3845; Costa, Fabio/0000-0001-9969-7300; Hutz,
   Mara/0000-0002-9146-1229
CR Barr CL, 2000, AM J MED GENET, V96, P262, DOI 10.1002/1096-8628(20000612)96:3<262::AID-AJMG5>3.0.CO;2-8
   Bau CHD, 1999, PSYCHIATR GENET, V9, P139, DOI 10.1097/00041444-199909000-00005
   Bau CHD, 2000, AM J MED GENET, V96, P302, DOI 10.1002/1096-8628(20000612)96:3<302::AID-AJMG13>3.0.CO;2-I
   Biederman J, 1998, BIOL PSYCHIAT, V44, P269, DOI 10.1016/S0006-3223(97)00406-X
   CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604
   Hu S, 2000, MOL PSYCHIATR, V5, P181, DOI 10.1038/sj.mp.4000690
   Lerman C, 2000, MOL PSYCHIATR, V5, P189, DOI 10.1038/sj.mp.4000672
   Roman T, 1999, ADDICT BIOL, V4, P203, DOI 10.1080/13556219971713
   Strobel A, 1999, MOL PSYCHIATR, V4, P378, DOI 10.1038/sj.mp.4000535
   Waldman ID, 1998, AM J HUM GENET, V63, P1767, DOI 10.1086/302132
NR 10
TC 38
Z9 39
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI BASINGSTOKE
PA HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND
SN 1359-4184
J9 MOL PSYCHIATR
JI Mol. Psychiatr.
PD JAN
PY 2001
VL 6
IS 1
BP 7
EP 9
DI 10.1038/sj.mp.4000819
PG 3
WC Biochemistry & Molecular Biology; Neurosciences; Psychiatry
SC Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry
GA 384NU
UT WOS:000165952400002
PM 11244477
OA Bronze
DA 2020-12-08
ER

PT J
AU Costa, FT
AF Costa, FT
TI Method for quick Coomassie Blue staining of polyacrylamide gets
SO AMERICAN BIOLOGY TEACHER
LA English
DT Article
C1 St Petersburg Jr Coll, Div Nat Sci, Clearwater, FL 33765 USA.
RP Costa, FT (corresponding author), St Petersburg Jr Coll, Div Nat Sci, Clearwater Campus, Clearwater, FL 33765 USA.
RI Costa, Fabio/E-1181-2012
OI Costa, Fabio/0000-0001-9969-7300
CR *BIOR, 1991, MIN PROT 2 EL CELL I
   Bollag D. M., 1991, PROTEIN METHODS
   Carlson S, 1998, SCI AM, V279, P110, DOI 10.1038/scientificamerican1298-110
   Hames BD, 1990, GEL ELECTROPHORESIS
   KISIEL D, 1980, INTRO LAB EXERCISES
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEWIS C, 1998, LAB INQUIRY PROGRAMS, V2
NR 7
TC 1
Z9 1
U1 0
U2 2
PU NATL ASSOC BIOLOGY TEACHERS INC
PI RESTON
PA 12030 SUNRISE VALLEY DR, #110, RESTON, VA 20191 USA
SN 0002-7685
J9 AM BIOL TEACH
JI Am. Biol. Teach.
PD APR
PY 2000
VL 62
IS 4
BP 285
EP 287
DI 10.1662/0002-7685(2000)062[0285:MFQCBS]2.0.CO;2
PG 3
WC Biology; Education, Scientific Disciplines
SC Life Sciences & Biomedicine - Other Topics; Education & Educational
   Research
GA 545QX
UT WOS:000175229900010
DA 2020-12-08
ER

PT J
AU Rodrigues, MM
   Ribeirao, M
   Pereira-Chioccola, V
   Renia, L
   Costa, F
AF Rodrigues, MM
   Ribeirao, M
   Pereira-Chioccola, V
   Renia, L
   Costa, F
TI Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization
   of the cellular immune response generated by immunization with a DNA
   vaccine containing a Trypanosoma cruzi gene
SO INFECTION AND IMMUNITY
LA English
DT Article
ID CHRONIC CHAGAS-DISEASE; NECROSIS-FACTOR-ALPHA; PLASMID DNA;
   TRANS-SIALIDASE; T-CELLS; PREFERENTIAL INDUCTION; IMMUNOSTIMULATORY DNA;
   MACROPHAGE ACTIVATION; INTERFERON-GAMMA; SURFACE-ANTIGEN
AB Immunization with a plasmid DNA containing the gene encoding the catalytic domain of trans-sialidase (TS) elicits protective immune responses against experimental Trypanosoma cruzi infection. As several studies provided strong evidence that during infection CD4 Th1 and CD8 T cytotoxic type 1 (Tc1) cells are important factors in host resistance, the present study was designed to evaluate which T-cell types were activated in DNA-vaccinated BALB/c mice. We found that bulk cells from DNA-immunized mice had CD4 and CD8 T cells that produced gamma interferon (IFN-gamma) but not interleukin-4 (IL-4) or IL-10. To characterize the TS-specific T cells at the clonal level, we generated CD4 and CD8 clones. We obtained cytotoxic CD4 clones of the Th1 type that secreted large amounts of IFN-gamma but not IL-4 or IL-10. Unexpectedly, we obtained other CD4 clones with a Th2 phenotype, secreting IL-4 and IL-10 but not IFN-gamma. All CD8 clones were cytotoxic and produced IFN-gamma. IL-4 and IL-10 were not secreted by these cells. Using synthetic peptides, we determined a CDS epitope recognized by several clones as being represented by amino acids IYNVGQVSI. The antiparasitic activity of a CD4 Th1 and a CDS Tc1 clone was assessed in vitro. CD4 or CD8 T cells significantly inhibited T. cruzi development in infected macrophages or fibroblasts, respectively. We concluded that DNA vaccine efficiently generates potentially protective CD4 Th1 and CD8 Tc1 cells specific for a T. cruzi antigen, therefore reinforcing the possibility of using this strategy for developing a preventive or therapeutic vaccine against Chagas' disease.
C1 Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, BR-04023062 Sao Paulo, Brazil.
   Inst Dante Pazzanese Cardiol Estado Sao Paulo, Lab Xenodiagnost, Sao Paulo, Brazil.
   Univ Paris 05, Hop Cochin 27, Inst Cochin Genet Mol,Lab Immunol Pathol Infect &, INSERM,U445, F-75014 Paris, France.
RP Rodrigues, MM (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, Rua Botucatu 862,6 Andar, BR-04023062 Sao Paulo, Brazil.
EM Rodriguesm.dmip@epm.br
RI Rodrigues, Mauricio M./B-8512-2012; , RENIA/E-2117-2011;
   Pereira-Chioccola, Vera Lucia/N-8432-2019; Pereira-Chioccola, Vera
   Lucia/F-2452-2014; Costa, Fabio/E-1181-2012
OI , RENIA/0000-0003-0349-1557; Pereira-Chioccola, Vera
   Lucia/0000-0003-3317-195X; Costa, Fabio/0000-0001-9969-7300
CR ABRAHAMSOHN IA, 1995, J IMMUNOL, V155, P3955
   ARNHOLDT ACV, 1993, J IMMUNOL, V151, P3171
   Bonato VLD, 1998, INFECT IMMUN, V66, P169, DOI 10.1128/IAI.66.1.169-175.1998
   Chow YH, 1998, J IMMUNOL, V160, P1320
   Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623
   Costa F, 1998, VACCINE, V16, P768, DOI 10.1016/S0264-410X(97)00277-6
   CROSS GAM, 1993, ANNU REV MICROBIOL, V47, P385, DOI 10.1146/annurev.mi.47.100193.002125
   Davis HL, 1998, J IMMUNOL, V160, P870
   deAndrade ALSS, 1996, LANCET, V348, P1407
   Denis O, 1998, INFECT IMMUN, V66, P1527, DOI 10.1128/IAI.66.4.1527-1533.1998
   DosReis GA, 1997, PARASITOL TODAY, V13, P335, DOI 10.1016/S0169-4758(97)01073-9
   FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425
   Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50
   Feltquate DM, 1997, J IMMUNOL, V158, P2278
   Gurunathan S, 1997, J EXP MED, V186, P1137, DOI 10.1084/jem.186.7.1137
   HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S
   Holscher C, 1998, INFECT IMMUN, V66, P1208
   Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893
   Jakob T, 1998, J IMMUNOL, V161, P3042
   Klinman DM, 1997, J IMMUNOL, V158, P3635
   Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879
   Leclerc C, 1997, CELL IMMUNOL, V179, P97, DOI 10.1006/cimm.1997.1161
   Li XM, 1998, J EXP MED, V188, P681, DOI 10.1084/jem.188.4.681
   MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A
   MOR G, 1995, J IMMUNOL, V155, P2039
   MUNOZFERNANDEZ MA, 1992, EUR J IMMUNOL, V22, P301, DOI 10.1002/eji.1830220203
   NICKELL SP, 1993, INFECT IMMUN, V61, P3250, DOI 10.1128/IAI.61.8.3250-3258.1993
   Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141
   REED SG, 1988, J IMMUNOL, V140, P4342
   Ribeirao M, 1997, GLYCOBIOLOGY, V7, P1237, DOI 10.1093/glycob/7.8.1237
   ROCHA A, 1994, AM J TROP MED HYG, V50, P261, DOI 10.4269/ajtmh.1994.50.261
   RODRIGUES M, 1992, J EXP MED, V175, P895, DOI 10.1084/jem.175.4.895
   RODRIGUES MM, 1991, INT IMMUNOL, V3, P579, DOI 10.1093/intimm/3.6.579
   RODRIGUES MM, UNPUB
   ROTTENBERG ME, 1993, INFECT IMMUN, V61, P5129, DOI 10.1128/IAI.61.12.5129-5133.1993
   Sambrook J., 1989, MOL CLONING LAB MANU
   Sartori AMC, 1998, CLIN INFECT DIS, V26, P177, DOI 10.1086/516257
   Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352
   SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M
   SILVA JS, 1995, INFECT IMMUN, V63, P4862, DOI 10.1128/IAI.63.12.4862-4867.1995
   SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169
   TARLETON RL, 1995, PARASITOL TODAY, V11, P7, DOI 10.1016/0169-4758(95)80095-6
   Tarleton RL, 1996, INT IMMUNOL, V8, P13, DOI 10.1093/intimm/8.1.13
   TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008
   UEMURA H, 1992, EMBO J, V11, P3837, DOI 10.1002/j.1460-2075.1992.tb05476.x
   Ulmer JB, 1996, CURR OPIN IMMUNOL, V8, P531, DOI 10.1016/S0952-7915(96)80042-2
   Ulmer JB, 1998, J VIROL, V72, P5648, DOI 10.1128/JVI.72.7.5648-5653.1998
   VIOTTI R, 1994, AM HEART J, V127, P151, DOI 10.1016/0002-8703(94)90521-5
   Wizel B, 1997, J IMMUNOL, V159, P6120
   Wizel B, 1998, INFECT IMMUN, V66, P5073, DOI 10.1128/IAI.66.11.5073-5081.1998
   Zhu XJ, 1997, J IMMUNOL, V158, P5921
NR 51
TC 48
Z9 48
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0019-9567
EI 1098-5522
J9 INFECT IMMUN
JI Infect. Immun.
PD AUG
PY 1999
VL 67
IS 8
BP 3855
EP 3863
DI 10.1128/IAI.67.8.3855-3863.1999
PG 9
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 219ZA
UT WOS:000081637400023
PM 10417149
OA Bronze, Green Published
DA 2020-12-08
ER

PT J
AU Costa, F
   Pereira-Chioccola, VL
   Ribeirao, M
   Schenkman, S
   Rodrigues, MM
AF Costa, F
   Pereira-Chioccola, VL
   Ribeirao, M
   Schenkman, S
   Rodrigues, MM
TI Trans-sialidase delivered as a naked DNA vaccine elicits an
   immunological response similar to a Trypanosoma cruzi infection
SO BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH
LA English
DT Article; Proceedings Paper
CT International Symposium on the 3rd Revolution on Vaccines - DNA Vaccines
CY NOV 03-07, 1997
CL BELO HORIZONT, BRAZIL
DE DNA vaccination; trans-sialidase; Chagas' disease
ID NEURAMINIDASE ACTIVITIES; CHAGAS-DISEASE; SURFACE; BENZNIDAZOLE;
   ADHESION; RECEPTOR; INVASION; EPITOPE; EXPRESS; FAMILY
AB Trypanosoma cruzi, the protozoan parasite that causes Chagas' disease, does not synthesize sialic acid, but expresses a trans-sialidase (TS) that catalyzes the transfer of sialic acid from host glycoconjugates to the parasite surface. Here, we review studies that characterize the immune response to the catalytic domain of the enzyme in humans during Chagas' disease or in mice following immunization with the TS gene. In both cases, there are antibodies that strongly inhibit the enzymatic activity and generation of interferon-gamma-producing T cells.
C1 Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Immunol & Parasitol, BR-04023062 Sao Paulo, Brazil.
   Inst Dante Pazzanese Cardiol Estado Sao Paulo, Lab Xenodiagnostico, Sao Paulo, Brazil.
RP Rodrigues, MM (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Immunol & Parasitol, Rua Botucatu 862,6 Andar, BR-04023062 Sao Paulo, Brazil.
RI Pereira-Chioccola, Vera Lucia/N-8432-2019; Rodrigues, Mauricio
   M./B-8512-2012; Costa, Fabio/E-1181-2012; Pereira-Chioccola, Vera
   Lucia/F-2452-2014; Schenkman, Sergio/A-9227-2013
OI Costa, Fabio/0000-0001-9969-7300; Pereira-Chioccola, Vera
   Lucia/0000-0003-3317-195X; Schenkman, Sergio/0000-0001-9353-8480
CR CAZZULO JJ, 1992, FASEB J, V6, P3259
   CHUENKOVA M, 1995, J EXP MED, V181, P1693, DOI 10.1084/jem.181.5.1693
   Costa F, 1998, VACCINE, V16, P768, DOI 10.1016/S0264-410X(97)00277-6
   CROSS GAM, 1993, ANNU REV MICROBIOL, V46, P383
   deAndrade ALSS, 1996, LANCET, V348, P1407
   Franchin G, 1997, INFECT IMMUN, V65, P2548, DOI 10.1128/IAI.65.7.2548-2554.1997
   GIORDANO R, 1994, MOL BIOCHEM PARASIT, V65, P85, DOI 10.1016/0166-6851(94)90117-1
   Holscher C, 1998, INFECT IMMUN, V66, P1208
   KAHN S, 1995, J EXP MED, V182, P1243, DOI 10.1084/jem.182.5.1243
   LEGUIZAMON MS, 1994, J INFECT DIS, V170, P1570, DOI 10.1093/infdis/170.6.1570
   LIMA MF, 1989, MOL BIOCHEM PARASIT, V33, P159, DOI 10.1016/0166-6851(89)90030-3
   MING M, 1993, MOL BIOCHEM PARASIT, V59, P234
   OUASSI MA, 1986, MOL BIOCHEM PARASIT, V19, P201
   PARODI AJ, 1992, EMBO J, V11, P1705, DOI 10.1002/j.1460-2075.1992.tb05221.x
   Pereira MEA, 1996, INFECT IMMUN, V64, P3884, DOI 10.1128/IAI.64.9.3884-3892.1996
   PEREIRA MEA, 1991, J EXP MED, V174, P179, DOI 10.1084/jem.174.1.179
   PEREIRACHIOCCOL.VL, 1998, IN PRESS PARASITE IM, V20
   PEREIRACHIOCCOLA VL, 1994, INFECT IMMUN, V62, P2973, DOI 10.1128/IAI.62.7.2973-2978.1994
   Ribeirao M, 1997, GLYCOBIOLOGY, V7, P1237, DOI 10.1093/glycob/7.8.1237
   SCHENKMAN RPF, 1993, INFECT IMMUN, V61, P898, DOI 10.1128/IAI.61.3.898-902.1993
   SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M
   SCHENKMAN S, 1994, ANNU REV MICROBIOL, V48, P499, DOI 10.1146/annurev.mi.48.100194.002435
   SCHENKMAN S, 1992, J EXP MED, V175, P567, DOI 10.1084/jem.175.2.567
   UEMURA H, 1992, EMBO J, V11, P3837, DOI 10.1002/j.1460-2075.1992.tb05476.x
   VIOTTI R, 1994, AM HEART J, V127, P151, DOI 10.1016/0002-8703(94)90521-5
NR 25
TC 13
Z9 13
U1 0
U2 0
PU ASSOC BRAS DIVULG CIENTIFICA
PI SAO PAULO
PA FACULDADE MEDICINA, SALA 21, 14049 RIBEIRAO PRETO, SAO PAULO, BRAZIL
SN 0100-879X
J9 BRAZ J MED BIOL RES
JI Brazilian J. Med. Biol. Res.
PD FEB
PY 1999
VL 32
IS 2
BP 235
EP 239
DI 10.1590/S0100-879X1999000200013
PG 5
WC Biology; Medicine, Research & Experimental
SC Life Sciences & Biomedicine - Other Topics; Research & Experimental
   Medicine
GA 169JU
UT WOS:000078745300013
PM 10347760
OA DOAJ Gold, Green Published
DA 2020-12-08
ER

PT J
AU Pereira-Chioccola, VL
   Costa, F
   Ribeirao, M
   Soares, IS
   Arena, F
   Schenkman, S
   Rodrigues, MM
AF Pereira-Chioccola, VL
   Costa, F
   Ribeirao, M
   Soares, IS
   Arena, F
   Schenkman, S
   Rodrigues, MM
TI Comparison of antibody and protective immune responses against
   Trypanosoma cruzi infection elicited by immunization with a parasite
   antigen delivered as naked DNA or recombinant protein
SO PARASITE IMMUNOLOGY
LA English
DT Article
DE DNA immunization; recombinant protein
ID TRANS-SIALIDASE; PLASMID DNA; NEURAMINIDASE ACTIVITIES; MICE; GENE;
   INVASION; MALARIA; EPITOPE; SURFACE; MEMBERS
AB Immunization with naked DNA represents an attractive strategy for development of vaccines against a variety of infections including those caused by protozoan parasites. Recently, we have described that immunization with a plasmid containing the trans-sialidase (TS) gene induced protective immunity against Trypanosoma cruzi infection in BALB/c mice. The present study was aimed at examining and comparing the effectiveness of immunization using either plasmid or recombinant delivered antigens in a mouse strain highly susceptible to infection (A/Sn). Two plasmids were generated containing the coding region for the catalytic domain of TS. TS gene was inserted into pcDNA3 vector with or without the coding region for TS signal peptide. These two plasmids were found to be equally immunogenic at inducing antibodies to TS or inhibition of T. cruzi infection. A third plasmid, in which the TS gene was inserted into the vector VR1012, was as immunogenic as the two others. Immunization with a TS recombinant protein in alum generated a significantly higher antibody response as measured by ELISA or inhibition of TS enzymatic activity. Most relevant, this immunization reduced the mortality due to acute infection.
C1 UNIFESP, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, BR-04023062 Sao Paulo, Brazil.
   Inst Dante Pazzanese Cardiol Estado Sao Paulo, Lab Xenodiagnost, Sao Paulo, Brazil.
   Fed Univ Para, Ctr Ciencias Biol, Dept Patol, BR-66075900 Belem, Para, Brazil.
RP Rodrigues, MM (corresponding author), UNIFESP, Escola Paulista Med, Dept Microbiol Imunol & Parasitol, Rua Botucatu 862 8A,6th Floor, BR-04023062 Sao Paulo, Brazil.
RI Rodrigues, Mauricio M./B-8512-2012; Schenkman, Sergio/A-9227-2013;
   Costa, Fabio/E-1181-2012; Pereira-Chioccola, Vera Lucia/N-8432-2019;
   Pereira-Chioccola, Vera Lucia/F-2452-2014; Soares, Irene
   Silva/C-5974-2012
OI Schenkman, Sergio/0000-0001-9353-8480; Costa, Fabio/0000-0001-9969-7300;
   Pereira-Chioccola, Vera Lucia/0000-0003-3317-195X; Soares, Irene
   Silva/0000-0002-3336-6856
CR CHUENKOVA M, 1995, J EXP MED, V181, P1693, DOI 10.1084/jem.181.5.1693
   Costa F, 1998, VACCINE, V16, P768, DOI 10.1016/S0264-410X(97)00277-6
   Doolan DL, 1996, J EXP MED, V183, P1739, DOI 10.1084/jem.183.4.1739
   Doolan DL, 1997, PARASITOL TODAY, V13, P171, DOI 10.1016/S0169-4758(97)01040-5
   DosReis GA, 1997, PARASITOL TODAY, V13, P335, DOI 10.1016/S0169-4758(97)01073-9
   FELQUATE DM, 1997, J IMMUNOL, V158, P1178
   Franchin G, 1997, INFECT IMMUN, V65, P2548, DOI 10.1128/IAI.65.7.2548-2554.1997
   GRUNATHAN S, 1997, J EXP MED, V186, P1137
   Haddad D, 1997, FEMS IMMUNOL MED MIC, V18, P193, DOI 10.1111/j.1574-695X.1997.tb01045.x
   Hartikka J, 1996, HUM GENE THER, V7, P1205, DOI 10.1089/hum.1996.7.10-1205
   KRETTLI AU, 1976, J IMMUNOL, V116, P755
   Leclerc C, 1997, CELL IMMUNOL, V179, P97, DOI 10.1006/cimm.1997.1161
   MING M, 1993, MOL BIOCHEM PARASIT, V59, P234
   MOR G, 1995, J IMMUNOL, V155, P2039
   Pereira MEA, 1996, INFECT IMMUN, V64, P3884, DOI 10.1128/IAI.64.9.3884-3892.1996
   RAZ E, 1996, P NATL ACAD SCI USA, V93, P511
   Ribeirao M, 1997, GLYCOBIOLOGY, V7, P1237, DOI 10.1093/glycob/7.8.1237
   Sambrook J, 1989, MOL CLONING LAB MANU
   Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352
   SCHENKMAN RPF, 1993, INFECT IMMUN, V61, P898, DOI 10.1128/IAI.61.3.898-902.1993
   SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M
   SCHENKMAN S, 1994, J BIOL CHEM, V269, P7970
   SCHENKMAN S, 1992, J EXP MED, V175, P567, DOI 10.1084/jem.175.2.567
   SILVA JS, 1992, J EXP MED, V175, P169, DOI 10.1084/jem.175.1.169
   TARLETON RL, 1995, PARASITOL TODAY, V11, P7, DOI 10.1016/0169-4758(95)80095-6
   UEMURA H, 1992, EMBO J, V11, P3837, DOI 10.1002/j.1460-2075.1992.tb05476.x
   Ulmer JB, 1996, CURR OPIN IMMUNOL, V8, P531, DOI 10.1016/S0952-7915(96)80042-2
   UMEKITA LF, 1988, IMMUNOL LETT, V17, P85, DOI 10.1016/0165-2478(88)90106-X
   Wizel B, 1997, J IMMUNOL, V159, P6120
NR 29
TC 32
Z9 33
U1 0
U2 2
PU BLACKWELL SCIENCE LTD
PI OXFORD
PA P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND
SN 0141-9838
J9 PARASITE IMMUNOL
JI Parasite Immunol.
PD FEB
PY 1999
VL 21
IS 2
BP 103
EP 110
PG 8
WC Immunology; Parasitology
SC Immunology; Parasitology
GA 222RW
UT WOS:000081799400005
PM 10101720
DA 2020-12-08
ER

PT J
AU Costa, F
   Franchin, G
   Pereira-Chioccola, VL
   Ribeirao, M
   Schenkman, S
   Rodrigues, MM
AF Costa, F
   Franchin, G
   Pereira-Chioccola, VL
   Ribeirao, M
   Schenkman, S
   Rodrigues, MM
TI Immunization with a plasmid DNA containing the gene of trans-sialidase
   reduces Trypanosoma cruzi infection in mice
SO VACCINE
LA English
DT Article
DE Trypanosoma cruzi; DNA immunization
ID NEURAMINIDASE ACTIVITIES; MAMMALIAN-CELLS; CHAGAS-DISEASE; INVASION;
   BENZNIDAZOLE; PROTECTION; ANTIGEN; DOMAIN
AB Trypanosoma cruzi, the protozoan parasite that causes Chagas' disease, does not synthesize sialic acid, but expresses a trans-sialidase that catalyses the transfer of sialic acid from host glycoconjugates to the parasite surface. Several lines of evidence suggest that this enzyme is a virulence factor implicated in the establishment of infection. Here we studied whether immunization with a plasmid DNA containing a gene encoding for rite catalytic domain of the enzyme could elicit protective immunity against T. cruzi infection in mice. We observed that immunization with this plasmid DNA generated antibody and T-cell mediated immune responses. Antibodies recognized the native enzyme and inhibited its activity in vitro. Upon challenge with bloodstream trypomastigotes, immunized animals displayed reduced parasitemia and mortality. (C) 1998 Elsevier Science Ltd. All rights reserved.
C1 Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Immunol & Parasitol, BR-04023062 Sao Paulo, Brazil.
   Inst Dante Pazzanese Cardiol Estado Sao Paulo, Lab Xenodiagnost, Sao Paulo, Brazil.
RP Rodrigues, MM (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Dept Microbiol Immunol & Parasitol, Rua Botucatu 862 8A,6 Andar, BR-04023062 Sao Paulo, Brazil.
RI Costa, Fabio/E-1181-2012; Franchin, Giovanni/AAC-2398-2020; Schenkman,
   Sergio/A-9227-2013; Pereira-Chioccola, Vera Lucia/F-2452-2014;
   Rodrigues, Mauricio M./B-8512-2012; Pereira-Chioccola, Vera
   Lucia/N-8432-2019
OI Costa, Fabio/0000-0001-9969-7300; Franchin,
   Giovanni/0000-0003-1988-2739; Schenkman, Sergio/0000-0001-9353-8480;
   Pereira-Chioccola, Vera Lucia/0000-0003-3317-195X; Franchin,
   Giovanni/0000-0003-2609-7974
CR CHUENKOVA M, 1995, J EXP MED, V181, P1693, DOI 10.1084/jem.181.5.1693
   CROSS GAM, 1993, ANNU REV MICROBIOL, V46, P383
   deAndrade ALSS, 1996, LANCET, V348, P1407
   Ertl HCJ, 1996, VIRAL IMMUNOL, V9, P1, DOI 10.1089/vim.1996.9.1
   Franchin G, 1997, INFECT IMMUN, V65, P2548, DOI 10.1128/IAI.65.7.2548-2554.1997
   MICHEL ML, 1995, P NATL ACAD SCI USA, V92, P5307, DOI 10.1073/pnas.92.12.5307
   Pereira MEA, 1996, INFECT IMMUN, V64, P3884, DOI 10.1128/IAI.64.9.3884-3892.1996
   PEREIRACHIOCCOLA VL, 1994, INFECT IMMUN, V62, P2973, DOI 10.1128/IAI.62.7.2973-2978.1994
   SAMBROOK J, 1989, MOL CLONING LAB MANU, V1, P42
   SCHENKMAN RPF, 1993, INFECT IMMUN, V61, P898, DOI 10.1128/IAI.61.3.898-902.1993
   SCHENKMAN S, 1991, CELL, V65, P1117, DOI 10.1016/0092-8674(91)90008-M
   SCHENKMAN S, 1992, J EXP MED, V175, P1635, DOI 10.1084/jem.175.6.1635
   SCHENKMAN S, 1994, J BIOL CHEM, V269, P7970
   SCHENKMAN S, 1992, J EXP MED, V175, P567, DOI 10.1084/jem.175.2.567
   SEDEGAH M, 1994, P NATL ACAD SCI USA, V91, P9866, DOI 10.1073/pnas.91.21.9866
   TARLETON RL, 1995, PARASITOL TODAY, V11, P7, DOI 10.1016/0169-4758(95)80095-6
   UEMURA H, 1992, EMBO J, V11, P3837, DOI 10.1002/j.1460-2075.1992.tb05476.x
   Ulmer JB, 1996, CURR OPIN IMMUNOL, V8, P531, DOI 10.1016/S0952-7915(96)80042-2
   VIOTTI R, 1994, AM HEART J, V127, P151, DOI 10.1016/0002-8703(94)90521-5
   XU D, 1995, IMMUNOLOGY, V84, P173
NR 20
TC 91
Z9 93
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
J9 VACCINE
JI Vaccine
PD MAY
PY 1998
VL 16
IS 8
BP 768
EP 774
DI 10.1016/S0264-410X(97)00277-6
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA ZP179
UT WOS:000073725300002
PM 9627933
DA 2020-12-08
ER

EF